PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wu, CI; Shi, SH; Zhang, YP				Wu, CI; Shi, SH; Zhang, YP			A case for conservation	NATURE			English	Editorial Material									Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Guangzhou 510275, Peoples R China; Chinese Acad Sci, Kunming Inst Zool, Kunming, Yunnan, Peoples R China; Yunnan Univ, Kunming 650091, Yunnan, Peoples R China	University of Chicago; Sun Yat Sen University; Chinese Academy of Sciences; Kunming Institute of Zoology; Yunnan University	Wu, CI (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57th St, Chicago, IL 60637 USA.							Normile D, 2003, SCIENCE, V302, P559, DOI 10.1126/science.302.5645.559	1	10	10	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					213	214		10.1038/428213a	http://dx.doi.org/10.1038/428213a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014510				2022-12-28	WOS:000220103600059
J	Maria, V; Albuquerque, A; Loureiro, A; Sousa, A; Victorino, R				Maria, V; Albuquerque, A; Loureiro, A; Sousa, A; Victorino, R			Lesson of the week - Severe cholestatic hepatitis induced by pyritinol	BRITISH MEDICAL JOURNAL			English	Review									Hosp Santa Maria, Inst Mol Med, Clin Immunol Unit, P-1649028 Lisbon, Portugal; Hosp Santa Maria, Fac Med Lisbon, Dept Med 2, P-1649028 Lisbon, Portugal	Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa; Hospital Santa Maria	Maria, V (corresponding author), Hosp Santa Maria, Inst Mol Med, Clin Immunol Unit, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	vascomaria@fm.ul.pt	Sousa, Ana E./L-2642-2014; Victorino, Rui/N-7948-2013	Sousa, Ana E./0000-0002-4618-9799; Maria, Vasco/0000-0003-4378-0265; Albuquerque, Adriana/0000-0002-4455-4916; Victorino, Rui/0000-0001-7567-1704				Cavaleiro R, 2000, AIDS, V14, P2679, DOI 10.1097/00002030-200012010-00007; IMOTO S, 1979, ANN INTERN MED, V91, P129, DOI 10.7326/0003-4819-91-1-129_1; JAFFE IA, 1986, AM J MED, V80, P471, DOI 10.1016/0002-9343(86)90722-9; LEMMEL EM, 1993, BRIT J RHEUMATOL, V32, P375; MACEDO G, 1992, GASTROEN CLIN BIOL, V16, P186; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; Maria VAJ, 1997, GUT, V41, P534, DOI 10.1136/gut.41.4.534; Straumann A, 1998, GASTROENTEROLOGY, V115, P452, DOI 10.1016/S0016-5085(98)70212-4	8	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					572	574		10.1136/bmj.328.7439.572	http://dx.doi.org/10.1136/bmj.328.7439.572			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	15001508	Green Published			2022-12-28	WOS:000220091800028
J	Bliss, SJ; Flanders, SA; Saint, S				Bliss, SJ; Flanders, SA; Saint, S			A pain in the neck	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEMIERRES-SYNDROME; NECROBACILLOSIS; ANTIBIOTICS; DIAGNOSIS		Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Michigan Hlth Syst, Canton Hlth Ctr, Canton, MI 48187 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of California System; University of California San Francisco; University of Michigan System; University of Michigan	Bliss, SJ (corresponding author), Univ Michigan Hlth Syst, Canton Hlth Ctr, 1051 N Canton Ctr Rd, Canton, MI 48187 USA.	sbliss@umich.edu	Saint, Sanjay/AAF-5126-2019; Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bisno AL, 2002, CLIN INFECT DIS, V35, P113, DOI 10.1086/340949; Chirinos JA, 2002, MEDICINE, V81, P458, DOI 10.1097/00005792-200211000-00006; Ellis GR, 1998, J INFECTION, V36, P340, DOI 10.1016/S0163-4453(98)94711-9; Ghosh T K, 1999, Indian J Pathol Microbiol, V42, P31; Golpe R, 1999, POSTGRAD MED J, V75, P141, DOI 10.1136/pgmj.75.881.141; HAGELSKJAER KJ, 2000, CLIN INFECT DIS, V31, P524; Hagelskjaer LH, 1998, EUR J CLIN MICROBIOL, V17, P561, DOI 10.1007/BF01708619; Jacobs RF, 2000, PEDIATR INFECT DIS J, V19, P938, DOI 10.1097/00006454-200009000-00038; Jones J W, 2001, Commun Dis Public Health, V4, P278; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; Lemierre A, 1936, LANCET, V1, P701; Liu ACY, 2002, CLIN RADIOL, V57, P332, DOI 10.1053/crad.2001.0806; Ortiz J A, 1987, Emerg Med Clin North Am, V5, P359; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; TVETERAS K, 1986, CLIN OTOLARYNGOL, V11, P383, DOI 10.1111/j.1365-2273.1986.tb00141.x	15	29	30	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1037	1042		10.1056/NEJMcps032253	http://dx.doi.org/10.1056/NEJMcps032253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999116				2022-12-28	WOS:000189363600013
J	Dussutour, A; Fourcassie, V; Helbing, D; Deneubourg, JL				Dussutour, A; Fourcassie, V; Helbing, D; Deneubourg, JL			Optimal traffic organization in ants under crowded conditions	NATURE			English	Article							LEAF-CUTTING ANT; TRAILS; SPEED	Efficient transportation, a hot topic in nonlinear science(1), is essential for modern societies and the survival of biological species. Biological evolution has generated a rich variety of successful solutions(2), which have inspired engineers to design optimized artificial systems(3,4). Foraging ants, for example, form attractive trails that support the exploitation of initially unknown food sources in almost the minimum possible time(5,6). However, can this strategy cope with bottleneck situations, when interactions cause delays that reduce the overall flow? Here, we present an experimental study of ants confronted with two alternative routes. We find that pheromone-based attraction generates one trail at low densities, whereas at a high level of crowding, another trail is established before traffic volume is affected, which guarantees that an optimal rate of food return is maintained. This bifurcation phenomenon is explained by nonlinear modelling approach. Surprisingly, the underlying mechanism is based on inhibitory interactions. It points to capacity reserves, a limitation of the density-induced speed reduction, and a sufficient pheromone concentration for reliable trail perception. The balancing mechanism between cohesive and dispersive forces appears to be generic in natural, urban and transportation systems.	Univ Toulouse 3, CNRS, UMR 5169, Ctr Rech Cognit Anim, 118 Route Narbonne, F-31062 Toulouse 4, France; Free Univ Brussels, Ctr Etud Phenomenes Nonlineaires & Syst Complexe, B-1050 Brussels, Belgium; Tech Univ Dresden, Inst Econ & Traff, D-01062 Dresden, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Technische Universitat Dresden	Dussutour, A (corresponding author), Univ Toulouse 3, CNRS, UMR 5169, Ctr Rech Cognit Anim, 118 Route Narbonne, F-31062 Toulouse 4, France.		Helbing, Dirk/C-6114-2008; Fourcassié, Vincent/AAJ-9016-2020; Dussutour, Audrey/A-2399-2012	Dussutour, Audrey/0000-0002-1377-3550; Fourcassie, Vincent/0000-0002-3605-6351				BECKERS R, 1992, J THEOR BIOL, V159, P397, DOI 10.1016/S0022-5193(05)80686-1; Bonabeau E, 2000, NATURE, V406, P39, DOI 10.1038/35017500; Bonabeau E DdRDF, 1999, SWARM INTELLIGENCE N; Burd M, 2003, INSECT SOC, V50, P3, DOI 10.1007/s000400300001; Burd M, 2002, AM NAT, V159, P283, DOI 10.1086/338541; CALENBUHR V, 1992, J THEOR BIOL, V158, P395, DOI 10.1016/S0022-5193(05)80739-8; Camazine S., 2001, SELF ORG BIOL SYSTEM, DOI DOI 10.1515/9780691212920; Couzin ID, 2003, P ROY SOC B-BIOL SCI, V270, P139, DOI 10.1098/rspb.2002.2210; EDELSTEINKESHET L, 1995, BEHAV ECOL SOCIOBIOL, V36, P119, DOI 10.1007/s002650050132; ERLANDSSON J, 1995, MAR BIOL, V122, P87, DOI 10.1007/BF00349281; FEENER DH, 1990, BEHAV ECOL SOCIOBIOL, V49, P348; FITZGERALD TD, 1995, TENT CATERPILLARS; FRETWELL S D, 1969, Acta Biotheoretica, V19, P16, DOI 10.1007/BF01601953; Fujita M., 1999, SPATIAL EC CITIES RE; Galef BG, 1996, ANIM BEHAV, V51, P765, DOI 10.1006/anbe.1996.0081; GOSS S, 1989, NATURWISSENSCHAFTEN, V76, P579, DOI 10.1007/BF00462870; Helbing D, 1997, NATURE, V388, P47, DOI 10.1038/40353; Helbing D, 2002, EUROPHYS LETT, V60, P227, DOI 10.1209/epl/i2002-00342-y; Helbing D, 2001, REV MOD PHYS, V73, P1067, DOI 10.1103/RevModPhys.73.1067; Holldobler B., 1990, pi; Krause J, 2002, LIVING GROUPS; Miura T, 1998, J INSECT BEHAV, V11, P179, DOI 10.1023/A:1021039722402; O'Toole DV, 1999, J THEOR BIOL, V198, P305, DOI 10.1006/jtbi.1999.0917; Parrish J., 1997, ANIMAL GROUPS 3 DIME; Pasteels J.M., 1987, Experientia Supplementum (Basel), V54, P155; SCHWEITZER E, 2003, BROWNIAN AGENTS ACTI; Traniello James F.A., 1995, P241; WILSON EDWARD O., 1962, ANIMAL BEHAVIOR, V10, P134, DOI 10.1016/0003-3472(62)90141-0	28	198	213	1	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					70	73		10.1038/nature02345	http://dx.doi.org/10.1038/nature02345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999281	Green Submitted			2022-12-28	WOS:000189363800036
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for family and intimate partner violence: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE CHILDHOOD EXPERIENCES; HOUSEHOLD DYSFUNCTION; DOMESTIC VIOLENCE; HOME VISITATION; HEALTH-CARE; ABUSE; RISK; NEGLECT; WOMEN; VICTIMIZATION	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for family and intimate partner violence, based on the USPSTF's examination of evidence specific to family and intimate partner violence, and updates the 1996 recommendations on this topic. In 1996, the USPSTF found insufficient evidence to recommend for or against the use of specific instruments to detect domestic violence (a grade C recommendation, according to 1996 grade definitions). The USPSTF now uses an explicit process in which the balance of benefits and harms is determined exclusively by the quality and magnitude of the evidence. As a result, current letter grades are based on different criteria from those in 1996. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the USPSTF Web site (www.preventive services.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov). The USPSTF recommendation, the accompanying summary article, and the complete systematic evidence review are available through the USPSTF Web site (www.preventiveservices.ahrq.gov). The summary article and the USPSTF recommendation statement are available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).	Univ Washington, Seattle, WA 98195 USA; Univ Maryland, Baltimore, MD 21201 USA; Univ Rochester, Sch Med, Rochester, NY USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Women & Infants Hosp Rhode Isl, Providence, RI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mt Sinai Sch Med, New York, NY USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Robert Wood Johnson Foundation (RWJF); Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							*AM AC FAM PHYS, 2003, FAM VIOL AB; *AM COLL OBST GYN, 2002, GUID WOM HLTH CARE; *AM MED ASS, 2003, AM MED ASS POL STAT; *AM MED ASS, 1993, ARCH FAM MED, V2, P19; American Medical Association, 1992, ARCH FAM MED, V1, P187, DOI 10.1001/archfami.1.2.187; American Medical Association Council on Scientific Affairs, 1992, DIAGN TREATM GUID EL; Anda RF, 2002, OBSTET GYNECOL, V100, P37, DOI 10.1016/S0029-7844(02)02063-X; [Anonymous], 1991, PEDIATRICS, V87, P254; Campbell Doris Williams, 2002, Online J Issues Nurs, V7, P5; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; Coker AL, 2002, J WOMEN HEALTH GEN-B, V11, P465, DOI 10.1089/15246090260137644; *COMM FUND, 1993, 1 COMPR NATL HLTH SU; Diaz A, 2002, ARCH PEDIAT ADOL MED, V156, P811, DOI 10.1001/archpedi.156.8.811; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; Duggan A, 2000, PEDIATRICS, V105, P250; DURANT RH, 1994, J ADOLESCENT HEALTH, V15, P311, DOI 10.1016/1054-139X(94)90604-1; Eckenrode J, 2000, JAMA-J AM MED ASSOC, V284, P1385, DOI 10.1001/jama.284.11.1385; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; GARBARINO J, 1991, AM PSYCHOL, V46, P376, DOI 10.1037/0003-066X.46.4.376; Glass N, 2001, J Emerg Nurs, V27, P141, DOI 10.1067/men.2001.114387; Hahn Robert A, 2003, MMWR Recomm Rep, V52, P1; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P966; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; JOHNSON CF, 1990, PEDIATR CLIN N AM, V37, P791; Korfmacher J, 2000, CHILD ABUSE NEGLECT, V24, P129, DOI 10.1016/S0145-2134(99)00115-5; LACHS MS, 1995, NEW ENGL J MED, V332, P437, DOI 10.1056/NEJM199502163320706; Lansford JE, 2002, ARCH PEDIAT ADOL MED, V156, P824, DOI 10.1001/archpedi.156.8.824; MacMillan HL, 2000, CAN MED ASSOC J, V163, P1451; Maxfield MG, 1996, ARCH PEDIAT ADOL MED, V150, P390, DOI 10.1001/archpedi.1996.02170290056009; McFarlane J, 2000, PUBLIC HEALTH NURS, V17, P443, DOI 10.1046/j.1525-1446.2000.00443.x; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; *NEAIS, 1998, FIN REP NAT CTR ELD; Nelson H, 2004, SCREENING FAMILY INT; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; OSOFSKY JD, 1993, PSYCHIATRY, V56, P36; Parker B, 1999, RES NURS HEALTH, V22, P59; Reid Bernadette, 2002, J Pediatr Nurs, V17, P229, DOI 10.1053/jpdn.2002.123524; Sachs CJ, 2002, WOMEN HEALTH, V35, P121, DOI 10.1300/J013v35n02_08; Sedlak A., 1996, 3 NATL INCIDENCE STU; SHAKOOR BH, 1991, J NATL MED ASSOC, V83, P233; Silverman JG, 2001, JAMA-J AM MED ASSOC, V286, P572, DOI 10.1001/jama.286.5.572; The Commonwealth Fund, 1999, HLTH CONC WOM LIF CO; U. S. Department of Health andHumanServices, 2001, CHILD MALTR 1999 REP; United States Department of Justice, 1998, VIOL INT AN DAT CRIM; Wathen CN, 2003, CAN MED ASSOC J, V169, P582	46	126	126	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					382	386		10.7326/0003-4819-140-5-200403020-00021	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00021			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996680				2022-12-28	WOS:000189246800008
J	Pound, P; Ebrahim, S; Sandercock, P; Bracken, MB; Roberts, I				Pound, P; Ebrahim, S; Sandercock, P; Bracken, MB; Roberts, I		RATS Grp	Where is the evidence that animal research benefits humans?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODEL EXPERIMENTS; COLON-CANCER; METAANALYSIS; ATTITUDES; BLOCKADE; EXPOSURE; THERAPY; SUPPORT; MICE	Much animal research into potential treatments for humans is wasted because it is poorly conducted and not evaluated through systematic reviews	London Sch Hyg & Trop Med, London WC1B 3DP, England; Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT 06520 USA; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; Yale University; University of Bristol; University of Edinburgh	Roberts, I (corresponding author), London Sch Hyg & Trop Med, London WC1B 3DP, England.	Ian.Roberts@lshtm.ac.uk						Aghajafari F, 2002, AM J OBSTET GYNECOL, V186, P843, DOI 10.1067/mob.2002.121624; Bailey B, 2003, J TOXICOL-CLIN TOXIC, V41, P595, DOI 10.1081/CLT-120023761; Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684; Blackman K, 2001, Emerg Med (Fremantle), V13, P204, DOI 10.1046/j.1442-2026.2001.00213.x; Boissier J, 2001, INT J PARASITOL, V31, P1597, DOI 10.1016/S0020-7519(01)00277-6; Borrelli F, 2002, EUR J CLIN PHARMACOL, V58, P235, DOI 10.1007/s00228-002-0457-2; BRUNNER EJ, 2000, SOCIAL EPIDEMIOLOGY, P306; CICCONE A, 2003, P EUR STROK C VAL MA; Collins JJ, 2001, REGUL TOXICOL PHARM, V34, P17, DOI 10.1006/rtph.2001.1486; COMROE JH, 1976, SCIENCE, V192, P105, DOI 10.1126/science.769161; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; Corpet DE, 2002, NUTR CANCER, V43, P1, DOI 10.1207/S15327914NC431_1; Dagg A I, 1999, J Appl Anim Welf Sci, V2, P337, DOI 10.1207/s15327604jaws0204_7; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; Fox CH, 2002, COMPLEMENT THER MED, V10, P229, DOI 10.1016/S0965-2299(02)00092-4; FREEDMAN LS, 1994, ADV EXP MED BIOL, V364, P93; Glatt SJ, 2000, NEUROTOXICOL TERATOL, V22, P617, DOI 10.1016/S0892-0362(00)00088-X; GRANT J, 2003, BEDSIDE BENCH CONROE; Horn J, 2001, STROKE, V32, P570, DOI 10.1161/01.STR.32.2.570; Horn J, 2001, STROKE, V32, P2433, DOI 10.1161/hs1001.096009; *HOUS LORDS, 2002, REP SEL COMM AN SCI, V22; Kelley G, 1996, J APPL PHYSIOL, V81, P1584, DOI 10.1152/jappl.1996.81.4.1584; Klinge B, 2002, J CLIN PERIODONTOL, V29, P213, DOI 10.1034/j.1600-051X.29.s3.13.x; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Lee DS, 2003, J CARD FAIL, V9, P368, DOI 10.1054/S1071-9164(03)00125-8; Lucas C, 2002, LASER MED SCI, V17, P110, DOI 10.1007/s101030200018; Mapstone J, 2003, J TRAUMA, V55, P571, DOI 10.1097/01.TA.0000062968.69867.6F; *MED RES COUNC, CLIN TRIALS OUTL FOR; Meune C, 2003, DRUG SAFETY, V26, P975, DOI 10.2165/00002018-200326130-00005; Nava-Ocampo AA, 2000, MED HYPOTHESES, V54, P77, DOI 10.1054/mehy.1998.0831; Page K, 2003, LANCET NEUROL, V2, P136, DOI 10.1016/S1474-4422(03)00335-1; Petticrew M., 2003, J EPIDEMIOL COMMU S1, V57, pA1; Plous S, 1996, AM PSYCHOL, V51, P1167, DOI 10.1037/0003-066X.51.11.1167; REINES BP, 1991, J MED PHILOS, V16, P183, DOI 10.1093/jmp/16.2.183; Ren YJ, 2003, ANGLE ORTHOD, V73, P86; Roberts I, 2001, LANCET, V357, P385, DOI 10.1016/S0140-6736(00)03653-9; Roberts I, 2002, BRIT MED J, V324, P474, DOI 10.1136/bmj.324.7335.474; Schechter AN, 2002, JAMA-J AM MED ASSOC, V288, P832, DOI 10.1001/jama.288.7.832; Shapiro Kenneth J., 1998, ANIMAL MODELS HUMAN; SMITH R, 1987, BRIT MED J, V295, P1404, DOI 10.1136/bmj.295.6610.1404; Smith R, 2001, BMJ-BRIT MED J, V322, P248, DOI 10.1136/bmj.322.7281.248; Stewart PM, 2003, BMJ-BRIT MED J, V327, P999, DOI 10.1136/bmj.327.7422.999; VITTEK J, 1995, EXPERIENTIA, V51, P927, DOI 10.1007/BF01921742; Woodman R, 1999, BRIT MED J, V318, P1438, DOI 10.1136/bmj.318.7196.1438a	44	324	338	1	48	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					514	517		10.1136/bmj.328.7438.514	http://dx.doi.org/10.1136/bmj.328.7438.514			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988196	Green Published, Green Accepted			2022-12-28	WOS:000220002900037
J	Bhargava, SK; Sachdev, HS; Fall, CHD; Osmond, C; Lakshmy, R; Barker, DJP; Biswas, SKD; Ramji, S; Prabhakaran, D; Reddy, KS				Bhargava, SK; Sachdev, HS; Fall, CHD; Osmond, C; Lakshmy, R; Barker, DJP; Biswas, SKD; Ramji, S; Prabhakaran, D; Reddy, KS			Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIABETES-MELLITUS; BIRTH-WEIGHT; GROWTH; FETAL; INDIA; PREVALENCE; RISK	BACKGROUND: The risk of type 2 diabetes mellitus is increased in people who have low birth weights and who subsequently become obese as adults. Whether their obesity originates in childhood and, if so, at what age are unknown. Understanding the origin of obesity may be especially important in developing countries, where type 2 diabetes is rapidly increasing yet public health messages still focus on reducing childhood ``undernutrition.'' METHODS: We evaluated glucose tolerance and plasma insulin concentrations in 1492 men and women 26 to 32 years of age who had been measured at birth and at intervals of three to six months throughout infancy, childhood, and adolescence in a prospective, population-based study. RESULTS: The prevalence of impaired glucose tolerance was 10.8 percent, and that of diabetes was 4.4 percent. Subjects with impaired glucose tolerance or diabetes typically had a low body-mass index up to the age of two years, followed by an early adiposity rebound (the age after infancy when body mass starts to rise) and an accelerated increase in body-mass index until adulthood. However, despite an increase in body-mass index between the ages of 2 and 12 years, none of these subjects were obese at the age of 12 years. The odds ratio for disease associated with an increase in the body-mass index of 1 SD from 2 to 12 years of age was 1.36 (95 percent confidence interval, 1.18 to 1.57; P<0.001). CONCLUSIONS: There is an association between thinness in infancy and the presence of impaired glucose tolerance or diabetes in young adulthood. Crossing into higher categories of body-mass index after the age of two years is also associated with these disorders.	Sunder Lal Jain Hosp, Dept Pediat, Delhi, India; Maulana Azad Med Coll, Dept Pediat, New Delhi, India; All India Inst Med Sci, Dept Cardiol, New Delhi, India; Indian Council Med Res, New Delhi, India; Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton, Hants, England	Maulana Azad Medical College; All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR); University of Southampton	Sachdev, HS (corresponding author), E-6-12 Vasant Vihar, New Delhi 110057, India.	hpssachdev@hotmail.com	Prabhakaran, Dorairaj/B-4147-2011; Barker, David JP/A-5671-2013; Robles-Sardin, Alma E/M-7714-2015	Prabhakaran, Dorairaj/0000-0002-3172-834X; Robles-Sardin, Alma E/0000-0003-2044-7793; Osmond, Clive/0000-0002-9054-4655; Sachdev, Harshpal Singh/0000-0002-4956-9391; Fall, Caroline/0000-0003-4402-5552	British Heart Foundation [PG/05/046/18730] Funding Source: Medline; Medical Research Council [U.1475.00.004.00005.01(74245), MC_U147574245] Funding Source: Medline	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Delisle H, 2002, PROGRAMMING CHRONIC; Eriksson JG, 2003, DIABETOLOGIA, V46, P190, DOI 10.1007/s00125-002-1012-5; Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.0.CO;2-O; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; GHOSH S, 1979, LONGITUDINAL STUDY S; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; *HLTH COMM AUSTR, 2000, AS PAC PERSP RED OB, P18; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Newsome CA, 2003, DIABETIC MED, V20, P339, DOI 10.1046/j.1464-5491.2003.00871.x; Pradeepa R, 2002, INDIAN J MED RES, V116, P121; Ramachandran A, 1997, DIABETOLOGIA, V40, P232, DOI 10.1007/s001250050668; Rich-Edwards JW, 1999, ANN INTERN MED, V130, P278, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00005; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; SACHDEV HPS, 2003, NFI B, V24, P6; Wareham N J, 1995, Diabet Med, V12, P931; WHO, 1995, WHO TECH REP SER, V854, P329; *WHO CONS, 1999, WHONCDNCS992 WHO CON; Yajnik C S, 2002, Obes Rev, V3, P217, DOI 10.1046/j.1467-789X.2002.00072.x	21	709	729	3	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					865	875		10.1056/NEJMoa035698	http://dx.doi.org/10.1056/NEJMoa035698			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985484	Green Accepted			2022-12-28	WOS:000189197300005
J	Ling, EM; Smith, T; Nguyen, XD; Pridgeon, C; Dallman, M; Arbery, J; Carr, VA; Robinson, DS				Ling, EM; Smith, T; Nguyen, XD; Pridgeon, C; Dallman, M; Arbery, J; Carr, VA; Robinson, DS			Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease	LANCET			English	Article							IN-VITRO; FUNCTIONAL-CHARACTERIZATION; PRIMARY CULTURE; RESPONSES; PROLIFERATION; IMMUNOTHERAPY; TOLERANCE; IMMUNITY; ASTHMA; FOXP3	Background Allergic diseases are frequent and rising in prevalence, and result from activation of T-helper (Th) 2 cells by allergens. CD4+CD25+ regulatory T cells suppress T-cell activation in vitro and prevent pathological findings in animal models of disease. We aimed to investigate whether the amount of inhibition of allergic responses by CD4+CD25+ T cells was related to atopy and allergic disease. Methods Blood CD4+CD25+ and CD4+CD25- T cells were isolated from three groups of donors: non-atopic individuals; those atopic with no present symptoms; and patients with hayfever studied during and out of the grass-pollen season. We investigated the ability of CD25+ T cells from these donors to suppress allergen-stimulated T-cell proliferation and cytokine production in vitro. Findings CD4+CD25+ T cells from non-atopic donors suppressed proliferation and interleukin 5 production by their own allergen-stimulated CD4+CD25- T cells. Inhibition of proliferation by CD4+CD25+ T cells from atopic donors was significantly reduced (p=0.0012), and was even more diminished by CD4+CD25+ T cells isolated from patients with hayfever during the pollen season (p=0.0003). In patients with hayfever, out-of-season suppression remained less than that seen by regulatory cells from non-atopic donors. Interpretation Allergic disease can result from an inappropriate balance between allergen activation of regulatory CD4+CD25+ T cells and effector Th2 cells. This imbalance could result from a deficiency in suppression by regulatory T cells or strong activation signals could overcome such regulation. Treatment to enhance regulatory T-cell responses, in concert with reduction of Th2 cell activation, might be useful in prevention and treatment of allergic disease.	Natl Heart & Lung Inst, Imperial Coll London, Dept Allergy & Clin Immunol, London SW3 6LY, England; Natl Heart & Lung Inst, Imperial Coll London, Dept Upper Resp Med, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London; Imperial College London; Imperial College London	Robinson, DS (corresponding author), Univ London Imperial Coll Sci Technol & Med, NHLI Fac Med, Dovehouse St, London NW3 6LY, England.	d.s.robinson@imperial.ac.uk		Dallman, Margaret/0000-0002-9079-3344; Spencely, Carol/0000-0002-0773-3632				Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; IMADA M, 1995, IMMUNOLOGY, V85, P373; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272	29	580	639	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					608	615		10.1016/S0140-6736(04)15592-X	http://dx.doi.org/10.1016/S0140-6736(04)15592-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987885				2022-12-28	WOS:000189104900009
J	Martinez, V; Rolland, E; Bricaire, F; Caumes, E				Martinez, V; Rolland, E; Bricaire, F; Caumes, E			Tuberculous paravertebral abscess	LANCET			English	Editorial Material									Hop La Pitie Salpetriere, Dept Infect & Trop Dis, F-75651 Paris, France; Hop La Pitie Salpetriere, Dept Orthopaed, F-75651 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Martinez, V (corresponding author), Hop La Pitie Salpetriere, Dept Infect & Trop Dis, F-75651 Paris, France.								0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					615	615		10.1016/S0140-6736(04)15593-1	http://dx.doi.org/10.1016/S0140-6736(04)15593-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987886				2022-12-28	WOS:000189104900010
J	Perissi, V; Aggarwal, A; Glass, CK; Rose, DW; Rosenfeld, MG				Perissi, V; Aggarwal, A; Glass, CK; Rose, DW; Rosenfeld, MG			A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors	CELL			English	Article							EMBRYONIC STEM-CELLS; UBIQUITIN-DEPENDENT PROTEOLYSIS; IN-VITRO DIFFERENTIATION; GENE-EXPRESSION; COMBINATORIAL CONTROL; COREPRESSOR COMPLEX; SMRT COREPRESSOR; PROTEASOME; DEGRADATION; PATHWAY	The mechanisms that control the precisely regulated switch from gene repression to gene activation represent a central question in mammalian development Here, we report that transcriptional activation mediated by liganded nuclear receptors unexpectedly requires the actions of two highly related F box/WD-40-containing factors, TBL1 and TBLR1, initially identified as components of an N-CoR corepressor complex. TBL1/TBLR1 serve as specific adaptors for the recruitment of the ubiquitin conjugating/19S proteasome complex, with TBLR1 selectively serving to mediate a required exchange of the nuclear receptor corepressors, N-CoR and SMRT, for coactivators upon ligand binding. Tbl1 gene deletion in embryonic stem cells severely impairs PPARgamma-induced adipogenic differentiation, indicating that TBL1 function is also biologically indispensable for specific nuclear receptor-mediated gene activation events. The role of TBLR1 and TBL1 in cofactor exchange appears to also operate for c-Jun and NFkappaB and is therefore likely to be prototypic of similar mechanisms for other signal-dependent transcription factors.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Mol Pathol Grad Program, Sch Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Sch Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Sch Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Rose, DW (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dwrose@popmail.ucsd.edu; mrosenfeld@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Perissi, Valentina/0000-0002-3716-0003	Telethon [484/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Bassi MT, 1999, AM J HUM GENET, V64, P1604, DOI 10.1086/302408; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; Boulton SJ, 2000, EMBO J, V19, P5376, DOI 10.1093/emboj/19.20.5376; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Disteche CM, 1998, MAMM GENOME, V9, P1062, DOI 10.1007/s003359900926; Dong XZ, 1999, GENE DEV, V13, P954, DOI 10.1101/gad.13.8.954; FEMANDES I, 2003, MOL CELL, V11, P139; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glass CK, 2000, GENE DEV, V14, P121; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grimaldi PA, 2001, PROG LIPID RES, V40, P269, DOI 10.1016/S0163-7827(01)00005-4; Guenther MG, 2000, GENE DEV, V14, P1048; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jepsen K, 2002, J CELL SCI, V115, P689; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KIPREOS ET, 2000, GENOME BIOL, P1; Langston AW, 1997, J BIOL CHEM, V272, P2167, DOI 10.1074/jbc.272.4.2167; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li X, 2002, SCIENCE, V297, P1180; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Liu YY, 2002, ENDOCRINOLOGY, V143, P2664, DOI 10.1210/en.143.7.2664; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rosen ED, 2000, GENE DEV, V14, P1293; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sasik R, 2002, BIOINFORMATICS, V18, P1633, DOI 10.1093/bioinformatics/18.12.1633; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsuda L, 2002, CELL, V110, P625, DOI 10.1016/S0092-8674(02)00875-9; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yan F, 2003, MOL ENDOCRINOL, V17, P1315, DOI 10.1210/me.2002-0209; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	71	437	448	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					511	526		10.1016/S0092-8674(04)00133-3	http://dx.doi.org/10.1016/S0092-8674(04)00133-3			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980219	Bronze			2022-12-28	WOS:000189184200006
J	Raftopoulou, M; Etienne-Manneville, S; Self, A; Nicholls, S; Hall, A				Raftopoulou, M; Etienne-Manneville, S; Self, A; Nicholls, S; Hall, A			Regulation of cell migration by the C2 domain of the tumor suppressor PTEN	SCIENCE			English	Article							PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE-ACTIVITY; SIGNALING PATHWAY; CATALYTIC DOMAIN; PHOSPHORYLATION; INHIBITION; ACTIVATION; DELETION; GROWTH; SIZE	PTEN is a tumor suppressor protein that dephosphorylates phosphatidylinositol 3,4,5 trisphosphate and antagonizes the phosphatidylinositol-3 kinase signaling pathway. We show here that PTEN can also inhibit cell migration through its C2 domain, independent of its lipid phosphatase activity. This activity depends on the protein phosphatase activity of PTEN and on dephosphorylation at a single residue, threonine(383). The ability of PTEN to control cell migration through its C2 domain is likely to be an important feature of its tumor suppressor activity.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Cell Biol Unit, Canc Res UK Oncogene & Signal Transduct Grp, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk	Etienne-Manneville, Sandrine/C-5879-2015	Etienne-Manneville, Sandrine/0000-0001-6651-3675				Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Huang H, 1999, DEVELOPMENT, V126, P5365; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000	22	261	285	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1179	1181		10.1126/science.1092089	http://dx.doi.org/10.1126/science.1092089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976311				2022-12-28	WOS:000189074700042
J	Hiraga, T; Anderson, IM; Kohlstedt, DL				Hiraga, T; Anderson, IM; Kohlstedt, DL			Grain boundaries as reservoirs of incompatible elements in the Earth's mantle	NATURE			English	Article							SPINEL PERIDOTITE XENOLITHS; TRACE-ELEMENT; ENRICHMENT; MELTS; METASOMATISM; GEOCHEMISTRY; SEGREGATION; DIFFUSION; CHEMISTRY; EVOLUTION	The concentrations and locations of elements that strongly partition into the fluid phase in rocks provide essential constraints on geochemical and geodynamical processes in Earth's interior. A fundamental question remains, however, as to where these incompatible elements reside before formation of the fluid phase. Here we show that partitioning of calcium between the grain interiors and grain boundaries of olivine in natural and synthetic olivine-rich aggregates follows a thermodynamic model for equilibrium grain-boundary segregation. The model predicts that grain boundaries can be the primary storage sites for elements with large ionic radius-that is, incompatible elements in the Earth's mantle. This observation provides a mechanism for the selective extraction of these elements and gives a framework for interpreting geochemical signatures in mantle rocks.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Oak Ridge Natl Lab, Div Met & Ceram, Oak Ridge, TN 37831 USA	University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Oak Ridge National Laboratory	Hiraga, T (corresponding author), Tohoku Univ, Grad Sch Engn, Sendai, Miyagi 9808579, Japan.	hirag001@umn.edu						BEATTIE P, 1994, CHEM GEOL, V117, P57, DOI 10.1016/0009-2541(94)90121-X; BLUNDY J, 1994, NATURE, V372, P452, DOI 10.1038/372452a0; BRICE JC, 1975, J CRYST GROWTH, V28, P249, DOI 10.1016/0022-0248(75)90241-9; CLIFF G, 1975, J MICROSC-OXFORD, V103, P203, DOI 10.1111/j.1365-2818.1975.tb03895.x; FRASER DG, 1984, NATURE, V312, P352, DOI 10.1038/312352a0; FREY FA, 1978, EARTH PLANET SC LETT, V38, P129, DOI 10.1016/0012-821X(78)90130-9; GERMAN RM, 1986, INT J POWDER METALL, V22, P31; HAURI EH, 1994, CHEM GEOL, V117, P149, DOI 10.1016/0009-2541(94)90126-0; Hiraga T, 2003, AM MINERAL, V88, P1015, DOI 10.2138/am-2003-0709; Hiraga T, 2002, CONTRIB MINERAL PETR, V144, P163, DOI 10.1007/s00410-002-0394-1; IONOV DA, 1992, CONTRIB MINERAL PETR, V111, P235, DOI 10.1007/BF00348954; ISAAK DG, 1992, J GEOPHYS RES-SOL EA, V97, P1871, DOI 10.1029/91JB02675; JOHNSON WC, 1977, METALL TRANS A, V8, P1413, DOI 10.1007/BF02642854; KINGERY WD, 1974, J AM CERAM SOC, V57, P74, DOI 10.1111/j.1151-2916.1974.tb10818.x; LI CW, 1985, ADV CERAM, P368; MAURY RC, 1992, NATURE, V360, P661, DOI 10.1038/360661a0; MCLEAN D, 1957, GRAIN BOUNDARIES MET, P346; MENZIES MM, 1978, EARTH PLANET SC LETT, V38, P346, DOI 10.1016/0012-821X(78)90108-5; Nakamura M, 2001, GEOFLUIDS, V1, P73, DOI 10.1046/j.1468-8123.2001.00007.x; OTTONELLO G, 1980, GEOCHIM COSMOCHIM AC, V44, P1885, DOI 10.1016/0016-7037(80)90237-9; Oxburgh E.R., 1964, GEOL MAG, V101, P1; Purton JA, 1996, GEOCHIM COSMOCHIM AC, V60, P4977, DOI 10.1016/S0016-7037(96)00300-6; SHERVAIS JW, 1979, J PETROL, V20, P795, DOI 10.1093/petrology/20.4.795; STOSCH HG, 1986, GEOCHIM COSMOCHIM AC, V50, P2601, DOI 10.1016/0016-7037(86)90213-9; SUZUKI K, 1987, CHEM GEOL, V63, P319, DOI 10.1016/0009-2541(87)90169-0; TAKEUCHI Y, 1984, MAT SCI EARTHS INTER, P191; Tan BH, 2001, PHYS CHEM MINER, V28, P641, DOI 10.1007/s002690100189; Van Orman JA, 1998, EARTH PLANET SC LETT, V160, P505, DOI 10.1016/S0012-821X(98)00107-1; WAFF HS, 1981, J GEOPHYS RES, V86, P3677, DOI 10.1029/JB086iB05p03677; Wang WY, 2000, J GEOPHYS RES-SOL EA, V105, P2855, DOI 10.1029/1999JB900366; Watson E.B, 1991, CONTINENTAL MANTLE, P111; Xu XS, 2003, CHEM GEOL, V198, P163, DOI 10.1016/S0009-2541(03)00004-4; Yan Y, 1998, J ELECTRON MICROSC, V47, P115, DOI 10.1093/oxfordjournals.jmicro.a023567; Zanetti A, 1999, CONTRIB MINERAL PETR, V134, P107, DOI 10.1007/s004100050472; ZINDLER A, 1988, GEOCHIM COSMOCHIM AC, V52, P319, DOI 10.1016/0016-7037(88)90087-7	35	143	146	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	2004	427	6976					699	703		10.1038/nature02259	http://dx.doi.org/10.1038/nature02259			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973476				2022-12-28	WOS:000189026000034
J	Sheridan, RL; Schulz, JT; McGinnis, PJ; Ryan, CM; Harris, NL				Sheridan, RL; Schulz, JT; McGinnis, PJ; Ryan, CM; Harris, NL			Case 6-2004: A 35-year-old woman with extensive, deep burns from a nightclub fire	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPERBARIC-OXYGEN; MANAGEMENT; RESUSCITATION; CHILDREN		Massachusetts Gen Hosp, Burn Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Trauma Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Shriners Hosp Children, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Sheridan, RL (corresponding author), Massachusetts Gen Hosp, Burn Serv, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X				American Burn Association, 2003, J Am Coll Surg, V196, P307; Artz CP, 1969, TREATMENT BURNS, P1; Cartotto RC, 2002, J BURN CARE REHABIL, V23, P258, DOI 10.1097/00004630-200207000-00006; Iliopoulou E., 1993, Archives d'Anatomie et de Cytologie Pathologiques, V41, P5; LINN BS, 1977, J SURG RES, V23, P1, DOI 10.1016/0022-4804(77)90180-9; Mayhall CG, 2003, CLIN INFECT DIS, V37, P543, DOI 10.1086/376993; Monafo WW, 1996, NEW ENGL J MED, V335, P1581, DOI 10.1056/NEJM199611213352108; ONAN S, 2000, CIR5CUS FIRE TRUE ST; Palmieri TL, 2002, CRIT CARE MED, V30, P922, DOI 10.1097/00003246-200204000-00036; Rosenkranz KM, 2002, BURNS, V28, P665, DOI 10.1016/S0305-4179(02)00109-2; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; RYAN CM, 2002, J BURN CARE REHABI S, V23, pS156; SAFFLE JR, 1993, AM J SURG, V166, P581, DOI 10.1016/S0002-9610(05)80661-0; SHERIDAN RL, 1994, J TRAUMA, V36, P301, DOI 10.1097/00005373-199403000-00003; Sheridan RL, 2000, JAMA-J AM MED ASSOC, V283, P69, DOI 10.1001/jama.283.1.69; Sheridan RL, 1999, J TRAUMA, V47, P426, DOI 10.1097/00005373-199908000-00045; SHERIDAN RL, 1995, J TRAUMA, V38, P406, DOI 10.1097/00005373-199503000-00022; Sheridan RL, 1997, J TRAUMA, V42, P629, DOI 10.1097/00005373-199704000-00008; Sheridan RL, 2000, ARCH PEDIAT ADOL MED, V154, P245, DOI 10.1001/archpedi.154.3.245; Sheridan RL, 2003, JAMA-J AM MED ASSOC, V290, P719, DOI 10.1001/jama.290.6.719; Sheridan RL, 1999, BURNS, V25, P97, DOI 10.1016/S0305-4179(98)00176-4; Sheridan RL, 2001, CURR PROB SURG, V38, P657, DOI 10.1067/msg.2001.115979; Shirani KZ, 1996, SHOCK, V5, P4; THOMPSON P, 1987, J TRAUMA, V27, P205, DOI 10.1097/00005373-198702000-00019; Underhill FP, 1930, J AMER MED ASSOC, V95, P852, DOI 10.1001/jama.1930.02720120020006; WARDEN GD, 1992, WORLD J SURG, V16, P16, DOI 10.1007/BF02067109; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Willebrand M, 2002, BURNS, V28, P549, DOI 10.1016/S0305-4179(02)00064-5; WINERMURAM HT, 1995, RADIOLOGY, V195, P247, DOI 10.1148/radiology.195.1.7892480; Yu YM, 1999, JPEN-PARENTER ENTER, V23, P160, DOI 10.1177/0148607199023003160	30	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					810	821		10.1056/NEJMcpc049001	http://dx.doi.org/10.1056/NEJMcpc049001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973211				2022-12-28	WOS:000189006400011
J	Thomas, JM; Newton-Bishop, J; A'Hern, R; Coombes, G; Timmons, M; Evans, J; Cook, M; Theaker, J; Fallowfield, M; O'Neill, T; Ruka, W; Bliss, JM				Thomas, JM; Newton-Bishop, J; A'Hern, R; Coombes, G; Timmons, M; Evans, J; Cook, M; Theaker, J; Fallowfield, M; O'Neill, T; Ruka, W; Bliss, JM		United Kingdom Melanoma Study Grp; British Assoc Plastic Surg; Scottish Canc Therapy Network	Excision margins in high-risk malignant melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN JOINT COMMITTEE; LYMPH-NODE DISSECTION; CUTANEOUS MELANOMA; INTERFERON-ALPHA; FOLLOW-UP; MANAGEMENT; CM; RECURRENCES; GUIDELINES; FREQUENCY	Background: Controversy exists concerning the necessary margin of excision for cutaneous melanoma 2 mm or greater in thickness. Methods: We conducted a randomized clinical trial comparing 1-cm and 3-cm margins. Results: Of the 900 patients who were enrolled, 453 were randomly assigned to undergo surgery with a 1-cm margin of excision and 447 with a 3-cm margin of excision; the median follow-up was 60 months. A 1-cm margin of excision was associated with a significantly increased risk of locoregional recurrence. There were 168 locoregional recurrences (as first events) in the group with 1-cm margins of excision, as compared with 142 in the group with 3-cm margins (hazard ratio, 1.26; 95 percent confidence interval, 1.00 to 1.59; P=0.05). There were 128 deaths attributable to melanoma in the group with 1-cm margins, as compared with 105 in the group with 3-cm margins (hazard ratio, 1.24; 95 percent confidence interval, 0.96 to 1.61; P=0.1); overall survival was similar in the two groups (hazard ratio for death, 1.07; 95 percent confidence interval, 0.85 to 1.36; P=0.6). Conclusions: A 1-cm margin of excision for melanoma with a poor prognosis (as defined by a tumor thickness of at least 2 mm) is associated with a significantly greater risk of regional recurrence than is a 3-cm margin, but with a similar overall survival rate.	Royal Marsden Hosp Natl Hlth Serv Trust, London, England; Canc Res UK, Ctr Clin, Div Genet Epidemiol, Leeds, W Yorkshire, England; Inst Canc Res, Surrey, England; Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England; Nuffield Hosp, Plymouth, Devon, England; Royal Surrey Hosp, Guildford, Surrey, England; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Broomfield Hosp, Colchester, Essex, England; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England; Marie Sklodowska Curie Mem Canc Ctr, Warsaw, Poland	Royal Marsden NHS Foundation Trust; Cancer Research UK; University of London; Institute of Cancer Research - UK; Bradford Royal Infirmary; Royal Surrey County Hospital; University of Southampton; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Maria Sklodowska-Curie National Research Institute of Oncology	Thomas, JM (corresponding author), Royal Marsden NHS Trust, Fulham Rd, London SW3 7JJ, England.			Newton-Bishop, Julia/0000-0001-9147-6802; A'Hern, Roger/0000-0003-0593-8391; Bliss, Judith/0000-0001-7957-7424				Balch CM, 2002, ANZ J SURG, V72, P251, DOI 10.1046/j.1445-2197.2002.02374.x; Balch CM, 2001, ANN SURG ONCOL, V8, P101, DOI 10.1007/s10434-001-0101-x; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Bishop JAN, 2002, BRIT J PLAST SURG, V55, P46, DOI 10.1054/bjps.2001.3745; Breslow A, 1980, Pathol Annu, V15, P1; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D; COX DR, 1972, J R STAT SOC B, V34, P187; Dong XD, 2000, CANCER-AM CANCER SOC, V88, P1063, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E; ELDER DE, 1991, MELANOCYTIC TUMORS S, P103; Essner R, 1999, ANN SURG ONCOL, V6, P442, DOI 10.1007/s10434-999-0442-4; Estourgie SH, 2003, ANN SURG ONCOL, V10, P681, DOI 10.1245/ASO.2003.01.023; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaufmann R, 2000, CLIN EXP DERMATOL, V25, P476, DOI 10.1046/j.1365-2230.2000.00691.x; Kroon BBR, 1999, MELANOMA RES, V9, P207, DOI 10.1097/00008390-199906000-00001; Kroon BBR, 2000, ANN CHIR GYNAECOL, V89, P242; LAKHANI S, 1990, BRIT J CANCER, V61, P330, DOI 10.1038/bjc.1990.65; Lens MB, 2002, J CLIN ONCOL, V20, P1818, DOI 10.1200/JCO.2002.07.070; MCCARTHY WH, 1988, SURG GYNECOL OBSTET, V166, P497; Muller MGS, 2002, WORLD J SURG, V26, P1405, DOI 10.1007/s00268-002-6197-8; *NAT HLTH MED RES, 1999, MAN CUT MEL CLIN PRA; Shen P, 2000, ANN SURG ONCOL, V7, P114, DOI 10.1007/s10434-000-0114-x; STEHLIN JS, 1966, SURG GYNECOL OBSTETR, V122, P3; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; VERONESI U, 1991, NEW ENGL J MED, V325, P292; Wheatley K, 2003, CANCER TREAT REV, V29, P241, DOI 10.1016/S0305-7372(03)00074-4	26	289	305	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					757	766		10.1056/NEJMoa030681	http://dx.doi.org/10.1056/NEJMoa030681			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973217				2022-12-28	WOS:000189006400004
J	Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R				Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R		Heart Protect Study Collaborat	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions	LANCET			English	Article							HEALTH-CARE PROFESSIONALS; CORONARY-HEART-DISEASE; CAROTID ATHEROSCLEROSIS; PRIMARY PREVENTION; ISCHEMIC-STROKE; MORTALITY; PRAVASTATIN; STATINS; MEN; REDUCTION	Background Lower blood cholesterol concentrations have consistently been found to be strongly associated with lower risks of coronary disease but not with lower risks of stroke. Despite this observation, previous randomised trials had indicated that cholesterol-lowering statin therapy reduces the risk of stroke, but large-scale prospective confirmation has been needed. Methods 3280 adults with cerebrovascular disease, and an additional 17 256 with other occlusive arterial disease or diabetes, were randomly allocated 40 mg simvastatin daily or matching placebo. Subgroup analyses were prespecified of first "major vascular event" (ie, non-fatal myocardial infarction or coronary death, stroke of any type, or any revascularisation procedure) in prior disease subcategories. Subsidiary outcomes included any stroke, and stroke subtype. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, "intention-to-treat"), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period. Findings Overall, there was a highly significant 25% (95% CI 15-34) proportional reduction in the first event rate for stroke (444 [4.3%] simvastatin vs 585 [5.7%] placebo; p<0.0001), reflecting a definite 28% (19-37) reduction in presumed ischaemic strokes (p<0.0001) and no apparent difference in strokes attributed to haemorrhage (51 [0.5%] vs 53 [0.5%]; rate ratio 0.95 [0.65-1.40]; p=0.8). In addition, simvastatin reduced the numbers having transient cerebral ischaemic attacks alone (2.0% vs 2.4%; p=0.02) or requiring carotid endarterectomy or angioplasty (0.4% vs 0.8%; p=0.0003). The reduction in stroke was not significant during the first year, but was already significant (p=0.0004) by the end of the second year. Among patients with pre-existing cerebrovascular disease there was no apparent reduction in the stroke rate, but there was a highly significant 20% (8-29) reduction in the rate of any major vascular event (406 [24.7%] vs 488 [29.8%]; p=0.001). The proportional reductions in stroke were about one-quarter in each of the other subcategories of participant studied, including: those with coronary disease or diabetes; those aged under or over 70 years at entry; and those presenting with different levels of blood pressure or lipids (even when the pretreatment LDL cholesterol was below 3.0 mmol/L [116 mg/dL]). Interpretation Much larger numbers of people in the present study suffered a stroke than in any previous cholesterol-lowering trial. The results demonstrate that statin therapy rapidly reduces the incidence not only of coronary events but also of ischaemic strokes, with no apparent effect on cerebral haemorrhage, even among individuals who do not have high cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rate of ischaemic strokes by about one-quarter and so, after making allowance for noncompliance in the trial, actual use of this regimen would probably reduce the stroke rate by about a third. HIPS also provides definitive evidence that statin therapy is beneficial for people with pre-existing cerebrovascular disease, even if they do not already have manifest coronary disease.	Radcliffe Infirm, Heart Protect Study, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), Radcliffe Infirm, Heart Protect Study, Clin Trial Serv Unit, Harkness Bldg, Oxford OX2 6HE, England.		Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679				*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; Amarenco P, 2001, NEUROLOGY, V57, pS35, DOI 10.1212/WNL.57.suppl_2.S35; [Anonymous], 1995, Am J Cardiol, V75, P1130; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Byington RP, 2001, CIRCULATION, V103, P387; Campeau L, 1997, NEW ENGL J MED, V336, P153; Chen J., 1990, DIET LIFE STYLE MORT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Collins R, 2003, LANCET, V361, P2005; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Di Mascio R, 2000, CEREBROVASC DIS, V10, P85, DOI 10.1159/000016035; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Gaist D, 2002, NEUROLOGY, V58, P1333, DOI 10.1212/WNL.58.9.1333; Gaist D, 2001, EUR J CLIN PHARMACOL, V56, P931, DOI 10.1007/s002280000248; GISSI Prevenzione Investigators, 2000, ITAL HEART J, V1, P810; Goldstein LB, 2001, CIRCULATION, V103, P163; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HEBERT PR, 1995, ARCH INTERN MED, V155, P50, DOI 10.1001/archinte.155.1.50; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; MacMahon S, 1998, CIRCULATION, V97, P1784, DOI 10.1161/01.CIR.97.18.1784; Meade T, 1999, EUR HEART J, V20, P725; MURRAY CJL, 1996, GLOBAL PATTERN CAUSE; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Qizilbash N, 1995, LANCET, V346, P1647; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Rodgers A, 1998, LANCET, V352, P1801; Sandercock P, 2001, LANCET, V357, P1548, DOI 10.1016/S0140-6736(00)04779-6; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sillesen H, 2003, CEREBROVASC DIS, V16, P389, DOI 10.1159/000072562; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Wagstaff LR, 2003, PHARMACOTHERAPY, V23, P871, DOI 10.1592/phco.23.7.871.32720; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991; Zhang X, 2003, INT J EPIDEMIOL, V32, P563, DOI 10.1093/ije/dyg106	51	804	847	0	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					757	767						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016485				2022-12-28	WOS:000220092000006
J	Fonseca, DM; Keyghobadi, N; Malcolm, CA; Mehmet, C; Schaffner, F; Mogi, M; Fleischer, RC; Wilkerson, RC				Fonseca, DM; Keyghobadi, N; Malcolm, CA; Mehmet, C; Schaffner, F; Mogi, M; Fleischer, RC; Wilkerson, RC			Emerging vectors in the Culex pipiens complex	SCIENCE			English	Article							WEST-NILE-VIRUS; NEW-YORK-CITY; MOSQUITOS; CULICIDAE; DIPTERA; QUINQUEFASCIATUS; POPULATIONS; INFECTION; BIRDS	In the Old World, some mosquitoes in the Culex pipiens complex are excellent enzootic vectors of West Nile virus, circulating the virus among birds, whereas others bite mainly humans and other mammals. Here we show that, in northern Europe, such forms differing in behavior and physiology have unique microsatellite fingerprints with no evidence of gene flow between them, as would be expected from distinct species. In the United States, however, hybrids between these forms are ubiquitous. Such hybrids between human-biters and bird-biters may be the bridge vectors contributing to the unprecedented severity and range of the West Nile virus epidemic in North America.	Smithsonian Inst, Natl Museum Nat Hist, Genet Program, Washington, DC 20008 USA; Walter Reed Army Inst Res, Dept Entomol, Div Communicable Dis & Immunol, Silver Spring, MD 20910 USA; Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England; Adege, Entente Interdept Demousticat Mediterranee, F-34184 Montpellier 4, France; Saga Med Sch, Dept Microbiol, Div Parasitol, Saga 8498501, Japan	Smithsonian Institution; Smithsonian National Museum of Natural History; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of London; Queen Mary University London; Saga University	Fonseca, DM (corresponding author), Acad Nat Sci Philadelphia, 1900 Benjamin Franklin Pkwy, Philadelphia, PA 19103 USA.	fonseca@acnatsci.org	Fonseca, Dina Madeira/B-9951-2011; Fonseca, Dina/HHS-1320-2022	Fonseca, Dina Madeira/0000-0003-4726-7100; Schaffner, Francis/0000-0001-9166-7617	NIGMS NIH HHS [1R01GM063258] Funding Source: Medline; ODCDC CDC HHS [U50/CCU220532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063258] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ODCDC CDC HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR AR, 1957, AM J TROP MED HYG, V6, P153, DOI 10.4269/ajtmh.1957.6.153; Bernard KA, 2001, EMERG INFECT DIS, V7, P679; Byrne K, 1999, HEREDITY, V82, P7, DOI 10.1038/sj.hdy.6884120; Cavalli-Sforza LL, 1995, GREAT HUMAN DIASPORA; CHEVILLON C, 1995, GENET RES, V66, P147, DOI 10.1017/S0016672300034492; Cornel AJ, 2003, J MED ENTOMOL, V40, P36, DOI 10.1603/0022-2585-40.1.36; Crook P D, 2002, Commun Dis Public Health, V5, P138; De Zulueta J., 1994, Parassitologia (Rome), V36, P7; Dohm DJ, 2002, J MED ENTOMOL, V39, P640, DOI 10.1603/0022-2585-39.4.640; DRUMMOND F. H., 1951, The Culex pipiens Complex in Australia., P369; Fonseca DM, 1998, MOL ECOL, V7, P1617; Guillemaud T, 1997, P ROY SOC B-BIOL SCI, V264, P245, DOI 10.1098/rspb.1997.0035; HARBACH RE, 1985, P ENTOMOL SOC WASH, V87, P1; HARBACH RE, 1984, P ENTOMOL SOC WASH, V86, P521; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Hubalek Z, 2000, VIRAL IMMUNOL, V13, P415, DOI 10.1089/vim.2000.13.415; Keyghobadi N, 2004, MOL ECOL NOTES, V4, P20, DOI 10.1046/j.1471-8286.2003.00557.x; Knight K. L., 1978, CATALOG MOSQUITOES S, V6; Kulasekera VL, 2001, EMERG INFECT DIS, V7, P722, DOI 10.3201/eid0704.010421; MATTINGLY P. F., 1951, TRANS ROY ENT SOC LONDON, V102, P331; Nasci RS, 2001, EMERG INFECT DIS, V7, P742; Pritchard JK, 2000, GENETICS, V155, P945; Richards A. G. jr., 1941, Entomological News Philadelphia, V52, P211; Savage HM, 1999, AM J TROP MED HYG, V61, P600, DOI 10.4269/ajtmh.1999.61.600; Spielman A, 2001, ANN NY ACAD SCI, V951, P220; TANAKA K, 1979, Contributions of the American Entomological Institute, V16, P1; Turell MJ, 2001, J MED ENTOMOL, V38, P130, DOI 10.1603/0022-2585-38.2.130; Urbanelli S, 1997, J MED ENTOMOL, V34, P116, DOI 10.1093/jmedent/34.2.116; Urbanelli S., 1981, EC ATT 1 C NAZ ZAR, P305; Vinagradova E. B., 2000, CULEX PIPIENS PIPIEN; Zhang DX, 2003, MOL ECOL, V12, P563, DOI 10.1046/j.1365-294X.2003.01773.x	31	344	362	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	2004	303	5663					1535	1538		10.1126/science.1094247	http://dx.doi.org/10.1126/science.1094247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001783				2022-12-28	WOS:000220000100048
J	Mitchell, WJ				Mitchell, WJ			Beyond the ivory tower - Constructing complexity in the digital age	SCIENCE			English	Editorial Material									MIT, Sch Architecture & Planning, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Mitchell, WJ (corresponding author), MIT, Sch Architecture & Planning, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	wjm@mit.edu						CHAITIN GJ, 1974, IEEE T INFORM THEORY, V20, P10, DOI 10.1109/TIT.1974.1055172; CHAITIN GJ, 1970, IEEE T INFORM THEORY, V16, P5, DOI 10.1109/TIT.1970.1054390; KOLMOGOROV AN, 1968, IEEE T INFORM THEORY, V14, P662, DOI 10.1109/TIT.1968.1054210; Mitchell W.J., 2001, F GEHRY ARCHITECT, P352; MITCHELL WJ, 1988, ART COMPUTER GRAPHIC	5	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	2004	303	5663					1472	1473						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001762				2022-12-28	WOS:000220000100024
J	Neil, HAW; Hammond, T; Mant, D; Humphries, SE				Neil, HAW; Hammond, T; Mant, D; Humphries, SE			Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002	BRITISH MEDICAL JOURNAL			English	Article									Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7HJ, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England; UCL Royal Free & UCL Med Sch, British Heart Fdn Lab, Ctr Cardiovasc Genet, London WC1E 6JJ, England	University of Oxford; University of Oxford; University of London; University College London	Neil, HAW (corresponding author), Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7HJ, England.	andrew.neil@wolfson.ox.ac.uk	Humphries, Stephen E/C-5075-2008; Mant, David CA/C-7763-2009	Humphries, Stephen E/0000-0002-8221-6547				Mayor S, 2001, BRIT MED J, V323, P1021, DOI 10.1136/bmj.323.7320.1021; Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105; NEIL HAW, 1991, BRIT MED J, V302, P891, DOI 10.1136/bmj.302.6781.891; Neil HAW, 2000, BRIT MED J, V321, P148, DOI 10.1136/bmj.321.7254.148; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476	5	21	22	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					500	501		10.1136/bmj.328.7438.500	http://dx.doi.org/10.1136/bmj.328.7438.500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988185	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000220002900026
J	Aho, AV				Aho, AV			Software and the future of programming languages	SCIENCE			English	Editorial Material								Although software is the key enabler of the global information infrastructure, the amount and extent of software in use in the world today are not widely understood, nor are the programming languages and paradigms that have been used to create the software. The vast size of the embedded base of existing software and the increasing costs of software maintenance, poor security, and limited functionality are posing significant challenges for the software RD community.	Columbia Univ, Dept Comp Sci, New York, NY 10027 USA	Columbia University	Aho, AV (corresponding author), Columbia Univ, Dept Comp Sci, New York, NY 10027 USA.	aho@cs.columbia.edu						BRILLIANT SS, 1990, IEEE T SOFTWARE ENG, V16, P238, DOI 10.1109/32.44387; NYGAARD K, 1981, ACM MONOGRAPH SERIES, P439; OSTERHOUT J, 1998, HIGHER LEVEL PROGRAM, P23; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x	5	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1331	1333		10.1126/science.1096169	http://dx.doi.org/10.1126/science.1096169			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988553				2022-12-28	WOS:000189238600039
J	Graddol, D				Graddol, D			The future of language	SCIENCE			English	Editorial Material								The world's language system is undergoing rapid change because of demographic trends, new technology, and international communication. These changes will affect both written and spoken communication. English may not be the dominant language of the future, and the need to be multilingual will be enhanced. Although many languages are going extinct, new ones are emerging in cities and extended social groups.	English Co UK Ltd, Milton Keynes MK12 5AF, Bucks, England		Graddol, D (corresponding author), English Co UK Ltd, 2 Western Rd, Milton Keynes MK12 5AF, Bucks, England.	david@english.co.uk						Chomsky N., 2002, JANUA LINGUARUM; Crystal David, 1995, CAMBRIDGE ENCY ENGLI; *EUR COMM, 2000, STAND EUR, P52; GRADDOL D, 1994, ENGLISH HIST DIVERSI, P136; Graddol D., 2000, GUIDE FORECASTING PO, V2nd ed.; Graddol D., 1999, AILA REV, V13, P57; SAPIR E, 1921, LANGUAGE, P39; SEBEOK TA, 1985, SIGNS, P448	8	72	75	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1329	1331		10.1126/science.1096546	http://dx.doi.org/10.1126/science.1096546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988552				2022-12-28	WOS:000189238600038
J	Cattin, MF; Bersier, LF; Banasek-Richter, C; Baltensperger, R; Gabriel, JP				Cattin, MF; Bersier, LF; Banasek-Richter, C; Baltensperger, R; Gabriel, JP			Phylogenetic constraints and adaptation explain food-web structure	NATURE			English	Article							CONNECTANCE; STABILITY; PATTERNS	Food webs are descriptions of who eats whom in an ecosystem. Although extremely complex and variable, their structure possesses basic regularities(1-6). A fascinating question is to find a simple model capturing the underlying processes behind these repeatable patterns. Until now, two models have been devised for the description of trophic interactions within a natural community(7,8). Both are essentially based on the concept of ecological niche, with the consumers organized along a single niche dimension; for example, prey size(8,9). Unfortunately, they fail to describe adequately recent and high-quality data. Here, we propose a new model built on the hypothesis that any species' diet is the consequence of phylogenetic constraints and adaptation. Simple rules incorporating both concepts yield food webs whose structure is very close to real data. Consumers are organized in groups forming a nested hierarchy, which better reflects the complexity and multidimensionality of most natural systems.	Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland; Swiss Fed Inst Technol, Dept Math, Chair Stat, CH-1015 Lausanne, Switzerland; Univ Fribourg, Dept Math, CH-1700 Fribourg, Switzerland	University of Neuchatel; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Fribourg	Bersier, LF (corresponding author), Univ Neuchatel, Inst Zool, Rue Emile Argand 11,CP2, CH-2007 Neuchatel, Switzerland.	louis-felix.bersier@unine.ch	Bersier, Louis-Félix/G-8018-2011	Bersier, Louis-Félix/0000-0001-9552-8032				BAIRD D, 1989, ECOL MONOGR, V59, P329, DOI 10.2307/1943071; Bersier LF, 1997, P NATL ACAD SCI USA, V94, P1247, DOI 10.1073/pnas.94.4.1247; Cohen J.E., 1990, COMMUNITY FOOD WEBS; Cohen JE, 2003, P NATL ACAD SCI USA, V100, P1781, DOI 10.1073/pnas.232715699; COHEN JE, 1985, PROC R SOC SER B-BIO, V224, P449, DOI 10.1098/rspb.1985.0043; COHEN JE, 1978, FOOD WEBS NICHE SPAC; COUSINS SH, 1985, CAN B FISH AQUAT SCI, V213, P76; DEANGELIS DL, 1975, ECOLOGY, V56, P238; Diamond J.M., 1975, P342; GARDNER MR, 1970, NATURE, V228, P784, DOI 10.1038/228784a0; GOLDWASSER L, 1993, ECOLOGY, V74, P1216, DOI 10.2307/1940492; HALL SJ, 1991, J ANIM ECOL, V60, P823, DOI 10.2307/5416; HAVENS K, 1992, SCIENCE, V257, P1107, DOI 10.1126/science.257.5073.1107; Jaccard P., 1908, B SOC VAUD SCI N, V44, P223; Kondoh M, 2003, SCIENCE, V299, P1388, DOI 10.1126/science.1079154; LAWTON JH, 1988, TRENDS ECOL EVOL, V3, P242, DOI 10.1016/0169-5347(88)90167-X; Legendre P., 2012, NUMERICAL ECOLOGY; MARTINEZ ND, 1991, ECOL MONOGR, V61, P367, DOI 10.2307/2937047; MARTINEZ ND, 1992, AM NAT, V139, P1208, DOI 10.1086/285382; May R.M., 1974, STABILITY COMPLEXITY; PIMM SL, 1982, FOOD WEBS; POLIS GA, 1991, AM NAT, V138, P123, DOI 10.1086/285208; Price P.W., 2003, MACROEVOLUTIONARY TH; Solow AR, 1998, ECOLOGY, V79, P2013, DOI 10.1890/0012-9658(1998)079[2013:OLSIFW]2.0.CO;2; Sugihara G, 2003, P NATL ACAD SCI USA, V100, P5246, DOI 10.1073/pnas.0831096100; Sugihara G., 1982, THESIS PRINCETON U P; SUGIHARA G, 1984, POPULATION BIOL, P83; WARREN PH, 1989, OIKOS, V55, P299, DOI 10.2307/3565588; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572	29	263	273	3	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					835	839		10.1038/nature02327	http://dx.doi.org/10.1038/nature02327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985761	Green Published			2022-12-28	WOS:000189207500039
J	Peiris, JSM; Yu, WC; Leung, CW; Cheung, CY; Ng, WF; Nicholls, JM; Ng, TK; Chan, KH; Lai, ST; Lim, WL; Yuen, KY; Guan, Y				Peiris, JSM; Yu, WC; Leung, CW; Cheung, CY; Ng, WF; Nicholls, JM; Ng, TK; Chan, KH; Lai, ST; Lim, WL; Yuen, KY; Guan, Y			Re-emergence of fatal human influenza A subtype H5N1 disease	LANCET			English	Article							VIRUS	Human disease associated with influenza A subtype H5N1 re-emerged in January, 2003, for the first time since an outbreak in Hong Kong in 1997. Patients with H5N1 disease had unusually high serum concentrations of chemokines (eg, interferon induced protein-10 [IP-10] and monokine induced by interferon gamma [MIG]). Taken together with a previous report that H5N1 influenza viruses induce large amounts of proinflammatory cytokines from macrophage cultures in vitro, our findings suggest that cytokine dysfunction contributes to the pathogenesis of H5N1 disease. Development of vaccines against influenza A (H5N1) virus should be made a priority.	Univ Hong Kong, Dept Pathol & Microbiol, Pokfulam, Hong Kong, Peoples R China; Queen Mary Hosp, Pokfulam, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Intens Care, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Peiris, JSM (corresponding author), Univ Hong Kong, Dept Pathol & Microbiol, Pokfulam, Hong Kong, Peoples R China.	malik@hkucc.hku.hk	Chan, Kwok Hung/ABD-5399-2021; Cheung, Chung Yan/C-4233-2009; Yuen, Kwok Yung/C-4465-2009; Nicholls, John Malcolm/C-4375-2009	Nicholls, John Malcolm/0000-0001-7217-7444; Guan, Yi/0000-0001-6057-9243; Yuen, Kwok-yung/0000-0002-2083-1552	NIAID NIH HHS [N01AI95357, AI95357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; World Health Organization, CONF HUM CAS AV INFL; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	6	596	685	0	73	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					617	619		10.1016/S0140-6736(04)15595-5	http://dx.doi.org/10.1016/S0140-6736(04)15595-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987888	Green Published, Bronze			2022-12-28	WOS:000189104900012
J	van den Heuvel, EPJ				van den Heuvel, EPJ			Double pulsar jackpot	SCIENCE			English	Editorial Material							BINARY PULSAR; PSR 1913&16; ORIGIN		Univ Amsterdam, Inst Astron, NL-1098 SJ Amsterdam, Netherlands; Univ Amsterdam, Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam	van den Heuvel, EPJ (corresponding author), Univ Amsterdam, Inst Astron, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.	edvdh@science.uva.nl	van den Heuvel, Edward P.J./C-1262-2018					BHATTACHARYA D, 1991, PHYS REP, V203, P1, DOI 10.1016/0370-1573(91)90064-S; Bisnovatyi-Kogan G. S., 1974, Soviet Astronomy, V18, P217; Burgay M, 2003, NATURE, V426, P531, DOI 10.1038/nature02124; FLANNERY BP, 1975, ASTRON ASTROPHYS, V39, P61; Kim C, 2003, ASTROPHYS J, V584, P985, DOI 10.1086/345740; Lyne A. G., 1990, PULSAR ASTRONOMY; Lyne AG, 2004, SCIENCE, V303, P1153, DOI 10.1126/science.1094645; RADHAKRISHNAN V, 1982, CURR SCI INDIA, V51, P1096; SMARR LL, 1976, ASTROPHYS J, V207, P574, DOI 10.1086/154524; SRINIVASAN G, 1982, ASTRON ASTROPHYS, V108, P143; TAYLOR JH, 1994, REV MOD PHYS, V66, P711, DOI 10.1103/RevModPhys.66.711	12	22	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1143	1144		10.1126/science.1095394	http://dx.doi.org/10.1126/science.1095394			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976299				2022-12-28	WOS:000189074700029
J	Beyrer, C				Beyrer, C			Is trafficking a health issue?	LANCET			English	Editorial Material									Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Beyrer, C (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	cbeyrer@jhsph.edu						Gushulak B D, 2000, J Immigr Health, V2, P67, DOI 10.1023/A:1009581817682; ZIMMERMAN C, 2003, HLTH REISKS CONSEQUE	2	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					564	564		10.1016/S0140-6736(04)15546-3	http://dx.doi.org/10.1016/S0140-6736(04)15546-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14976979				2022-12-28	WOS:000188999900025
J	Loff, B; Sanghera, J				Loff, B; Sanghera, J			Distortions and difficulties in data for trafficking	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3800, Australia; UN Off High Commissioner Human Rights, Geneva, Switzerland	Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3800, Australia.	Bebe.Loff@Med.monash.edu.au	Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503				[Anonymous], TRAFF STAT PROJ; DANDREA LA, 2002, RES SEX WORK    0605, P30; UN, 2000, PROT PREV SUPPR PUN	3	22	23	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					566	566		10.1016/S0140-6736(04)15548-7	http://dx.doi.org/10.1016/S0140-6736(04)15548-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975621				2022-12-28	WOS:000188999900027
J	Halme, A; Bumgarner, S; Styles, C; Fink, GR				Halme, A; Bumgarner, S; Styles, C; Fink, GR			Genetic and epigenetic regulation of the FLO gene family generates cell-surface variation in yeast	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; ANTIGENIC VARIATION; INVASIVE GROWTH; SIR PROTEINS; EXPRESSION; MUTATIONS; KINASE; GLYCOPROTEIN; INFORMATION	The FLO gene family of Saccharomyces cerevisiae includes an expressed gene, FLO11, and a set of silent, telomere-adjacent FLO genes. This gene family encodes cell-wall glycoproteins that regulate cell-cell and cell-surface adhesion. Epigenetic silencing of FLO11 regulates a key developmental switch: when FLO11 is expressed, diploid cells form pseudohyphal filaments; when FLO11 is silent, the cells grow in yeast form. The epigenetic state of FLO11 is heritable for many generations and regulated by the histone deacetylase (HDAC) Hda1p. The silent FLO10 gene is activated by high-frequency loss-of-function mutations at either IRA1 or IRA2. FLO10 is regulated by the same transcription factors that control FLO11: Sfl1p and Flo8p, but is silenced by a distinct set of HDACs: Hst1p and Hst2p. These sources of epigenetic and genetic variation explain the observed heterogeneity of cell-surface protein expression within a population of cells derived from a single clone.	Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.	gfink@wi.mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010, R01GM040266] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRANDRISS MC, 1979, J BACTERIOL, V140, P504, DOI 10.1128/JB.140.2.504-507.1979; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; Conlan RS, 2001, J MOL BIOL, V309, P1007, DOI 10.1006/jmbi.2001.4742; Cormack BP, 1999, SCIENCE, V285, P578, DOI 10.1126/science.285.5427.578; De las Penas A, 2003, GENE DEV, V17, P2245, DOI 10.1101/gad.1121003; Gagiano M, 1999, MOL MICROBIOL, V31, P103, DOI 10.1046/j.1365-2958.1999.01151.x; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; Guo B, 2000, P NATL ACAD SCI USA, V97, P12158, DOI 10.1073/pnas.220420397; HABER JE, 1979, GENETICS, V93, P13; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Howell-Adams B, 2000, MOL MICROBIOL, V37, P1146, DOI 10.1046/j.1365-2958.2000.02067.x; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; Jiang YW, 1996, GENE DEV, V10, P604, DOI 10.1101/gad.10.5.604; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kumar A, 2002, METHOD ENZYMOL, V350, P219, DOI 10.1016/S0076-6879(02)50965-4; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mehr IJ, 1998, MOL MICROBIOL, V30, P697, DOI 10.1046/j.1365-2958.1998.01089.x; MICHELS PAM, 1984, EMBO J, V3, P1345, DOI 10.1002/j.1460-2075.1984.tb01975.x; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Otto SP, 2002, ADV GENET, V46, P451; Pan XW, 2002, MOL CELL BIOL, V22, P3981, DOI 10.1128/MCB.22.12.3981-3993.2002; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1983, CELL, V35, P721, DOI 10.1016/0092-8674(83)90105-8; PAYS E, 1983, CELL, V34, P371, DOI 10.1016/0092-8674(83)90371-9; Reynolds TB, 2001, SCIENCE, V291, P878, DOI 10.1126/science.291.5505.878; RINE J, 1979, GENETICS, V93, P877; RINE J, 1987, GENETICS, V116, P9; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rose MD., 1990, METHODS YEAST GENETI; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saville SP, 2003, EUKARYOT CELL, V2, P1053, DOI 10.1128/EC.2.5.1053-1060.2003; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WEIDEN M, 1991, MOL CELL BIOL, V11, P3823, DOI 10.1128/MCB.11.8.3823; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	50	273	286	3	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					405	415		10.1016/S0092-8674(04)00118-7	http://dx.doi.org/10.1016/S0092-8674(04)00118-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016375	Bronze			2022-12-28	WOS:000188825800009
J	Li, YL; Kinloch, IA; Windle, AH				Li, YL; Kinloch, IA; Windle, AH			Direct spinning of carbon nanotube fibers from chemical vapor deposition synthesis	SCIENCE			English	Article							FILMS; STRANDS; RIBBONS	Many routes have been developed for the synthesis of carbon nanotubes, but their assembly into continuous fibers has been achieved only through post-processing methods. We spun fibers and ribbons of carbon nanotubes directly from the chemical vapor deposition (CVD) synthesis zone of a furnace using a liquid source of carbon and an iron nanocatalyst. This process was realized through the appropriate choice of reactants, control of the reaction conditions, and continuous withdrawal of the product with a rotating spindle used in various geometries. This direct spinning from a CVD reaction zone is extendable to other types of fiber and to the spin coating of rotating objects in general.	Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England	University of Cambridge	Windle, AH (corresponding author), Univ Cambridge, Dept Mat Sci & Met, Pembroke St, Cambridge CB2 3QZ, England.	ahw1@cam.ac.uk	Funde, Adinath M./D-8169-2012; Kinloch, Ian/AAI-3965-2021; Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; CALLISTER WD, 1997, MATER SCI ENG, P798; Casavant MJ, 2003, J APPL PHYS, V93, P2153, DOI 10.1063/1.1536732; Dalton AB, 2003, NATURE, V423, P703, DOI 10.1038/423703a; Davis VA, 2004, MACROMOLECULES, V37, P154, DOI 10.1021/ma0352328; Fischer JE, 2003, J APPL PHYS, V93, P2157, DOI 10.1063/1.1536733; Gommans HH, 2000, J APPL PHYS, V88, P2509, DOI 10.1063/1.1287128; Harris P.J.F., 1999, CARBON NANOTUBES REL; Hoque A, 2001, CHEM ENG SCI, V56, P4233, DOI 10.1016/S0009-2509(01)00042-2; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Li YH, 2002, CHEM MATER, V14, P483, DOI 10.1021/cm010738v; Poulin P, 2002, CARBON, V40, P1741, DOI 10.1016/S0008-6223(02)00042-8; Shaffer MSP, 1998, CARBON, V36, P1603, DOI 10.1016/S0008-6223(98)00130-4; Sharma RK, 1998, ENERG FUEL, V12, P312, DOI 10.1021/ef970121t; Smith BW, 2000, APPL PHYS LETT, V77, P663, DOI 10.1063/1.127078; Sreekumar TV, 2003, CHEM MATER, V15, P175, DOI 10.1021/cm020367y; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Vigolo B, 2002, APPL PHYS LETT, V81, P1210, DOI 10.1063/1.1497706; Wei BQ, 2002, NANO LETT, V2, P1105, DOI [10.1021/nl025719e, 10.1021/n1025719e]; Zhu HW, 2002, CHEM COMMUN, P1858, DOI 10.1039/b205401a; Zhu HW, 2002, SCIENCE, V296, P884, DOI 10.1126/science.1066996	21	1142	1229	38	739	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					276	278		10.1126/science.1094982	http://dx.doi.org/10.1126/science.1094982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15016960				2022-12-28	WOS:000220719400042
J	Kalas, P; Liu, MC; Matthews, BC				Kalas, P; Liu, MC; Matthews, BC			Discovery of a large dust disk around the nearby star AU Microscopii	SCIENCE			English	Article							BETA-PICTORIS; SIGNATURES; PLANETS; DEBRIS	We present the discovery of a circumstellar dust disk surrounding AU Microscopii (AU Mic, GJ 803, HD 197481). This young M star at 10 parsec has the same age and origin as beta Pictoris, another nearby star surrounded by a dust disk. The AU Mic disk is detected between 50 astronomical units ( AU) and 210 AU radius, a region where dust lifetimes exceed the present stellar age. Thus, AU Mic is the nearest star where we directly observe the solid material required for planet formation. Because 85% of stars are M-type, the AU Mic disk provides new clues on how the majority of planetary systems might form and evolve.	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Radio Astron Lab, Berkeley, CA 94720 USA; Univ Calif Santa Cruz, Natl Sci Fdn, Ctr Adapt Opt, Santa Cruz, CA 95064 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; National Science Foundation (NSF); University of California System; University of California Santa Cruz; University of Hawaii System	Kalas, P (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	kalas@astro.berkeley.edu		Liu, Michael C/0000-0003-2232-7664; Kalas, Paul/0000-0002-6221-5360				ARTYMOWICZ P, 1988, ASTROPHYS J, V335, pL79, DOI 10.1086/185344; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; Bessell MS, 1998, ASTRON ASTROPHYS, V333, P231; Crifo F, 1997, ASTRON ASTROPHYS, V320, pL29; Dent WRF, 2000, MON NOT R ASTRON SOC, V314, P702, DOI 10.1046/j.1365-8711.2000.03331.x; Greaves JS, 1998, ASTROPHYS J, V506, pL133, DOI 10.1086/311652; Holland WS, 1998, NATURE, V392, P788, DOI 10.1038/33874; KALAS P, 1995, ASTRON J, V110, P794, DOI 10.1086/117565; Kalas P, 1996, ASTRON J, V111, P1347, DOI 10.1086/117881; Larwood JD, 2001, MON NOT R ASTRON SOC, V323, P402, DOI 10.1046/j.1365-8711.2001.04212.x; Liou JC, 1999, ASTRON J, V118, P580, DOI 10.1086/300938; LIU MC, IN PRESS ASTROPHYS J; Navascues DBY, 1999, ASTROPHYS J, V520, pL123, DOI 10.1086/312162; Ozernoy LM, 2000, ASTROPHYS J, V537, pL147, DOI 10.1086/312779; ROQUES F, 1994, ICARUS, V108, P37, DOI 10.1006/icar.1994.1040; Saija R, 2003, MON NOT R ASTRON SOC, V341, P1239, DOI 10.1046/j.1365-8711.2003.06490.x; Schneider G, 1999, ASTROPHYS J, V513, pL127, DOI 10.1086/311921; Silverstone M.D., 1998, BAAS, V30, P1363; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Song I, 2002, ASTRON J, V124, P514, DOI 10.1086/341164; TSIKOUDI V, 1988, ASTRON J, V95, P1797, DOI 10.1086/114776; Zuckerman B, 2001, ASTROPHYS J, V562, pL87, DOI 10.1086/337968	22	168	168	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1990	1992		10.1126/science.1093420	http://dx.doi.org/10.1126/science.1093420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	14988511				2022-12-28	WOS:000220429800033
J	Mokdad, AH; Marks, JS; Stroup, DF; Gerberding, JL				Mokdad, AH; Marks, JS; Stroup, DF; Gerberding, JL			Actual causes of death in the United States, 2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-ABUSE; ALCOHOL-CONSUMPTION; DIABETES-MELLITUS; LIFE EXPECTANCY; NATIONAL-HEALTH; US ADULTS; MORTALITY; OBESITY; DISEASE; TRENDS	Context Modifiable behavioral risk factors are leading causes of mortality in the United States. Quantifying these will provide insight into the effects of recent trends and the implications of missed prevention opportunities. Objectives To identify and quantify the leading causes of mortality in the United States. Design Comprehensive MEDLINE search of English-language articles that identified epidemiological, clinical, and laboratory studies linking risk behaviors and mortality. The search was initially restricted to articles published during or after 1990, but we later included relevant articles published in 1980 to December 31, 2002. Prevalence and relative risk were identified during the literature search. We used 2000 mortality data reported to the Centers for Disease Control and Prevention to identify the causes and number of deaths. The estimates of cause of death were computed by multiplying estimates of the cause-attributable fraction of preventable deaths with the total mortality data. Main Outcome Measures Actual causes of death. Results The leading causes of death in 2000 were tobacco (435000 deaths; 18.1% of total US deaths), poor diet and physical inactivity (400000 deaths; 16.6%), and alcohol consumption (85000 deaths; 3.5%). Other actual causes of death were microbial agents (75000), toxic agents (55000), motor vehicle crashes (43000), incidents involving firearms (29000), sexual behaviors (20000), and illicit use of drugs (17000). Conclusions These analyses show that smoking remains the leading cause of mortality. However, poor diet and physical inactivity may soon overtake tobacco as the leading cause of death. These findings, along with escalating health care costs and aging population, argue persuasively that the need to establish a more preventive orientation in the US health care and public health systems has become more urgent.	CDCP, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; CDCP, Off Director, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mokdad, AH (corresponding author), CDCP, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K66, Atlanta, GA 30341 USA.	amokdad@cdc.gov	Kennedy, Kristen M/B-4699-2008; Duran, Bonnie m/A-3029-2009	Kennedy, Kristen M/0000-0001-5373-9026; 				Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 1994, VITAL HLTH STAT, V1, P1; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Beckett WS, 2000, NEW ENGL J MED, V342, P406, DOI 10.1056/NEJM200002103420607; BERKHAM LF, 1983, HLTH WAYS LIVING ALA; Blair SN, 2002, MAYO CLIN PROC, V77, P109; Brook DW, 2002, ARCH GEN PSYCHIAT, V59, P1039, DOI 10.1001/archpsyc.59.11.1039; BRUKE W, 2002, NEW ENGL J MED, V347, P1867; Bruner AB, 1998, JAMA-J AM MED ASSOC, V280, P597, DOI 10.1001/jama.280.7.597; Burnett RT, 1998, CAN J PUBLIC HEALTH, V89, P152, DOI 10.1007/BF03404464; Cates W, 1999, SEX TRANSM DIS, V26, pS2, DOI 10.1097/00007435-199904001-00002; *CDC, 2002, DHHS PUBL, V1232; *CDCP NAT HIGHW TR, 1992, POS PAP 3 NAT INJ CO; Centers for Disease Control and Prevention, 2001, MMWR-MORBID MORTAL W, V50, P166, DOI DOI 10.1001/JAMA.285.14.1835-JWR0411-3-1; Centers for Disease Control and Prevention, SMOK ATTR MORT MORB; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P621; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P369; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P1066; Centers of Disease Control and Prevention, 2000, SEX TRANSM DIS SURV; Cox C S, 1997, Vital Health Stat 1, P1; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawson DA, 2000, ALCOHOL CLIN EXP RES, V24, P72, DOI 10.1097/00000374-200001000-00012; de Hollander AEM, 1999, EPIDEMIOLOGY, V10, P606, DOI 10.1097/00001648-199909000-00030; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; Ebrahim SH, 1997, AM J PUBLIC HEALTH, V87, P938, DOI 10.2105/AJPH.87.6.938; English D.R., 1995, QUANTIFICATION DRUG; EPSTEIN FH, 1970, ARCH ENVIRON HEALTH, V21, P402, DOI 10.1080/00039896.1970.10667258; Ernst Nancy D., 1997, American Journal of Clinical Nutrition, V66, p965S, DOI 10.1093/ajcn/66.4.965S; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Ford ES, 2003, CIRCULATION, V107, P2185, DOI 10.1161/01.CIR.0000066320.27195.B4; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; [Internet] Centers for Disease Control and Prevention, NAT HLTH INT SURV; JOHNSTON LD, 2000, NATL SURVEY RESULTS, V1; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658, DOI 10.1136/bmj.314.7095.1658; Khan AS, 2001, PUBLIC HEALTH REP, V116, P3, DOI 10.1093/phr/116.1.3; Khoury M, 1993, FUNDAMENTALS GENETIC; Koplan JP, 1999, JAMA-J AM MED ASSOC, V282, P1579, DOI 10.1001/jama.282.16.1579; KOZIEL H, 1995, INFECT DIS CLIN N AM, V9, P65; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Li RW, 2000, AM J PUBLIC HEALTH, V90, P777, DOI 10.2105/AJPH.90.5.777; Liao YL, 2000, AM J EPIDEMIOL, V151, P651, DOI 10.1093/oxfordjournals.aje.a010259; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad Ali H, 2003, MMWR Recomm Rep, V52, P1; MURRY CJL, 1998, HLTH DIMENSIONS SEX; *NAT HIGHW TRAFF S, 2001, TRAFF SAF FACT 2000; *NAT I OCC SAF HLT, 2000, WORK HLTH CHARTB; National Institutes of Health National Heart Lung and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases, 1998, CLIN GUID ID EV TREA; ORTQVIST A, 1993, CHEST, V103, P710, DOI 10.1378/chest.103.3.710; Oyefeso A, 1999, SOC PSYCH PSYCH EPID, V34, P437, DOI 10.1007/s001270050166; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Philips DP, 1999, NEW ENGL J MED, V341, P93, DOI 10.1056/NEJM199907083410206; POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; Pope HG, 2001, AM J PSYCHIAT, V158, P1519, DOI 10.1176/appi.ajp.158.9.1519; Rehm J, 2001, AM J EPIDEMIOL, V153, P64, DOI 10.1093/aje/153.1.64; Rivara FP, 1997, JAMA-J AM MED ASSOC, V278, P569, DOI 10.1001/jama.278.7.569; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Simonsen L, 1997, EPIDEMIOLOGY, V8, P390, DOI 10.1097/00001648-199707000-00007; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; Single E, 2000, CAN MED ASSOC J, V162, P1669; Smith KR, 1999, EPIDEMIOLOGY, V10, P573, DOI 10.1097/00001648-199909000-00027; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENSON RB, 2001, QUANTIFICATION DRUG; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; STYPER P, 1995, ENV HLTH PERSPECT, V103, P490; Thun MJ, 1997, NATL CANCER I MONOGR, P305; *TRANSP RES BOARD, 1990, 229 NAT RES COUNC TR; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US DEP TRANSP NAT, 2000, US DEP TRANSP PUBL; *US EPA, AIR TRENDS 6 PRINC P; *US EPA, 2001, NAT AIR QUAL EM TREN; Valdez R, 1999, AM J PUBLIC HEALTH, V89, P1715, DOI 10.2105/AJPH.89.11.1715; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Volkow ND, 2001, AM J PSYCHIAT, V158, P1181, DOI 10.1176/appi.ajp.158.8.1181; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979; Zador PL, 2000, J STUD ALCOHOL, V61, P387, DOI 10.15288/jsa.2000.61.387; Zaza S, 2000, AM J PREV MED, V18, P44, DOI 10.1016/S0749-3797(99)00122-1; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660; 2002, MMWR MORB MORTAL WKL, V51, P300; 2001, MMWR MORB MORTAL WKL, V50, P847; 2002, MMWR MORB MORTAL WKL, V51, P1019; 1999, MMWR MORB MORTAL WKL, V48, P473; 1997, MMWR MORB MORTAL WKL, V46, P665	97	3772	3853	4	327	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1238	1245		10.1001/jama.291.10.1238	http://dx.doi.org/10.1001/jama.291.10.1238			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800XV	15010446				2022-12-28	WOS:000220061900025
J	Vahtera, J; Kivimaki, M; Pentti, J; Linna, A; Virtanen, M; Virtanen, P; Ferrie, JE				Vahtera, J; Kivimaki, M; Pentti, J; Linna, A; Virtanen, M; Virtanen, P; Ferrie, JE			Organisational downsizing, sickness absence, and mortality: 10-town prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; HEALTH; WORK; EMPLOYEES; EMPLOYMENT; STRESS; RISK; MEN	Objective To examine whether downsizing, the reduction of personnel in organisations, is a predictor of increased sickness absence and mortality among employees. Design Prospective cohort study over 7.5 years of employees grouped into categories on the basis of reductions of personnel in their occupation and workplace: no downsizing (< 8% reduction), minor downsizing (8-18%), and major downsizing (> 18%). Setting Four towns in Finland. Participants 5909 male and 16 521 female municipal employees, aged 19-62 years, who kept their jobs. Main outcome measures Annual sickness absence rate based on employers' records before and after downsizing by employment contract; all cause and cause specific mortality obtained from the national mortality register. Results Major downsizing was associated with an increase in sickness absence (P for trend < 0.001) in permanent employees but not in temporary employees. The extent of downsizing was also associated with cardiovascular deaths (P for trend < 0.01) but not with deaths from other causes. Cardiovascular mortality was 2.0 (95% confidence interval 1.0 to 3.9) times higher after major downsizing than after no downsizing. Splitting the follow up period into two halves showed a 5.1 (1.4 to 19.3) times increase in cardiovascular mortality for major downsizing during the first four years after downsizing. The corresponding hazard ratio was 1.4 (0.6 to 3.1) during the second half of follow up. Conclusion Organisational downsizing may increase sickness absence and the risk of death from cardiovascular disease in employees who keep their jobs.	Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Univ Tampere, Sch Med, FIN-33014 Tampere, Finland; UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England	Finnish Institute of Occupational Health; Tampere University; University of London; University College London; UCL Medical School	Vahtera, J (corresponding author), Finnish Inst Occupat Hlth, Hameenkatu 10, FIN-20500 Turku, Finland.	jussi.vahtera@ttl.fi	Kivimaki, Mika/B-3607-2012; Vahtera, Jussi/J-3271-2013; Ferrie, Jane/AAZ-2009-2020	Kivimaki, Mika/0000-0002-4699-5627; 				Aronsson G, 2000, J EPIDEMIOL COMMUN H, V54, P502, DOI 10.1136/jech.54.7.502; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; Everson SA, 1997, BRIT MED J, V314, P553, DOI 10.1136/bmj.314.7080.553; FERRIE JE, 1997, J HEALTH PSYCHOL, V2, P273; Hart CL, 1999, BMJ-BRIT MED J, V318, P1725, DOI 10.1136/bmj.318.7200.1725; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; Kivimaki M, 2000, BRIT MED J, V320, P971, DOI 10.1136/bmj.320.7240.971; Kivimaki M, 2003, BRIT MED J, V327, P364, DOI 10.1136/bmj.327.7411.364; Kivimaki M, 2002, BRIT MED J, V325, P857, DOI 10.1136/bmj.325.7369.857; Kivimaki M, 2001, ANXIETY STRESS COPIN, V14, P59, DOI 10.1080/10615800108248348; Lichtenstein P, 1998, PSYCHOL MED, V28, P635, DOI 10.1017/S0033291798006692; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; Martikainen P, 1996, AM J PUBLIC HEALTH, V86, P1087, DOI 10.2105/AJPH.86.8_Pt_1.1087; MCLEOD J, 2002, BMJ-BRIT MED J, V324, P1247; Melchior M, 2003, J EPIDEMIOL COMMUN H, V57, P285, DOI 10.1136/jech.57.4.285; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; Quinlan M, 2001, INT J HEALTH SERV, V31, P335, DOI 10.2190/607H-TTV0-QCN6-YLT4; Smith GD, 1998, BMJ-BRIT MED J, V317, P1351, DOI 10.1136/bmj.317.7169.1351; Statistics Finland, 1987, CLASS OCC HDB, V14; Theorell T, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.9.e9; Vahtera J, 1997, LANCET, V350, P1124, DOI 10.1016/S0140-6736(97)03216-9; Virtanen M, 2003, OCCUP ENVIRON MED, V60, P948, DOI 10.1136/oem.60.12.948; Weiss NS, 2002, EPIDEMIOLOGY, V13, P6, DOI 10.1097/00001648-200201000-00003	23	231	236	1	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					555	558		10.1136/bmj.37972.496262.0D	http://dx.doi.org/10.1136/bmj.37972.496262.0D			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	14980982	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000220091800019
J	Goring, DR; Walker, JC				Goring, DR; Walker, JC			Self-rejection - A new kinase connection	SCIENCE			English	Editorial Material							E3 UBIQUITIN LIGASE; PROTEIN-KINASE; INCOMPATIBILITY; GENE; ARC1		Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Toronto; University of Missouri System; University of Missouri Columbia	Goring, DR (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	goring@botany.utoronto.ca		Goring, Daphne/0000-0001-5295-4744; Walker, John/0000-0002-2050-1641				Fukai E, 2001, MOL GENET GENOMICS, V265, P519, DOI 10.1007/s004380000440; Hiscock SJ, 2003, TRENDS PLANT SCI, V8, P606, DOI 10.1016/j.tplants.2003.10.007; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Mudgil Y, 2004, PLANT PHYSIOL, V134, P59, DOI 10.1104/pp.103.029553; Murase K, 2004, SCIENCE, V303, P1516, DOI 10.1126/science.1093586; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nasrallah ME, 2002, SCIENCE, V297, P247, DOI 10.1126/science.1072205; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Stone SL, 2003, PLANT CELL, V15, P885, DOI 10.1105/tpc.009845; [No title captured]	14	27	38	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1474	1475		10.1126/science.1095764	http://dx.doi.org/10.1126/science.1095764			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001763				2022-12-28	WOS:000220000100025
J	Nguyen, AN; Zinner, E				Nguyen, AN; Zinner, E			Discovery of ancient silicate stardust in a meteorite	SCIENCE			English	Article							ASYMPTOTIC GIANT BRANCH; ISOTOPIC COMPOSITION; DEEP CIRCULATION; SOLAR-SYSTEM; RICH RIMS; STARS; DUST; CORUNDUM; GRAINS; NUCLEOSYNTHESIS	We have discovered nine presolar silicate grains from the carbonaceous chondrite Acfer 094. Their anomalous oxygen isotopic compositions indicate formation in the atmospheres of evolved stars. Two grains are identified as pyroxene, two as olivine, one as a glass with embedded metal and sulfides (GEMS), and one as an Al-rich silicate. One grain is enriched in Mg-26, which is attributed to the radioactive decay of Al-26 and provides information about mixing processes in the parent star. This discovery opens new means for studying stellar processes and conditions in various solar system environments.	Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; Washington Univ, Dept Phys, St Louis, MO 63130 USA	Washington University (WUSTL); Washington University (WUSTL)	Nguyen, AN (corresponding author), Washington Univ, Space Sci Lab, St Louis, MO 63130 USA.	nguyen@wustl.edu						Alexander CMO, 1999, ASTROPHYS J, V519, P222, DOI 10.1086/307340; ALEXANDER CMO, 2001, LUNAR PLANET SCI, V32, pA2191; Boothroyd AI, 1999, ASTROPHYS J, V510, P232, DOI 10.1086/306546; BOOTHROYD AI, 1995, ASTROPHYS J, V442, pL21, DOI 10.1086/187806; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; Busso M, 1999, ANNU REV ASTRON ASTR, V37, P239, DOI 10.1146/annurev.astro.37.1.239; CANNON RC, 1995, NUCLEI COSMOS, V3, P469; Choi BG, 1998, SCIENCE, V282, P1284, DOI 10.1126/science.282.5392.1284; Choi BG, 1999, ASTROPHYS J, V522, pL133, DOI 10.1086/312239; Demyk K, 2000, ASTRON ASTROPHYS, V364, P170; FLOSS C, 2004, LUNAR PLANET SCI, V35, pA1281; FORESTINI M, 1991, ASTRON ASTROPHYS, V252, P597; HUA X, 1988, GEOCHIM COSMOCHIM AC, V52, P1389, DOI 10.1016/0016-7037(88)90210-4; HUTCHEON ID, 1994, ASTROPHYS J, V425, pL97, DOI 10.1086/187319; Karakas AI, 2003, PUBL ASTRON SOC AUST, V20, P279, DOI 10.1071/AS03010; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; Messenger S, 2000, METEORIT PLANET SCI, V35, pA109; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; Molster FJ, 1999, NATURE, V401, P563, DOI 10.1038/44085; Molster FJ, 2002, ASTRON ASTROPHYS, V382, P241, DOI 10.1051/0004-6361:20011552; Mostefaoui S, 2003, METEORIT PLANET SCI, V38, pA99, DOI 10.1111/j.1945-5100.2003.tb00289.x; MOSTEFAOUI S, 2004, LUNAR PLANET SCI, V35, pA1593; Mowlavi N, 2000, ASTRON ASTROPHYS, V361, P959; Nguyen A, 2003, PUBL ASTRON SOC AUST, V20, P382, DOI 10.1071/AS03030; Nittler L. R., 1996, THESIS WASHINGTON U; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; Nollett KM, 2003, ASTROPHYS J, V582, P1036, DOI 10.1086/344817; Waelkens C, 1996, ASTRON ASTROPHYS, V315, pL245; WASSERBURG GJ, 1995, ASTROPHYS J, V447, pL37, DOI 10.1086/309555; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WEINBRUCH S, 1990, METEORITICS, V25, P115, DOI 10.1111/j.1945-5100.1990.tb00983.x; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147; Zinner EK, 2005, TREATISE GEOCHEM, V1, P17	33	196	200	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1496	1499		10.1126/science.1094389	http://dx.doi.org/10.1126/science.1094389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001773				2022-12-28	WOS:000220000100035
J	Wild, C; Huettel, M; Klueter, A; Kremb, SG; Rasheed, MYM; Jorgensen, BB				Wild, C; Huettel, M; Klueter, A; Kremb, SG; Rasheed, MYM; Jorgensen, BB			Coral mucus functions as an energy carrier and particle trap in the reef ecosystem	NATURE			English	Article							WATER-MOVEMENT; ZOOXANTHELLAE; RESPIRATION; POPULATIONS; ECOLOGY; RELEASE	Zooxanthellae, endosymbiotic algae of reef-building corals, substantially contribute to the high gross primary production of coral reefs(1), but corals exude up to half of the carbon assimilated by their zooxanthellae as mucus(2,3). Here we show that released coral mucus efficiently traps organic matter from the water column and rapidly carries energy and nutrients to the reef lagoon sediment, which acts as a biocatalytic mineralizing filter. In the Great Barrier Reef, the dominant genus of hard corals, Acropora, exudes up to 4.8 litres of mucus per square metre of reef area per day. Between 56% and 80% of this mucus dissolves in the reef water, which is filtered through the lagoon sands. Here, coral mucus is degraded at a turnover rate of at least 7% per hour. Detached undissolved mucus traps suspended particles, increasing its initial organic carbon and nitrogen content by three orders of magnitude within 2 h. Tidal currents concentrate these mucus aggregates into the lagoon, where they rapidly settle. Coral mucus provides light energy harvested by the zooxanthellae and trapped particles to the heterotrophic reef community, thereby establishing a recycling loop that supports benthic life, while reducing loss of energy and nutrients from the reef ecosystem.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Florida State Univ, Dept Oceanog, Tallahassee, FL 32306 USA; Australian Inst Marine Sci, Townsville, Qld 4810, Australia; Alfred Wegener Inst Polar & Marine Res, Dept Benth Ecosyst, D-27570 Bremerhaven, Germany; Yarmouk Univ, Aqaba, Jordan; Univ Jordan, Marine Sci Stn, Aqaba, Jordan	Max Planck Society; State University System of Florida; Florida State University; Australian Institute of Marine Science; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Yarmouk University; University of Jordan	Wild, C (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	cwild@mpi-bremen.de	Jorgensen, Bo B/C-2214-2013; Huettel, Markus/F-8940-2011	Jorgensen, Bo B/0000-0001-9398-8027; Huettel, Markus/0000-0003-4844-7525; Rasheed, Mohammed/0000-0002-6131-368X				BENSON AA, 1974, LIMNOL OCEANOGR, V19, P810, DOI 10.4319/lo.1974.19.5.0810; COLES SL, 1973, LIMNOL OCEANOGR, V18, P673, DOI 10.4319/lo.1973.18.4.0673; CROSSLAND CJ, 1980, MAR BIOL, V60, P81, DOI 10.1007/BF00389151; DAVIES PS, 1984, CORAL REEFS, V2, P181; DUCKLOW HW, 1979, LIMNOL OCEANOGR, V24, P715, DOI 10.4319/lo.1979.24.4.0715; Ferrier-Pages C, 2000, AQUAT MICROB ECOL, V21, P203, DOI 10.3354/ame021203; GOREAU TF, 1979, SCI AM, V241, P124, DOI 10.1038/scientificamerican0879-124; HERNDL GJ, 1986, MAR BIOL, V90, P363, DOI 10.1007/BF00428560; HUETTEL M, 1992, MAR ECOL PROG SER, V82, P187, DOI 10.3354/meps082187; JOHANNES RE, 1967, LIMNOL OCEANOGR, V12, P189, DOI 10.4319/lo.1967.12.2.0189; KRUPP DA, 1984, PAC SCI, V38, P1; MARSDEN J, 1990, J EXP MAR BIOL ECOL, V137, P97; MARSHALL N, 1968, Marine Biology (Berlin), V2, P50, DOI 10.1007/BF00351638; MEIKLE P, 1988, MAR BIOL, V99, P187, DOI 10.1007/BF00391980; MORIARTY DJW, 1985, MAR BIOL, V85, P285, DOI 10.1007/BF00393249; MUSCATINE L, 1981, LIMNOL OCEANOGR, V26, P601, DOI 10.4319/lo.1981.26.4.0601; OBERDORFER JA, 1986, CORAL REEFS, V5, P7, DOI 10.1007/BF00302165; PARNELL KE, 1986, CORAL REEFS, V5, P1, DOI 10.1007/BF00302164; RICHMAN S, 1975, LIMNOL OCEANOGR, V20, P918, DOI 10.4319/lo.1975.20.6.0918; Richter C, 2001, NATURE, V413, P726, DOI 10.1038/35099547; RIEDL RJ, 1972, MAR BIOL, V13, P210, DOI 10.1007/BF00391379; Romaine S, 1997, MAR BIOL, V129, P175, DOI 10.1007/s002270050158; SCHUHMACHER H, 1977, P 3 INT COR REEF S M, P503; SHANKS AL, 1989, MAR BIOL, V101, P463, DOI 10.1007/BF00541648; STIMSON J, 1991, J EXP MAR BIOL ECOL, V153, P63, DOI 10.1016/S0022-0981(05)80006-1; VACELET E, 1991, HYDROBIOLOGIA, V211, P19, DOI 10.1007/BF00008613; Wild C, 2004, MAR ECOL PROG SER, V267, P159, DOI 10.3354/meps267159; WILKINSON CR, 1987, SEARCH, V18, P31	28	425	435	10	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	2004	428	6978					66	70		10.1038/nature02344	http://dx.doi.org/10.1038/nature02344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999280				2022-12-28	WOS:000189363800035
J	Williams, CF; Klinzman, D; Yamashita, TE; Xiang, JH; Polgreen, PM; Rinaldo, C; Liu, CL; Phair, J; Margolick, JB; Zdunek, D; Hess, G; Stapleton, JT				Williams, CF; Klinzman, D; Yamashita, TE; Xiang, JH; Polgreen, PM; Rinaldo, C; Liu, CL; Phair, J; Margolick, JB; Zdunek, D; Hess, G; Stapleton, JT			Persistent GB virus C infection and survival in HIV-infected men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-G VIRUS; MULTICENTER AIDS COHORT; C/HEPATITIS-G VIRUS; DISEASE PROGRESSION; RNA; COINFECTION; HEMOPHILIA; TRANSMISSION; ASSOCIATION; PREVALENCE	BACKGROUND: GB virus C (GBV-C), which is not known to be pathogenic in humans, replicates in lymphocytes, inhibits the replication of human immunodeficiency virus (HIV) in vitro, and has been associated with a decreased risk of death among HIV-positive persons in some, but not all, studies. Previous studies did not control for differences in the duration of HIV or GBV-C infection. METHODS: We evaluated 271 men who were participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-C viremia (by means of a reverse-transcriptase-polymerase-chain-reaction assay) or E2 antibody (by means of an enzyme-linked immunosorbent assay) 12 to 18 months after seroconversion to positivity for HIV (the early visit); a subgroup of 138 patients was also evaluated 5 to 6 years after HIV seroconversion (the late visit). RESULTS: GBV-C infection was detected in 85 percent of men with HIV seroconversion on the basis of the presence of E2 antibody (46 percent) or GBV-C RNA (39 percent). Only one man acquired GBV-C viremia between the early and the late visit, but 9 percent of men had clearance of GBV-C RNA between these visits. GBV-C status 12 to 18 months after HIV seroconversion was not significantly associated with survival; however, men without GBV-C RNA 5 to 6 years after HIV seroconversion were 2.78 times as likely to die as men with persistent GBV-C viremia (95 percent confidence interval, 1.34 to 5.76; P=0.006). The poorest prognosis was associated with the loss of GBV-C RNA (relative hazard for death as compared with men with persistent GBV-C RNA, 5.87; P=0.003). CONCLUSIONS: GBV-C viremia was significantly associated with prolonged survival among HIV-positive men 5 to 6 years after HIV seroconversion, but not at 12 to 18 months, and the loss of GBV-C RNA by 5 to 6 years after HIV seroconversion was associated with the poorest prognosis. Understanding the mechanisms of interaction between GBV-C and HIV may provide insight into the progression of HIV disease.	NIAID, Epidemiol Branch, Div AIDS, Bethesda, MD 20892 USA; Univ Iowa, Iowa City, IA USA; Iowa City Vet Affairs Med Ctr, Iowa City, IA USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Northwestern Univ, Howard Brown Hlth Ctr, Chicago, IL 60611 USA; Roche Diagnost, Penzberg, Germany; Roche Diagnost, Mannheim, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; Northwestern University; Roche Holding; Roche Holding	Stapleton, JT (corresponding author), UIHC, GH, SW 34-P, Iowa City, IA 52242 USA.	jack-stapleton@uiowa.edu		Stapleton, Jack/0000-0002-2302-9055; Liu, Chenglong/0000-0001-8235-8513; Polgreen, Philip/0000-0002-0630-5898	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035040, U01AI035043, U01AI037613, U01AI035039, U01AI027661, U01AI035041, U01AI037984, U01AI035042] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR-00722] Funding Source: Medline; NIAID NIH HHS [UO1-AI-35039, UO1-AI-37984, UO1-AI-37613, UO1-AI-35040, UO1-AI-35042, UO1-AI-35041, UO1-AI-35043, AI 250478, AI 27661] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; Birk M, 2002, AIDS, V16, P2482, DOI 10.1097/00002030-200212060-00017; BRUST D, 2002, 14 INT AIDS C BARC S; Buchbinder S, 1999, MICROBES INFECT, V1, P1113, DOI 10.1016/S1286-4579(99)00204-X; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Dawson GJ, 1996, J MED VIROL, V50, P97, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;97::AID-JMV16&gt;3.0.CO;2-V; Dean M, 1996, SCIENCE, V274, P1069; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; DUDLEY J, 1995, AM J EPIDEMIOL, V142, P323, DOI 10.1093/oxfordjournals.aje.a117638; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; Fischler B, 1997, J INFECT DIS, V176, P281, DOI 10.1086/517267; Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431; Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KLINZMAN D, IN PRESS VIRAL HEPAT; Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mosier DE, 2002, NEW ENGL J MED, V346, P377; Rowland-Jones S, 1999, J INFECTION, V38, P67, DOI 10.1016/S0163-4453(99)90070-1; Rubio A, 1997, JAMA-J AM MED ASSOC, V277, P532, DOI 10.1001/jama.1997.03540310030026; Sabin CA, 1998, J ACQ IMMUN DEF SYND, V19, P546, DOI 10.1097/00042560-199812150-00016; Semprini AE, 1998, J INFECT DIS, V177, P848, DOI 10.1086/515257; Stapleton JT, 1999, J CLIN MICROBIOL, V37, P484, DOI 10.1128/JCM.37.3.484-489.1999; Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137; Tacke M, 1997, HEPATOLOGY, V26, P1626, DOI 10.1002/hep.510260635; Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209, DOI 10.1097/00042560-199803010-00004; Toyoda H, 2000, J MED VIROL, V60, P34, DOI 10.1002/(SICI)1096-9071(200001)60:1&lt;34::AID-JMV6&gt;3.0.CO;2-#; Wu JC, 1997, J MED VIROL, V52, P83, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;83::AID-JMV13&gt;3.0.CO;2-1; Xiang JH, 1998, J VIROL, V72, P2738, DOI 10.1128/JVI.72.4.2738-2744.1998; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364; Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000; Yeo AET, 2000, ANN INTERN MED, V132, P959, DOI 10.7326/0003-4819-132-12-200006200-00006	36	206	214	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					981	990		10.1056/NEJMoa030107	http://dx.doi.org/10.1056/NEJMoa030107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999110				2022-12-28	WOS:000189363600006
J	Kong, XY; Ding, Y; Yang, R; Wang, ZL				Kong, XY; Ding, Y; Yang, R; Wang, ZL			Single-crystal nanorings formed by epitaxial self-coiling of polar nanobelts	SCIENCE			English	Article								Freestanding single-crystal complete nanorings of zinc oxide were formed via a spontaneous self-coiling process during the growth of polar nanobelts. The nanoring appeared to be initiated by circular folding of a nanobelt, caused by long-range electrostatic interaction. Coaxial and uniradial loop-by-loop winding of the nanobelt formed a complete ring. Short-range chemical bonding among the loops resulted in a single-crystal structure. The self-coiling is likely to be driven by minimizing the energy contributed by polar charges, surface area, and elastic deformation. Zinc oxide nanorings formed by self-coiling of nanobelts may be useful for investigating polar surface - induced growth processes, fundamental physics phenomena, and nanoscale devices.	Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Wang, ZL (corresponding author), Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.	zhong.wang@mse.gatech.edu	Ding, Yong/F-3705-2017; Kong, Xiangyang/F-2999-2013; Wang, Zhong Lin/E-2176-2011; wang, jie/GRS-0942-2022; Yang, Rusen/D-5536-2009; Kong, Xiang Yang/E-1593-2012	Ding, Yong/0000-0001-5805-347X; Wang, Zhong Lin/0000-0002-5530-0380; Yang, Rusen/0000-0002-4019-4642; Kong, Xiang Yang/0000-0003-0659-4084				Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; Germain V, 2003, J PHYS CHEM B, V107, P8717, DOI 10.1021/jp0303826; Kong XY, 2003, NANO LETT, V3, P1625, DOI 10.1021/nl034463p; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120; Romer RA, 2000, PHYS STATUS SOLIDI B, V221, P535, DOI 10.1002/1521-3951(200009)221:1<535::AID-PSSB535>3.0.CO;2-M; SHUVALOV LA, 1988, SPRINGER SERIES SOLI, V37, P109; Stampfl C, 1998, PHYS REV B, V57, P15052, DOI 10.1103/PhysRevB.57.R15052; Vigue F, 2001, APPL PHYS LETT, V79, P194, DOI 10.1063/1.1384907; Whetten RL, 1996, ADV MATER, V8, P428, DOI 10.1002/adma.19960080513	10	1390	1468	14	386	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1348	1351		10.1126/science.1092356	http://dx.doi.org/10.1126/science.1092356			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988559				2022-12-28	WOS:000189238600045
J	Li, XQ; Kind, R; Yuan, XH; Wolbern, I; Hanka, W				Li, XQ; Kind, R; Yuan, XH; Wolbern, I; Hanka, W			Rejuvenation of the lithosphere by the Hawaiian plume	NATURE			English	Article							VELOCITY; ORIGIN; SWELL	The volcanism responsible for creating the chain of the Hawaiian islands and seamounts is believed to mark the passage of the oceanic lithosphere over a mantle plume(1,2). In this picture hot material rises from great depth within a fixed narrow conduit to the surface, penetrating the moving lithosphere(3). Although a number of models describe possible plume - lithosphere interactions(4), seismic imaging techniques have not had sufficient resolution to distinguish between them. Here we apply the S-wave 'receiver function' technique to data of three permanent seismic broadband stations on the Hawaiian islands, to map the thickness of the underlying lithosphere. We find that under Big Island the lithosphere is 100 - 110 km thick, as expected for an oceanic plate 90 - 100 million years old that is not modified by a plume. But the lithosphere thins gradually along the island chain to about 50 - 60 km below Kauai. The width of the thinning is about 300 km. In this zone, well within the larger-scale topographic swell, we infer that the rejuvenation model(5) ( where the plume thins the lithosphere) is operative; however, the larger-scale topographic swell is probably supported dynamically.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Free Univ Berlin, D-12249 Berlin, Germany	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Free University of Berlin	Kind, R (corresponding author), Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany.	kind@gfz-potsdam.de	Woelbern, Ingo/J-2882-2012; Yuan, Xiaohui/G-5149-2010	Yuan, Xiaohui/0000-0002-2891-1354				BOCK G, 1991, GEOPHYS RES LETT, V18, P869, DOI 10.1029/91GL01055; Collins JA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013302; DETRICK RS, 1978, J GEOPHYS RES, V83, P1236, DOI 10.1029/JB083iB03p01236; FABER S, 1980, B SEISMOL SOC AM, V70, P487; Farra V, 2000, GEOPHYS J INT, V141, P699, DOI 10.1046/j.1365-246x.2000.00118.x; Jordan T. H., 1979, MANTLE SAMPLE INCLUS, P1, DOI DOI 10.1029/SP016P0001; Laske G, 1999, GEOPHYS RES LETT, V26, P3397, DOI 10.1029/1999GL005401; Li X, 2000, NATURE, V405, P938, DOI 10.1038/35016054; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P12753, DOI 10.1029/95JB00041; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Nataf HC, 2000, ANNU REV EARTH PL SC, V28, P391, DOI 10.1146/annurev.earth.28.1.391; Priestley K, 1999, GEOPHYS RES LETT, V26, P1493, DOI 10.1029/1999GL900299; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; ROBINSON EM, 1988, EARTH PLANET SC LETT, V90, P221, DOI 10.1016/0012-821X(88)90102-1; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094; WOODS MT, 1991, GEOPHYS RES LETT, V18, P105, DOI 10.1029/90GL02718; Woods MT, 1996, GEOPHYS J INT, V125, P325, DOI 10.1111/j.1365-246X.1996.tb00002.x	18	193	200	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					827	829		10.1038/nature02349	http://dx.doi.org/10.1038/nature02349			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985758	Green Published			2022-12-28	WOS:000189207500036
J	Kastrati, A; Mehilli, J; Schlotterbeck, K; Dotzer, F; Dirschinger, J; Schmitt, C; Nekolla, SG; Seyfarth, M; Martinoff, S; Markwardt, C; Clermont, G; Gerbig, HW; Leiss, J; Schwaiger, M; Schomig, A				Kastrati, A; Mehilli, J; Schlotterbeck, K; Dotzer, F; Dirschinger, J; Schmitt, C; Nekolla, SG; Seyfarth, M; Martinoff, S; Markwardt, C; Clermont, G; Gerbig, HW; Leiss, J; Schwaiger, M; Schomig, A		BRAVE Study Investigators	Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; PRIMARY ANGIOPLASTY; IMMEDIATE THROMBOLYSIS; MULTICENTER TRIAL; THERAPY; FEASIBILITY; REPERFUSION; TRANSPORT; BLOCKADE; STRATEGY	Context The optimal pharmacological strategy for bridging the delay between admission and performance of percutaneous coronary intervention (PCl) in patients with acute myocardial infarction (Ml) is not known. Objective To assess whether early administration of reteplase plus abciximab produces better results compared with abciximab alone in patients with acute MI referred for PCl. Design, Setting, and Patients Open-label, randomized controlled study conducted from May 3, 2001, through June 2, 2003, of 253 patients who were admitted to 13 community hospitals without catheterization facilities (n= 186) and to 5 hospitals with catheterization facilities (M=67), with the diagnosis of an ST-segment elevation acute MI within 12 hours from onset of symptoms. Interventions Patients received intravenously either the combination of a half-dose reteplase (two 5-U boluses, 30 minutes apart) with a standard dose of abciximab (0.25 mg/kg bolus, 0.1-25 mug/kg per minute infusion [maximum 10 mug/min for 12 hours]) or the standard dose of abciximab alone; all patients were then transferred for PCl. Main Outcome Measure Final infarct size according to a single-photon emission computed tomography study with technetium Tc 99m sestamibi performed between 5 and 10 days after randomization in 228 patients (90.1 % of entire sample). Results Of the 253 patients enrolled, 125 were assigned to reteplase plus abciximab and 128 to abciximab alone. The median (interquartile range) of the final infarct size of the left ventricle was 13.0% (3.0%-28.0%) in the reteplase plus abciximab group and 11.5% (3.0%-26.3%) in the abciximab-alone group (P=.81). The mean difference in final infarct size of left ventricle between the reteplase plus abciximab group and the abciximab group was 1.3 % (95% confidence interval [CI], -3.1 % to 5.7%). Within 6 months after randomization, the composite secondary end point of death, recurrent Ml, or stroke occurred in 8 patients (6.4%) in the reteplase plus abciximab group and 6 patients (4.7%) in the abciximab group (relative risk, 1.4; 95% Cl, 0.5-3.9; log-rank P=.56). Major bleeding complications were observed in 7 patients (5.6%) in the reteplase plus abciximab group and 2 patients (1.6%) in the abciximab group (P=16). Conclusion Early administration of reteplase plus abciximab does not lead to a reduction of infarct size compared with abciximab alone in patients with acute MI referred for PCl.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Klinikum Traunstein, Munich, Germany; Klinikum Garmisch Partenkirchen, Munich, Germany; Tech Univ Munich, Med Klin Rechts Isar 1, D-8000 Munich, Germany; Tech Univ Munich, Klin & Poliklin Nukl Med Rechts Isar, D-8000 Munich, Germany; Asklepios Stadtklin, Bad Tolz, Germany; Kreiskrankenhaus Erding Dorfen, Erding, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich	Kastrati, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	, Kastrati/Y-2389-2019; Nekolla, Stephan G/L-1857-2013; Mehilli, Julinda/F-2629-2016	Nekolla, Stephan G/0000-0002-8817-1482; schwaiger, markus/0000-0002-2305-7144				Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; [Anonymous], 1989, NEW ENGL J MED, V320, P618; Berger VW, 2002, CONTROL CLIN TRIALS, V23, P502, DOI 10.1016/S0197-2456(02)00233-7; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; *BOEHR ING, 2003, BOEHR ING GEN ANN CL; Dauerman HL, 2003, J AM COLL CARDIOL, V42, P646, DOI 10.1016/S0735-1097(03)00762-9; ELASHOF JD, 1999, NQUERY ADVISOR VERSI; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; Gibson CM, 2000, J AM COLL CARDIOL, V36, P1497, DOI 10.1016/S0735-1097(00)00926-8; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; HERMANN HC, 2001, J INVASIVE CARDIO SA, V13, pA10; Herrmann HC, 2000, J AM COLL CARDIOL, V36, P1489, DOI 10.1016/S0735-1097(00)00923-2; Kastrati A, 2002, LANCET, V359, P920, DOI 10.1016/S0140-6736(02)08022-4; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Nekolla SG, 1998, EUR J NUCL MED, V25, P1313, DOI 10.1007/s002590050301; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; OCONNOR MK, 1995, J NUCL MED, V36, P1130; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; *TIMI STUD GROUP, DEF US TIMI TRIALS; Topol E, 1997, NEW ENGL J MED, V337, P1118; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 1998, CIRCULATION, V97, P211, DOI 10.1161/01.CIR.97.2.211; Topol EJ, 2001, LANCET, V357, P1905; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2	30	125	132	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					947	954		10.1001/jama.291.8.947	http://dx.doi.org/10.1001/jama.291.8.947			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982910	Bronze			2022-12-28	WOS:000189182000022
J	Gottlieb, GS; Nickle, DC; Jensen, MA; Wong, KG; Grobler, J; Li, FS; Liu, SL; Rademeyer, C; Learn, GH; Karim, SSA; Williamson, C; Corey, L; Margolick, JB; Mullins, JI				Gottlieb, GS; Nickle, DC; Jensen, MA; Wong, KG; Grobler, J; Li, FS; Liu, SL; Rademeyer, C; Learn, GH; Karim, SSA; Williamson, C; Corey, L; Margolick, JB; Mullins, JI			Dual HIV-1 infection associated with rapid disease progression	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SUPERINFECTION; AIDS	Infection with two strains of HIV-1 has implications for understanding HIV transmission and vaccine development; however, frequency and pathogenic consequences of dual infection are unknown. We assessed 64 patients for dual infection with heteroduplex mobility assay, viral sequencing, and phylogenetic methods. HIV disease outcomes were available in 34 patients. Five of these with AIDS endpoints had dual infection with HIV-1: four were cases of coinfection and one was superinfection. In all five, time from seroconversion to clinical AIDS or to CD4+ T-cell count less than 200 cells per muL was very rapid (<3.4 and <3.1 years, respectively). Our findings should prompt larger studies to assess the effect of dual infection at the population level.	Univ Washington, Sch Med, Div Allergy & Infect Dis, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Cape Town, Div Med Virol, ZA-7925 Cape Town, South Africa; Univ Natal, ZA-4001 Durban, South Africa; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Cape Town; University of Kwazulu Natal; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gottlieb, GS (corresponding author), Univ Washington, Sch Med, Div Allergy & Infect Dis, Dept Med, Seattle, WA 98195 USA.	gottlieb@u.washington.edu	Karim, Salim Safurdeen Abdool/N-5947-2013; Corey, Lawrence/AAE-1796-2020; Learn, Gerald H/B-6934-2011; Karim, Salim Abdool/AAE-7118-2019; Liu, Shan-Lu/L-5923-2016; Karim, Salim Abdool/P-3117-2019; Nickle, David/ABF-2727-2020; Learn, Jerry/E-3356-2012	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Corey, Lawrence/0000-0002-2179-2436; Learn, Gerald H/0000-0003-0434-7733; Liu, Shan-Lu/0000-0003-1620-3817; Karim, Salim Abdool/0000-0002-4986-2133; Jensen, Mark/0000-0001-5215-101X; , Carolyn/0000-0003-0125-1226; Gottlieb, Geoffrey/0000-0002-5749-481X	NCRR NIH HHS [RR0772] Funding Source: Medline; NIAID NIH HHS [AI35042, AI47734, AI07140, AI35039, AI37984, AI35040, AI35041, AI49755] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035042, R01AI047734, U01AI035039, R37AI047734, K08AI049755, U01AI037984, U01AI035040] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Goulder PJR, 2002, NEW ENGL J MED, V347, P756, DOI 10.1056/NEJMe020091; Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490	7	151	155	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					619	622		10.1016/S0140-6736(04)15596-7	http://dx.doi.org/10.1016/S0140-6736(04)15596-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987889				2022-12-28	WOS:000189104900013
J	Leigh, B				Leigh, B			Commentary: what's the problem?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Hempsons Solicitors, London WC2N 6NJ, England		Leigh, B (corresponding author), Hempsons Solicitors, London WC2N 6NJ, England.	mamsl@hempsons.co.uk						National Audit Office, 2001, HANDL CLIN NEGL CLAI	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					460	460		10.1136/bmj.328.7437.460	http://dx.doi.org/10.1136/bmj.328.7437.460			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976105	Green Published			2022-12-28	WOS:000189161000027
J	Beuther, H; Schilke, P				Beuther, H; Schilke, P			Fragmentation in massive star formation	SCIENCE			English	Article							PROTOSTELLAR CANDIDATES; EMISSION; CONTINUUM; MASSES; CLOUD	Studies of evolved massive stars indicate that they form in a clustered mode. During the earliest evolutionary stages, these regions are embedded within their natal cores. Here we present high-spatial-resolution interferometric dust continuum observations disentangling the cluster-like structure of a young massive star-forming region. The derived protocluster mass distribution is consistent with the stellar initial mass function. Thus, fragmentation of the initial massive cores may determine the initial mass function and the masses of the final stars. This implies that stars of all masses can form via accretion processes, and coalescence of intermediate-mass protostars appears not to be necessary.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Max Planck Inst Astrophys, D-53121 Bonn, Germany	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Max Planck Society	Beuther, H (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	hbeuther@cfa.harvard.edu		Beuther, Henrik/0000-0002-1700-090X				ADAMS FC, 1985, ASTROPHYS J, V296, P655, DOI 10.1086/163483; Beuther H, 2002, ASTRON ASTROPHYS, V383, P892, DOI 10.1051/0004-6361:20011808; Beuther H, 2002, ASTROPHYS J, V566, P945, DOI 10.1086/338334; Beuther H, 2002, ASTRON ASTROPHYS, V395, P169, DOI 10.1051/0004-6361:20021261; Bonnell IA, 1998, MON NOT R ASTRON SOC, V298, P93, DOI 10.1046/j.1365-8711.1998.01590.x; GUILLOTEAU S, 1992, ASTRON ASTROPHYS, V262, P624; HILDEBRAND RH, 1983, Q J ROY ASTRON SOC, V24, P267; KROUPA P, 1993, MON NOT R ASTRON SOC, V262, P545, DOI 10.1093/mnras/262.3.545; Kurtz S., 2000, Protostars and planets 4, P299; McKee CF, 2002, NATURE, V416, P59, DOI 10.1038/416059a; MILLER GE, 1979, ASTROPHYS J SUPPL S, V41, P513, DOI 10.1086/190629; Motte F, 1998, ASTRON ASTROPHYS, V336, P150; Pudritz RE, 2002, SCIENCE, V295, P68, DOI 10.1126/science.1068298; SALPETER EE, 1955, ASTROPHYS J, V121, P161, DOI 10.1086/145971; Sridharan TK, 2002, ASTROPHYS J, V566, P931, DOI 10.1086/338332; Stahler S. W., 2000, Protostars and planets 4, P327	16	66	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1167	1169		10.1126/science.1094014	http://dx.doi.org/10.1126/science.1094014			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976307				2022-12-28	WOS:000189074700038
J	Lau, HC; Rogers, RD; Haggard, P; Passingham, RE				Lau, HC; Rogers, RD; Haggard, P; Passingham, RE			Attention to intention	SCIENCE			English	Article							EXTERNALLY TRIGGERED MOVEMENTS; CONSCIOUS INTENTION; PARKINSONS-DISEASE; PREFRONTAL CORTEX; VOLUNTARY; POTENTIALS; BRAIN; MODULATION; ACTIVATION; AWARENESS	Intention is central to the concept of voluntary action. Using functional magnetic resonance imaging, we compared conditions in which participants made self-paced actions and attended either to their intention to move or to the actual movement. When they attended to their intention rather than their movement, there was an enhancement of activity in the pre-supplementary motor area (pre-SMA). We also found activations in the right dorsal prefrontal cortex and left intraparietal cortex. Prefrontal activity, but not parietal activity, was more strongly coupled with activity in the pre-SMA. We conclude that activity in the pre-SMA reflects the representation of intention.	Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Univ Oxford, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford, England; Univ Oxford, Dept Psychiat, Oxford, England; Univ Oxford, Ctr Clin Magnet Resonance Res, Oxford, England; UCL, Inst Congnit Neurosci, London WC1E 6BT, England; UCL, Dept Psychol, London WC1E 6BT, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of London; University College London; University of London; University College London	Lau, HC (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	chris.lau@psy.ox.ac.uk	Rogers, Robert/AAF-7621-2019; Haggard, Patrick/A-5081-2010	Rogers, Robert/0000-0001-5010-069X; Haggard, Patrick/0000-0001-7798-793X				Baars B. J., 1988, COGNITIVE THEORY CON; Beck DM, 2001, NAT NEUROSCI, V4, P645, DOI 10.1038/88477; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; FRIED I, 1991, J NEUROSCI, V11, P3656; Haggard P, 1999, EXP BRAIN RES, V126, P128, DOI 10.1007/s002210050722; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; Jenkins IH, 2000, BRAIN, V123, P1216, DOI 10.1093/brain/123.6.1216; Johansen-Berg H, 2002, EXP BRAIN RES, V142, P13, DOI 10.1007/s00221-001-0905-8; Joordens S, 2002, CONSCIOUS COGN, V11, P231, DOI 10.1006/ccog.2002.0559; KELLER I, 1990, ELECTROEN CLIN NEURO, V76, P351, DOI 10.1016/0013-4694(90)90036-J; Klein S, 2002, CONSCIOUS COGN, V11, P273, DOI 10.1006/ccog.2002.0557; LAU HC, IN PRESS NEUROIMAGE; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; Matelli M, 2001, NEUROIMAGE, V14, pS27, DOI 10.1006/nimg.2001.0835; Moutoussis K, 2002, P NATL ACAD SCI USA, V99, P9527, DOI 10.1073/pnas.142305699; PASSINGHAM RE, IN PRESS ATTENTION A; Pochon JB, 2001, CEREB CORTEX, V11, P260, DOI 10.1093/cercor/11.3.260; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Rowe J, 2002, BRAIN, V125, P276, DOI 10.1093/brain/awf036; Rowe J, 2002, NEUROIMAGE, V17, P988, DOI 10.1006/nimg.2002.1156; Rowe JB, 2001, NEUROIMAGE, V14, P77, DOI 10.1006/nimg.2001.0784; Sirigu A, 2004, NAT NEUROSCI, V7, P80, DOI 10.1038/nn1160; THALER D, 1995, EXP BRAIN RES, V102, P445; Thoenissen D, 2002, J NEUROSCI, V22, P9024; Toni I, 2002, J COGNITIVE NEUROSCI, V14, P769, DOI 10.1162/08989290260138663	30	394	395	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1208	1210		10.1126/science.1090973	http://dx.doi.org/10.1126/science.1090973			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976320				2022-12-28	WOS:000189074700051
J	Lin, BZ; Kolluri, SK; Lin, F; Liu, W; Han, YH; Cao, XH; Dawson, MI; Reed, JC; Zhang, XK				Lin, BZ; Kolluri, SK; Lin, F; Liu, W; Han, YH; Cao, XH; Dawson, MI; Reed, JC; Zhang, XK			Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3	CELL			English	Article							LUNG-CANCER CELLS; PROSTATE-CANCER; RECEPTOR TR3; CYTOCHROME-C; BH3 DOMAIN; APOPTOSIS; DEATH; BAX; PROTEIN; INDUCTION	The Bcl-2 family proteins are key regulators of apoptosis in human diseases and cancers. Though known to block apoptosis, Bcl-2 promotes cell death through an undefined mechanism. Here, we show that Bcl-2 interacts with orphan nuclear receptor Nur77 (also known as TR3), which is required for cancer cell apoptosis induced by many antineoplastic agents. The interaction is mediated by the N-terminal loop region of Bcl-2 and is required for Nur77 mitochondrial localization and apoptosis. Nur77 binding induces a Bcl-2 conformational change that exposes its BH3 domain, resulting in conversion of Bcl-2 from a protector to a killer. These findings establish the coupling of Nur77 nuclear receptor with the Bcl-2 apoptotic machinery and demonstrate that Bcl-2 can manifest opposing phenotypes, induced by interactions with proteins such as Nur77, suggesting novel strategies for regulating apoptosis in cancer and other diseases.	Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org; xzhang@burnham.org			NCI NIH HHS [CA60988, CA87000] Funding Source: Medline; NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087000, R01CA060988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; TANAKA S, 1992, LEUKEMIA, V6, pS15; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wilson AJ, 2003, CANCER RES, V63, P5401; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087	51	532	564	0	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					527	540		10.1016/S0092-8674(04)00162-X	http://dx.doi.org/10.1016/S0092-8674(04)00162-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980220	Bronze			2022-12-28	WOS:000189184200007
J	Vik, JO; Stenseth, NC; Tavecchia, G; Mysterud, A; Lingjaerde, OC				Vik, JO; Stenseth, NC; Tavecchia, G; Mysterud, A; Lingjaerde, OC			Living in synchrony on Greenland coasts?	NATURE			English	Editorial Material							DYNAMICS		Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, N-0316 Oslo, Norway; Univ Oslo, Dept Informat, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Vik, JO (corresponding author), Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, POB 1050 Blindern, N-0316 Oslo, Norway.	n.c.stenseth@bio.uio.no	Vik, Jon Olav/B-9350-2008; Tavecchia, Giacomo/N-3961-2014; Mysterud, Atle/AAQ-2864-2020; Stenseth, Nils Chr./G-5212-2016	Vik, Jon Olav/0000-0002-7778-4515; Tavecchia, Giacomo/0000-0001-5435-2691; Mysterud, Atle/0000-0001-8993-7382; Stenseth, Nils Chr./0000-0002-1591-5399; Lingjaerde, Ole Christian/0000-0003-3565-4912				Forchhammer MC, 2002, POPUL ECOL, V44, P113, DOI 10.1007/s101440200013; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; Post E, 2002, NATURE, V420, P168, DOI 10.1038/nature01064	4	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					697	698		10.1038/427697a	http://dx.doi.org/10.1038/427697a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973473				2022-12-28	WOS:000189026000031
J	Baas, AF; Kuipers, J; van der Wel, NN; Batlle, E; Koerten, HK; Peters, PJ; Clevers, HC				Baas, AF; Kuipers, J; van der Wel, NN; Batlle, E; Koerten, HK; Peters, PJ; Clevers, HC			Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD	CELL			English	Article							PEUTZ-JEGHERS-SYNDROME; DEPENDENT PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; TUMOR-SUPPRESSOR; CYTOPLASMIC LOCALIZATION; TIGHT JUNCTION; PAR GENES; GROWTH; POLARITY; CANCER	The LKB1 gene encodes a serine/threonine kinase that is mutated in the Peutz-Jeghers cancer syndrome. LKB1 is homologous to the Par-4 polarity genes in C. elegans and D. melanogaster. We have previously reported the identification and characterization of an LKB1-specific adaptor protein, STRAD, which activates LKB1 and translocates it from nucleus to cytoplasm. We have now constructed intestinal epithelial cell lines in which inducible STRAD activates LKB1. Upon LKB1 activation, single cells rapidly remodel their actin cytoskeleton to form an apical brush border. The junctional proteins ZO-1 and p120 redistribute in a dotted circle peripheral to the brush border, in the absence of cell-cell contacts. Apical and basolateral markers sort to their respective membrane domains. We conclude that LKB1 can induce complete polarity in intestinal epithelial cells. In contrast to current thinking on polarization of simple epithelia, these cells can fully polarize in the absence of junctional cell-cell contacts.	Ctr Biomed Genet, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Clevers, HC (corresponding author), Ctr Biomed Genet, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Van Der Wel, Nicole/AAE-7569-2020; Batlle, Eduard/K-8080-2014	Batlle, Eduard/0000-0003-2422-0326; van der Wel, Nicole/0000-0001-6392-3417				ALBERTS B, 2002, MOL BIOL CELL, P609; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Bowerman B, 1997, DEVELOPMENT, V124, P3815; CEREIJIDO M, 1980, J MEMBRANE BIOL, V52, P147, DOI 10.1007/BF01869120; CHENG NN, 1995, GENETICS, V139, P549; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Fleming TP, 2000, SEMIN CELL DEV BIOL, V11, P291, DOI 10.1006/scdb.2000.0179; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; MORTON DG, 1992, GENETICS, V130, P771; Nakau M, 2002, CANCER RES, V62, P4549; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Peters PJ, 2001, METHOD ENZYMOL, V329, P210; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; PINTO M, 1983, BIOL CELL, V47, P323; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; Watts JL, 2000, DEVELOPMENT, V127, P1467; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	49	404	413	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					457	466		10.1016/S0092-8674(04)00114-X	http://dx.doi.org/10.1016/S0092-8674(04)00114-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016379	Bronze			2022-12-28	WOS:000188825800013
J	Landick, R				Landick, R			Active-site dynamics in RNA polymerases	CELL			English	Editorial Material							STRUCTURAL BASIS; TRANSLOCATION; TRANSCRIPTION; ELONGATION; RESOLUTION; MECHANISM		Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Landick, R (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.							Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; TERNIAKOV D, 2004, CELL, V116, P381; Wang H, 2002, APPL PHYS A-MATER, V75, P315, DOI 10.1007/s003390201340; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5	10	33	39	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	2004	116	3					351	353		10.1016/S0092-8674(04)00121-7	http://dx.doi.org/10.1016/S0092-8674(04)00121-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016367	Bronze			2022-12-28	WOS:000188825800001
J	Bird, JP; Ochiai, Y				Bird, JP; Ochiai, Y			Electron spin polarization in nanoscale constrictions	SCIENCE			English	Editorial Material									Arizona State Univ, Dept Elect Engn, Tempe, AZ 85287 USA; Chiba Univ, Dept Mat Technol, Inage Ku, Chiba, Japan	Arizona State University; Arizona State University-Tempe; Chiba University	Bird, JP (corresponding author), Arizona State Univ, Dept Elect Engn, Tempe, AZ 85287 USA.	jpbird@imap3.asu.edu	Bird, Jonathan P/G-4068-2010	Bird, Jonathan P/0000-0002-6966-9007				Berggren KF, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.085323; Cronenwett SM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226805; Hirose K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026804; Kristensen A, 1998, PHYSICA B, V249, P180, DOI 10.1016/S0921-4526(98)00094-5; Morimoto T, 2003, APPL PHYS LETT, V82, P3952, DOI 10.1063/1.1579851; Puller VI, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.096802; Reilly DJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.246801; Thomas KJ, 1996, PHYS REV LETT, V77, P135, DOI 10.1103/PhysRevLett.77.135; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; WHARAM DA, 1988, J PHYS C SOLID STATE, V21, pL209, DOI 10.1088/0022-3719/21/8/002	10	43	43	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1621	1622		10.1126/science.1094520	http://dx.doi.org/10.1126/science.1094520			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016986				2022-12-28	WOS:000220151400029
J	Hsiao, JC; Fong, K				Hsiao, JC; Fong, K			Making big money from small technology	NATURE			English	Editorial Material							NANOTECHNOLOGY		Inframat, Farmington, CT 06032 USA; Kenson Ventures, Menlo Pk, CA 94025 USA		Hsiao, JC (corresponding author), Inframat, 74 Batterson Pk Rd, Farmington, CT 06032 USA.							Bai CL, 2001, J NANOPART RES, V3, P251, DOI 10.1023/A:1017988725647; Christensen C.M., 2013, INNOVATORS DILEMMA N; HSIAO JC, 2002, P 5 ANN BCC C NAN 20; MOORE GA, 2002, LIVING FAULT LINE; Paull R, 2003, NAT BIOTECHNOL, V21, P1144, DOI 10.1038/nbt1003-1144	5	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					218	220		10.1038/428218a	http://dx.doi.org/10.1038/428218a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014512				2022-12-28	WOS:000220103600061
J	Rowshani, AT; Schot, LJ; ten Berge, IJM				Rowshani, AT; Schot, LJ; ten Berge, IJM			c-ANCA as a serological pitfall	LANCET			English	Editorial Material							VASCULITIS		Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Clin Immunol & Rheumatol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Rowshani, AT (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Clin Immunol & Rheumatol, NL-1100 DE Amsterdam, Netherlands.	T.Rowshani@AMC.UVA.NL						Armstrong M Jr, 1996, Ear Nose Throat J, V75, P623; CHEVALIER X, 1995, CLIN NEPHROL, V43, P348; Gertner E, 2002, J RHEUMATOL, V29, P1795; KRENDEL DA, 1990, NEUROLOGY, V40, P1092, DOI 10.1212/WNL.40.7.1092; Trimarchi M, 2001, MEDICINE, V80, P391, DOI 10.1097/00005792-200111000-00005	5	21	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					782	782		10.1016/S0140-6736(04)15694-8	http://dx.doi.org/10.1016/S0140-6736(04)15694-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016489				2022-12-28	WOS:000220092000009
J	Nishimura, I; Yang, YF; Lu, BW				Nishimura, I; Yang, YF; Lu, BW			PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED-HELICAL-FILAMENT; C-ELEGANS PAR-1; ALZHEIMERS-DISEASE; TRANSGENIC MICE; PROTEIN-KINASE; NEUROFIBRILLARY TANGLES; FRONTOTEMPORAL DEMENTIA; NEURONAL POLARITY; IN-VIVO	Multisite hyperphosphorylation of tau has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD). However, the phosphorylation events critical for tau toxicity and mechanisms regulating these events are largely unknown. Here we show that Drosophila PAR-1 kinase initiates tau toxicity by triggering a temporally ordered phosphorylation process. PAR-1 directly phosphorylates tau at S262 and S356. This phosphorylation event is a prerequisite for the action of downstream kinases, including glycogen synthase kinase 3 (GSK-3) and cyclin-dependent kinase-5 (Cdk5), to phosphorylate several other sites and generate disease-associated phospho-epitopes. The initiator role of PAR-1 is further underscored by the fact that mutating PAR-1 phosphorylation sites causes a much greater reduction of overall tau phosphorylation and toxicity than mutating S202, one of the downstream sites whose phosphorylation depends on prior PAR-1 action. These findings begin to differentiate the effects of various phosphorylation events on tau toxicity and provide potential therapeutic targets.	Rockefeller Univ, Dev Neurobiol Lab, New York, NY 10021 USA	Rockefeller University	Lu, BW (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	bingwei@stanford.edu		Lu, Bingwei/0000-0002-5807-7014				Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAND AH, 1993, DEVELOPMENT, V118, P401; Connell-Crowley L, 2000, CURR BIOL, V10, P599, DOI 10.1016/S0960-9822(00)00487-5; Cox DN, 2001, CURR BIOL, V11, P75, DOI 10.1016/S0960-9822(01)00027-6; Davies P, 2000, ANN NY ACAD SCI, V924, P8, DOI 10.1111/j.1749-6632.2000.tb05553.x; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Goedert M, 1998, PROG BRAIN RES, V117, P287; GOEDERT M, 1995, NEUROBIOL AGING, V16, P325, DOI 10.1016/0197-4580(95)00017-9; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heidary G, 2001, MECH DEVELOP, V108, P171, DOI 10.1016/S0925-4773(01)00487-7; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jenkins SM, 2000, J NEUROCHEM, V74, P1463, DOI 10.1046/j.1471-4159.2000.0741463.x; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Liu JH, 2002, ASIAN J SOC PSYCHOL, V5, P3, DOI 10.1111/1467-839X.00091; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mandelkow E, 1999, NATURE, V402, P588, DOI 10.1038/45095; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; MORENO FJ, 1995, FEBS LETT, V372, P65, DOI 10.1016/0014-5793(95)00934-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Riechmann V, 2002, NAT CELL BIOL, V4, P337, DOI 10.1038/ncb782; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	53	247	256	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					671	682		10.1016/S0092-8674(04)00170-9	http://dx.doi.org/10.1016/S0092-8674(04)00170-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006350	Bronze			2022-12-28	WOS:000221499700008
J	Woolhead, CA; McCormick, PJ; Johnson, AE				Woolhead, CA; McCormick, PJ; Johnson, AE			Nascent membrane and secretory proteins differ in FRET-detected folding far inside the ribosome and in their exposure to ribosomal proteins	CELL			English	Article							FLUORESCENCE ENERGY-TRANSFER; ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; ER MEMBRANE; TRANSLOCON PORE; ANGSTROM RESOLUTION; ORIENTATION FACTOR; STRUCTURAL BASIS; TRANSFER-RNA; TUNNEL	Fluorescence resonance energy transfer measurements reveal that a transmembrane sequence within a nascent membrane protein folds into a compact conformation near the peptidyltransferase center and remains folded as the sequence moves through a membrane bound ribosome into the translocon. This compact conformation is compatible with an alpha helix because nearly the same energy transfer efficiency was observed when the transmembrane sequence was integrated into the lipid bilayer. Since the transmembrane sequence unfolds upon emerging from a free ribosome, this nascent chain folding is ribosome induced and stabilized. In contrast, a nascent secretory protein is in an extended conformation in the exit tunnel. Furthermore, two ribosomal proteins photo-crosslink to nascent membrane but not secretory proteins. These interactions coincide with the previously described sequential closing and opening of the two ends of the aqueous translocon pore, thereby suggesting that ribosomal recognition of nascent chain folding controls the operational mode of the translocon at the ER membrane.	Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.	aejohnson@tamu.edu	Johnson, Arthur E/G-3457-2012; McCormick, Peter/E-7387-2012	McCormick, Peter/0000-0002-2225-5181	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Berisio R, 2003, NAT STRUCT BIOL, V10, P366, DOI 10.1038/nsb915; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; HILLEL Z, 1976, BIOCHEMISTRY-US, V15, P2105, DOI 10.1021/bi00655a012; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Kramer G, 2001, INT J BIOCHEM CELL B, V33, P541, DOI 10.1016/S1357-2725(01)00044-9; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; WATSON BS, 1995, BIOCHEMISTRY-US, V34, P7904, DOI 10.1021/bi00024a015; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wirth A, 2003, MOL CELL, V12, P261, DOI 10.1016/S1097-2765(03)00283-1; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	37	302	307	1	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					725	736		10.1016/S0092-8674(04)00169-2	http://dx.doi.org/10.1016/S0092-8674(04)00169-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006354	Bronze			2022-12-28	WOS:000221499700012
J	Guppy, MPB; Mickan, SM; Del Mar, CB				Guppy, MPB; Mickan, SM; Del Mar, CB			"Drink plenty of fluids": a systematic review of evidence for this recommendation in acute respiratory infections	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PNEUMONIA; HYPONATREMIA; INFANTS; WATER		Univ Queensland, Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia	University of Queensland	Del Mar, CB (corresponding author), Univ Queensland, Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia.	c.delmar@cgp.uq.edu.au	Mickan, Sharon/AAZ-6262-2021; Del Mar, Chris B/B-1136-2008; Mickan, Sharon m/C-8840-2012	Mickan, Sharon/0000-0002-5690-1997; Del Mar, Chris B/0000-0003-3821-8163; Mickan, Sharon m/0000-0002-5690-1997; Guppy, Michelle/0000-0001-7256-4938				DHAWAN A, 1992, ANN TROP PAEDIATR, V12, P455, DOI 10.1080/02724936.1992.11747614; DREYFUSS D, 1988, AM REV RESPIR DIS, V138, P583, DOI 10.1164/ajrccm/138.3.583; GOZAL D, 1990, PEDIATR RES, V27, P204, DOI 10.1203/00006450-199002000-00023; RIVERS RPA, 1981, ARCH DIS CHILD, V56, P358, DOI 10.1136/adc.56.5.358; SHANN F, 1985, ARCH DIS CHILD, V60, P963, DOI 10.1136/adc.60.10.963	5	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					499	500		10.1136/bmj.38028.627593.BE	http://dx.doi.org/10.1136/bmj.38028.627593.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988184	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220002900025
J	Harker, N; Montgomery, A; Fahey, T				Harker, N; Montgomery, A; Fahey, T			Interactive case report - Treating nausea and vomiting during pregnancy: case outcome	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Dean Lane Family Practice, Bristol, Avon, England; Univ Bristol, Div Primary Hlth Care, Bristol BS8 1TH, Avon, England	University of Bristol	Fahey, T (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland.	t.p.fahey@dundee.ac.uk	Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Montgomery, Alan/0000-0003-0450-1606				Jewell D, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000145; Jewell David, 2003, Clin Evid, P1561; Magee LA, 1996, BRIT J OBSTET GYNAEC, V103, P478, DOI 10.1111/j.1471-0528.1996.tb09779.x; Niebyl JR, 2002, AM J OBSTET GYNECOL, V186, pS253, DOI 10.1067/mob.2002.122595; Ranzini Angela, 2001, Obstetrics and Gynecology, V97, p46S, DOI 10.1016/S0029-7844(01)01255-8	5	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					503	503		10.1136/bmj.328.7438.503	http://dx.doi.org/10.1136/bmj.328.7438.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988187	Green Published			2022-12-28	WOS:000220002900028
J	Andreae, MO; Rosenfeld, D; Artaxo, P; Costa, AA; Frank, GP; Longo, KM; Silva-Dias, MAF				Andreae, MO; Rosenfeld, D; Artaxo, P; Costa, AA; Frank, GP; Longo, KM; Silva-Dias, MAF			Smoking rain clouds over the Amazon	SCIENCE			English	Article							CONDENSATION NUCLEI; AEROSOL-PARTICLES; FOREST; PRECIPITATION; ATMOSPHERE; CLIMATE	Heavy smoke from forest. res in the Amazon was observed to reduce cloud droplet size and so delay the onset of precipitation from 1.5 kilometers above cloud base in pristine clouds to more than 5 kilometers in polluted clouds and more than 7 kilometers in pyro-clouds. Suppression of low-level rainout and aerosol washout allows transport of water and smoke to upper levels, where the clouds appear "smoking" as they detrain much of the pollution. Elevating the onset of precipitation allows invigoration of the updrafts, causing intense thunderstorms, large hail, and greater likelihood for overshooting cloud tops into the stratosphere. There, detrained pollutants and water vapor would have profound radiative impacts on the climate system. The invigorated storms release the latent heat higher in the atmosphere. This should substantially affect the regional and global circulation systems. Together, these processes affect the water cycle, the pollution burden of the atmosphere, and the dynamics of atmospheric circulation.	Max Planck Inst Chem, Biogeochem Dept, D-55020 Mainz, Germany; Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel; Univ Sao Paulo, Inst Fis, BR-05508900 Sao Paulo, Brazil; Univ Estadual Ceara, BR-60740000 Fortaleza, Ceara, Brazil; Inst Nacl Pesquisas Espaciais, Ctr Previsao Tempo & Estudo Climat, BR-12630000 Sao Paulo, Brazil; Univ Sao Paulo, Inst Astron Geofis & Ciencias Atmosfer, Dept Ciencias Atmosfer, BR-05508900 Sao Paulo, Brazil	Max Planck Society; Hebrew University of Jerusalem; Universidade de Sao Paulo; Universidade Estadual do Ceara; Instituto Nacional de Pesquisas Espaciais (INPE); Universidade de Sao Paulo	Andreae, MO (corresponding author), Max Planck Inst Chem, Biogeochem Dept, POB 3060, D-55020 Mainz, Germany.	andreae@mpch-mainz.mpg.de; Daniel.rosenfeld@huji.ac.il	Rosenfeld, Daniel/AAJ-4617-2021; Andreae, Meinrat O./B-1068-2008; Costa, Alexandre Augusto da/HCJ-0140-2022; Rosenfeld, Daniel/F-6077-2016; Artaxo, Paulo/E-8874-2010; Costa, Alexandre/AAM-3227-2021	Rosenfeld, Daniel/0000-0002-0784-7656; Andreae, Meinrat O./0000-0003-1968-7925; Costa, Alexandre Augusto da/0000-0001-7558-5435; Rosenfeld, Daniel/0000-0002-0784-7656; Artaxo, Paulo/0000-0001-7754-3036; Costa, Alexandre/0000-0002-1905-6456; Frank, Goran/0000-0003-4207-7391				Andreae MO, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000524; Andreae MO, 2001, GEOPHYS RES LETT, V28, P951, DOI 10.1029/2000GL012391; ANDREAE MO, 1995, J GEOPHYS RES-ATMOS, V100, P11335, DOI 10.1029/94JD02828; ANDREAE MO, UNPUB; BAKER MB, 1990, NATURE, V345, P142, DOI 10.1038/345142a0; Dias MAFS, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000335; EAGAN RC, 1974, J APPL METEOROL, V13, P553, DOI 10.1175/1520-0450(1974)013<0553:MOCCNA>2.0.CO;2; Feingold G, 2001, J GEOPHYS RES-ATMOS, V106, P22907, DOI 10.1029/2001JD000732; Ferek RJ, 1998, J GEOPHYS RES-ATMOS, V103, P32107, DOI 10.1029/98JD00692; Freitas S. R., 2000, HYBRID METHODS ENG, V3, P317; Graham B, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000336; GRIMM AM, 1995, J ATMOS SCI, V52, P3538, DOI 10.1175/1520-0469(1995)052<3538:AOTIWI>2.0.CO;2; Guyon P, 2003, ATMOS CHEM PHYS, V3, P951, DOI 10.5194/acp-3-951-2003; Hobbs PV, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002352; JOHNSON DB, 1982, J ATMOS SCI, V39, P448, DOI 10.1175/1520-0469(1982)039<0448:TROGAU>2.0.CO;2; KASAHARA A, 1986, J ATMOS SCI, V43, P1893, DOI 10.1175/1520-0469(1986)043<1893:ROPWTS>2.0.CO;2; Kaufman YJ, 1997, SCIENCE, V277, P1636, DOI 10.1126/science.277.5332.1636; Mayol-Bracero OL, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000522; MOLINIE J, 1995, GEOPHYS RES LETT, V22, P1085, DOI 10.1029/95GL01036; Nober FJ, 2003, GLOBAL PLANET CHANGE, V37, P57, DOI 10.1016/S0921-8181(02)00191-1; Procopio AS, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018063; RADKE LF, 1991, GLOBAL BIOMASS BURNING, P209; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Reid JS, 1999, J GEOPHYS RES-ATMOS, V104, P6145, DOI 10.1029/1998JD200119; Reid JS, 1998, J GEOPHYS RES-ATMOS, V103, P32059, DOI 10.1029/98JD00458; Roberts GC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD000985; Roberts GC, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000583; Roberts MC, 2001, GEOPHYS RES LETT, V28, P2807, DOI 10.1029/2000GL012585; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 1998, B AM METEOROL SOC, V79, P2457, DOI 10.1175/1520-0477(1998)079<2457:SBIIPF>2.0.CO;2; Rosenfeld D, 2002, SCIENCE, V297, P1667, DOI 10.1126/science.1073869; ROSENFELD D, 1999, 7 WORLD MET ORG SCI; ROSENFELD D, 2003, CLOUD SYSTEMS HURRIC, V51, P59; Sherwood S, 2002, SCIENCE, V295, P1272, DOI 10.1126/science.1065080; Williams E, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000380; ZIPSER EJ, 1994, MON WEATHER REV, V122, P1837, DOI 10.1175/1520-0493(1994)122<1837:DCCSIT>2.0.CO;2	36	1021	1068	12	258	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1337	1342		10.1126/science.1092779	http://dx.doi.org/10.1126/science.1092779			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988556	Green Submitted			2022-12-28	WOS:000189238600042
J	Montgomery, S				Montgomery, S			Of towers, walls, and fields: Perspectives on language in science	SCIENCE			English	Editorial Material								Language in science is in the midst of change and appears dominated by two contradictory trends. Globalization of scientific English seems to promise greater international unity, while growth of field-specific jargon suggests communicational diaspora. Real in part, each trend is complex and multileveled, and includes elements of convergence and divergence, along with important implications for the present and future of technical knowledge.			Montgomery, S (corresponding author), 1511 18th Ave E, Seattle, WA 98112 USA.	scott.montgomery@prodigy.net						[Anonymous], 1997, ENGLISH GLOBAL LANGU; Canagarajah A. S., 1999, RESISTING LINGUISTIC; CRYSTAL D, 1995, CAMBRIDGE ENCY ENGLI, P119; Gorlach Manfred, 2002, STILL MORE ENGLISHES; Graddol D., 1999, AILA REV, V13, P57; KACHRU B, 1909, OTHER TONGUE ENGLISH; Kachru B. B., 2001, ANAL ENGLISH GLOBAL, P9; LARGE A, 1983, FOREIGN LANGUAGE BAR; McArthur T, 1998, ENGLISH LANGUAGES, P247; MONTGOMERY SL, 2000, SCI TRANSLATION MOVE, P258; Pennycook Alastair, 1994, CULTURAL POLITICS EN; Phillipson R., 1992, LINGUISTIC IMPERIALI	12	46	47	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1333	1335		10.1126/science.1095204	http://dx.doi.org/10.1126/science.1095204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988554				2022-12-28	WOS:000189238600040
J	Shimojima, M; Miyazawa, T; Ikeda, Y; McMonagle, EL; Haining, H; Akashi, H; Takeuchi, Y; Hosie, MJ; Willett, BJ				Shimojima, M; Miyazawa, T; Ikeda, Y; McMonagle, EL; Haining, H; Akashi, H; Takeuchi, Y; Hosie, MJ; Willett, BJ			Use of CD134 as a primary receptor by the feline immunodeficiency virus	SCIENCE			English	Article							ACTIVATED RAT; SHARED USAGE; CXCR4; EXPRESSION; INFECTION; OX40; MOLECULE; TROPISM; ANTIGEN; LIGAND	Feline immunodeficiency virus (FIV) induces a disease similar to acquired immunodeficiency syndrome (AIDS) in cats, yet in contrast to human immunodeficiency virus (HIV), CD4 is not the viral receptor. We identified a primary receptor for FIV as CD134 (OX40), a T cell activation antigen and costimulatory molecule. CD134 expression promotes viral binding and renders cells permissive for viral entry, productive infection, and syncytium formation. Infection is CXCR4-dependent, analogous to infection with X4 strains of HIV. Thus, despite the evolutionary divergence of the feline and human lentiviruses, both viruses use receptors that target the virus to a subset of cells that are pivotal to the acquired immune response.	Univ Glasgow, Inst Comparat Med, Retrovirus Res Lab, Glasgow G61 1QH, Lanark, Scotland; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Microbiol, Bunkyo Ku, Tokyo 1138657, Japan; Obihiro Univ Agr & Vet Med, Dept Vet Publ Hlth, Obihiro, Hokkaido 0808555, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; UCL, Windeyer Inst Med Sci, Dept Immunol & Mol Pathol, London W1T 4JF, England	University of Glasgow; University of Tokyo; Obihiro University of Agriculture & Veterinary Medicine; Japan Science & Technology Agency (JST); University of London; University College London	Willett, BJ (corresponding author), Univ Glasgow, Inst Comparat Med, Retrovirus Res Lab, Glasgow G61 1QH, Lanark, Scotland.	b.willett@vet.gla.ac.uk	Willett, Brian J/F-3396-2011	Miyazawa, Takayuki/0000-0003-1938-9661	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049765] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49765-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlShamkhani A, 1996, EUR J IMMUNOL, V26, P1695, DOI 10.1002/eji.1830260805; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; de Parseval A, 2001, J VIROL, V75, P4528, DOI 10.1128/JVI.75.10.4528-4539.2001; Dean GA, 1996, J VIROL, V70, P5165, DOI 10.1128/JVI.70.8.5165-5169.1996; Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9; DURKOP H, 1995, BRIT J HAEMATOL, V91, P927, DOI 10.1111/j.1365-2141.1995.tb05413.x; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENGLISH RV, 1993, J VIROL, V67, P5175, DOI 10.1128/JVI.67.9.5175-5186.1993; Gramaglia I, 1998, J IMMUNOL, V161, P6510; HOSIE MJ, 1992, VET IMMUNOL IMMUNOP, V35, P191, DOI 10.1016/0165-2427(92)90131-9; Hosie MJ, 1998, J VIROL, V72, P2097, DOI 10.1128/JVI.72.3.2097-2104.1998; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lerner DL, 2000, J VIROL, V74, P1854, DOI 10.1128/JVI.74.4.1854-1863.2000; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MIYAZAWA T, 1989, ARCH VIROL, V108, P131, DOI 10.1007/BF01313750; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PEDERSEN NC, 1993, RETROVIRIDAE, V2, pCH3; Richardson J, 1999, J VIROL, V73, P3661, DOI 10.1128/JVI.73.5.3661-3671.1999; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; Shimojimaa M, 2003, ANAL BIOCHEM, V315, P138, DOI 10.1016/S0003-2697(02)00708-X; Stuber E, 1996, J EXP MED, V183, P979, DOI 10.1084/jem.183.3.979; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Willett BJ, 1998, J VIROL, V72, P6475, DOI 10.1128/JVI.72.8.6475-6481.1998; Willett BJ, 1997, J VIROL, V71, P6407, DOI 10.1128/JVI.71.9.6407-6415.1997; Willett BJ, 2003, J VIROL, V77, P709, DOI 10.1128/JVI.77.1.709-712.2003; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681	29	143	150	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1192	1195		10.1126/science.1092124	http://dx.doi.org/10.1126/science.1092124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976315	Green Accepted			2022-12-28	WOS:000189074700046
J	Rothwell, N				Rothwell, N			One more thing... How an extra control experiment led to a change of research field.	NATURE			English	Editorial Material									Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Rothwell, N (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	2004	427	6976					683	683		10.1038/427683a	http://dx.doi.org/10.1038/427683a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973460				2022-12-28	WOS:000189026000020
J	Cormack, B				Cormack, B			Can you adhere me now? Good	CELL			English	Editorial Material							YEAST; MODEL		Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21210 USA	Johns Hopkins University	Cormack, B (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21210 USA.							Barry JD, 2003, INT J PARASITOL, V33, P29, DOI 10.1016/S0020-7519(02)00247-3; Boucher JC, 1997, INFECT IMMUN, V65, P3838, DOI 10.1128/IAI.65.9.3838-3846.1997; De las Penas A, 2003, GENE DEV, V17, P2245, DOI 10.1101/gad.1121003; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; Halme A, 2004, CELL, V116, P405, DOI 10.1016/S0092-8674(04)00118-7; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; Reynolds TB, 2001, SCIENCE, V291, P878, DOI 10.1126/science.291.5505.878; SOLL DR, 1992, CLIN MICROBIOL REV, V5, P183, DOI 10.1128/CMR.5.2.183-203.1992; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U	10	3	3	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					353	354		10.1016/S0092-8674(04)00124-2	http://dx.doi.org/10.1016/S0092-8674(04)00124-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016368	Bronze			2022-12-28	WOS:000188825800002
J	Wang, Z; Lin, HF				Wang, Z; Lin, HF			Nanos maintains germline stem cell self-renewal by preventing differentiation	SCIENCE			English	Article							DROSOPHILA; PUMILIO; GENE; TRANSCRIPTION; DIVISION; PROTEINS; ROLES; RNA	Despite much progress in understanding how extrinsic signaling regulates stem cell self-renewal, little is known about how cell-autonomous gene regulation controls this process. In Drosophila ovaries, germline stem cells (GSCs) divide asymmetrically to produce daughter GSCs and cystoblasts, the latter of which develop into germline cysts. Here, we show that removing the translational repressor Nanos from either GSCs or their precursors, the primordial germ cells (PGCs), causes both cell types to differentiate into germline cysts. Thus, Nanos is essential for both establishing and maintaining GSCs by preventing their precocious entry into oogenesis. These functions are likely achieved by repressing the translation of differentiation factors in PGCs and GSCs.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Lin, HF (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	h.lin@cellbio.duke.edu	Wang, Zhong/J-3244-2019; Wang, Zhong/E-7897-2011	Wang, Zhong/0000-0002-6307-0458; 	NICHD NIH HHS [HD33760] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033760] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Bhat KM, 1999, GENETICS, V151, P1479; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; CHOU TB, 1992, GENETICS, V131, P643; Deshpande G, 1999, CELL, V99, P271, DOI 10.1016/S0092-8674(00)81658-X; Forbes A, 1998, DEVELOPMENT, V125, P679; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; KING RC, 1970, OVARIAN DEV DROSOPHI, P54; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Koprunner M, 2001, GENE DEV, V15, P2877; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; LIN H, 1993, DEV BIOL, V159, P140, DOI 10.1006/dbio.1993.1228; LIN H, 2004, STEM CELLS HDB, P57; LIN HF, 1995, DEV GENET, V16, P6, DOI 10.1002/dvg.1020160104; Lin HF, 1997, DEVELOPMENT, V124, P2463; Parisi M, 1999, GENETICS, V153, P235; POIRIE M, 1995, DEVELOPMENT, V121, P1867; Song XQ, 2004, DEVELOPMENT, V131, P1353, DOI 10.1242/dev.01026; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; Tsuda M, 2003, SCIENCE, V301, P1239, DOI 10.1126/science.1085222; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; Zhu CH, 2003, DEVELOPMENT, V130, P2579, DOI 10.1242/dev.00499	25	183	197	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2016	2019		10.1126/science.1093983	http://dx.doi.org/10.1126/science.1093983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	14976263				2022-12-28	WOS:000220429800041
J	Gibbs, JL; Monro, JL; Cunningham, D; Rickards, A				Gibbs, JL; Monro, JL; Cunningham, D; Rickards, A			Survival after surgery or therapeutic catheterisation for congenital heart disease in children in the United Kingdom: analysis of the central cardiac audit database for 2000-1	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE	Objectives To analyse simple national statistics and survival data collected in the central cardiac audit database after treatment for congenital heart disease and to provide long term comparative statistics for each contributing centre. Design Prospective, longitudinal, observational, national cohort survival study. Setting UK central cardiac audit database. Main outcome measures Survival at 30 days and one year after treatment in the year April 2006-March 200 1, assessed by using both volunteered life status and independently validated life status through the Office for National Statistics, using the patient's unique NHS number, or the general register offices of Scotland and Northern Ireland. Institutional results following a group of six benchmark operations and three benchmark catheterisation procedures. Results Since April 2000 data have been received from all 13 UK tertiary centres performing cardiac surgery or therapeutic cardiac catheterisation in children with congenital heart disease. Altogether 3666 surgical procedures and 1828 therapeutic catheterisations were performed. Central tracking of mortality identified 469 deaths, 194 occurring within, 30 days and 27 5 later. Forty two of the 194 deaths within 30 days were detected by central tracking but not by volunteered data. For surgery overall, survival at 30 days was 94.9%, falling to 91.2% at one year; this effect was most marked for infants. For therapeutic catheterisation survival at 30 days was 99.1%, falling to 98.1% at one year. Survival of individual centres or individual operators did not differ from the national average after benchmark procedures. Conclusions Independent data validation is essential for accurate survival analysis. One year survival gives a more realistic view of outcome than traditional perioperative mortality. Currently no detectable difference exists in survival between any of the 13 UK tertiary congenital heart disease centres, but confidence intervals for small centres are wide, limiting our power to detect underperformance from analysis of a single year's data. Appropriately resourced, focused national audit is capable of accurate data collection on which nationwide, long term quality control can be based.	Gen Infirm, Dept Pediat Cardiol, Cent Cardiac Audit Database, Leeds LS1 3EX, W Yorkshire, England; Southampton Gen Hosp, Soc Cardiothorac Surg England & Ireland, Southampton SO16 6YD, Hants, England; Royal Brompton Hosp, Cent Cardiac Audit Database, London SW3 6NP, England	Leeds General Infirmary; University of Southampton; Royal Brompton Hospital	Gibbs, JL (corresponding author), Gen Infirm, Dept Pediat Cardiol, Cent Cardiac Audit Database, Leeds LS1 3EX, W Yorkshire, England.	jgibbs@boltblue.com						Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Franklin R C, 2000, Cardiol Young, V10 Suppl 1, P1; Gallivan S, 2001, EUR J CARDIO-THORAC, V20, P1214, DOI 10.1016/S1010-7940(01)01008-9; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; Lacour-Gayet F, 2000, EUR J CARDIO-THORAC, V18, P128, DOI 10.1016/S1010-7940(00)00463-2; Mavroudis C, 2000, Ann Thorac Surg, V69, pS2; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Nieminen HP, 2001, CIRCULATION, V104, P570, DOI 10.1161/hc3101.093968; Stark J, 2000, LANCET, V355, P1004, DOI 10.1016/S0140-6736(00)90001-1; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774	10	63	68	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 13	2004	328	7440					611	615		10.1136/bmj.38027.613403.F6	http://dx.doi.org/10.1136/bmj.38027.613403.F6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	14982866	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000220208100017
J	Brose, U; Ostling, A; Harrison, K; Martinez, ND				Brose, U; Ostling, A; Harrison, K; Martinez, ND			Unified spatial scaling of species and their trophic interactions	NATURE			English	Article							FOOD-WEB STRUCTURE; AREA; CONNECTANCE; PATTERNS; ENDEMISM	Two largely independent bodies of scaling theory address the quantitative relationships between habitat area, species diversity and trophic interactions. Spatial theory within macroecology addresses how species richness scales with area in landscapes, while typically ignoring interspecific interactions(1-6). Complexity theory within community ecology addresses how trophic links scale with species richness in food webs, while typically ignoring spatial considerations(7-12). Recent studies suggest unifying these theories by demonstrating how spatial patterns influence food-web structure(13-16) and vice versa(17). Here, we follow this suggestion by developing and empirically testing a more unified scaling theory. On the basis of power-law species-area relationships, we develop link-area and non-power-law link-species models that accurately predict how trophic links scale with area and species richness of microcosms, lakes and streams from community to metacommunity levels. In contrast to previous models that assume that species richness alone determines the number of trophic links(7,8), these models include the species' spatial distribution, and hence extend the domain of complexity theory to metacommunity scales. This generality and predictive success shows how complexity theory and spatial theory can be unified into a much more general theory addressing new domains of ecology.	Rocky Mt Biol Labs, Pacific Ecoinformat & Computat Ecol Lab, Crested Butte, CO 81224 USA; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; San Francisco State Univ, Dept Comp Sci, San Francisco, CA 94132 USA	University of California System; University of California Berkeley; California State University System; San Francisco State University	Brose, U (corresponding author), Tech Univ Darmstadt, Dept Biol, Schnittspahnstr 3, D-64287 Darmstadt, Germany.	brose@sfsu.edu	Brose, Ulrich/I-3488-2014; Brose, Ulrich/AAT-7547-2020; Martinez, Neo/A-5312-2008	Brose, Ulrich/0000-0001-9156-583X; Martinez, Neo/0000-0002-1130-5550				Bersier LF, 1997, P NATL ACAD SCI USA, V94, P1247, DOI 10.1073/pnas.94.4.1247; Brose U, 2003, SCIENCE, V301; CARTER JL, 2000, 00346 CAL US GEOL SU; CARTER JL, 2000, 0068 CAL US GEOL SUR; COHEN JE, 1984, P NATL ACAD SCI-BIOL, V81, P4105, DOI 10.1073/pnas.81.13.4105; COHEN JE, 1991, AM NAT, V138, P1542, DOI 10.1086/285299; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; Dunne JA, 2002, ECOL LETT, V5, P558, DOI 10.1046/j.1461-0248.2002.00354.x; Green JL, 2003, ECOL LETT, V6, P919, DOI 10.1046/j.1461-0248.2003.00519.x; HARRISON K, 2003, THESIS SAN FRANCISCO; Harte J, 1997, OIKOS, V80, P417, DOI 10.2307/3546614; HAVENS K, 1992, SCIENCE, V257, P1107, DOI 10.1126/science.257.5073.1107; Holt RD, 2002, ECOL RES, V17, P261, DOI 10.1046/j.1440-1703.2002.00485.x; Holt RD, 1999, ECOLOGY, V80, P1495, DOI 10.2307/176542; Holyoak M, 2000, AM NAT, V156, P378, DOI 10.1086/303395; HUBBELL SP, 1997, UNIFIED THEORY BIOGE; MACARTHUR RH, 1962, THEORY ISLAND BIOGEO; MARTINEZ ND, 1995, OIKOS, V73, P148, DOI 10.2307/3545903; MARTINEZ ND, 1995, LINKING SPECIES & ECOSYSTEMS, P166; Martinez ND, 1999, ECOLOGY, V80, P1044, DOI 10.1890/0012-9658(1999)080[1044:EOSEOC]2.0.CO;2; MARTINEZ ND, 1992, AM NAT, V139, P1208, DOI 10.1086/285382; May R.M., 1974, STABILITY COMPLEXITY; PIMM SL, 1991, NATURE, V350, P669, DOI 10.1038/350669a0; Post DM, 2000, NATURE, V405, P1047, DOI 10.1038/35016565; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Schmid-Araya JM, 2002, J ANIM ECOL, V71, P1056, DOI 10.1046/j.1365-2656.2002.00668.x; SCHOENER TW, 1989, ECOLOGY, V70, P1559, DOI 10.2307/1938088; Spencer M, 1996, OIKOS, V75, P419, DOI 10.2307/3545882; SUTHERLAND JW, 1989, FIELD SURVEY BIOTA S; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572	30	98	102	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					167	171		10.1038/nature02297	http://dx.doi.org/10.1038/nature02297			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014497				2022-12-28	WOS:000220103600045
J	Wu, R				Wu, R			Making an impact	NATURE			English	Editorial Material									Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Wu, R (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.							WU R, 2003, CHINESE AM SCI TECHN, P37	1	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					206	207		10.1038/428206a	http://dx.doi.org/10.1038/428206a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014507				2022-12-28	WOS:000220103600056
J	Tuomilehto, J; Hu, G; Bidel, S; Lindstrom, J; Jousilahti, P				Tuomilehto, J; Hu, G; Bidel, S; Lindstrom, J; Jousilahti, P			Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; CHLOROGENIC ACID; CAFFEINE INTAKE; LEISURE-TIME; LIFE-STYLE; GREEN TEA; DISEASE	Context Only a few studies of coffee consumption and diabetes mellitus (DM) have been reported, even though coffee is the most consumed beverage in the world. Objective To determine the relationship between coffee consumption and the incidence of type 2 DM among Finnish individuals, who have the highest coffee consumption in the world. Design, Setting, and Participants A prospective study from combined surveys conducted in 1982, 1987, and 1992 of 6974 Finnish men and 7655 women aged 35 to 64 years without history of stroke, coronary heart disease, or DM at baseline, with 175682 person-years of follow-up. Coffee consumption and other study parameters were determined at baseline using standardized measurements. Main Outcome Measures Hazard ratios (HRs) for the incidence of type 2 DM were estimated for different levels of daily coffee consumption. Results During a mean follow-up of 12 years, there were 381 incident cases of type 2 DM. After adjustment for confounding factors (age, study year, body mass index, systolic blood pressure, education, occupational, commuting and leisure-time physical activity, alcohol and tea consumption, and smoking), the HRs of DM associated with the amount of coffee consumed daily (0-2, 3-4, 5-6, 7-9, greater than or equal to10 cups) were 1.00, 0.71 (95% confidence interval [CI], 0.48-1.05), 0.39 (95% CI, 0.25-0.60), 0.39 (95% CI, 0.20-0.74), and 0.21 (95% CI, 0.06-0.69) (P for trend <.001) in women, and 1.00, 0.73 (95% CI, 0.47-1.13), 0.70 (95% CI, 0.45-1.05), 0.67 (95% CI, 0.40-1.12), and 0.45 (95% CI, 0.25-0.81) (P for trend=.12) in men, respectively. In both sexes combined, the multivariate-adjusted inverse association was significant (P for trend <.001) and persisted when stratified by younger and older than 50 years; smokers and never smokers; healthy weight, overweight, and obese participants; alcohol drinker and nondrinker; and participants drinking filtered and nonfiltered coffee. Conclusion Coffee drinking has a graded inverse association with the risk of type 2 DM; however, the reasons for this risk reduction associated with coffee remain unclear.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Inst Biomed, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki	Tuomilehto, J (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	jaakko.tuomilehto@ktl.fi	Hu, Gang/V-7947-2019; Hu, Gang/N-1971-2017	Hu, Gang/0000-0002-6172-8017; Hu, Gang/0000-0002-6172-8017; Lindstrom, Jaana/0000-0001-9255-020X				Andersen LB, 2000, ARCH INTERN MED, V160, P1621, DOI 10.1001/archinte.160.11.1621; Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; ARO A, 1990, COFFEE CORONARY HEAR, P71; Barbagallo Mario, 2003, Molecular Aspects of Medicine, V24, P39, DOI 10.1016/S0098-2997(02)00090-0; Curhan GC, 1998, ANN INTERN MED, V128, P534, DOI 10.7326/0003-4819-128-7-199804010-00003; del Castillo MD, 2002, J AGR FOOD CHEM, V50, P3698, DOI 10.1021/jf011702q; Ferrini RL, 1996, AM J EPIDEMIOL, V144, P642, DOI 10.1093/oxfordjournals.aje.a008975; Goodman-Gruen D, 2001, J NUTR, V131, P1202, DOI 10.1093/jn/131.4.1202; Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x; Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X; Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832; Leitzmann MF, 1999, JAMA-J AM MED ASSOC, V281, P2106, DOI 10.1001/jama.281.22.2106; Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337/diabetes.50.11.2497; Nagata C, 1998, NUTR CANCER, V30, P21, DOI 10.1080/01635589809514635; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; PAJAK A, 1988, World Health Statistics Quarterly, V41, P115; Paolisso G, 1997, AM J HYPERTENS, V10, P346, DOI 10.1016/S0895-7061(96)00342-1; PAOLISSO G, 1990, DIABETOLOGIA, V33, P511, DOI 10.1007/BF00404136; PAOLISSO G, 1995, J CLIN ENDOCR METAB, V80, P1382, DOI 10.1210/jc.80.4.1382; PIETINEN P, 1990, INT J EPIDEMIOL, V19, P586, DOI 10.1093/ije/19.3.586; Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657; Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4; ROBERTSON D, 1984, AM J MED, V77, P54, DOI 10.1016/0002-9343(84)90435-2; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Tuomilehto J, 2003, DIABETES CARE, V26, P61; Tuomilehto J, 2003, DIABETES CARE, V26, P1770; TUOMILEHTO J, 1990, BRIT MED J, V300, P642, DOI 10.1136/bmj.300.6725.642; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X; Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49; *WHO STUD GROUP DI, 1985, WHO TECHN REP SER, V727; *WORLD RES I, EARTH TRENDS DAT TAB; Yoshioka K, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12585-8; YOUN JH, 1986, J BIOL CHEM, V261, P5960; Zeegers MPA, 2001, INT J EPIDEMIOL, V30, P353, DOI 10.1093/ije/30.2.353	44	206	222	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1213	1219		10.1001/jama.291.10.1213	http://dx.doi.org/10.1001/jama.291.10.1213			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010442	Bronze			2022-12-28	WOS:000220061900021
J	Dai, JY; Liu, J; Deng, YQ; Smith, TM; Lu, M				Dai, JY; Liu, J; Deng, YQ; Smith, TM; Lu, M			Structure and protein design of a human platelet function inhibitor	CELL			English	Article							MACROMOLECULAR STRUCTURES; EXPRESSION; THROMBOREGULATION; NUCLEOTIDASE; DIFFRACTION; REFINEMENT; HEMOSTASIS; PROPELLER; CLONING; BLOOD	Hematophagous arthropods secrete a salivary apyrase that inhibits platelet activation by catabolizing ADP released from damaged tissues and blood cells. We report the X-ray crystal structures of a human enzyme of the soluble apyrase family in its apo state and bound to a substrate analog. The structures reveal a nucleotide binding domain comprising a five-blade P propeller, binding determinants of the substrate and the active site, and an unusual calcium binding site with a potential regulatory function. Using a comparative structural biology approach, we were able to redesign the human apyrase so as to enhance its ADPase activity by more than 100-fold. The engineered enzyme is a potent inhibitor of platelet aggregation and may serve as the basis for the development of a new class of antithrombotic agents.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Wyeth Ayerst Res, Dept Cardiovasc & Metab Dis, Cambridge, MA 02140 USA	Cornell University; Pfizer	Lu, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA.	mlu@med.cornell.edu	Dai, Jiayin/C-6654-2012; Deng, Yiqun/K-7709-2013	Dai, Jiayin/0000-0003-4908-5597; Deng, Yiqun/0000-0002-6838-3779	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041461] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41461] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basanova AV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P143, DOI 10.1023/A:1013968618120; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Chen W, 2001, BIOCHEM BIOPH RES CO, V282, P90, DOI 10.1006/bbrc.2001.4555; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P317, DOI 10.1007/BF01741386; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Murphy DM, 2003, BIOCHEMISTRY-US, V42, P2412, DOI 10.1021/bi026763b; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Sevigny J, 2002, BLOOD, V99, P2801, DOI 10.1182/blood.V99.8.2801; Smith TM, 2002, ARCH BIOCHEM BIOPHYS, V406, P105, DOI 10.1016/S0003-9861(02)00420-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vargas CM, 1998, J CLIN EPIDEMIOL, V51, P739, DOI 10.1016/S0895-4356(98)00047-X; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	25	46	49	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					649	659		10.1016/S0092-8674(04)00172-2	http://dx.doi.org/10.1016/S0092-8674(04)00172-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006348	Bronze			2022-12-28	WOS:000221499700006
J	Yen, TJ; Padilla, WJ; Fang, N; Vier, DC; Smith, DR; Pendry, JB; Basov, DN; Zhang, X				Yen, TJ; Padilla, WJ; Fang, N; Vier, DC; Smith, DR; Pendry, JB; Basov, DN; Zhang, X			Terahertz magnetic response from artificial materials	SCIENCE			English	Article							LOW-FREQUENCY PLASMONS; LIGHT-SCATTERING; SURFACE; FILTERS; MAGNONS; BULK	We show that magnetic response at terahertz frequencies can be achieved in a planar structure composed of nonmagnetic conductive resonant elements. The effect is realized over a large bandwidth and can be tuned throughout the terahertz frequency regime by scaling the dimensions of the structure. We suggest that artificial magnetic structures, or hybrid structures that combine natural and artificial magnetic materials, can play a key role in terahertz devices.	Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Condensed Matter Theory Grp, London SW7 2AZ, England	University of California System; University of California Los Angeles; University of California System; University of California San Diego; Imperial College London	Zhang, X (corresponding author), Univ Calif Los Angeles, Dept Mech & Aerosp Engn, 420 Westwood Plaza, Los Angeles, CA 90095 USA.	xiang@seas.ucla.edu	Padilla, Willie John/K-2131-2019; Fang, Nicholas/A-5856-2008; Padilla, Willie J/A-7235-2008; Smith, David R/E-4710-2012; Zhang, Xiang/F-6905-2011	Padilla, Willie John/0000-0001-7734-8847; Fang, Nicholas/0000-0001-5713-629X; Padilla, Willie J/0000-0001-7734-8847; Zhang, Xiang/0000-0002-3272-894X; Pendry, John/0000-0001-5145-5441; Yen, Ta-Jen/0000-0003-3613-699X				CAMLEY RE, 1982, PHYS REV B, V26, P1280, DOI 10.1103/PhysRevB.26.1280; CAMLEY RE, 1980, PHYS REV B, V22, P5420, DOI 10.1103/PhysRevB.22.5420; CHASE ST, 1983, APPL OPTICS, V22, P1775, DOI 10.1364/AO.22.001775; GRUNBERG P, 1977, PHYS REV LETT, V39, P1561, DOI 10.1103/PhysRevLett.39.1561; Gupta S, 1997, APPL PHYS LETT, V71, P2412, DOI 10.1063/1.120077; Jensen MRF, 1997, PHYS REV B, V55, P2745, DOI 10.1103/PhysRevB.55.2745; O'Brien S, 2002, J PHYS-CONDENS MAT, V14, P6383, DOI 10.1088/0953-8984/14/25/307; Parazzoli CG, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107401; Pendry JB, 1998, J PHYS-CONDENS MAT, V10, P4785, DOI 10.1088/0953-8984/10/22/007; Pendry JB, 1996, PHYS REV LETT, V76, P4773, DOI 10.1103/PhysRevLett.76.4773; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; REMER L, 1986, PHYS REV LETT, V56, P2752, DOI 10.1103/PhysRevLett.56.2752; SANDERCOCK JR, 1979, J APPL PHYS, V50, P7784, DOI 10.1063/1.326763; SCHELKUNOFF IS, 1952, ANTENNAS THEORY PRAC, P584; SCHURIG D, UNPUB; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Sirtori C, 2002, NATURE, V417, P132, DOI 10.1038/417132b; Smith DR, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.195104; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; Wu DM, 2003, APPL PHYS LETT, V83, P201, DOI 10.1063/1.1591083; Zhang XC, 2002, PHYS MED BIOL, V47, P3667, DOI 10.1088/0031-9155/47/21/301	22	1265	1325	37	460	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1494	1496		10.1126/science.1094025	http://dx.doi.org/10.1126/science.1094025			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001772				2022-12-28	WOS:000220000100034
J	Campo, R				Campo, R			Questions for an epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Campo, R (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					968	970		10.1056/NEJMp038236	http://dx.doi.org/10.1056/NEJMp038236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999108				2022-12-28	WOS:000189363600004
J	Chlebowski, RT; Wactawski-Wende, J; Ritenbaugh, C; Hubbell, FA; Ascensao, J; Rodabough, RJ; Rosenberg, CA; Taylor, VM; Harris, R; Chen, C; Adams-Campbell, LL; White, E; Alving, B; Rossouw, J; Pottern, L; Ludlam, S; McGowan, J; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Paskett, E; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Shikany, JM; Safford, M; Britt, BK; Bassford, T; Mattox, J; Ko, M; Lohman, T; Wactawski-Wende, J; Trevisan, M; Smit, E; Graham, S; Chang, J; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; Monk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, J; Rosal, M; Ockene, I; Yood, R; Aronson, P; Lasser, N; Singh, B; Lasser, V; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Kempainen, S; Brunner, R; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Cauley, J; Milas, NC; Johnson, KC; Satterfield, S; Ke, RW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Sarto, G; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Bonds, D; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeely, G; Gordon, P; Makela, P; Allen, C; Dougherty, S; Carleton, R				Chlebowski, RT; Wactawski-Wende, J; Ritenbaugh, C; Hubbell, FA; Ascensao, J; Rodabough, RJ; Rosenberg, CA; Taylor, VM; Harris, R; Chen, C; Adams-Campbell, LL; White, E; Alving, B; Rossouw, J; Pottern, L; Ludlam, S; McGowan, J; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Paskett, E; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Shikany, JM; Safford, M; Britt, BK; Bassford, T; Mattox, J; Ko, M; Lohman, T; Wactawski-Wende, J; Trevisan, M; Smit, E; Graham, S; Chang, J; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; Monk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, J; Rosal, M; Ockene, I; Yood, R; Aronson, P; Lasser, N; Singh, B; Lasser, V; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Kempainen, S; Brunner, R; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Cauley, J; Milas, NC; Johnson, KC; Satterfield, S; Ke, RW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Sarto, G; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Bonds, D; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeely, G; Gordon, P; Makela, P; Allen, C; Dougherty, S; Carleton, R		Women's Hlth Initiative Investigat	Estrogen plus progestin and colorectal cancer in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; COLON-CANCER; HORMONE-THERAPY; ESTROGEN/PROGESTIN REPLACEMENT; RISK; GUIDELINES; SULINDAC; INSULIN	BACKGROUND: Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of colorectal cancer. We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants. METHODS: In the WHI trial, 16,608 postmenopausal women who were 50 to 79 years of age and had an intact uterus were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The main outcome measures were the incidence, stages, and types of colorectal cancer, as determined by blinded central adjudication. RESULTS: There were 43 invasive colorectal cancers in the hormone group and 72 in the placebo group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003). The invasive colorectal cancers in the hormone group were similar in histologic features and grade to those in the placebo group but with a greater number of positive lymph nodes (mean +/-SD, 3.2+/-4.1 vs. 0.8+/-1.7; P=0.002) and were more advanced (regional or metastatic disease, 76.2 percent vs. 48.5 percent; P=0.004). In exploratory analyses, women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater number of positive nodes than women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006). CONCLUSIONS: Relatively short-term use of estrogen plus progestin was associated with a decreased risk of colorectal cancer. However, colorectal cancers in women who took estrogen plus progestin were diagnosed at a more advanced stage than those in women who took placebo.	Harbor UCLA Res & Educ Inst, Dept Med, Torrance, CA 90502 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Gynecol & Obstet, Buffalo, NY 14260 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; George Washington Univ, Dept Med, Div Hematol Oncol, Washington, DC USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Evanston NW Healthcare, Dept Internal Med, Evanston, IL USA; Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Howard Univ, Ctr Canc, Dept Med, Washington, DC 20059 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kaiser Permanente; University of California System; University of California Irvine; George Washington University; Fred Hutchinson Cancer Center; NorthShore University Health System; University System of Ohio; Ohio State University; Howard University	Chlebowski, RT (corresponding author), Harbor UCLA Res & Educ Inst, Dept Med, 1124 W Carson St, Torrance, CA 90502 USA.	rchlebowski@rei.edu	Sueta, Carla/AAH-8100-2021; Greenland, Philip/ABD-5528-2021; Mysiw, Walter/E-3724-2011; Rosenberg, Carol/AAZ-5018-2020; Wactawski-Wende, Jean/AGH-5457-2022; Cauley, Jane A/N-4836-2015; Rexrode, Kathryn M/I-1177-2018; Kaunitz, Andrew/AAL-8448-2020; Kristal, Alan/A-8779-2008; Stafford, Randall/F-3974-2017	Wactawski-Wende, Jean/0000-0003-3096-9595; Cauley, Jane A/0000-0003-0752-4408; Stafford, Randall/0000-0003-1805-1271; Ritenbaugh, Cheryl/0000-0002-3307-2727				ALBERTS DS, 2003, P AN M AM SOC CLIN, V22, P91; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 2001, MMWR MORB MORTAL WKL, V50, P162; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Fernandez E, 1998, CANCER EPIDEM BIOMAR, V7, P329; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Langenbach MR, 2003, WORLD J SURG, V27, P304, DOI 10.1007/s00268-002-6678-9; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Majumdar SR, 1999, AM J GASTROENTEROL, V94, P3039, DOI 10.1111/j.1572-0241.1999.01454.x; MARSHALL JR, 1986, WOMEN HEALTH, V11, P67; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; Mor V, 1990, J Community Health, V15, P253, DOI 10.1007/BF01350291; NEWCOMB PA, 1995, J NATL CANCER I, V87, P1416; Paganini-Hill A, 1999, DIS COLON RECTUM, V42, P1300, DOI 10.1007/BF02234219; Pardi DS, 2003, GASTROENTEROLOGY, V124, P889, DOI 10.1053/gast.2003.50156; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; Ries LAG, 2003, SEER CANC STAT REV 1; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 2003, NEW ENGL J MED, V348, P1939; Saydah SH, 2003, CANCER EPIDEM BIOMAR, V12, P412; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Smith RA, 2003, CA-CANCER J CLIN, V53, P27, DOI 10.3322/canjclin.53.1.27; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; TIETZ NW, 1987, FUNDAMENTALS CLIN CH, P544; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Witte D, 2001, HUM PATHOL, V32, P940, DOI 10.1053/hupa.2001.27117; Zhang YQ, 2001, AM J EPIDEMIOL, V153, P31, DOI 10.1093/aje/153.1.31	40	462	478	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					991	1004		10.1056/NEJMoa032071	http://dx.doi.org/10.1056/NEJMoa032071			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999111	Bronze			2022-12-28	WOS:000189363600007
J	Jean-Baptiste, P; Fourre, E				Jean-Baptiste, P; Fourre, E			Artic Ocean - Communications arising - Hydrothermal activity on Gakkel Ridge	NATURE			English	Editorial Material							ARCTIC-OCEAN; MANTLE HE-3		CEA, CNRS, Ctr Etud Saclay, IPSL,Lab Sci Climat Environm, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Jean-Baptiste, P (corresponding author), CEA, CNRS, Ctr Etud Saclay, IPSL,Lab Sci Climat Environm, F-91191 Gif Sur Yvette, France.	pjb@lsce.saclay.cea.fr	Fourre, Elise/H-8066-2013					Baker ET, 1996, EARTH PLANET SC LETT, V142, P137, DOI 10.1016/0012-821X(96)00097-0; BOENISCH G, 1995, PROG OCEANOGR, V35, P29; Craig H., 1981, SEA, V7, P391; DUTAY JC, IN PRESS J MAR SYST; Edmonds HN, 2003, NATURE, V421, P252, DOI 10.1038/nature01351; FARLEY KA, 1995, J GEOPHYS RES-SOL EA, V100, P3829, DOI 10.1029/94JB02913; Jean-Baptiste P, 1998, EARTH PLANET SC LETT, V157, P69, DOI 10.1016/S0012-821X(98)00022-3; JEANBAPTISTE P, IN PRESS J MAR SYST; Michael PJ, 2003, NATURE, V423, P956, DOI 10.1038/nature01704; SCHLOSSER P, 1995, PROG OCEANOGR, V35, P1, DOI 10.1016/0079-6611(95)00003-Y	10	4	4	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					36	36		10.1038/428036a	http://dx.doi.org/10.1038/428036a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999274	Bronze			2022-12-28	WOS:000189363800027
J	Floss, C; Stadermann, FJ; Bradley, J; Dai, ZR; Bajt, S; Graham, G				Floss, C; Stadermann, FJ; Bradley, J; Dai, ZR; Bajt, S; Graham, G			Carbon and nitrogen isotopic anomalies in an anhydrous interplanetary dust particle	SCIENCE			English	Article							MACROMOLECULAR ORGANIC-MATTER; FRACTIONATION; PRESOLAR; ORIGIN; IDENTIFICATION; ABUNDANCES; CHEMISTRY; GRAINS	Because hydrogen and nitrogen isotopic anomalies in interplanetary dust particles have been associated with carbonaceous material, the lack of similar anomalies in carbon has been a major conundrum. We report here the presence of a C-13 depletion associated with a N-15 enrichment in an anhydrous interplanetary dust particle. Our observations suggest that the anomalies are carried by heteroatomic organic compounds. Theoretical models indicate that low-temperature formation of organic compounds in cold interstellar molecular clouds can produce carbon and nitrogen fractionations, but it remains to be seen whether the specific effects observed here can be reproduced.	Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA	Washington University (WUSTL); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Floss, C (corresponding author), Washington Univ, Space Sci Lab, St Louis, MO 63130 USA.	floss@wustl.edu	Bajt, Sasa/G-2228-2010; 1.4, ALS Beamline/I-1886-2014; Dai, Zurong/E-6732-2010; Bajt, Sasa/O-4695-2019	Bajt, Sasa/0000-0002-7163-7602; Dai, Zurong/0000-0002-4209-8718				Aleon J, 2003, GEOCHIM COSMOCHIM AC, V67, P3773, DOI [10.1016/S0016-7037(03)00170-4, 10.1016/S0016-7037(00)00170-4]; ALEON J, 2002, LUNAR PLANET SCI, V33, P1397; ALEON J, 2003, LUNAR PLANET SCI, V34, P1308; Alexander CMO, 1998, METEORIT PLANET SCI, V33, P603, DOI 10.1111/j.1945-5100.1998.tb01667.x; Arpigny C, 2003, SCIENCE, V301, P1522, DOI 10.1126/science.1086711; Bradley JP, 2005, TREATISE GEOCHEM, V1, P689; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; BRADLEY JP, 1986, SCIENCE, V231, P1542, DOI 10.1126/science.231.4745.1542; BROWNLEE DE, 2002, LPI, V33, P1786; BROWNLEE DE, 1994, AIP C P, V310, P5; Charnley SB, 2002, ASTROPHYS J, V569, pL133, DOI 10.1086/340484; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; FLOSS C, 2003, LUNAR PLANET SCI, V34, P1238; FLOSS C, 2002, LUNAR PLANET SCI, V33, P1350; FLYNN GJ, 2002, LUNAR PLANET SCI, V33, P1320; Fouchet T, 2000, ICARUS, V143, P223, DOI 10.1006/icar.1999.6255; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; Hashizume K, 2004, ASTROPHYS J, V600, P480, DOI 10.1086/379637; Heaney PJ, 2001, AM MINERAL, V86, P1094; HOPPE P, 1995, GEOCHIM COSMOCHIM AC, V59, P4029, DOI 10.1016/0016-7037(95)00280-D; Keller LP, 2000, J GEOPHYS RES-SPACE, V105, P10397, DOI 10.1029/1999JA900395; KELLER LP, 1997, LUNAR PLANET SCI C, V28, P707; LANGER WD, 1989, ASTROPHYS J SUPPL S, V69, P241, DOI 10.1086/191313; LANGER WD, 1984, ASTROPHYS J, V277, P581, DOI 10.1086/161730; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Messenger S, 2003, SPACE SCI REV, V106, P155, DOI 10.1023/A:1024637704533; MESSENGER S, 1997, AIP C P, V402, P545; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Owen T, 2001, ASTROPHYS J, V553, pL77, DOI 10.1086/320501; Sandford SA, 2001, METEORIT PLANET SCI, V36, P1117, DOI 10.1111/j.1945-5100.2001.tb01948.x; Terzieva R, 2000, MON NOT R ASTRON SOC, V317, P563, DOI 10.1046/j.1365-8711.2000.03618.x; TIELENS AGG, 1998, AIP C P, V402, P523	33	95	98	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1355	1358		10.1126/science.1093283	http://dx.doi.org/10.1126/science.1093283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988560				2022-12-28	WOS:000189238600047
J	Graf, HF				Graf, HF			Atmospheric science - The complex interaction of aerosols and clouds	SCIENCE			English	Editorial Material									Univ Cambridge, Dept Geog, Ctr Atmospher Sci, Cambridge CB2 3EN, England; Max Planck Inst Meteorol, Hamburg, Germany	University of Cambridge; Max Planck Society	Graf, HF (corresponding author), Univ Cambridge, Dept Geog, Ctr Atmospher Sci, Downing Pl, Cambridge CB2 3EN, England.	hfg21@cam.ac.uk	Graf, Hans/GQQ-2206-2022					Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Koren I, 2004, SCIENCE, V303, P1342, DOI 10.1126/science.1089424; Nober FJ, 2003, GLOBAL PLANET CHANGE, V37, P57, DOI 10.1016/S0921-8181(02)00191-1; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Roeckner E., 1996, 218 M PLANCK I MET; Rosenfeld D, 2002, SCIENCE, V297, P1667, DOI 10.1126/science.1073869; Rosenfeld D, 2000, NATURE, V405, P440, DOI 10.1038/35013030; Sherwood S, 2002, SCIENCE, V295, P1272, DOI 10.1126/science.1065080; Tao WK, 2003, B AM METEOROL SOC, V84, P1055, DOI 10.1175/BAMS-84-8-1055	9	41	45	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1309	1311		10.1126/science.1094411	http://dx.doi.org/10.1126/science.1094411			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988543				2022-12-28	WOS:000189238600029
J	Accardi, A; Miller, C				Accardi, A; Miller, C			Secondary active transport mediated by a prokaryotic homologue of ClC Cl- channels	NATURE			English	Article							CHLORIDE CHANNEL; SEROTONIN TRANSPORTER; ESCHERICHIA-COLI; IONIC CURRENTS; RECONSTITUTION; MECHANISM; SOLUBILIZATION; SELECTIVITY; CONDUCTANCE; HYDROLYSIS	ClC Cl- channels make up a large molecular family, ubiquitous with respect to both organisms and cell types. In eukaryotes, these channels fulfill numerous biological roles requiring gated anion conductance, from regulating skeletal muscle excitability to facilitating endosomal acidification by (H+) ATPases. In prokaryotes, ClC functions are unknown except in Escherichia coli, where the ClC- ec1 protein promotes H+ extrusion activated in the extreme acid-resistance response common to enteric bacteria. Recently, the high-resolution structure of ClC- ec1 was solved by X-ray crystallography. This primal prokaryotic ClC structure has productively guided understanding of gating and anion permeation in the extensively studied eukaryotic ClC channels. We now show that this bacterial homologue is not an ion channel, but rather a H+-Cl- exchange transporter. As the same molecular architecture can support two fundamentally different transport mechanisms, it seems that the structural boundary separating channels and transporters is not as clear cut as generally thought.	Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute	Miller, C (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.	cmiller@brandeis.edu		Accardi, Alessio/0000-0002-6584-0102				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935; Adams SV, 2003, BIOPHYS J, V85, P1548, DOI 10.1016/S0006-3495(03)74587-1; Artigas P, 2003, P NATL ACAD SCI USA, V100, P501, DOI 10.1073/pnas.0135849100; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Chen MF, 2003, J GEN PHYSIOL, V122, P133, DOI 10.1085/jgp.200308844; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Estevez R, 2003, NEURON, V38, P47, DOI 10.1016/S0896-6273(03)00168-5; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FOSTER DL, 1982, BIOCHEMISTRY-US, V21, P5634, DOI 10.1021/bi00265a038; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; Lin CW, 2003, J GEN PHYSIOL, V122, P147, DOI 10.1085/jgp.200308845; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MITCHELL P, 1965, NATURE, V208, P147, DOI 10.1038/208147a0; PUSCH M, 1994, BIOPHYS J, V66, P149, DOI 10.1016/S0006-3495(94)80753-2; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; Robinson R.A., 1965, ELECTROLYTE SOLUTION, V2nd; SCHELLENBERG GD, 1982, BIOCHIM BIOPHYS ACTA, V690, P133, DOI 10.1016/0005-2736(82)90247-4; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Traverso S, 2003, J GEN PHYSIOL, V122, P295, DOI 10.1085/jgp.200308784; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P1, DOI 10.1007/BF01872814; Weinreich F, 2001, J BIOL CHEM, V276, P2347, DOI 10.1074/jbc.M005733200; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	35	496	513	3	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					803	807		10.1038/nature02314	http://dx.doi.org/10.1038/nature02314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985752				2022-12-28	WOS:000189207500030
J	Gladwin, MT; Sachdev, V; Jison, ML; Shizukuda, Y; Plehn, JF; Minter, K; Brown, B; Coles, WA; Nichols, JS; Ernst, I; Hunter, LA; Blackwelder, WC; Schechter, AN; Rodgers, GP; Castro, O; Ognibene, FP				Gladwin, MT; Sachdev, V; Jison, ML; Shizukuda, Y; Plehn, JF; Minter, K; Brown, B; Coles, WA; Nichols, JS; Ernst, I; Hunter, LA; Blackwelder, WC; Schechter, AN; Rodgers, GP; Castro, O; Ognibene, FP			Pulmonary hypertension as a risk factor for death in patients with sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRIC-OXIDE BIOAVAILABILITY; RELATIVE HYPERTENSION; FETAL-HEMOGLOBIN; ENDOTHELIN-1; STROKE; ECHOCARDIOGRAPHY; PRESSURE; ARGININE; ANEMIA	BACKGROUND: The prevalence of pulmonary hypertension in adults with sickle cell disease, the mechanism of its development, and its prospective prognostic significance are unknown. METHODS: We performed Doppler echocardiographic assessments of pulmonary-artery systolic pressure in 195 consecutive patients (82 men and 113 women; mean [+/-SD] age, 36+/-12 years). Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second. Patients were followed for a mean of 18 months, and data were censored at the time of death or loss to follow-up. RESULTS: Doppler-defined pulmonary hypertension occurred in 32 percent of patients. Multiple logistic-regression analysis, with the use of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second or 2.5 m per second or more, identified a self-reported history of cardiovascular or renal complications, increased systolic blood pressure, high lactate dehydrogenase levels (a marker of hemolysis), high levels of alkaline phosphatase, and low transferrin levels as significant independent correlates of pulmonary hypertension. The fetal hemoglobin level, white-cell count, and platelet count and the use of hydroxyurea therapy were unrelated to pulmonary hypertension. A tricuspid regurgitant jet velocity of at least 2.5 m per second, as compared with a velocity of less than 2.5 m per second, was strongly associated with an increased risk of death (rate ratio, 10.1; 95 percent confidence interval, 2.2 to 47.0; P<0.001) and remained so after adjustment for other possible risk factors in a proportional-hazards regression model. CONCLUSIONS: Pulmonary hypertension, diagnosed by Doppler echocardiography, is common in adults with sickle cell disease. It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death. Therapeutic trials targeting this population of patients are indicated.	NHLBI, Dept Crit Care Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Lab Chem Biol, NIH, Bethesda, MD 20892 USA; NIDDKD, Mol & Clin Hematol Branch, NIH, Bethesda, MD 20892 USA; Howard Univ, Coll Med, Dept Med, Div Cardiol, Washington, DC USA; Howard Univ, Coll Med, Ctr Sickle Cell Dis, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Howard University; Howard University	Gladwin, MT (corresponding author), NHLBI, Dept Crit Care Med, Ctr Clin, NIH, Bldg 10,Rm 7D-43,10 Ctr Dr, Bethesda, MD 20892 USA.	mgladwin@nih.gov		Schechter, Alan N/0000-0002-5235-9408	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025093, Z01DK027001, Z01DK025093] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL001174, Z01CL001173] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CLINICAL CENTER		Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Adedeji MO, 2001, ARCH PATHOL LAB MED, V125, P1436; Aessopos A, 2001, BLOOD, V97, P3411, DOI 10.1182/blood.V97.11.3411; Appleton CP, 1997, J AM SOC ECHOCARDIOG, V10, P271, DOI 10.1016/S0894-7317(97)70063-4; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; Castro O, 1996, HEMATOL ONCOL CLIN N, V10, P1289, DOI 10.1016/S0889-8588(05)70401-9; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; CHOPRA HK, 1989, J AM COLL CARDIOL, V14, P1266, DOI 10.1016/0735-1097(89)90426-9; COLLINS FS, 1982, AM J MED, V73, P814, DOI 10.1016/0002-9343(82)90763-X; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Derchi G, 1999, AM HEART J, V138, P384, DOI 10.1016/S0002-8703(99)70129-8; Du ZD, 1997, AM HEART J, V134, P532, DOI 10.1016/S0002-8703(97)70091-7; Escoffery CT, 2002, FORENSIC SCI INT, V129, P116, DOI 10.1016/S0379-0738(02)00268-2; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161/01.CIR.0000044943.12533.A8; GRISARU D, 1990, CHEST, V98, P1138, DOI 10.1378/chest.98.5.1138; Hahalis G, 2002, EUR HEART J, V23, P147, DOI 10.1053/euhj.2001.2709; Hammerman SI, 1997, AM J RESP CRIT CARE, V156, P280, DOI 10.1164/ajrccm.156.1.9611085; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053/hupa.2002.128059; Hayag-Barin JE, 1998, AM J HEMATOL, V57, P82, DOI 10.1002/(SICI)1096-8652(199801)57:1<82::AID-AJH15>3.0.CO;2-B; HELLER PG, 1992, CHEST, V102, P642, DOI 10.1378/chest.102.2.642; KIRCHER BJ, 1990, AM J CARDIOL, V66, P493, DOI 10.1016/0002-9149(90)90711-9; LEWIS JF, 1984, CIRCULATION, V70, P425, DOI 10.1161/01.CIR.70.3.425; LIESNER RJ, 1993, J ROY SOC MED, V86, P484; Lin G, 2001, BIOCHEM BIOPH RES CO, V280, P824, DOI 10.1006/bbrc.2000.4167; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Morris CR, 2000, J PEDIAT HEMATOL ONC, V22, P515, DOI 10.1097/00043426-200011000-00009; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; Norris S L, 1992, J Assoc Acad Minor Phys, V3, P20; Ohene-Frempong K, 1998, BLOOD, V91, P288; Pegelow CH, 1997, AM J MED, V102, P171; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; Quinones MA, 2002, J AM SOC ECHOCARDIOG, V15, P167, DOI 10.1067/mje.2002.120202; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; RODGERS GP, 1993, AM J MED SCI, V305, P150, DOI 10.1097/00000441-199303000-00004; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Rybicki AC, 1998, BLOOD, V92, P2594, DOI 10.1182/blood.V92.7.2594.2594_2594_2596; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SIMMONS BE, 1988, ARCH INTERN MED, V148, P1526, DOI 10.1001/archinte.148.7.1526; SUTTON LL, 1994, AM J CARDIOL, V74, P626, DOI 10.1016/0002-9149(94)90760-9; VANENK A, 1992, BRIT J OBSTET GYNAEC, V99, P162	43	893	919	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					886	895		10.1056/NEJMoa035477	http://dx.doi.org/10.1056/NEJMoa035477			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985486				2022-12-28	WOS:000189197300007
J	Rentel, MC; Lecourieux, D; Ouaked, F; Usher, SL; Petersen, L; Okamoto, H; Knight, H; Peck, SC; Grierson, CS; Hirt, H; Knight, MR				Rentel, MC; Lecourieux, D; Ouaked, F; Usher, SL; Petersen, L; Okamoto, H; Knight, H; Peck, SC; Grierson, CS; Hirt, H; Knight, MR			OXI1 kinase is necessary for oxidative burst-mediated signalling in Arabidopsis	NATURE			English	Article							HYDROGEN-PEROXIDE; DEFENSE RESPONSE; PLANTS; TRANSFORMATION; PATHWAYS; GROWTH; GENES; ACCUMULATION; EXPRESSION; SYSTEMIN	Active oxygen species (AOS) generated in response to stimuli and during development can function as signalling molecules in eukaryotes, leading to specific downstream responses(1,2). In plants these include such diverse processes as coping with stress ( for example pathogen attack(3), wounding(4) and oxygen deprivation(5)), abscisic-acid-induced guard-cell closure(6), and cellular development ( for example root hair growth(7)). Despite the importance of signalling via AOS in eukaryotes, little is known about the protein components operating downstream of AOS that mediate any of these processes. Here we show that expression of an Arabidopsis thaliana gene (OXI1) encoding a serine/threonine kinase is induced in response to a wide range of H2O2-generating stimuli. OXI1 kinase activity is itself also induced by H2O2 in vivo. OXI1 is required for full activation of the mitogen-activated protein kinases ( MAPKs) MPK3 and MPK6 after treatment with AOS or elicitor and is necessary for at least two very different AOS-mediated processes: basal resistance to Peronospora parasitica infection, and root hair growth. Thus, OXI1 is an essential part of the signal transduction pathway linking oxidative burst signals to diverse downstream responses.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Vienna, Max F Perutz Labs, A-1030 Vienna, Austria; Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, A-1030 Vienna, Austria; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England; Univ Cape Town, Dept Mol & Cell Biol, ZA-7701 Rondebosch, South Africa; Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	University of Oxford; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Austrian Academy of Sciences; Vienna Biocenter (VBC); Gregor Mendel Institute of Molecular Plant Biology (GMI); University of Bristol; University of Cape Town; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Rentel, MC (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	mrentel@cmp.ucsf.edu; heribert.hirt@univie.ac.at	Lecourieux, David/AAD-5429-2019; Okamoto, Haruko/AAG-9512-2021; lecourieux, fatma/AAC-2039-2019; Hirt, Heribert/A-2061-2013	Okamoto, Haruko/0000-0001-5981-6571; lecourieux, fatma/0000-0003-1601-2500; Knight, Heather/0000-0003-2047-6084; Rentel, Maike/0000-0002-0964-4377; Knight, Marc/0000-0002-4830-8608	Biotechnology and Biological Sciences Research Council [G19475] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Baxter-Burrell A, 2003, ANN BOT-LONDON, V91, P129, DOI 10.1093/aob/mcf119; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Borden S, 2002, PHYSIOL MOL PLANT P, V61, P227, DOI 10.1006/pmpp.2002.0435; Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; Huckelhoven R, 1999, PLANT PHYSIOL, V119, P1251, DOI 10.1104/pp.119.4.1251; Ichimura K, 2000, PLANT J, V24, P655, DOI 10.1046/j.1365-313x.2000.00913.x; Knight H, 1998, PLANT J, V16, P681, DOI 10.1046/j.1365-313x.1998.00332.x; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Martin T, 1992, PLANT MOL BIOL REP, V10, P37, DOI 10.1007/BF02669263; Orozco-Cardenas M, 1999, P NATL ACAD SCI USA, V96, P6553, DOI 10.1073/pnas.96.11.6553; Orozco-Cardenas ML, 2001, PLANT CELL, V13, P179, DOI 10.1105/tpc.13.1.179; Oyama T, 2002, PLANT J, V30, P289, DOI 10.1046/j.1365-313X.2002.01290.x; Parker JS, 2000, PLANT CELL, V12, P1961, DOI 10.1105/tpc.12.10.1961; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; Samaj J, 2002, EMBO J, V21, P3296, DOI 10.1093/emboj/cdf349; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Weigel D., 2001, ARABIDOPSIS LAB MANU; Wymer CL, 1997, PLANT J, V12, P427, DOI 10.1046/j.1365-313X.1997.12020427.x	28	412	458	5	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					858	861		10.1038/nature02353	http://dx.doi.org/10.1038/nature02353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985766				2022-12-28	WOS:000189207500044
J	Tsao, H; Sober, AJ; Niendorf, KB; Zembowicz, A				Tsao, H; Sober, AJ; Niendorf, KB; Zembowicz, A			Case 6-2004: A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma - Hereditary melanoma with a deleterious CDKN2A mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MELANOCORTIN-1 RECEPTOR MC1R; CUTANEOUS MELANOMA; XERODERMA-PIGMENTOSUM; MALIGNANT-MELANOMA; DYSPLASTIC NEVI; RISK; GENETICS; MARKERS; DISEASE		Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pigmented Les Clin, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dermatopathol Unit, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Dermatol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Tsao, H (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.							Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Burke W, 2002, NEW ENGL J MED, V347, P1867, DOI 10.1056/NEJMoa012113; CLARK WH, 1978, ARCH DERMATOL, V114, P723; ELDER DE, 1982, AM J DERMATOPATH, V4, P455, DOI 10.1097/00000372-198210000-00014; FORD D, 1995, INT J CANCER, V62, P377, DOI 10.1002/ijc.2910620403; GARBE C, 1989, INT J DERMATOL, V28, P517, DOI 10.1111/j.1365-4362.1989.tb04604.x; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; Goldstein AM, 1997, J NATL CANCER I, V89, P676, DOI 10.1093/jnci/89.10.676; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; Hall MA, 2000, AM J HUM GENET, V66, P293, DOI 10.1086/302714; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kefford R, 2002, LANCET ONCOL, V3, P653, DOI 10.1016/S1470-2045(02)00894-X; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; KOPF AW, 1990, J AM ACAD DERMATOL, V22, P117, DOI 10.1016/S0190-9622(08)80006-0; KRAEMER KH, 1983, LANCET, V2, P1076; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P705, DOI 10.1067/mjd.2000.104687; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; Wachsmuth RC, 2001, J INVEST DERMATOL, V117, P348, DOI 10.1046/j.0022-202x.2001.01415.x	31	8	8	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					924	932		10.1056/NEJMcpc030035	http://dx.doi.org/10.1056/NEJMcpc030035			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985491				2022-12-28	WOS:000189197300013
J	Staessen, JA; Den Hond, E; Celis, H; Fagard, R; Keary, L; Vandenhoven, G; O'Brien, ET				Staessen, JA; Den Hond, E; Celis, H; Fagard, R; Keary, L; Vandenhoven, G; O'Brien, ET		THOP Trial Investigators	Antihypertensive treatment based on blood pressure measurement at home or in the physician's office - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CORONARY-HEART-DISEASE; EUROPEAN-SOCIETY; SELF-MEASUREMENT; OLDER PATIENTS; HYPERTENSION; RECOMMENDATIONS; METAANALYSIS; REGRESSION; VALUES	Context Self-measurement of blood pressure is increasingly used in clinical practice, but how it affects the treatment of hypertension requires further study. Objective To compare use of blood pressure (BP) measurements taken in physicians' offices and at home in the treatment of patients with hypertension. Design, Setting, and Participants Blinded randomized controlled trial conducted from March 1997 to April 2002 at 56 primary care practices and 3 hospital-based outpatient clinics in Belgium and 1 specialized hypertension clinic in Dublin, Ireland. Four hundred participants with a diastolic BP (DBP) of 95 mm Hg or more as measured at physicians' offices were,enrolled and followed up for 1 year. Interventions Anti hypertensive drug treatment was adjusted in a stepwise fashion based on either the self-measured DBP at home (average of 6 measurements per day during 1 week; n = 203) or the average of 3 sitting DBP readings at the physician's off ice (n = 197). If the DBP guiding treatment was above (>89 mm Hg), at (80-89 mm Hg), or below (<80 mm Hg) target, a physician blinded to randomization intensified anti hypertensive treatment, left it unchanged, or reduced it, respectively. Mean Outcome Measures Office and home BP levels, 24-hour ambulatory BP, intensity of drug treatment, electrocardiographic and echocardiographic left ventricular mass, symptoms reported by questionnaire, and costs of treatment. Results At the end of the study (median follow-up, 350 days; interquartile range, 326409 days), More home BP than office BP patients had. stopped antihypertensive drug treatment (25.6% vs 11.3%; P<.001) with no significant difference in the proportions of patients progressing to multiple-drug treatment (38.7% vs 45.1%; P=.14). The final office, home, and 24-hour ambulatory BP measurements were higher (P<.001) in the home BP group than in the office BP group. The mean baseline-adjusted systolic/diastolic differences between the home and office BP groups averaged 6.8/3.5 mm Hg, 4.9/2.9 mm Hg, and 4.9/2.9 mm Hg, respectively. Left ventricular mass and reported symptoms were similar in the 2 groups. Costs per 100 patients followed up for 1 month were only slightly lower in the home BID group E3875 vs E3522 [$4921 vs $4473]; P=.04). Conclusions Adjustment of anti hypertensive treatment based on home BP instead of office BP led to less intensive drug treatment and marginally lower costs but also to less BP control, with no differences in general well-being or left ventricular mass. Self-measurement allowed identification of patients with white-coat hypertension. Our findings support a stepwise strategy for the evaluation of BP in which self-measurement and ambulatory monitoring are complementary to conventional office measurement and highlight the need for prospective outcome studies to establish the normal range of home-measured BP.	Katholieke Univ Leuven, Study Coordinating Ctr, Hypertens & Cardiovasc Rehabil Unit, Dept Mol & Cardiovasc Res, Louvain, Belgium; Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland; Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; AstraZeneca NV, Brussels, Belgium	KU Leuven; Royal College of Surgeons - Ireland; AstraZeneca	Staessen, JA (corresponding author), Studiecoordinatiecentrum, Lab Hypertens, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				*41 WORLD MED ASS, 1990, B PAN AM HLTH ORG, V24, P606; Asmar R, 2000, J HYPERTENS, V18, P493, DOI 10.1097/00004872-200018050-00001; Aurigemma GP, 2003, AM J HYPERTENS, V16, P180, DOI 10.1016/S0895-7061(02)03258-2; Bobrie G, 2001, ARCH INTERN MED, V161, P2205, DOI 10.1001/archinte.161.18.2205; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; Celis H, 1997, J HUM HYPERTENS, V11, P673, DOI 10.1038/sj.jhh.1000517; CELIS H, 1998, BLOOD PRESS MONIT S, V3, pS29; Chatellier G, 1996, AM J HYPERTENS, V9, P644, DOI 10.1016/0895-7061(96)00018-0; Chatellier G, 2003, J HYPERTENS, V21, pS9; DEGAUDEMARIS R, 1994, J HYPERTENS, V12, P831; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FAGARD R, 1995, AM J HYPERTENS, V8, P533, DOI 10.1016/0895-7061(95)00043-O; Franklin SS, 2001, CIRCULATION, V103, P1245; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mancia G, 1995, J HYPERTENS, V13, P1377; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MEJIA AD, 1990, ARCH INTERN MED, V150, P1209, DOI 10.1001/archinte.150.6.1209; MOLLOY TJ, 1992, J AM COLL CARDIOL, V20, P1180, DOI 10.1016/0735-1097(92)90376-X; O'Brien E, 2003, J HYPERTENS, V21, P821, DOI 10.1097/00004872-200305000-00001; O'Brien E, 2001, BMJ-BRIT MED J, V322, P531, DOI 10.1136/bmj.322.7285.531; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sega R, 2001, CIRCULATION, V104, P1385, DOI 10.1161/hc3701.096100; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Staessen, 1996, Blood Press Monit, V1, P13; Staessen JA, 2003, J HYPERTENS, V21, pS215; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Staessen JA, 1997, JAMA-J AM MED ASSOC, V278, P1065, DOI 10.1001/jama.278.13.1065; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 2003, J HYPERTENS, V21, P1055, DOI 10.1097/00004872-200306000-00002; Stergiou GS, 2000, AM J HYPERTENS, V13, P678, DOI 10.1016/S0895-7061(99)00266-6; Thijs L, 1998, ARCH INTERN MED, V158, P481, DOI 10.1001/archinte.158.5.481; Thijs L, 1999, Blood Press Monit, V4, P77, DOI 10.1097/00126097-199902000-00004; Turnbull F, 2003, LANCET, V362, P1527; Verdecchia P, 1996, LANCET, V348, P1444, DOI 10.1016/S0140-6736(04)70084-7; Weisser B, 2000, AM J HYPERTENS, V13, P940, DOI 10.1016/S0895-7061(00)00259-4	38	210	214	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					955	964		10.1001/jama.291.8.955	http://dx.doi.org/10.1001/jama.291.8.955			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982911				2022-12-28	WOS:000189182000023
J	Sathyanarayanan, S; Zheng, XZ; Xiao, R; Sehgal, A				Sathyanarayanan, S; Zheng, XZ; Xiao, R; Sehgal, A			Posttranslational regulation of Drosophila PERIOD protein by protein phosphatase 2A	CELL			English	Article							KINASE-I-EPSILON; CIRCADIAN-CLOCK; DOUBLE-TIME; BETA-CATENIN; NUCLEAR ACCUMULATION; BEHAVIORAL RHYTHMS; SIGNALING PATHWAYS; NERVOUS-SYSTEM; GENE; 2A	The posttranscriptional mechanisms that control the cycling of circadian clock protein levels are not known. Here we demonstrate a role for protein phosphatase 2A (PP2A) in the cyclic expression of the PER protein. PP2A regulatory subunits TWS and WDB target PER and stabilize it in S2 cells. In adult fly heads, expression of tws cycles robustly under control of the circadian clock. Hypomorphic tws mutants show delayed accumulation of PER, while overexpression of tws in clock neurons produces shorter, weaker rhythms. Reduction of PP2A activity reduces PER expression in central clock neurons and results in long periods and arrhythmia. In addition, overexpression of the PP2A catalytic subunit results in loss of behavioral rhythms and constitutive nuclear expression of PER. PP2A also affects PER phosphorylation in vitro and in vivo. We propose that the posttranslational mechanisms that drive cycling of PER require the rhythmic expression of PP2A.	Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Mol & Cellular Biol Program, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Sehgal, A (corresponding author), Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA.	amita@mail.med.upenn.edu						Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; Allada R, 2003, CELL, V112, P284, DOI 10.1016/S0092-8674(03)00076-X; Ashmore LJ, 2003, J NEUROSCI, V23, P7810; Bao S, 2001, J NEUROSCI, V21, P7117, DOI 10.1523/JNEUROSCI.21-18-07117.2001; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616; Glossop NRJ, 2002, J CELL SCI, V115, P3369; Greaves S, 1999, GENETICS, V153, P1753; Grima B, 2002, NATURE, V420, P178, DOI 10.1038/nature01122; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannus M, 2002, DEVELOPMENT, V129, P3493; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 2000, J NEUROBIOL, V43, P207, DOI 10.1002/(SICI)1097-4695(20000605)43:3<207::AID-NEU1>3.0.CO;2-0; Kins S, 2001, J BIOL CHEM, V276, P38193; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; MAYERJAEKEL RE, 1995, SEMIN CANCER BIOL, V6, P249, DOI 10.1006/scbi.1995.0032; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2607; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Myers EM, 2003, CURR BIOL, V13, P526, DOI 10.1016/S0960-9822(03)00167-2; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; Perrimon N, 1996, GENETICS, V144, P1681; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rothenfluh A, 2000, CURR BIOL, V10, P1399, DOI 10.1016/S0960-9822(00)00786-7; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shafer OT, 2002, J NEUROSCI, V22, P5946; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Snaith HA, 1996, J CELL SCI, V109, P3001; Stanewsky R, 2002, CELL TISSUE RES, V309, P11, DOI 10.1007/s00441-002-0569-0; Stempfl T, 2002, GENETICS, V160, P571; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	58	215	218	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					603	615		10.1016/S0092-8674(04)00128-X	http://dx.doi.org/10.1016/S0092-8674(04)00128-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980226	Bronze			2022-12-28	WOS:000189184200013
J	Brecht, M; Schneider, M; Sakmann, B; Margrie, TW				Brecht, M; Schneider, M; Sakmann, B; Margrie, TW			Whisker movements evoked by stimulation of single pyramidal cells in rat motor cortex	NATURE			English	Article							SOMATOSENSORY CORTEX; CORTICAL-NEURONS; FIRING PATTERNS; BARREL CORTEX; TRACT CELLS; REPRESENTATION; CATS; MICROSTIMULATION; ORGANIZATION; FACILITATION	Neuronal activity in the motor cortex is understood to be correlated with movements, but the impact of action potentials (APs) in single cortical neurons on the generation of movement has not been fully determined. Here we show that trains of APs in single pyramidal cells of rat motor cortex can evoke long sequences of small whisker movements. For layer-5 pyramids, we find that evoked rhythmic movements have a constant phase relative to the AP train, indicating that single layer-5 pyramids can reset the rhythm of whisker movements. Action potentials evoked in layer-6 pyramids can generate bursts of rhythmic whisking, with a variable phase of movements relative to the AP train. An increasing number of APs decreases the latency to onset of movement, whereas AP frequency determines movement direction and amplitude. We find that the efficacy of cortical APs in evoking whisker movements is not dependent on background cortical activity and is greatly enhanced in waking rats. We conclude that in vibrissae motor cortex sparse AP activity can evoke movements.	Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; UCL, Dept Physiol, Wolfson Inst Biomed Res, London WC1E 6BT, England	Max Planck Society; University of London; University College London	Brecht, M (corresponding author), Max Planck Inst Med Res, Dept Cell Physiol, Jahnstr 29, D-69120 Heidelberg, Germany.	brecht@mpimf-heidelberg.mpg.de		Brecht, Michael/0000-0002-5387-0953				Adrian ED, 1941, J PHYSIOL-LONDON, V100, P159, DOI 10.1113/jphysiol.1941.sp003932; Anderson J, 2000, NAT NEUROSCI, V3, P617, DOI 10.1038/75797; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35, DOI 10.1152/jn.1967.30.1.35; ASANUMA H, 1968, J NEUROPHYSIOL, V31, P670, DOI 10.1152/jn.1968.31.5.670; ASANUMA H, 1971, BRAIN RES, V27, P97, DOI 10.1016/0006-8993(71)90374-X; Asanuma H., 1989, MOTOR CORTEX; Berg RW, 2003, J NEUROPHYSIOL, V90, P2950, DOI 10.1152/jn.00511.2003; Bermejo R, 1996, SOMATOSENS MOT RES, V13, P225, DOI 10.3109/08990229609052578; BERMEJO R, 2001, SOC NEUR ABSTR; Brecht M, 2002, J PHYSIOL-LONDON, V543, P49, DOI 10.1113/jphysiol.2002.018465; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Carvell GE, 1996, SOMATOSENS MOT RES, V13, P115, DOI 10.3109/08990229609051399; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; CHENEY PD, 1985, J NEUROPHYSIOL, V53, P786, DOI 10.1152/jn.1985.53.3.786; COWAN RL, 1994, J NEUROPHYSIOL, V71, P17, DOI 10.1152/jn.1994.71.1.17; ECCLES JC, 1976, UNDERSTANDING BRAIN; EVARTS EV, 1969, J NEUROPHYSIOL, V32, P375, DOI 10.1152/jn.1969.32.3.375; FETZ EE, 1976, BRAIN RES, V114, P505, DOI 10.1016/0006-8993(76)90973-2; Fritsch G, 1870, ARCH ANAT PHYSL WISS, V37, P300, DOI 10.1007/bf01759916; Gao PH, 2001, J NEUROSCI, V21, P5374, DOI 10.1523/JNEUROSCI.21-14-05374.2001; GEORGOPOULOS AP, 1995, TRENDS NEUROSCI, V18, P506, DOI 10.1016/0166-2236(95)92775-L; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Hattox A, 2003, NEURON, V39, P343, DOI 10.1016/S0896-6273(03)00391-X; Hattox AM, 2002, J COMP NEUROL, V442, P266, DOI 10.1002/cne.10089; JANKOWSKA E, 1975, J PHYSIOL-LONDON, V249, P617, DOI 10.1113/jphysiol.1975.sp011034; Jones E. G., 1984, CELLULAR COMPONENTS, P521; Kleinfeld D, 1999, SOMATOSENS MOT RES, V16, P69, DOI 10.1080/08990229970528; LERMA J, 1985, ELECTROEN CLIN NEURO, V60, P46, DOI 10.1016/0013-4694(85)90950-2; Leyton ASF, 1917, Q J EXP PHYSIOL, V11, P135, DOI 10.1113/expphysiol.1917.sp000240; Margrie TW, 2002, PFLUG ARCH EUR J PHY, V444, P491, DOI 10.1007/s00424-002-0831-z; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882, DOI 10.1152/jn.1998.80.6.2882; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Phillips C.G., 1977, MONOGR PHYSL SOC, V34; Porter R, 1995, CORTICOSPINAL FUNCTI; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; Schwartz AB, 2000, EUR J NEUROSCI, V12, P1851, DOI 10.1046/j.1460-9568.2000.00097.x; Schwartz AB, 2001, CURR OPIN NEUROBIOL, V11, P701, DOI 10.1016/S0959-4388(01)00272-0; STONEY SD, 1968, J NEUROPHYSIOL, V31, P659, DOI 10.1152/jn.1968.31.5.659; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; TIMOIARIA C, 1990, BRAZ J MED BIOL RES, V23, P617; Welker W. I., 1964, Behaviour, V22, P223, DOI 10.1163/156853964X00030; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; WOODY CD, 1973, J NEUROPHYSIOL, V36, P1104, DOI 10.1152/jn.1973.36.6.1104; Zhu JJ, 1999, J NEUROPHYSIOL, V81, P1171, DOI 10.1152/jn.1999.81.3.1171	45	247	253	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	2004	427	6976					704	710		10.1038/nature02266	http://dx.doi.org/10.1038/nature02266			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973477				2022-12-28	WOS:000189026000035
J	Nawrot, TS; Staessen, JA; Gardner, JP; Aviv, A				Nawrot, TS; Staessen, JA; Gardner, JP; Aviv, A			Telomere length and possible link to X chromosome	LANCET			English	Article							PULSE PRESSURE; DISEASE	Background Because telomeres are eroded during mitosis, telomere length indicates the replicative history of human somatic cells. Clinical markers of ageing-such as pulse pressure and survival-are associated with telomere length. On the basis of findings of studies in twins, telomere length seems to be familial, but little is known about its mode of inheritance. We aimed to investigate the inheritance of telomere length. Methods We measured terminal restriction fragment (TRF) length in white-blood-cell DNA taken from individuals from the family-based cohort of the Flemish Study on Environment, Genes, and Health Outcomes. Findings We recorded no correlation in sex and age adjusted TRF length between spouses (r=-0.05; p=0.70) nor between fathers and sons (r=-0.16; p=0.35). By contrast, we noted robust correlations in TRF length between fathers and daughters (r=0.60; p<0.0001); between mothers and sons (r=0.41; p=0.0017) and daughters (r=0.59; p<0.0001); and among siblings (r=greater than or equal to0.61; pless than or equal to0.0004). Interpretation X-linked inheritance of TRF length is the most probable explanation for our findings. Pending confirmation, our observations suggest that the process of ageing might be an X-linked trait.	Univ Louvain, Study Coordinating Ctr, Lab Hypertens, Dept Mol & Cardiovasc Res, B-3000 Louvain, Belgium; Univ Med & Dent New Jersey, New Jersey Med Sch, Hypertens Res Ctr, Newark, NJ 07103 USA	KU Leuven; Rutgers State University New Brunswick; Rutgers State University Medical Center	Staessen, JA (corresponding author), Univ Louvain, Study Coordinating Ctr, Lab Hypertens, Dept Mol & Cardiovasc Res, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011; Nawrot, Tim/AAA-4531-2019	Staessen, Jan A/0000-0002-3026-1637; Nawrot, Tim/0000-0002-3583-3593	NIA NIH HHS [AG021593] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021593] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aviv A, 2002, J MOL MED, V80, P689, DOI 10.1007/s00109-002-0377-8; Ayaori M, 2000, ENVIRON HEALTH PERSP, V108, P105, DOI 10.2307/3454507; Benetos A, 2001, HYPERTENSION, V37, P381, DOI 10.1161/01.HYP.37.2.381; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Jeanclos E, 2000, HYPERTENSION, V36, P195, DOI 10.1161/01.HYP.36.2.195; Kyo S, 1999, CANCER RES, V59, P5917; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Okuda K, 2002, PEDIATR RES, V52, P377, DOI 10.1203/01.PDR.0000022341.72856.72; Samani NJ, 2001, LANCET, V358, P472, DOI 10.1016/S0140-6736(01)05633-1; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; Staessen JA, 2001, J HYPERTENS, V19, P1349, DOI 10.1097/00004872-200108000-00002; vanKlaveren RJ, 1997, EUR RESPIR J, V10, P1392, DOI 10.1183/09031936.97.10061392; Vina J, 2003, ANTIOXID REDOX SIGN, V5, P549, DOI 10.1089/152308603770310194; Volpe M, 2003, J HYPERTENS, V21, P1429, DOI 10.1097/00004872-200308000-00001; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Youngren K, 1998, HUM GENET, V102, P640, DOI 10.1007/s004390050755	19	282	293	2	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					507	510		10.1016/S0140-6736(04)15535-9	http://dx.doi.org/10.1016/S0140-6736(04)15535-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975611	Green Accepted			2022-12-28	WOS:000188999900006
J	Han, X; Wang, CT; Bai, JH; Chapman, ER; Jackson, MB				Han, X; Wang, CT; Bai, JH; Chapman, ER; Jackson, MB			Transmembrane segments of syntaxin line the fusion pore of Ca2+-triggered exocytosis	SCIENCE			English	Article							ADRENAL CHROMAFFIN CELLS; KISS-AND-RUN; MEMBRANE-FUSION; VESICLE; SYNAPTOTAGMIN; HPC-1/SYNTAXIN; CONDUCTANCE; MODULATION; MECHANISMS; SECRETION	The fusion pore of regulated exocytosis is a channel that connects and spans the vesicle and plasma membranes. The molecular composition of this important intermediate structure of exocytosis is unknown. Here, we found that mutations of some residues within the transmembrane segment of syntaxin (Syx), a plasma membrane protein essential for exocytosis, altered neurotransmitter flux through fusion pores and altered pore conductance. The residues that influenced fusion-pore flux lay along one face of an alpha-helical model. Thus, the fusion pore is formed at least in part by a circular arrangement of 5 to 8 Syx transmembrane segments in the plasma membrane.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	mjackson@physiology.wisc.edu	Wang, Chih-Tien/GRE-8232-2022	Wang, Chih-Tien/0000-0001-7639-7508; Chapman, Edwin/0000-0001-9787-8140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044057, R01NS030016, R37NS030016] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56827] Funding Source: Medline; NIMH NIH HHS [MH61876] Funding Source: Medline; NINDS NIH HHS [NS30016, NS44057] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern GP, 2002, TRENDS NEUROSCI, V25, P510, DOI 10.1016/S0166-2236(02)02254-3; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALVAREZ DT, 1993, NATURE, V363, P554, DOI DOI 10.1038/363554A0; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colliver TL, 2000, J NEUROCHEM, V74, P1086; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hille B., 1992, ION CHANNELS EXCITAB; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; NEHER E, 1988, NEUROSCIENCE, V26, P727, DOI 10.1016/0306-4522(88)90094-2; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Suga K, 2003, J BIOCHEM, V133, P325, DOI 10.1093/jb/mvg044; Wang CT, 2003, NATURE, V424, P943, DOI 10.1038/nature01857; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200	30	254	261	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					289	292		10.1126/science.1095801	http://dx.doi.org/10.1126/science.1095801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15016962				2022-12-28	WOS:000220719400047
J	Brosnan, SF; de Waal, FBM				Brosnan, SF; de Waal, FBM			Fair refusal by capuchin monkeys - Reply	NATURE			English	Letter									Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	Emory University	de Waal, FBM (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.			Wynne, Clive/0000-0001-8408-1466				Brosnan SF, 2003, NATURE, V425, P297, DOI 10.1038/nature01963; BROSNAN SF, IN PRESS J COMP PSYC; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Sigmund K, 2002, SCI AM, V286, P82, DOI 10.1038/scientificamerican0102-82; Zar JH, 1996, BIOSTATISTICAL ANAL	6	69	70	1	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					140	140		10.1038/428140b	http://dx.doi.org/10.1038/428140b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014490	Bronze			2022-12-28	WOS:000220103600036
J	Schneeweiss, S; Maclure, M; Carleton, B; Glynn, RJ; Avorn, J				Schneeweiss, S; Maclure, M; Carleton, B; Glynn, RJ; Avorn, J			Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING-ENZYME INHIBITORS; METERED-DOSE INHALERS; PRESCRIPTION DRUGS; BRITISH-COLUMBIA; COST DATA; CARE; EVENTS; TRIALS; FORMULARY; OUTCOMES	Objective To compare the results of a randomised and an observational evaluation of the same policy that restricted reimbursement for nebulised respiratory medications in adult patients in a community setting. Designs Cluster randomised controlled trial and observational time series with historical controls. Setting Pharmacare, the government funded drug benefits plan for elderly people and patients receiving social assistance in British Columbia, Canada. Participants In the randomised controlled trial 104 clusters of medical practices, pair matched by geography and approximately by practice size, were randomised to the intervention group (449 patients affected by the policy on I March 1999), and the control group (offered a six month exemption, affecting 386 patients). The observational analysis included all Pharmacare beneficiaries (excluding the 386 exempt patients) who had used any nebulised drugs six months before die policy (4624 patients). Intervention Pharmacare restricted reimbursement for nebulised bronchodilators, steroids, and cromoglycate to patients whose doctors applied for an individual patient's exemption, giving an appropriate clinical reason. Main outcome measures Number of contacts with doctors and services, emergency admissions to hospital, and utilisation of and expenditure for respiratory drugs in databases of British Columbia's Ministry of Health. Results Contacts with doctors or emergency admissions to hospital did not increase in association with the restriction, regardless of the analytical approach. In the observational analysis, we found a reduction of $C24 (pound10, $18, E14) per patient month in all nebulised drug use (95% confidence interval 19 to 29) and an increase of $C3 per patient month in all expenditure for inhalers (1.4 to 4.5). The randomised evaluation found savings of $C8 per patient month for nebulisers (P = 0.24) and no increase in spending on inhalers (P = 0.79). Correcting for 60% non-compliance by exempt doctors in a sensitivity analysis yielded similar results as the observational evaluation. Conclusions Observational as well as randomised analyses found moderate net savings and no increase in unintended healthcare outcomes after restricting reimbursement for nebulised respiratory drugs. Randomised policy trials are feasible and, if carefully implemented, likely to be concordant with observational evaluations.	Brigham & Womens Hosp, Boston, MA 02120 USA; Harvard Univ, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Univ Victoria, Victoria, BC, Canada; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Victoria; Harvard University; Harvard T.H. Chan School of Public Health; University of British Columbia	Schneeweiss, S (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	schneeweiss@post.harvard.edu	Schneeweiss, Sebastian/C-2125-2013	Schneeweiss, Sebastian/0000-0003-2575-467X; Carleton, Bruce/0000-0002-4485-4054	NATIONAL INSTITUTE ON AGING [R03AG019463] Funding Source: NIH RePORTER; NIA NIH HHS [AG19463] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELSMITH B, 1994, HEALTH POLICY, V28, P89, DOI 10.1016/0168-8510(94)90030-2; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; ANDERSON GM, 1993, INQUIRY-J HEALTH CAR, V30, P199; *AUD COMM, 2003, PRIM CAR PRESCR B PR; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Barnett AA, 1996, LANCET, V347, P894; Bourgault C, 1999, CAN MED ASSOC J, V161, P255; BOWTON DL, 1992, CHEST, V101, P305, DOI 10.1378/chest.101.2.305; *BRIT COL MIN HLTH, 2001, PHARM TRENDS 2000; *CACC, 1996, CAN RESP J, V3, P89; CHAPPELL NL, 1997, CANADIAN J AGING CAN, P114; COOK TD, 1979, QUASI EXPT DESIGN AN; DANIEL W, 1991, BIOSTATISTICS FDN AN; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Ess SM, 2003, PHARMACOECONOMICS, V21, P89, DOI 10.2165/00019053-200321020-00002; FAIRMAN K, 1996, AM J MANAGE CARE, V2, P588; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Horn S., 1996, AM J MANAG CARE, V2, P253; Horn SD, 1998, AM J MANAG CARE, V4, P1105; JASPER AC, 1987, CHEST, V91, P614, DOI 10.1378/chest.91.4.614; KRAVITZ RL, 1996, AM J MANAG CARE, V2, P323; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACHURE M, 1996, CMAJ, V155, P986; Maclure M, 1997, CAN J AGING, V16, P132; MACLURE M, 2001, INFORMING JUDGMENT C, P35; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V96, P278, DOI 10.1016/S0091-6749(95)70206-7; Motheral BR, 1999, INQUIRY-J HEALTH CAR, V36, P481; Muers M. F., 1997, Thorax, V52, pS1; Muers MF, 1997, THORAX, V52, pS25, DOI 10.1136/thx.52.2008.S25; *ORG EC COOP DEV, 2001, HLTH DAT 2001 COMP A; Pounsford JC, 1997, THORAX, V52, pS53, DOI 10.1136/thx.52.2008.S53; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Schneeweiss S, 2002, J CLIN EPIDEMIOL, V55, P833, DOI 10.1016/S0895-4356(02)00437-7; SOUMERAI S, 1996, LANCET, V347, P1264; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Thomas M, 1998, LANCET, V352, P1830, DOI 10.1016/S0140-6736(05)79893-7; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; VENEY JE, 1991, EVALUATION DECISIO 5; Williams JI, 1996, INVENTORY STUDIES AC; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1991, BIOMETRICS, V47, P778	46	46	46	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					560	563		10.1136/bmj.38020.698194.F6	http://dx.doi.org/10.1136/bmj.38020.698194.F6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	801JI	14982865	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220091800021
J	Younus, F; Steigbigel, RT				Younus, F; Steigbigel, RT			Nodular Clostridium difficile colitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									SUNY Stony Brook, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Younus, F (corresponding author), SUNY Stony Brook, Stony Brook, NY 11794 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					E9	E9		10.1056/ENEJMicm010423	http://dx.doi.org/10.1056/ENEJMicm010423			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999125				2022-12-28	WOS:000189363600012
J	Nissen, SE; Tuzcu, EM; Schoenhagen, P; Brown, BG; Ganz, P; Vogel, RA; Crowe, T; Howard, G; Cooper, CJ; Brodie, B; Grines, CL; DeMaria, AN				Nissen, SE; Tuzcu, EM; Schoenhagen, P; Brown, BG; Ganz, P; Vogel, RA; Crowe, T; Howard, G; Cooper, CJ; Brodie, B; Grines, CL; DeMaria, AN		REVERSAL Investigators	Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; INTRAVASCULAR ULTRASOUND; ARTERY-DISEASE; HEART-DISEASE; TASK-FORCE; PRAVASTATIN; ATORVASTATIN; PREVENTION; EVENTS; AVERAGE	Context Statin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality. However, the optimal strategy and target level for lipid reduction remain uncertain. Objective To compare the effect of regimens designed to produce intensive lipid lowering or moderate lipid lowering on coronary artery atheroma burden and progression. Design, Setting, and Patients Double-blind, randomized active control multicenter trial (Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL]) performed at 34 community and tertiary care centers in the United States comparing the effects of 2 different statins administered for 18 months. Intravascular ultrasound was used to measure progression of atherosclerosis. Between June 1999 and September 2001, 654 patients were randomized and received study drug; 502 had evaluable intravascular ultrasound examinations at baseline and after 18 months of treatment. Interventions Patients were randomly assigned to receive a moderate lipid-lowering regimen consisting of 40 mg of pravastatin or an intensive lipid-lowering regimen consisting of 80 mg of atorvastatin. Main Outcome Measures The primary efficacy parameter was the percentage change in atheroma volume (follow-up minus baseline). Results Baseline low-density lipoprotein cholesterol level (mean, 150.2 mg/dL [3.89 mmol/L] in both treatment groups) was reduced to 110 mg/dL (2.85 mmol/L) in the pravastatin group and to 79 mg/dL (2.05 mmol/L) in the atorvastatin group (P<.001). C-reactive protein decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<.001). The primary end point (percentage change in atheroma volume) showed a significantly lower progression rate in the atorvastatin (intensive) group (P=.02). Similar differences between groups were observed foe secondary efficacy parameters, including change in total atheroma volume (P=.02), change in percentage atheroma volume (P<.001), and change in atheroma volume in the most severely diseased 10-mm vessel subsegment (P<.01). For the primary end point, progression of coronary atherosclerosis occurred in the pravastatin group (2.7%; 95% confidence interval [CI], 0.2% to 4.7%; P=.001) compared with baseline. Progression did not occur in the atorvastatin group (-0.4%; CI -2.4% to 1.5%; P=.98) compared with baseline. Conclusions For patients with coronary heart disease, intensive lipid-lowering treatment with atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin. Compared with baseline values, patients treated with atorvastatin had no change in atheroma burden, whereas patients treated with pravastatin showed progression of coronary atherosclerosis. These differences may be related to the greater reduction in atherogenic lipoproteins and C-reactive protein in patients treated with atorvastatin.	Cleveland Clin, Lerner Sch Med, Dept Cardiovasc Med, Cleveland, OH 44106 USA; Cleveland Clin, Lerner Sch Med, Dept Diagnost Radiol, Cleveland, OH 44106 USA; Univ Washington, Dept Med, Seattle, WA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Maryland, Dept Med, Baltimore, MD 21201 USA; Pfizer Inc, New York, NY USA; Med Coll Ohio, Dept Med, Toledo, OH 43699 USA; LeBauer Cardiovasc Res Fdn, Greensboro, NC USA; William Beaumont Hosp, Div Cardiac Dis, Cardiac Catheterizat Lab, Royal Oak, MI 48072 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; University System of Maryland; University of Maryland Baltimore; Pfizer; LeBauer-Brodie Center for Cardiovascular Research & Education; Beaumont Health; University of California System; University of California San Diego	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Schoenhagen, Paul/A-2808-2012	Schoenhagen, Paul/0000-0002-7751-5243; Ganz, Peter/0000-0002-0437-8882				Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Brown AS, 1998, J AM COLL CARDIOL, V32, P665, DOI 10.1016/S0735-1097(98)00300-3; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Nissen SE, 2001, CIRCULATION, V103, P604, DOI 10.1161/01.CIR.103.4.604; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schoenhagen P, 2003, J AM SOC ECHOCARDIOG, V16, P277, DOI 10.1067/mje.2003.45; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8; Taylor AJ, 2002, CIRCULATION, V106, P2055, DOI 10.1161/01.CIR.0000034508.55617.65; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X	23	1728	1880	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1071	1080		10.1001/jama.291.9.1071	http://dx.doi.org/10.1001/jama.291.9.1071			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996776	Bronze			2022-12-28	WOS:000189348900024
J	Pulzer, F; Bennek, J; Robel-Tillig, E; Knupfer, M; Vogtmann, C				Pulzer, F; Bennek, J; Robel-Tillig, E; Knupfer, M; Vogtmann, C			Gastric perforation in a newborn	LANCET			English	Editorial Material									Univ Leipzig, Childrens Hosp, Dept Neonatol, Leipzig, Germany; Univ Leipzig, Childrens Hosp, Dept Paediat Surg, Leipzig, Germany	Leipzig University; Leipzig University	Pulzer, F (corresponding author), Univ Leipzig, Childrens Hosp, Dept Neonatol, Leipzig, Germany.								0	7	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					703	703		10.1016/S0140-6736(04)15644-4	http://dx.doi.org/10.1016/S0140-6736(04)15644-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001328				2022-12-28	WOS:000189266900011
J	Chan, SWL; Zilberman, D; Xie, ZX; Johansen, LK; Carrington, JC; Jacobsen, SE				Chan, SWL; Zilberman, D; Xie, ZX; Johansen, LK; Carrington, JC; Jacobsen, SE			RNA silencing genes control de novo DNA methylation	SCIENCE			English	Article							DRM		Univ Calif Los Angeles, Dept MCD Biol, Los Angeles, CA 90095 USA; Oregon State Univ, CGRB, Corvallis, OR 97331 USA; Oregon State Univ, Bot Plant Pathol Dept, Corvallis, OR 97331 USA	University of California System; University of California Los Angeles; Oregon State University; Oregon State University	Jacobsen, SE (corresponding author), Univ Calif Los Angeles, Dept MCD Biol, Los Angeles, CA 90095 USA.	jacobsen@ucla.edu	Carrington, James C/A-4656-2012	Carrington, James C/0000-0003-3572-129X; Zilberman, Daniel/0000-0002-0123-8649; Xie, Zhixin/0000-0002-6191-5170	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM060398, R01GM060398] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60398] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; XIE Z, IN PRESS PLOS BIOL; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	8	412	453	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1336	1336		10.1126/science.1095989	http://dx.doi.org/10.1126/science.1095989			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988555				2022-12-28	WOS:000189238600041
J	deHaseth, PL; Nilsen, TW				deHaseth, PL; Nilsen, TW			Molecular biology - When a part is as good as the whole	SCIENCE			English	Editorial Material							RNA-POLYMERASE HOLOENZYME; TRANSCRIPTION INITIATION; ANGSTROM RESOLUTION; PROMOTER; DNA; SIGMA(70); PROTEIN; BINDING		Case Western Reserve Univ, RNA Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	deHaseth, PL (corresponding author), Case Western Reserve Univ, RNA Ctr, Cleveland, OH 44106 USA.	pld2@po.cwru.edu						BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462; Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1	13	8	8	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1307	1308		10.1126/science.1095483	http://dx.doi.org/10.1126/science.1095483			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988541				2022-12-28	WOS:000189238600027
J	Movshovich, R; Bianchi, A; Capan, C; Jaime, M; Goodrich, RG				Movshovich, R; Bianchi, A; Capan, C; Jaime, M; Goodrich, RG			Electron-spin domains - Magnetic enhancement of superconductivity	NATURE			English	Editorial Material							STATE; FIELD		Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Forschungszentrum Rossendorf EV, Hochfeld Lab Dresden, D-01314 Dresden, Germany; Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Louisiana State University System; Louisiana State University	Movshovich, R (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	roman@lanl.gov	Bianchi, Andrea/AAZ-8661-2021; Jaime, Marcelo/F-3791-2015	Bianchi, Andrea/0000-0001-9340-6971; Jaime, Marcelo/0000-0001-5360-5220				Buzdin AI, 1996, EUROPHYS LETT, V35, P707, DOI 10.1209/epl/i1996-00152-9; Buzdin AI, 1996, PHYS LETT A, V218, P359, DOI 10.1016/0375-9601(96)00362-3; FULDE P, 1964, PHYS REV           A, V135, P550; GINZBURG VL, 1957, SOV PHYS JETP-USSR, V4, P153; JAITRE M, 2002, PHYS REV LETT, V89, P7201; Larkin A I, 1964, ZH EKSP TEOR FIZ, V47, P1136; Radovan HA, 2003, NATURE, V425, P51, DOI 10.1038/nature01842; Shimahara H, 1997, J PHYS SOC JPN, V66, P3591, DOI 10.1143/JPSJ.66.3591	9	3	3	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					802	802		10.1038/427802a	http://dx.doi.org/10.1038/427802a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985750	Bronze			2022-12-28	WOS:000189207500028
J	Christ-Crain, M; Jaccard-Stolz, D; Bingisser, R; Gencay, MM; Huber, PR; Tamm, M; Muller, B				Christ-Crain, M; Jaccard-Stolz, D; Bingisser, R; Gencay, MM; Huber, PR; Tamm, M; Muller, B			Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial	LANCET			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; ACUTE BRONCHITIS; MANAGEMENT; EXACERBATIONS; THERAPY; IMPACT; DIAGNOSIS; ETIOLOGY; SEPSIS	Background Lower respiratory tract infections are often treated with antibiotics without evidence of clinically relevant bacterial disease. Serum calcitonin precursor concentrations, including procalcitonin, are raised in bacterial infections. We aimed to assess a procalcitonin-based therapeutic strategy to reduce antibiotic use in lower respiratory tract infections with a new rapid and sensitive assay. Methods 243 patients admitted with suspected lower respiratory tract infections were randomly assigned standard care (standard group; n=119) or procalcitonin-guided treatment (procalcitonin group; n=124). On the basis of serum procalcitonin concentrations, use of antibiotics was more or less discouraged (<0.1 mu g/L or <0.25 mug/L) or encouraged (greater than or equal to0.5 mug/L or greater than or equal to0.25 mug/L), respectively. Re-evaluation was possible after 6-24 h in both groups. Primary endpoint was use of antibiotics and analysis was by intention to treat. Findings Final diagnoses were pneumonia (n=87; 36%), acute exacerbation of chronic obstructive pulmonary disease (60; 25%), acute bronchitis (59; 24%), asthma (13; 5%), and other respiratory affections (24; 10%). Serological evidence of viral infection was recorded in 141 of 175 tested patients (81%). Bacterial cultures were positive from sputum in 51 (21%) and from blood in 16 (7%). In the procalcitonin group, the adjusted relative risk of antibiotic exposure was 0.49 (95% CI 0.44-0.55; p<0.0001) compared with the standard group. Antibiotic use was significantly reduced in all diagnostic subgroups. Clinical and laboratory outcome was similar in both groups and favourable in 235 (97%). Interpretation Procalcitonin guidance substantially reduced antibiotic use in lower respiratory tract infections. Withholding antimicrobial treatment did not compromise outcome. In view of the current overuse of antimicrobial therapy in often self-limiting acute respiratory tract infections, treatment based on procalcitonin measurement could have important clinical and financial implications.	Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Pneumol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Endocrinol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Clin Chem, CH-4031 Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel	Muller, B (corresponding author), Univ Basel Hosp, Dept Internal Med, Petersgraben 4, CH-4031 Basel, Switzerland.	happymiller@bluewin.ch	Mueller, Beat/G-2662-2012	Bingisser, Roland/0000-0001-8223-9792; Christ-Crain, Mirjam/0000-0002-6336-0965				ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Ball P, 2002, J ANTIMICROB CHEMOTH, V49, P31, DOI 10.1093/jac/49.1.31; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Evans AT, 2002, LANCET, V359, P1648, DOI 10.1016/S0140-6736(02)08597-5; Fluckiger U, 2000, EUR J CLIN MICROBIOL, V19, P493, DOI 10.1007/s100960000306; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gonzales R, 2003, JAMA-J AM MED ASSOC, V289, P2701, DOI 10.1001/jama.289.20.2701; Gonzales R, 2000, ANN INTERN MED, V133, P981, DOI 10.7326/0003-4819-133-12-200012190-00014; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Guillemot D, 2001, CLIN INFECT DIS, V33, P542, DOI 10.1086/322583; HALLS GA, 1993, J ANTIMICROB CHEMOTH, V31, P985, DOI 10.1093/jac/31.6.985; Halm EA, 2002, NEW ENGL J MED, V347, P2039, DOI 10.1056/NEJMcp020499; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770; Karzai W, 1997, INFECTION, V25, P329, DOI 10.1007/BF01740811; Korppi M, 2002, APMIS, V110, P515, DOI 10.1034/j.1600-0463.2002.11007801.x; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; Marik PE, 2000, J CRIT CARE, V15, P85, DOI 10.1053/jcrc.2000.16460; Marrie TJ, 2003, EUR RESPIR J, V21, P779, DOI 10.1183/09031936.03.00095403; Meisner M, 2002, CLIN CHIM ACTA, V323, P17, DOI 10.1016/S0009-8981(02)00101-8; Muller B, 2000, CRIT CARE MED, V28, P977, DOI 10.1097/00003246-200004000-00011; Muller B, 2001, SWISS MED WKLY, V131, P595; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; *NIH NAT HEART LUN, 1997, NIH PUBL; Nylen E, 2003, CLIN INFECT DIS, V36, P823, DOI 10.1086/368088; Nylen ES, 1996, AM J MED SCI, V312, P12, DOI 10.1016/S0002-9629(15)41740-9; ORTQVIST A, 1995, J ANTIMICROB CHEMOTH, V35, P205, DOI 10.1093/jac/35.1.205; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Ruokonen E, 2002, ACTA ANAESTH SCAND, V46, P398, DOI 10.1034/j.1399-6576.2002.460412.x; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; Snider RH, 1997, J INVEST MED, V45, P552; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; Strausbaugh LJ, 2003, CLIN INFECT DIS, V36, P870, DOI 10.1086/368197; Uyeki TM, 2003, PEDIATR INFECT DIS J, V22, P164; Wenzel RP, 1999, CLIN INFECT DIS, V28, P1126, DOI 10.1086/514753	38	763	860	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					600	607		10.1016/S0140-6736(04)15591-8	http://dx.doi.org/10.1016/S0140-6736(04)15591-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987884				2022-12-28	WOS:000189104900008
J	Fournier, P				Fournier, P			Diverticulosis	LANCET			English	Editorial Material												pierreoffice@shaw.ca							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					640	640		10.1016/S0140-6736(04)15598-0	http://dx.doi.org/10.1016/S0140-6736(04)15598-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987891				2022-12-28	WOS:000189104900024
J	Thapar, N; Sanderson, IR				Thapar, N; Sanderson, IR			Diarrhoea in children: an interface between developing and developed countries	LANCET			English	Review							ORAL REHYDRATION SOLUTION; NATURAL ROTAVIRUS INFECTION; VITAMIN-A SUPPLEMENTATION; NF-KAPPA-B; YOUNG-CHILDREN; PEDIATRIC GASTROENTEROLOGY; NUTRITIONAL MANAGEMENT; BISMUTH SUBSALICYLATE; HOSPITALIZED CHILDREN; BANGLADESHI CHILDREN	Despite much progress in the understanding of pathogenesis and of management, diarrhoeal illnesses remain one of the most important causes of global childhood mortality and morbidity. Infections account for most illnesses, with pathogens employing ingenious mechanisms to establish disease. In the developed world, an upsurge in immune-mediated gut disorders might have resulted from a disruption of normal bacteria I-epithelial cross-talk and impaired maturation of the gut's immune system. Oral rehydration therapies are the mainstay of management of gastroenteritis, and their composition continues to improve. Malnutrition remains the major adverse prognostic indicator for diarrhoea-related mortality, emphasising the importance of nutrition in early management. Drugs are of little use, except for specific indications although new agents that target mechanisms of secretory diarrhoea show promise, as do probiotics. However, preventive strategies on a global scale might ultimately hold the greatest potential to reduce the burden of diarrhoeal disease. These strategies include vaccines and, most importantly, policies to address persisting inequalities between the developed and developing worlds with respect to nutrition, sanitation, and access to safe drinking water.	Univ London, Barts & London Queen Mary Sch Med & Dent, Inst Cell & Mol Sci, Ctr Adult & Paediat Gastroenterol, London, England	University of London; Queen Mary University London	Thapar, N (corresponding author), Royal London Hosp, Digest Dis Res Ctr, Turner St, London E1 2AD, England.	thaparn@doctors.org.uk		Sanderson, Ian/0000-0002-9814-0161				Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Ali M, 2000, J HEALTH POPUL NUTR, V18, P103; Arias CF, 2002, ARCH MED RES, V33, P356, DOI 10.1016/S0188-4409(02)00374-0; Ashraf H, 1996, B WORLD HEALTH ORGAN, V74, P479; Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; Ballal Mamatha, 2002, Indian Journal of Pediatrics, V69, P393; Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057; BARNES G, 2000, PEDIAT GASTROINTESTI, P501; Bergogne-Berezin E, 2000, INT J ANTIMICROB AG, V16, P521, DOI 10.1016/S0924-8579(00)00293-4; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; Bhan MK, 2000, INT J ANTIMICROB AG, V14, P71, DOI 10.1016/S0924-8579(99)00150-8; BHAN MK, 2000, PEDIAT GASTROINTESTI, P603; Bhandari N, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e86; Bhatnagar S, 2004, J PEDIATR GASTR NUTR, V38, P34, DOI 10.1097/00005176-200401000-00010; BISHOP RF, 1973, LANCET, V2, P1281, DOI 10.1016/s0140-6736(73)92867-5; BROWN KH, 1994, PEDIATRICS, V93, P17; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; CASH RA, 1970, LANCET, V2, P549; Castagliuolo I, 1999, INFECT IMMUN, V67, P302, DOI 10.1128/IAI.67.1.302-307.1999; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Cezard JP, 2001, GASTROENTEROLOGY, V120, P799, DOI 10.1053/gast.2001.22544; Charmandari E, 2001, J PEDIATR GASTR NUTR, V32, P423, DOI 10.1097/00005176-200104000-00006; CHEW F, 1993, LANCET, V341, P194, DOI 10.1016/0140-6736(93)90063-M; *CHILD AD HLTH DEV, CHILD HLTH EP CURR E; Chowdhury HR, 2001, ACTA PAEDIATR, V90, P605, DOI 10.1080/080352501750258630; Cohen J, 2001, SCIENCE, V293, P1576, DOI 10.1126/science.293.5535.1576; Cojocaru B, 2002, ARCH PEDIATRIE, V9, P774, DOI 10.1016/S0929-693X(01)00988-5; Cremonini F, 2002, ALIMENT PHARM THER, V16, P1461, DOI 10.1046/j.1365-2036.2002.01318.x; Cummings JH, 2002, BRIT J NUTR, V87, pS145, DOI 10.1079/BJN/2002530; Cunliffe NA, 2002, LANCET, V359, P640, DOI 10.1016/S0140-6736(02)07781-4; D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361; Davidson G, 2002, J PEDIATR GASTR NUTR, V35, pS143, DOI 10.1097/00005176-200208002-00012; DAVIDSON GP, 1979, ACTA PAEDIATR SCAND, V68, P181, DOI 10.1111/j.1651-2227.1979.tb04986.x; Dewan V, 1995, Indian Pediatr, V32, P21; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; Dutta D, 2000, ACTA PAEDIATR, V89, P787, DOI 10.1080/080352500750043657; Elmer GW, 2001, GASTROENTEROL CLIN N, V30, P837, DOI 10.1016/S0889-8553(05)70213-2; Eriksson K, 2002, CURR OPIN IMMUNOL, V14, P666, DOI 10.1016/S0952-7915(02)00384-9; Fagundes-Neto U, 1999, J AM COLL NUTR, V18, P303, DOI 10.1080/07315724.1999.10718868; Farthing M.J.G., 1997, DIARRHEAL DIS, P55; Farthing MJG, 2002, GUT, V50, P15; FARTHING MJG, 2000, PEDIAT GASTROINTESTI, P512; Fasano A, 2002, GUT, V50, P9; Fasano A, 2000, PEDIAT GASTROINTESTI, P463; FAYAD IM, 1993, LANCET, V342, P772, DOI 10.1016/0140-6736(93)91540-3; FENTON TR, 1983, GUT, V24, P897, DOI 10.1136/gut.24.10.897; Fischer TK, 2002, J INFECT DIS, V186, P593, DOI 10.1086/342294; Fontaine O, 2000, COCHRANE DB SYST REV; Gerhard R, 1998, INFECT IMMUN, V66, P5125, DOI 10.1128/IAI.66.11.5125-5131.1998; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; GRACEY M, 1997, DIARRHEAL DIS, V38; GREEN KY, 1992, J VIROL, V66, P548, DOI 10.1128/JVI.66.1.548-553.1992; Grimprel E, 2001, ARCH PEDIATRIE, V8, P1318, DOI 10.1016/S0929-693X(01)00652-2; GUANDALINI S, 1982, GASTROENTEROLOGY, V83, P15; Guandalini S, 2000, J PEDIATR GASTR NUTR, V30, P54, DOI 10.1097/00005176-200001000-00018; Guarino A, 2001, ACTA PAEDIATR, V90, P601, DOI 10.1080/080352501750258621; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; Hanson LA, 2002, PEDIATR INT, V44, P347, DOI 10.1046/j.1442-200X.2002.01592.x; Hilton, 1997, J Travel Med, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x; HOEKSTRA JH, 1995, EUR J PEDIATR, V154, P362, DOI 10.1007/BF02072103; Hoekstra JH, 1998, ARCH DIS CHILD, V79, P2, DOI 10.1136/adc.79.1.2; Hoekstra JH, 2001, J PEDIATR GASTR NUTR, V33, pS31, DOI 10.1097/00005176-200110002-00006; Hogenauer C, 1998, CLIN INFECT DIS, V27, P702, DOI 10.1086/514958; HOLMES IH, 1975, J VIROL, V16, P937; Hooper LV, 1998, BIOESSAYS, V20, P336, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;336::AID-BIES10&gt;3.0.CO;2-3; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HUFFMAN S L, 1990, Journal of Diarrhoeal Diseases Research, V8, P68; Isolauri E, 1999, ANN MED, V31, P299, DOI 10.3109/07853899908995894; ISOLAURI E, 1985, J PEDIATR GASTR NUTR, V4, P366, DOI 10.1097/00005176-198506000-00008; Isolauri E, 2001, AM J CLIN NUTR, V73, p1142S; Jaimes MC, 2002, J VIROL, V76, P4741, DOI 10.1128/JVI.76.10.4741-4749.2002; Jain Vivek, 2001, Indian Journal of Pediatrics, V68, P855, DOI 10.1007/BF02762113; Jiang BM, 2002, CLIN INFECT DIS, V34, P1351, DOI 10.1086/340103; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; KALJOT KT, 1988, J VIROL, V62, P1136, DOI 10.1128/JVI.62.4.1136-1144.1988; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kang G, 2001, EPIDEMIOL INFECT, V127, P107, DOI 10.1017/S0950268801005799; Kapikian AZ, 2001, NOVART FDN SYMP, V238, P153; Khatun UHF, 2001, ACTA PAEDIATR, V90, P376, DOI 10.1080/080352501750126159; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Kirkwood CD, 2003, EXPERT OPIN BIOL TH, V3, P97, DOI 10.1517/eobt.3.1.97.20948; KLEINMAN RE, 1991, J PEDIATR-US, V118, pS111, DOI 10.1016/S0022-3476(05)81437-4; Knutton S, 2001, J PEDIATR GASTR NUTR, V33, P32, DOI 10.1097/00005176-200107000-00006; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; KUMARCHANDRA R, 1991, NESTL NUTR WORKSH, V23; Lu L, 2001, AM J CLIN NUTR, V73, p1124S; Lundegard PD, 2000, ENVIRON FORENSICS, V1, P3, DOI 10.1006/enfo.1998.0002; Lundgren O, 2002, PHARMACOL TOXICOL, V90, P109, DOI 10.1034/j.1600-0773.2002.900301.x; Lynch M, 2000, CURR OPIN INFECT DIS, V13, P495, DOI 10.1097/00001432-200010000-00011; MAHALANABIS D, 2000, PEDIAT GASTROINTESTI, P1676; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Mittal S. K., 1999, Indian Journal of Pediatrics, V66, pS4; Mittal SK, 2001, J PEDIATR GASTR NUTR, V33, pS26, DOI 10.1097/00005176-200110002-00005; MOLLA AM, 1997, DIARRHEAL DIS; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Nager AL, 2002, PEDIATRICS, V109, P566, DOI 10.1542/peds.109.4.566; Neto UF, 2000, LANCET, V356, pS27, DOI 10.1016/S0140-6736(00)92013-0; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; Oldfield EC, 2001, GASTROENTEROL CLIN N, V30, P817, DOI 10.1016/S0889-8553(05)70212-0; Orellana C, 2003, LANCET INFECT DIS, V3, P396, DOI 10.1016/S1473-3099(03)00686-8; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Pierce NF, 2001, J HEALTH POPUL NUTR, V19, P1; Pothoulakis C, 1996, EUR J GASTROEN HEPAT, V8, P1041, DOI 10.1097/00042737-199611000-00003; Rahman MM, 2001, BMJ-BRIT MED J, V323, P314, DOI 10.1136/bmj.323.7308.314; Rahman S, 2001, PUBLIC HEALTH, V115, P292, DOI 10.1016/S0033-3506(01)00462-0; Ramakrishna BS, 2000, NEW ENGL J MED, V342, P308, DOI 10.1056/NEJM200002033420502; Ramaswamy K, 2001, GASTROENTEROL CLIN N, V30, P611, DOI 10.1016/S0889-8553(05)70201-6; Ramzan NN, 2001, GASTROENTEROL CLIN N, V30, P665, DOI 10.1016/S0889-8553(05)70204-1; Reinshagen K, 2002, GUT, V51, P514, DOI 10.1136/gut.51.4.514; Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207; Rosenfeldt V, 2002, PEDIATR INFECT DIS J, V21, P411, DOI 10.1097/00006454-200205000-00012; Ruiz MC, 1997, J GEN VIROL, V78, P2883, DOI 10.1099/0022-1317-78-11-2883; Russo P., 2002, Clinical and Applied Immunology Reviews, V2, P203, DOI 10.1016/S1529-1049(02)00043-0; Saavedra JM, 2002, BRIT J NUTR, V87, pS241, DOI 10.1079/BJN/2002543; Saavedra JM, 2001, AM J CLIN NUTR, V73, p1147S; Salazar-Lindo E, 2000, NEW ENGL J MED, V343, P463, DOI 10.1056/NEJM200008173430703; SANDERSON IR, 1987, CURR OPIN GASTROEN, V3, P142, DOI 10.1097/00001574-198701000-00029; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; Sandhu BK, 2001, J PEDIATR GASTR NUTR, V33, pS13, DOI 10.1097/00005176-200110002-00003; Sandhu BK, 2001, J PEDIATR GASTR NUTR, V33, pS36, DOI 10.1097/00005176-200110002-00007; Sandhu BK, 1997, J PEDIATR GASTR NUTR, V24, P522, DOI 10.1097/00005176-199705000-00006; Santosham M, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e10; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; Sherman PM, 2004, J PEDIATR GASTR NUTR, V38, P16, DOI 10.1097/00005176-200401000-00007; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; STERN M, 2000, PEDIAT GASTROINTESTI, P746; Strand TA, 2002, PEDIATRICS, V109, P898, DOI 10.1542/peds.109.5.898; Sullivan PB, 1998, NUTRITION, V14, P758, DOI 10.1016/S0899-9007(98)00078-1; Szajewska H, 2001, J PEDIATR GASTR NUTR, V33, pS17, DOI 10.1097/00005176-200110002-00004; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; *UN, 2002, JOH WORLD SUMM 2002; *UNICEF, 2002, STAT WORLDS CHILDR 2; Van Niel CW, 2002, PEDIATRICS, V109, P678, DOI 10.1542/peds.109.4.678; Vanderhoof JA, 2001, AM J CLIN NUTR, V73, p1152S; Vanderhoof JA., 2000, PEDIAT GASTROINTESTI, P583; Vashishtha VM, 2001, BRIT MED J, V323, P1068; Velazquez FR, 2000, J INFECT DIS, V182, P1602, DOI 10.1086/317619; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; WALKER WA, 2000, PEDIAT GASTROINTESTI; Walker-Smith JA, 1998, NUTRITION, V14, P775, DOI 10.1016/S0899-9007(98)00082-3; WALKERSMITH JA, 1992, J PEDIATR GASTR NUTR, V14, P113, DOI 10.1097/00005176-199201000-00023; Waters V, 2000, PEDIATR INFECT DIS J, V19, P843, DOI 10.1097/00006454-200009000-00007; *WHO, 1985, CCDDDM851; WHO, FACTS FIG WAT SAN HY; *WHO, EXP CONS OR REH NEW; WHO, 1995, WHOCDR953; *WHO, 1993, WHOCDD9344; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; World Health Organization, 1994, WHOCDD9449; Youssef M, 2000, FEMS IMMUNOL MED MIC, V28, P257, DOI 10.1111/j.1574-695X.2000.tb01485.x; Yurdakok K, 2000, J PEDIATR GASTR NUTR, V31, P234, DOI 10.1097/00005176-200009000-00006; Zimmerman CM, 2001, PEDIATR INFECT DIS J, V20, P14, DOI 10.1097/00006454-200101000-00004; 2000, IMCI INTEGRATED MANA	160	265	285	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					641	653		10.1016/S0140-6736(04)15599-2	http://dx.doi.org/10.1016/S0140-6736(04)15599-2			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987892				2022-12-28	WOS:000189104900025
J	Chodosh, J; Burris, RD				Chodosh, J; Burris, RD			Ocular melanocytosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dean McGee Eye Inst, Oklahoma City, OK 73104 USA		Chodosh, J (corresponding author), Dean McGee Eye Inst, Oklahoma City, OK 73104 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					809	809		10.1056/NEJMicm990154	http://dx.doi.org/10.1056/NEJMicm990154			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973212				2022-12-28	WOS:000189006400009
J	Heil, F; Hemmi, H; Hochrein, H; Ampenberger, F; Kirschning, C; Akira, S; Lipford, G; Wagner, H; Bauer, S				Heil, F; Hemmi, H; Hochrein, H; Ampenberger, F; Kirschning, C; Akira, S; Lipford, G; Wagner, H; Bauer, S			Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8	SCIENCE			English	Article							TOLL-LIKE RECEPTORS; PLASMACYTOID DENDRITIC CELLS; BACTERIAL-DNA; IN-VITRO; B-CELLS; ACTIVATION; ANTIGEN; RESPONSIVENESS; MATURATION; SUBFAMILY	Double-stranded ribonucleic acid (dsRNA) serves as a danger signal associated with viral infection and leads to stimulation of innate immune cells. In contrast, the immunostimulatory potential of single-stranded RNA (ssRNA) is poorly understood and innate immune receptors for ssRNA are unknown. We report that guanosine (G)- and uridine (U)-rich ssRNA oligonucleotides derived from human immunodeficiency virus-1 (HIV-1) stimulate dendritic cells (DC) and macrophages to secrete interferon-alpha and proinflammatory, as well as regulatory, cytokines. By using Toll-like receptor (TLR)-deficient mice and genetic complementation, we show that murine TLR7 and human TLR8 mediate species-specific recognition of GU-rich ssRNA. These data suggest that ssRNA represents a physiological ligand for TLR7 and TLR8.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Osaka 5650047, Japan; Coley Pharmaceut Grp Inc, Wellesley, MA 02481 USA	Technical University of Munich; Osaka University; Japan Science & Technology Agency (JST); Coley Pharmaceutical Group	Bauer, S (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 9, D-81675 Munich, Germany.	stefan.bauer@lrz.tum.de	Akira, Shizuo/C-3134-2009; Yang, Chen/G-1379-2010; Hochrein, Hubertus/L-3697-2013	Hochrein, Hubertus/0000-0001-9904-1934; Bauer, Stefan/0000-0002-8462-1845				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; HEIL F, UNPUB; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HEMMI H, UNPUB; HOET RM, 1992, J CLIN INVEST, V90, P1753, DOI 10.1172/JCI116049; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Koido S, 2000, J IMMUNOL, V165, P5713, DOI 10.4049/jimmunol.165.10.5713; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Riedl P, 2002, J IMMUNOL, V168, P4951, DOI 10.4049/jimmunol.168.10.4951; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710	25	2789	3116	9	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1526	1529		10.1126/science.1093620	http://dx.doi.org/10.1126/science.1093620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	14976262				2022-12-28	WOS:000220000100045
J	Larson, EL; Lin, SX; Gomez-Pichardo, C; Della-Latta, P				Larson, EL; Lin, SX; Gomez-Pichardo, C; Della-Latta, P			Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							HAND SANITIZER USE; UNITED-STATES; ENVIRONMENTAL SURFACES; CHEMICAL DISINFECTION; FOODBORNE PATHOGENS; ROTAVIRUS DIARRHEA; OUTPATIENT VISITS; CONTROL PROGRAM; TRANSMISSION; COMMUNITY	Background: Despite the widespread household use of cleaning and personal hygiene products containing antibacterial ingredients, their effects on the incidence of infectious disease symptoms have not been studied. Objective: To evaluate the effect of antibacterial cleaning and handwashing products for consumers on the occurrence of infectious disease symptoms in households. Design: Randomized, double-blind clinical trial. Setting: Northern Manhattan inner-city neighborhood, New York. Participants: 238 primarily Hispanic households (1178 persons) that included at least one preschool-age child. Interventions: Households were randomly assigned to use either antibacterial or nonantibacterial products for general cleaning, laundry, and handwashing. All products were commercially available, but the packaging was blinded and the products were provided free to participants. Measurements: Hygiene practices and infectious disease symptoms were monitored by weekly telephone calls, monthly home visits, and quarterly interviews for 48 weeks. Results: Symptoms were primarily respiratory: During 26.2% (717 of 2736) of household-months, 23.3% (640 of 2737) of household-months, and 10.2% (278 of 2737) of household-months, one or more members of the household had a runny nose, cough, or sore throat, respectively. Fever was present during 11% (301 of 2737) of household-months, vomiting was present in 2.2% (61 of 2737), diarrhea was present in 2.5% (69 of 2737), and boils or conjunctivitis were present in 0.77% (21 of 2737). Differences between intervention and control groups were not significant for any symptoms (all unadjusted and adjusted relative risks included 1.0) or for numbers of symptoms (overall incidence density ratio, 0.96 [95% CI, 0.82 to 1.12]). Conclusions: The tested antibacterial products did not reduce the risk for symptoms of viral infectious diseases in households that included essentially healthy persons. This does not preclude the potential contribution of these products to reducing symptoms of bacterial diseases in the home.	Columbia Univ, Sch Nursing, New York, NY 10032 USA; Columbia Univ, Med Ctr, New York, NY USA	Columbia University; Columbia University	Larson, EL (corresponding author), Columbia Univ, Sch Nursing, 630 W 168th St, New York, NY 10032 USA.	ELL23@Columbia.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005251] Funding Source: NIH RePORTER; NINR NIH HHS [1 R01 NR05251, R01 NR005251-02] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Aiello AE, 2003, LANCET INFECT DIS, V3, P501, DOI 10.1016/S1473-3099(03)00723-0; Aiello AE, 2002, LANCET INFECT DIS, V2, P103, DOI 10.1016/S1473-3099(02)00184-6; ANSARI SA, 1991, J CLIN MICROBIOL, V29, P2115, DOI 10.1128/JCM.29.10.2115-2119.1991; Armstrong GL, 1999, ARCH INTERN MED, V159, P2531, DOI 10.1001/archinte.159.21.2531; Bloomfield S, 2001, J INFECTION, V43, P23, DOI 10.1053/jinf.2001.0848; Bloomfield SF, 2003, INT J ENVIRON HEAL R, V13, pS57, DOI 10.1080/0960312031000102804; Bloomfield SF, 1997, RES CLIN FORUMS, V19, P37; Breneman DL, 2000, CUTIS, V66, P296; Bryan J L, 1995, Crit Care Nurs Clin North Am, V7, P617; BUTZ AM, 1990, AM J INFECT CONTROL, V18, P347, DOI 10.1016/0196-6553(90)90248-Q; Collins JE, 1997, EMERG INFECT DIS, V3, P471, DOI 10.3201/eid0304.970409; Cunliffe NA, 1998, B WORLD HEALTH ORGAN, V76, P525; Darville T, 1998, Pediatr Rev, V19, P55, DOI 10.1542/pir.19-2-55; Dennehy PH, 2000, PEDIATR INFECT DIS J, V19, pS103, DOI 10.1097/00006454-200010001-00003; Denton M, 1998, J CLIN MICROBIOL, V36, P1953, DOI 10.1128/JCM.36.7.1953-1958.1998; Dharan S, 1999, J HOSP INFECT, V42, P113, DOI 10.1053/jhin.1999.0567; EVANS CA, 1975, J INVEST DERMATOL, V64, P42, DOI 10.1111/1523-1747.ep12540897; Fendler EJ, 2002, AM J INFECT CONTROL, V30, P226, DOI 10.1067/mic.2002.120129; GARFIELD R, 1995, ACAD MED, V70, P405, DOI 10.1097/00001888-199505000-00017; Goldmann DA, 2000, PEDIATR INFECT DIS J, V19, pS97, DOI 10.1097/00006454-200010001-00002; Gubareva LV, 2002, J INFECT DIS, V186, P1575, DOI 10.1086/345372; Guinan M, 2002, AM J INFECT CONTROL, V30, P217, DOI 10.1067/mic.2002.120366; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9; HALL GS, 1986, J HYG-CAMBRIDGE, V97, P289, DOI 10.1017/S0022172400065384; Hammond B, 2000, AM J INFECT CONTROL, V28, P340, DOI 10.1067/mic.2000.107276; Hooton TM, 2001, AM FAM PHYSICIAN, V63, P1087; Josephson KL, 1997, J APPL MICROBIOL, V83, P737, DOI 10.1046/j.1365-2672.1997.00308.x; KESWICK BH, 1997, CUTANEOUS INFECT THE, P49; Krilov LR, 1996, AM J INFECT CONTROL, V24, P167, DOI 10.1016/S0196-6553(96)90008-5; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468; Larson E, 2001, PUBLIC HEALTH NURS, V18, P116, DOI 10.1046/j.1525-1446.2001.00116.x; Larson E L, 2001, J Community Health Nurs, V18, P139, DOI 10.1207/153276501750408835; Levy SB, 2000, PEDIATR INFECT DIS J, V19, pS120, DOI 10.1097/00006454-200010001-00008; LEYDEN JJ, 1987, J INVEST DERMATOL, V88, pS65, DOI 10.1111/1523-1747.ep12468965; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507; Makris AT, 2000, AM J INFECT CONTROL, V28, P3, DOI 10.1016/S0196-6553(00)90004-X; Medves JM, 2001, BIRTH-ISS PERINAT C, V28, P161, DOI 10.1046/j.1523-536x.2001.00161.x; MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158; Parashar UD, 1998, J INFECT DIS, V177, P13, DOI 10.1086/513808; PARNES CA, 1997, ENV HLTH         JAN, P14; Parry SM, 1998, EMERG INFECT DIS, V4, P657, DOI 10.3201/eid0404.980419; Perencevich EN, 2001, AM J INFECT CONTROL, V29, P281, DOI 10.1067/mic.2001.115469; Rheinbaben F, 2000, J Hosp Infect, V46, P61, DOI 10.1053/jhin.2000.0794; Rosenberg S, 2000, PEDIATR INFECT DIS J, V19, pS114, DOI 10.1097/00006454-200010001-00006; Rutala WA, 2000, INFECT CONT HOSP EP, V21, P33, DOI 10.1086/501694; SATCHER D, 1995, EMERG INFECT DIS, V1, P1, DOI 10.3201/eid0101.950101; SATTAR SA, 1994, INFECT CONT HOSP EP, V15, P751; SATTAR SA, 1993, APPL ENVIRON MICROB, V59, P1579, DOI 10.1128/AEM.59.5.1579-1585.1993; Schutze GE, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.1.e1; SCOTT E, 1984, J HYG-CAMBRIDGE, V92, P193, DOI 10.1017/S0022172400064214; Scott E, 2000, PEDIATR INFECT DIS J, V19, pS111, DOI 10.1097/00006454-200010001-00005; Shah BV, 1997, SUDAAN USERS MANUAL; SHEARS P, 1995, J INFECTION, V30, P173, DOI 10.1016/S0163-4453(95)80016-6; SPEERS R, 1966, LANCET, V1, P1298; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zimmerman CM, 2001, PEDIATR INFECT DIS J, V20, P14, DOI 10.1097/00006454-200101000-00004; 2002, DEMOGRAPHIC HLTH SNA	60	75	75	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					321	329		10.7326/0003-4819-140-5-200403020-00007	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996673	Green Accepted			2022-12-28	WOS:000189246800001
J	Metcalfe, MS; Bridgewater, FHG; Mullin, EJ; Maddern, GJ				Metcalfe, MS; Bridgewater, FHG; Mullin, EJ; Maddern, GJ			Lesson of the week - Useless and dangerous - fine needle aspiration of hepatic colorectal metastases	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEPATOCELLULAR-CARCINOMA; PERCUTANEOUS BIOPSY; TRACT IMPLANTATION; LIVER-LESIONS; RESECTION; CANCER; PET; COMPLICATIONS; CYTOLOGY; CT		Univ Adelaide, Queen Elizabeth Hosp, Dept Surg, Woodville, SA 5011, Australia	University of Adelaide	Maddern, GJ (corresponding author), Univ Adelaide, Queen Elizabeth Hosp, Dept Surg, Woodville, SA 5011, Australia.	guy.maddern@adelaide.edu.au		Maddern, Guy/0000-0003-2064-181X				Chapoutot C, 1999, GASTROEN CLIN BIOL, V23, P552; Clayton RAE, 2003, SURG J R COLL SURG E, V1, P32, DOI 10.1016/S1479-666X(03)80006-9; Durand F, 2001, J HEPATOL, V35, P254, DOI 10.1016/S0168-8278(01)00108-8; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; FORNARI F, 1989, SCAND J GASTROENTERO, V24, P949, DOI 10.3109/00365528909089239; Goletti O, 1992, Eur J Surg Oncol, V18, P636; Herszenyi L, 1995, ITAL J GASTROENTEROL, V27, P473; Jourdan JL, 1996, NEW ZEAL MED J, V109, P469; Kim SH, 2000, ABDOM IMAGING, V25, P246, DOI 10.1007/s002610000025; Kinkel K, 2002, RADIOLOGY, V224, P748, DOI 10.1148/radiol.2243011362; Luketich JD, 1997, SURG ENDOSC-ULTRAS, V11, P1213, DOI 10.1007/s004649900572; MCGRATH FP, 1991, CLIN RADIOL, V43, P130, DOI 10.1016/S0009-9260(05)81594-6; Ohlsson B, 2002, BRIT J SURG, V89, P757, DOI 10.1046/j.1365-2168.2002.02111.x; SCHEELE J, 1990, HEPATO-GASTROENTEROL, V37, P335; SMITH EH, 1991, RADIOLOGY, V178, P253, DOI 10.1148/radiology.178.1.1984314; Strasberg SM, 2001, ANN SURG, V233, P293, DOI 10.1097/00000658-200103000-00001; Takamori R, 2000, LIVER TRANSPLANT, V6, P67, DOI 10.1002/lt.500060103; VERGARA V, 1993, J HEPATOL, V18, P276, DOI 10.1016/S0168-8278(05)80269-7	18	41	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					507	508		10.1136/bmj.328.7438.507	http://dx.doi.org/10.1136/bmj.328.7438.507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988193	Green Published, Green Submitted			2022-12-28	WOS:000220002900034
J	Klein, R				Klein, R			Britain's National Health Service revisited	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									London Sch Hyg, London, England; London Sch Econ, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School Economics & Political Science	Klein, R (corresponding author), London Sch Hyg, London, England.							*BRIT MED ASS, 2002, GUID WORK PATT JUN D; Collins Ben., 2015, FDN TRUSTS NHS TRUST; Commission for Health Improvement, 2003, GETT BETT REP NHS; *DEP HLTH, 2003, DEL NHS PLAN EXP REP; Department of Health, 2002, REF NHS FIN FLOWS IN; ENTHOVEN A, 1999, PURSUIT IMPROVING NA; Klein R, 2001, NEW ENGL J MED, V345, P305, DOI 10.1056/NEJM200107263450422; Laugesen MJ, 2003, J HEALTH POLIT POLIC, V28, P289, DOI 10.1215/03616878-28-2-3-289; Martin RM, 2003, BMJ-BRIT MED J, V326, P188, DOI 10.1136/bmj.326.7382.188; Robinson R, 1993, EVALUATING NHS REFOR; Secretary of State for Health, 1997, NEW NHS MOD DEP; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; 2003, ECONOMIST       0508, P27	13	13	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					937	942		10.1056/NEJMhpr031628	http://dx.doi.org/10.1056/NEJMhpr031628			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985493	Green Published			2022-12-28	WOS:000189197300015
J	Vichinsky, EP				Vichinsky, EP			Pulmonary hypertension in sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp & Res Ctr, No Calif Sickle Cell Ctr, Dept Hematol Oncol, Oakland, CA 94609 USA		Vichinsky, EP (corresponding author), Childrens Hosp & Res Ctr, No Calif Sickle Cell Ctr, Dept Hematol Oncol, Oakland, CA 94609 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC	1	64	65	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					857	859		10.1056/NEJMp038250	http://dx.doi.org/10.1056/NEJMp038250			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985481				2022-12-28	WOS:000189197300002
J	Luo, LF; Yang, XP; Takihara, Y; Knoetgen, H; Kessel, M				Luo, LF; Yang, XP; Takihara, Y; Knoetgen, H; Kessel, M			The cell-cycle regulator geminin inhibits Hox function through direct and polycomb-mediated interactions	NATURE			English	Article							DNA-REPLICATION; GENE-EXPRESSION; SEX COMB; PROTEIN; PROLIFERATION; BINDING; SPECIFICATION; PROGRESSION; REPRESSION; HOMOLOG	Embryonic development is tightly controlled. The clustered genes of the Hox family of homeobox proteins play an important part in regulating this development and also proliferation. They specify embryonic structures along the body axis, and are associated with normal and malignant cell growth(1-4). The cell-cycle regulator geminin controls replication by binding to the licensing factor Cdt1, and is involved in neural differentiation(5-7). Here, we show that murine geminin associates transiently with members of the Hox-repressing polycomb complex, with the chromatin of Hox regulatory DNA elements and with Hox proteins. Gain- and loss-of-function experiments in the chick neural tube demonstrate that geminin modulates the anterior boundary of Hoxb9 transcription, which suggests a polycomblike activity for geminin. The interaction between geminin and Hox proteins prevents Hox proteins from binding to DNA, inhibits Hox-dependent transcriptional activation of reporter and endogenous downstream target genes, and displaces Cdt1 from its complex with geminin. By establishing competitive regulation, geminin functions as a coordinator of developmental and proliferative control.	Max Planck Inst Biophys Chem, Dept Mol Cell Biol, Res Grp Dev Biol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Mol Genet, D-37077 Gottingen, Germany; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Stem Cell Biol, Hiroshima 7348553, Japan	Max Planck Society; Max Planck Society; Hiroshima University	Kessel, M (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Cell Biol, Res Grp Dev Biol, D-37077 Gottingen, Germany.	mkessel1@gwdg.de						Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Care A, 1996, MOL CELL BIOL, V16, P4842; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Megason SG, 2002, DEVELOPMENT, V129, P2087; Pekarik V, 2003, NAT BIOTECHNOL, V21, P93, DOI 10.1038/nbt770; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SEMENZA GL, 1995, BIOCHEM BIOPH RES CO, V209, P257, DOI 10.1006/bbrc.1995.1497; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Suzuki M, 2002, DEVELOPMENT, V129, P4171; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; Thornhill S, 1997, PHYS WORLD, V10, P17; Tomotsune D, 1999, DIFFERENTIATION, V65, P229, DOI 10.1046/j.1432-0436.1999.6540229.x; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309	29	179	181	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					749	753		10.1038/nature02305	http://dx.doi.org/10.1038/nature02305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973489	Green Published			2022-12-28	WOS:000189026000047
J	Yue, YZ; Angell, CA				Yue, YZ; Angell, CA			Clarifying the glass-transition behaviour of water by comparison with hyperquenched inorganic glasses	NATURE			English	Article							AMORPHOUS SOLID WATER; HEAT-CAPACITY CHANGES; LIQUID WATER; ENTHALPY RELAXATION; AQUEOUS-SOLUTIONS; CUBIC ICE; T-G; FICTIVE TEMPERATURE; CRYSTALLIZATION; FRAGILITY	The formation of glasses is normal for substances that remain liquid over a wide temperature range (the 'good glassformers') and can be induced for most liquids if cooling is fast enough to bypass crystallization. During reheating but still below the melting point, good glassformers exhibit glass transitions as they abruptly transform into supercooled liquids, whereas other substances transform directly from the glassy to the crystalline state. Whether water exhibits a glass transition before crystallization has been much debated over five decades(1,2-6). For the last 20 years, the existence of a glass transition at 136 K (ref. 3) has been widely accepted(2-4), but the transition exhibits qualities difficult to reconcile with our current knowledge of glass transitions(2,5,6). Here we report detailed calorimetric characterizations of hyperquenched inorganic glasses that, when heated, do not crystallize before reaching their glass transition temperatures. We compare our results to the behaviour of glassy water and find that small endothermic effects, such as the one attributed to the glass transition of water, are only a 'shadow' of the real glass transition occurring at higher temperatures, thus substantiating the conclusion(6) that the glass transition of water cannot be probed directly.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Univ Aalborg, Sect Chem, Dept Life Sci, DK-9000 Aalborg, Denmark	Arizona State University; Arizona State University-Tempe; Aalborg University	Angell, CA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.	caa@asu.edu	Yue, Yuanzheng/H-1313-2011	Yue, Yuanzheng/0000-0002-6048-5236				Angell CA, 2004, ANNU REV PHYS CHEM, V55, P559, DOI 10.1146/annurev.physchem.55.091602.094156; Angell CA, 2003, J PHYS-CONDENS MAT, V15, pS1051, DOI 10.1088/0953-8984/15/11/327; Angell CA, 2002, CHEM REV, V102, P2627, DOI 10.1021/cr000689q; ANGELL CA, 1980, J PHYS CHEM-US, V84, P268, DOI 10.1021/j100440a009; ANGELL CA, 2001, WATER SCI FOOD HLTH, P1; Axten CW, 1991, MAN MADE VITREOUS FI, P17; Fleissner G, 1998, J PHYS CHEM B, V102, P6239, DOI 10.1021/jp981779q; GHORMLEY JA, 1968, J CHEM PHYS, V48, P503, DOI 10.1063/1.1667954; HALLBRUCKER A, 1989, J PHYS CHEM-US, V93, P4986, DOI 10.1021/j100349a061; HALLBRUCKER A, 1987, J PHYS CHEM-US, V91, P503, DOI 10.1021/j100287a002; HANDA YP, 1988, J PHYS CHEM-US, V92, P3323, DOI 10.1021/j100323a005; HODGE IM, 1994, J NON-CRYST SOLIDS, V169, P211, DOI 10.1016/0022-3093(94)90321-2; HOFER K, 1989, J PHYS CHEM-US, V93, P4674, DOI 10.1021/j100348a053; HUANG J, 1992, J NON-CRYST SOLIDS, V151, P175, DOI 10.1016/0022-3093(92)90026-G; INOUE A, 1985, J MATER SCI, V20, P4057, DOI 10.1007/BF00552399; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; Jenniskens P, 1997, J CHEM PHYS, V107, P1232, DOI 10.1063/1.474468; Johari GP, 1998, J PHYS CHEM B, V102, P4711, DOI 10.1021/jp980765h; JOHARI GP, 1991, J CHEM PHYS, V95, P6849, DOI 10.1063/1.461495; Johari GP, 1996, SCIENCE, V273, P90, DOI 10.1126/science.273.5271.90; Johari GP, 2003, J CHEM PHYS, V119, P2935, DOI 10.1063/1.1586256; JOHARI GP, 1987, NATURE, V330, P552, DOI 10.1038/330552a0; Johari GP, 2002, J CHEM PHYS, V116, P8067, DOI 10.1063/1.1466469; Kivelson D, 2001, J PHYS CHEM B, V105, P6620, DOI 10.1021/jp010104b; Kohl I, 2000, PHYS CHEM CHEM PHYS, V2, P1579, DOI 10.1039/a908688i; MACFARLANE DR, 1984, J PHYS CHEM-US, V88, P759, DOI 10.1021/j150648a029; Ngai KL, 2000, J CHEM PHYS, V112, P1887, DOI 10.1063/1.480752; PRYDE JA, 1952, NATURE, V170, P635; Smith RS, 1999, NATURE, V398, P788, DOI 10.1038/19725; Velikov V, 2001, SCIENCE, V294, P2335, DOI 10.1126/science.1061757; Yue YZ, 2002, APPL PHYS LETT, V81, P2983, DOI 10.1063/1.1514386; Yue YZ, 2002, CHEM PHYS LETT, V357, P20, DOI 10.1016/S0009-2614(02)00434-7	32	205	208	5	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					717	720		10.1038/nature02295	http://dx.doi.org/10.1038/nature02295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973480				2022-12-28	WOS:000189026000038
J	Ferrando, AA; Neuberg, DS; Dodge, RK; Paietta, E; Larson, RA; Wiernik, PH; Rowe, JM; Caligiuri, MA; Bloomfield, CD; Look, AT				Ferrando, AA; Neuberg, DS; Dodge, RK; Paietta, E; Larson, RA; Wiernik, PH; Rowe, JM; Caligiuri, MA; Bloomfield, CD; Look, AT			Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia	LANCET			English	Article								The activation of oncogenic transcription factors defines distinct molecular subsets of T-cell acute lymphoblastic leukaemia and has prognostic. relevance in children. We investigated the prognostic effect of the expression levels of eight oncogenic transcription factors-TLX1 (HOX11), TLX3 (HOX11L2), TAL1, TAL2, LYL1, OLIG2 (BHLHB1), LMO1, and LMO2-in 52 adults with T-cell acute lymphoblastic leukaemia. The leukaemia-specific survival rate for the 16 TLX1-positive patients was 88% (90% CI 73-100%), compared with 56% (42-70%) for all other cases (p=0.019). Only the TLX1 oncogene expression subgroup showed difference in leukaemia-specific survival. Our results suggest that overexpression of TLX1 confers a good outlook for adults with T-cell acute lymphoblastic leukaemia. Furthermore, our findings lead to questions about whether stem-cell transplantation in first remission is necessary for effective treatment of patients in the low-risk subgroup of patients with TLX1 oncogene expression.	Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Our Lady Mercy Med Ctr, Eastern Cooperat Oncol Grp, Bronx, NY USA; Duke Univ, Med Ctr, Canc & Leukemia Grp B, Durham, NC 27706 USA; Univ Chicago, Chicago, IL 60637 USA; Rambam Med Ctr, Dept Hematol & BMT, Haifa, Israel; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Duke University; University of Chicago; Rambam Health Care Campus; Technion Israel Institute of Technology; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Look, AT (corresponding author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,Mayer 630, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Larson, Richard A./AAE-7223-2019	Larson, Richard A./0000-0001-9168-3203	NATIONAL CANCER INSTITUTE [U10CA077658, U10CA023318, P30CA016058, U10CA021115, U10CA101140, U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [CA101140, CA16058, CA77658, CA31946, CA23318, CA21115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1016/S0037-1963(00)90018-0; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FIERE D, 1993, J CLIN ONCOL, V11, P1990, DOI 10.1200/JCO.1993.11.10.1990; Gray R, 1988, ANN STAT, V16, P1140; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892	5	106	114	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					535	536		10.1016/S0140-6736(04)15542-6	http://dx.doi.org/10.1016/S0140-6736(04)15542-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975618				2022-12-28	WOS:000188999900013
J	King, KM; Ghali, WA; Faris, PD; Curtis, MJ; Galbraith, PD; Graham, MM; Knudtson, ML				King, KM; Ghali, WA; Faris, PD; Curtis, MJ; Galbraith, PD; Graham, MM; Knudtson, ML			Sex differences in outcomes after cardiac catheterization - Effect modification by treatment strategy and time	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; ARTERY-BYPASS-SURGERY; GENDER BIAS; WOMEN; DISEASE; REVASCULARIZATION; MEN	Context Studies comparing outcomes of cardiac care in women vs men yield various results, with some suggesting worse outcomes for women and others suggesting equivalent outcomes. Objective To determine whether extent of coronary disease, treatment strategy, and follow-up time influence the risk of death in women vs men among patients who have had cardiac catheterization. Design, Setting, and Patients We studied a large inception cohort by using detailed clinical data from a registry of 37401 patients undergoing cardiac catheterization in Alberta, Canada, from 1995-2000, with follow-up through December 31, 2001. Main Outcome Measures The risk of death for women vs men was assessed for all patients combined and then in analyses stratified by degree of coronary anatomic risk and by treatment strategy (no revascularization, percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery). The latter analysis included a graphic assessment of the changing relative risk over time for women vs men. Results Women had higher 1-year mortality than men did (5.6% vs 4.6%; P<.001). However, stratified analyses demonstrated that sex differences in risk occurred only early after catheterization and were most apparent among patients undergoing revascularization. The early risk-adjusted relative risks for women vs men were elevated at 3.49 (95% confidence interval [CI], 1.95-6.24) for CABG surgery and 2.38 (95% CI, 1.48-3.83) for PCI on day 1 after catheterization, with a subsequent decrease in relative risk over time to equivalence in risk between sexes before 1 year. Conclusions Sex-based differences in death rates after cardiac catheterization are time- and treatment-specific. This finding may at least partially explain the discrepancies in results from earlier studies on sex differences in outcomes of cardiac care.	Univ Calgary, Fac Nursing, Calgary, AB T2N 1N, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Ctr Hlth & Policy Studies, Calgary, AB, Canada; Univ Alberta, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Alberta; University of Calgary	King, KM (corresponding author), Univ Calgary, Fac Nursing, 2500 Univ Dr NW, Calgary, AB T2N 1N, Canada.	kingk@ucalgary.ca	Faris, Peter/AAJ-3436-2020	Faris, Peter/0000-0001-5208-817X				Abramov D, 2000, ANN THORAC SURG, V70, P800, DOI 10.1016/S0003-4975(00)01563-0; Abramson JL, 2003, AM J CARDIOL, V91, P968, DOI 10.1016/S0002-9149(03)00114-0; BELL MR, 1995, J AM COLL CARDIOL, V25, P1650, DOI 10.1016/0735-1097(95)00044-5; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CALIFF RM, 1985, J AM COLL CARDIOL, V5, P1055, DOI 10.1016/S0735-1097(85)80005-X; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; DASH H, 1977, BRIT HEART J, V39, P733; FLEMING RF, 1991, COUNTING PROCESSES S; Gan SC, 2000, NEW ENGL J MED, V343, P8, DOI 10.1056/NEJM200007063430102; Ghali WA, 2002, ANN INTERN MED, V136, P723, DOI 10.7326/0003-4819-136-10-200205210-00007; Ghali WA, 2000, CAN J CARDIOL, V16, P1225; Graham MM, 2001, AM HEART J, V142, P254, DOI 10.1067/mhj.2001.116481; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Iezzoni LI, 1997, MED CARE, V35, P158, DOI 10.1097/00005650-199702000-00006; JELINSKI SE, IN PRESS CAN J CARDI; LEGATO MJ, 2000, J GEND SPEC MED  OCT, P15; Malenka DJ, 1996, CIRCULATION, V94, P99; Mehilli J, 2002, JAMA-J AM MED ASSOC, V287, P210, DOI 10.1001/jama.287.2.210; Miller TD, 2001, J AM COLL CARDIOL, V38, P690, DOI 10.1016/S0735-1097(01)01413-9; Mueller C, 2002, J AM COLL CARDIOL, V40, P245, DOI 10.1016/S0735-1097(02)01949-6; O'Rourke DJ, 2001, ANN THORAC SURG, V71, P507, DOI 10.1016/S0003-4975(00)02236-0; Rathore SS, 2001, JAMA-J AM MED ASSOC, V286, P2849, DOI 10.1001/jama.286.22.2849; Roger VL, 2000, JAMA-J AM MED ASSOC, V283, P646, DOI 10.1001/jama.283.5.646; SMITH LR, 1991, CIRCULATION, V84, P245; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Vaccarino V, 2002, CIRCULATION, V105, P1176, DOI 10.1161/hc1002.105133	27	53	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1220	1225		10.1001/jama.291.10.1220	http://dx.doi.org/10.1001/jama.291.10.1220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010443				2022-12-28	WOS:000220061900022
J	Pantell, RH; Newman, TB; Bernzweig, J; Bergman, DA; Takayama, JI; Segal, M; Finch, SA; Wasserman, RC				Pantell, RH; Newman, TB; Bernzweig, J; Bergman, DA; Takayama, JI; Segal, M; Finch, SA; Wasserman, RC			Management and outcomes of care of fever in early infancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERIOUS BACTERIAL-INFECTIONS; FEBRILE INFANTS; LOW-RISK; OUTPATIENT TREATMENT; PRACTICE GUIDELINES; AGE; CHILDREN; ILLNESS; YOUNGER; IDENTIFICATION	Context Fever in infants challenges clinicians in distinguishing between serious conditions, such as bacteremia or bacterial meningitis, and minor illnesses. To date, the practice patterns of office-based pediatricians in treating febrile infants and the clinical outcomes resulting from their care have not been systematically studied. Objectives To characterize the management and clinical outcomes of fever in infants, develop a clinical prediction model for the identification of bacteremia/bacterial meningitis, and compare the accuracy of various strategies. Design Prospective cohort study. Setting Offices of 573 practitioners from the Pediatric Research in Office Settings (PROS) network of the American Academy of Pediatrics in 44 states, the District of Columbia, and Puerto Rico. Patients Consecutive sample of 3066 infants aged 3 months or younger with temperatures of at least 38degreesC seen by PROS practitioners from February 28, 1995, through April 25, 1998. Main Outcome Measures Management strategies, illness frequency, and rates and accuracy of treating bacteremia/bacterial meningitis. Results The PROS clinicians hospitalized 36% of the infants, performed laboratory testing in 75%, and initially treated 57% with antibiotics. The majority (64%) were treated exclusively outside of the hospital. Bacteremia was detected in 1.8% of infants (2.4% of those tested) and bacterial meningitis in 0.5%. Well-appearing infants aged 25 days or older with fever of less than 38.6degreesC had a rate of 0.4% for bacteremia/bacterial meningitis. Frequency of other illnesses included urinary tract infection, 5.4%; otitis media, 12.2%; upper respiratory tract infection, 25.6%; bronchiolitis, 7.8%; and gastroenteritis, 7.2%. Practitioners followed current guidelines in 42% of episodes. However, in the initial visit, they treated 61 of the 63 cases of bacteremia/bacterial meningitis with antibiotics. Neither current guidelines nor the model developed in this study performed with greater accuracy than observed practitioner management. Conclusions Pediatric clinicians in the United States use individualized clinical judgment in treating febrile infants. In this study, relying on current clinical guidelines would not have improved care but would have resulted in more hospitalizations and laboratory testing.	Univ Calif San Francisco, Sch Med, Dept Pediat, Div Gen Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Stanford Med Ctr, Lucile Salter Packard Childrens Hosp, Stanford, CA USA; Amer Acad Pediat, Ctr Child Hlth Res, Dept Practice & Res, Pediat Res Off Settings, Elk Grove Village, IL USA; Vermont Coll Med, Dept Pediat, Burlington, VT USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Lucile Packard Children's Hospital (LPCH); Stanford University; American Academy of Pediatrics	Pantell, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pediat, Div Gen Pediat, Box 0503, San Francisco, CA 94143 USA.	pantell@itsa.ucsf.edu	Wasserman, Richard/G-3775-2015		AHRQ HHS [R01 HS06485] Funding Source: Medline; PHS HHS [MCJ-177022] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006485] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANBAR RD, 1986, J PEDIATR-US, V109, P483, DOI 10.1016/S0022-3476(86)80122-6; Avner JR, 2002, EMERG MED CLIN N AM, V20, P49, DOI 10.1016/S0733-8627(03)00051-8; Bachur RG, 2001, PEDIATRICS, V108, P311, DOI 10.1542/peds.108.2.311; Baker MD, 1999, ARCH PEDIAT ADOL MED, V153, P508; BAKER MD, 1990, PEDIATRICS, V85, P1040; Baker MD, 1999, PEDIATRICS, V103, P627, DOI 10.1542/peds.103.3.627; BARAFF LJ, 1992, PEDIATR INFECT DIS J, V11, P257, DOI 10.1097/00006454-199204000-00001; BARAFF LJ, 1993, ANN EMERG MED, V22, P1198, DOI 10.1016/S0196-0644(05)80991-6; Baraff LJ, 2000, ANN EMERG MED, V36, P602, DOI 10.1067/mem.2000.110820; BASKIN MN, 1992, J PEDIATR-US, V120, P22, DOI 10.1016/S0022-3476(05)80591-8; BASKIN MN, 1993, PEDIATR ANN, V22, P462, DOI 10.3928/0090-4481-19930801-06; Bennett JE, 2000, ARCH PEDIAT ADOL MED, V154, P43; BRATTON L, 1977, J PEDIATR-US, V90, P703, DOI 10.1016/S0022-3476(77)81231-6; Breiman L., 1984, CLASSIFICATION REGRE; DAGAN R, 1988, J PEDIATR-US, V112, P355, DOI 10.1016/S0022-3476(88)80312-3; DAGAN R, 1985, J PEDIATR-US, V107, P855, DOI 10.1016/S0022-3476(85)80175-X; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1146, DOI 10.1001/archpedi.1983.02140380006003; DEANGELIS C, 1983, AM J DIS CHILD, V137, P1150, DOI 10.1001/archpedi.1983.02140380010004; FEDER HM, 1980, CLIN PEDIATR, V19, P457, DOI 10.1177/000992288001900705; GOTOFF SP, 1970, J PEDIATR-US, V76, P142, DOI 10.1016/S0022-3476(70)80148-2; Herr SM, 2001, PEDIATRICS, V108, P866, DOI 10.1542/peds.108.4.866; JONES RG, 1993, PEDIATR INFECT DIS J, V12, P179, DOI 10.1097/00006454-199303000-00001; Kadish HA, 2000, CLIN PEDIATR, V39, P81, DOI 10.1177/000992280003900202; Kramer MS, 1997, PEDIATRICS, V100, P128, DOI 10.1542/peds.100.1.128; Kuppermann N, 2003, ARCH PEDIAT ADOL MED, V157, P508, DOI 10.1001/archpedi.157.6.508; MCCARTHY PL, 1981, PEDIATRICS, V67, P687; MCCARTHY PL, 1987, J PEDIATR-US, V110, P26, DOI 10.1016/S0022-3476(87)80282-2; Newman TB, 2002, ARCH PEDIAT ADOL MED, V156, P44, DOI 10.1001/archpedi.156.1.44; ROBERTS KB, 1977, JOHNS HOPKINS MED J, V141, P9; Segal M R, 1995, Stat Methods Med Res, V4, P219, DOI 10.1177/096228029500400304; YOUNG PC, 1995, PEDIATRICS, V95, P623	31	186	193	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1203	1212		10.1001/jama.291.10.1203	http://dx.doi.org/10.1001/jama.291.10.1203			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010441	Bronze			2022-12-28	WOS:000220061900020
J	Roberts, CGP; Ladenson, PW				Roberts, CGP; Ladenson, PW			Hypothyroidism	LANCET			English	Review							MILD THYROID FAILURE; THYROTROPIN-RELEASING-HORMONE; NUTRITION EXAMINATION SURVEY; L-THYROXINE THERAPY; 20-YEAR FOLLOW-UP; SUBCLINICAL HYPOTHYROIDISM; AUTOIMMUNE-THYROIDITIS; GRAVES-DISEASE; MYXEDEMA COMA; JUVENILE HYPOTHYROIDISM	Hypothyroidism is common, potentially serious, often clinically overlooked, readily diagnosed by laboratory testing, and eminently treatable. The condition is particularly prevalent in older women, in whom autoimmune thyroiditis is common. Other important causes include congenital thyroid disorders, previous thyroid surgery and irradiation, drugs such as lithium carbonate and amiodarone, and pituitary and hypothalamic disorders. Worldwide, dietary iodine deficiency remains an important cause. Hypothyroidism can present with nonspecific constitutional and neuropsychiatric complaints, or with hypercholesterolaemia, hyponatraemia, hyperprolactinaemia, or hyperhomocysteinaemmia. Severe untreated hypothyroidism can lead to heart failure, psychosis, and coma. Although these manifestations are neither specific nor sensitive, the diagnosis is confirmed or excluded by measurements of serum thyrotropin and free thyroxine. Thyroxine replacement therapy is highly effective and safe, but suboptimal dosing is common in clinical practice. Patient noncompliance, drug interactions, and pregnancy can lead to inadequate treatment. latrogenic thyrotoxicosis can cause symptoms, and, even when mild, provoke atrial fibrillation and osteoporosis. We summarise present understanding of the history, epidemiology, pathophysiology, and clinical diagnosis and management of hypothyroidism.	Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Baltimore, MD 21205 USA	Johns Hopkins University	Ladenson, PW (corresponding author), 1830 E Monument St,Suite 333, Baltimore, MD 21287 USA.	ladenson@jhmi.edu		Roberts, Caroline/0000-0002-0237-1038				Abramson J, 2001, THYROID, V11, P57, DOI 10.1089/10507250150500676; AKAMIZU T, 1987, CLIN ENDOCRINOL, V26, P311, DOI 10.1111/j.1365-2265.1987.tb00788.x; Allen EM, 2003, J CLIN ENDOCR METAB, V88, P1292, DOI 10.1210/jc.2002-020634; AMINO N, 1976, CLIN ENDOCRINOL, V5, P115, DOI 10.1111/j.1365-2265.1976.tb02822.x; AMINO N, 1982, NEW ENGL J MED, V306, P849, DOI 10.1056/NEJM198204083061405; Arafah BM, 2001, NEW ENGL J MED, V344, P1743, DOI 10.1056/NEJM200106073442302; ASHER R, 1949, BRIT MED J, V2, P555, DOI 10.1136/bmj.2.4627.555; Ayala AR, 2000, ENDOCRIN METAB CLIN, V29, P399, DOI 10.1016/S0889-8529(05)70139-0; AZIZI F, 1979, ANN INTERN MED, V90, P941, DOI 10.7326/0003-4819-90-6-941; BARNES ND, 1973, MAYO CLIN PROC, V48, P849; BECKER D V, 1971, Seminars in Nuclear Medicine, V1, P442; BeckPeccoz P, 1996, ENDOCR REV, V17, P610, DOI 10.1210/er.17.6.610; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; Bell D S, 2001, Endocr Pract, V7, P193; BELL NH, 1991, ENDOCRIN METAB CLIN, V20, P645, DOI 10.1016/S0889-8529(18)30262-7; Beyer IW, 1998, THYROID, V8, P1029, DOI 10.1089/thy.1998.8.1029; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; BIGOS ST, 1978, J CLIN ENDOCR METAB, V46, P317, DOI 10.1210/jcem-46-2-317; Biondi B, 2002, ANN INTERN MED, V137, P904, DOI 10.7326/0003-4819-137-11-200212030-00011; Bolon M, 2000, EUR J CLIN PHARMACOL, V56, P771, DOI 10.1007/s002280000209; Bona M, 1998, PHARMACOECONOMICS, V14, P209, DOI 10.2165/00019053-199814020-00009; BORST GC, 1983, J CLIN ENDOCR METAB, V57, P380, DOI 10.1210/jcem-57-2-380; BORUCHOW IB, 1966, ARCH SURG-CHICAGO, V92, P960; BOUKIS MA, 1983, J CLIN ENDOCR METAB, V57, P859, DOI 10.1210/jcem-57-4-859; Brenta G, 2003, AM J CARDIOL, V91, P1327, DOI 10.1016/S0002-9149(03)00322-9; Bunevicius R, 1999, NEW ENGL J MED, V340, P424, DOI 10.1056/NEJM199902113400603; CAMPBELL NRC, 1992, ANN INTERN MED, V117, P1010, DOI 10.7326/0003-4819-117-12-1010; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Canaris GJ, 1997, J GEN INTERN MED, V12, P544, DOI 10.1046/j.1525-1497.1997.07109.x; Chiu AC, 1998, THYROID, V8, P667, DOI 10.1089/thy.1998.8.667; CHOPRA IJ, 1977, J CLIN ENDOCR METAB, V45, P45, DOI 10.1210/jcem-45-1-45; Chu JW, 2001, J CLIN ENDOCR METAB, V86, P4591, DOI 10.1210/jc.86.10.4591; CLARNETTE RM, 1994, J GERIATR PSYCH NEUR, V7, P23, DOI 10.1177/089198879400700105; Collins MT, 2000, J ENDOCRINOL INVEST, V23, P383, DOI 10.1007/BF03343742; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; de la Breteche R, 2000, INDAGAT MATH NEW SER, V11, P437, DOI 10.1016/S0019-3577(00)80008-7; Demers LM, 2002, NATL ACAD CLIN BIOCH; DIEKMAN T, 1995, ARCH INTERN MED, V155, P1490, DOI 10.1001/archinte.155.14.1490; DOHERTY JE, 1966, ANN INTERN MED, V64, P489, DOI 10.7326/0003-4819-64-3-489; Dugbartey AT, 1998, ARCH INTERN MED, V158, P1413, DOI 10.1001/archinte.158.13.1413; EDSON JR, 1975, ANN INTERN MED, V82, P342, DOI 10.7326/0003-4819-82-3-342; EDWARDS CQ, 1983, ARCH INTERN MED, V143, P1890, DOI 10.1001/archinte.143.10.1890; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FARTHING MJG, 1982, CLIN ENDOCRINOL, V16, P525, DOI 10.1111/j.1365-2265.1982.tb03169.x; Fatourechi V, 2003, J CLIN ENDOCR METAB, V88, P2100, DOI 10.1210/jc.2002-021799; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FISH LH, 1988, ARCH INTERN MED, V148, P709, DOI 10.1001/archinte.148.3.709; FOLEY TP, 2000, THYROID FUNDAMENTAL, P977; FOLEY TP, 2000, THYROID FUNDAMENTAL, P983; Gillam MP, 2001, CURR OPIN PEDIATR, V13, P364, DOI 10.1097/00008480-200108000-00014; Gillam MP, 2001, CURR OPIN PEDIATR, V13, P358, DOI 10.1097/00008480-200108000-00013; GLINOER D, 1994, J CLIN ENDOCR METAB, V79, P197, DOI 10.1210/jcem.79.1.8027226; Goldsmith JR, 1999, ENVIRON HEALTH PERSP, V107, P303; GOTEHRER A, 1990, CHEST, V98, P1130, DOI 10.1378/chest.98.5.1130; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; HAMBLIN PS, 1986, J CLIN ENDOCR METAB, V62, P717, DOI 10.1210/jcem-62-4-717; HANAFUSA T, 1983, LANCET, V2, P1111; HAYSLIP CC, 1988, AM J OBSTET GYNECOL, V159, P203, DOI 10.1016/0002-9378(88)90522-4; HIRANO T, 1978, J PEDIATR-US, V93, P262, DOI 10.1016/S0022-3476(78)80514-9; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; HOLVEY DN, 1964, ARCH INTERN MED, V113, P89, DOI 10.1001/archinte.1964.00280070091015; Huang SA, 2000, NEW ENGL J MED, V343, P185, DOI 10.1056/NEJM200007203430305; ISLEY WL, 1987, ANN INTERN MED, V107, P517, DOI 10.7326/0003-4819-107-4-517; Jackson IMD, 1998, THYROID, V8, P951, DOI 10.1089/thy.1998.8.951; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; KAHN BB, 1988, J CLIN ENDOCR METAB, V66, P526, DOI 10.1210/jcem-66-3-526; Kaptein EM, 1996, ENDOCR REV, V17, P45, DOI 10.1210/er.17.1.45; KAPTEIN EM, 1980, J CLIN ENDOCR METAB, V51, P488, DOI 10.1210/jcem-51-3-488; KAPTEIN EM, 1981, J CLIN ENDOCR METAB, V53, P764, DOI 10.1210/jcem-53-4-764; KATZ SM, 1974, HUM PATHOL, V5, P161, DOI 10.1016/S0046-8177(74)80063-8; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Klein RZ, 2002, CURR OPIN PEDIATR, V14, P443, DOI 10.1097/00008480-200208000-00016; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P5251, DOI 10.1073/pnas.89.12.5251; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; LADENSON PW, 1984, AM J MED, V77, P261, DOI 10.1016/0002-9343(84)90701-0; Ladenson PW, 1997, NEW ENGL J MED, V337, P888, DOI 10.1056/NEJM199709253371304; LADENSON PW, 2000, THYROID FUNDAMENTAL, P848; LADENSON PW, 2002, DIS THYROID; LaFranchi S, 1999, THYROID, V9, P735, DOI 10.1089/thy.1999.9.735; Lazarus JH, 2002, SEMIN REPROD MED, V20, P381, DOI 10.1055/s-2002-36711; Lee E, 1999, CLIN ENDOCRINOL, V50, P487, DOI 10.1046/j.1365-2265.1999.00678.x; Liel Y, 1996, J CLIN ENDOCR METAB, V81, P857, DOI 10.1210/jc.81.2.857; Lin CT, 2003, JPN HEART J, V44, P447, DOI 10.1536/jhj.44.447; LOGOTHETIS J, 1963, J NERV MENT DIS, V136, P561, DOI 10.1097/00005053-196306000-00008; MALLYA RK, 1978, BRIT MED J, V2, P1535, DOI 10.1136/bmj.2.6151.1535; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; McDermott MT, 2001, J CLIN ENDOCR METAB, V86, P4585, DOI 10.1210/jc.86.10.4585; MCNEIL LW, 1983, AM J MED SCI, V285, P7, DOI 10.1097/00000441-198305000-00002; Meyer CM, 2000, AM J MANAG CARE, V6, P457; Michalopoulou G, 1998, EUR J ENDOCRINOL, V138, P141, DOI 10.1530/eje.0.1380141; Michiels JJ, 2001, CLIN APPL THROMB-HEM, V7, P113, DOI 10.1177/107602960100700206; MONZANI F, 1993, CLIN INVESTIGATOR, V71, P367; Morris MS, 2001, ATHEROSCLEROSIS, V155, P195, DOI 10.1016/S0021-9150(00)00537-2; Muller AF, 2001, ENDOCR REV, V22, P605, DOI 10.1210/er.22.5.605; MURKIN JM, 1982, ANESTH ANALG, V61, P371; NAJJAR SS, 1974, J PEDIATR-US, V85, P236, DOI 10.1016/S0022-3476(74)80403-8; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; NICKEL SN, 1958, NEUROLOGY, V8, P511, DOI 10.1212/WNL.8.7.511; NICOLOFF JT, 1993, ENDOCRIN METAB CLIN, V22, P279, DOI 10.1016/S0889-8529(18)30166-X; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; OCONNOR P, 1987, CLIN PHARMACOKINET, V13, P345, DOI 10.2165/00003088-198713060-00001; OLeary KA, 1997, MOL PHARMACOL, V52, P46, DOI 10.1124/mol.52.1.46; Order SE, 1989, ONCOLOGY, V3, P115; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Perk M, 1997, CAN J CARDIOL, V13, P273; PHILLIPS D, 1990, J CLIN ENDOCR METAB, V70, P742, DOI 10.1210/jcem-70-3-742; PRICE TR, 1966, NEUROLOGY, V16, P957, DOI 10.1212/WNL.16.10.957; Quan ML, 2002, J SURG ONCOL, V79, P62, DOI 10.1002/jso.10043; QUIN JD, 1994, SCOT MED J, V39, P82; RAM PA, 1992, J BIOL CHEM, V267, P3294; RE RN, 1976, J CLIN ENDOCR METAB, V43, P338, DOI 10.1210/jcem-43-2-338; REED HL, 1990, J CLIN ENDOCR METAB, V70, P965, DOI 10.1210/jcem-70-4-965; REINWEIN D, 1988, J ENDOCRINOL INVEST, V11, P193, DOI 10.1007/BF03350134; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; RICE AJ, 1971, AM J MED SCI, V262, P211, DOI 10.1097/00000441-197110000-00003; Rose NR, 1999, ENVIRON HEALTH PERSP, V107, P749, DOI 10.2307/3434337; Rose SR, 2001, TRENDS ENDOCRIN MET, V12, P97, DOI 10.1016/S1043-2760(00)00359-3; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; Ross DS, 1998, ENDOCRIN METAB CLIN, V27, P169, DOI 10.1016/S0889-8529(05)70305-4; Ross DS, 2001, ENDOCRIN METAB CLIN, V30, P245, DOI 10.1016/S0889-8529(05)70186-9; ROTI E, 1992, CLIN CHEM, V38, P88; Saravanan P, 2002, CLIN ENDOCRINOL, V57, P577, DOI 10.1046/j.1365-2265.2002.01654.x; Sarich Troy C., 1996, Drug Metabolism and Drug Interactions, V13, P155; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P4551, DOI 10.1210/jc.2003-030139; Segal-Lieberman G, 2000, Pituitary, V3, P181, DOI 10.1023/A:1011407910913; Shakir KMM, 2000, MAYO CLIN PROC, V75, P189; SHENFIELD GM, 1977, EUR J CLIN PHARMACOL, V12, P437, DOI 10.1007/BF00561063; SHERMAN SI, 1991, AM J MED, V90, P367, DOI 10.1016/0002-9343(91)90578-L; Sherman SI, 1999, NEW ENGL J MED, V340, P1075, DOI 10.1056/NEJM199904083401404; Singh N, 2000, JAMA-J AM MED ASSOC, V283, P2822, DOI 10.1001/jama.283.21.2822; Sklar C, 2000, J CLIN ENDOCR METAB, V85, P3227, DOI 10.1210/jc.85.9.3227; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; Spencer CA, 1996, CLIN CHEM, V42, P140; SPENCER CA, 1993, J CLIN ENDOCR METAB, V76, P494, DOI 10.1210/jc.76.2.494; Stafford E A, 2000, Int Rev Immunol, V19, P501, DOI 10.3109/08830180009088510; TACHMAN ML, 1984, ENDOCR REV, V5, P456, DOI 10.1210/edrv-5-3-456; TAMAI H, 1980, J CLIN ENDOCR METAB, V51, P1123, DOI 10.1210/jcem-51-5-1123; TOFT AD, 1994, NEW ENGL J MED, V331, P174; TOPLISS DJ, 1980, J CLIN ENDOCR METAB, V50, P52, DOI 10.1210/jcem-50-1-52; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL OXF, V7, P115; VAGENAKIS AG, 1976, ANN INTERN MED, V85, P195, DOI 10.7326/0003-4819-85-2-195; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, THYROID, V6, P155; VANWYK JJ, 1960, J PEDIATR-US, V57, P416; Walfish P G, 1997, Curr Ther Endocrinol Metab, V6, P117; Walsh JP, 2003, J CLIN ENDOCR METAB, V88, P4543, DOI 10.1210/jc.2003-030249; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; Weiss R E, 2000, Rev Endocr Metab Disord, V1, P97, DOI 10.1023/A:1010072605757; WOODS KL, 1977, POSTGRAD MED J, V53, P46, DOI 10.1136/pgmj.53.615.46; Yamamoto T, 1999, THYROID, V9, P1167, DOI 10.1089/thy.1999.9.1167; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; ZIMMERMAN RS, 1986, ANN INTERN MED, V104, P355, DOI 10.7326/0003-4819-104-3-355; Zondek H., 1918, MIINCHEN MED WCHNSCH, V65, P1180; ZWILLICH CW, 1975, NEW ENGL J MED, V292, P662, DOI 10.1056/NEJM197503272921302	164	364	392	1	90	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					793	803		10.1016/S0140-6736(04)15696-1	http://dx.doi.org/10.1016/S0140-6736(04)15696-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016491				2022-12-28	WOS:000220092000020
J	Gerber, DJ; Tonegawa, S				Gerber, DJ; Tonegawa, S			Psychotomimetic effects of drugs - A common pathway to schizophrenia?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		MIT, Picower Ctr, Boston, MA USA	Massachusetts Institute of Technology (MIT)	Gerber, DJ (corresponding author), MIT, Picower Ctr, Boston, MA USA.							Gerber DJ, 2003, P NATL ACAD SCI USA, V100, P8993, DOI 10.1073/pnas.1432927100; Miyakawa T, 2003, P NATL ACAD SCI USA, V100, P8987, DOI 10.1073/pnas.1432926100; Ralph-Williams RJ, 2002, J NEUROSCI, V22, P9604; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681	4	8	8	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1047	1048		10.1056/NEJMcibr033201	http://dx.doi.org/10.1056/NEJMcibr033201			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999118				2022-12-28	WOS:000189363600015
J	Rennard, SI				Rennard, SI			Looking at the patient - Approaching the problem of COPD	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Nebraska, Med Ctr, Omaha, NE 68105 USA	University of Nebraska System; University of Nebraska Medical Center	Rennard, SI (corresponding author), Univ Nebraska, Med Ctr, 600 S 42nd St, Omaha, NE 68105 USA.							*NHLBI, 2003, GOLD WORKSH REP GLOB	1	14	15	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					965	966		10.1056/NEJMp048022	http://dx.doi.org/10.1056/NEJMp048022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999106				2022-12-28	WOS:000189363600002
J	Klareskog, L; van der Heijde, D; de Jager, JP; Gough, A; Kalden, J; Malaise, M; Mola, EM; Pavelka, K; Sany, J; Settas, L; Wajdula, J; Pedersen, R; Fatenejad, S; Sanda, M				Klareskog, L; van der Heijde, D; de Jager, JP; Gough, A; Kalden, J; Malaise, M; Mola, EM; Pavelka, K; Sany, J; Settas, L; Wajdula, J; Pedersen, R; Fatenejad, S; Sanda, M		TEMPO Study Investigators	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial	LANCET			English	Article							NECROSIS-FACTOR; HEALING PHENOMENA; DISEASE-ACTIVITY; CLINICAL-TRIALS; INTERLEUKIN-1; IMPROVEMENT; PROGRESSION; GUIDELINES; DISABILITY; EFFICACY	Background Etanercept and methotrexate are effective in the treatment of rheumatoid arthritis but no data exist on concurrent initiation or use of the combination compared with either drug alone. We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis. Methods In a double-blind, randomised, clinical efficacy, safety, and radiographic study, 686 patients with active rheumatoid arthritis were randomly allocated to treatment with etanercept 25 mg (subcutaneously twice a week), oral methotrexate (up to 20 mg every week), or the combination. Clinical response was assessed by criteria of the American College of Rheumatology (ACR). The primary efficacy endpoint was the numeric index of the ACR response (ACR-N) area under the curve (AUC) over the first 24 weeks. The primary radiographic endpoint was change from baseline to week 52 in total joint damage and was assessed with the modified Sharp score. Analysis was by intention to treat. Findings Four patients did not receive any drug; thus 682 were studied. ACR-N AUC at 24 weeks was greater for the combination group compared with etanercept alone and methotrexate alone (18.3% years [95% CI 17.1-19.6] vs 14.7%-years [13.5-16.0], p<0.0001, and 12.2%-years [11.0-13.4], p<0.0001; respectively). The mean difference in ACR-N AUC between combination and methotrexate alone was 6.1 (95% CI 4.5-7.8, p<0.0001) and between etanercept and methotrexate was 2.5 (0.8-4.2, p=0.0034). The combination was more efficacious than methotrexate or etanercept alone in retardation of joint damage (mean total Sharp score -0.54 [95% CI -1.00 to -0.07] vs 2.80 [1.08 to 4.51], p<0.0001, and 0.52 [-0.10 to 1.15], p=0.0006; respectively). The mean difference in total Sharp score between combination and methotrexate alone was -3.34 (95% CI -4.86 to -1.81, p<0.0001) and between etanercept and methotrexate was -2.27 (-3.81 to -0.74, p=0.0469). The number of patients reporting infections or adverse events was similar in all groups. Interpretation The combination of etanercept and methotrexate was significantly better in reduction of disease activity, improvement of functional disability, and retardation of radiographic progression compared with methotrexate or etanercept alone. These findings bring us closer to achievement of remission and repair of structural damage in rheumatoid arthritis.	Karolinska Inst, Karolinska Hosp, Dept Med, Rheumatol Unit, S-17176 Stockholm, Sweden; Univ Hosp, Dept Rheumatol, Maastricht, Netherlands; Gold Coast Rheumatol, Southport, Qld, Australia; Harrogate Dist Hosp, Dept Rheumatol, Harrogate, England; Univ Erlangen Nurnberg, Dept Med 3, Inst Clin Immunol, Erlangen, Germany; Univ Hosp, Ctr Sart Tilman, Dept Rheumatol, Liege, Belgium; Hosp La Paz, Rheumatol Unit, Madrid, Spain; Inst Rheumatol, Prague, Czech Republic; Hosp Lapeyronie, Rheumatol Unit, Montpellier, France; Univ Thessaloniki, AHEPA Gen Hosp, Dept Rheumatol, GR-54006 Thessaloniki, Greece; Wyeth Res, Collegeville, PA USA	Karolinska Institutet; Karolinska University Hospital; Maastricht University; University of Erlangen Nuremberg; University of Liege; Hospital Universitario La Paz; Institute of Rheumatology; Universite de Montpellier; CHU de Montpellier; Aristotle University of Thessaloniki; Ahepa University Hospital; Pfizer	Klareskog, L (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Med, Rheumatol Unit, S-17176 Stockholm, Sweden.	Lars.Klareskog@medks.ki.se	Pavelka, Karel/E-6578-2017	Pavelka, Karel/0000-0003-1952-8422; Klareskog, Lars/0000-0001-9601-6186				AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; BRENNAN FM, 1989, LANCET, V2, P244; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Drossaers-Bakker KW, 1999, ARTHRITIS RHEUM, V42, P1854, DOI 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F; EBERHARDT KB, 1995, J RHEUMATOL, V22, P1037; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1564, DOI 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M; FRIES JF, 1982, J RHEUMATOL, V9, P789; Furst DE, 2002, ANN RHEUM DIS, V61, P2; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Lassere M, 1999, J RHEUMATOL, V26, P731; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 2001, J RHEUMATOL, V28, P1238; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1234, DOI 10.1002/1529-0131(200106)44:6<1234::AID-ART213>3.0.CO;2-R; Rau R, 1996, ARTHRITIS RHEUM, V39, P162, DOI 10.1002/art.1780390123; Rau R, 2001, J RHEUMATOL, V28, P2608; Sharp JT, 2003, J RHEUMATOL, V30, P1102; SILMAN AJ, 1993, EPIDEMIOLOGY RHEUMAT; van der Heijde D, 2002, ARTHRIT RHEUM-ARTHR, V47, P215, DOI 10.1002/art.10181; van Vollenhoven RF, 2003, ARTHRITIS RES THER, V5, pR347, DOI 10.1186/ar1005; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579; VANRIEL PL, 2000, ANN RHEUM DIS S1, V59, pI29; Weinblatt ME, 1999, RHEUMATOLOGY, V38, P19; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Weinblatt ME, 1995, BRIT J RHEUMATOL, V34, P43	31	1400	1467	0	67	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					675	681		10.1016/S0140-6736(04)15640-7	http://dx.doi.org/10.1016/S0140-6736(04)15640-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001324				2022-12-28	WOS:000189266900007
J	Korgel, BA				Korgel, BA			Materials science - Self-assembled nanocoils	SCIENCE			English	Editorial Material							NANORINGS		Univ Texas, Texas Mat Inst, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Ctr Nano & Mol Sci & Technol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Korgel, BA (corresponding author), Univ Texas, Texas Mat Inst, Dept Chem Engn, Austin, TX 78712 USA.	korgel@mail.che.utexas.edu	Korgel, Brian A/I-5771-2013					AMELINCKX S, 1994, SCIENCE, V265, P635, DOI 10.1126/science.265.5172.635; Bai XD, 2003, APPL PHYS LETT, V82, P4806, DOI 10.1063/1.1587878; Hanrath T, 2003, ADV MATER, V15, P437, DOI 10.1002/adma.200390101; Kong XY, 2004, SCIENCE, V303, P1348, DOI 10.1126/science.1092356; Kong XY, 2003, NANO LETT, V3, P1625, DOI 10.1021/nl034463p; Lee ST, 2000, MAT SCI ENG A-STRUCT, V286, P16, DOI 10.1016/S0921-5093(00)00658-4; Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120; Wang ZL, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.185502	8	25	26	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1308	1309		10.1126/science.1095178	http://dx.doi.org/10.1126/science.1095178			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988542				2022-12-28	WOS:000189238600028
J	Xiong, ZH; Wu, D; Vardeny, ZV; Shi, J				Xiong, ZH; Wu, D; Vardeny, ZV; Shi, J			Giant magnetoresistance in organic spin-valves	NATURE			English	Article							MAGNETIC TUNNEL-JUNCTIONS; ROOM-TEMPERATURE; SEMICONDUCTOR; INJECTION; POLARIZATION; ELECTRONICS; DEPENDENCE; INTERFACES; POLYMERS	A spin valve is a layered structure of magnetic and non-magnetic (spacer) materials whose electrical resistance depends on the spin state of electrons passing through the device and so can be controlled by an external magnetic field. The discoveries of giant magnetoresistance(1) and tunnelling magnetoresistance(2) in metallic spin valves have revolutionized applications such as magnetic recording and memory, and launched the new field of spin electronics(3) -'spintronics'. Intense research efforts are now devoted to extending these spin-dependent effects to semiconductor materials. But while there have been noteworthy advances in spin injection and detection using inorganic semiconductors(4-6), spin-valve devices with semiconducting spacers have not yet been demonstrated. pi-conjugated organic semiconductors may offer a promising alternative approach to semiconductor spintronics, by virtue of their relatively strong electron phonon coupling(7) and large spin coherence(8). Here we report the injection, transport and detection of spin-polarized carriers using an organic semiconductor as the spacer layer in a spin-valve structure, yielding low-temperature giant magnetoresistance effects as large as 40 per cent.	Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Shi, J (corresponding author), Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.	jshi@physics.utah.edu		Wu, Di/0000-0003-2073-1022; Xiong, Zu-hong/0000-0003-4729-300X				Arisi E, 2003, J APPL PHYS, V93, P7682, DOI 10.1063/1.1556118; BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Bowen M, 2003, APPL PHYS LETT, V82, P233, DOI 10.1063/1.1534619; De Teresa JM, 1999, SCIENCE, V286, P507, DOI 10.1126/science.286.5439.507; De Teresa JM, 1999, PHYS REV LETT, V82, P4288, DOI 10.1103/PhysRevLett.82.4288; Dediu V, 2002, SOLID STATE COMMUN, V122, P181, DOI 10.1016/S0038-1098(02)00090-X; DIENY B, 1992, PHYS REV B, V45, P806, DOI 10.1103/PhysRevB.45.806; Forrest S, 2000, IEEE SPECTRUM, V37, P29, DOI 10.1109/6.861775; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; Hanbicki AT, 2002, APPL PHYS LETT, V80, P1240, DOI 10.1063/1.1449530; Hayakawa J, 2002, J APPL PHYS, V91, P8792, DOI 10.1063/1.1452239; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Krinichnyi VI, 2000, SYNTHETIC MET, V108, P173, DOI 10.1016/S0379-6779(99)00262-3; Lee ST, 1998, APPL PHYS LETT, V72, P1593, DOI 10.1063/1.121125; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; Tsukagoshi K, 1999, NATURE, V401, P572, DOI 10.1038/44108; Voss D, 2000, NATURE, V407, P442, DOI 10.1038/35035212; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Xie SJ, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.125202	21	1235	1277	25	696	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					821	824		10.1038/nature02325	http://dx.doi.org/10.1038/nature02325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985756				2022-12-28	WOS:000189207500034
J	Miller, SA; Collettini, C; Chiaraluce, L; Cocco, M; Barchi, M; Kaus, BJP				Miller, SA; Collettini, C; Chiaraluce, L; Cocco, M; Barchi, M; Kaus, BJP			Aftershocks driven by a high-pressure CO2 source at depth	NATURE			English	Article							FAULT-VALVE BEHAVIOR; FLUID PRESSURES; SEISMICITY; SEQUENCE; EXAMPLE; CRUST; MODEL; FLOW	In northern Italy in 1997, two earthquakes of magnitudes 5.7 and 6 (separated by nine hours) marked the beginning of a sequence that lasted more than 30 days, with thousands of aftershocks including four additional events with magnitudes between 5 and 6. This normal-faulting sequence is not well explained with models of elastic stress transfer(1,2), particularly the persistence of hanging-wall seismicity(3) that included two events with magnitudes greater than 5. Here we show that this sequence may have been driven by a fluid pressure pulse generated from the coseismic release of a known deep source(4) of trapped high-pressure carbon dioxide (CO2). We find a strong correlation between the high-pressure front and the aftershock hypocentres over a two-week period, using precise hypocentre locations(5) and a simple model of nonlinear diffusion. The triggering amplitude (10-20 MPa) of the pressure pulse overwhelms the typical (0.1-0.2 MPa) range from stress changes in the usual stress triggering models(1,6). We propose that aftershocks of large earthquakes in such geologic environments may be driven by the coseismic release of trapped, high-pressure fluids propagating through damaged zones created by the mainshock. This may provide a link between earthquakes, aftershocks, crust/mantle degassing and earthquake-triggered large-scale fluid flow.	ETH, Inst Geophys, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland; Univ Perugia, I-06100 Perugia, Italy; Inst Nazl Geofis & Vulcanol, I-00143 Rome, Italy; ETH, Inst Geol, Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Perugia; Istituto Nazionale Geofisica e Vulcanologia (INGV); Swiss Federal Institutes of Technology Domain; ETH Zurich	Miller, SA (corresponding author), ETH, Inst Geophys, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland.	steve.miller@erdw.ethz.ch	Barchi, Massimiliano Rinaldo/S-6917-2019; Chiaraluce, Lauro/A-4410-2012; Kaus, Boris J.P./B-4126-2010; Cocco, Massimo/G-6872-2012	Chiaraluce, Lauro/0000-0002-9697-6504; Kaus, Boris J.P./0000-0002-0247-8660; Cocco, Massimo/0000-0001-6798-4225; collettini, cristiano/0000-0002-4828-2516				Baisch S, 2003, GEOPHYS J INT, V152, P160, DOI 10.1046/j.1365-246X.2003.01837.x; Bosl WJ, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000155; Brauer K, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002077; Chiaraluce L, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002166; Chiodini G, 2000, J GEOPHYS RES-SOL EA, V105, P8423, DOI 10.1029/1999JB900355; CHIODINI R, 1989, APPL GEOCHEM, V4, P564; Cocco M, 2000, J SEISMOL, V4, P501, DOI 10.1023/A:1026507917308; Cocco M, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000138; COLLETTINI C, 2002, B SOC GEOL ITAL, V1, P873; COX SF, 1995, J GEOPHYS RES-SOL EA, V100, P12841, DOI 10.1029/95JB00915; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Jaeger J., 1979, ROCK MECH; Lee HS, 2002, ROCK MECH ROCK ENG, V35, P299, DOI 10.1007/s00603-002-0028-y; Manning CE, 1999, REV GEOPHYS, V37, P127, DOI 10.1029/1998RG900002; Miller SA, 1996, GEOPHYS RES LETT, V23, P197, DOI 10.1029/95GL03178; Miller SA, 2003, TECTONOPHYSICS, V370, P241, DOI 10.1016/S0040-1951(03)00189-6; Noir J, 1997, GEOPHYS RES LETT, V24, P2335, DOI 10.1029/97GL02182; NUR A, 1972, SCIENCE, V175, P885, DOI 10.1126/science.175.4024.885; Quattrocchi F, 1999, ANN GEOFIS, V42, P609; REUTTER K, 1980, TECTONOPHYSICS, V64, P1; Revil A, 2002, EARTH PLANET SC LETT, V202, P321, DOI 10.1016/S0012-821X(02)00784-7; Rice J., 1992, FAULT MECH TRANSPORT, P476; SEGALL P, 1995, J GEOPHYS RES-SOL EA, V100, P22155, DOI 10.1029/95JB02403; SIBSON RH, 1992, EARTH-SCI REV, V32, P141, DOI 10.1016/0012-8252(92)90019-P; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Streit JE, 2001, J GEOPHYS RES-SOL EA, V106, P2235, DOI 10.1029/2000JB900359; Toda S, 2002, NATURE, V419, P58, DOI 10.1038/nature00997; Waldhauser F, 2000, B SEISMOL SOC AM, V90, P1353, DOI 10.1785/0120000006; Wong TF, 1997, J GEOPHYS RES-SOL EA, V102, P841, DOI 10.1029/96JB02484; [No title captured]	30	576	588	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					724	727		10.1038/nature02251	http://dx.doi.org/10.1038/nature02251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973482				2022-12-28	WOS:000189026000040
J	Votier, SC; Furness, RW; Bearhop, S; Crane, JE; Caldow, RWG; Catry, P; Ensor, K; Hamer, KC; Hudson, AV; Kalmbach, E; Klomp, NI; Pfeiffer, S; Phillips, RA; Prieto, I; Thompson, DR				Votier, SC; Furness, RW; Bearhop, S; Crane, JE; Caldow, RWG; Catry, P; Ensor, K; Hamer, KC; Hudson, AV; Kalmbach, E; Klomp, NI; Pfeiffer, S; Phillips, RA; Prieto, I; Thompson, DR			Changes in fisheries discard rates and seabird communities	NATURE			English	Article							SKUAS CATHARACTA-SKUA; GREAT SKUAS; NORTH-SEA; COMMERCIAL FISHERIES; FOOD AVAILABILITY; SHETLAND; PREDATION; KITTIWAKES; NUMBERS; ECOLOGY	It is clear that discards from commercial fisheries are a key food resource for many seabird species around the world(1-8). But predicting the response of seabird communities to changes in discard rates is problematic and requires historical data to elucidate the confounding effects of other, more 'natural' ecological processes. In the North Sea, declining stocks, changes in technical measures, changes in population structure(9) and the establishment of a recovery programme for cod (Gadus morhua(10)) will alter the amount of fish discarded. This region also supports internationally important populations of seabirds(11), some of which feed extensively, but facultatively, on discards, in particular on undersized haddock (Melanogrammus aeglefinus) and whiting (Merlangius merlangus)(1-3). Here we use long-term data sets from the northern North Sea to show that there is a direct link between discard availability and discard use by a generalist predator and scavenger-the great skua (Stercorarius skua). Reduced rates of discarding, particularly when coupled with reduced availability of small shoaling pelagic fish such as sandeel (Ammodytes marinus), result in an increase in predation by great skuas on other birds. This switching of prey by a facultative scavenger presents a potentially serious threat to some seabird communities.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland; Winfrith Newburgh, Winfrith Technol Ctr, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, Dorset, England; ISPA, Unidade Invest Ecoetol, Lisbon, Portugal; Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Groningen, Dept Anim Ecol, NL-9751 NN Haren, Netherlands; Charles Sturt Univ, Johnstone Ctr, Sch Environm & Informat Sci, Albury, NSW 2640, Australia; Univ Jena, Inst Ecol, D-07743 Jena, Germany; British Antarctic Survey, Cambridge CB3 0ET, England; Natl Inst Water & Atmospher Res Ltd, Wellington, New Zealand	University of Glasgow; Queens University Belfast; UK Centre for Ecology & Hydrology (UKCEH); Instituto Superior Psicologia Aplicada (ISPA); University of Leeds; University of Groningen; Charles Sturt University; Friedrich Schiller University of Jena; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; National Institute of Water & Atmospheric Research (NIWA) - New Zealand	Votier, SC (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	s.votier@bio.gla.ac.uk; r.furness@bio.gla.ac.uk	Votier, Stephen C/G-2348-2014; Bond, Alexander L/A-3786-2010; Catry, Paulo/I-5408-2013; Bearhop, Stuart/G-3105-2012	Votier, Stephen C/0000-0002-0976-0167; Catry, Paulo/0000-0003-3000-0522; Bearhop, Stuart/0000-0002-5864-0129; Klomp, Nicholas/0000-0002-2367-0125				[Anonymous], 2002, 255 ICES; Arcos JM, 1996, COLON WATERBIRD, V19, P128, DOI 10.2307/1521817; Bearhop S, 2001, CONDOR, V103, P802, DOI 10.1650/0010-5422(2001)103[0802:AVIGSD]2.0.CO;2; Catry P, 1998, CONDOR, V100, P448, DOI 10.2307/1369710; CROXALL JP, 1991, BIRD POPULATION STUD, P272; Furness RW, 2003, SCI MAR, V67, P33, DOI 10.3989/scimar.2003.67s233; Furness RW, 2002, ICES J MAR SCI, V59, P261, DOI 10.1006/jmsc.2001.1155; FURNESS RW, 1981, J ZOOL, V195, P1, DOI 10.1111/j.1469-7998.1981.tb01890.x; Garthe S, 1996, MAR ECOL PROG SER, V136, P1, DOI 10.3354/meps136001; HAMER KC, 1991, J ZOOL, V223, P175, DOI 10.1111/j.1469-7998.1991.tb04758.x; Harkonen T.J., 1986, GUIDE OTOLITHS BONY, P256; HARVEY P, 2001, SHETLAND BIRD REPORT, P99; Heubeck M, 1999, BIRD STUDY, V46, P48, DOI 10.1080/00063659909461114; HUDSON AV, 1989, IBIS, V131, P225, DOI 10.1111/j.1474-919X.1989.tb02765.x; Huppop O, 2000, MAR ECOL PROG SER, V194, P241, DOI 10.3354/meps194241; *ICES, 1998, ICES CM 1998 ASSESS, V7; *ICES, 2003, ICES ADV ZER CATCH C; KLOMP NI, 1992, J APPL ECOL, V29, P341, DOI 10.2307/2404503; Lloyd C, 1991, STATUS SEABIRDS BRIT; Mark Freeberg J.G.Pope, 1994, GLOBAL ASSESSMENT FI; Oro D, 2002, ECOLOGY, V83, P2516; Oro D, 1996, MAR ECOL PROG SER, V132, P43, DOI 10.3354/meps132043; Phillips RA, 1999, J APPL ECOL, V36, P218, DOI 10.1046/j.1365-2664.1999.00391.x; Regehr HM, 1997, MAR ECOL PROG SER, V155, P249, DOI 10.3354/meps155249; Russell J, 1996, IBIS, V138, P791, DOI 10.1111/j.1474-919X.1996.tb08839.x; SNOW DW, 1998, BIRDS W PALEARCTIC C, V1; Stratoudakis Y, 1999, ICES J MAR SCI, V56, P592, DOI 10.1006/jmsc.1999.0500; THOMPSON KR, 1992, IBIS, V134, P11, DOI 10.1111/j.1474-919X.1992.tb07223.x; Votier SC, 2003, POLAR BIOL, V26, P20, DOI 10.1007/s00300-002-0446-z	29	195	211	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	2004	427	6976					727	730		10.1038/nature02315	http://dx.doi.org/10.1038/nature02315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973483				2022-12-28	WOS:000189026000041
J	Smith, AG; Fear, NT; Law, GR; Roman, E				Smith, AG; Fear, NT; Law, GR; Roman, E			Representativeness of samples from general practice lists in epidemiological studies: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Leeds, Epidemiol & Genet Unit, Leeds LS2 9LN, W Yorkshire, England	University of Leeds		alex.smith@egu.leeds.ac.uk	Law, Graham R/B-9654-2008; Fear, Nicola/A-1917-2012	Law, Graham R/0000-0001-7904-0264; Fear, Nicola/0000-0002-5792-2925; Roman, Eve/0000-0001-7603-3704				*DHSS, 1980, INEQ HLTH; Kane EV, 1999, BRIT J CANCER, V81, P1228, DOI 10.1038/sj.bjc.6690833; Townsend PP., 1988, HLTH DEPRIVATION INE	3	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 17	2004	328	7445					932	932		10.1136/bmj.38029.672662.AE	http://dx.doi.org/10.1136/bmj.38029.672662.AE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	14990513	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000220994400024
J	Venter, JC; Remington, K; Heidelberg, JF; Halpern, AL; Rusch, D; Eisen, JA; Wu, DY; Paulsen, I; Nelson, KE; Nelson, W; Fouts, DE; Levy, S; Knap, AH; Lomas, MW; Nealson, K; White, O; Peterson, J; Hoffman, J; Parsons, R; Baden-Tillson, H; Pfannkoch, C; Rogers, YH; Smith, HO				Venter, JC; Remington, K; Heidelberg, JF; Halpern, AL; Rusch, D; Eisen, JA; Wu, DY; Paulsen, I; Nelson, KE; Nelson, W; Fouts, DE; Levy, S; Knap, AH; Lomas, MW; Nealson, K; White, O; Peterson, J; Hoffman, J; Parsons, R; Baden-Tillson, H; Pfannkoch, C; Rogers, YH; Smith, HO			Environmental genome shotgun sequencing of the Sargasso Sea	SCIENCE			English	Article							MARINE NITRIFYING BACTERIA; COMMUNITY STRUCTURE; DIVERSITY; PHOTOINHIBITION; PHOTOTROPHY; ABUNDANCE; NUMBER; OCEAN	We have applied "whole-genome shotgun sequencing" to microbial populations collected en masse on tangential flow and impact filters from seawater samples collected from the Sargasso Sea near Bermuda. A total of 1.045 billion base pairs of nonredundant sequence was generated, annotated, and analyzed to elucidate the gene content, diversity, and relative abundance of the organisms within these environmental samples. These data are estimated to derive from at least 1800 genomic species based on sequence relatedness, including 148 previously unknown bacterial phylotypes. We have identified over 1.2 million previously unknown genes represented in these samples, including more than 782 new rhodopsin-like photoreceptors. Variation in species present and stoichiometry suggests substantial oceanic microbial diversity.	Inst Biol Energy Alternat, Rockville, MD 20850 USA; Ctr Advancement Genom, Rockville, MD 20850 USA; Inst Genom Res, Rockville, MD 20850 USA; J Craig Venter Sci Fdn, Joint Technol Ctr, Rockville, MD 20850 USA; Univ So Calif, Los Angeles, CA 90089 USA; Bermuda Biol Stn Res Inc, St George GE01, Bermuda	J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; University of Southern California	Venter, JC (corresponding author), Inst Biol Energy Alternat, 1901 Res Blvd, Rockville, MD 20850 USA.	jcventer@tcag.org	WU, TAKLON/A-2827-2010; Nelson, William C/E-9263-2016; Paulsen, Ian T/K-3832-2012; Eisen, Jonathan A./H-2706-2019; Parsons, Rachel J/B-1475-2016	Nelson, William C/0000-0002-1873-3929; Paulsen, Ian T/0000-0001-9015-9418; Eisen, Jonathan A./0000-0002-0159-2197; Parsons, Rachel/0000-0003-3634-8220; Lomas, Michael/0000-0003-1209-3753; Heidelberg, John/0000-0003-0673-3224				ALLDREDGE AL, 1987, SCIENCE, V235, P689, DOI 10.1126/science.235.4789.689; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; Carlson CA, 2002, AQUAT MICROB ECOL, V30, P19, DOI 10.3354/ame030019; Cavender-Bares KK, 2001, DEEP-SEA RES PT I, V48, P2373, DOI 10.1016/S0967-0637(01)00027-9; CHAO A, 1984, SCAND J STAT, V11, P265; CHRETIENNOTDINET MJ, 1995, PHYCOLOGIA, V34, P285, DOI 10.2216/i0031-8884-34-4-285.1; Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039; Conte M, 1997, OCEANUS, V40, P15; Curtis TP, 2002, P NATL ACAD SCI USA, V99, P10494, DOI 10.1073/pnas.142680199; de la Torre JR, 2003, P NATL ACAD SCI USA, V100, P12830, DOI 10.1073/pnas.2133554100; delGiorgio PA, 1997, MICROBIAL ECOL, V34, P144; DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924, DOI 10.4319/lo.1993.38.5.0924; Giovannoni SJ., 2000, MICROBIAL ECOLOGY OC, P47; Guerrero MA, 1996, MAR ECOL PROG SER, V141, P183, DOI 10.3354/meps141183; Guerrero MA, 1996, MAR ECOL PROG SER, V141, P193, DOI 10.3354/meps141193; Guillou L, 1999, J PHYCOL, V35, P368, DOI 10.1046/j.1529-8817.1999.3520368.x; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Hicks CL, 2000, AUST VET J, V78, P193, DOI 10.1111/j.1751-0813.2000.tb10593.x; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; KARLIN S, 1995, TRENDS GENET, V11, P283; Klappenbach JA, 2000, APPL ENVIRON MICROB, V66, P1328, DOI 10.1128/AEM.66.4.1328-1333.2000; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; NEALSON KH, 2003, PROKARYOTES EVOLVING; PALENIK B, 1994, APPL ENVIRON MICROB, V60, P3212, DOI 10.1128/AEM.60.9.3212-3219.1994; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Parsons T.R., 1984, BIOL OCEANOGRAPHIC P, V3rd; Passow U, 2002, PROG OCEANOGR, V55, P287, DOI 10.1016/S0079-6611(02)00138-6; PROCTOR LM, 1990, NATURE, V343, P60, DOI 10.1038/343060a0; Rappe MS, 2002, NATURE, V418, P630, DOI 10.1038/nature00917; Raymont J.E.G., 1980, PLANKTON PRODUCTIVIT; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rondon MR, 2000, APPL ENVIRON MICROB, V66, P2541, DOI 10.1128/AEM.66.6.2541-2547.2000; Sabehi G, 2003, ENVIRON MICROBIOL, V5, P842, DOI 10.1046/j.1462-2920.2003.00493.x; Scanlan DJ, 1999, HYDROBIOLOGIA, V401, P149, DOI 10.1023/A:1003742528262; Scanlan DJ, 1997, APPL ENVIRON MICROB, V63, P2411, DOI 10.1128/AEM.63.6.2411-2420.1997; Stein JL, 1996, J BACTERIOL, V178, P591, DOI 10.1128/jb.178.3.591-599.1996; Steinberg DK, 2001, DEEP-SEA RES PT II, V48, P1405, DOI 10.1016/S0967-0645(00)00148-X	40	2925	3181	21	756	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					66	74		10.1126/science.1093857	http://dx.doi.org/10.1126/science.1093857			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15001713				2022-12-28	WOS:000220567900037
J	Earl, PL; Americo, JL; Wyatt, LS; Eller, LA; Whitbeck, JC; Cohen, GH; Eisenberg, RJ; Hartmann, CJ; Jackson, DL; Kulesh, DA; Martinez, MJ; Miller, DM; Mucker, EM; Shamblin, JD; Zwiers, SH; Huggins, JW; Jahrling, PB; Moss, B				Earl, PL; Americo, JL; Wyatt, LS; Eller, LA; Whitbeck, JC; Cohen, GH; Eisenberg, RJ; Hartmann, CJ; Jackson, DL; Kulesh, DA; Martinez, MJ; Miller, DM; Mucker, EM; Shamblin, JD; Zwiers, SH; Huggins, JW; Jahrling, PB; Moss, B			Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox	NATURE			English	Article							VIRUS PROPAGATION; STRAIN MVA; PROTEIN; NEUTRALIZATION; IMMUNIZATION; ANTIBODIES; CHALLENGE; INFECTION; VARIOLA; VECTOR	The potential use of smallpox as a biological weapon has led to the production and stockpiling of smallpox vaccine and the immunization of some healthcare workers. Another public health goal is the licensing of a safer vaccine that could benefit the millions of people advised not to take the current one because they or their contacts have increased susceptibility to severe vaccine side effects(1). As vaccines can no longer be tested for their ability to prevent smallpox, licensing will necessarily include comparative immunogenicity and protection studies in non-human primates. Here we compare the highly attenuated modified vaccinia virus Ankara (MVA)(2) with the licensed Dryvax vaccine in a monkey model. After two doses of MVA or one dose of MVA followed by Dryvax, antibody binding and neutralizing titres and T-cell responses were equivalent or higher than those induced by Dryvax alone. After challenge with monkeypox virus, unimmunized animals developed more than 500 pustular skin lesions and became gravely ill or died, whereas vaccinated animals were healthy and asymptomatic, except for a small number of transient skin lesions in animals immunized only with MVA.	NIAID, NIH, Bethesda, MD 20892 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA; Univ Penn, Sch Dent, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; University of Pennsylvania; University of Pennsylvania	Moss, B (corresponding author), NIAID, NIH, Bethesda, MD 20892 USA.	bmoss@nih.gov		Moss, Bernard/0000-0002-2154-8564; Mucker, Eric/0000-0002-4656-5379; Miller, David/0000-0002-5746-3909	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000416, Z01AI000416] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123; APPLEYARD G, 1971, J GEN VIROL, V13, P9, DOI 10.1099/0022-1317-13-1-9; ARITA I, 1985, AM J TROP MED HYG, V34, P781, DOI 10.4269/ajtmh.1985.34.781; Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159; Breman JG, 1998, NEW ENGL J MED, V339, P556, DOI 10.1056/NEJM199808203390811; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845; Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347; Earl PL, 2003, J VIROL, V77, P10684, DOI 10.1128/JVI.77.19.10684-10688.2003; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P251, DOI 10.1086/375825; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; HOCHSTEI.V, 1972, ZENTRALBL BAKTER PAR, V156, P30; HOCHSTEINMINTZEL V, 1975, ZBL BAKT-INT J MED M, V230, P283; Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; Law M, 2002, J GEN VIROL, V83, P209, DOI 10.1099/0022-1317-83-1-209; Law M, 2001, VIROLOGY, V280, P132, DOI 10.1006/viro.2000.0750; LeDuc JW, 2002, EMERG INFECT DIS, V8, P743, DOI 10.3201/eid0807.020032; MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375; Mayr A, 1999, BERL MUNCH TIERARZTL, V112, P322; Mayr A., 1975, INFECTION, V3, P6, DOI [10.1007/BF01641272, DOI 10.1007/BF01641272]; MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Speller SA, 2002, J IMMUNOL METHODS, V262, P167, DOI 10.1016/S0022-1759(02)00025-X; STICKL H, 1974, DEUT MED WOCHENSCHR, V99, P2386, DOI 10.1055/s-0028-1108143; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; WOLFFE EJ, 1995, VIROLOGY, V211, P53, DOI 10.1006/viro.1995.1378; Zaucha GM, 2001, LAB INVEST, V81, P1581, DOI 10.1038/labinvest.3780373	30	284	294	8	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					182	185		10.1038/nature02331	http://dx.doi.org/10.1038/nature02331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014500				2022-12-28	WOS:000220103600049
J	Huang, ASH				Huang, ASH			Follow your nose	NATURE			English	Editorial Material									CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Huang, ASH (corresponding author), CALTECH, Mail Code 1-9, Pasadena, CA 91125 USA.							HUANG AS, 1970, NATURE, V226, P325, DOI 10.1038/226325a0	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					221	222		10.1038/428221a	http://dx.doi.org/10.1038/428221a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014513				2022-12-28	WOS:000220103600062
J	Logroscino, G; Kang, JH; Grodstein, F				Logroscino, G; Kang, JH; Grodstein, F			Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; INSULIN; POPULATION; HEALTH	Objective To examine the association of type 2 diabetes with baseline cognitive function and cognitive decline over two years of follow up, focusing on women living in the community and on the effects of treatments for diabetes. Design Nurses' health study in the United States. Two cognitive interview's were by carried out by telephone during 1995-2003. Participants 18 999 women aged 70-81 years who had been registered nurses completed the baseline interview; to date, 16 596 participants have completed follow up interviews after two years. Main outcome measures Cognitive assessments included telephone interview of cognitive status, immediate and delayed recalls of the East Boston memory test, test of verbal fluency, delayed recall of 10 word list, and digit span backwards. Global scores were calculated by averaging the results of all tests with z scores. Results After multivariate adjustment, women with type 2 diabetes performed worse on all cognitive tests than women without diabetes at baseline. For example, women with diabetes were at 25-35% increased odds of poor baseline score (defined as bottom 10% of the distribution) compared with women without diabetes on the telephone interview of cognitive status and the global composite score (odds ratios 1.34, 95% confidence interval 1.14 to 1.57, and 1.26,1.06 to 1.51, respectively). Odds of poor cognition were particularly high for women who had had diabetes for a long time (1.52,1.15 to 1.99, and 1.49, 1.11 to 2.00, respectively, for greater than or equal to 15 years' duration). In contrast, women with diabetes who were on oral hypoglycaemic agents performed similarly to women without diabetes (1.06 and 0.99), while women not using any medication had the greatest odds of poor performance (1.71,1.28 to 2.281, and 1.45,1.04 to 2.02) compared with women without diabetes. There was also a modest increase in odds of poor cognition among women using insulin treatment. All findings were similar when cognitive decline was examined over time. Conclusions Women with type 2 diabetes had increased odds of poor cognitive function and substantial cognitive decline. Use of oral hypoglycaemic therapy, however, may ameliorate risk.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Logroscino, G (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.	glogrosc@hsph.harvard.edu	LOGROSCINO, GIANCARLO/K-5148-2016	LOGROSCINO, GIANCARLO/0000-0003-0423-3242	NCI NIH HHS [CA87969] Funding Source: Medline; NIA NIH HHS [AG15424] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015424] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bozoki A, 2001, ARCH NEUROL-CHICAGO, V58, P411, DOI 10.1001/archneur.58.3.411; Coker LH, 2003, J PSYCHOSOM RES, V54, P129, DOI 10.1016/S0022-3999(02)00523-8; Elias PK, 1997, DIABETES CARE, V20, P1388, DOI 10.2337/diacare.20.9.1388; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gregg EW, 2000, ARCH INTERN MED, V160, P174, DOI 10.1001/archinte.160.2.174; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; Kang JH, 2003, NEUROLOGY, V60, P1591; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Testa MA, 1998, JAMA-J AM MED ASSOC, V280, P1490, DOI 10.1001/jama.280.17.1490; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Watson GS, 2003, NEUROLOGY, V60, P1899, DOI 10.1212/01.WNL.0000065916.25128.25; Wu JH, 2003, ANN EPIDEMIOL, V13, P369, DOI 10.1016/S1047-2797(02)00464-7	14	138	163	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					548	551		10.1136/bmj.37977.495729.EE	http://dx.doi.org/10.1136/bmj.37977.495729.EE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	14980984	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000220091800017
J	Senthil, T; Vishwanath, A; Balents, L; Sachdev, S; Fisher, MPA				Senthil, T; Vishwanath, A; Balents, L; Sachdev, S; Fisher, MPA			Deconfined quantum critical points	SCIENCE			English	Article							PHASE-TRANSITIONS; GROUND-STATES; 2 DIMENSIONS; ANTIFERROMAGNETS; SUPERCONDUCTIVITY; METALS; MODEL; SPIN	The theory of second-order phase transitions is one of the foundations of modern statistical mechanics and condensed-matter theory. A central concept is the observable order parameter, whose nonzero average value characterizes one or more phases. At large distances and long times, fluctuations of the order parameter(s) are described by a continuum field theory, and these dominate the physics near such phase transitions. We show that near second-order quantum phase transitions, subtle quantum interference effects can invalidate this paradigm, and we present a theory of quantum critical points in a variety of experimentally relevant two-dimensional antiferromagnets. The critical points separate phases characterized by conventional "confining" order parameters. Nevertheless, the critical theory contains an emergent gauge field and "deconfined" degrees of freedom associated with fractionalization of the order parameters. We propose that this paradigm for quantum criticality may be the key to resolving a number of experimental puzzles in correlated electron systems and offer a new perspective on the properties of complex materials.	MIT, Dept Phys, Cambridge, MA 02139 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Yale Univ, Dept Phys, New Haven, CT 06520 USA; Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California Santa Barbara; Yale University; University of California System; University of California Santa Barbara	Senthil, T (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	senthil@rnit.edu	Sachdev, Subir/A-8781-2013; Sachdev, Subir/Y-3037-2019; Vishwanath, Ashvin/AAO-6878-2020; Todadri, Senthil/ABG-1337-2021	Sachdev, Subir/0000-0002-2432-7070; Sachdev, Subir/0000-0002-2432-7070; 				CHAKRAVARTY S, 1989, PHYS REV B, V39, P2344, DOI 10.1103/PhysRevB.39.2344; CHUBUKOV AV, 1994, PHYS REV B, V49, P11919, DOI 10.1103/PhysRevB.49.11919; Coleman P, 2001, J PHYS-CONDENS MAT, V13, pR723, DOI 10.1088/0953-8984/13/35/202; DASGUPTA C, 1981, PHYS REV LETT, V47, P1556, DOI 10.1103/PhysRevLett.47.1556; HALDANE FDM, 1982, PHYS REV B, V25, P4925, DOI 10.1103/PhysRevB.25.4925; HALDANE FDM, 1988, PHYS REV LETT, V61, P1029, DOI 10.1103/PhysRevLett.61.1029; HALPERIN BI, 1974, PHYS REV LETT, V32, P292, DOI 10.1103/PhysRevLett.32.292; LANDAU LD, 1999, STAT PHYSICS; Lannert C, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.134510; Laughlin RB, 1998, ADV PHYS, V47, P943, DOI 10.1080/000187398243483; Moessner R, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.024504; READ N, 1989, PHYS REV LETT, V62, P1694, DOI 10.1103/PhysRevLett.62.1694; ROKHSAR DS, 1988, PHYS REV LETT, V61, P2376, DOI 10.1103/PhysRevLett.61.2376; Sachdev S, 2002, ANN PHYS-NEW YORK, V298, P58, DOI 10.1006/aphy.2002.6232; Sachdev S., 1999, QUANTUM PHASE TRANSI; Sandvik AW, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.247201; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; Troyer M, 1997, J PHYS SOC JPN, V66, P2957, DOI 10.1143/JPSJ.66.2957; Wilson K. G., 1974, Physics Reports. Physics Letters Section C, V12c, P75, DOI 10.1016/0370-1573(74)90023-4	19	953	963	6	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1490	1494		10.1126/science.1091806	http://dx.doi.org/10.1126/science.1091806			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001771	Green Submitted			2022-12-28	WOS:000220000100033
J	Bhattacharya, K; Conti, S; Zanzotto, G; Zimmer, J				Bhattacharya, K; Conti, S; Zanzotto, G; Zimmer, J			Crystal symmetry and the reversibility of martensitic transformations	NATURE			English	Article							PHASE-TRANSITIONS; LATTICES	Martensitic transformations are diffusionless, solid-to-solid phase transitions, and have been observed in metals, alloys, ceramics and proteins(1,2). They are characterized by a rapid change of crystal structure, accompanied by the development of a rich microstructure. Martensitic transformations can be irreversible, as seen in steels upon quenching(1), or they can be reversible, such as those observed in shape-memory alloys(3,4). In the latter case, the microstructures formed on cooling are easily manipulated by loads and disappear upon reheating. Here, using mathematical theory and numerical simulation, we explain these sharp differences in behaviour on the basis of the change in crystal symmetry during the transition. We find that a necessary condition for reversibility is that the symmetry groups of the parent and product phases be included in a common finite symmetry group. In these cases, the energy barrier to lattice-invariant shear is generically higher than that pertaining to the phase change and, consequently, transformations of this type can occur with virtually no plasticity. Irreversibility is inevitable in all other martensitic transformations, where the energy barrier to plastic deformation (via lattice-invariant shears, as in twinning or slip) is no higher than the barrier to the phase change itself. Various experimental observations confirm the importance of the symmetry of the stable states in determining the macroscopic reversibility of martensitic transformations.	CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Max Planck Inst Math Sci, D-04103 Leipzig, Germany; Univ Padua, Dipartimento Metodi & Modelli Matemat Sci Applica, I-35131 Padua, Italy	California Institute of Technology; Max Planck Society; University of Padua	Bhattacharya, K (corresponding author), CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA.	bhatta@caltech.edu	Conti, Sergio/S-3616-2019; Conti, Sergio/B-3214-2009; Zimmer, Johannes/E-2386-2011	Conti, Sergio/0000-0001-7987-9174; Conti, Sergio/0000-0001-7987-9174; Zimmer, Johannes/0000-0002-7606-2422; Bhattacharya, Kaushik/0000-0003-2908-5469				[Anonymous], 2002, CONTINUUM MODELS PHA; BALL JM, 1992, PHILOS T R SOC A, V338, P389, DOI 10.1098/rsta.1992.0013; Barker-Benfield Ben, 1972, FEMINIST STUD, V1, P45; BARRETT C, 1987, STRUCTURE METALS; Bhattacharya K., 2003, MICROSTRUCTURE MARTE; Bocanegra-Bernal MH, 2002, J MATER SCI, V37, P4947, DOI 10.1023/A:1021099308957; CONTI S, IN PRESS ARCH RATION; de Gennes PG, 2003, EUROPHYS LETT, V63, P76, DOI 10.1209/epl/i2003-00480-8; ERICKSEN JL, 1989, ARCH RATION MECH AN, V107, P23, DOI 10.1007/BF00251425; ERICKSEN JL, 1980, ARCH RATION MECH AN, V73, P99, DOI 10.1007/BF00258233; FONSECA I, 1987, ARCH RATION MECH AN, V97, P189, DOI 10.1007/BF00250808; HUA LK, 1949, T AM MATH SOC, V65, P415; Hull D., 2011, INTRO TC DISLOCATION, V5th, DOI DOI 10.1016/B978-0-08-096672-4.00001-3; James RD, 1998, PHILOS MAG A, V77, P1273, DOI 10.1080/01418619808214252; Kadau K, 2002, SCIENCE, V296, P1681, DOI 10.1126/science.1070375; Lee HH, 2002, MACROMOLECULES, V35, P785, DOI 10.1021/ma010951c; LIU Y, IN PRESS J ALLOYS CO; MAKI T, 1986, P ICOMAT 86, P963; MATSUMOTO S, 1994, ACTA METALL MATER, V42, P1207, DOI 10.1016/0956-7151(94)90137-6; Olson G., 1992, MARTENSITE; OLSON GB, 1982, J PHYS-PARIS, V43, P855, DOI 10.1051/jphyscol:19824140; OTSUKA K, 1977, SCRIPTA METALL MATER, V11, P757, DOI 10.1016/0036-9748(77)90071-0; PITTERI M, 1984, J ELASTICITY, V14, P175, DOI 10.1007/BF00041664; SALJE EKH, 1993, PHASE TRANSITIONS FE; SCHWARZENBERGER RL, 1972, PROC CAMB PHILOS S-M, V72, P325; Shu YC, 2001, PHILOS MAG B, V81, P2021, DOI 10.1080/13642810110069576; Sozinov A, 2002, APPL PHYS LETT, V80, P1746, DOI 10.1063/1.1458075; Toledano P., 1996, RECONSTRUCTIVE PHASE; Wayman C.M., 1998, SHAPE MEMORY MAT; YANG JH, 1992, ACTA METALL MATER, V40, P2011, DOI 10.1016/0956-7151(92)90187-J	30	262	268	15	218	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					55	59		10.1038/nature02378	http://dx.doi.org/10.1038/nature02378			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999277	Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000189363800032
J	Clavel, F; Hance, AJ				Clavel, F; Hance, AJ			Medical progress: HIV drug resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE INHIBITORS; DYNAMICS IN-VIVO; PROTEASE INHIBITORS; CROSS-RESISTANCE; ANTIRETROVIRAL THERAPY; ZIDOVUDINE-RESISTANT; VIROLOGICAL FAILURE; HIV-1-INFECTED INDIVIDUALS		Hop Bichat Claude Bernard, INSERM, U552, IMEA,Unite Rech Antivirale, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Clavel, F (corresponding author), Hop Bichat Claude Bernard, INSERM, U552, IMEA,Unite Rech Antivirale, 46 Rue Henri Huchard, F-75018 Paris, France.	clavel@bichat.inserm.fr						Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Bacheler LT, 2000, ANTIMICROB AGENTS CH, V44, P2475, DOI 10.1128/AAC.44.9.2475-2484.2000; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Barbour JD, 2002, J VIROL, V76, P11104, DOI 10.1128/JVI.76.21.11104-11112.2002; Bleiber G, 2001, J VIROL, V75, P3291, DOI 10.1128/JVI.75.7.3291-3300.2001; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; BOYER PL, 1993, J VIROL, V67, P2412, DOI 10.1128/JVI.67.4.2412-2420.1993; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Chamberlain PP, 2002, J VIROL, V76, P10015, DOI 10.1128/JVI.76.19.10015-10019.2002; Charpentier C, 2002, ANTIVIR THER, V7, pS55; CHEN ZG, 1995, J BIOL CHEM, V270, P21433, DOI 10.1074/jbc.270.37.21942; Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; DeGruttola V, 2000, ANTIVIR THER, V5, P41; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Descamps D, 2000, JAMA-J AM MED ASSOC, V284, P1518; Descamps D, 1998, AIDS, V12, P1109; Descamps D, 1997, J VIROL, V71, P8893, DOI 10.1128/JVI.71.11.8893-8898.1997; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Doyon L, 1996, J VIROL, V70, P3763, DOI 10.1128/JVI.70.6.3763-3769.1996; Droz C, 2002, ANTIVIR THER, V7, pS146; Dulioust A, 1999, J VIROL, V73, P850, DOI 10.1128/JVI.73.1.850-854.1999; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERICKSON J, 1994, ARCH VIROL, P19; Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Hanna GJ, 2000, J INFECT DIS, V181, P904, DOI 10.1086/315329; Haubrich R, 2001, J ACQ IMMUN DEF SYND, V26, pS51, DOI 10.1097/00126334-200103011-00006; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hertogs K, 2000, AIDS, V14, P1203, DOI 10.1097/00002030-200006160-00018; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hong L, 2000, PROTEIN SCI, V9, P1898, DOI 10.1110/ps.9.10.1898; Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648; *INT AIDS SOC US, 2002, HIV DRUG RES MUT; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Izopet J, 2002, J INFECT DIS, V185, P1506, DOI 10.1086/340215; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; Labrosse B, 2003, J VIROL, V77, P1610, DOI 10.1128/JVI.77.2.1610-1613.2003; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Mammano F, 2000, J VIROL, V74, P8524, DOI 10.1128/JVI.74.18.8524-8531.2000; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; Miller V, 2001, ANTIVIR THER, V6, P25; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Picard V, 2001, J INFECT DIS, V184, P781, DOI 10.1086/323088; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; PRABUJEYABALAN MM, 2002, ANTIVIR THER, V7, pS36; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Race E, 1999, AIDS, V13, P2061, DOI 10.1097/00002030-199910220-00008; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; Resch W, 2001, P NATL ACAD SCI USA, V98, P176, DOI 10.1073/pnas.011511298; RICHMAN D, 2001, INT C ANT AG CHEM CH; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RICHMAN DD, 1990, AM J MED, V88, pS8, DOI 10.1016/0002-9343(90)90414-9; Ridky TW, 1998, BIOCHEMISTRY-US, V37, P13835, DOI 10.1021/bi980612k; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; Ross L, 2000, AIDS, V14, P813, DOI 10.1097/00002030-200005050-00007; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Schapiro JM, 1999, AIDS, V13, P359, DOI 10.1097/00002030-199902250-00008; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; Shafer RW, 1997, J VIROL, V71, P5441, DOI 10.1128/JVI.71.7.5441-5448.1997; Shafer RW, 1996, J INFECT DIS, V174, P448, DOI 10.1093/infdis/174.2.448; Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099; Verhofstede C, 1999, AIDS, V13, P2541, DOI 10.1097/00002030-199912240-00007; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	101	539	584	0	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1023	1035		10.1056/NEJMra025195	http://dx.doi.org/10.1056/NEJMra025195			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999114				2022-12-28	WOS:000189363600010
J	Kulkarni, RN; Kahn, CR				Kulkarni, RN; Kahn, CR			Molecular biology - HNFs - Linking the liver and pancreatic islets in diabetes	SCIENCE			English	Editorial Material							INSULIN-RECEPTOR SUBSTRATE-1; BETA-CELL GROWTH; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION; HEPATOCYTES; MECHANISMS; SURVIVAL; DELETION; STORES; LEADS		Joslin Diabet Ctr, Dept Cell & Mol Physiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kulkarni, RN (corresponding author), Joslin Diabet Ctr, Dept Cell & Mol Physiol, Boston, MA 02215 USA.	rohit.kulkarni@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Baier LJ, 1998, DIABETES, V47, P973, DOI 10.2337/diabetes.47.6.973; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; Borge PD, 2003, J BIOL CHEM, V278, P11359, DOI 10.1074/jbc.M209521200; DASILVAXAVIER G, 2003, BIOCHEM J, V377, P149; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kulkarni RN, 2002, BIOCHEM SOC T, V30, P317, DOI 10.1042/bst0300317; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; KULKARNI RN, 2000, EN SOC 82 ANN M 21 2, P75; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LOVEGREGORY L, IN PRESS DIABETES; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; SILANDER K, IN PRESS DIABETES; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Zhu Q, 2003, DIABETOLOGIA, V46, P567, DOI 10.1007/s00125-003-1067-y	27	27	29	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1311	1312		10.1126/science.1095486	http://dx.doi.org/10.1126/science.1095486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988544				2022-12-28	WOS:000189238600030
J	Kawahara, Y; Ito, K; Sun, H; Aizawa, H; Kanazawa, I; Kwak, S				Kawahara, Y; Ito, K; Sun, H; Aizawa, H; Kanazawa, I; Kwak, S			Glutamate receptors: RNA editing and death of motor neurons	NATURE			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; LOW RELATIVE ABUNDANCE; GLUR2 MESSENGER-RNA; MICE; LETHALITY; DEFICIENT; DISEASE; BRAIN; ADAR2		Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138655, Japan; Asahikawa Med Coll, Dept Internal Med 1, Asahikawa, Hokkaido 0788510, Japan; Japan Sci & Technol Corp, SORST, Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878502, Japan	University of Tokyo; Asahikawa Medical College; Japan Science & Technology Agency (JST); National Center for Neurology & Psychiatry - Japan	Kawahara, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kwak-tky@umin.ac.jp						AKBARIAN S, 1995, BRAIN RES, V699, P297, DOI 10.1016/0006-8993(95)00922-D; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Kawahara Y, 2003, EUR J NEUROSCI, V18, P23, DOI 10.1046/j.1460-9568.2003.02718.x; Kawahara Y, 2003, J NEUROCHEM, V85, P680, DOI 10.1046/j.1471-4159.2003.01703.x; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Takuma H, 1999, ANN NEUROL, V46, P806, DOI 10.1002/1531-8249(199912)46:6<806::AID-ANA2>3.0.CO;2-S	10	415	438	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					801	801		10.1038/427801a	http://dx.doi.org/10.1038/427801a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985749	Bronze			2022-12-28	WOS:000189207500027
J	Stremlau, M; Owens, CM; Perron, MJ; Kiessling, M; Autissier, P; Sodroski, J				Stremlau, M; Owens, CM; Perron, MJ; Kiessling, M; Autissier, P; Sodroski, J			The cytoplasmic body component TRIM5 alpha restricts HIV-1 infection in Old World monkeys	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROMYELOCYTIC LEUKEMIA PROTEIN; SIMIAN CELLS; REVERSE TRANSCRIPTION; VIRAL REPLICATION; MOTIF PROTEIN; RING FINGER; ENTRY; RECRUITMENT; COMPLEXES	Host cell barriers to the early phase of immunodeficiency virus replication explain the current distribution of these viruses among human and non-human primate species(1-4). Human immunodeficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome ( AIDS) in humans, efficiently enters the cells of Old World monkeys but encounters a block before reverse transcription(2-4). This species-specific restriction acts on the incoming HIV-1 capsid(5-7) and is mediated by a dominant repressive factor(7-9). Here we identify TRIM5alpha, a component of cytoplasmic bodies, as the blocking factor. HIV-1 infection is restricted more efficiently by rhesus monkey TRIM5alpha than by human TRIM5alpha. The simian immunodeficiency virus, which naturally infects Old World monkeys(10), is less susceptible to the TRIM5alpha-mediated block than is HIV-1, and this difference in susceptibility is due to the viral capsid. The early block to HIV-1 infection in monkey cells is relieved by interference with TRIM5alpha expression. Our studies identify TRIM5alpha as a species-specific mediator of innate cellular resistance to HIV-1 and reveal host cell components that modulate the uncoating of a retroviral capsid.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Dept Pathol, Div Aids, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Div Aids, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Dept Pathol, Div Aids, Boston, MA 02115 USA.	joseph_sodroski@dfci.harvard.edu	Liu, FL/D-1795-2009					Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Bonilla WV, 2002, J VIROL, V76, P3810, DOI 10.1128/JVI.76.8.3810-3818.2002; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Chee AV, 2003, J VIROL, V77, P7101, DOI 10.1128/JVI.77.12.7101-7105.2003; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Fassati A, 2001, J VIROL, V75, P3626, DOI 10.1128/JVI.75.8.3626-3635.2001; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; Himathongkham S, 1996, VIROLOGY, V219, P485, DOI 10.1006/viro.1996.0276; Hofmann W, 1999, J VIROL, V73, P10020, DOI 10.1128/JVI.73.12.10020-10028.1999; KANKI PJ, 1985, SCIENCE, V230, P951, DOI 10.1126/science.2997923; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; LaBonte JA, 2002, J EXP MED, V196, P431, DOI 10.1084/jem.20020468; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; Marcello A, 2003, EMBO J, V22, P2156, DOI 10.1093/emboj/cdg205; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Owens CA, 2003, J VIROL, V77, P726, DOI 10.1128/JVI.77.1.726-731.2003; OWENS CM, IN PRESS J VIROL; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rhodes DA, 2002, IMMUNOLOGY, V106, P246, DOI 10.1046/j.1365-2567.2002.01417.x; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Toniato E, 2002, J BIOL CHEM, V277, P37315, DOI 10.1074/jbc.M205900200; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Xu LX, 2003, EXP CELL RES, V288, P84, DOI 10.1016/S0014-4827(03)00187-3	30	1457	1530	4	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					848	853		10.1038/nature02343	http://dx.doi.org/10.1038/nature02343			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985764				2022-12-28	WOS:000189207500042
J	Keene, WE; Markum, AC; SAmadpour, M				Keene, WE; Markum, AC; SAmadpour, M			Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; PERICHONDRITIS; CHONDRITIS; HEPATITIS; PINNA	Context Sporadic infections following ear piercing are well documented, but common-source outbreaks are rarely recognized. Objective To investigate reports of auricular chondritis subsequent to commercial ear piercing. Design, Setting, and Subjects Outbreak investigation by Oregon public health agencies, including cohort study of persons pierced at a jewelry kiosk in August-September 2000, environmental sampling, and molecular subtyping of isolates. Confirmed cases had Pseudomonas aeruginosa cultured from ear wounds. Suspected cases had signs and symptoms of external ear infection, including drainage of pus or blood for at least 14 days. Main Outcome Measures Risk factors for infection and comparison of bacterial isolates by molecular subtyping. Results From 186 piercings in 118 individuals, we identified 7 confirmed P aeruginosa infections and 18 suspected infections. Confirmed cases were 10 to 19 years old. Most were initially treated with antibiotics ineffective against Pseudomonas. Four were hospitalized, 4 underwent incision and drainage surgeries (1 as an outpatient), and several were cosmetically deformed. Upper ear cartilage piercing was more likely to result in either confirmed or suspected infection than was lobe piercing (confirmed: RR undefined, P<.001; suspected: RR, 3.6; 95% confidence interval, 1.5-8.5). All persons with confirmed infections had their ear cartilage pierced With an open, spring-loaded piercing gun. Patient isolates were indistinguishable by molecular subtyping, and matching isolates were recovered from a disinfectant bottle and nearby sink. At least 1 worker admitted sometimes spraying the disinfectant on the ear studs before piercing. Conclusions Ear cartilage piercing is inherently more risky than lobe piercing. Clinicians should respond aggressively to potential auricular chondritis and consider Pseudomonas a possible cause pending culture results.	Oregon Dept Human Serv, Acute & Communicable Dis Program, Portland, OR 97232 USA; Klamath Cty Dept Publ Hlth, Klamath Falls, OR USA; Univ Washington, Sch Publ Hlth, Dept Environm Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Keene, WE (corresponding author), Oregon Dept Human Serv, Acute & Communicable Dis Program, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.	william.e.keene@state.or.us			ODCDC CDC HHS [U50/CCU011184] Funding Source: Medline	ODCDC CDC HHS		BIGGAR RJ, 1975, NEW YORK STATE J MED, V75, P1460; Braithwaite RL, 1999, J PUBLIC HEALTH POL, V20, P459, DOI 10.2307/3343131; Cicchetti S, 2002, BRIT J PLAST SURG, V55, P194, DOI 10.1054/bjps.2001.3799; CORTESE TA, 1971, AM FAM PHYSICIAN, V4, P66; CUMBERWORTH VL, 1990, BRIT J CLIN PRACT, V44, P512; FRANK MJ, 1976, JAMA-J AM MED ASSOC, V236, P2418, DOI 10.1001/jama.236.21.2418; Hanif J, 2001, BRIT MED J, V322, P906, DOI 10.1136/bmj.322.7291.906; Heal MR, 1999, ENVIRON INT, V25, P3, DOI 10.1016/S0160-4120(98)00092-0; JOHNSON CJ, 1974, JAMA-J AM MED ASSOC, V227, P1165, DOI 10.1001/jama.1974.03230230041022; Kent SE, 2001, BRIT MED J, V323, P400, DOI 10.1136/bmj.323.7309.400; Koenig LM, 1999, J GEN INTERN MED, V14, P379, DOI 10.1046/j.1525-1497.1999.00357.x; LEE J, 1960, JAMA-J AM MED ASSOC, V177, P708; More DR, 1999, PEDIATR EMERG CARE, V15, P189, DOI 10.1097/00006565-199906000-00007; ORTICOCHEA M, 1980, BRIT J PLAST SURG, V33, P38, DOI 10.1016/0007-1226(80)90049-1; Roush S, 1999, JAMA-J AM MED ASSOC, V282, P164, DOI 10.1001/jama.282.2.164; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; Sanders D Y, 1971, Woman Physician, V26, P459; Simplot TC, 1998, AM J OTOLARYNG, V19, P305, DOI 10.1016/S0196-0709(98)90003-5; Staley R, 1997, PEDIATRICS, V99, P610, DOI 10.1542/peds.99.4.610; TURKELTAUB SH, 1990, ANN PLAS SURG, V24, P279, DOI 10.1097/00000637-199003000-00015; Tweeten SSM, 1998, CLIN INFECT DIS, V26, P735, DOI 10.1086/514586; VANSCIVER AE, 1969, J AMER MED ASSOC, V207, P2285, DOI 10.1001/jama.1969.03150250115028	22	40	42	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					981	985		10.1001/jama.291.8.981	http://dx.doi.org/10.1001/jama.291.8.981			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982914				2022-12-28	WOS:000189182000026
J	Padera, TP; Stoll, BR; Tooredman, JB; Capen, D; di Tomaso, E; Jain, RK				Padera, TP; Stoll, BR; Tooredman, JB; Capen, D; di Tomaso, E; Jain, RK			Cancer cells compress intratumour vessels	NATURE			English	Editorial Material							SOLID TUMORS; PRESSURE		Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Padera, TP (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017; Padera, Timothy/R-2982-2019	Jain, Rakesh K/0000-0001-7571-3548; Padera, Timothy/0000-0002-3453-9384				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Arbiser JL, 1999, AM J PATHOL, V155, P723, DOI 10.1016/S0002-9440(10)65171-1; BOUCHER Y, 1992, CANCER RES, V52, P5110; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Koike C, 2002, BRIT J CANCER, V86, P947, DOI 10.1038/sj.bjc.6600158; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; REINHOLD HS, 1971, EUR J CANCER, V7, P273, DOI 10.1016/0014-2964(71)90069-7; Schmid-Schonbein Geert W, 2003, Lymphat Res Biol, V1, P25, DOI 10.1089/15396850360495664	10	605	623	6	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					695	695		10.1038/427695a	http://dx.doi.org/10.1038/427695a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973470	Bronze			2022-12-28	WOS:000189026000028
J	Smith, EJ; Rothman, MT; Timmis, AD				Smith, EJ; Rothman, MT; Timmis, AD			Prolonged hospital stay after acute myocardial infarction: assessing the evidence	LANCET			English	Editorial Material							EARLY DISCHARGE; PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; MANAGEMENT; REGISTRY; THERAPY		London Chest Hosp, Dept Cardiol, London E2 9JX, England	University of London; Queen Mary University London	Timmis, AD (corresponding author), London Chest Hosp, Dept Cardiol, London E2 9JX, England.	timmis@lch.demon.co.uk						ENWBY LK, 2003, EUR HEART J, V24, P182; Every NR, 1996, J AM COLL CARDIOL, V28, P287, DOI 10.1016/0735-1097(96)00168-4; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Sayer JW, 2000, HEART, V84, P258, DOI 10.1136/heart.84.3.258; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Varnava AM, 2002, HEART, V87, P216, DOI 10.1136/heart.87.3.216; Wallentin L, 1999, LANCET, V354, P708	13	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					502	503		10.1016/S0140-6736(04)15574-8	http://dx.doi.org/10.1016/S0140-6736(04)15574-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975607				2022-12-28	WOS:000188999900002
J	Dobbins, IG; Schnyer, DM; Verfaellie, M; Schacter, DL				Dobbins, IG; Schnyer, DM; Verfaellie, M; Schacter, DL			Cortical activity reductions during repetition priming can result from rapid response learning	NATURE			English	Article							INFERIOR PREFRONTAL CORTEX; FUSIFORM CORTEX; IMPLICIT MEMORY; FUNCTIONAL MRI; MECHANISMS; SPECIFICITY; RETRIEVAL; BRAIN; TASKS	Recent observation of objects speeds up their subsequent identification and classification(1,2). This common form of learning, known as repetition priming, can operate in the absence of explicit memory for earlier experiences(3,4), and functional neuroimaging has shown that object classification improved in this way is accompanied by 'neural priming' ( reduced neural activity) in prefrontal, fusiform and other cortical regions(5-10). These observations have led to suggestions that cortical representations of items undergo 'tuning', whereby neurons encoding irrelevant information respond less as a given object is observed repeatedly(10), thereby facilitating future availability of pertinent object knowledge. Here we provide experimental support for an alternative hypothesis, in which reduced cortical activity occurs because subjects rapidly learn their previous responses(11). After a primed object classification ( such as 'bigger than a shoebox'), cue reversal ('smaller than a shoebox') greatly slowed performance and completely eliminated neural priming in fusiform cortex, which suggests that these cortical item representations were no more available for primed objects than they were for new objects. In contrast, prefrontal cortex activity tracked behavioural priming and predicted the degree to which cue reversal would slow down object classification - highlighting the role of the prefrontal cortex in executive control.	Duke Univ, Durham, NC 27708 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Boston VA Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02118 USA; MGH MIT HMS, Athinoua A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Duke University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University	Dobbins, IG (corresponding author), Duke Univ, Durham, NC 27708 USA.	ian.dobbins@duke.edu	Schnyer, David/ABD-6372-2021	Schnyer, David/0000-0002-7472-2853; Verfaellie, Mieke/0000-0001-5535-4584; Schacter, Daniel/0000-0002-2460-6061				BUCKNER RL, 1995, J NEUROSCI, V15, P12; Dale AM, 1999, HUM BRAIN MAPP, V8, P109, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<109::AID-HBM7>3.3.CO;2-N; DEMB JB, 1995, J NEUROSCI, V15, P5870; Gauthier I, 2001, CURR OPIN NEUROBIOL, V11, P219, DOI 10.1016/S0959-4388(00)00200-2; HAYMAN CAG, 1989, J EXP PSYCHOL LEARN, V15, P941, DOI 10.1037/0278-7393.15.5.941; Henson R, 2000, SCIENCE, V287, P1269, DOI 10.1126/science.287.5456.1269; Henson RN, 2003, CEREB CORTEX, V13, P793, DOI 10.1093/cercor/13.7.793; Henson RNA, 2003, PROG NEUROBIOL, V70, P53, DOI 10.1016/S0301-0082(03)00086-8; Kane MJ, 2002, PSYCHON B REV, V9, P637, DOI 10.3758/BF03196323; Koutstaal W, 2001, NEUROPSYCHOLOGIA, V39, P184, DOI 10.1016/S0028-3932(00)00087-7; LOGAN GD, 1990, COGNITIVE PSYCHOL, V22, P1, DOI 10.1016/0010-0285(90)90002-L; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1985, MEMORY SYSTEMS BRAIN, P351; Simons JS, 2003, NEUROIMAGE, V19, P613, DOI 10.1016/S1053-8119(03)00096-X; SQUIRE LR, 1992, J EXP PSYCHOL LEARN, V18, P106, DOI 10.1037/0278-7393.18.1.106; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Thompson-Schill SL, 1999, NEURON, V23, P513, DOI 10.1016/S0896-6273(00)80804-1; TOTH JP, 1996, IMPLICIT COGNITION, P41; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; VRIEZEN ER, 1995, J EXP PSYCHOL LEARN, V21, P933, DOI 10.1037/0278-7393.21.4.933; Wagner AD, 1997, J COGNITIVE NEUROSCI, V9, P714, DOI 10.1162/jocn.1997.9.6.714; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X	25	242	245	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	2004	428	6980					316	319		10.1038/nature02400	http://dx.doi.org/10.1038/nature02400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	14990968				2022-12-28	WOS:000220250200043
J	Hien, TT; Liem, NT; Dung, NT; San, LT; Mai, PP; Chau, NVV; Suu, PT; Dong, VC; Mai, LTQ; Thi, NT; Khoa, DB; Phat, LP; Truong, NT; Long, HT; Tung, CV; Giang, LT; Tho, ND; Nga, LH; Tien, NTK; San, LH; Tuan, LV; Dolecek, C; Thanh, TT; de Jong, M; Schultsz, C; Cheng, P; Lim, W; Horby, P; Farrar, J				Hien, TT; Liem, NT; Dung, NT; San, LT; Mai, PP; Chau, NVV; Suu, PT; Dong, VC; Mai, LTQ; Thi, NT; Khoa, DB; Phat, LP; Truong, NT; Long, HT; Tung, CV; Giang, LT; Tho, ND; Nga, LH; Tien, NTK; San, LH; Tuan, LV; Dolecek, C; Thanh, TT; de Jong, M; Schultsz, C; Cheng, P; Lim, W; Horby, P; Farrar, J		World Hlth Org Int Avian Influenza	Avian influenza A (H5N1) in 10 patients in Vietnam.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HONG-KONG; INFECTION; VIRUS; DISEASE; RISK	Background: Recent outbreaks of avian influenza A (H5N1) in poultry throughout Asia have had major economic and health repercussions. Human infections with this virus were identified in Vietnam in January 2004. Methods: We report the clinical features and preliminary epidemiologic findings among 10 patients with confirmed cases of avian influenza A (H5N1) who presented to hospitals in Ho Chi Minh City and Hanoi, Vietnam, in December 2003 and January 2004. Results: In all 10 cases, the diagnosis of influenza A (H5N1) was confirmed by means of viral culture or reverse transcriptase-polymerase chain reaction with primers specific for H5 and N1. None of the 10 patients (mean age, 13.7 years) had preexisting medical conditions. Nine of them had a clear history of direct contact with poultry (median time before onset of illness, three days). All patients presented with fever (temperature, 38.5 to 40.0degreesC), <LF>respiratory symptoms, and clinically significant lymphopenia (median lymphocyte count, 700 per cubic millimeter). The median platelet count was 75,500 per cubic millimeter. Seven patients had diarrhea. In all patients, there were marked abnormalities on chest radiography. There was no definitive evidence of human-to-human transmission. Eight patients died, one patient has recovered, and one is recovering. Conclusions: Influenza A (H5N1) infection, characterized by fever, respiratory symptoms, and lymphopenia, carries a high risk of death. Although in all 10 cases the infection appears to have been acquired directly from infected poultry, the potential exists for genetic reassortment with human influenzaviruses and the evolution of human-to-human transmission. Containment of influenza A (H5N1) in poultry throughout Asia is therefore urgently required.	Hosp Trop Dis, Ho Chi Minh City, Vietnam; Hosp Trop Dis, Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam; Pediat Hosp Number Two, Ho Chi Minh City, Vietnam; Hlth Serv Ho Chi Minh City, Ho Chi Minh City, Vietnam; Inst Pasteur, Ho Chi Minh City, Vietnam; Prevent Med Ctr, Ho Chi Minh City, Vietnam; Natl Pediat Hosp, Hanoi, Vietnam; Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China; WHO, Vietnam Off, Hanoi, Vietnam	National Institute of Hygiene & Epidemiology (NIHE); World Health Organization	Farrar, J (corresponding author), Hosp Trop Dis, 190 Ben Ham Tu,Quan 5, Ho Chi Minh City, Vietnam.	jeremyjf@hcm.vnn.vn	Horby, Peter/D-1585-2013; Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X; Tran Tan, Thanh/0000-0002-8096-7750; Horby, Peter/0000-0002-9822-1586				Bridges CB, 2002, J INFECT DIS, V185, P1005, DOI 10.1086/340044; Chan PKS, 2002, CLIN INFECT DIS, V34, pS58, DOI 10.1086/338820; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5; van Kolfschooten F, 2003, LANCET, V361, P1444, DOI 10.1016/S0140-6736(03)13156-X; WRIGHT KE, 1995, J CLIN MICROBIOL, V33, P1180, DOI 10.1128/JCM.33.5.1180-1184.1995; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	10	649	724	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1179	1188		10.1056/NEJMoa040419	http://dx.doi.org/10.1056/NEJMoa040419			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	14985470				2022-12-28	WOS:000220242400005
J	Whicker, FW; Hinton, TG; MacDonell, MM; Pinder, JE; Habegger, LJ				Whicker, FW; Hinton, TG; MacDonell, MM; Pinder, JE; Habegger, LJ			Environment - Avoiding destructive remediation at DOE sites	SCIENCE			English	Editorial Material							GRASSLAND; PLUTONIUM		Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; Univ Georgia, Savannah River Ecol Lab, Aiken, SC 29802 USA; Argonne Natl Lab, Environm Assessment Div, Argonne, IL 60439 USA	Colorado State University; United States Department of Energy (DOE); Savannah River Ecology Laboratory; University System of Georgia; University of Georgia; United States Department of Energy (DOE); Argonne National Laboratory	Whicker, FW (corresponding author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA.	ward.whicker@colostate.edu						Breshears DD, 2003, EARTH SURF PROC LAND, V28, P1189, DOI 10.1002/esp.1034; Church BW, 2001, ENVIRON SCI POLLUT R, P9, DOI 10.1065/espr2001.11.099.4; DOE, 1997, DOEEM0319; HEBERT HJ, 2003, ASSOCIATED PRES 0717; Johansen MP, 2003, J ENVIRON QUAL, V32, P2150, DOI 10.2134/jeq2003.2150; LITTLE CA, 1978, HEALTH PHYS, V34, P451, DOI 10.1097/00004032-197805000-00005; LITTLE CA, 1980, J ENVIRON QUAL, V9, P350, DOI 10.2134/jeq1980.00472425000900030004x; MARCY BC, 1994, 19 ANN C P NEW ORL L; NELSON RH, 2001, WASTE WILDERNESS MAI; PASTERNAK D, 1992, US NEWS WORLD R 1214, P34; *US DOE, 2003, 4551 US DOE; US DoE, 2002, DOESTD11532002; *US DOE, 2002, REV ENV MAN PROGR; *US DOE, 2003, GUID DEV SIT SPEC RI; Whicker FW, 1995, INT AEAPS 2, P561; WHICKER FW, 1990, ECOL MONOGR, V60, P471, DOI 10.2307/1943017; WHICKER FW, 1997, FRESHWATER ESTUARINE; WHICKER FW, 1993, ENV HLTH PHYSICS, P473; ROCKY FLATS CLEANUP; 1993, FED REG         0325, V58, P16268	20	77	86	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1615	1616		10.1126/science.1093187	http://dx.doi.org/10.1126/science.1093187			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016982				2022-12-28	WOS:000220151400025
J	Laurance, WF; Oliveira, AA; Laurance, SG; Condit, R; Nascimento, HEM; Sanchez-Thorin, AC; Lovejoy, TE; Andrade, A; D'Angelo, S; Ribeiro, JE; Dick, CW				Laurance, WF; Oliveira, AA; Laurance, SG; Condit, R; Nascimento, HEM; Sanchez-Thorin, AC; Lovejoy, TE; Andrade, A; D'Angelo, S; Ribeiro, JE; Dick, CW			Pervasive alteration of tree communities in undisturbed Amazonian forests	NATURE			English	Article							TROPICAL RAIN-FOREST; EL-NINO; GROWTH; VARIABILITY; SEEDLINGS	Amazonian rainforests are some of the most species-rich tree communities on earth(1). Here we show that, over the past two decades, forests in a central Amazonian landscape have experienced highly nonrandom changes in dynamics and composition. Our analyses are based on a network of 18 permanent plots unaffected by any detectable disturbance. Within these plots, rates of tree mortality, recruitment and growth have increased over time. Of 115 relatively abundant tree genera, 27 changed significantly in population density or basal area-a value nearly 14 times greater than that expected by chance. An independent, eight-year study in nearby forests corroborates these shifts in composition. Contrary to recent predictions(2-5), we observed no increase in pioneer trees. However, genera of faster-growing trees, including many canopy and emergent species, are increasing in dominance or density, whereas genera of slower-growing trees, including many subcanopy species, are declining. Rising atmospheric CO2 concentrations(6) may explain these changes, although the effects of this and other large-scale environmental alterations remain uncertain. These compositional changes could have important impacts on the carbon storage, dynamics and biota of Amazonian forests.	Smithsonian Trop Res Inst, Balboa, Panama; INPA, Dept Bot, BR-69011970 Manaus, Amazonas, Brazil; INPA, Biol Dynam Forest Fragments Project, BR-69011970 Manaus, Amazonas, Brazil; Univ Sao Paulo, Dept Biol, BR-14040901 Sao Paulo, Brazil	Smithsonian Institution; Smithsonian Tropical Research Institute; Institute Nacional de Pesquisas da Amazonia; Institute Nacional de Pesquisas da Amazonia; Universidade de Sao Paulo	Laurance, WF (corresponding author), Smithsonian Trop Res Inst, Apartado 2072, Balboa, Panama.	laurancew@tivoli.si.edu	Ribeiro, Jose Eduardo L. S./A-8574-2013; Nascimento, Henrique E/F-8612-2012; Laurance, William F/B-2709-2012; Laurance, Susan/G-6021-2011; Oliveira, Alexandre/ABH-1255-2020; de Oliveira, Alexandre Adalardo/G-8830-2012	Ribeiro, Jose Eduardo L. S./0000-0002-2389-5631; Laurance, William F/0000-0003-4430-9408; Laurance, Susan/0000-0002-2831-2933; Oliveira, Alexandre/0000-0001-5526-8109; de Oliveira, Alexandre Adalardo/0000-0001-5526-8109				ARTAXO P, 2003, INT GLOB ATMOS CHEM, V27, P12; BAKER TR, IN PRESS PHIL T R B; CASPER BB, 1992, OECOLOGIA, V90, P212, DOI 10.1007/BF00317178; Clark DA, 2003, P NATL ACAD SCI USA, V100, P5852, DOI 10.1073/pnas.0935903100; CLARK DA, 1994, J ECOL, V82, P865, DOI 10.2307/2261450; Condit R, 1996, J VEG SCI, V7, P405, DOI 10.2307/3236284; De Oliveira AA, 1999, BIODIVERS CONSERV, V8, P1219, DOI 10.1023/A:1008908615271; Dunbar RB, 2000, NATURE, V407, P956, DOI 10.1038/35039661; GRACE J, 1995, SCIENCE, V270, P778, DOI 10.1126/science.270.5237.778; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; Korner C, 1998, CLIMATIC CHANGE, V39, P297, DOI 10.1023/A:1005325204713; Laurance WF, 1997, SCIENCE, V278, P1117, DOI 10.1126/science.278.5340.1117; Laurance WF, 2000, NATURE, V404, P836, DOI 10.1038/35009032; LEWIS SL, IN PRESS PHIL T R B; Malhi Y, 1998, J GEOPHYS RES-ATMOS, V103, P31593, DOI 10.1029/98JD02647; MALHI Y, IN PRESS PHIL T R B; Phillips OL, 1998, SCIENCE, V282, P439, DOI 10.1126/science.282.5388.439; Phillips OL, 2002, NATURE, V418, P770, DOI 10.1038/nature00926; PHILLIPS OL, 1994, SCIENCE, V263, P954, DOI 10.1126/science.263.5149.954; PHILLIPS OL, IN PRESS PHIL T R B; Piperno DR, 1996, QUATERNARY RES, V45, P202, DOI 10.1006/qres.1996.0020; REEKIE EG, 1989, OECOLOGIA, V79, P212, DOI 10.1007/BF00388481; Ter Steege H, 2001, ECOLOGY, V82, P3197, DOI 10.1890/0012-9658(2001)082[3197:CCDADI]2.0.CO;2; Thomas SC, 1996, AM J BOT, V83, P556, DOI 10.2307/2445913; Tian HQ, 1998, NATURE, V396, P664, DOI 10.1038/25328; Timmermann A, 1999, NATURE, V398, P694, DOI 10.1038/19505; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837; Winter K, 1999, FLORA, V194, P221, DOI 10.1016/S0367-2530(17)30900-3; Wright SJ, 1999, ECOLOGY, V80, P1632, DOI 10.2307/176552	29	195	215	2	61	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					171	175		10.1038/nature02383	http://dx.doi.org/10.1038/nature02383			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014498	Green Published			2022-12-28	WOS:000220103600046
J	Luterbacher, J; Dietrich, D; Xoplaki, E; Grosjean, M; Wanner, H				Luterbacher, J; Dietrich, D; Xoplaki, E; Grosjean, M; Wanner, H			European seasonal and annual temperature variability, trends, and extremes since 1500	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; CLIMATE-CHANGE; LAST MILLENNIUM; RECONSTRUCTION; RECORDS; INDEX; BACK	Multiproxy reconstructions of monthly and seasonal surface temperature fields for Europe back to 1500 show that the late 20th- and early 21st-century European climate is very likely (>95% confidence level) warmer than that of any time during the past 500 years. This agrees with findings for the entire Northern Hemisphere. European winter average temperatures during the period 1500 to 1900 were reduced by similar to0.5degreesC (0.25degreesC for annual mean temperatures) compared to the 20th century. Summer temperatures did not experience systematic century-scale cooling relative to present conditions. The coldest European winter was 1708/1709; 2003 was by far the hottest summer.	Univ Bern, NCCR Climate, CH-3012 Bern, Switzerland; Univ Bern, Inst Geog Climatol & Meteorol, CH-3012 Bern, Switzerland; Univ Bern, Dept Math Stat & Actuarial Sci, CH-3012 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Luterbacher, J (corresponding author), Univ Bern, NCCR Climate, CH-3012 Bern, Switzerland.	juerg@giub.unibe.ch	Xoplaki, Elena/AAF-1901-2020	Xoplaki, Elena/0000-0002-2745-2467; Luterbacher, Juerg/0000-0002-8569-0973				AUER E, 2003, GEOPHYS RES LETT, V30, P1276; Bradley RS, 2003, SCIENCE, V302, P404, DOI 10.1126/science.1090372; Bradley RS., 1993, HOLOCENE, V3, P367, DOI [10.1177/095968369300300409, DOI 10.1177/095968369300300409]; BRAZDIL R, UNPUB; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 1999, SCIENCE, V284, P926, DOI 10.1126/science.284.5416.926; Briffa KR, 2000, QUATERNARY SCI REV, V19, P87, DOI 10.1016/S0277-3791(99)00056-6; Briffa KR, 2002, SCIENCE, V295, P2227, DOI 10.1126/science.1069486; Cook ER, 2002, J CLIMATE, V15, P1754, DOI 10.1175/1520-0442(2002)015<1754:AWVMRO>2.0.CO;2; COOK ER, 1994, INT J CLIMATOL, V14, P379, DOI 10.1002/joc.3370140404; Cramer W, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, P641; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Fisher DA, 2002, HOLOCENE, V12, P401, DOI 10.1191/0959683602hl546rp; Gerber S, 2003, CLIM DYNAM, V20, P281, DOI 10.1007/s00382-002-0270-8; GUIOT J, 1991, EUROPEAN PALEOCLIMAT, V7, P93; Hansen J, 2001, J GEOPHYS RES-ATMOS, V106, P23947, DOI 10.1029/2001JD000354; HURRELL JW, IN PRESS CLIM DYN; Jones PD, 2001, SCIENCE, V292, P662, DOI 10.1126/science.1059126; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Jones PD, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003695; JONES PD, 2003, GEOPHYSICAL MONOGRAP, V134; Koslowski G, 1999, CLIMATIC CHANGE, V41, P175, DOI 10.1023/A:1005466226797; Legutke S., 2003, 200312 GKSS; LUTERBACHER J, 2001, ATMOS SCI LETT, V0002; Luterbacher J, 2002, CLIM DYNAM, V18, P545, DOI 10.1007/s00382-001-0196-6; Luterbacher J. S., UNPUB; Mann M. E., 2000, EARTH INTERACT, V4, P1, DOI DOI 10.1175/1087-3562(2000)004<0001:GTPIPC>2.3.C0;2; Mann M. E., 2003, EOS, V84, P256, DOI DOI 10.1029/2003EO270003; Mann ME, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002532; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Moberg A, 2003, INT J CLIMATOL, V23, P1495, DOI 10.1002/joc.945; NAKICENOVIC N, 2000, INTEGROVERNMENTAL PA; New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2; Overpeck J, 1997, SCIENCE, V278, P1251, DOI 10.1126/science.278.5341.1251; Pauling A, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017589; PFISTER C, IN PRESS KULTURELLE; Pfister C, 1999, WETTERNACHHERSAGE 50; Rodrigo FS, 2001, J GEOPHYS RES-ATMOS, V106, P14805, DOI 10.1029/2000JD900728; Rodwell MJ, 1999, NATURE, V398, P320, DOI 10.1038/18648; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Shindell DT, 2003, J CLIMATE, V16, P4094, DOI 10.1175/1520-0442(2003)016<4094:VASFOC>2.0.CO;2; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; VANLOON H, 1978, MON WEATHER REV, V106, P296, DOI 10.1175/1520-0493(1978)106<0296:TSIWTB>2.0.CO;2; Zwiers FW, 2003, J CLIMATE, V16, P793, DOI 10.1175/1520-0442(2003)016<0793:TRSCCD>2.0.CO;2	46	1242	1267	11	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1499	1503		10.1126/science.1093877	http://dx.doi.org/10.1126/science.1093877			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001774				2022-12-28	WOS:000220000100036
J	Celli, BR; Cote, CG; Marin, JM; Casanova, C; de Oca, MM; Mendez, RA; Pinto Plata, V; Cabral, HJ				Celli, BR; Cote, CG; Marin, JM; Casanova, C; de Oca, MM; Mendez, RA; Pinto Plata, V; Cabral, HJ			The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; 6-MINUTE WALK; LUNG-FUNCTION; MORTALITY; COPD; PROGNOSIS; RATINGS; MODELS	BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable -- the forced expiratory volume in one second (FEV(sub 1)) -- is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV(sub 1). We hypothesized that a multidimensional grading system that assessed the respiratory and systemic expressions of COPD would better categorize and predict outcome in these patients. METHODS: We first evaluated 207 patients and found that four factors predicted the risk of death in this cohort: the body-mass index (B), the degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), measured by the six-minute-walk test. We used these variables to construct the BODE index, a multidimensional 10-point scale in which higher scores indicate a higher risk of death. We then prospectively validated the index in a cohort of 625 patients, with death from any cause and from respiratory causes as the outcome variables. RESULTS: There were 25 deaths among the first 207 patients and 162 deaths (26 percent) in the validation cohort. Sixty-one percent of the deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infarction, 12 percent to lung cancer, and 13 percent to other causes. Patients with higher BODE scores were at higher risk for death; the hazard ratio for death from any cause per one-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001). The C statistic for the ability of the BODE index to predict the risk of death was larger than that for the FEV(sub 1) (0.74 vs. 0.65). CONCLUSIONS: The BODE index, a simple multidimensional grading system, is better than the FEV(sub 1) at predicting the risk of death from any cause and from respiratory causes among patients with COPD.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, COPD Ctr, Boston, MA 02135 USA; Bay Pines Vet Affairs Med Ctr, Bay Pines, FL USA; Hosp Miguel Servet, Zaragoza, Spain; Hosp Nuestra Senora La Candelaria, Tenerife, Spain; Hosp Univ Caracas, Caracas, Venezuela; Hosp Jose I Baldo, Caracas, Venezuela; Boston Univ, Sch Publ Hlth, Boston, MA USA	St. Elizabeth's Medical Center; Tufts University; Miguel Servet University Hospital; Boston University	Celli, BR (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, COPD Ctr, 736 Cambridge St, Boston, MA 02135 USA.	bcelli@copdnet.org	de, Maria Montes/AAP-7687-2021	Cabral, Howard/0000-0002-1185-8331				American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Burrows B., 1991, EUR RESPIR REV, V1, P340; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; COX DR, 1972, J R STAT SOC B, V34, P187; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Decramer M, 1997, EUR RESPIR J, V10, P417, DOI 10.1183/09031936.97.10020417; Dewan NA, 2000, CHEST, V117, P662, DOI 10.1378/chest.117.3.662; Domingo-Salvany A, 2002, AM J RESP CRIT CARE, V166, P680, DOI 10.1164/rccm.2112043; Ferrer M, 1997, ANN INTERN MED, V127, P1072, DOI 10.7326/0003-4819-127-12-199712150-00003; Friedman M, 1999, CHEST, V115, P635, DOI 10.1378/chest.115.3.635; Gerardi DA, 1996, EUR RESPIR J, V9, P431, DOI 10.1183/09031936.96.09030431; Hajiro T, 1998, AM J RESP CRIT CARE, V157, P785, DOI 10.1164/ajrccm.157.3.9703055; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Landbo C, 1999, AM J RESP CRIT CARE, V160, P1856, DOI 10.1164/ajrccm.160.6.9902115; MAHLER DA, 1992, AM REV RESPIR DIS, V145, P467, DOI 10.1164/ajrccm/145.2_Pt_1.467; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nam BH, 2002, STAT IND TECHNOL, P267; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; RIES AL, 1991, J CLIN EPIDEMIOL, V44, P497, DOI 10.1016/0895-4356(91)90212-R; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Shah MR, 2001, AM J CARDIOL, V88, P987, DOI 10.1016/S0002-9149(01)01975-0; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Szekely LA, 1997, CHEST, V111, P550, DOI 10.1378/chest.111.3.550; WEGNER RE, 1994, EUR RESPIR J, V7, P725, DOI 10.1183/09031936.94.07040725; 1995, AM J RESP CRIT CAR S, V152, pS78	35	2557	2689	6	168	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1005	1012		10.1056/NEJMoa021322	http://dx.doi.org/10.1056/NEJMoa021322			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999112				2022-12-28	WOS:000189363600008
J	Odom, DT; Zizlsperger, N; Gordon, DB; Bell, GW; Rinaldi, NJ; Murray, HL; Volkert, TL; Schreiber, J; Rolfe, PA; Gifford, DK; Fraenkel, E; Bell, GI; Young, RA				Odom, DT; Zizlsperger, N; Gordon, DB; Bell, GW; Rinaldi, NJ; Murray, HL; Volkert, TL; Schreiber, J; Rolfe, PA; Gifford, DK; Fraenkel, E; Bell, GI; Young, RA			Control of pancreas and liver gene expression by HNF transcription factors	SCIENCE			English	Article							BETA-CELL FUNCTION; DIABETES-MELLITUS; HNF-4-ALPHA GENE; DIFFERENTIATION; SPECIFICATION; HEPATOCYTES; UPSTREAM; NETWORKS; COMPLEX; YOUNG/	The transcriptional regulatory networks that specify and maintain human tissue diversity are largely uncharted. To gain insight into this circuitry, we used chromatin immunoprecipitation combined with promoter microarrays to identify systematically the genes occupied by the transcriptional regulators HNF1alpha, HNF4alpha, and HNF6, together with RNA polymerase II, in human liver and pancreatic islets. We identified tissue-specific regulatory circuits formed by HNF1alpha, HNF4alpha, and HNF6 with other transcription factors, revealing how these factors function as master regulators of hepatocyte and islet transcription. Our results suggest how misregulation of HNF4alpha can contribute to type 2 diabetes.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Comp Sci Lab, Cambridge, MA 02139 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Chicago; University of Chicago; University of Chicago	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012; Rinaldi, Nicola J/J-5858-2017	Young, Richard A/0000-0001-8855-8647; Rinaldi, Nicola J/0000-0002-0358-0747; Odom, Duncan/0000-0001-6201-5599; Fraenkel, Ernest/0000-0001-9249-8181	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK092310] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG002668, R01 HG002668-01] Funding Source: Medline; NIDDK NIH HHS [N01-DK-9-2310] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2001, NUCL RECEPTORS GENET; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; Bort R, 2002, NAT GENET, V32, P85, DOI 10.1038/ng0902-85; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Ferrer J, 2002, DIABETES, V51, P2355, DOI 10.2337/diabetes.51.8.2355; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; LOVEGREGORY L, IN PRESS DIABETES; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; SILANDER K, IN PRESS DIABETES; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837; Zhu Q, 2003, DIABETOLOGIA, V46, P567, DOI 10.1007/s00125-003-1067-y	29	1021	1102	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1378	1381		10.1126/science.1089769	http://dx.doi.org/10.1126/science.1089769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988562	Green Accepted			2022-12-28	WOS:000189238600054
J	Brandes, JL; Saper, JR; Diamond, M; Couch, JR; Lewis, DW; Schmitt, J; Neto, W; Schwabe, S; Jacobs, D				Brandes, JL; Saper, JR; Diamond, M; Couch, JR; Lewis, DW; Schmitt, J; Neto, W; Schwabe, S; Jacobs, D		MIGR-002 Study Grp	Topiramate for migraine prevention - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; DIVALPROEX SODIUM; UNITED-STATES; 160 MG; PROPHYLAXIS; PROPRANOLOL; PREVALENCE; POPULATION	Context Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention. Objective To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial. Design, Setting, and Patients A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine (International Headache Society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase. Interventions After a washout period, patients meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo. Topiramate was titrated by 25 mg/wk for 8 weeks to the assigned or maximum tolerated dose, whichever was less. Patients continued receiving that dose for 18 weeks. Main Outcome Measures The primary efficacy measure was change from baseline in mean monthly migraine frequency. Secondary efficacy measures included responder rate (proportion of patients with greater than or equal to50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events. The month of onset of preventive treatment action was assessed. Results Of 483 patients randomized, 468 provided at least 1 postbaseline efficacy assessment and comprised the intent-to-treat population. Mean monthly migraine frequency decreased significantly for patients receiving topiramate at 100 mg/d (-2.1, P=.008) and topiramate at 200 mg/d (-2.4, P<.001) vs placebo (-1.1). Statistically significant reductions (P<.05) occurred within the first month with topiramate at 100 and 200 mg/d. The responder rate was significantly greater with topiramate at 50 mg/d (39%, P=.01), 100 mg/d (49%, P<.001), and 200 mg/d (47%, P<001) vs placebo (23%). Reductions in migraine days were significant for the 100-mg/d (P=.003) and 200-mg/d (P<001) topiramate groups. Rescue medication use was reduced in the 100-mg/d (P=.01) and 200-mg/d (P=.005) topiramate groups. Adverse events resulting in discontinuation in the topiramate groups included paresthesia, fatigue, and nausea. Conclusion Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.	Nashville Neurosci Grp, Nashville, TN 37203 USA; Michigan Head Pain & Neurol Inst, Ann Arbor, MI USA; Diamond Headache Clin Ltd, Chicago, IL USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Childrens Hosp Kings Daughters, Norfolk, VA USA; Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Johnson & Johnson; Johnson & Johnson USA	Brandes, JL (corresponding author), Nashville Neurosci Grp, 300 20th Ave N,Suite 603, Nashville, TN 37203 USA.	jbrandes@nashvilleneuroscience.com						ALQASSAB HK, 1993, CEPHALALGIA, V13, P128, DOI 10.1046/j.1468-2982.1993.1302128.x; [Anonymous], 1991, Cephalalgia, V11, P1; Brandes JL, 2002, CNS DRUGS, V16, P13, DOI 10.2165/00023210-200216001-00003; Connor GS, 2002, NEUROLOGY, V59, P132, DOI 10.1212/WNL.59.1.132; DIAMOND S, 1976, HEADACHE, V16, P24, DOI 10.1111/j.1526-4610.1976.hed1601024.x; Diener HC, 2002, CEPHALALGIA, V22, P209, DOI 10.1046/j.1468-2982.2002.t01-1-00309.x; Edwards KR, 2003, CNS SPECTRUMS, V8, P428, DOI 10.1017/S1092852900018733; Freitag FG, 2002, NEUROLOGY, V58, P1652, DOI 10.1212/WNL.58.11.1652; Galvez-Jimenez N, 2000, ANN NEUROL, V47, P837, DOI 10.1002/1531-8249(200006)47:6<837::AID-ANA24>3.0.CO;2-2; GAWEL MJ, 1992, CAN J NEUROL SCI, V19, P340, DOI 10.1017/S0317167100041962; Henry P, 2002, NEUROLOGY, V59, P232, DOI 10.1212/WNL.59.2.232; Hoopes SP, 2003, J CLIN PSYCHIAT, V64, P1335, DOI 10.4088/JCP.v64n1109; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; Klapper J, 1997, CEPHALALGIA, V17, P103, DOI 10.1046/j.1468-2982.1997.1702103.x; KRUSZ JC, 1999, HEADACHE, V39, P363; Limmroth V, 2002, NEUROLOGY, V59, P1011, DOI 10.1212/WNL.59.7.1011; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Lipton RB, 2000, NEUROLOGY, V55, P629, DOI 10.1212/WNL.55.5.629; Martin S, 2001, CAN MED ASSOC J, V164, P1481; MATHEW NT, 1995, ARCH NEUROL-CHICAGO, V52, P281, DOI 10.1001/archneur.1995.00540270077022; McElroy SL, 2003, AM J PSYCHIAT, V160, P255, DOI 10.1176/appi.ajp.160.2.255; PRADALIER A, 1989, CEPHALALGIA, V9, P247, DOI 10.1046/j.1468-2982.1989.0904247.x; Ramadan NM, EVIDENCE BASED GUIDE; Shank RP, 2000, EPILEPSIA, V41, pS3, DOI 10.1111/j.1528-1157.2000.tb06045.x; Shuaib A, 1999, CEPHALALGIA, V19, P379; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2002, HEADACHE, V42, P85, DOI 10.1046/j.1526-4610.2002.02020.x; STEWART WF, 1994, NEUROLOGY, V44, P17; Storer R. James, 2003, Neurology, V60, pA238; Terwindt GM, 2000, NEUROLOGY, V55, P624, DOI 10.1212/WNL.55.5.624; Tronvik E, 2003, JAMA-J AM MED ASSOC, V289, P65, DOI 10.1001/jama.289.1.65; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; Van Gaal L., 2003, International Journal of Obesity, V27, pS14; Young WB, 2002, CEPHALALGIA, V22, P659, DOI 10.1046/j.1468-2982.2002.00380.x; ZIEGLER DK, 1987, ARCH NEUROL-CHICAGO, V44, P486, DOI 10.1001/archneur.1987.00520170016015	35	494	523	2	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					965	973		10.1001/jama.291.8.965	http://dx.doi.org/10.1001/jama.291.8.965			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982912	Bronze			2022-12-28	WOS:000189182000024
J	Holroyd-Leduc, JM; Straus, SE				Holroyd-Leduc, JM; Straus, SE			Management of urinary incontinence in women - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; RISK-FACTORS; DOUBLE-BLIND; ELECTRICAL-STIMULATION; DETRUSOR INSTABILITY; STRESS-INCONTINENCE; OVERACTIVE BLADDER; URGE INCONTINENCE; OLDER PERSONS; PREVALENCE	Context Urinary incontinence is a common health problem among women that negatively impacts quality of life. Therefore, it is important that primary care physicians have an understanding of how to manage urinary incontinence effectively. Objective To review the most recent, high-quality evidence regarding the etiology and management of urinary incontinence in women. Data Sources and Study Selection Searches of MEDLINE, EMBASE, The Cochrane Library, and the ACP Journal Club were performed to identify English-language articles published between 1998-2003 that focused on the etiology or treatment of urinary incontinence in adult women. The references of each retrieved article were reviewed and an expert in the field was contacted to identify additional relevant articles. Data Extraction Using a combination of more than 80 search terms, we included articles of etiology that were cohort studies, case-control studies, cross-sectional studies, or systematic reviews of cohort, case-control, and/or cross-sectional studies. Studies of treatment had to be randomized controlled trials or systematic reviews of randomized controlled trials. The quality of each article was assessed independently by each author and inclusion (n = 66) was determined by consensus. Data Synthesis Multiple factors have been found to be associated with urinary incontinence, some of which are amenable to modification. Factors associated with incontinence include age, white race, higher educational attainment, pregnancy-related factors, gynecological factors, urological and gastrointestinal tract factors, comorbid diseases, higher body mass index, medications, smoking, caffeine, and functional impairment. There are several effective non pharmacological treatments including pelvic floor muscle training, electrical stimulation, bladder training, and prompted voiding. Anticholinergic drugs are effective in the treatment of urge urinary incontinence. Several surgical interventions are effective in the management of stress incontinence, including open retropubic colposuspension and suburethral sling procedure. Conclusion Urinary incontinence in women is an important public health concern, and effective treatment options exist.	San Francisco VA Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; Univ Toronto, Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Holroyd-Leduc, JM (corresponding author), SFVAMC 181G, 4150 Clement St,Bldg 1, San Francisco, CA 94121 USA.	Jayna.Holroyd-Leduc@med.va.gov; sstraus@mtsinai.on.ca						Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Aggazzotti G, 2000, UROLOGY, V56, P245, DOI 10.1016/S0090-4295(00)00643-9; ALHASSO A, 2003, COCHRANE LIB; Appell RA, 2001, MAYO CLIN PROC, V76, P358; Arya LA, 2000, OBSTET GYNECOL, V96, P85, DOI 10.1016/S0029-7844(00)00808-5; Arya LA, 2001, AM J OBSTET GYNECOL, V185, P1318, DOI 10.1067/mob.2001.120365; Aukee P, 2002, UROLOGY, V60, P1020, DOI 10.1016/S0090-4295(02)02125-8; BEZERRA CA, 2003, COCHRANE LIB; Bo K, 2001, MED SCI SPORT EXER, V33, P1797; Bortolotti A, 2000, EUR UROL, V37, P30, DOI 10.1159/000020096; Brown JS, 2000, LANCET, V356, P535, DOI 10.1016/S0140-6736(00)02577-0; Brown JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Chaliha C, 1999, OBSTET GYNECOL, V94, P689, DOI 10.1016/S0029-7844(99)00364-6; Chiarelli P, 1999, NEUROUROL URODYNAM, V18, P567, DOI 10.1002/(SICI)1520-6777(1999)18:6<567::AID-NAU7>3.0.CO;2-F; Davila GW, 2001, J UROLOGY, V166, P140, DOI 10.1016/S0022-5347(05)66095-8; DeLancey J, 2001, AM J OBSTET GYNECOL, V185, P1323; Dugan E, 2000, J AM GERIATR SOC, V48, P413, DOI 10.1111/j.1532-5415.2000.tb04699.x; EUSTICE S, 2003, COCHRANE LIB; Finkelstein MM, 2002, CAN FAM PHYSICIAN, V48, P96; Foldspang A, 1999, AM J PUBLIC HEALTH, V89, P209, DOI 10.2105/AJPH.89.2.209; Fultz NH, 1999, J GERONTOL A-BIOL, V54, pM299, DOI 10.1093/gerona/54.6.M299; Garcia A, 2000, Can J Urol, V7, P1077; GLAZENER CM, 2003, COCHRANE LIB; Goode PS, 2003, JAMA-J AM MED ASSOC, V290, P345, DOI 10.1001/jama.290.3.345; Gordon D, 1998, BRIT J OBSTET GYNAEC, V105, P667, DOI 10.1111/j.1471-0528.1998.tb10183.x; Haeusler G, 2002, OBSTET GYNECOL, V100, P1003, DOI 10.1016/S0029-7844(02)02238-X; HAYSMITH EJ, 2003, COCHRANE LIB; HAYSMITH J, 2003, COCHRANE LIB; HERBISON P, 2003, COCHRANE LIB; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Holtedahl K, 1998, MATURITAS, V28, P205, DOI 10.1016/S0378-5122(97)00085-6; HROBJARTSSON A, 2003, COCHRANE LIB; Janssen CCM, 2001, BJU INT, V87, P201, DOI 10.1046/j.1464-410x.2001.02040.x; Jeyaseelan SM, 2000, CLIN REHABIL, V14, P631, DOI 10.1191/0269215500cr372oa; Johnson TM, 1998, J AM GERIATR SOC, V46, P693, DOI 10.1111/j.1532-5415.1998.tb03802.x; Kjerulff KH, 2002, J UROLOGY, V167, P2088, DOI 10.1016/S0022-5347(05)65091-4; Kuh D, 1999, J EPIDEMIOL COMMUN H, V53, P453, DOI 10.1136/jech.53.8.453; Landi F, 2002, CLIN PHARMACOL THER, V72, P729, DOI 10.1067/mcp.2002.129318; LAPITAN MC, 2003, COCHRANE LIB; Lee JG, 2002, INT J UROL, V9, P247, DOI 10.1046/j.1442-2042.2002.00460.x; Lee PE, 2001, J UROLOGY, V165, P153, DOI 10.1097/00005392-200101000-00037; Leung HY, 2002, BJU INT, V90, P375, DOI 10.1046/j.1464-410X.2002.02905.x; Maggi S, 2001, J GERONTOL A-BIOL, V56, pM14, DOI 10.1093/gerona/56.1.M14; Malone-Lee J, 2001, J UROLOGY, V165, P1452, DOI 10.1016/S0022-5347(05)66326-4; McDowell BJ, 1999, J AM GERIATR SOC, V47, P309, DOI 10.1111/j.1532-5415.1999.tb02994.x; MOEHRER B, 2003, COCHRANE LIB; Moller LA, 2000, OBSTET GYNECOL, V96, P446, DOI 10.1097/00006250-200009000-00022; Morkved S, 2002, OBSTET GYNECOL, V100, P730, DOI 10.1016/S0029-7844(02)02160-9; Naglie G, 2002, J UROLOGY, V167, P586, DOI 10.1016/S0022-5347(01)69090-6; Nelson R, 2001, J AGING HEALTH, V13, P539, DOI 10.1177/089826430101300406; Norton PA, 2002, AM J OBSTET GYNECOL, V187, P40, DOI 10.1067/mob.2002.124840; Persson J, 2000, OBSTET GYNECOL, V96, P440, DOI 10.1016/S0029-7844(00)00950-9; PICKARD R, 2003, COCHRANE LIB; ROE B, 2003, COCHRANE LIB; Roovers JPWR, 2001, ACTA OBSTET GYN SCAN, V80, P945, DOI 10.1080/791200711; Rortveit G, 2001, OBSTET GYNECOL, V98, P1004, DOI 10.1016/S0029-7844(01)01566-6; Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sampselle CM, 2002, OBSTET GYNECOL, V100, P1230, DOI 10.1016/S0029-7844(02)02241-X; Samuelsson E, 2000, ACTA OBSTET GYN SCAN, V79, P208, DOI 10.1034/j.1600-0412.2000.079003208.x; Samuelsson EC, 2000, AM J OBSTET GYNECOL, V183, P568, DOI 10.1067/mob.2000.106763; Schmidbauer J, 2001, EUR UROL, V39, P565, DOI 10.1159/000052504; Sherburn M, 2001, OBSTET GYNECOL, V98, P628, DOI 10.1016/S0029-7844(01)01508-3; Temml C, 2000, NEUROUROL URODYNAM, V19, P259, DOI 10.1002/(SICI)1520-6777(2000)19:3<259::AID-NAU7>3.0.CO;2-U; Thom D, 1998, J AM GERIATR SOC, V46, P473, DOI 10.1111/j.1532-5415.1998.tb02469.x; van der Vaart CH, 2002, BJOG-INT J OBSTET GY, V109, P149, DOI 10.1016/S1470-0328(02)01332-0; Van Kessel K, 2001, AM J OBSTET GYNECOL, V184, P1571, DOI 10.1067/mob.2001.114856; Van Oyen H, 2002, ACTA CLIN BELG, V57, P207, DOI 10.1179/acb.2002.043; Viktrup L, 2001, AM J OBSTET GYNECOL, V185, P82, DOI 10.1067/mob.2001.114501; Wyman JF, 1998, AM J OBSTET GYNECOL, V179, P999, DOI 10.1016/S0002-9378(98)70206-6; WYMAN JF, 1990, J AM GERIATR SOC, V38, P282, DOI 10.1111/j.1532-5415.1990.tb03505.x; Yamanishi T, 2000, UROLOGY, V55, P353, DOI 10.1016/S0090-4295(99)00476-8; Zinner NR, 2002, J AM GERIATR SOC, V50, P799, DOI 10.1046/j.1532-5415.2002.50203.x	75	135	138	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					986	995		10.1001/jama.291.8.986	http://dx.doi.org/10.1001/jama.291.8.986			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777MK	14982915	Bronze			2022-12-28	WOS:000189182000027
J	Capstick, B				Capstick, B			The future of clinical negligence litigation?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Capsticks Solicitors, London SW15 2TT, England		Capstick, B (corresponding author), Capsticks Solicitors, London SW15 2TT, England.	jbc@capsticks.co.uk						CAPSTICK B, 1991, QUALITY COUNTS YOUR; CAPSTICK JB, 1990, LANCET, V336, P931, DOI 10.1016/0140-6736(90)92291-O; *DOH, 2003, MAK AM CONS PAP SETT; *DOH, 2000, ORG MEM, P86; Evans K, 2001, J Obstet Gynaecol, V21, P114, DOI 10.1080/01443610020025967; GAFFNEY G, 1994, ARCH DIS CHILD-FETAL, V70, pF101, DOI 10.1136/fn.70.2.F101; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; National Audit Office, 2001, HANDL CLIN NEGL CLAI; NHS Litigation Authority, 2003, FACTSH 3 INF CLAIMS; *NHSLA, 2003, REP ACC 2003, P4; [No title captured]	11	6	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					457	459		10.1136/bmj.328.7437.457	http://dx.doi.org/10.1136/bmj.328.7437.457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976104	Green Published			2022-12-28	WOS:000189161000026
J	Carli, P; Orliaguet, G				Carli, P; Orliaguet, G			Severe traumatic brain injury in children	LANCET			English	Editorial Material							SEVERE HEAD-INJURIES; CEREBRAL BLOOD-FLOW; BLUNT TRAUMA; PEDIATRIC-PATIENTS; HYPOTENSION; INTUBATION; MANAGEMENT; GUIDELINES; SURVIVAL; CARE		Hop Necker Enfants Malad, Dept Anesthesie & Reanimat Chirurg, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Carli, P (corresponding author), Hop Necker Enfants Malad, Dept Anesthesie & Reanimat Chirurg, F-75743 Paris, France.	pCarli.samu@invivo.edu		Orliaguet, Gilles/0000-0003-0930-2251				Azocar F, 2003, J BEHAV HEALTH SER R, V30, P109, DOI 10.1007/BF02287816; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Meyer PG, 2000, PAEDIATR ANAESTH, V10, P253, DOI 10.1046/j.1460-9592.2000.00496.x; Orliaguet G, 2001, INTENS CARE MED, V27, P743, DOI 10.1007/s001340100905; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Suominen P, 1998, INJURY, V29, P425; Suominen P, 1998, J PEDIATR SURG, V33, P1388, DOI 10.1016/S0022-3468(98)90014-8	17	8	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					584	585		10.1016/S0140-6736(04)15626-2	http://dx.doi.org/10.1016/S0140-6736(04)15626-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987880				2022-12-28	WOS:000189104900004
J	Pizzarello, S; Weber, AL				Pizzarello, S; Weber, AL			Prebiotic amino acids as asymmetric catalysts	SCIENCE			English	Article							NUCLEIC-ACID; ORIGIN		Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; NASA, Ames Res Ctr, SETI Inst, Moffett Field, CA 94035 USA	Arizona State University; Arizona State University-Tempe; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Pizzarello, S (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.							BADA JL, 1987, BIOSYSTEMS, V20, P21, DOI 10.1016/0303-2647(87)90016-5; Notz W, 2000, J AM CHEM SOC, V122, P7386, DOI 10.1021/ja001460v; Orgel L, 2000, SCIENCE, V290, P1306, DOI 10.1126/science.290.5495.1306; Pizzarello S, 2003, GEOCHIM COSMOCHIM AC, V67, P1589, DOI 10.1016/S0016-7037(02)01283-8; Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347; Thomas P. J., 1997, COMETS ORIGIN EVOLUT; Weber AL, 2001, ORIGINS LIFE EVOL B, V31, P71, DOI 10.1023/A:1006750423942	7	274	277	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1151	1151		10.1126/science.1093057	http://dx.doi.org/10.1126/science.1093057			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976304				2022-12-28	WOS:000189074700034
J	Sharma, P; Varma, R; Sarasij, RC; Ira; Gousset, K; Krishnamoorthy, G; Rao, M; Mayor, S				Sharma, P; Varma, R; Sarasij, RC; Ira; Gousset, K; Krishnamoorthy, G; Rao, M; Mayor, S			Nanoscale organization of multiple GPI-anchored proteins in living cell membranes	CELL			English	Article							LIPID RAFTS; CHOLESTEROL DEPLETION; FRET MICROSCOPY; DOMAINS; MICRODOMAINS; SURFACE; RESOLUTION; MOLECULES; DYNAMICS; CAVEOLAE	Cholesterol and sphingolipid-enriched "rafts" have long been proposed as platforms for the sorting of specific membrane components including glycosylphosphatidylinositol-anchored proteins (GPI-APs), however, their existence and physical properties have been controversial. Here, we investigate the size of lipid-dependent organization of GPI-APs in live cells, using homo and hetero-FRET-based experiments combined with theoretical modeling. These studies reveal an unexpected organization wherein cell surface GPI-APs are present as monomers and a smaller fraction (20%-40%) as nanoscale (<5 nm) cholesterol-sensitive clusters. These clusters are composed of at most four molecules and accommodate diverse GPI-AP species; crosslinking GPI-APs segregates them from preexisting GPI-AP clusters and prevents endocytosis of the crosslinked species via a GPI-AP-selective pinocytic pathway. In conjunction with an analysis of the statistical distribution of the clusters, these observations suggest a mechanism for functional lipid-dependent clustering of GPI-APs.	Natl Ctr Biol Sci TIFR, Bangalore 560065, Karnataka, India; Raman Res Inst, Bangalore 560080, Karnataka, India; Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Department of Science & Technology (India); Raman Research Institute (RRI); Tata Institute of Fundamental Research (TIFR)	Rao, M (corresponding author), Natl Ctr Biol Sci TIFR, UAS GKVK Campus,GKVK PO, Bangalore 560065, Karnataka, India.	madan@rri.res.in	Gousset, Karine/ADS-3249-2022; Varma, Rajat/I-1209-2012; Probodh, Ira/G-7725-2012; Rao, Madan/E-2927-2012	Gousset, Karine/0000-0002-0988-2332; Varma, Rajat/0000-0001-5131-0402; Probodh, Ira/0000-0002-9346-9726; 				Agranovich V. M., 1982, ELECT EXCITATION ENE; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Clayton AHA, 2002, BIOPHYS J, V83, P1631, DOI 10.1016/S0006-3495(02)73932-5; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Gautier I, 2001, BIOPHYS J, V80, P3000, DOI 10.1016/S0006-3495(01)76265-0; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Irvine DJ, 2002, BIOPHYS J, V82, P120, DOI 10.1016/S0006-3495(02)75379-4; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Krishnan RV, 2001, J FLUORESC, V11, P211, DOI 10.1023/A:1012201201651; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lakshmikanth GS, 1999, BIOPHYS J, V77, P1100, DOI 10.1016/S0006-3495(99)76960-2; MATSUE H, 1992, P NATL ACAD SCI USA, V89, P6006, DOI 10.1073/pnas.89.13.6006; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; TANAKA F, 1979, PHOTOCHEM PHOTOBIOL, V29, P1091, DOI 10.1111/j.1751-1097.1979.tb07825.x; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zurzolo C, 2003, EMBO REP, V4, P1117, DOI 10.1038/sj.embor.7400032	46	667	681	1	104	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					577	589		10.1016/S0092-8674(04)00167-9	http://dx.doi.org/10.1016/S0092-8674(04)00167-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980224	Bronze			2022-12-28	WOS:000189184200011
J	Singer, T; Seymour, B; O'Doherty, J; Kaube, H; Dolan, RJ; Frith, CD				Singer, T; Seymour, B; O'Doherty, J; Kaube, H; Dolan, RJ; Frith, CD			Empathy for pain involves the affective but not sensory components of pain	SCIENCE			English	Article							HUMAN CINGULATE CORTEX; BRAIN RESPONSES; PHYSIOLOGICAL CONDITION; INSULAR CORTEX; NEURAL SYSTEMS; FMRI; INTEROCEPTION; METAANALYSIS; ACTIVATION; HUMANS	Our ability to have an experience of another's pain is characteristic of empathy. Using functional imaging, we assessed brain activity while volunteers experienced a painful stimulus and compared it to that elicited when they observed a signal indicating that their loved one-present in the same room-was receiving a similar pain stimulus. Bilateral anterior insula (AI), rostral anterior cingulate cortex (ACC), brainstem, and cerebellum were activated when subjects received pain and also by a signal that a loved one experienced pain. AI and ACC activation correlated with individual empathy scores. Activity in the posterior insula/secondary somatosensory cortex, the sensorimotor cortex (SI/MI), and the caudal ACC was specific to receiving pain. Thus, a neural response in AI and rostral ACC, activated in common for "self" and "other" conditions, suggests that the neural substrate for empathic experience does not involve the entire "pain matrix." We conclude that only that part of the pain network associated with its affective qualities, but not its sensory qualities, mediates empathy.	UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, London WC1N 3AR, England; UCL, Inst Neurol, Headache Grp, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Singer, T (corresponding author), UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3AR, England.	t.singer@fil.ion.ucl.ac.uk	Frith, Chris D/A-2171-2009; Girault, Johann/B-2430-2012; O'Doherty, John P/F-1204-2013	Frith, Chris D/0000-0002-8665-0690; Seymour, Ben/0000-0003-1724-5832; Dolan, Ray/0000-0001-9356-761X				Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Bingel U, 2003, NEUROIMAGE, V18, P740, DOI 10.1016/S1053-8119(02)00033-2; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Brooks JCW, 2002, NEUROIMAGE, V15, P293, DOI 10.1006/nimg.2001.0974; Brothers L., 1990, CONCEPTS NEUROSCIENC, V1, P27, DOI DOI 10.1093/SCHBUL/SBQ012; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Churchland PS, 2002, SCIENCE, V296, P308, DOI 10.1126/science.1070564; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; DAMASIO AR, 1994, DESCARTES ERROR; Davis KD, 2000, NEUROL RES, V22, P313; Davis M. H., 1980, JSAS CATALOG SELECTE, V10, P1, DOI DOI 10.1037/0022-3514.44.1.113; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallese V, 2003, PHILOS T R SOC B, V358, P517, DOI 10.1098/rstb.2002.1234; Grezes J, 2001, HUM BRAIN MAPP, V12, P1, DOI 10.1002/1097-0193(200101)12:1<1::AID-HBM10>3.0.CO;2-V; Hutchison WD, 1999, NAT NEUROSCI, V2, P403, DOI 10.1038/8065; LANGER SK, 1988, ESSAY HUMAN FEELINGS; LEVENSON RW, 1992, J PERS SOC PSYCHOL, V63, P234, DOI 10.1037/0022-3514.63.2.234; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Prinz W, 1997, EUR J COGN PSYCHOL, V9, P129, DOI 10.1080/713752551; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816	38	2495	2575	16	605	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1157	1162		10.1126/science.1093535	http://dx.doi.org/10.1126/science.1093535			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	775RP	14976305	Green Submitted			2022-12-28	WOS:000189074700036
J	Loscalzo, J				Loscalzo, J			Ozone - From environmental pollutant to atherogenic determinant	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-DENSITY LIPOPROTEIN; DEGRADATION		Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.		Loscalzo, Joseph/ABD-8980-2021					GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100	5	12	14	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					834	835		10.1056/NEJMcibr033352	http://dx.doi.org/10.1056/NEJMcibr033352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973208				2022-12-28	WOS:000189006400014
J	Wang, LC; Bu, DF; Yang, Y; Chen, XX; Zhu, XJ				Wang, LC; Bu, DF; Yang, Y; Chen, XX; Zhu, XJ			Castleman's tumours and production of autoantibody in paraneoplastic pemphigus	LANCET			English	Article							NON-HODGKINS-LYMPHOMA; INDIRECT IMMUNOFLUORESCENCE; DISEASE; MALIGNANCIES; ANTIBODIES; NEOPLASIA; ANTIGEN; PATIENT; FAMILY	Background Paraneoplastic pemphigus is an autoimmune mucocutaneous disease associated with Castleman's tumours, which when surgically removed often result in great improvement of mucocutaneous lesions. An IgG autoantibody against epidermal proteins is often used as a diagnostic marker for disease. Our aim was to ascertain the role of Castleman's tumours in production of the autoantibody and pathogenesis of paraneoplastic pemphigus. Methods We enrolled seven patients with paraneoplastic pemphigus associated with Castleman's disease and assessed the effect of removal of tumours on mucocutaneous lesions in six individuals and on autoantibody titre with indirect immunofluorescence in four patients. We cultured tumour cells from one patient and assayed the secreted autoantibody. Finally, we characterised the gene sequence and expression of the variable region of the immunoglobulin heavy chain (IgV(H)) in tumour B cells from all patients by reverse transcription-PCR, DNA sequencing, and in-situ hybridisation. Findings Cutaneous lesions disappeared within 6-11 weeks after resection of tumours. Mucosal lesions also improved in this period, but lasted for 5-10 months overall. Autoantibody titre decreased and became undetectable within 5-9 weeks in three of four patients assessed. We identified secreted autoantibody, similar to that identified in patients' serum, in cultured tumour cells. The tumour B-cells of the seven patients shared and expressed two rearrangement patterns of complementarity determining region 3 (CDR3) of IgV(H). Interpretation Secreted autoantibody from Castleman's tumours, which reacts against epidermal proteins, could be an essential factor in the pathogenesis of paraneoplastic pemphigus. We noted clonal rearrangement, resulting in similar variable regions of IgV(H), in tumour B cells isolated from all seven patients. However, whether this pattern is associated with autoimmunity remains to be ascertained.	Peking Univ, Hosp 1, Dept Dermatol, Beijing 100034, Peoples R China	Peking University	Zhu, XJ (corresponding author), Peking Univ, Hosp 1, Dept Dermatol, Beijing 100034, Peoples R China.	ZHUXJ@public.bta.net.cn	Wang, Liangchun/C-5995-2018	Wang, Liangchun/0000-0002-5169-2751				Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Anhalt G J, 1997, Adv Dermatol, V12, P77; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; AUBIN J, 1995, LEUKEMIA, V9, P471; BERG WA, 1993, SOUTHERN MED J, V86, P215, DOI 10.1097/00007611-199302000-00014; Bowen GM, 2000, ARCH DERMATOL, V136, P652, DOI 10.1001/archderm.136.5.652; Bowne WB, 1999, CANCER, V85, P706, DOI 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7; CAMISA C, 1993, ARCH DERMATOL, V129, P883, DOI 10.1001/archderm.129.7.883; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; Chan LS, 2000, ARCH DERMATOL, V136, P663, DOI 10.1001/archderm.136.5.663; HELOU J, 1995, J AM ACAD DERMATOL, V32, P441, DOI 10.1016/0190-9622(95)90066-7; Hsiao CJ, 2001, BRIT J DERMATOL, V144, P372, DOI 10.1046/j.1365-2133.2001.04030.x; JANSEN T, 1995, DERMATOLOGY, V190, P245, DOI 10.1159/000246701; Kim SC, 1997, J INVEST DERMATOL, V109, P365, DOI 10.1111/1523-1747.ep12336235; Lemon MA, 1997, BRIT J DERMATOL, V136, P115, DOI 10.1111/j.1365-2133.1997.tb08759.x; LIU AY, 1993, J AM ACAD DERMATOL, V28, P696, DOI 10.1016/0190-9622(93)70095-B; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; Marzano AV, 2001, BRIT J DERMATOL, V145, P127, DOI 10.1046/j.1365-2133.2001.04296.x; Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805; OURSLER JR, 1992, J CLIN INVEST, V89, P1775, DOI 10.1172/JCI115781; Plumb R, 1996, AM J HEMATOL, V52, P58, DOI 10.1002/(SICI)1096-8652(199605)52:1<58::AID-AJH10>3.0.CO;2-3; Robinson ND, 1999, J AM ACAD DERMATOL, V40, P649, DOI 10.1016/S0190-9622(99)70145-3; Schlesinger T, 1998, CUTIS, V61, P94; TURNER M, 1998, IMMUNOLOGY, P73; Wolff H, 1999, BRIT J DERMATOL, V140, P313; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123	26	91	123	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					525	531		10.1016/S0140-6736(04)15539-6	http://dx.doi.org/10.1016/S0140-6736(04)15539-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975615				2022-12-28	WOS:000188999900010
J	Shulman, AI; Larson, C; Mangelsdorf, DJ; Ranganathan, R				Shulman, AI; Larson, C; Mangelsdorf, DJ; Ranganathan, R			Structural determinants of allosteric ligand activation in RXR heterodimers	CELL			English	Article							RETINOID-X-RECEPTORS; VITAMIN-D-RECEPTOR; NUCLEAR RECEPTOR; CRYSTAL-STRUCTURE; PROTEIN FAMILIES; MOLECULAR-BASIS; BINDING DOMAIN; LXR-ALPHA; ACID; IDENTIFICATION	Allosteric communication underlies ligand-dependent transcriptional responses mediated by nuclear receptors. While studies have elucidated many of the components involved in this process, the energetic architecture within the receptor protein that mediates allostery remains unknown. Using a sequence-based method designed to detect coevolution of amino acids in a protein, termed the statistical coupling analysis (SCA), we identify a network of energetically coupled residues that link the functional surfaces of nuclear receptor ligand binding domains. Functional analysis of these predicted residues demonstrates their participation in an allosteric network that governs the ability of heterodimeric receptors to activate transcription in response to ligand binding by either partner. Interestingly, mutation of a single network residue can discriminate between receptor activation by endocrine dietary, and synthetic agonists. These results reveal a structural network required for RXR heterodimer allosteric communication and suggest that the specificity of ligand response and permissivity coevolved to enable signal discrimination.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu		Mangelsdorf, David/0000-0002-4355-0796				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; Doolittle R. F, 1996, COMPUTER METHODS MAC; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	34	265	270	4	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					417	429		10.1016/S0092-8674(04)00119-9	http://dx.doi.org/10.1016/S0092-8674(04)00119-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016376	Bronze			2022-12-28	WOS:000188825800010
J	't Jong, GW; Stricker, BHC; Sturkenboom, MCJM				't Jong, GW; Stricker, BHC; Sturkenboom, MCJM			Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Erasmus Univ, Med Ctr, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Sturkenboom, MCJM (corresponding author), Erasmus Univ, Med Ctr, Dept Med Informat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	m.sturkenboom@crasmusmc.nl						BRAUTIGAM M, 1995, BRIT MED J, V311, P919, DOI 10.1136/bmj.311.7010.919; Sheldon T, 2002, BRIT MED J, V325, P355, DOI 10.1136/bmj.325.7360.355; Vlug AE, 1999, METHOD INFORM MED, V38, P339	3	35	35	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					931	931		10.1136/bmj.38007.711481.F7	http://dx.doi.org/10.1136/bmj.38007.711481.F7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	14988148	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220994400023
J	Paul, M; Benuri-Silbiger, I; Soares-Weiser, K; Leibovici, L				Paul, M; Benuri-Silbiger, I; Soares-Weiser, K; Leibovici, L			beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SERIOUS BACTERIAL-INFECTIONS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; NEGATIVE BACILLARY INFECTIONS; RESPIRATORY-TRACT INFECTIONS; PLUS CLAVULANIC ACID; PSEUDOMONAS-AERUGINOSA; HOSPITALIZED-PATIENTS; ANTIMICROBIAL THERAPY; TOBRAMYCIN-TICARCILLIN; IMIPENEM-CILASTATIN	Objective To compare beta lactam monotherapy with lactam-aminoglycoside combination therapy for severe infections. Data sources Medline, Embase, Lilacs, Cochrane Library, and conference proceedings, to 2003; references of included studies; contact with all authors. No restrictions, such as language, year of publication, or publication status. Study selection All randomised trials of beta lactam monotherapy compared with beta lactam-aminoglycoside combination therapy for patients without neutropenia who fulfilled criteria for sepsis. Data selection Two reviewers independently applied selection criteria, performed quality assessment, and extracted the data. The primary outcome assessed was all cause fatality by intention to treat. Relative risks were pooled with the random effect model (relative risk <1 favours monotherapy). Results 64 trials with 7586 patients were included. There was no difference in all cause fatality (relative risk 0.90, 95% confidence interval 0.77 to 1.06). 12 studies compared the same beta lactam (1.02,0.76 to 1.38), and 31 studies compared different beta lactams (0.85,0.69 to 1.05). Clinical failure was more common with combination treatment overall (0.87,0.78 to 0.97) and among studies comparing different beta lactams (0.76,0.68 to 0.86). There was no advantage to combination therapy among patients with Gram negative infections (1835 patients) or Pseudomonas aeruginosa infections (426 patients). There was no difference in the rate of development of resistance. Nephrotoxicity was significantly more common with combination therapy (0.36,0.28 to 0.47). Heterogeneity was not significant for these comparisons. Conclusions In the treatment of sepsis the addition of an aminoglycoside to beta lactams should be discouraged. Fatality remains unchanged, while the risk for adverse events is increased.	Rabin Med Ctr, Dept Med E, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Rabin Medical Center	Paul, M (corresponding author), Rabin Med Ctr, Dept Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	mica@zahav.net.il						ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ARICH C, 1987, PATHOL BIOL PARIS, V36, P613; Bailey Jeffrey A, 2002, Surg Infect (Larchmt), V3, P315, DOI 10.1089/109629602762539544; Bayer AS, 1998, CIRCULATION, V98, P2936, DOI 10.1161/01.CIR.98.25.2936; BERGER A, 1988, PROG MATER SCI, V32, P1, DOI 10.1016/0079-6425(88)90009-6; Biglino A, 1991, J Chemother, V3 Suppl 1, P208; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; BROWN RB, 1984, CURR THER RES CLIN E, V36, P557; Carbon C, 1987, Chemioterapia, V6, P367; CARDOZO M, 2001, PEDIAT ASUNCION, V28, P15; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Clarke Mike, 2003, COCHRANE REV HDB 4 1; COMETTA A, 1994, ANTIMICROB AGENTS CH, V38, P1309, DOI 10.1128/AAC.38.6.1309; CONE LA, 1985, ANTIMICROB AGENTS CH, V28, P33, DOI 10.1128/AAC.28.1.33; COPPENS L, 1983, ANTIMICROB AGENTS CH, V23, P36, DOI 10.1128/AAC.23.1.36; Crabtree TD, 1999, ARCH SURG-CHICAGO, V134, P1293, DOI 10.1001/archsurg.134.12.1293; DANTONIO D, 1992, CHEMOTHERAPY, V38, P420, DOI 10.1159/000239037; denHollander JG, 1997, ANTIMICROB AGENTS CH, V41, P95, DOI 10.1128/AAC.41.1.95; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUFF P, 1982, AM J OBSTET GYNECOL, V142, P996, DOI 10.1016/0002-9378(82)90782-7; Dupont H, 2000, ANTIMICROB AGENTS CH, V44, P2028, DOI 10.1128/AAC.44.8.2028-2033.2000; FELISART J, 1985, HEPATOLOGY, V5, P457, DOI 10.1002/hep.1840050319; FINER N, 1992, J ROY SOC MED, V85, P530; GERECHT WB, 1989, ARCH INTERN MED, V149, P1279, DOI 10.1001/archinte.149.6.1279; GIAMARELLOU H, 1986, AM J MED, V80, P126, DOI 10.1016/0002-9343(86)90490-0; GIAMARELLOU H, 1984, ANTIMICROB AGENTS CH, V25, P534, DOI 10.1128/AAC.25.4.534; GRASELA TH, 1990, DICP ANN PHARMAC, V24, P1220, DOI 10.1177/106002809002401215; HAVIG O, 1973, SCAND J GASTROENTERO, V8, P55; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; HOEPELMAN IM, 1988, LANCET, V1, P1305, DOI 10.1016/S0140-6736(88)92121-6; HOLLOWAY WJ, 1985, AM J MED, V79, P168, DOI 10.1016/0002-9343(85)90153-6; Iakovlev S V, 1998, Antibiot Khimioter, V43, P15; Jaspers CAJJ, 1998, ANTIMICROB AGENTS CH, V42, P1233, DOI 10.1128/AAC.42.5.1233; KLASTERSKY J, 1977, AM J MED SCI, V273, P157, DOI 10.1097/00000441-197703000-00005; KLASTERSKY J, 1973, CANCER-AM CANCER SOC, V31, P331, DOI 10.1002/1097-0142(197302)31:2<331::AID-CNCR2820310210>3.0.CO;2-S; KLASTERSKY J, 1982, REV INFECT DIS, V4, P294; KLJUCAR S, 1990, 30 INT C ANT AG CHEM; KOEHLER C O, 1990, International Journal of Experimental and Clinical Chemotherapy, V3, P211; Kollef MH, 1999, CHEST, V115, P462, DOI 10.1378/chest.115.2.462; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P2639, DOI 10.1128/AAC.36.12.2639; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LANDAU Z, 1990, Harefuah, V118, P152; Leibovici L, 1997, ANTIMICROB AGENTS CH, V41, P1127, DOI 10.1128/AAC.41.5.1127; Leibovici L, 1998, J INTERN MED, V244, P379; Leone M, 2003, CRIT CARE MED, V31, P462, DOI 10.1097/01.CCM.0000050298.59549.4A; Lerma FA, 2001, J CHEMOTHERAPY, V13, P70, DOI 10.1179/joc.2001.13.1.70; Levison ME, 2000, INFECT DIS CLIN N AM, V14, P281, DOI 10.1016/S0891-5520(05)70248-8; LIBIEN J E M, 1992, Compendium de Investigaciones Clinicas Latinoamericanas, V12, P42; LIMSON BM, 1988, CLIN THER, V10, P589; MANDELL LA, 1987, J ANTIMICROB CHEMOTH, V20, P95, DOI 10.1093/jac/20.1.95; Martin P Y, 1991, Rev Med Suisse Romande, V111, P609; McCormick PA, 1997, HEPATOLOGY, V25, P833, DOI 10.1002/hep.510250408; MERGONI M, 1987, CHEMIOTERAPIA, V6, P286; MOELLERING RS, 2000, MANDELL DOUGLAS BENN; Montravers P, 2002, CRIT CARE MED, V30, P368, DOI 10.1097/00003246-200202000-00017; Moreno A, 1997, REV ESP QUIM, V10, P138; Mouton JW, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561666; MOUTON Y, 1990, PRESSE MED, V19, P607; MOUTON YJ, 1995, J ANTIMICROB CHEMOTH, V36, P145, DOI 10.1093/jac/36.suppl_A.145; MULLER EL, 1987, SURG GYNECOL OBSTET, V165, P285; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Paul M, 2003, BRIT MED J, V326, P1111, DOI 10.1136/bmj.326.7399.1111; PAUL M, 2003, COCHRANE LIB; PICCART M, 1984, ANTIMICROB AGENTS CH, V26, P870, DOI 10.1128/AAC.26.6.870; Ramirez de Aguilar R., 1992, COMPEND INVEST CLIN, V12, P75; RAPP RP, 1984, PHARMACOTHERAPY, V4, P211; RASMUSSEN D, 1986, DAN MED BULL, V33, P49; Ribera E, 1996, ANN INTERN MED, V125, P969, DOI 10.7326/0003-4819-125-12-199612150-00005; RUBINSTEIN E, 1995, CLIN INFECT DIS, V20, P1217, DOI 10.1093/clinids/20.5.1217; Ruiz G, 1990, REV ESP QUIM, V3, P35; SAGE R, 1987, SCAND J INFECT DIS, V19, P331, DOI 10.3109/00365548709018479; Sandberg T, 1997, SCAND J INFECT DIS, V29, P175, DOI 10.3109/00365549709035880; Sanfilippo JS, 1989, INT PEDIAT, V4, P53; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCULIER JP, 1982, J ANTIMICROB CHEMOTH, V9, P63, DOI 10.1093/jac/9.1.63; Sexton DJ, 1998, CLIN INFECT DIS, V27, P1470, DOI 10.1086/515038; Sieger B, 1997, CRIT CARE MED, V25, P1663, DOI 10.1097/00003246-199710000-00015; Siegman-Igra Y, 1998, Int J Infect Dis, V2, P211, DOI 10.1016/S1201-9712(98)90055-8; SMITH CR, 1984, ANN INTERN MED, V101, P469, DOI 10.7326/0003-4819-101-4-469; Speich R, 1998, EUR J CLIN MICROBIOL, V17, P313, DOI 10.1007/BF01709453; STILLE W, 1992, EUR J CLIN MICROBIOL, V11, P683; Sukoh Matsunobu, 1994, Japanese Journal of Antibiotics, V47, P170; Takamoto Masahiro, 1994, Japanese Journal of Antibiotics, V47, P1131; THOMPSON JE, 1990, SURG GYNECOL OBSTET, V171, P275; THOMPSON JE, 1993, SURG GYNECOL OBSTET, V177, P30; VERGNON J M, 1985, Revue de Pneumologie Clinique, V41, P205; VERZASCONI R, 1995, SCHWEIZ MED WSCHR, V125, P1533; WARREN JW, 1983, REV INFECT DIS, V5, pS173; WIECEK A, 1986, Polski Tygodnik Lekarski, V41, P1242; Wing DA, 1998, OBSTET GYNECOL, V92, P249, DOI 10.1016/S0029-7844(98)00156-2; Wu YL, 1999, J ANTIMICROB CHEMOTH, V44, P389, DOI 10.1093/jac/44.3.389; YELLIN AE, 1993, SURG GYNECOL OBSTET, V177, P23; Zavala Trujillo I, 1992, COMPUT INVEST CLIN L, V12, P31	95	294	320	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					668	672F		10.1136/bmj.38028.520995.63	http://dx.doi.org/10.1136/bmj.38028.520995.63			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	14996699	Green Published, Bronze			2022-12-28	WOS:000220392700016
J	Hunter, DJ				Hunter, DJ			Commentary: Getting a grip on clinical variations in hospital services	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Durham, Sch Hlth, Wolfson Res Inst, Thornaby TS17 6BH, Stockton On Tee, England	Durham University	Hunter, DJ (corresponding author), Univ Durham, Sch Hlth, Wolfson Res Inst, Queens Campus, Thornaby TS17 6BH, Stockton On Tee, England.	d.j.hunter@durham.ac.uk						Degeling P, 2003, BRIT MED J, V326, P649, DOI 10.1136/bmj.326.7390.649; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2000, SHAP FUT NHS LONG TE; Leatherman S.T., 2003, QUEST QUALITY NHS MI; ROLAND M, 2003, QUEST QUALITY NHS MI; Smith J, 2001, BRIT MED J, V323, P1262, DOI 10.1136/bmj.323.7324.1262; WENNBERG JE, 2004, FBMJ, V328, P607	7	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					610	610		10.1136/bmj.328.7440.610	http://dx.doi.org/10.1136/bmj.328.7440.610			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016693	Green Published			2022-12-28	WOS:000220208100016
J	Lee, DM; Yeoman, RR; Battaglia, DE; Stouffer, RL; Zelinski-Wooten, B; Fanton, JW; Wolf, DP				Lee, DM; Yeoman, RR; Battaglia, DE; Stouffer, RL; Zelinski-Wooten, B; Fanton, JW; Wolf, DP			Live birth after ovarian tissue transplant	NATURE			English	Editorial Material							NONHUMAN-PRIMATES; FERTILIZATION; FERTILITY		Oregon Hlth & Sci Univ, Dept Obstet & Gynecol Pediat Physiol & Pharmacol, Oregon Natl Primate Res Ctr, Div Reprod Sci, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center	Lee, DM (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol Pediat Physiol & Pharmacol, Oregon Natl Primate Res Ctr, Div Reprod Sci, Portland, OR 97201 USA.	leedavi@ohsu.edu		Zelinski, Mary/0000-0002-8513-1549				Duffy DM, 2002, HUM REPROD, V17, P2825, DOI 10.1093/humrep/17.11.2825; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; LEPORRIER M, 1987, CANCER, V60, P2201, DOI 10.1002/1097-0142(19871101)60:9<2201::AID-CNCR2820600915>3.0.CO;2-Z; LUTJEN P, 1984, NATURE, V307, P174, DOI 10.1038/307174a0; Oktay K, 2001, JAMA-J AM MED ASSOC, V286, P1490, DOI 10.1001/jama.286.12.1490; Ouhibi N, 2001, CONT ENDOCRINOL, P253; PARROTT DMV, 1960, J REPROD FERTIL, V1, P230, DOI 10.1530/jrf.0.0010230; Schnorr J, 2002, HUM REPROD, V17, P612, DOI 10.1093/humrep/17.3.612	8	139	155	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					137	138		10.1038/428137a	http://dx.doi.org/10.1038/428137a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014485				2022-12-28	WOS:000220103600032
J	Renton, P				Renton, P			Has the Higgs boson been discovered?	NATURE			English	Article								The standard model of particle physics describes the strong and electroweak interactions of fermions (spin-1/2), gauge bosons (spin-1) and a final vital ingredient-the spin-0 Higgs boson, which gives masses to the other particles. But the Higgs boson has yet to be discovered, and its own mass is not specified by the theory. There is some evidence (although statistically not very significant) for its detection at a mass of about 115 GeV/c(2), from electron-positron interactions at LEP (the Large Electron Positron collider). Indirect methods can also be used to constrain the mass of the Higgs boson, because it affects other observable quantities (for example, the mass of the W boson and some measurable properties of the Z boson). An indirect determination of the Higgs boson mass from the most recent measurements of such quantities yields a value compatible with 115 GeV/c(2), but with some important caveats arising from inconsistencies in the present data.	Univ Oxford, Dept Phys, Oxford OX1 3RH, England	University of Oxford	Renton, P (corresponding author), Univ Oxford, Dept Phys, Denys Wilkinson Bldg, Oxford OX1 3RH, England.	p.renton1@physics.ox.ac.uk						ABACHI S, 1995, PHYS REV LETT, V74, P2632, DOI 10.1103/PhysRevLett.74.2632; Abbaneo D, 2003, PHYS LETT B, V565, P61, DOI 10.1016/S0370-2693(03)00614-2; Abbott B, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.012001; ABE F, 1995, PHYS REV LETT, V74, P2626, DOI 10.1103/PhysRevLett.74.2638; Affolder T, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.032003; DEMORTIER L, 1999, FERMILABTM2084; GAMBINO P, IN PRESS P LEPT PHOT; Hagiwara K, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.010001; HIGGS PW, 1966, PHYS REV, V145, P1156, DOI 10.1103/PhysRev.145.1156; HIGGS PW, 1964, PHYS LETT, V12, P132, DOI 10.1016/0031-9163(64)91136-9; *LEP COLL ALEPH DE, 1994, CERNPPE94187 LEP COL; Renton P, 1990, ELECTROWEAK INTERACT; Renton PB, 2002, REP PROG PHYS, V65, P1271, DOI 10.1088/0034-4885/65/9/202	14	4	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					141	144		10.1038/nature02324	http://dx.doi.org/10.1038/nature02324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014491				2022-12-28	WOS:000220103600038
J	Schwartz, RS				Schwartz, RS			Paul Ehrlich's magic bullets.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	124	126	2	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1079	1080		10.1056/NEJMp048021	http://dx.doi.org/10.1056/NEJMp048021			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014180				2022-12-28	WOS:000220110100004
J	Jan, YW; Matter, M; Pai, JT; Chen, YL; Pilch, J; Komatsu, M; Ong, E; Fukuda, M; Ruoslahti, E				Jan, YW; Matter, M; Pai, JT; Chen, YL; Pilch, J; Komatsu, M; Ong, E; Fukuda, M; Ruoslahti, E			A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors	CELL			English	Article							FIBRONECTIN RECEPTOR; SIGNALING PATHWAY; EPITHELIAL-CELLS; ENDONUCLEASE-G; ANOIKIS; EXPRESSION; SURVIVAL; KINASE; ADHESION; BCL-2	A delicate balance of signals regulates cell survival. One set of these signals is derived from integrin-mediated cell adhesion to the extracellular matrix (ECM). Loss of cell attachment to the ECM causes apoptosis, a process known as anoikis. In searching for proteins involved in cell adhesion-dependent regulation of anoikis, we identified Bit1, a mitochondrial protein that is released into the cytoplasm during apoptosis. Cytoplasmic Bit1 forms a complex with AES, a small Groucho/transducin-like enhancer of split (TLE) protein, and induces cell death with characteristics of caspase-independent apoptosis. Cell attachment to fibronectin counteracts the apoptotic effect of Bit1 and AES. Increasing Bit1 expression enhances anoikis, while suppressing the expression reduces it. Thus, we have elucidated an integrin-controlled pathway that is, at least in part, responsible for the cell survival effects of cell-ECM interactions.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Burnham Inst, Program Mol Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Ruoslahti, E (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham.org	Matter, Michelle/GSN-9703-2022; Pilch, Jan/AAM-1976-2020; Pilch, Jan/AAJ-3614-2021	Pilch, Jan/0000-0002-6427-5738; Matter, Michelle/0000-0002-5988-9663; Pilch, Jan/0000-0002-2682-4708; Komatsu, Masanobu/0000-0001-7548-137X	NATIONAL CANCER INSTITUTE [P30CA030199, R01CA033000, R37CA033000, P01CA082713, R01CA079984] Funding Source: NIH RePORTER; NCI NIH HHS [CA33000, CA82713, CA 30199, CA79984] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BROTHERICK I, 1994, CYTOMETRY, V16, P262, DOI 10.1002/cyto.990160311; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li GY, 1999, CANCER RES, V59, P6267; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rosas-Sandoval G, 2002, P NATL ACAD SCI USA, V99, P16707, DOI 10.1073/pnas.222659199; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Wang WF, 2002, DEV DYNAM, V224, P79, DOI 10.1002/dvdy.10089; Wang XD, 2001, GENE DEV, V15, P2922; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	47	131	149	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					751	762		10.1016/S0092-8674(04)00204-1	http://dx.doi.org/10.1016/S0092-8674(04)00204-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006356	Bronze			2022-12-28	WOS:000221499700014
J	Laughlin, RB				Laughlin, RB			The cup of the hand	SCIENCE			English	Editorial Material							RENORMALIZATION-GROUP		Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Stanford University	Laughlin, RB (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	rbl@large.stanford.edu						FISHER ME, 1974, REV MOD PHYS, V46, P597, DOI 10.1103/RevModPhys.46.597; Guth A.H, 1998, INFLATIONARY UNIVERS; Otomo Katsuhiro, 1988, AKIRA; Peskin M., 1995, INTRO QUANTUM FIELD; REES MJ, 2000, NEW PERSPECTIVES AST; Senthil T, 2004, SCIENCE, V303, P1490, DOI 10.1126/science.1091806; Takhtadzhan L.A., 1979, RUSS MATH SURV, V34, P11, DOI [10.1070/RM1979v034n05ABEH003909, DOI 10.1070/RM1979V034N05ABEH003909]; Volovik G.E., 2003, UNIVERSE HELIUM DROP; WEINBERG S, 1994, 1 3 MINUTES MODERN V; WILSON KG, 1983, REV MOD PHYS, V55, P583, DOI 10.1103/RevModPhys.55.583	10	5	5	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	2004	303	5663					1475	1477		10.1126/science.1095266	http://dx.doi.org/10.1126/science.1095266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001764				2022-12-28	WOS:000220000100026
J	Murase, K; Shiba, H; Iwano, M; Che, FS; Watanabe, M; Isogai, A; Takayama, S				Murase, K; Shiba, H; Iwano, M; Che, FS; Watanabe, M; Isogai, A; Takayama, S			A membrane-anchored protein kinase involved in Brassica self-incompatibility signaling	SCIENCE			English	Article							RECEPTOR KINASE; S-LOCUS; GENOMIC ORGANIZATION; PLANTS; GENE; POLLEN; DETERMINANT; CAMPESTRIS; MUTATION; OLERACEA	Self-incompatibility (SI) response in Brassica is initiated by haplotype-specific interactions between the pollen-borne ligand S locus protein 11/SCR and its stigmatic S receptor kinase, SRK. This binding induces autophosphorylation of SRK, which is then thought to trigger a signaling cascade that leads to self-pollen rejection. A recessive mutation of the modifier (m) gene eliminates the SI response in stigma. Positional cloning of M has revealed that it encodes a membrane-anchored cytoplasmic serine/threonine protein kinase, designated M locus protein kinase (MLPK). Transient expression of MLPK restores the ability of mm papilla cells to reject self-pollen, suggesting that MLPK is a positive mediator of Brassica SI signaling.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan	Nara Institute of Science & Technology; Iwate University	Takayama, S (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	takayama@bs.aist-nara.ac.jp	Isogai, Akira/O-8897-2017; Watanabe, Masao/N-1465-2019; Watanabe, Masao/E-6300-2011	Isogai, Akira/0000-0001-8095-0441; Watanabe, Masao/0000-0002-9419-5149; Watanabe, Masao/0000-0002-9419-5149				Fukai E, 2001, MOL GENET GENOMICS, V265, P519, DOI 10.1007/s004380000440; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; Kachroo A, 2001, SCIENCE, V293, P1824, DOI 10.1126/science.1062509; Marin-Olivier M, 2000, PLANT J, V24, P231, DOI 10.1046/j.1365-313x.2000.00874.x; Martin N, 2002, NAT GENET, V32, P443, DOI 10.1038/ng1016; McCubbin AG, 2000, ANNU REV CELL DEV BI, V16, P333, DOI 10.1146/annurev.cellbio.16.1.333; MIYAKE Y, 1992, EUR J BIOCHEM, V210, P1, DOI 10.1111/j.1432-1033.1992.tb17383.x; Murase K., UNPUB; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Shiba H, 2003, BIOSCI BIOTECH BIOCH, V67, P622, DOI 10.1271/bbb.67.622; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Stone SL, 2003, PLANT CELL, V15, P885, DOI 10.1105/tpc.009845; Suzuki G, 1999, GENETICS, V153, P391; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; Takayama S, 2002, CURR OPIN PLANT BIOL, V5, P382, DOI 10.1016/S1369-5266(02)00284-4; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thompson GA, 2000, PROG LIPID RES, V39, P19, DOI 10.1016/S0163-7827(99)00014-4; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; [No title captured]	26	171	206	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1516	1519		10.1126/science.1093586	http://dx.doi.org/10.1126/science.1093586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001779				2022-12-28	WOS:000220000100042
J	Cairns, J				Cairns, J			The usefulness of parody	NATURE			English	Editorial Material									Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Cairns, J (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.								0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	2004	428	6978					23	23		10.1038/428023a	http://dx.doi.org/10.1038/428023a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999263	Bronze			2022-12-28	WOS:000189363800018
J	Sigman, DM; Jaccard, SL; Haug, GH				Sigman, DM; Jaccard, SL; Haug, GH			Polar ocean stratification in a cold climate	NATURE			English	Article							SOUTHERN-OCEAN; NORTH-ATLANTIC; CYCLE; NITRATE; CARBON	The low-latitude ocean is strongly stratified by the warmth of its surface water. As a result, the great volume of the deep ocean has easiest access to the atmosphere through the polar surface ocean. In the modern polar ocean during the winter, the vertical distribution of temperature promotes overturning, with colder water over warmer, while the salinity distribution typically promotes stratification, with fresher water over saltier. However, the sensitivity of seawater density to temperature is reduced as temperature approaches the freezing point, with potential consequences for global ocean circulation under cold climates(1,2). Here we present deep-sea records of biogenic opal accumulation and sedimentary nitrogen isotopic composition from the Sub-arctic North Pacific Ocean and the Southern Ocean. These records indicate that vertical stratification increased in both northern and southern high latitudes 2.7 million years ago, when Northern Hemisphere glaciation intensified in association with global cooling during the late Pliocene epoch. We propose that the cooling caused this increased stratification by weakening the role of temperature in polar ocean density structure so as to reduce its opposition to the stratifying effect of the vertical salinity distribution. The shift towards stratification in the polar ocean 2.7 million years ago may have increased the quantity of carbon dioxide trapped in the abyss, amplifying the global cooling.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany	Princeton University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences	Sigman, DM (corresponding author), Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA.	sigman@princeton.edu	Sigman, Daniel M/A-2649-2008; Jaccard, Samuel/G-3447-2014	Sigman, Daniel M/0000-0002-7923-1973; Jaccard, Samuel/0000-0002-5793-0896				Adkins JF, 2002, SCIENCE, V298, P1769, DOI 10.1126/science.1076252; ALTABET MA, 1994, GLOBAL BIOGEOCHEM CY, V8, P103, DOI 10.1029/93GB03396; Andreev A, 2002, DEEP-SEA RES PT II, V49, P5577, DOI 10.1016/S0967-0645(02)00200-X; BARKER PF, 1988, PALAEOGEOGR PALAEOCL, V67, P75, DOI 10.1016/0031-0182(88)90123-X; BOYLE EA, 1982, SCIENCE, V218, P784, DOI 10.1126/science.218.4574.784; BREWSTER NA, 1980, GEOL SOC AM BULL, V91, P337; Brzezinski MA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014349; BURCKLE LH, 1987, P ODP SCI RES, V113, P803; Conkright M., 2002, NOAA ATLAS NESDIS42; Diekmann B, 2003, SEDIMENTOLOGY, V50, P511, DOI 10.1046/j.1365-3091.2003.00562.x; Francois R, 1997, NATURE, V389, P929, DOI 10.1038/40073; FROELICH PN, 1991, P OCEAN DRILLING PRO, V0114; Gildor H, 2001, GEOPHYS RES LETT, V28, P2421, DOI 10.1029/2000GL012571; Haug GH, 1999, NATURE, V401, P779, DOI 10.1038/44550; HILLENBRAND CD, 2001, P OCEAN DRILLING PRO, V0178; Lefevre N, 1999, GLOBAL BIOGEOCHEM CY, V13, P727, DOI 10.1029/1999GB900034; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; Martin F, 1996, GESTA, V35, P177, DOI 10.2307/767181; MITCHELL BG, 1991, LIMNOL OCEANOGR, V36, P1662, DOI 10.4319/lo.1991.36.8.1662; Narita H, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014320; ORSI AH, 1995, DEEP-SEA RES PT I, V42, P641, DOI 10.1016/0967-0637(95)00021-W; REA DK, 1993, P ODP INIT REP, V145, P5; SARMIENTO JL, 1984, NATURE, V308, P621, DOI 10.1038/308621a0; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; Sigman DM, 1999, GLOBAL BIOGEOCHEM CY, V13, P1149, DOI 10.1029/1999GB900038; Sigmon DE, 2002, DEEP-SEA RES PT II, V49, P1747, DOI 10.1016/S0967-0645(02)00010-3; TOGGWEILER JR, 2003, EOS S, V84; WANG WG, 2002, NETW MAG, V17, P10; WARREN BA, 1983, J MAR RES, V41, P327, DOI 10.1357/002224083788520207; Winton M, 1997, J CLIMATE, V10, P37, DOI 10.1175/1520-0442(1997)010<0037:TEOCCU>2.0.CO;2	30	190	198	5	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					59	63		10.1038/nature02357	http://dx.doi.org/10.1038/nature02357			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999278	Green Submitted			2022-12-28	WOS:000189363800033
J	Wong, GY; Schroeder, DR; Carns, PE; Wilson, JL; Martin, DP; Kinney, MO; Mantilla, CB; Warner, DO				Wong, GY; Schroeder, DR; Carns, PE; Wilson, JL; Martin, DP; Kinney, MO; Mantilla, CB; Warner, DO			Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Pancreatic cancer is an aggressive tumor associated with high mortality. Optimal pain control may improve quality of life (QOL) for these patients. Objective To test the hypothesis that neurolytic celiac plexus block (NCPB) vs opioids alone improves pain relief, QOL, and survival in patients with unresectable pancreatic cancer. Design, Setting, and Patients Double-blind, randomized clinical trial conducted at Mayo Clinic, Rochester, Minn. Enrolled (October 1997 and January 2001) were 100 eligible patients with unresectable pancreatic cancer experiencing pain. Patients were followed up for at least 1 year or until death. Intervention Patients were randomly assigned to receive either NCPB or systemic analgesic therapy alone with a sham injection. All patients could receive additional opioids managed by a clinician blinded to the treatment assignment. Main Outcome Measures Pain intensity (0-10 numerical rating scale), QOL, opioid consumption and related adverse effects, and survival time were assessed weekly by a blinded observer. Results Mean (SD) baseline pain was 4.4 (1.7) for NCPB vs 4.1 (1.8) for opioids alone. The first week after randomization, pain intensity and QOL scores were improved (pain intensity, Pless than or equal to.01 for both groups; QOL, P<.001 for both groups), with a larger decrease in pain for the NCPB group (P=.005). From repeated measures analysis, pain was also lower for NCPB over time (P=.01). However, opioid consumption (P=.93), frequency of opioid adverse effects (all P>.10), and QOL (P=.46) were not significantly different between groups. In the first 6 weeks, fewer NCPB patients reported moderate or severe pain (pain intensity rating of greater than or equal to5/10) vs opioid-only patients (14% vs 40%, P=.005). At 1 year, 16% of NCPB patients and 6% of opioid-only patients were alive. However, survival did not differ significantly between groups (P=.26, proportional hazards regression). Conclusion Although NCPB improves pain relief in patients with pancreatic cancer vs optimized systemic analgesic therapy alone, it does not affect QOL or survival.	Mayo Clin, Coll Med, Dept Anesthesiol, Div Pain Med, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Wong, GY (corresponding author), Mayo Clin, Coll Med, Dept Anesthesiol, Div Pain Med, 200 1st St SW, Rochester, MN 55905 USA.	wong.gilbert@mayo.edu	Mantilla, Carlos B/A-3562-2013; Mantilla, Carlos/AAQ-2133-2020	Mantilla, Carlos/0000-0001-5446-9208				*AJCC, 2002, AJCC CANC STAG MAN; ANDERSON K, 2001, HDB PAIN ASSESSMENT; Cella D F, 1995, Oncology (Williston Park), V9, P47; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; GOUDAS L, 2001, AHCPR PUBLICATION; Grahm AL, 1997, DIGESTION, V58, P542, DOI 10.1159/000201499; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; ISCHIA S, 1992, ANESTHESIOLOGY, V76, P534, DOI 10.1097/00000542-199204000-00008; Jacox A, 1994, AHCPR PUBLICATION; KALSER MH, 1985, CANCER, V56, P397, DOI 10.1002/1097-0142(19850715)56:2<397::AID-CNCR2820560232>3.0.CO;2-I; Kawamata M, 1996, PAIN, V64, P597, DOI 10.1016/0304-3959(95)00189-1; Kelsen DP, 1997, SURGERY, V122, P53, DOI 10.1016/S0039-6060(97)90264-6; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; LILLEMOE KD, 1993, ANN SURG, V217, P447, DOI 10.1097/00000658-199305010-00004; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; MERCADANTE S, 1993, PAIN, V52, P187, DOI 10.1016/0304-3959(93)90130-H; MOORE DC, 1981, REGIONAL BLOCK; PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7; Polati E, 1998, BRIT J SURG, V85, P199; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; World Health Organization, 1996, CANC PAIN REL	23	273	289	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1092	1099		10.1001/jama.291.9.1092	http://dx.doi.org/10.1001/jama.291.9.1092			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996778	Bronze			2022-12-28	WOS:000189348900026
J	Couch, RB				Couch, RB			Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Couch, RB (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257					0	102	111	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					860	861		10.1056/NEJMp048006	http://dx.doi.org/10.1056/NEJMp048006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985482				2022-12-28	WOS:000189197300003
J	Mutsch, M; Zhou, WG; Rhodes, P; Bopp, M; Chen, RT; Linder, T; Spyr, C; Steffen, R				Mutsch, M; Zhou, WG; Rhodes, P; Bopp, M; Chen, RT; Linder, T; Spyr, C; Steffen, R			Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAT-LABILE TOXIN; CASE SERIES; SAFETY; IMMUNOGENICITY; TRIVALENT; EFFICACY	BACKGROUND: After the introduction of an inactivated intranasal influenza vaccine that was used only in Switzerland, 46 cases of Bell's palsy were reported. METHODS: We conducted a matched case-control study and a case-series analysis. All primary care physicians, ear, nose, and throat specialists, and neurologists in German-speaking regions of Switzerland were requested to identify cases of Bell's palsy diagnosed in adults between October 1, 2000, and April 30, 2001. Each physician was invited to select three control patients for each patient with Bell's palsy, with matching according to age, date of the clinic visit, and physician. Vaccination information was provided by the physicians. RESULTS: A total of 773 patients with Bell's palsy were identified. Of the 412 (53.3 percent) who could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control patients; the other 162 patients had no controls. In the case-control study, we found that 68 patients with Bell's palsy (27.2 percent) and 8 controls (1.1 percent) had received the intranasal vaccine (P<0.001). In contrast to parenteral vaccines, the intranasal vaccine significantly increased the risk of Bell's palsy (adjusted odds ratio, 84.0; 95 percent confidence interval, 20.1 to 351.9). Even according to conservative assumptions, the relative risk of Bell's palsy was estimated to be 19 times the risk in the controls, corresponding to 13 excess cases per 10,000 vaccinees within 1 to 91 days after vaccination. In the case-series analysis, the period of highest risk was 31 to 60 days after vaccination. CONCLUSIONS: This study suggests a strong association between the inactivated intranasal influenza vaccine used in Switzerland and Bell's palsy. This vaccine is no longer in clinical use.	Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland; Univ Zurich, Div Communicable Dis, WHO, Collaborating Ctr Travellers Hlth, CH-8006 Zurich, Switzerland; CDCP, Epidemiol Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; CDCP, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA USA; Kantonsspital Lucerne, Dept Otorhinolaryngol & Head & Neck Surg, Luzern, Switzerland; Berna Biotech, Bern, Switzerland	University of Zurich; University of Zurich; World Health Organization; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Lucerne Cantonal Hospital	Mutsch, M (corresponding author), Univ Zurich, Inst Social & Prevent Med, Sumatra Str 30, CH-8006 Zurich, Switzerland.	muetsch@ifspm.unizh.ch	Chen, Robert T/AIA-8164-2022; Linder, Thomas/ABH-6961-2020	Chen, Robert T/0000-0002-3094-8367; Mutsch, Margot/0000-0003-0620-5376; Bopp, Matthias/0000-0003-0766-3723				Adour KK, 1996, ANN OTO RHINOL LARYN, V105, P371, DOI 10.1177/000348949610500508; ANDERSON RN, 2000, NATL VITAL STAT REP, V50, P1; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BRANDENBURG NA, 1993, NEUROEPIDEMIOLOGY, V12, P313, DOI 10.1159/000110333; Davis SS, 2001, ADV DRUG DELIVER REV, V51, P21, DOI 10.1016/S0169-409X(01)00162-4; De Diego JI, 1999, OTOLARYNG HEAD NECK, V120, P269, DOI 10.1016/S0194-5998(99)70418-3; di Valserra MDB, 2002, CLIN THER, V24, P100, DOI 10.1016/S0149-2918(02)85008-1; Ellenberg SS, 2001, PHARMACOEPIDEM DR S, V10, P411, DOI 10.1002/pds.616; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; FARRINGTON CP, 1995, BIOMETRICS, V51, P228, DOI 10.2307/2533328; Fujihashi K, 2002, VACCINE, V20, P2431, DOI 10.1016/S0264-410X(02)00155-X; Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337; Gluck U, 1999, J VIROL, V73, P7780; Glueck R, 2001, VACCINE, V20, pS42, DOI 10.1016/S0264-410X(01)00292-4; Glueck R, 2001, ADV DRUG DELIVER REV, V51, P203, DOI 10.1016/S0169-409X(01)00174-0; GoncalvesCoelho TD, 1997, ARQ NEURO-PSIQUIAT, V55, P722, DOI 10.1590/S0004-282X1997000500007; Isaacson JE, 2002, OTOL NEUROTOL, V23, P589, DOI 10.1097/00129492-200207000-00031; Jacobson RM, 2001, VACCINE, V19, P2428, DOI 10.1016/S0264-410X(00)00467-9; KATUSIC SK, 1986, ANN NEUROL, V20, P622, DOI 10.1002/ana.410200511; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; Marson AG, 2000, WESTERN J MED, V173, P266, DOI 10.1136/ewjm.173.4.266; McNeela EA, 2001, ADV DRUG DELIVER REV, V51, P43, DOI 10.1016/S0169-409X(01)00169-7; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; PAOLINO E, 1985, J NEUROL, V232, P363, DOI 10.1007/BF00313837; Papaevangelou V, 1999, PEDIATR INFECT DIS J, V18, P1024, DOI 10.1097/00006454-199911000-00022; PEITERSEN E, 1992, ACTA OTO-LARYNGOL, P122; Rowlands S, 2002, EUR J NEUROL, V9, P63, DOI 10.1046/j.1468-1331.2002.00343.x; Savettieri G, 1996, ACTA NEUROL SCAND, V94, P71, DOI 10.1111/j.1600-0404.1996.tb00043.x; TOVI F, 1986, European Journal of Epidemiology, V2, P228; YANAGIHARA N, 1984, ARCH OTOLARYNGOL, V110, P374; YANAGIHARA N, 1988, ANN OTO RHINOL LARYN, V97, P3, DOI 10.1177/00034894880976S301; Zurbriggen Rinaldo, 2003, Expert Rev Vaccines, V2, P295, DOI 10.1586/14760584.2.2.295; [No title captured]	33	613	650	2	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					896	903		10.1056/NEJMoa030595	http://dx.doi.org/10.1056/NEJMoa030595			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985487	Green Accepted			2022-12-28	WOS:000189197300008
J	Jenkins, C; Costello, J; Hodge, L				Jenkins, C; Costello, J; Hodge, L			Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHRONIC CHILDHOOD ASTHMA; ANTI-INFLAMMATORY DRUGS; SENSITIVE PATIENTS; ORAL CHALLENGE; INTOLERANCE; ACETAMINOPHEN; DIAGNOSIS; ACID; HYPERSENSITIVITY; POPULATION	Objectives To reassess the prevalence of aspirin induced asthma and other issues related to the syndrome. Data sources Biosis, SciSearch (1990 to March 2002), Embase (1974 to March 2002), Medline (1966 to March 2002), Toxline, Derwent Drug File (1964 to March 2002), Conference Papers Index and Inside Conferences, Int'l Pharmaceutical Abstracts, Pharma-Online (1978 to March 2002). Selection criteria Study type, patient population, and outcome measures. Review was restricted to respiratory responses to analgesics avail able without prescription. Results The prevalence of aspirin induced asthma was highest when determined by oral provocation testing (adults 21%, 95% confidence interval 14% to 29%; children 5%, 0% to 14%) than by verbal history (adults 3%,2% to 4%; children 2%, 1% to 3%). Cross sensitivity to doses of over the counter non-steroidal anti-inflammatory drugs was present in most patients with aspirin induced asthma: ibuprofen, 98%; naproxen, 100%; and diclolenac, 93%. The incidence of cross sensitivity to paracetamol among such patients was only 7%. Conclusions Aspirin induced asthma in adults is more prevalent than previously suggested. When there is a clinical necessity to use aspirin or a non-steroidal anti-inflammatory drug and there is uncertainty about safety, oral provocation testing should be performed.	Royal Prince Alfred Hosp, Woolcock Inst Med Res, Camperdown, NSW 2050, Australia; Kings Coll Hosp London, London SE5 9RS, England; Royal Prince Alfred Hosp, Asthma Ctr, Camperdown, NSW 2050, Australia	University of Sydney; Woolcock Institute of Medical Research; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Sydney	Jenkins, C (corresponding author), Suite 702,26 Ridge St N, Sydney, NSW 2060, Australia.	crj@med.usyd.edu.au						BARLES PG, 1988, ALLERGOL IMMUNOPATH, V16, P321; CASTILLO JA, 1986, RESPIRATION, V50, P153, DOI 10.1159/000194922; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; FALLIERS CJ, 1983, J ASTHMA, V20, P39, DOI 10.3109/02770908309078051; FALLIERS CJ, 1973, J ALLERGY CLIN IMMUN, V52, P141, DOI 10.1016/0091-6749(73)90030-4; FISCHER TJ, 1983, PEDIATRICS, V71, P313; Ispano M, 1993, Drugs, V46 Suppl 1, P253; KWOH CK, 1986, CLIN PHARMACOL THER, V40, P494, DOI 10.1038/clpt.1986.214; Levy S, 2001, DRUG SAFETY, V24, P829, DOI 10.2165/00002018-200124110-00004; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MILOSEVIC D, 1990, ALLERGOLOGIE, V13, P205; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; PEARSON RSB, 1963, SALICYLATES INT S, P170; PICADO C, 1982, EUR J RESPIR DIS, V63, P226; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; SCHUHL JF, 1979, CLIN ALLERGY, V9, P83, DOI 10.1111/j.1365-2222.1979.tb01526.x; Schwab JM, 2003, LANCET, V361, P981, DOI 10.1016/S0140-6736(03)12841-3; SETTIPANE RA, 1995, J ALLERGY CLIN IMMUN, V96, P480, DOI 10.1016/S0091-6749(95)70290-3; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1977, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6081.231; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szczeklik A, 2000, ACI INT, V12, P171; TOWNS SJ, 1984, PEDIATRICS, V73, P631; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; VEDANTHAN PK, 1997, J ALLERGY CLIN IMMUN, V60, P8; WALTON C H, 1957, Can Med Assoc J, V76, P1016; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0	38	302	316	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					434	437		10.1136/bmj.328.7437.434	http://dx.doi.org/10.1136/bmj.328.7437.434			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976098	Green Published, Bronze			2022-12-28	WOS:000189161000017
J	Csankovszki, G; McDonel, P; Meyer, BJ				Csankovszki, G; McDonel, P; Meyer, BJ			Recruitment and spreading of the C-elegans dosage compensation complex along X chromosomes	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; SEX-DETERMINATION; ROX GENES; RNA; SEGREGATION; MACHINERY; CHROMATIN; NEMATODE; PROTEINS	To achieve X-chromosome dosage compensation, organisms must distinguish X chromosomes from autosomes. We identified multiple, cis-acting regions that recruit the Caenorhabditis elegans dosage compensation complex (DCC) through a search for regions of X that bind the complex when detached from X. The DCC normally assembles along the entire X chromosome, but not all detached regions recruit the complex, despite having genes known to be dosage compensated on the native X. Thus, the DCC binds first to recruitment sites, then spreads to neighboring X regions to accomplish chromosome-wide gene repression. From a large chromosomal domain, we defined a 793-base pair fragment that functions in vivo as an X-recognition element to recruit the DCC.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	bjmeyer@uclink.berkeley.edu		Csankovszki, Gyorgyi/0000-0001-5918-034X; Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065007, R01GM030702, R37GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM30702, R01 GM030702, F32-GM065007, F32 GM065007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CSANKOVSZKI G, UNPUB; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Lieb JD, 2000, GENETICS, V156, P1603; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Meller VH, 2002, ADV GENET, V46, P1; Meller VH, 2002, EMBO J, V21, P1084, DOI 10.1093/emboj/21.5.1084; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Meyer BJ, 2000, TRENDS GENET, V16, P247, DOI 10.1016/S0168-9525(00)02004-7; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Oh K, 2003, GENE DEV, V17, P1334, DOI 10.1101/gad.1082003; Park Y, 2003, MOL CELL, V11, P977, DOI 10.1016/S1097-2765(03)00147-3; Park Y, 2002, SCIENCE, V298, P1620, DOI 10.1126/science.1076686; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433	19	97	113	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1182	1185		10.1126/science.1092938	http://dx.doi.org/10.1126/science.1092938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976312				2022-12-28	WOS:000189074700043
J	Motta, MC; Divecha, N; Lemieux, M; Kamel, C; Chen, D; Gu, W; Bultsma, Y; McBurney, M; Guarente, L				Motta, MC; Divecha, N; Lemieux, M; Kamel, C; Chen, D; Gu, W; Bultsma, Y; McBurney, M; Guarente, L			Mammalian SIRT1 represses forkhead transcription factors	CELL			English	Article							PROTEIN-KINASE-B; PROMOTES CELL-SURVIVAL; CAENORHABDITIS-ELEGANS; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; FACTOR FKHR; FACTOR FOXO1; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SIGNALING PATHWAY	The NAD-dependent deacetylase SIR2 and the forkhead transcription factor DAF-16 regulate lifespan in model organisms, such as yeast and C. elegans. Here we show that the mammalian SIR2 ortholog SIRT1 deacetylates and represses the activity of the forkhead transcription factor Foxo3a and other mammalian forkhead factors. This regulation appears to be in the opposite direction from the genetic interaction of SIR2 with forkhead in C. elegans. By restraining mammalian forkhead proteins, SIRT1 also reduces forkhead-dependent apoptosis. The inhibition of forkhead activity by SIRT1 parallels the effect of this deacetylase on the tumor suppressor p53. We speculate how down-regulating these two classes of damage-responsive mammalian factors may favor long lifespan under certain environmental conditions, such as calorie restriction.	MIT, Dept Biol, Cambridge, MA 02139 USA; Antoni Van Leeuwenhoek Ziekenhuis, Dept Cellular Biochem H3, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Univ Ottawa, Dept Med, Ottawa, ON K1H 1C4, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 1C4, Canada; Ottawa Reg Canc Ctr, Ottawa, ON K1H 1C4, Canada	Massachusetts Institute of Technology (MIT); Netherlands Cancer Institute; Columbia University; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu		divecha, nullin/0000-0001-9695-6039; Lemieux, Madeleine/0000-0001-6355-8691				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Guarente L, 2000, GENE DEV, V14, P1021; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KAMEI Y, 2004, J LIPID RES, V1, P81; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nadal A, 2002, BIOCHEM J, V366, P289, DOI 10.1042/BJ20020598; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weindruch R., 1988, RETARDATION AGING DI; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000	64	1111	1179	1	83	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					551	563		10.1016/S0092-8674(04)00126-6	http://dx.doi.org/10.1016/S0092-8674(04)00126-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980222	Green Submitted, Bronze			2022-12-28	WOS:000189184200009
J	Kennedy, EM; Thomas, B				Kennedy, EM; Thomas, B			Dramatic improvement or death spiral - Two members of congress assess the Medicare bill	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*CTR MED MED SERV, 2003, MED CHOIC 2004; SAGER A, 2003, 61 PERCENT MED NEW P; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; THORPE KE, 2003, IMPLICATIONS MED PRE	4	13	13	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					747	+		10.1056/NEJMp048011	http://dx.doi.org/10.1056/NEJMp048011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973220				2022-12-28	WOS:000189006400001
J	Liu, ZH; Herbert, TD				Liu, ZH; Herbert, TD			High-latitude influence on the eastern equatorial Pacific climate in the early Pleistocene epoch	NATURE			English	Article							SEA-SURFACE TEMPERATURE; OCEAN; ATLANTIC; CALIBRATION; INSOLATION; CYCLES	Many records of tropical sea surface temperature and marine productivity exhibit cycles of 23 kyr (orbital precession) and 100 kyr during the past 0.5 Myr (refs 1-5), whereas high-latitude sea surface temperature records display much more pronounced obliquity cycles at a period of about 41 kyr (ref. 6). Little is known, however, about tropical climate variability before the mid-Pleistocene transition about 900 kyr ago, which marks the change from a climate dominated by 41-kyr cycles(7) (when ice-age cycles and high-latitude sea surface temperature variations were dictated by changes in the Earth's obliquity(8,9)) to the more recent 100-kyr cycles of ice ages. Here we analyse alkenones from marine sediments in the eastern equatorial Pacific Ocean to reconstruct sea surface temperatures and marine productivity over the past 1.8 Myr. We find that both records are dominated by the 41-kyr	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA	Brown University	Liu, ZH (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.	Zhonghui_Liu@brown.edu	Liu, Zhonghui/D-3163-2009	Liu, Zhonghui/0000-0002-2168-8305				[Anonymous], [No title captured]; Beaufort L, 2001, SCIENCE, V293, P2440, DOI 10.1126/science.293.5539.2440; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; BLOEMENDAL J, 1989, NATURE, V342, P897, DOI 10.1038/342897a0; Budziak D, 2000, PALEOCEANOGRAPHY, V15, P307, DOI 10.1029/1999PA000433; Bush ABG, 1998, SCIENCE, V279, P1341, DOI 10.1126/science.279.5355.1341; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; Emeis K.-C., 1995, P OCEAN DRILL PROGRA, V138, P605; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Herbert TD, 1998, PALEOCEANOGRAPHY, V13, P263, DOI 10.1029/98PA00069; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; LYLE MW, 1992, NATURE, V355, P812, DOI 10.1038/355812a0; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P839, DOI 10.2973/odp.proc.sr.138.160.1995; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; PERKS H, 2002, PALEOCEANOGRAPHY, V17, P63; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; PRAHL FG, 1988, GEOCHIM COSMOCHIM AC, V52, P2303, DOI 10.1016/0016-7037(88)90132-9; Raymo ME, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000791; Rostek F, 1997, DEEP-SEA RES PT II, V44, P1461, DOI 10.1016/S0967-0645(97)00008-8; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1984, GEOL SOC AM BULL, V95, P381, DOI 10.1130/0016-7606(1984)95<381:ITRACR>2.0.CO;2; Schneider RR, 1996, SOUTH ATLANTIC, P527; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782	27	152	160	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					720	723		10.1038/nature02338	http://dx.doi.org/10.1038/nature02338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973481				2022-12-28	WOS:000189026000039
J	Shane, E; Addesso, V; Namerow, PB; McMahon, DJ; Lo, SH; Staron, RB; Zucker, M; Pardi, S; Maybaum, S; Mancini, D				Shane, E; Addesso, V; Namerow, PB; McMahon, DJ; Lo, SH; Staron, RB; Zucker, M; Pardi, S; Maybaum, S; Mancini, D			Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOCORTICOID-INDUCED OSTEOPOROSIS; INCIDENT VERTEBRAL FRACTURES; HEART-TRANSPLANTATION; LUNG TRANSPLANTATION; LIVER-TRANSPLANTATION; CYCLOSPORINE-A; SOLID-ORGAN; VITAMIN-D; RECIPIENTS; PAMIDRONATE	Background: Osteoporosis is a well-known complication of cardiac transplantation. We conducted a randomized trial comparing alendronate with calcitriol for the prevention of bone loss during the first year after cardiac transplantation. Methods: A total of 149 patients were randomly assigned to receive either alendronate (10 mg per day) or calcitriol (0.5 microg per day) a mean (+/-SD) of 21+/-11 days after transplantation. Estimates of bone loss and the incidence of fractures among untreated patients were obtained from a reference group of 27 prospectively recruited patients who received cardiac transplants within the same period as the intervention groups. Results: At one year, the bone mineral density at the lumbar spine had decreased by a mean of 0.7 percent in the alendronate group and 1.6 percent in the calcitriol group (P=0.25 for the test of no difference). The bone mineral density at the femoral neck decreased by a mean of 1.7 percent in the alendronate group and 2.1 percent in the calcitriol group (P=0.69). In the reference group, the mean bone mineral density at the lumbar spine decreased by 3.2 percent (P=0.03 for the comparison with the alendronate group; P=0.15 for the comparison with the calcitriol group), and the mean density at the femoral neck decreased by 6.2 percent (P=0.001 for comparisons with both intervention groups). The incidence of vertebral fractures did not differ significantly among the groups (6.8 percent in the alendronate group, 3.6 percent in the calcitriol group, and 13.6 percent in the reference group). Hypercalciuria developed in 27 percent of the patients in the calcitriol group and 7 percent of those in the alendronate group (P=0.01). Conclusions: The degree of bone loss and the rates of fracture did not differ significantly between the intervention groups. Calcitriol was associated with a higher risk of hypercalciuria. Alendronate-treated patients sustained less bone loss at the spine than those in the reference group, and both intervention groups sustained less bone loss at the hip than the reference group. The requirement for monitoring the serum and urinary calcium levels in calcitriol-treated patients makes alendronate more attractive for the prevention of bone loss early after cardiac transplantation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biostat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY 10032 USA; Newark Beth Israel Med Ctr, Dept Med, Newark, NJ USA	Columbia University; Columbia University; Columbia University; Columbia University; Newark Beth Israel Medical Center	Shane, E (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, PH8-864,630 W 168th St, New York, NY 10032 USA.		Mattos, Beatriz A/D-2432-2011	Zucker, Mark/0000-0002-2999-0146; McMahon, Donald/0000-0003-1506-4464	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041391] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-006645] Funding Source: Medline; NIAMS NIH HHS [AR-41391] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aris RM, 2000, AM J RESP CRIT CARE, V162, P941, DOI 10.1164/ajrccm.162.3.2002051; Baker Danial E, 2002, Rev Gastroenterol Disord, V2, P20; Bianda T, 2000, CALCIFIED TISSUE INT, V67, P116, DOI 10.1007/s00223001126; BLACK DM, 1995, J BONE MINER RES, V10, P890; Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749-6632.2002.tb04204.x; Cohen A, 2003, OSTEOPOROSIS INT, V14, P617, DOI 10.1007/s00198-003-1426-z; Epstein S, 2001, CALCIFIED TISSUE INT, V68, P240, DOI 10.1007/s002230001167; Fan SLS, 2000, KIDNEY INT, V57, P684, DOI 10.1046/j.1523-1755.2000.t01-1-00890.x; Genant HK, 1996, J BONE MINER RES, V11, P984; Giannini S, 2001, J BONE MINER RES, V16, P2111, DOI 10.1359/jbmr.2001.16.11.2111; Glendenning P, 1999, CLIN ENDOCRINOL, V50, P347, DOI 10.1046/j.1365-2265.1999.00657.x; Henderson K, 2001, J BONE MINER RES, V16, P565, DOI 10.1359/jbmr.2001.16.3.565; Hommann M, 2002, TRANSPLANT P, V34, P2296, DOI 10.1016/S0041-1345(02)03242-6; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Kovac D, 2001, TRANSPL P, V33, P1144, DOI 10.1016/S0041-1345(00)02464-7; Krieg MA, 2001, OSTEOPOROSIS INT, V12, P112, DOI 10.1007/s001980170142; Leidig-Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140-6736(00)03641-2; Lems WF, 1996, ANN RHEUM DIS, V55, P288, DOI 10.1136/ard.55.5.288; Ramsey-Goldman R, 1999, J BONE MINER RES, V14, P456, DOI 10.1359/jbmr.1999.14.3.456; Reeves HL, 1998, LIVER TRANSPLANT SUR, V4, P404, DOI 10.1002/lt.500040508; RICH GM, 1992, J HEART LUNG TRANSPL, V11, P950; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; Sambrook P, 2000, J BONE MINER RES, V15, P1818, DOI 10.1359/jbmr.2000.15.9.1818; Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919; SAMBROOK PN, 1994, J HEART LUNG TRANSPL, V13, P116; SAMBROOK PN, 1994, OSTEOPOROSIS INT, V4, P273, DOI 10.1007/BF01623351; SHANE E, 1993, AM J MED, V94, P257, DOI 10.1016/0002-9343(93)90057-V; Shane E, 1996, J CLIN ENDOCR METAB, V81, P1740, DOI 10.1210/jc.81.5.1740; Shane E, 1997, J CLIN ENDOCR METAB, V82, P1497, DOI 10.1210/jc.82.5.1497; Shane E, 1998, J HEART LUNG TRANSPL, V17, P1089; Shane E, 2001, TRANSPLANT REV, V15, P11; Thiebaud D, 1996, EUR J CLIN INVEST, V26, P549, DOI 10.1046/j.1365-2362.1996.00170.x; Valimaki MJ, 1999, OSTEOPOROSIS INT, V10, P128, DOI 10.1007/s001980050207; VanCleemput J, 1996, TRANSPLANTATION, V61, P1495, DOI 10.1097/00007890-199605270-00015; VANCLEEMPUT J, 1995, TRANSPLANT INT, V8, P196; WU CY, 1995, OSTEOPOROSIS INT, V5, P354, DOI 10.1007/BF01622258	37	112	118	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					767	776		10.1056/NEJMoa035617	http://dx.doi.org/10.1056/NEJMoa035617			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973216				2022-12-28	WOS:000189006400005
J	Zhang, J; Klebanoff, MA				Zhang, J; Klebanoff, MA			Small-for-gestational-age infants and risk of fetal death in subsequent pregnancies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NICHHD, Div Epidemiol Stat & Prevent Res, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, J (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, US Dept HHS, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008724] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))			0	11	12	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					754	756		10.1056/NEJMp038245	http://dx.doi.org/10.1056/NEJMp038245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973218				2022-12-28	WOS:000189006400003
J	Peters, B; Whittall, T; Babaahmady, K; Gray, K; Vaughan, R; Lehner, T				Peters, B; Whittall, T; Babaahmady, K; Gray, K; Vaughan, R; Lehner, T			Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection	LANCET			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; PRIMERS PCR-SSP; CLASS-I; LYMPHOCYTE-RESPONSES; VACCINE PROTECTION; RHESUS MACAQUES; SEX WORKERS; P27 ANTIGEN; T-CELLS; HLA	Background Unprotected sexual intercourse between regular heterosexual partners could elicit alloimmune responses that might be associated with inhibition of in-vitro HIV-1 infectivity. We investigated this hypothesis in people practising unprotected sex and those using protection. Methods We recruited 82 participants from an outpatient genitourinary medicine clinic. 29 monogamous heterosexual couples having unprotected sex; and 15 women and 10 men having condom protected or no sex. We used the mixed leucocyte reaction (MLR), stimulating one partner's peripheral blood mononuclear cells (PBMC) with the other partner's irradiated PBMC and compared the resulting response with control PBMC. We studied resistance to HIV-1 infection by challenging activated CD4-positive T cells with CCR5-binding and CXCR4-binding HIV-1 strains, and comparing the infectivity in participants having unprotected sex with those practising protected sex. We used the correlation coefficient to establish the significance of the relation between MLR and HIV-1 infectivity. Findings We recorded a significant increase in the stimulation indices in PBMC from women whose cells were stimulated with irradiated PBMC (2%, 10%, or 50%) from their regular partners. The mean with 10% partner's cells was 8.6 (SD 7.7), compared with those from unrelated cells (4.7 [3.9], p=0.009). Significant alloimmune responses were also seen in corresponding male partners, but only with 50% stimulating cells (p=0.013). Dose-dependent inhibition of activated CD4-positive T cells to HIV-1 infection with both binding strains was noted in vitro in women practising unprotected intercourse, compared with those having protected sex or having no sex for more than 1 year. Highly significant differences were found for CCR5 (p=0.0001) and for CXCR4 (p=0.001) strains of HIV-1 at all four virus-concentrations. Male partners also showed in-vitro inhibition of HIV-1 but this was less than that in women. Interpretation Unprotected sexual intercourse might result in alloimmunisation stimulated by HLA antigens in seminal or cervicovaginal fluid. Mucosal alloimmunisation may reduce infection by HIV-1, and the role of such immunisation in preventive and therapeutic vaccination should be investigated.	Guys Kings & St Thomas Hosp Med & Dent Sch, Dept Genitourinary Med, London SE1 9RT, England; Guys Kings & St Thomas Hosp Med & Dent Sch, Muscosal Immunol Unit, London SE1 9RT, England; Guys Kings & St Thomas Hosp Med & Dent Sch, Clin Transplantat Lab, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Lehner, T (corresponding author), Guys Kings & St Thomas Hosp Med & Dent Sch, Dept Genitourinary Med, London SE1 9RT, England.	thomas.lehner@kcl.ac.uk		Gray, Kimberly/0000-0003-4594-3144; Whittall, Trevor/0000-0002-2189-3675				ARTHUR LO, 1995, J VIROL, V69, P3117, DOI 10.1128/JVI.69.5.3117-3124.1995; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Beyrer C, 1999, J INFECT DIS, V179, P59, DOI 10.1086/314556; Bruhl P, 1996, AIDS RES HUM RETROV, V12, P31, DOI 10.1089/aid.1996.12.31; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELUM CL, 1994, ARCH INTERN MED, V154, P1129, DOI 10.1001/archinte.154.10.1129; CHAN WL, 1995, AIDS, V9, P223, DOI 10.1097/00002030-199509030-00002; Chaouat G, 2003, CLIN EXP IMMUNOL, V131, P393, DOI 10.1046/j.1365-2249.2003.02100.x; CLERICI M, 1993, EUR J IMMUNOL, V23, P2022, DOI 10.1002/eji.1830230845; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170; Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Goh WC, 1999, J INFECT DIS, V179, P548, DOI 10.1086/314632; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Koelman CA, 2000, J REPROD IMMUNOL, V46, P155, DOI 10.1016/S0165-0378(99)00062-5; Kristiansen TB, 2001, J IMMUNOL METHODS, V252, P147, DOI 10.1016/S0022-1759(01)00349-0; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LEHNER T, 1994, J IMMUNOL, V153, P1858; LEHNER T, 1994, J VIROL, V68, P1624, DOI 10.1128/JVI.68.3.1624-1632.1994; Lehner Thomas, 2000, AIDS Research and Human Retroviruses, V16, P309, DOI 10.1089/088922200309188; Levine WC, 1998, J INFECT DIS, V177, P167, DOI 10.1086/513820; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Martin-Villa JM, 1999, BIOL REPROD, V61, P1381, DOI 10.1095/biolreprod61.6.1381; Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; SHEARER GM, 1993, SCIENCE, V262, P161, DOI 10.1126/science.8211133; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; STOTT EJ, 1995, BIOTECHNOLOGY AIDS, P151; Wang YF, 1999, NAT MED, V5, P1004, DOI 10.1038/12440; Wang YF, 1998, P NATL ACAD SCI USA, V95, P5223, DOI 10.1073/pnas.95.9.5223; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	41	67	69	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					518	524		10.1016/S0140-6736(04)15538-4	http://dx.doi.org/10.1016/S0140-6736(04)15538-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975614				2022-12-28	WOS:000188999900009
J	Yin, YW; Steitz, TA				Yin, YW; Steitz, TA			The structural mechanism of translocation and helicase activity in T7 RNA polymerase	CELL			English	Article							3.3 ANGSTROM RESOLUTION; FAMILY DNA-POLYMERASE; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; LESION-BYPASS; POWER STROKE; ELONGATION COMPLEX; ERROR-PRONE; REVERSE-TRANSCRIPTASE; SINGLE MOLECULES	RNA polymerase functions like a molecular motor that can convert chemical energy into the work of strand separation and translocation along the DNA during transcription. The structures of phage T7 RNA polymerase in an elongation phase substrate complex that includes the incoming nucleoside triphosphate and a pretranslocation product complex that includes the product pyrophosphate (PPi) are described here. These structures and the previously determined posttranslocation elongation complex demonstrate that two enzyme conformations exist during a cycle of single nucleotide addition. One orientation of a five-helix subdomain is stabilized by the phosphates of either the incoming NTP or by the product PPi. A second orientation of this subdomain is stable in their absence and is associated with translocation of the heteroduplex product as well as strand separation of the downstream DNA. We propose that the dissociation of the product PPi after nucleotide addition produces the protein conformational change resulting in translocation and strand separation.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	eatherton@csb.yale.edu	Steitz, Thomas A./C-6559-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057510] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Chen CJ, 1999, ACTA CRYSTALLOGR D, V55, P1188, DOI 10.1107/S0907444999004400; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JIANG MY, 1994, BIOESSAYS, V16, P531, DOI 10.1002/bies.950160803; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KUHKO E, 1986, EUR J BIOCHEM, V127, P347; KUKKOKALSKE E, 1989, J BACTERIOL, V171, P4498, DOI 10.1128/JB.171.8.4498-4500.1989; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Marx A, 2002, CHEMBIOCHEM, V3, P405, DOI 10.1002/1439-7633(20020503)3:5<405::AID-CBIC405>3.0.CO;2-4; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Reedy MC, 2000, J CELL SCI, V113, P3551; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Tyska MJ, 2002, CELL MOTIL CYTOSKEL, V51, P1, DOI 10.1002/cm.10014; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Wang HY, 1998, BIOPHYS J, V74, P1186, DOI 10.1016/S0006-3495(98)77834-8; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Wendt TG, 2002, EMBO J, V21, P5969, DOI 10.1093/emboj/cdf622; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	68	260	270	2	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					393	404		10.1016/S0092-8674(04)00120-5	http://dx.doi.org/10.1016/S0092-8674(04)00120-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016374	Bronze			2022-12-28	WOS:000188825800008
J	Young, KV; Brodie, ED; Brodie, ED				Young, KV; Brodie, ED; Brodie, ED			How the horned lizard got its horns	SCIENCE			English	Editorial Material							SELECTION; STRENGTH		Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Utah State Univ, Dept Biol, Logan, UT 84322 USA	Indiana University System; Indiana University Bloomington; Utah System of Higher Education; Utah State University	Brodie, ED (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	edb3@bio.indiana.edu	Brodie, Edmund D/B-2335-2013	Young, Kevin/0000-0003-2590-2273				BRODIE ED, 1995, TRENDS ECOL EVOL, V10, P313, DOI 10.1016/S0169-5347(00)89117-X; Bumpus H.C., 1899, BIOL LECT WOODS HOLE, P209; Hoekstra HE, 2001, P NATL ACAD SCI USA, V98, P9157, DOI 10.1073/pnas.161281098; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; KIPLING R, 2002, JUST SO STORIES; LANDE R, 1983, EVOLUTION, V37, P1210, DOI 10.2307/2408842; YOSEF R, 1992, EVOL ECOL, V6, P527, DOI 10.1007/BF02270696	7	56	60	7	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					65	65		10.1126/science.1094790	http://dx.doi.org/10.1126/science.1094790			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15001716				2022-12-28	WOS:000220567900036
J	McKeever, J; Boca, A; Boozer, AD; Miller, R; Buck, JR; Kuzmich, A; Kimble, HJ				McKeever, J; Boca, A; Boozer, AD; Miller, R; Buck, JR; Kuzmich, A; Kimble, HJ			Deterministic generation of single photons from one atom trapped in a cavity	SCIENCE			English	Article							QUANTUM-DOT; FLUORESCENCE; MOLECULE	A single cesium atom trapped within the mode of an optical cavity is used to generate single photons on demand. The photon wave packets are emitted as a Gaussian beam with temporal pro. le and repetition rate controlled by external driving fields. Each generation attempt is inferred to succeed with a probability near unity, whereas the efficiency for creating an unpolarized photon in the total cavity output is 0.69 +/- 0.10, as limited by passive cavity losses. An average of 1.4 x 10(4) photons are produced by each trapped atom. These results constitute an important step in quantum information science, for example, toward the realization of distributed quantum networking.	CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA	California Institute of Technology	Kimble, HJ (corresponding author), CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA.	hjkimble@caltech.edu						BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; BOOZER AD, IN PRESS; Briegel HJ, 2000, PHYSICS OF QUANTUM INFORMATION, P191; Brouri R, 2000, OPT LETT, V25, P1294, DOI 10.1364/OL.25.001294; CHUANG IL, 1995, PHYS REV A, V52, P3489, DOI 10.1103/PhysRevA.52.3489; CLAUSER JF, 1974, PHYS REV D, V9, P853, DOI 10.1103/PhysRevD.9.853; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Duan LM, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032305; DUAN LM, IN PRESS; GRANGIER P, 1986, EUROPHYS LETT, V1, P173, DOI 10.1209/0295-5075/1/4/004; Kimble HJ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.249801; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kurtsiefer C, 2000, PHYS REV LETT, V85, P290, DOI 10.1103/PhysRevLett.85.290; Law CK, 1997, J MOD OPTIC, V44, P2067, DOI 10.1080/095003497152357; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; Lutkenhaus N, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.052304; McKeever J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133602; McKeever J, 2003, NATURE, V425, P268, DOI 10.1038/nature01974; Michler P, 2000, NATURE, V406, P968, DOI 10.1038/35023100; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; PARKINS AS, 1993, PHYS REV LETT, V71, P3095, DOI 10.1103/PhysRevLett.71.3095; Pelton M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233602; Santori C, 2001, PHYS REV LETT, V86, P1502, DOI 10.1103/PhysRevLett.86.1502; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987	28	510	529	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1992	1994		10.1126/science.1095232	http://dx.doi.org/10.1126/science.1095232			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	14988512				2022-12-28	WOS:000220429800034
J	Zeng, XB; Ungar, G; Liu, YS; Percec, V; Dulcey, SE; Hobbs, JK				Zeng, XB; Ungar, G; Liu, YS; Percec, V; Dulcey, SE; Hobbs, JK			Supramolecular dendritic liquid quasicrystals	NATURE			English	Article							LATTICE; DESIGN; DENDRIMERS; LIBRARIES; PHASE; STATE; ANGLE; SHAPE; AREA	A large number of synthetic and natural compounds self-organize into bulk phases exhibiting periodicities on the 10(-8)-10(-6) metre scale(1) as a consequence of their molecular shape, degree of amphiphilic character and, often, the presence of additional non-covalent interactions. Such phases are found in lyotropic systems(2) (for example, lipid-water, soap-water), in a range of block copolymers(3) and in thermotropic (solvent-free) liquid crystals(4). The resulting periodicity can be one-dimensional (lamellar phases), two-dimensional (columnar phases) or three dimensional ('micellar' or 'bicontinuous' phases). All such two- and three-dimensional structures identified to date obey the rules of crystallography and their symmetry can be described, respectively, by one of the 17 plane groups or 230 space groups. The 'micellar' phases have crystallographic counterparts in transition-metal alloys, where just one metal atom is equivalent to a 10(3)-10(4)-atom micelle. However, some metal alloys are known to defy the rules of crystallography and form so-called quasicrystals, which have rotational symmetry other than the allowed two-, three-, four- or six-fold symmetry(5). Here we show that such quasiperiodic structures can also exist in the scaled-up micellar phases, representing a new mode of organization in soft matter.	Univ Sheffield, Dept Mat Engn, Sheffield S1 3JD, S Yorkshire, England; Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England	University of Sheffield; University of Pennsylvania; University of Bristol	Ungar, G (corresponding author), Univ Sheffield, Dept Mat Engn, Sheffield S1 3JD, S Yorkshire, England.	g.ungar@sheffield.ac.uk	Percec, Virgil/H-6316-2014; Liu, Yongsong/G-9203-2011	Percec, Virgil/0000-0001-5926-0489; Ungar, Goran/0000-0002-9743-2656				BAAKE M, 1992, PHYSICA A, V191, P554, DOI 10.1016/0378-4371(92)90582-B; Balagurusamy VSK, 1997, J AM CHEM SOC, V119, P1539, DOI 10.1021/ja963295i; BATES FS, 1982, MACROMOLECULES, V15, P589, DOI 10.1021/ma00230a073; Bruinsma RF, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.248101; CHEN H, 1988, PHYS REV LETT, V60, P1645, DOI 10.1103/PhysRevLett.60.1645; Conrad M, 1998, ANGEW CHEM INT EDIT, V37, P1384, DOI 10.1002/(SICI)1521-3773(19980605)37:10<1383::AID-ANIE1383>3.0.CO;2-R; FRANK FC, 1958, ACTA CRYSTALLOGR, V11, P184, DOI 10.1107/S0365110X58000487; Gahler F., 1988, QUASICRYSTALLINE MAT, P272; HORNE RW, 1985, MOL PLANT VIROLOGY, V1, P1; Hudson SD, 1997, SCIENCE, V278, P449, DOI 10.1126/science.278.5337.449; ISHIMASA T, 1985, PHYS REV LETT, V55, P511, DOI 10.1103/PhysRevLett.55.511; Janot C., 1992, QUASICRYSTALS PRIMER; Kelvin L., 1887, PHILOS MAG, V24, P503, DOI [10.1080, 10.1080/14786448708628135, DOI 10.1080/14786448708628135]; Lopes WA, 2001, NATURE, V414, P735, DOI 10.1038/414735a; LUZZATI V, 1993, J MOL BIOL, V229, P540, DOI 10.1006/jmbi.1993.1053; NAVAILLES L, 1995, PHYS REV LETT, V74, P5224, DOI 10.1103/PhysRevLett.74.5224; NAVAILLES L, 1993, PHYS REV LETT, V71, P545, DOI 10.1103/PhysRevLett.71.545; Newkome GR, 2001, DENDRIMERS DENDRONS; Percec V, 2002, CHEM-EUR J, V8, P1106, DOI 10.1002/1521-3765(20020301)8:5<1106::AID-CHEM1106>3.0.CO;2-G; Percec V, 2001, J AM CHEM SOC, V123, P1302, DOI 10.1021/ja0037771; Percec V, 2001, BIOMACROMOLECULES, V2, P729, DOI 10.1021/bm015559l; Seddon JM, 1996, BER BUNSEN PHYS CHEM, V100, P380, DOI 10.1002/bbpc.19961000324; Service RF, 2002, SCIENCE, V295, P2395, DOI 10.1126/science.295.5564.2395; STAMPFLI P, 1986, HELV PHYS ACTA, V59, P1260; THOMAS EL, 1988, NATURE, V334, P598, DOI 10.1038/334598a0; Tschierske C, 2001, J MATER CHEM, V11, P2647, DOI 10.1039/b102914m; Ungar G, 2003, SCIENCE, V299, P1208, DOI 10.1126/science.1078849; Weaire D., 1997, KELVIN PROBLEM FOAM; Yeardley DJP, 2000, J AM CHEM SOC, V122, P1684, DOI 10.1021/ja993915q; YOSHIDA K, 1989, ACTA CRYSTALLOGR B, V45, P40, DOI 10.1107/S0108768188011024; Ziherl P, 2001, J PHYS CHEM B, V105, P10147, DOI 10.1021/jp010944q; Zoorob ME, 2000, NATURE, V404, P740, DOI 10.1038/35008023	32	506	517	4	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					157	160		10.1038/nature02368	http://dx.doi.org/10.1038/nature02368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014524	Green Accepted			2022-12-28	WOS:000220103600042
J	[Anonymous]				[Anonymous]			Running interference on the genome	NATURE			English	Article																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					225	225		10.1038/428225b	http://dx.doi.org/10.1038/428225b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014515	Bronze			2022-12-28	WOS:000220103600064
J	Matsubara, H				Matsubara, H			Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy	LANCET			English	Editorial Material							BLOOD MONONUCLEAR-CELLS; BONE-MARROW CELLS; PERIPHERAL-BLOOD; TRANSPLANTATION; ANGIOGENESIS; REPAIR; IMPLANTATION; MYOCARDIUM; REGENERATION; HEART		Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan; Kyoto Univ Hosp, Translat Res Ctr, Cardiac Stem Cell Project, Kyoto 606, Japan	Kyoto Prefectural University; Kyoto University	Matsubara, H (corresponding author), Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan.	matsubah@koto.kpu-m.ac.jp						Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Fukumoto Y, 1997, BRIT J HAEMATOL, V97, P666, DOI 10.1046/j.1365-2141.1997.842724.x; Hill JM, 2003, CIRCULATION, V108, P478; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Inaba S, 2002, LANCET, V360, P2083, DOI 10.1016/S0140-6736(02)11976-3; Kamihata H, 2002, ARTERIOSCL THROM VAS, V22, P1804, DOI 10.1161/01.ATV.0000039168.95670.B9; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3	14	35	53	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					746	747		10.1016/S0140-6736(04)15713-9	http://dx.doi.org/10.1016/S0140-6736(04)15713-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016481				2022-12-28	WOS:000220092000002
J	Contreras, G; Pardo, V; Leclercq, B; Lenz, O; Tozman, E; O'Nan, P; Roth, D				Contreras, G; Pardo, V; Leclercq, B; Lenz, O; Tozman, E; O'Nan, P; Roth, D			Sequential therapies for proliferative lupus nephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; CYCLOPHOSPHAMIDE THERAPY; PULSE CYCLOPHOSPHAMIDE; MYCOPHENOLATE-MOFETIL; ERYTHEMATOSUS; METHYLPREDNISOLONE; CLASSIFICATION; PREDNISONE	BACKGROUND: Long-term therapy with cyclophosphamide enhances renal survival in patients with proliferative lupus nephritis; however, the beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects. METHODS: Fifty-nine patients with lupus nephritis (12 in World Health Organization class III, 46 in class IV, and 1 in class Vb) received induction therapy consisting of a maximum of seven monthly boluses of intravenous cyclophosphamide (0.5 to 1.0 g per square meter of body-surface area) plus corticosteroids. Subsequently, the patients were randomly assigned to one of three maintenance therapies: quarterly intravenous injections of cyclophosphamide, oral azathioprine (1 to 3 mg per kilogram of body weight per day), or oral mycophenolate mofetil (500 to 3000 mg per day) for one to three years. The base-line characteristics of the three groups were similar, with the exception that the chronicity index was 1.9 points lower in the cyclophosphamide group than in the mycophenolate mofetil group (P=0.009). RESULTS: During maintenance therapy, five patients died (four in the cyclophosphamide group and one in the mycophenolate mofetil group), and chronic renal failure developed in five (three in the cyclophosphamide group and one each in the azathioprine and mycophenolate mofetil groups). The 72-month event-free survival rate for the composite end point of death or chronic renal failure was higher in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group (P=0.05 and P=0.009, respectively). The rate of relapse-free survival was higher in the mycophenolate mofetil group than in the cyclophosphamide group (P=0.02). The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was significantly lower in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group. CONCLUSIONS: For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide.	Univ Miami, Div Nephrol, Miami, FL 33136 USA; Univ Miami, Div Rheumatol & Immunol, Miami, FL 33136 USA; Vet Affairs Med Ctr, Dialysis Unit, Miami, FL 33125 USA; Vet Affairs Med Ctr, Electron Microscopy Unit, Miami, FL 33125 USA	University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Contreras, G (corresponding author), Univ Miami, Div Nephrol, 1600 NW 10th Ave,R-126, Miami, FL 33136 USA.	gcontrer@med.miami.edu	Lenz, Oliver/M-4672-2016	Lenz, Oliver/0000-0003-2997-3976				Alarcon GS, 2002, LUPUS, V11, P402, DOI 10.1191/0961303302lu215xx; Alarcon GS, 2002, LUPUS, V11, P95, DOI 10.1191/0961203302lu155oa; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; Chan TM, 2000, NEW ENGL J MED, V343, P1156, DOI 10.1056/NEJM200010193431604; CHAN TM, 1995, NEPHRON, V71, P321, DOI 10.1159/000188739; CHURG J, 1995, RENAL DIS CLASSIFICA, P151; Corna D, 1997, KIDNEY INT, V51, P1583, DOI 10.1038/ki.1997.217; Dooley MA, 1997, KIDNEY INT, V51, P1188, DOI 10.1038/ki.1997.162; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P175, DOI 10.1111/j.1365-3083.1991.tb03747.x; Eugui EM, 1998, SCAND J IMMUNOL, V48, P450; Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Houssiau FA, 2002, ARTHRITIS RHEUM-US, V46, P2121, DOI 10.1002/art.10461; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P39; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; POLLAK VE, 1964, J LAB CLIN MED, V63, P537; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803	23	569	629	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					971	980		10.1056/NEJMoa031855	http://dx.doi.org/10.1056/NEJMoa031855			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999109	Bronze			2022-12-28	WOS:000189363600005
J	Schett, G; Kiechl, S; Redlich, K; Oberhollenzer, F; Weger, S; Egger, G; Mayr, A; Jocher, J; Xu, QB; Pietschmann, P; Teitelbaum, S; Smolen, J; Willeit, J				Schett, G; Kiechl, S; Redlich, K; Oberhollenzer, F; Weger, S; Egger, G; Mayr, A; Jocher, J; Xu, QB; Pietschmann, P; Teitelbaum, S; Smolen, J; Willeit, J			Soluble RANKL and risk of nontraumatic fracture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; POSTMENOPAUSAL WOMEN; HIP FRACTURE; VERTEBRAL FRACTURE; BONE-DENSITY; ELDERLY-MEN; OSTEOPOROSIS; REGRESSION; ACTIVATION	Context The receptor activator of nuclear factor kappaB ligand (RANKL) is essential for osteoclast and, possibly, osteoblast activation and may represent a key link between bone formation and resorption. Objective To determine the relationship between serum level of RANKL and the risk of nontraumatic fracture. Design, Setting, and Participants As part of a prospective population-based study conducted in Bruneck, Italy, we recorded all fractures that occurred between 1990 and 2000 in 906 participants and classified them as traumatic (n=115) or nontraumatic (n=31). Serum levels of RANKL and osteoprotegerin and characteristics of bone metabolism and lifestyle were assessed in 1990 and at follow-up in 1995 and 2000. Main Outcome Measure Incident nontraumatic fracture by levels of RANKL. Results Levels of RANKL did not differ between sexes and were not related to age, menopausal status, lifestyle characteristics, or data from bone ultrasound at the heel. However, RANKL emerged as a significant predictor of nontraumatic fracture. in pooled logistic regression analysis, the relative risks of nontraumatic fracture in the lowest and middle vs highest tertile for RANKL were 10.0 (95% confidence interval [CI], 2.3-43.1) and 3.9 (95% CI, 0.8-19.0) (P<.001 for trend), respectively. Patients in the highest-tertile group had a low risk of fracture even in the presence of other predisposing factors, whereas women aged 60 years or older in the lowest tertile had a 5-year rate of nontraumatic fracture greater than 7%. Conclusions A low level of RANKL is an independent predictor of nontraumatic fracture. This finding is consistent with the hypothesis of an important role of RANKL in human bone turnover and if confirmed in future investigations may gain relevance for assessment of fracture risk.	Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria; Univ Vienna, Dept Pathophysiol, Vienna, Austria; Univ Clin Innsbruck, Dept Neurol, Innsbruck, Austria; Bruneck Hosp, Dept Internal Med, Brunico, Italy; Bruneck Hosp, Dept Lab Med, Brunico, Italy; Bruneck Hosp, Dept Radiol, Brunico, Italy; Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Vienna; University of Vienna; Medical University of Innsbruck; St Georges University London; Washington University (WUSTL)	Schett, G (corresponding author), Univ Vienna, Dept Internal Med 3, Div Rheumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	georg.schett@akh-wien.ac.at		Teitelbaum, Steven/0000-0002-4054-6679				Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Chapurlat RD, 2000, BONE, V27, P283, DOI 10.1016/S8756-3282(00)00325-2; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hannan MT, 2000, J BONE MINER RES, V15, P710, DOI 10.1359/jbmr.2000.15.4.710; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAM J, 2001, J BONE MINER RES  S1, V16, P1053; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mundy GR, 1999, PRIMER METABOLIC BON, P30, DOI DOI 10.1080/10255840802136150; Salmen T, 2000, J BONE MINER RES, V15, P2479, DOI 10.1359/jbmr.2000.15.12.2479; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITHBINDMAN R, 1991, J BONE MINER RES, V6, P25; Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502; Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; 2000, NIH CONSENS STATEMEN, V17, P1	28	127	134	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1108	1113		10.1001/jama.291.9.1108	http://dx.doi.org/10.1001/jama.291.9.1108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996780	Bronze			2022-12-28	WOS:000189348900028
J	Froberg, MK; Dannen, D; Bakken, JS				Froberg, MK; Dannen, D; Bakken, JS			Babesiosis and HIV	LANCET			English	Editorial Material									Univ Minnesota, Duluth Sch Med, Dept Pathol, Duluth, MN 55812 USA; Univ Minnesota, Duluth Sch Med, Dept Lab Med, Duluth, MN 55812 USA; Univ Minnesota, Duluth Sch Med, Dept Med Microbiol & Immunol, Duluth, MN 55812 USA; Univ Minnesota, Duluth Sch Med, St Lukes Hosp, Dept Infect Dis, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth	Froberg, MK (corresponding author), Univ Minnesota, Duluth Sch Med, Dept Pathol, Duluth, MN 55812 USA.	kfroberg@d.umn.edu						BENEZRA D, 1987, ANN INTERN MED, V107, P944, DOI 10.7326/0003-4819-107-6-944_1; FALGAS ME, 1996, CLIN INFECT DIS, V22, P809; Krause PJ, 1998, NEW ENGL J MED, V339, P160, DOI 10.1056/NEJM199807163390304; ONG KR, 1990, LANCET, V336, P112, DOI 10.1016/0140-6736(90)91624-J; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992	5	17	18	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					704	704		10.1016/S0140-6736(04)15645-6	http://dx.doi.org/10.1016/S0140-6736(04)15645-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001329				2022-12-28	WOS:000189266900012
J	Ruby, E; Henderson, B; McFall-Ngai, M				Ruby, E; Henderson, B; McFall-Ngai, M			Microbiology - We get by with a little help from our (little) friends	SCIENCE			English	Editorial Material									Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA; UCL, Cellular Microbiol Res Grp, London WC1X 8LD, England	University of Hawaii System; University of London; University College London	McFall-Ngai, M (corresponding author), Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA.	mcfallng@hawaii.edu						Blaser MJ, 2002, JNCI-J NATL CANCER I, V94, P1662; Darveau RP, 2003, ASM NEWS, V69, P186; Marie C, 2003, MOL PLANT MICROBE IN, V16, P743, DOI 10.1094/MPMI.2003.16.9.743; Relman DA, 2001, TRENDS MICROBIOL, V9, P206, DOI 10.1016/S0966-842X(01)02041-8; Whitfield J, 2003, NATURE, V423, P583, DOI 10.1038/423583a; Xu J, 2003, P NATL ACAD SCI USA, V100, P10452, DOI 10.1073/pnas.1734063100; 2003, INFLUENCE BENEFICIAL	8	50	50	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1305	1307		10.1126/science.1094662	http://dx.doi.org/10.1126/science.1094662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988540				2022-12-28	WOS:000189238600026
J	Folkman, J; Kalluri, R				Folkman, J; Kalluri, R			Cancer without disease	NATURE			English	Editorial Material							ANGIOGENESIS		Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Ctr Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Folkman, J (corresponding author), Childrens Hosp, Dept Surg, Boston, MA 02115 USA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X				BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com	5	396	419	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	2004	427	6977					787	787		10.1038/427787a	http://dx.doi.org/10.1038/427787a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985739	Bronze			2022-12-28	WOS:000189207500019
J	McCormack, MP; Rabbitts, TH				McCormack, MP; Rabbitts, TH			Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; LIM-PROTEIN RBTN2; HEMATOPOIETIC STEM-CELLS; CYSTEINE-RICH PROTEIN; ZINC-FINGER PROTEIN; LOOP-HELIX PROTEIN; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; TRANSGENIC MICE		Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Melbourne, Vic, Australia; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Royal Melbourne Hospital; MRC Laboratory Molecular Biology	McCormack, MP (corresponding author), Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Melbourne, Vic, Australia.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Akashi K, 1999, INT J HEMATOL, V69, P217; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BURNETT RC, 1991, GENE CHROMOSOME CANC, V3, P461, DOI 10.1002/gcc.2870030608; Check E, 2003, NATURE, V421, P678, DOI 10.1038/421678b; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CORNETTA K, 1991, HUM GENE THER, V2, P5, DOI 10.1089/hum.1991.2.1-5; Drynan LF, 2001, ONCOGENE, V20, P4412, DOI 10.1038/sj.onc.1204538; DUBE ID, 1991, BLOOD, V78, P2996; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GARCIA IS, 1991, ONCOGENE, V6, P577; GRAY DA, 1991, CANCER INVEST, V9, P295; GREAVES MF, 1991, LEUKEMIA, V5, P819; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hansen-Hagge TE, 2002, LEUKEMIA, V16, P2205, DOI 10.1038/sj.leu.2402671; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Karawajew L, 2000, BLOOD, V96, P297, DOI 10.1182/blood.V96.1.297.013k24_297_306; KARLSSON O, 1990, NATURE, V344, P89; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANDO Z, 1983, NATURE, V305, P733, DOI 10.1038/305733a0; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEONARD WJ, 1994, ADV EXP MED BIOL, V365, P225; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; NEALE GAM, 1995, BLOOD, V86, P3060; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shen HF, 2003, J VIROL, V77, P1584, DOI 10.1128/JVI.77.2.1584-1588.2003; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki T, 2002, NAT GENET, V32, P331; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	88	217	245	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					913	922		10.1056/NEJMra032207	http://dx.doi.org/10.1056/NEJMra032207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985489				2022-12-28	WOS:000189197300010
J	Cheng, Y; Zak, O; Alsen, P; Harrison, SC; Walz, T				Cheng, Y; Zak, O; Alsen, P; Harrison, SC; Walz, T			Structure of the human transferrin receptor-transferrin complex	CELL			English	Article							HEMOCHROMATOSIS PROTEIN HFE; INDUCED CONFORMATIONAL-CHANGE; IRON RELEASE; C-LOBE; CRYSTAL-STRUCTURE; MONOFERRIC-TRANSFERRINS; ELECTRON-MICROSCOPY; MUTATIONAL ANALYSIS; ERYTHROID-CELLS; LIGAND-BINDING	Iron, insoluble as free Fe3+ and toxic as free Fe2+, is distributed through the body as Fe3+ bound to transferrin (Tf) for delivery to cells by endocytosis of its complex with transferrin receptor (TfR). Although much is understood of the transferrin endocytotic cycle, little has been uncovered of the molecular details underlying the formation of the receptor-transferrin complex. Using cryo-electron microscopy, we have produced a density map of the TfR-Tf complex at subnanometer resolution. An atomic model, obtained by fitting crystal structures of diferric Tf and the receptor ectodomain into the map, shows that the Tf N-lobe is sandwiched between the membrane and the TfR ectodomain and that the C-lobe abuts the receptor helical domain. When Tf binds receptor, its N-lobe moves by about 9 Angstrom with respect to its C-lobe. The structure of TfR-Tf complex helps account for known differences in the iron-release properties of free and receptor bound Tf.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Walz, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	twalz@hms.harvard.edu		Cheng, Yifan/0000-0001-9535-0369; Walz, Thomas/0000-0003-2606-2835	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15056] Funding Source: Medline; NIGMS NIH HHS [GM62580] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BALDWIN DA, 1981, BIOCHEM BIOPH RES CO, V99, P1101, DOI 10.1016/0006-291X(81)90732-4; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bomford A, 2002, LANCET, V360, P1673, DOI 10.1016/S0140-6736(02)11607-2; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; CHAHINE JMEH, 1995, EUR J BIOCHEM, V230, P1102, DOI 10.1111/j.1432-1033.1995.tb20661.x; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; Crichton R., 2001, INORGANIC BIOCH IRON; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; Enns C.A., 1996, BIOMEMBRANE, V4, P255, DOI [10.1016/S1874-5342(96)80012-2, DOI 10.1016/S1874-5342(96)80012-2]; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; GIANNETTI AM, 2003, MECH MULTIPLE LIGAND; Grigorieff N, 2000, ACTA CRYSTALLOGR D, V56, P1270, DOI 10.1107/S0907444900009549; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Halbrooks PJ, 2003, BIOCHEMISTRY-US, V42, P3701, DOI 10.1021/bi027071q; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Jameson GB, 1998, ACTA CRYSTALLOGR D, V54, P1319, DOI 10.1107/S0907444998004417; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; KRETCHMAR SA, 1988, INORG CHEM, V27, P1436, DOI 10.1021/ic00281a028; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; LIM BC, 1987, J COMP PHYSIOL B, V157, P363, DOI 10.1007/BF00693363; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Mason A B, 1991, Protein Expr Purif, V2, P214, DOI 10.1016/1046-5928(91)90074-S; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Nick H, 2003, CURR MED CHEM, V10, P1065, DOI 10.2174/0929867033457610; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; RAWAS A, 1989, J MOL BIOL, V208, P213, DOI 10.1016/0022-2836(89)90100-9; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048; Wong JS, 2003, J IMMUNOL, V171, P867, DOI 10.4049/jimmunol.171.2.867; Zak O, 2003, BIOCHEMISTRY-US, V42, P12330, DOI 10.1021/bi034991f; Zak O, 2002, BIOCHEMISTRY-US, V41, P1647, DOI 10.1021/bi015868w; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; ZAK O, 1994, J BIOL CHEM, V269, P7110	55	379	395	7	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					565	576		10.1016/S0092-8674(04)00130-8	http://dx.doi.org/10.1016/S0092-8674(04)00130-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980223	Bronze			2022-12-28	WOS:000189184200010
J	Liu, L; Yan, Y; Zeng, M; Zhang, J; Hanes, MA; Ahearn, G; McMahon, TJ; Dickfeld, T; Marshall, HE; Que, LG; Stamler, JS				Liu, L; Yan, Y; Zeng, M; Zhang, J; Hanes, MA; Ahearn, G; McMahon, TJ; Dickfeld, T; Marshall, HE; Que, LG; Stamler, JS			Essential roles of S-nitrosothiols in vascular horneostasis and endotoxic shock	CELL			English	Article							NITRIC-OXIDE SYNTHASE; DEPENDENT FORMALDEHYDE DEHYDROGENASE; NITROSATIVE STRESS; ALCOHOL-DEHYDROGENASE; MICE LACKING; BLOOD-PRESSURE; ORGAN FAILURE; SEPTIC SHOCK; NITROSYLATION; SEPSIS	The current perspective of NO biology is formulated predominantly from studies of NO synthesis. The role of S-nitrosothiol (SNO) formation and turnover in governing NO-related bioactivity remains uncertain. We generated mice with a targeted gene deletion of S-nitrosoglutathione reductase (GSNOR), and show that they exhibit substantial increases in whole-cell S-nitrosylation, tissue damage, and mortality following endotoxic or bacterial challenge. Further, GSNOR(-/-) mice have increased basal levels of SNOs in red blood cells and are hypotensive under anesthesia. Thus, SNOs regulate innate immune and vascular function, and are cleared actively to ameliorate nitrosative stress. Nitrosylation of cysteine thiols is a critical mechanism of NO function in both health and disease.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Pulm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Lab Anim Resources, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	staml001@mc.duke.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223; Stamler, Jonathan/0000-0002-6866-1572				Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; CIRILLO M, 1992, HYPERTENSION, V20, P319, DOI 10.1161/01.HYP.20.3.319; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; de Jesus-Berrios M, 2003, CURR BIOL, V13, P1963, DOI 10.1016/j.cub.2003.10.029; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Didion SP, 2002, CIRC RES, V91, P938, DOI 10.1161/01.RES.0000043280.65241.04; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Feihl F, 2001, PHARMACOL THERAPEUT, V91, P179, DOI 10.1016/S0163-7258(01)00155-3; Foglio MH, 1996, EUR J BIOCHEM, V237, P496, DOI 10.1111/j.1432-1033.1996.0496k.x; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gonzalez-Alonso J, 2002, CIRC RES, V91, P1046, DOI 10.1161/01.RES.0000044939.73286.E2; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hausladen A, 1999, METHOD ENZYMOL, V300, P389; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jourd'heuil D, 2000, BIOCHEM BIOPH RES CO, V273, P22, DOI 10.1006/bbrc.2000.2892; Kirima K, 2003, AM J PHYSIOL-HEART C, V285, pH589, DOI 10.1152/ajpheart.01010.2002; Kluge I, 1997, J NEUROCHEM, V69, P2599; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Milsom AB, 2002, DIABETOLOGIA, V45, P1515, DOI 10.1007/s00125-002-0956-9; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nicholson SC, 1999, J SURG RES, V86, P198, DOI 10.1006/jsre.1999.5715; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Ortiz PA, 2003, AM J PHYSIOL-REG I, V284, pR628, DOI 10.1152/ajpregu.00401.2002; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; Rizzo MA, 2003, J CELL BIOL, V161, P243, DOI 10.1083/jcb.200301063; Rodriguez J, 2003, P NATL ACAD SCI USA, V100, P336, DOI 10.1073/pnas.0234600100; Romeo AA, 2003, J AM CHEM SOC, V125, P14370, DOI 10.1021/ja0289752; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1999, CORONARY ARTERY DIS, V10, P273, DOI 10.1097/00019501-199907000-00001; Stoll M, 2001, SCIENCE, V294, P1723, DOI 10.1126/science.1062117; Travis MD, 1997, AM J PHYSIOL-HEART C, V273, pH1493, DOI 10.1152/ajpheart.1997.273.3.H1493; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uotila L, 1997, ADV EXP MED BIOL, V414, P365; UOTILA L, 1989, GLUTATHIONE CHEM B A, P517; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021; Zunic G, 1999, J CHROMATOGR B, V727, P73, DOI 10.1016/S0378-4347(99)00054-7	68	445	475	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					617	628		10.1016/S0092-8674(04)00131-X	http://dx.doi.org/10.1016/S0092-8674(04)00131-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980227	Bronze			2022-12-28	WOS:000189184200014
J	Hackermuller, L; Hornberger, K; Brezger, B; Zeilinger, A; Arndt, M				Hackermuller, L; Hornberger, K; Brezger, B; Zeilinger, A; Arndt, M			Decoherence of matter waves by thermal emission of radiation	NATURE			English	Article							C-60; PHOTON; FRAGMENTATION; COHERENCE	Emergent quantum technologies have led to increasing interest in decoherence - the processes that limit the appearance of quantum effects and turn them into classical phenomena. One important cause of decoherence is the interaction of a quantum system with its environment, which 'entangles' the two and distributes the quantum coherence over so many degrees of freedom as to render it unobservable. Decoherence theory(1-4) has been complemented by experiments using matter waves coupled to external photons(5-7) or molecules(8), and by investigations using coherent photon states(9), trapped ions(10) and electron interferometers(11,12). Large molecules are particularly suitable for the investigation of the quantum-classical transition because they can store much energy in numerous internal degrees of freedom; the internal energy can be converted into thermal radiation and thus induce decoherence. Here we report matter wave interferometer experiments in which C-70 molecules lose their quantum behaviour by thermal emission of radiation. We find good quantitative agreement between our experimental observations and microscopic decoherence theory. Decoherence by emission of thermal radiation is a general mechanism that should be relevant to all macroscopic bodies.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria	University of Vienna	Arndt, M (corresponding author), Univ Vienna, Inst Expt Phys, Strudlhofgasse 4, A-1090 Vienna, Austria.	markus.arndt@univie.ac.at	Arndt, Markus/P-3852-2019; Arndt, Markus/A-4571-2012; Hornberger, Klaus/B-6059-2008; Zeilinger, Anton/A-1170-2011	Arndt, Markus/0000-0002-9487-4985; Arndt, Markus/0000-0002-9487-4985; Hornberger, Klaus/0000-0002-3145-1117; Hackermueller, Lucia/0000-0001-9880-2914				Arndt M, 1999, NATURE, V401, P680, DOI 10.1038/44348; Brezger B, 2003, J OPT B-QUANTUM S O, V5, pS82, DOI 10.1088/1464-4266/5/2/362; Brezger B, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.100404; Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; Buks E, 1998, NATURE, V391, P871, DOI 10.1038/36057; CHAPMAN MS, 1995, PHYS REV LETT, V75, P3783, DOI 10.1103/PhysRevLett.75.3783; Clauser J., 1997, EXPT METAPHYSICS, P1; CLAUSER JF, 1994, PHYS REV A, V49, pR2213, DOI 10.1103/PhysRevA.49.R2213; Coheur PF, 1996, J PHYS B-AT MOL OPT, V29, P4987, DOI 10.1088/0953-4075/29/21/013; DING D, 1994, PHYS REV LETT, V73, P1084, DOI 10.1103/PhysRevLett.73.1084; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Hackermuller L, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.090408; Hansen K, 1997, PHYS REV LETT, V78, P2337, DOI 10.1103/PhysRevLett.78.2337; Hansen K, 1998, PHYS REV E, V58, P5477, DOI 10.1103/PhysRevE.58.5477; Heszler P, 1997, J CHEM PHYS, V107, P10440, DOI 10.1063/1.474208; Hornberger K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.160401; IMRY Y, 2000, INTRO MESOSCOPIC PHY; Ji Y, 2003, NATURE, V422, P415, DOI 10.1038/nature01503; JOOS E, 1985, Z PHYS B CON MAT, V59, P223, DOI 10.1007/BF01725541; Joos E., 2003, DECOHERENCE APPEARAN; Kokorowski DA, 2001, PHYS REV LETT, V86, P2191, DOI 10.1103/PhysRevLett.86.2191; KOLODNEY E, 1995, J CHEM PHYS, V102, P9263, DOI 10.1063/1.469235; Matt S, 1999, CHEM PHYS LETT, V303, P379, DOI 10.1016/S0009-2614(99)00223-7; MITZNER R, 1995, J CHEM PHYS, V103, P2445, DOI 10.1063/1.469667; Nairz O, 2000, J MOD OPTIC, V47, P2811, DOI 10.1080/095003400750039717; PATORSKI K, 1989, PROG OPTICS, V27, P1, DOI 10.1016/S0079-6638(08)70084-2; PFAU T, 1994, PHYS REV LETT, V73, P1223, DOI 10.1103/PhysRevLett.73.1223; Zurek WH, 2003, REV MOD PHYS, V75, P715, DOI 10.1103/RevModPhys.75.715; [No title captured]	30	228	231	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					711	714		10.1038/nature02276	http://dx.doi.org/10.1038/nature02276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973478	Green Submitted			2022-12-28	WOS:000189026000036
J	Rozen, TD				Rozen, TD			Migraine prodrome: a nose on a face	LANCET			English	Editorial Material									Michigan Head Pain & Neurol Inst, Ann Arbor, MI 48104 USA		Rozen, TD (corresponding author), Michigan Head Pain & Neurol Inst, Ann Arbor, MI 48104 USA.								0	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					517	517		10.1016/S0140-6736(04)15537-2	http://dx.doi.org/10.1016/S0140-6736(04)15537-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975613				2022-12-28	WOS:000188999900008
J	Schroter, S; Morris, J; Chaudhry, S; Smith, R; Barratt, H				Schroter, S; Morris, J; Chaudhry, S; Smith, R; Barratt, H			Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial	BRITISH MEDICAL JOURNAL			English	Article									BMJ Editorial Off, London WC1H 9JR, England; Wythenshawe Hosp, Educ & Res Ctr, Dept Med Stat, Manchester M23 9LT, Lancs, England; N Staffordshire Univ Hosp, Stoke On Trent ST4 7LN, Staffs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Schroter, S (corresponding author), BMJ Editorial Off, BMA House,Tavistock Sq, London WC1H 9JR, England.	sschroter@bmj.com	Schroter, Sara/G-3427-2012	Schroter, Sara/0000-0002-8791-8564				Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Chaudhry S, 2002, BRIT MED J, V325, P1391, DOI 10.1136/bmj.325.7377.1391; COPLAN PM, 2000, BMJ; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247	5	67	67	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					742	743		10.1136/bmj.38035.705185.F6	http://dx.doi.org/10.1136/bmj.38035.705185.F6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	14980983	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220666300016
J	Hegarty, K; Gunn, J; Chondros, P; Small, R				Hegarty, K; Gunn, J; Chondros, P; Small, R			Association between depression and abuse by partners of women attending general practice: descriptive, cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; POSTNATAL DEPRESSION; DOMESTIC VIOLENCE; HEALTH; SCALE; VALIDATION; METAANALYSIS; COMMUNITY; SAMPLE	Objective To explore the association between depression and physical, emotional, and sexual abuse by partners or ex-partners of women attending general practice. Design Descriptive, cross sectional survey. Setting 30 general practitioners in Victoria, Australia. Participants 1257 consecutive female patients. Main outcome measures Some type of abuse in an adult intimate relationship (composite abuse scale), depression (Beck depression inventory or Edinburgh postnatal depression scale), and physical health (SF-36). Results 18.0% (218/1213) of women scored as currently probably depressed and 24.1% (277/1147) had experienced some type of abuse in an adult intimate relationship. Depressed women were significantly more likely to have experienced severe combined abuse than women who were not depressed after adjusting for other significant sociodemographic variables (odds ratio 5.8, 95% confidence interval 2.8 to 12.0). These variables included not being married, having a poor education, being on a low income, being unemployed or receiving a pension, pregnancy status, or being abused as a child. Conclusion Physical, emotional, and sexual abuse are strongly associated with depression in women attending general practice. Doctors should sensitively ask depressed women about their experiences of violence and abuse in intimate relationships. Research into depression should include measures of partner abuse in longitudinal and intervention studies.	Univ Melbourne, Dept Gen Practice, Melbourne, Vic 3053, Australia; La Trobe Univ, Ctr Study Mothers & Childrens Hlth, Melbourne, Vic 3053, Australia	University of Melbourne; La Trobe University	Hegarty, K (corresponding author), Univ Melbourne, Dept Gen Practice, Melbourne, Vic 3053, Australia.	k.hegarty@unimelb.edu.au	Chondros, Patty/AAT-6426-2020	Small, Rhonda/0000-0003-0345-4676; Hegarty, Kelsey/0000-0002-7532-5147; Gunn, Jane/0000-0001-8836-7525; Chondros, Patty/0000-0003-0393-8734				BOYCE P, 1993, AUST NZ J PSYCHIAT, V27, P472, DOI 10.3109/00048679309075805; Cabral M., 2000, WOMENS MENTAL HLTH E; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; CASTLES I, 1991, INFORMATION PAPER 19; Coid J, 2003, BRIT J PSYCHIAT, V183, P332, DOI 10.1192/bjp.183.4.332; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dowrick C, 1995, FAM PRACT, V12, P461, DOI 10.1093/fampra/12.4.461; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; Hegarty K, 1999, J FAM VIOLENCE, V14, P399, DOI 10.1023/A:1022834215681; Hegarty KL, 2002, AUST NZ J PUBL HEAL, V26, P437, DOI 10.1111/j.1467-842X.2002.tb00344.x; Herrman H, 2002, PSYCHOL MED, V32, P889, DOI 10.1017/S003329170200586X; Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; MacGillivray S, 2003, BMJ-BRIT MED J, V326, P1014, DOI 10.1136/bmj.326.7397.1014; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; Roberts GL, 1998, WOMEN HEALTH, V28, P117; van Weel-Baumgarten EM, 2000, J FAM PRACTICE, V49, P1113	19	157	158	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 13	2004	328	7440					621	624		10.1136/bmj.328.7440.621	http://dx.doi.org/10.1136/bmj.328.7440.621			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803CB	15016694	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220208100020
J	Fortin, D				Fortin, D			What biogenic minerals tell us	SCIENCE			English	Editorial Material							BACTERIA		Univ Ottawa, Dept Earth Sci, Ottawa, ON K1N 6N5, Canada	University of Ottawa	Fortin, D (corresponding author), Univ Ottawa, Dept Earth Sci, 140 Louis Pasteur, Ottawa, ON K1N 6N5, Canada.	dfortin@uottawa.ca						Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; BAZYLINSKI DA, 1993, NATURE, V366, P218, DOI 10.1038/366218a0; Chan CS, 2004, SCIENCE, V303, P1656, DOI 10.1126/science.1092098; FERRIS FG, 1986, NATURE, V320, P609, DOI 10.1038/320609a0; Fortin D, 1998, AM MINERAL, V83, P1399, DOI 10.2138/am-1998-11-1229; Glasauer S, 2002, SCIENCE, V295, P117, DOI 10.1126/science.1066577; MANDERNACK KW, 1995, GEOCHIM COSMOCHIM AC, V59, P4393, DOI 10.1016/0016-7037(95)00298-E; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; Ueshima M, 2001, CLAY CLAY MINER, V49, P292, DOI 10.1346/CCMN.2001.0490403; ASTROBIOLOGY ROADMAP; [No title captured]	12	30	37	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	2004	303	5664					1618	1619		10.1126/science.1095177	http://dx.doi.org/10.1126/science.1095177			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016984				2022-12-28	WOS:000220151400027
J	Chien, K; Chien, L				Chien, K; Chien, L			The new Silk Road	NATURE			English	Editorial Material							CHINA		Univ Calif San Diego, Inst Mol Med, Salk Inst, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Chien, K (corresponding author), Univ Calif San Diego, Inst Mol Med, Salk Inst, La Jolla, CA 92093 USA.							[Anonymous], 2004, NATURE, V427, P471; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Cyranoski D, 2003, NATURE, V425, P333, DOI 10.1038/425333a; Cyranoski D, 2002, NATURE, V420, P257, DOI 10.1038/420257b	4	3	4	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					208	209		10.1038/428208a	http://dx.doi.org/10.1038/428208a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014508				2022-12-28	WOS:000220103600057
J	Coombes, RC; Hall, E; Gibson, LJ; Paridaens, R; Jassem, J; Delozier, T; Jones, SE; Alvarez, I; Bertelli, G; Ortmann, O; Coates, AS; Bajetta, E; Dodwell, D; Coleman, RE; Fallowfield, LJ; Mickiewicz, E; Andersen, J; Lonning, PE; Cocconi, G; Stewart, A; Stuart, N; Snowdon, CF; Carpentieri, M; Massimini, G; Bliss, JM				Coombes, RC; Hall, E; Gibson, LJ; Paridaens, R; Jassem, J; Delozier, T; Jones, SE; Alvarez, I; Bertelli, G; Ortmann, O; Coates, AS; Bajetta, E; Dodwell, D; Coleman, RE; Fallowfield, LJ; Mickiewicz, E; Andersen, J; Lonning, PE; Cocconi, G; Stewart, A; Stuart, N; Snowdon, CF; Carpentieri, M; Massimini, G; Bliss, JM		Intergroup Exemestane Study	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL AROMATASE INHIBITORS; SURGICAL-ADJUVANT-BREAST; ESTROGEN-RECEPTOR-ALPHA; PHASE-II; HORMONAL TREATMENT; MEGESTROL-ACETATE; ANASTROZOLE; PREVENTION; LETROZOLE; COMBINATION	BACKGROUND: Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. METHODS: We conducted a double-blind, randomized trial to test whether, after two to three years of tamoxifen therapy, switching to exemestane was more effective than continuing tamoxifen therapy for the remainder of the five years of treatment. The primary end point was disease-free survival. RESULTS: Of the 4742 patients enrolled, 2362 were randomly assigned to switch to exemestane, and 2380 to continue to receive tamoxifen. After a median follow-up of 30.6 months, 449 first events (local or metastatic recurrence, contralateral breast cancer, or death) were reported -- 183 in the exemestane group and 266 in the tamoxifen group. The unadjusted hazard ratio in the exemestane group as compared with the tamoxifen group was 0.68 (95 percent confidence interval, 0.56 to 0.82; P<0.001 by the log-rank test), representing a 32 percent reduction in risk and corresponding to an absolute benefit in terms of disease-free survival of 4.7 percent (95 percent confidence interval, 2.6 to 6.8) at three years after randomization. Overall survival was not significantly different in the two groups, with 93 deaths occurring in the exemestane group and 106 in the tamoxifen group. Severe toxic effects of exemestane were rare. Contralateral breast cancer occurred in 20 patients in the tamoxifen group and 9 in the exemestane group (P=0.04). CONCLUSIONS: Exemestane therapy after two to three years of tamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxifen treatment.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London, England; Charing Cross Hosp, London, England; Inst Canc Res, Sutton, Surrey, England; SW Wales Canc Inst, Swansea, W Glam, Wales; Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England; Weston Pk Hosp, Canc Res Ctr, Sheffield, S Yorkshire, England; Univ Sussex, Psychosocial Oncol Grp, Brighton, E Sussex, England; Christie Hosp, Manchester, Lancs, England; Ysbyty Gwynedd, Bangor, Gwynedd, Wales; Univ Hosp St Raphael, B-3000 Louvain, Belgium; Med Univ Gdansk, Gdansk, Poland; Ctr Francois Baclesse, F-14021 Caen, France; US Oncol Res, Houston, TX USA; Hosp Donostia, San Sebastian, Spain; Univ Regensburg, D-8400 Regensburg, Germany; Univ Sydney, Sydney, NSW 2006, Australia; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy; Inst Angel Roffo, Buenos Aires, DF, Argentina; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Univ Bergen, Haukeland Hosp, N-5021 Bergen, Norway; Univ Hosp, Parma, Italy; Pharmacia Italia, PfizerGrp, Nerviano, Italy	Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; Swansea University; Cookridge Hospital; Weston Park Hospital; University of Sussex; Christie NHS Foundation Trust; Christie Hospital; Fahrenheit Universities; Medical University Gdansk; UNICANCER; Centre Francois Baclesse; US Oncology Network; University Hospital Donostia; University of Regensburg; University of Sydney; Fondazione IRCCS Istituto Nazionale Tumori Milan; Aarhus University; University of Bergen; University of Parma; University Hospital of Parma; Pfizer	Coombes, RC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Hosp, 6th Fl,Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.			Hall, Emma/0000-0001-5999-5020; Steer, Christopher/0000-0002-7677-3339; Bliss, Judith/0000-0001-7957-7424; Lonning, Per Eystein/0000-0002-8890-6303; Fallowfield, Lesley/0000-0003-0577-4518; Coombes, Raoul Charles/0000-0002-4811-1100				ABE O, 1992, LANCET, V339, P71; Abram P, 1996, J NATL CANCER I, V88, P1834; Abram P, 1997, J NATL CANCER I, V89, P590; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Atalay G, 2004, ANN ONCOL, V15, P211, DOI 10.1093/annonc/mdh064; Bajetta E, 2002, ANN ONCOL, V13, P1059, DOI 10.1093/annonc/mdf083; Baum M, 2002, LANCET, V359, P2131; Baum M, 2002, LANCET, V360, P1520; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Boccardo F, 2003, BREAST CANCER RES TR, V82, pS6; Boccardo F, 2001, J CLIN ONCOL, V19, P4209, DOI 10.1200/JCO.2001.19.22.4209; Buzdar AU, 1998, CANCER-AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7; Buzdar AU, 1999, CANCER, V85, P1010; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Clarke M, 1998, LANCET, V351, P1451; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; COX DR, 1972, J R STAT SOC B, V34, P187; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Dombernowsky P, 1998, J CLIN ONCOL, V16, P453, DOI 10.1200/JCO.1998.16.2.453; Donnellan PP, 2001, J CLIN ONCOL, V19, P2767; Dowsett M, 2003, BREAST CANCER RES TR, V82, pS7; EVANS TRJ, 1992, CANCER RES, V52, P5933; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Geisler J, 1998, CLIN CANCER RES, V4, P2089; GIUDICI D, 1988, J STEROID BIOCHEM, V30, P391, DOI 10.1016/0022-4731(88)90129-X; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Goldstein SR, 2001, ANN NY ACAD SCI, V949, P237; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Hamilton A, 1999, ANN ONCOL, V10, P377, DOI 10.1023/A:1008368300827; Harper-Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; Lonning PE, 2000, J CLIN ONCOL, V18, P2234, DOI 10.1200/JCO.2000.18.11.2234; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Paridaens R, 2003, ANN ONCOL, V14, P1391, DOI 10.1093/annonc/mdg362; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645	42	1349	1401	0	48	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1081	1092		10.1056/NEJMoa040331	http://dx.doi.org/10.1056/NEJMoa040331			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014181	Green Accepted, Bronze			2022-12-28	WOS:000220110100005
J	Tso, TC				Tso, TC			Agriculture of the future	NATURE			English	Editorial Material									ARS, Natl Program Staff, USDA, Beltsville, MD 20705 USA	United States Department of Agriculture (USDA)	Tso, TC (corresponding author), ARS, Natl Program Staff, USDA, Beltsville, MD 20705 USA.							Fan Shenggen, 2002, GROWTH INEQUALITY PO; LAMPE K, VISION 2050 AGR CHIN; TSO TC, 1998, AGR CHINA, P1949; TSO TC, IN PRESS VISION 2050; *WORLD BANKS, 2003, WORLD BANKS WORLD DE	5	36	39	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					215	217		10.1038/428215a	http://dx.doi.org/10.1038/428215a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014511				2022-12-28	WOS:000220103600060
J	Coleman, T				Coleman, T			ABC of smoking cessation - Special groups of smokers	BRITISH MEDICAL JOURNAL			English	Review									Univ Nottingham Hosp, Queens Med Ctr, Sch Community Hlth Sci, Div Primary Care, Nottingham NG7 2UH, England	University of Nottingham	Coleman, T (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Sch Community Hlth Sci, Div Primary Care, Nottingham NG7 2UH, England.			Coleman, Tim/0000-0002-7303-4805				Fiore M C, 2000, Respir Care, V45, P1200; LUMLEY J, 2003, COCHRANE DATABASE SY, DOI UNSP CD001055; OWEN L, 1999, SMOKING PREGNANCY SU; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1; EFFECTIVE HLTH CARE, V5	5	21	24	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					575	577		10.1136/bmj.328.7439.575	http://dx.doi.org/10.1136/bmj.328.7439.575			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	15001509	Green Published			2022-12-28	WOS:000220091800029
J	Xu, YW; Moseley, JB; Sagot, I; Poy, F; Pellman, D; Goode, BL; Eck, MJ				Xu, YW; Moseley, JB; Sagot, I; Poy, F; Pellman, D; Goode, BL; Eck, MJ			Crystal structures of a formin homology-2 domain reveal a tethered dimer architecture	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; ARP2/3 COMPLEX; BINDING PROTEIN; CELL POLARITY; YEAST; NUCLEATION; PROFILIN; BNI1P; POLYMERIZATION	Formin proteins participate in a wide range of cytoskeletal processes in all eukaryotes. The defining feature of formins is a highly conserved similar to400 residue region, the Formin Homology-2 (FH2) domain, which has recently been found to nucleate actin filaments' Here we report crystal structures of the S. cerevesiae Bni1p FH2 domain. The mostly alpha-helical FH2 domain forms a unique "tethered dimer" in which two elongated actin binding heads are tied together at either end by an unusual lasso and linker structure. Biochemical and crystallographic observations indicate that the dimer is stable but flexible, with flexibility between the two halves of the dimer conferred by the linker segments. Although each half of the dimer is competent to interact with filament ends, the intact dimer is required for actin nucleation and processive capping. The tethered dimer architecture may allow formins to stair-step on the barbed end of an elongating nascent filament.	Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat Hematol, Boston, MA 02115 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Mol Pharmacol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Brandeis University; Brandeis University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Pellman, D (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	David_Pellman@dfci.harvard.edu; eck@red.dfci.harvard.edu			NIGMS NIH HHS [GM63691, R01 GM061345, GM61345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM061345, R01GM061345, R01GM063691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Feierbach B, 2001, CURR BIOL, V11, P1656, DOI 10.1016/S0960-9822(01)00525-5; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	36	276	280	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					711	723		10.1016/S0092-8674(04)00210-7	http://dx.doi.org/10.1016/S0092-8674(04)00210-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006353	Bronze			2022-12-28	WOS:000221499700011
J	Wu, B; Ooi, TL; He, ZJJ				Wu, B; Ooi, TL; He, ZJJ			Perceiving distance accurately by a directional process of integrating ground information	NATURE			English	Article							VISUAL-PERCEPTION; MOTION; LOCATION; VISION; SLANT; SHAPE	By itself, the absolute distance of an object cannot be accurately judged beyond 2-3 m (refs 1-3). Yet, when it is viewed with reference to a flat terrain, humans accurately judge the absolute distance of the object up to 20 m, an ability that is important for various actions(4-8). Here we provide evidence that this is accomplished by integrating local patches of ground information into a global surface reference frame. We first show that restricting an observer's visual field of view to the local ground area around the target leads to distance underestimation, indicating that a relatively wide expanse of the ground surface is required for accurate distance judgement. Second, as proof of surface integration, we show that even with the restricted view, the observer can accurately judge absolute distance by scanning local patches of the ground surface, bit by bit, from near to far, but not in the reverse direction. This finding also reveals that the surface integration process uses the near-ground-surface information as a foundation for surface representation, and extrapolation to the far ground surface around the target for accurate absolute distance computation.	Penn Coll Optometry, Dept Basic Sci, Elkins Pk, PA 19027 USA; Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA	University of Louisville	He, ZJJ (corresponding author), Penn Coll Optometry, Dept Basic Sci, 8360 Old York Rd, Elkins Pk, PA 19027 USA.	tlooi@pco.edu; zjhe@louisville.edu			NATIONAL EYE INSTITUTE [R01EY014821] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY014821] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRAUNSTEIN ML, 1968, J EXP PSYCHOL, V78, P247, DOI 10.1037/h0026269; Dolezal H., 1982, LIVING WORLD TRANSFO; FREEMAN RB, 1965, PSYCHOL REV, V72, P501, DOI 10.1037/h0022614; GIBSON JJ, 1952, J EXP PSYCHOL, V44, P11, DOI 10.1037/h0060729; GIBSON JJ, 1950, AM J PSYCHOL, V63, P367, DOI 10.2307/1418003; Gibson JJ, 1950, PERCEPTION VISUAL WO; GOGEL WC, 1979, VISION RES, V19, P1161, DOI 10.1016/0042-6989(79)90013-0; HAGEN MA, 1978, PERCEPT PSYCHOPHYS, V23, P326, DOI 10.3758/BF03199716; Land MF, 1999, J COMP PHYSIOL A, V185, P341, DOI 10.1007/s003590050393; LAND MF, 1982, J EXP BIOL, V96, P427; Loomis JM, 1999, PERCEPT PSYCHOPHYS, V61, P397, DOI 10.3758/BF03211961; Loomis JM, 2003, VIRTUAL AND ADAPTIVE ENVIRONMENTS: APPLICATIONS, IMPLICATIONS, AND HUMAN PERFORMANCE ISSUES, P21; Loomis JM, 2002, J EXP PSYCHOL HUMAN, V28, P1202, DOI 10.1037//0096-1523.28.5.1202; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; Loomis JM, 1996, CURR DIR PSYCHOL SCI, V5, P72, DOI 10.1111/1467-8721.ep10772783; Meng JC, 2001, PERCEPT PSYCHOPHYS, V63, P1, DOI 10.3758/BF03200497; Ooi TL, 2001, NATURE, V414, P197, DOI 10.1038/35102562; Philbeck JW, 1997, J EXP PSYCHOL HUMAN, V23, P72, DOI 10.1037/0096-1523.23.1.72; RIESER JJ, 1990, PERCEPTION, V19, P675, DOI 10.1068/p190675; Sedgwick H. A., 1986, HDB PERCEPTION HUMAN, V1; Sinai MJ, 1998, NATURE, V395, P497, DOI 10.1038/26747; THOMSON JA, 1983, J EXP PSYCHOL HUMAN, V9, P427, DOI 10.1037/0096-1523.9.3.427	22	190	195	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					73	77		10.1038/nature02350	http://dx.doi.org/10.1038/nature02350			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999282				2022-12-28	WOS:000189363800037
J	Adams, KM; Nelson, JL				Adams, KM; Nelson, JL			Microchimerism - An investigative frontier in autoimmunity and transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYSTEMIC-SCLEROSIS; QUANTITATIVE-ANALYSIS; FETAL MICROCHIMERISM; ANTIGENS; DISEASE; WOMEN; CELLS; SURVIVAL; ORIGIN; DNA	Recent studies indicate cells transfer between fetus and mother during pregnancy and can persist in both decades later. The presence within one individual of a small population of cells from another genetically distinct individual is referred to as microchimerism. Naturally acquired microchimerism has recently been investigated in autoimmune diseases, including scleroderma, thyroiditis, primary biliary cirrhosis, Sjogren syndrome, systemic lupus, dermatomyositis, and neonatal lupus. latrogenic chimerism has been investigated in transplantation and following blood transfusion. Considering findings of naturally acquired microchimerism along with iatrogenic microchimerism suggests microchimerism can have detrimental and/or beneficial effects in both settings. Recent identification of tissue-specific microchimerism either from naturally acquired or iatrogenic microchimerism (eg, cardiac myocytes) raises the possibility that microchimerism can be a target of autoimmunity or alternatively contribute to tissue repair. Advances in this new frontier of research with varied and numerous implications for human health are summarized.	Fred Hutchinson Canc Res Ctr, Program Human Immunogenet, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med Rheumatol, Seattle, WA USA; Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nelson, JL (corresponding author), Fred Hutchinson Canc Res Ctr, Program Human Immunogenet, Div Clin Res, D2-100,1100 Fairview Ave N, Seattle, WA 98109 USA.	jbracken@fhcrc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041721, R01AI045659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048084] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-41721, AI-45659] Funding Source: Medline; NIAMS NIH HHS [AR-48084] Funding Source: Medline; NICHD NIH HHS [HD-01264] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams KM, 2003, BLOOD, V102, P3845, DOI 10.1182/blood-2003-05-1570; Ando T, 2002, J CLIN ENDOCR METAB, V87, P3315, DOI 10.1210/jc.87.7.3315; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Burlingham WJ, 1998, NEW ENGL J MED, V339, P1657, DOI 10.1056/NEJM199812033392302; Christner PJ, 2000, ARTHRITIS RHEUM, V43, P2598, DOI 10.1002/1529-0131(200011)43:11<2598::AID-ANR30>3.0.CO;2-8; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; Klintschar M, 2001, J CLIN ENDOCR METAB, V86, P2494, DOI 10.1210/jc.86.6.2494; LABERT NC, IN PRESS ARTHRITIS R; Lee TH, 1999, BLOOD, V93, P3127; Lo YMD, 2000, CLIN CHEM, V46, P1301; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; Nelson JL, 2003, AUTOIMMUNITY, V36, P5, DOI 10.1080/0891693031000067304; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; Ohtsuka T, 2001, ARCH DERMATOL RES, V293, P387, DOI 10.1007/s004030100245; Parikh-Patel A, 2002, ANN EPIDEMIOL, V12, P264, DOI 10.1016/S1047-2797(01)00277-0; Perreault C, 1998, IMMUNOL TODAY, V19, P69, DOI 10.1016/S0167-5699(97)01185-7; Reed AM, 2000, LANCET, V356, P2156, DOI 10.1016/S0140-6736(00)03500-5; Scaletti C, 2002, ARTHRITIS RHEUM, V46, P445, DOI 10.1002/art.10049; Shimazaki C, 2003, BLOOD, V101, P3334, DOI 10.1182/blood-2002-09-2883; Srivatsa B, 2001, LANCET, V358, P2034, DOI 10.1016/S0140-6736(01)07099-4; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; Stevens AM, 2003, LANCET, V362, P1617, DOI 10.1016/S0140-6736(03)14795-2; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; van Rood JJ, 2002, BLOOD, V99, P1572, DOI 10.1182/blood.V99.5.1572; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704	26	148	159	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1127	1131		10.1001/jama.291.9.1127	http://dx.doi.org/10.1001/jama.291.9.1127			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996783				2022-12-28	WOS:000189348900031
J	Crowley, WF; Sherwood, L; Salber, P; Scheinberg, D; Slavkin, H; Tilson, H; Reece, EA; Catanese, V; Johnson, SB; Dobs, A; Genel, M; Korn, A; Reame, N; Bonow, R; Grebb, J; Rimoin, D				Crowley, WF; Sherwood, L; Salber, P; Scheinberg, D; Slavkin, H; Tilson, H; Reece, EA; Catanese, V; Johnson, SB; Dobs, A; Genel, M; Korn, A; Reame, N; Bonow, R; Grebb, J; Rimoin, D			Clinical research in the United States at a crossroads - Proposal for a novel public-private partnership to establish a National Clinical Research Enterprise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; CHALLENGES; SCIENCE	The clinical research infrastructure of the United States is currently at a critical crossroads. To leverage the enormous biomedical research gains made in the past century efficiently, a drastic need exists to reengineer this system into a coordinated, safe, and more efficient and effective enterprise. To accomplish this task, clinical research must be transformed from its current state as a cottage industry to an enterprise-wide health care pipeline whose function is to bring the novel research from both government and private entities to the US public. We propose the establishment of a unique public-private partnership termed the National Clinical Research Enterprise (NCRE). Its agenda should consist of informed public participation, supportive information technologies, a skilled workforce, and adequate funding in clinical research. Devoting only 0.25% of the budgets from all health care stakeholders to support the NCRE would permit adequate funding to build the infrastructure required to address these problems in an enterprise fashion. All participants in the US health care delivery system must come together to focus on system-wide improvements that will benefit the public.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA; Ltd Liabil Corp, Med & Sci Associates, Lower Gwynedd, PA USA; Blue Shield Calif, San Francisco, CA USA; Univ So Calif, Sch Dent, Los Angeles, CA 90089 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NYU, Sch Med, New York, NY USA; Columbia Univ, New York, NY USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA; Univ Arkansas, Coll Med, Little Rock, AR 72205 USA; Johns Hopkins Univ, Baltimore, MD USA; Yale Univ, Sch Med, Woodbridge, CT USA; Blue Cross Blue Shield Assoc, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA; Janssen Res Fdn, Titusville, NJ USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Southern California; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Memorial Sloan Kettering Cancer Center; New York University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Johns Hopkins University; Yale University; Northwestern University; Feinberg School of Medicine; University of Michigan System; University of Michigan; Johnson & Johnson; Johnson & Johnson USA	Crowley, WF (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, BHX 511,55 Fruit St, Boston, MA 02114 USA.	crowley.william@mgh.harvard.edu		Johnson, Stephen/0000-0002-6079-8419				*ASS AM MED COLL, 2003, INF TECHN EN CLIN RE; Bloom FE, 2003, SCIENCE, V300, P1680, DOI 10.1126/science.1085535; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; DeAngelis CD, 2003, JAMA-J AM MED ASSOC, V289, P1492, DOI 10.1001/jama.289.12.1492; DOBSON A, 2000, FINANCIAL PERFORMANC; Friesen HG, 1999, CLIN INVEST MED, V22, P119; Genel M, 2003, J INVEST MED, V51, P64, DOI 10.1136/jim-51-02-07; *I MED, 2003, EXPL CHALL PROGR MOD; *I MED, 2002, ROL PURCH PAYERS CLI; Institute of Medicine, 2001, CROSSING QUALITY CHA; Korn D, 2002, SCIENCE, V296, P1401, DOI 10.1126/science.1072486; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MILLS RJ, 2002, HLTH INSURANCE COVER; *NAT RES COUNC I M, 2003, ENH VIT NAT I HLTH O; Rosenberg RN, 2003, JAMA-J AM MED ASSOC, V289, P1305, DOI 10.1001/jama.289.10.1305; Saiber PR, 2002, J INVEST MED, V50, P170, DOI 10.2310/6650.2002.33429; SCOTT JS, 2003, HLTH FINANC MANAGE, V57, P30; Sherwood L, 2002, ROY SOC MED INT CONG, V252, P49; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; THOMPSON T, HLTH CARE INFORMATIO; Tilson H, 2003, J INVEST MED, V51, P72, DOI 10.1136/jim-51-02-08; US Department of Health and Human Services, 2000, NIH PUBL; Wood A, 2001, CHEM WEEK, V163, P24	25	90	93	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1120	1126		10.1001/jama.291.9.1120	http://dx.doi.org/10.1001/jama.291.9.1120			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996782				2022-12-28	WOS:000189348900030
J	Rivers, JK				Rivers, JK			Is there more than one road to melanoma?	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; A RADIATION PUVA; MELANOCYTIC NEVI; MELANOCORTIN-1 RECEPTOR; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; SUN EXPOSURE; BASAL-CELL; RED HAIR; SUNSCREEN APPLICATION	Context Sunlight is the main environmental cause of most cutaneous melanomas. Exposure to intense bursts of ultraviolet radiation, especially in childhood, starts the transformation of benign melanocytes into a malignant phenotype. Paradoxically, outdoor workers have a decreased risk, of melanoma compared with indoor workers, suggesting that chronic sunlight exposure can have a protective effect. Further, some melanomas form on sun-exposed regions; others do not. Although some melanomas arise from pre-existing melanocytic naevi (moles), many arise de novo. These observations suggest that melanoma arises from multiple pathways, with initiating and promoting factors differing for each. Starting point Janet Maldonado and colleagues recently studied the distribution of BRAF gene mutations in 115 patients with invasive primary melanomas (J Natl Cancer Inst 2003; 95: 1878-80). These researchers found that BRAF mutations were statistically significantly more common in melanomas occurring on intermittently sun-exposed skin than elsewhere. By contrast, BRAF mutations in melanomas on chronically sun-damaged skin were rare. These findings strongly suggest that distinct genetic pathways lead to melanoma. Where next? The study of gene-environment interactions is clearly the next arena for epidemiological research into melanoma. The recent identification of polymorphisms in the melanocortin-1 receptor could open up an avenue of investigation into a molecular distinction between those individuals whose melanomas arise on chronic sun-exposed skin from those in whom tumours will develop on sun-protected skin or from melanocytic naevi. If a dual pathway for melanoma is supported by other investigations, public-health messages can be tailored to the population at risk.	Univ British Columbia, Div Dermatol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Vancouver, BC, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	University of British Columbia; University of British Columbia; British Columbia Cancer Agency	Rivers, JK (corresponding author), Skin Care Ctr, 835 W 10th Ave, Vancouver, BC V5Z 4E8, Canada.	jrivers@interchange.ubc.ca						Bauer J, 2003, PIGM CELL RES, V16, P297, DOI 10.1034/j.1600-0749.2003.00047.x; Bevona C, 2002, DERMATOL CLIN, V20, P589, DOI 10.1016/S0733-8635(02)00037-2; Bevona C, 2003, ARCH DERMATOL, V139, P1620, DOI 10.1001/archderm.139.12.1620; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Boyd AS, 2002, J AM ACAD DERMATOL, V46, P706, DOI 10.1067/mjd.2002.120467; Darlington S, 2003, ARCH DERMATOL, V139, P451, DOI 10.1001/archderm.139.4.451; de Vries E, 2003, INT J CANCER, V107, P119, DOI 10.1002/ijc.11360; Diffey B, 2001, J PHOTOCH PHOTOBIO B, V64, P105, DOI 10.1016/S1011-1344(01)00195-6; Elwood JM, 1996, SEMIN ONCOL, V23, P650; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; EVANS RD, 1988, J DERMATOL SURG ONC, V14, P393, DOI 10.1111/j.1524-4725.1988.tb03373.x; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; GREEN A, 1992, CANCER CAUSE CONTROL, V3, P513, DOI 10.1007/BF00052747; Hakansson N, 2001, EPIDEMIOLOGY, V12, P552, DOI 10.1097/00001648-200109000-00015; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; Karagas MR, 2002, J NATL CANCER I, V94, P224, DOI 10.1093/jnci/94.3.224; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; MacLennan R, 2003, J AM ACAD DERMATOL, V48, P367, DOI 10.1016/S0190-9622(03)70143-1; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Marks R, 1990, Australas J Dermatol, V31, P77, DOI 10.1111/j.1440-0960.1990.tb00656.x; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Schaffer JV, 2001, ARCH DERMATOL, V137, P1477; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Smolle J, 1999, MELANOMA RES, V9, P407, DOI 10.1097/00008390-199908000-00011; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; Veierod MB, 2003, J NATL CANCER I, V95, P1530, DOI 10.1093/jnci/djg075; Wenczl E, 1998, J INVEST DERMATOL, V111, P678, DOI 10.1046/j.1523-1747.1998.00357.x; Whiteman DC, 1998, INT J CANCER, V77, P843, DOI 10.1002/(SICI)1097-0215(19980911)77:6<843::AID-IJC8>3.0.CO;2-U; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806	31	94	95	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					728	730		10.1016/S0140-6736(04)15649-3	http://dx.doi.org/10.1016/S0140-6736(04)15649-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15005091				2022-12-28	WOS:000189266900025
J	Schnabel, A				Schnabel, A			Disease-modifying antirheumatic drugs: enhancing efficacy by combination	LANCET			English	Editorial Material							EARLY RHEUMATOID-ARTHRITIS; ANTITUMOR NECROSIS FACTOR; CONCOMITANT METHOTREXATE; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; THERAPY; INTERVENTION; ETANERCEPT		Sana Rheumazentrum Baden Wurttemberg, Klin Internist Rheumatol & Klin Immunol, D-75323 Bad Wildbad, Germany		Schnabel, A (corresponding author), Sana Rheumazentrum Baden Wurttemberg, Klin Internist Rheumatol & Klin Immunol, D-75323 Bad Wildbad, Germany.	a.schnabel@sana-wildbad.de						Emery P, 2002, J RHEUMATOL, V29, P3; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; Landewe RBM, 2002, ARTHRITIS RHEUM-US, V46, P347, DOI 10.1002/art.10083; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Mottonen T, 2002, ARTHRITIS RHEUM, V46, P894, DOI 10.1002/art.10135; Pincus T, 1999, ANN INTERN MED, V131, P768, DOI 10.7326/0003-4819-131-10-199911160-00009; van Jaarsveld CHM, 2000, ANN RHEUM DIS, V59, P468, DOI 10.1136/ard.59.6.468; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697	10	2	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					670	671		10.1016/S0140-6736(04)15660-2	http://dx.doi.org/10.1016/S0140-6736(04)15660-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001319				2022-12-28	WOS:000189266900002
J	Cawley, S; Bekiranov, S; Ng, HH; Kapranov, P; Sekinger, EA; Kampa, D; Piccolboni, A; Sementchenko, V; Cheng, J; Williams, AJ; Wheeler, R; Wong, B; Drenkow, J; Yamanaka, M; Patel, S; Brubaker, S; Tammana, H; Helt, G; Struhl, K; Gingeras, TR				Cawley, S; Bekiranov, S; Ng, HH; Kapranov, P; Sekinger, EA; Kampa, D; Piccolboni, A; Sementchenko, V; Cheng, J; Williams, AJ; Wheeler, R; Wong, B; Drenkow, J; Yamanaka, M; Patel, S; Brubaker, S; Tammana, H; Helt, G; Struhl, K; Gingeras, TR			Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs	CELL			English	Article							GENOME-WIDE LOCATION; CAENORHABDITIS-ELEGANS; ANTISENSE RNA; SACCHAROMYCES-CEREVISIAE; TARGET GENES; XIST GENE; IDENTIFICATION; EXPRESSION; ALGORITHM; SEQUENCE	Using high-density oligonucleotide arrays representing essentially all nonrepetitive sequences on human chromosomes 21 and 22, we map the binding sites in vivo for three DNA binding transcription factors, Sp1, cMyc, and p53, in an unbiased manner. This mapping reveals an unexpectedly large number of transcription factor binding site (TFBS) regions, with a minimal estimate of 12,000 for Sp1, 25,000 for cMyc, and 1600 for p53 when extrapolated to the full genome. Only 22% of these TFBS regions are located at the 5' termini of protein-coding genes while 36% lie within or immediately 3' to well-characterized genes and are significantly correlated with noncoding RNAs. A significant number of these noncoding RNAs are regulated in response to retinoic acid, and overlapping pairs of protein-coding and noncoding RNAs are often coregulated. Thus, the human genome contains roughly comparable numbers of protein-coding and noncoding genes that are bound by common transcription factors and regulated by common environmental signals.	Affymetrix, Santa Clara, CA 95051 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Genome Inst Singapore, Singapore 138672, Singapore	Affymetrix; Harvard University; Harvard Medical School; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Gingeras, TR (corresponding author), Affymetrix, 3380 Cent Expressway, Santa Clara, CA 95051 USA.	tom_gingeras@affymetrix.com	Ng, Huck Hui/A-1135-2009	Kapranov, Philipp/0000-0003-2647-4856; Gingeras, Thomas/0000-0001-9106-3573	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186, R01GM053720] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NIGMS NIH HHS [GM53720, GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carmichael GG, 2003, NAT BIOTECHNOL, V21, P371, DOI 10.1038/nbt0403-371; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; DAMJANOV I, 1993, LAB INVEST, V68, P220; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Horak CE, 2002, GENE DEV, V16, P3017, DOI 10.1101/gad.1039602; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kramer C, 2003, NATURE, V421, P948, DOI 10.1038/nature01427; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Lipman DJ, 1997, NUCLEIC ACIDS RES, V25, P3580, DOI 10.1093/nar/25.18.3580; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Mattick JS, 2001, EMBO REP, V2, P986, DOI 10.1093/embo-reports/kve230; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Patankar S, 2001, MOL BIOL CELL, V12, P3114, DOI 10.1091/mbc.12.10.3114; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Sleutels F, 2002, ADV GENET, V46, P119; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wagner EGH, 2002, TRENDS GENET, V18, P223, DOI 10.1016/S0168-9525(02)02658-6; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5	49	894	944	0	56	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 20	2004	116	4					499	509		10.1016/S0092-8674(04)00127-8	http://dx.doi.org/10.1016/S0092-8674(04)00127-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980218	Bronze			2022-12-28	WOS:000189184200005
J	Stern, PJ; Goldfarb, CA				Stern, PJ; Goldfarb, CA			Interdigital pilonidal sinus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Cincinnati, Cincinnati, OH 45206 USA; Washington Univ, St Louis, MO 63105 USA	University System of Ohio; University of Cincinnati; Washington University (WUSTL)	Stern, PJ (corresponding author), Univ Cincinnati, Cincinnati, OH 45206 USA.								0	11	11	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					E10	E10		10.1056/ENEJMicm020505	http://dx.doi.org/10.1056/ENEJMicm020505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014197				2022-12-28	WOS:000220110100011
J	Henikoff, S				Henikoff, S			Visualizing gene expression: an unfolding story	CELL			English	Editorial Material							ACTIVE CHROMATIN; RAPID EXCHANGE; LIVING CELLS	Eukaryotic transcription is a dynamic process in which RNA polymerases read DNA templates that are tightly wrapped around histones. In this issue of Cell, Janicki et al. (2004) provide a glimpse of the events that follow transcriptional induction, using an integrated cytological system observed in real time. They find that local decondensation of the template is accompanied by profound changes in chromatin composition.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	10	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	2004	116	5					633	634		10.1016/S0092-8674(04)00209-0	http://dx.doi.org/10.1016/S0092-8674(04)00209-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006344	Bronze			2022-12-28	WOS:000221499700002
J	Dhallan, R; Au, WC; Mattagajasingh, S; Emche, S; Bayliss, P; Damewood, M; Cronin, M; Chou, V; Mohr, M				Dhallan, R; Au, WC; Mattagajasingh, S; Emche, S; Bayliss, P; Damewood, M; Cronin, M; Chou, V; Mohr, M			Methods to increase the percentage of free fetal DNA recovered from the maternal circulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-DIAGNOSIS; DOWNS-SYNDROME; PLASMA; SERUM; TRISOMY-18; BLOOD	Context Noninvasive prenatal diagnostic tests using free fetal DNA provide an alternative to invasive tests and their attendant risks; however, free fetal DNA exists in the maternal circulation at low percentages, which has hindered development of noninvasive tests. Objective To test the hypothesis that using formaldehyde to reduce cell lysis could increase the relative percentage of free fetal DNA in samples of maternal blood. Design, Setting, and Patients The first phase of the study was conducted from January through February 2002 at a single US clinical site; 2 samples of blood were collected from each of 10 pregnant women, and the percentage of free fetal DNA in formaldehyde-treated and untreated samples was determined. The second phase of the study was conducted from March 2002 through May 2003, and measured the percentage of free fetal DNA in 69 formaldehyde-treated samples of maternal blood obtained from a network of 27 US clinical sites in 16 states. Main Outcome Measure Percentage of free fetal DNA in samples of maternal blood. Results In the first phase of the study, the mean percentage of free fetal DNA in the untreated samples was 7.7% (range, 0.32%-40%), while the mean percentage of free fetal DNA in the formaldehyde-treated samples was 20.2% (range, 1.6%-40%) (P=.02 for difference). in the second phase, a median of 25% (range, 3.1% to >50%) free fetal DNA was obtained forthe 69 formaldehyde-treated maternal blood samples. Approximately 59% of the samples in this study had 25% or greater fetal DNA, and only 16% of the samples had less than 10% fetal DNA. In addition, 27.5% of the samples in this study had 50% or greater fetal DNA. Conclusion Addition of formaldehyde to maternal blood samples, coupled with careful processing protocols, increases the relative percentage of free fetal DNA, providing a foundation for development of noninvasive prenatal diagnostic tests to distinguish fetal DNA from maternal DNA in the maternal circulation.	Ravgen Inc, Columbia, MD 21045 USA; York Hosp, Dept Obstet & Gynecol, York, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Dhallan, R (corresponding author), Ravgen Inc, 9241 Rumsey Rd, Columbia, MD 21045 USA.	rdhallan@ravgen.com						Alfirevic Z, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003252, 10.1002/14651858]; COX RA, 1976, BIOCHEM MED METAB B, V15, P126, DOI 10.1016/0006-2944(76)90039-9; d'Ercole C, 2003, CHILD NERV SYST, V19, P444, DOI 10.1007/s00381-003-0788-z; KAMM RC, 1972, CLIN CHEM, V18, P519; Lo YMD, 2000, CLIN CHEM, V46, P1903; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; LO YMD, 1989, LANCET, V2, P1363; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lo YMD, 1999, CLIN CHEM, V45, P1747; Loncar J, 1995, Obstet Gynecol Surv, V50, P316, DOI 10.1097/00006254-199504000-00027; LOWRY DLB, 1995, FETAL DIAGN THER, V10, P286, DOI 10.1159/000264245; MACDONALD ML, 1991, OBSTET GYNECOL, V77, P63; Meier C, 2003, PRENATAL DIAG, V23, P443, DOI 10.1002/pd.614; Pertl B, 2001, OBSTET GYNECOL, V98, P483, DOI 10.1016/S0029-7844(01)01195-4; Poon LLM, 2000, LANCET, V356, P1819, DOI 10.1016/S0140-6736(00)03237-2; Samura O, 2001, CLIN CHEM, V47, P1622; Skinner Juliet, 2003, J Obstet Gynaecol, V23, P228; Summers AM, 2003, OBSTET GYNECOL, V101, P1301, DOI 10.1016/S0029-7844(03)00235-7; Verma L, 1998, LANCET, V352, P9, DOI 10.1016/S0140-6736(97)11090-X; WALKNOWSKA J, 1969, LANCET, V1, P1119; Wataganara T, 2003, HUM GENET, V112, P204, DOI 10.1007/s00439-002-0853-9	21	109	185	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1114	1119		10.1001/jama.291.9.1114	http://dx.doi.org/10.1001/jama.291.9.1114			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780AQ	14996781	Bronze			2022-12-28	WOS:000189348900029
J	O'Brien, JM; Welsh, CH; Fish, RH; Ancukiewicz, M; Kramer, AM				O'Brien, JM; Welsh, CH; Fish, RH; Ancukiewicz, M; Kramer, AM		Natl Heart Lung & Blood Inst Acute	Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury	ANNALS OF INTERNAL MEDICINE			English	Article							MORBID-OBESITY; UNITED-STATES; MASS INDEX; TRACHEAL INTUBATION; GENERAL-ANESTHESIA; TRENDS; COMPLICATIONS; PREVALENCE; OVERWEIGHT; MORTALITY	Background: Despite an epidemic of obesity among adults, the effect of excess body weight on outcome from critical illness is not well studied. Objective: To examine the association between excess body weight and outcome in mechanically ventilated patients with acute lung injury. Design: Secondary analysis of participants in trials of therapy for acute lung injury. Setting: 10 U.S. medical centers that participate in the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Patients: 902 mechanically ventilated patients who were enrolled in randomized, controlled trials of therapy for acute lung injury. Intervention: Assignment to higher (12 mL/kg of predicted weight) or lower (6 mL/kg of predicted weight) tidal volume ventilation strategies with specified weaning protocols. Some patients also received ketoconazole, lisofylline, or placebo by factorial design. Measurements: Mortality rate, rate of unassisted ventilation by day 28, and number of ventilator-free days. Results: Indirect causes of lung injury, including trauma, were more common in obese patients. Overweight and obese patients had higher peak and plateau airway pressures before enrollment because of higher set tidal volumes. After risk adjustment, excess body weight was not associated with death, achievement of unassisted ventilation, or number of ventilator-free days. This lack of effect persisted with categorical or continuous measures of body mass index (BMI). We found no significant interaction between ventilator protocol assignment and BMI category. Conclusions: After risk adjustment, overweight and obese patients with acute lung injury have outcomes similar to those of patients with normal BMI. The lack of interaction between ventilator protocol assignment and BMI suggests that patients with normal, overweight, or obese BMI benefit from lower tidal volume ventilation for acute lung injury.	Univ Colorado, Hlth Sci Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	O'Brien, JM (corresponding author), Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Box C-272, Denver, CO 80262 USA.	James.OBrien@uchsc.edu	O'Brien, James M/A-2624-2009		NHLBI NIH HHS [T32-HL07085, N01-HR 46054-64] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007085] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS CH, 1993, WOMEN HEALTH, V20, P45, DOI 10.1300/J013v20n02_04; ALPERT MA, 1993, AM J MED SCI, V306, P117, DOI 10.1097/00000441-199308000-00011; BLUMBERG P, 1985, INT J EAT DISORDER, V4, P169, DOI 10.1002/1098-108X(198505)4:2<169::AID-EAT2260040204>3.0.CO;2-F; Brodsky JB, 2002, ANESTH ANALG, V94, P732, DOI 10.1097/00000539-200203000-00047; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHOBAN PS, 1991, J TRAUMA, V31, P1253, DOI 10.1097/00005373-199109000-00009; DEURENBERG P, 1991, BRIT J NUTR, V65, P105, DOI 10.1079/BJN19910073; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ERIKSEN J, 1978, ACTA ANAESTH SCAND, V22, P241, DOI 10.1111/j.1399-6576.1978.tb01298.x; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FORREST JB, 1992, ANESTHESIOLOGY, V76, P3, DOI 10.1097/00000542-199201000-00002; Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; GOULD AB, 1962, ANESTH ANALG, V41, P448, DOI 10.1213/00000539-196241040-00012; Hebl MR, 2001, INT J OBESITY, V25, P1246, DOI 10.1038/sj.ijo.0801681; Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; MADDOX GL, 1969, J MED EDUC, V44, P214; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; *NIH, 1998, NIH PUBL; POE RH, 1988, AM J MED SCI, V295, P29, DOI 10.1097/00000441-198801000-00007; PURDUE G F, 1990, Journal of Burn Care and Rehabilitation, V11, P32, DOI 10.1097/00004630-199001000-00007; RAND CSW, 1990, SOUTHERN MED J, V83, P1390, DOI 10.1097/00007611-199012000-00006; Teachman BA, 2001, INT J OBESITY, V25, P1525, DOI 10.1038/sj.ijo.0801745; Tremblay A, 2003, CHEST, V123, P1202, DOI 10.1378/chest.123.4.1202; Troiano RP, 1996, INT J OBESITY, V20, P63; VAUGHAN RW, 1980, LIFE SCI, V26, P2119, DOI 10.1016/0024-3205(80)90598-6; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Wiedemann HP, 2002, CRIT CARE MED, V30, P1	35	110	114	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					338	345		10.7326/0003-4819-140-5-200403020-00009	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996675				2022-12-28	WOS:000189246800003
J	Warner, J				Warner, J			Risk of choking in mental illness	LANCET			English	Editorial Material							PSYCHIATRIC-PATIENTS; EXCESS MORTALITY; DEATH		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Psychiat, London W2 1PD, England	Imperial College London	Warner, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Psychiat, London W2 1PD, England.	j.warner@imperial.ac.uk						Appleby L, 2000, BRIT J PSYCHIAT, V176, P405, DOI 10.1192/bjp.176.5.405; Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212; Corcoran E, 2003, IRISH J PSYCHOL MED, V20, P88, DOI 10.1017/S079096670000776X; Fioritti A, 1997, CAN J PSYCHIAT, V42, P515, DOI 10.1177/070674379704200509; GIACOTTO L, 1998, MINERVA PSYCHIAT, V39, P37; HAMMOND WA, 1883, TREATISE INSANITY IT, P724; Osborn DPJ, 2001, WESTERN J MED, V175, P329, DOI 10.1136/ewjm.175.5.329; REILLEY JG, 2002, BRIT J PSYCHIAT, V100, P515; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; Ruschena D, 1998, BRIT J PSYCHIAT, V172, P331, DOI 10.1192/bjp.172.4.331; Ruschena D, 2003, BRIT J PSYCHIAT, V183, P446, DOI 10.1192/bjp.183.5.446	11	5	5	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					674	674		10.1016/S0140-6736(04)15664-X	http://dx.doi.org/10.1016/S0140-6736(04)15664-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	778XP	15001323				2022-12-28	WOS:000189266900006
J	Lindenmayer, DB; Foster, DR; Franklin, JF; Hunter, ML; Noss, RF; Schmiegelow, FA; Perry, D				Lindenmayer, DB; Foster, DR; Franklin, JF; Hunter, ML; Noss, RF; Schmiegelow, FA; Perry, D			Ecology - Salvage harvesting policies after natural disturbance	SCIENCE			English	Editorial Material							FORESTS		Australian Natl Univ, Ctr Resource & Environm Studies, Canberra, ACT 0200, Australia; Harvard Univ, Harvard Forest, Petersham, MA 01366 USA; Univ Washington, Coll Forest Resources, Seattle, WA 98195 USA; Univ Maine, Dept Wildlife Ecol, Orono, ME 04469 USA; Univ Cent Florida, Dept Biol, Orlando, FL 32816 USA; Univ Alberta, Dept Renewable Resources, Edmonton, AB T6G 2H1, Canada; Univ Hawaii, Kapaau, HI 96755 USA	Australian National University; Harvard University; University of Washington; University of Washington Seattle; University of Maine System; University of Maine Orono; State University System of Florida; University of Central Florida; University of Alberta; University of Hawaii System	Lindenmayer, DB (corresponding author), Australian Natl Univ, Ctr Resource & Environm Studies, Canberra, ACT 0200, Australia.	davidl@cres.anu.edu.au	Lindenmayer, David B/P-7183-2017	Lindenmayer, David B/0000-0002-4766-4088				Bradstock RA., 2002, FLAMMABLE AUSTR FIRE; *CAN COUNC FOR MIN, 2003, CAN WILDL FIR INF SY; *DEP SUST ENV, 2003, SALV HARV PRESCR 200; *FAO UN, 2001, STAT WORLDS FOR; Foster DR, 1997, BIOSCIENCE, V47, P437, DOI 10.2307/1313059; Franklin J.F., 2000, CONSERVATION BIOL PR, V1, P9, DOI DOI 10.1111/J.1526-4629.2000.TB00155.X; Gregory S. V., 1997, CREATING FORESTRY 21, P69; Hansen SB, 1983, THESIS U MAINE; Hoyt JS, 2002, CAN J FOREST RES, V32, P1881, DOI [10.1139/x02-109, 10.1139/X02-109]; HUTTO RL, 1995, CONSERV BIOL, V9, P1041, DOI [10.1046/j.1523-1739.1995.9051041.x, 10.1046/j.1523-1739.1995.9051033.x-i1]; KENNEDY P, 2003, GLOBE MAIL TORO 0905, P81; Lindenmayer D.B., 2002, CONSERVING FOREST BI; Lindenmayer DB, 1997, CONSERV BIOL, V11, P1053, DOI 10.1046/j.1523-1739.1997.96150.x; Ough K., 1996, Australian Forestry, V59, P178; Pahl-Wostl C., 1995, DYNAMIC NATURE ECOSY; Paine RT, 1998, ECOSYSTEMS, V1, P535, DOI 10.1007/s100219900049; Van Nieuwstadt MGL, 2001, CONSERV BIOL, V15, P1183, DOI 10.1046/j.1523-1739.2001.0150041183.x	17	204	213	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1303	1303		10.1126/science.1093438	http://dx.doi.org/10.1126/science.1093438			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988539				2022-12-28	WOS:000189238600025
J	Fukasawa, M; Freeland, H; Perkin, R; Watanabe, T; Uchida, H; Nishina, A				Fukasawa, M; Freeland, H; Perkin, R; Watanabe, T; Uchida, H; Nishina, A			Bottom water warming in the North Pacific Ocean	NATURE			English	Article							WORLD OCEAN; SCALE	Observations of changes in the properties of ocean waters have been restricted to surface(1) or intermediate-depth waters(2,3), because the detection of change in bottom water is extremely difficult owing to the small magnitude of the expected signals. Nevertheless, temporal changes in the properties of such deep waters across an ocean basin are of particular interest, as they can be used to constrain the transport of water at the bottom of the ocean and to detect changes in the global thermohaline circulation. Here we present a comparison of a trans-Pacific survey completed in 1985 ( refs 4, 5) and its repetition in 1999 ( ref. 6). We find that the deepest waters of the North Pacific Ocean have warmed significantly across the entire width of the ocean basin. Our observations imply that changes in water properties are now detectable in water masses that have long been insulated from heat exchange with the atmosphere.	Japan Marine Sci & Technol Ctr, Ocean Observat & Res Dept, Yokosuka, Kanagawa 2370061, Japan; Fisheries Oceans Canada Inst Ocean Sci, Sidney, BC V8L 4B2, Canada; Japan Fisheries Agcy, Far Fisheries Lab, Shimizu, Shizuoka 4248633, Japan; Kagoshima Univ, Fac Fisheries, Kagoshima 8900056, Japan	Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Fisheries & Oceans Canada; Japan Fisheries Research & Education Agency (FRA); Kagoshima University	Fukasawa, M (corresponding author), Japan Marine Sci & Technol Ctr, Ocean Observat & Res Dept, Yokosuka, Kanagawa 2370061, Japan.	fksw@jamstec.go.jp; FreelandHj@pac.dfo-mpo.gc.ca	atsu, nishi/L-4874-2019					Aoyama M, 2002, DEEP-SEA RES PT I, V49, P1103, DOI 10.1016/S0967-0637(02)00018-3; Gille ST, 2002, SCIENCE, V295, P1275, DOI 10.1126/science.1065863; Johnson GC, 1997, J CLIMATE, V10, P306, DOI 10.1175/1520-0442(1997)010<0306:SPOWMC>2.0.CO;2; JOHNSON GC, 1994, J MAR RES, V52, P177, DOI 10.1357/0022240943077118; JOYCE TM, 1986, DEEP-SEA RES, V33, P1003, DOI 10.1016/0198-0149(86)90026-9; KAWANO T, 2001, J JPN SOC MAR SURV T, V13, P11; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; MANTYLA AW, 1987, J PHYS OCEANOGR, V17, P543, DOI 10.1175/1520-0485(1987)017<0543:SSCU>2.0.CO;2; MANTYLA AW, 1983, DEEP-SEA RES, V30, P805, DOI 10.1016/0198-0149(83)90002-X; PRESTONTHOMAS H, 1990, METROLOGIA, V27, P3, DOI 10.1088/0026-1394/27/1/002; Reid JL, 1997, PROG OCEANOGR, V39, P263, DOI 10.1016/S0079-6611(97)00012-8; ROEMMICH D, 1984, NATURE, V307, P447, DOI 10.1038/307447a0; SCLATER JG, 1981, J GEOPHYS RES, V86, P1535, DOI 10.1029/JB086iB12p11535; TALLEY LD, 1991, DEEP SEA RES S, V38, P63; TALLEY LD, 1988, TRANSPACIFIC SECTION; UCHIDA H, 2002, WHP P01 REVISIT DATA, P1; Wong APS, 1999, NATURE, V400, P440, DOI 10.1038/22733	17	99	106	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					825	827		10.1038/nature02337	http://dx.doi.org/10.1038/nature02337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985757				2022-12-28	WOS:000189207500035
J	Kienberger, R; Goulielmakis, E; Uiberacker, M; Baltuska, A; Yakovlev, V; Bammer, F; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F				Kienberger, R; Goulielmakis, E; Uiberacker, M; Baltuska, A; Yakovlev, V; Bammer, F; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F			Atomic transient recorder	NATURE			English	Article							ORDER HARMONIC-GENERATION; FEMTOSECOND PULSES; ATTOSECOND PULSES; LASER-PULSES; IONIZATION; FIELDS; GASES	In Bohr's model of the hydrogen atom, the electron takes about 150 attoseconds (1 as = 10(-18) s) to orbit around the proton, defining the characteristic timescale for dynamics in the electronic shell of atoms. Recording atomic transients in real time requires excitation and probing on this scale. The recent observation of single sub-femtosecond ( 1 fs = 10(-15) s) extreme ultraviolet (XUV) light pulses(1) has stimulated the extension of techniques of femtochemistry(2) into the attosecond regime(3,4). Here we demonstrate the generation and measurement of single 250-attosecond XUV pulses. We use these pulses to excite atoms, which in turn emit electrons. An intense, waveform-controlled, few cycle laser pulse(5) obtains 'tomographic images' of the time-momentum distribution of the ejected electrons. Tomographic images of primary ( photo) electrons yield accurate information of the duration and frequency sweep of the excitation pulse, whereas the same measurements on secondary ( Auger) electrons will provide insight into the relaxation dynamics of the electronic shell following excitation. With the current similar to750-nm laser probe and similar to100-eV excitation, our transient recorder is capable of resolving atomic electron dynamics within the Bohr orbit time.	Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria; Tech Univ Vienna, Inst Spanlose Fertigung & Hochleistungslasertech, A-1030 Vienna, Austria; Univ Bielefeld, Fak Phys, D-33615 Bielefeld, Germany; Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Technische Universitat Wien; Technische Universitat Wien; University of Bielefeld; Max Planck Society	Krausz, F (corresponding author), Vienna Tech Univ, Inst Photon, Gusshausstr 27, A-1040 Vienna, Austria.	ferenc.krausz@tuwien.ac.at	Heinzmann, Ulrich/A-6248-2012; Baltuska, ANDRIUS/ABE-2033-2020; Goulielmakis, Eleftherios/AAZ-1052-2020; Goulielmakis, Eleftherios/F-1693-2011; Yakovlev, Vladislav S/C-4091-2015	Goulielmakis, Eleftherios/0000-0003-3386-0245; Yakovlev, Vladislav S/0000-0002-0648-9375; Kienberger, Reinhard/0000-0001-8781-3685; Baltuska, Andrius/0000-0002-5267-0626				Baltuska A, 2003, NATURE, V421, P611, DOI 10.1038/nature01414; Bradley D. J., 1971, Optics Communications, V2, P391, DOI 10.1016/0030-4018(71)90252-5; Christov IP, 1997, PHYS REV LETT, V78, P1251, DOI 10.1103/PhysRevLett.78.1251; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; de Bohan A, 1998, PHYS REV LETT, V81, P1837, DOI 10.1103/PhysRevLett.81.1837; Drescher M, 2002, NATURE, V419, P803, DOI 10.1038/nature01143; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Itatani J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173903; Kan C, 1997, PHYS REV LETT, V79, P2971, DOI 10.1103/PhysRevLett.79.2971; KANE DJ, 1993, IEEE J QUANTUM ELECT, V29, P571, DOI 10.1109/3.199311; Kitzler M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173904; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; LHUILLIER A, 1993, PHYS REV LETT, V70, P774, DOI 10.1103/PhysRevLett.70.774; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; Mairesse Y, 2003, SCIENCE, V302, P1540, DOI 10.1126/science.1090277; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; SCHAFER KJ, 1993, PHYS REV LETT, V70, P1599, DOI 10.1103/PhysRevLett.70.1599; SCHELEV MY, 1971, APPL PHYS LETT, V18, P354, DOI 10.1063/1.1653694; Sekikawa T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.193902; Tempea G, 1999, J OPT SOC AM B, V16, P669, DOI 10.1364/JOSAB.16.000669; Tzallas P, 2003, NATURE, V426, P267, DOI 10.1038/nature02091; Zewail AH, 2000, J PHYS CHEM A, V104, P5660, DOI 10.1021/jp001460h	22	1112	1136	4	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					817	821		10.1038/nature02277	http://dx.doi.org/10.1038/nature02277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985755				2022-12-28	WOS:000189207500033
J	Kashyap, AS; Anand, KP				Kashyap, AS; Anand, KP			Primary amenorrhoea and xanthomatosis	LANCET			English	Editorial Material									Armed Forces Med Coll, Dept Med, Pune 411040, Maharashtra, India	Armed Forces Medical College	Kashyap, AS (corresponding author), Armed Forces Med Coll, Dept Med, Pune 411040, Maharashtra, India.	kashyapajits@hotmail.com						Davignon J, 1998, ENDOCRIN METAB CLIN, V27, P521, DOI 10.1016/S0889-8529(05)70024-4; Jameson JL, 2001, HARRISONS PRINCIPLES, V2, P2060; Krsek M, 2000, ACTA PAEDIATR, V89, P1023; MAHLEY RW, 2002, OXFORD TXB ENDOCRINO, P1555; STONE NJ, 1994, MED CLIN N AM, V78, P117, DOI 10.1016/S0025-7125(16)30179-1	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					616	616		10.1016/S0140-6736(04)15594-3	http://dx.doi.org/10.1016/S0140-6736(04)15594-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987887				2022-12-28	WOS:000189104900011
J	Ogawa, T; Nitta, R; Okada, Y; Hirokawa, N				Ogawa, T; Nitta, R; Okada, Y; Hirokawa, N			A common mechanism for microtubule destabilizers - M type kinesins stabilize curling of the protofilament using the class-specific neck and loops	CELL			English	Article							CENTROMERE-ASSOCIATED KINESIN; DYNEIN SUPERFAMILY PROTEINS; MOTOR PROTEIN; DEPOLYMERIZING ACTIVITY; ORGANELLE TRANSPORT; C-TERMINUS; K-LOOP; TUBULIN; DOMAIN; ATPASE	Unlike other kinesins, middle motor domain-type kinesins depolymerize the microtubule from its ends. To elucidate its mechanism, we solved the X-ray crystallographic structure of KIF2C, a murine member of this family. Three major class-specific features were identified. The class-specific N-terminal neck adopts a long and rigid helical structure extending out vertically into the interprotofilament groove. This structure explains its dual roles in targeting to the end of the microtubule and in destabilization of the lateral interaction of the protofilament. The loop L2 forms a unique finger-like structure, long and rigid enough to reach the next tubulin subunit to stabilize the peeling of the protofilament. The open conformation of the switch I loop could be reversed by the shift of the microtubule binding L8 loop, suggesting its role as the sensor to trigger ATP hydrolysis. Mutational analysis supports these structural implications.	Univ Tokyo, Dept Cell Biol & Anat, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Dept Cell Biol & Anat, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp	Nitta, Ryo/Q-9958-2019; Nitta, Ryo/C-3727-2017; Okada, Yasushi/N-5067-2015; Tadayuki, Ogawa/P-5451-2018	Nitta, Ryo/0000-0002-6537-9272; Nitta, Ryo/0000-0002-6537-9272; Okada, Yasushi/0000-0003-2601-3689; Tadayuki, Ogawa/0000-0002-4627-0693				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Dagenbach EM, 2004, J CELL SCI, V117, P3, DOI 10.1242/jcs.00875; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Endow SA, 2000, NATURE, V406, P913, DOI 10.1038/35022617; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa N, 1996, J CELL BIOL, V132, P667, DOI 10.1083/jcb.132.4.667; Homma N, 2003, CELL, V114, P229, DOI 10.1016/S0092-8674(03)00522-1; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kim AJ, 2000, J CELL SCI, V113, P3681; Maney T, 2001, J BIOL CHEM, V276, P34753, DOI 10.1074/jbc.M106626200; Miki H, 2003, GENOME RES, V13, P1455, DOI 10.1101/gr.984503; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moores CA, 2003, J CELL BIOL, V163, P963, DOI 10.1083/jcb.200304034; Moores CA, 2002, MOL CELL, V9, P903, DOI 10.1016/S1097-2765(02)00503-8; Niederstrasser H, 2002, J MOL BIOL, V316, P817, DOI 10.1006/jmbi.2001.5360; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ovechkina Y, 2002, J CELL BIOL, V159, P557, DOI 10.1083/jcb.200205089; REICHERT TM, 1998, P NATL ACAD SCI USA, V95, P3661; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; TAKEMURA R, 1992, J CELL SCI, V103, P953; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Watts NR, 2000, J CELL BIOL, V150, P349, DOI 10.1083/jcb.150.2.349; Wendt TG, 2002, EMBO J, V21, P5969, DOI 10.1093/emboj/cdf622; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Yun M, 2003, EMBO J, V22, P5382, DOI 10.1093/emboj/cdg531; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	42	153	159	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					591	602		10.1016/S0092-8674(04)00129-1	http://dx.doi.org/10.1016/S0092-8674(04)00129-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980225	Bronze			2022-12-28	WOS:000189184200012
J	Kales, SN; Christiani, DC				Kales, SN; Christiani, DC			Current concepts - Acute chemical emergencies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SUBWAY SARIN ATTACK; EAR VESICANT MODEL; HYDROGEN-SULFIDE; SULFUR MUSTARD; HYDROFLUORIC-ACID; HYPERBARIC-OXYGEN; TOKYO SUBWAY; SODIUM-NITRITE; WARFARE AGENTS; UNITED-STATES		Harvard Univ, Sch Med, Cambridge Hlth Alliance, Dept Med Occupat & Environm Hlth, Cambridge, MA 02139 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program, Boston, MA 02115 USA; Massachusetts Gen Hosp, Pulm Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NE Specialty & Rehabil Hosp, Ctr Occupat & Environm Med, Braintree, MA USA	Harvard University; Cambridge Health Alliance; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kales, SN (corresponding author), Harvard Univ, Sch Med, Cambridge Hlth Alliance, Dept Med Occupat & Environm Hlth, 1493 Cambridge St, Cambridge, MA 02139 USA.	skales@challiance.org			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 2001, MAN HAZ MAT INC, V3; Babin MC, 2000, J APPL TOXICOL, V21, pS141; BAUD FJ, 1991, NEW ENGL J MED, V325, P1761, DOI 10.1056/NEJM199112193252502; BLEICH A, 1992, JAMA-J AM MED ASSOC, V268, P613, DOI 10.1001/jama.268.5.613; Blodgett DW, 2001, AM J IND MED, V40, P215, DOI 10.1002/ajim.1090.abs; BORAK J, 1992, ANN EMERG MED, V21, P303, DOI 10.1016/S0196-0644(05)80892-3; Borak J, 2001, J OCCUP ENVIRON MED, V43, P110, DOI 10.1097/00043764-200102000-00008; Brennan RJ, 1999, ANN EMERG MED, V34, P191, DOI 10.1016/S0196-0644(99)70229-5; Burgess JL, 1997, J OCCUP ENVIRON MED, V39, P760, DOI 10.1097/00043764-199708000-00011; Burgess JL, 1999, ANN EMERG MED, V34, P205, DOI 10.1016/S0196-0644(99)70230-1; CARAVATI EM, 1988, AM J EMERG MED, V6, P143, DOI 10.1016/0735-6757(88)90053-8; Carlton F. B., 1998, CLIN MANAGEMENT POIS, P836; Curry S., 2001, CLIN ENV HLTH TOXIC, P705; Dachir S, 2002, HUM EXP TOXICOL, V21, P197, DOI 10.1191/0960327102ht229oa; Davis KG, 2001, ANN EMERG MED, V37, P653, DOI 10.1067/mem.2001.114322; DOYLE CJ, 1998, CLIN MANAGEMENT POIS, P319; Ellenhorn MJ, 1997, ELLENHORNS MED TOXIC, P1267; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; Fuller DC, 2000, J OCCUP ENVIRON MED, V42, P939, DOI 10.1097/00043764-200009000-00019; Gabbay DS, 2001, J EMERG MED, V20, P141, DOI 10.1016/S0736-4679(00)00301-2; GRAUDINS A, 1998, CLIN MANAGEMENT POIS, P987; Greenfield RA, 2002, AM J MED SCI, V323, P326, DOI 10.1097/00000441-200206000-00005; GREGORAKOS L, 1995, ANGIOLOGY, V46, P1123, DOI 10.1177/000331979504601208; GUNDERSON CH, 1992, NEUROLOGY, V42, P946, DOI 10.1212/WNL.42.5.946; Gunn B, 2001, Emerg Med (Fremantle), V13, P240, DOI 10.1046/j.1442-2026.2001.00220.x; Hall AH, 1997, VET HUM TOXICOL, V39, P152; Hall Alan H., 1998, CLIN MANAGEMENT POIS, P899; Hall H. Irene, 1994, Morbidity and Mortality Weekly Report, V43, P1; Henretig FM, 2002, J PEDIATR-US, V141, P311, DOI 10.1067/mpd.2002.127408; Houck Peter M., 1997, Journal of Emergency Medicine, V15, P469, DOI 10.1016/S0736-4679(97)00079-6; Hurst CG, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P245; Kales SN, 1996, J OCCUP ENVIRON MED, V38, P394, DOI 10.1097/00043764-199604000-00018; Kerns W, 2002, GOLDFRANKS TOXICOLOG, V7th, P1498; Knudson G B, 2001, Mil Med, V166, P63; KULIG K, 1991, NEW ENGL J MED, V325, P1801, DOI 10.1056/NEJM199112193252508; LINDEN CH, 1998, CLIN MANAGEMENT POIS, P876; Macintyre AG, 2000, JAMA-J AM MED ASSOC, V283, P242, DOI 10.1001/jama.283.2.242; MARSHALL MD, 1995, CLIN CHEM, V41, P1434; MCMULLEN MJ, 1998, CLIN MANAGEMENT POIS, P978; MELIUS JM, 1998, ENV OCCUPATIONAL MED, P1239; Milby TH, 1999, AM J IND MED, V35, P192, DOI 10.1002/(SICI)1097-0274(199902)35:2<192::AID-AJIM11>3.3.CO;2-3; Moore DH, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P409; MRVOS R, 1993, SOUTHERN MED J, V86, P654, DOI 10.1097/00007611-199306000-00013; Nelson LS, 2002, GOLDFRANKS TOXICOLOG, P1453; Okudera H, 2002, J CLIN NEUROSCI, V9, P17, DOI 10.1054/jocn.2001.1020; Okumura T, 1998, ACAD EMERG MED, V5, P618, DOI 10.1111/j.1553-2712.1998.tb02471.x; Okumura T, 1996, ANN EMERG MED, V28, P129, DOI 10.1016/S0196-0644(96)70052-5; Piantadosi CA, 2002, NEW ENGL J MED, V347, P1054, DOI 10.1056/NEJMp020104; Ruhl Charles M., 1994, Journal of Emergency Medicine, V12, P159, DOI 10.1016/0736-4679(94)90693-9; Safarinejad MR, 2001, MIL MED, V166, P67, DOI 10.1093/milmed/166.1.67; Salem H, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P321; SALKOWSKI AA, 1994, VET HUM TOXICOL, V36, P455; SCOLNICK B, 1993, J OCCUP ENVIRON MED, V35, P577, DOI 10.1097/00043764-199306000-00014; SEGER DL, 2001, CLIN ENV HLTH TOXIC, P722; Sexton JD, 1998, J TOXICOL-CLIN TOXIC, V36, P87, DOI 10.3109/15563659809162593; Sharp TW, 1998, ANN EMERG MED, V32, P214, DOI 10.1016/S0196-0644(98)70139-8; SIDELL FR, 1990, POSTGRAD MED, V88, P70, DOI 10.1080/00325481.1990.11716446; SIDELL FR, 1994, J APPL TOXICOL, V14, P111, DOI 10.1002/jat.2550140212; SIDELL FR, 1992, ANN EMERG MED, V21, P865, DOI 10.1016/S0196-0644(05)81036-4; SMITH KJ, 1995, J AM ACAD DERMATOL, V32, P765, DOI 10.1016/0190-9622(95)91457-9; SNYDER JW, 1995, AM J EMERG MED, V13, P199, DOI 10.1016/0735-6757(95)90094-2; SPANJAARD H, 2003, TERRORISM PUBLIC HLT, P199; SUZUKI T, 1995, LANCET, V345, P980, DOI 10.1016/S0140-6736(95)90726-2; Thom SR, 2002, NEW ENGL J MED, V347, P1105, DOI 10.1056/NEJMe020103; Tomaszewski Christian A., 1994, Emergency Medicine Clinics of North America, V12, P437; *US ARM FORC RAD R, 1999, MED MAN RAD CAS; *US ARM MED COMM, 2001, BIOL CHEM WARF TERR; *US ARM MED RES I, 1999, MED MAN CHEM CAS HDB; *US ARM MED RES I, 1999, MED MAN CHEM CAS VES; Valent F, 2002, CHEST, V121, P969, DOI 10.1378/chest.121.3.969; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Wheeler R, 1999, JAMA-J AM MED ASSOC, V282, P1326; Winder C, 2001, ENVIRON RES, V85, P105, DOI 10.1006/enrs.2000.4110; WING JS, 1991, ARCH ENVIRON HEALTH, V46, P155, DOI 10.1080/00039896.1991.9937443; 1999, ANN EMERG MED, V33, P735; 2002, MED LETT DRUGS THER, V44, P1	77	103	106	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					800	808		10.1056/NEJMra030370	http://dx.doi.org/10.1056/NEJMra030370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973213				2022-12-28	WOS:000189006400008
J	Sharp, D				Sharp, D			Butter-fingers	LANCET			English	Editorial Material							FLY BALLS; CATCH; FIELDER; RUN		Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, London NW1 7BY, England.							FERRY G, 2001, OXFORD TODAY; McLeod P, 2003, NATURE, V426, P244, DOI 10.1038/426244a; McLeod P, 2002, J EXP PSYCHOL HUMAN, V28, P1499, DOI 10.1037//0096-1523.28.6.1499; McLeod P, 2001, J EXP PSYCHOL HUMAN, V27, P1347, DOI 10.1037/0096-1523.27.6.1347; Shaffer DM, 2003, J EXP PSYCHOL HUMAN, V29, P1244, DOI 10.1037/0096-1523.29.6.1244; Shaffer DM, 2002, J EXP PSYCHOL HUMAN, V28, P335, DOI 10.1037//0096-1523.28.2.335; TALLIS R, 2003, HAND PHILOS INQUIRY, P146	7	0	0	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					506	506		10.1016/S0140-6736(04)15577-3	http://dx.doi.org/10.1016/S0140-6736(04)15577-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774TA	14975610				2022-12-28	WOS:000188999900005
J	Williams, B; Poulter, NR; Brown, MJ; Davis, M; McInnes, GT; Potter, MF; Sever, PS; Thom, SM				Williams, B; Poulter, NR; Brown, MJ; Davis, M; McInnes, GT; Potter, MF; Sever, PS; Thom, SM		British Hypertension Soc	British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVELY-DESIGNED OVERVIEWS; BLOOD-PRESSURE; RANDOMIZED TRIAL; CARDIOVASCULAR EVENTS; EDUCATION-PROGRAM; EUROPEAN-SOCIETY; DIETARY-SODIUM; WORKING PARTY; CHOLESTEROL; INDIVIDUALS		Univ Leicester, Leicester Royal Infirm, Dept Cardiovasc Sci, Leicester, Leics, England; Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London SW7 2AZ, England; St Marys Hosp, London, England; Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 1TN, England; Moorfield House Surg, Leeds, W Yorkshire, England; Univ Glasgow, Western Infirm, Gardiner Inst,Div Cardiovasc & Med Sci, Sect Clin Pharmacol & Stroke Med, Glasgow G11 6NT, Lanark, Scotland; Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Ageing & Stroke Med Sect, Leicester, Leics, England	University of Leicester; Imperial College London; Imperial College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Glasgow; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Williams, B (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Cardiovasc Sci, Clin Sci Bldg, Leicester, Leics, England.	BWilliamsbw17@le.ac.uk		Williams, Bryan/0000-0002-8094-1841; Thom, Simon/0000-0002-3020-1351				Brown MJ, 2003, J HUM HYPERTENS, V17, P81, DOI 10.1038/sj.jhh.1001511; Chalmers J, 1999, J HYPERTENS, V17, P151; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dickerson JEC, 1999, LANCET, V353, P2008, DOI 10.1016/S0140-6736(98)07614-4; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; He JA, 2000, HYPERTENSION, V35, P544, DOI 10.1161/01.HYP.35.2.544; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MATERSON BJ, 1995, AM J HYPERTENS, V8, P189, DOI 10.1016/0895-7061(94)00196-I; Neal B, 2000, LANCET, V356, P1955; O'Brien E, 2003, J HYPERTENS, V21, P821, DOI 10.1097/00004872-200305000-00001; Primatesta P, 2001, HYPERTENSION, V38, P827, DOI 10.1161/hyp.38.4.827; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Turnbull F, 2003, LANCET, V362, P1527; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Yusuf S, 2000, NEW ENGL J MED, V342, P145	22	584	604	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					634	640		10.1136/bmj.328.7440.634	http://dx.doi.org/10.1136/bmj.328.7440.634			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016698	Green Published, Green Submitted			2022-12-28	WOS:000220208100024
J	Slutsky, AS; Lavery, JV				Slutsky, AS; Lavery, JV			Data safety and monitoring boards	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIALS; COMMITTEES		St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Inner City Hlth Res Unit, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Biomed Engn, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Slutsky, AS (corresponding author), St Michaels Hosp, Dept Med, Queen Wing,Rm 4-042,30 Bond St, Toronto, ON M5B 1W8, Canada.	arthur.slutsky@utoronto.ca	Slutsky, Arthur/M-3325-2019; Lavery, James/E-5254-2012; Slutsky, Arthur S/A-6013-2008	Slutsky, Arthur S/0000-0002-6063-3876				Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Angell M, 2000, NEW ENGL J MED, V342, P967, DOI 10.1056/NEJM200003303421309; BAUM M, 1994, STAT MED, V13, P1459, DOI 10.1002/sim.4780131322; Califf RM, 2001, AM HEART J, V141, P301, DOI 10.1067/mhj.2001.113152; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Dixon DO, 2000, CONTROL CLIN TRIALS, V21, P1, DOI 10.1016/S0197-2456(99)00042-2; Ellenberg SS., 2002, DATA MONITORING COMM; *FDA, 2001, GUID CLIN TRIAL SPON; Fleming TR, 2002, STAT MED, V21, P2843, DOI 10.1002/sim.1288; Gordon Valery M, 1998, IRB, V20, P1, DOI 10.2307/3564020; Miller FG, 2003, NEW ENGL J MED, V348, P1383, DOI 10.1056/NEJMsb030228; Miller PB, 2003, KENNEDY INST ETHIC J, V13, P93, DOI 10.1353/ken.2003.0014; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Ross LF, 2002, J LAW MED ETHICS, V30, P50, DOI 10.1111/j.1748-720X.2002.tb00719.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Veatch Robert M, 1979, IRB, V1, P1, DOI 10.2307/3564210; WALTERS L, 1993, STAT MED, V12, P575, DOI 10.1002/sim.4780120526; Wells R J, 2000, IRB, V22, P7, DOI 10.2307/3564196; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8	21	70	71	1	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1143	1147		10.1056/NEJMsb033476	http://dx.doi.org/10.1056/NEJMsb033476			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014189				2022-12-28	WOS:000220110100014
J	Steinbrook, R				Steinbrook, R			Surgery for severe obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AM SOC BAR SURG, 2000, SAGES ASBS GUID LAP; *BLUE CROSS BLUE S, 2003, SPEC REP REL WEIGHT; *BLUE CROSS BLUE S, 2003, NEW TECHN BAR SURG M; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; GRUNDY SM, 1991, ANN INTERN MED, V115, P956	5	388	409	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1075	1079		10.1056/NEJMp048029	http://dx.doi.org/10.1056/NEJMp048029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014179				2022-12-28	WOS:000220110100003
J	Burns, RB; Hartman, EE				Burns, RB; Hartman, EE			Update: A 75-year-old man with depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Kroenke K, 2002, JAMA-J AM MED ASSOC, V287, P1568, DOI 10.1001/jama.287.12.1568	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1260	1260		10.1001/jama.291.10.1260	http://dx.doi.org/10.1001/jama.291.10.1260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010449				2022-12-28	WOS:000220061900028
J	Haile-Selassie, Y; Suwa, G; White, TD				Haile-Selassie, Y; Suwa, G; White, TD			Late Miocene teeth from Middle Awash, Ethiopia, and early hominid dental evolution	SCIENCE			English	Article							AUSTRALOPITHECUS; PALEOANTHROPOLOGY; PALEONTOLOGY; BEARING; GEOLOGY	Late Miocene fossil hominid teeth recovered from Ethiopia's Middle Awash are assigned to Ardipithecus kadabba. Their primitive morphology and wear pattern demonstrate that A. kadabba is distinct from Ardipithecus ramidus. These fossils suggest that the last common ancestor of apes and humans had a functionally honing canine-third premolar complex. Comparison with teeth of Sahelanthropus and Orrorin, the two other named late Miocene hominid genera, implies that these putative taxa are very similar to A. kadabba. It is therefore premature to posit extensive late Miocene hominid diversity on the basis of currently available samples.	Cleveland Museum Nat Hist, Cleveland, OH 44106 USA; Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo 1130033, Japan; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA	Cleveland Museum of Natural History; University of Tokyo; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Haile-Selassie, Y (corresponding author), Cleveland Museum Nat Hist, 1 Wade Oval Dr, Cleveland, OH 44106 USA.	yhailese@cmnh.org						Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; CONDE CJC, 2003, P NATL ACAD SCI USA, V100, P7684; de Bonis L., 1978, Annales de Paleontologie Vertebres, V64, P185; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P545, DOI 10.1002/ajpa.1330570406; Leakey MG, 1998, NATURE, V393, P62, DOI 10.1038/29972; Lovejoy CO, 2002, AM J PHYS ANTHROPOL, V119, P97, DOI 10.1002/ajpa.10111; McHenry H.M., 1991, P133; Pickford M, 2002, C R PALEVOL, V1, P191, DOI 10.1016/S1631-0683(02)00028-3; SARMIENTO EE, 1987, AM J PHYS ANTHROPOL, V72, P250; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; Stern JT, 2000, EVOL ANTHROPOL, V9, P113, DOI 10.1002/1520-6505(2000)9:3<113::AID-EVAN2>3.0.CO;2-W; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; Ward CV, 2001, J HUM EVOL, V41, P255, DOI 10.1006/jhev.2001.0507; White TD, 2002, CAM S BIO EVOL ANTHR, V33, P407; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1977, AM J PHYS ANTHROPOL, V46, P197, DOI 10.1002/ajpa.1330460203; Wildman DE, 2003, P NATL ACAD SCI USA, V100, P7181, DOI 10.1073/pnas.1232172100; WoldeGabriel G, 2001, NATURE, V412, P175, DOI 10.1038/35084058; Wolpoff MH, 2002, NATURE, V419, P581, DOI 10.1038/419581a; Wood B, 2002, NATURE, V418, P133, DOI 10.1038/418133a	24	143	147	4	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1503	1505		10.1126/science.1092978	http://dx.doi.org/10.1126/science.1092978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001775				2022-12-28	WOS:000220000100037
J	Rajagopalan, H; Jallepalli, PV; Rago, C; Velculescu, VE; Kinzler, KW; Vogelstein, B; Lengauer, C				Rajagopalan, H; Jallepalli, PV; Rago, C; Velculescu, VE; Kinzler, KW; Vogelstein, B; Lengauer, C			Inactivation of hCDC4 can cause chromosomal instability	NATURE			English	Article							CYCLIN-E; GENETIC INSTABILITY; COLORECTAL CANCERS; UBIQUITIN LIGASE; CELL-CYCLE; PHOSPHORYLATION; TUMORIGENESIS; ARCHIPELAGO; MUTATIONS; ONSET	Aneuploidy, an abnormal chromosome number, has been recognized as a hallmark of human cancer for nearly a century(1); however, the mechanisms responsible for this abnormality have remained elusive. Here we report the identification of mutations in hCDC4 (also known as Fbw7 or Archipelago) in both human colorectal cancers and their precursor lesions. We show that genetic inactivation of hCDC4, by means of targeted disruption of the gene in karyotypically stable colorectal cancer cells, results in a striking phenotype associated with micronuclei and chromosomal instability. This phenotype can be traced to a defect in the execution of metaphase and subsequent transmission of chromosomes, and is dependent on cyclin E-a protein that is regulated by hCDC4 (refs 2-4). Our data suggest that chromosomal instability is caused by specific genetic alterations in a large fraction of human cancers and can occur before malignant conversion.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Johns Hopkins University	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	lengauer@jhmi.edu	Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X				Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bartek J, 2001, SCIENCE, V294, P66, DOI 10.1126/science.1066237; Boveri T, 1914, FRAGE ENTSTEHUNG MAL; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Goh PY, 1999, MOL CELL BIOL, V19, P5512; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Pihan GA, 1998, CANCER RES, V58, P3974; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; SAVAGE JRK, 1989, MUTAT RES, V225, P171, DOI 10.1016/0165-7992(89)90115-2; Schwab M, 2001, NATURE, V413, P268, DOI 10.1038/35095157; Shih IM, 2001, CANCER RES, V61, P818; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P16910, DOI 10.1073/pnas.012679099; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4	28	447	476	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					77	81		10.1038/nature02313	http://dx.doi.org/10.1038/nature02313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999283				2022-12-28	WOS:000189363800038
J	Cavazzana-Calvo, M; Thrasher, A; Mavilio, F				Cavazzana-Calvo, M; Thrasher, A; Mavilio, F			The future of gene therapy	NATURE			English	Editorial Material							HEMATOPOIETIC STEM-CELLS		Hop Necker Enfants Malad, Immunol & Pediat Haematol Unit, F-75743 Paris 15, France; Inst Child Hlth, London WC1N 1EH, England; Ist Sci H San Raffaele, I-20132 Milan, Italy; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Universita di Modena e Reggio Emilia	Cavazzana-Calvo, M (corresponding author), Hop Necker Enfants Malad, Immunol & Pediat Haematol Unit, F-75743 Paris 15, France.			Mavilio, Fulvio/0000-0003-0459-4320				Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bonini C, 2003, NAT MED, V9, P367, DOI 10.1038/nm0403-367; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dave UP, 2004, SCIENCE, V303, P333, DOI 10.1126/science.1091667; Fischer A, 2001, LANCET, V357, P1863, DOI 10.1016/S0140-6736(00)04959-X; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Williams DA, 2003, SCIENCE, V302, P400, DOI 10.1126/science.1091258	9	189	207	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	2004	427	6977					779	781		10.1038/427779a	http://dx.doi.org/10.1038/427779a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985734				2022-12-28	WOS:000189207500016
J	Halic, M; Becker, T; Pool, MR; Spahn, CMT; Grassucci, RA; Frank, J; Beckmann, R				Halic, M; Becker, T; Pool, MR; Spahn, CMT; Grassucci, RA; Frank, J; Beckmann, R			Structure of the signal recognition particle interacting with the elongation-arrested ribosome	NATURE			English	Article							ESCHERICHIA-COLI RIBOSOME; 7SL RNA; ANGSTROM RESOLUTION; SACCHAROMYCES-CEREVISIAE; CRYOELECTRON MICROSCOPY; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; SECRETORY PROTEIN; CRYSTAL-STRUCTURE; 80S RIBOSOME	Cotranslational translocation of proteins across or into membranes is a vital process in all kingdoms of life. It requires that the translating ribosome be targeted to the membrane by the signal recognition particle (SRP), an evolutionarily conserved ribonucleoprotein particle. SRP recognizes signal sequences of nascent protein chains emerging from the ribosome. Subsequent binding of SRP leads to a pause in peptide elongation and to the ribosome docking to the membrane-bound SRP receptor. Here we present the structure of a targeting complex consisting of mammalian SRP bound to an active 80S ribosome carrying a signal sequence. This structure, solved to 12 Angstrom by cryo-electron microscopy, enables us to generate a molecular model of SRP in its functional conformation. The model shows how the S domain of SRP contacts the large ribosomal subunit at the nascent chain exit site to bind the signal sequence, and that the Alu domain reaches into the elongation-factor- binding site of the ribosome, explaining its elongation arrest activity.	Humboldt Univ, Univ Med Sch, Charite, Inst Biochem, D-10117 Berlin, Germany; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Humboldt Univ, Univ Med Sch, Charite, Inst Med Phys & Biophys, D-10117 Berlin, Germany; Hlth Res Inc, Wadsworth Ctr, Howard Hughes Med Inst, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Manchester; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Beckmann, R (corresponding author), Humboldt Univ, Univ Med Sch, Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	roland.beckmann@charite.de	Halic, Mario/X-2163-2018; Pool, Martin R./AAB-9181-2021	Pool, Martin R./0000-0003-3071-1535				ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLOBEL G, 1971, BIOMEMBRANE, P193; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P103; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; Huang QJ, 2002, BIOCHEMISTRY-US, V41, P11362, DOI 10.1021/bi025765t; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kuglstatter A, 2002, NAT STRUCT BIOL, V9, P740, DOI 10.1038/nsb843; MARTOGLIO B, 1997, CELL BIOL LAB HDB, P265; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Nagai K, 2003, EMBO J, V22, P3479, DOI 10.1093/emboj/cdg337; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; Padmanabhan S, 2001, STRUCTURE, V9, P859, DOI 10.1016/S0969-2126(01)00641-4; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Rinke-Appel J, 2002, RNA, V8, P612, DOI 10.1017/S1355838202020095; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Rosenblad MA, 2003, NUCLEIC ACIDS RES, V31, P363, DOI 10.1093/nar/gkg107; Rosendal KR, 2003, P NATL ACAD SCI USA, V100, P14701, DOI 10.1073/pnas.2436132100; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SPAHN C, IN PRESS EMBO J; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Thomas Y, 1997, NUCLEIC ACIDS RES, V25, P1920, DOI 10.1093/nar/25.10.1920; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; Weichenrieder O, 2000, NATURE, V408, P167, DOI 10.1038/35041507; Wilson DN, 2002, CURR PROTEIN PEPT SC, V3, P1, DOI 10.2174/1389203023380846; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	50	320	330	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					808	814		10.1038/nature02342	http://dx.doi.org/10.1038/nature02342			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985753				2022-12-28	WOS:000189207500031
J	von Elm, E; Poglia, G; Walder, B; Tramer, MR				von Elm, E; Poglia, G; Walder, B; Tramer, MR			Different patterns of duplicate publication - An analysis of articles used in systematic reviews	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIOPERATIVE BLOOD-TRANSFUSION; PLACEBO-CONTROLLED TRIALS; POSTOPERATIVE NAUSEA; FLUID RESUSCITATION; CARDIAC-SURGERY; DOSE-RESPONSE; KNEE SURGERY; ONDANSETRON; ANESTHESIA; METAANALYSIS	Context Duplicate publication is publication of an article that overlaps substantially with an article published elsewhere. Patterns of duplication are not well understood. Objective To investigate duplication patterns and propose a decision tree for classification. Data Sources We searched a comprehensive list of systematic reviews (1989 through August 15, :2002) in anesthesia and analgesia that is accessible on the Internet. We selected published full articles of duplicates that had been identified in these systematic reviews. Abstracts, letters, or book chapters were excluded. Study Selection and Data Extraction Authors of 56 (40%) of 141 systematic reviews acknowledged identification of duplicates. Duplication patterns were identified independently by all investigators comparing samples and outcomes of pairs of duplicates and main articles. Information on cross-reference, sponsorship, authorship, and publication characteristics was extracted from the articles. Data Synthesis The 56 systematic reviews included 1131 main articles (129337 subjects) and excluded 103 duplicates (12589 subjects) that originated from 78 main articles. Sixty articles were published twice, 13 three times, 3 four times, and 2 five times. We identified 6 duplication patterns: 0 A) identical samples and identical outcomes (21 pairs); (113) same as 1A but several duplicates assembled (n=16); (2) identical samples and different outcomes (n=24); (3A) increasing sample and identical outcomes (n=1 1); (313) decreasing sample and identical outcomes (n=1 1); (4) different samples and different outcomes (n=20). The prevalence of covert duplicate articles (without a cross-reference to the main article) was 5.3% (65/1234). Of the duplicates, 34 (33%) were sponsored by the pharmaceutical industry, and 66 (64%) had authorship that differed partly or completely from the main article. The median journal impact factor was 1.8 (range, 0.1-29.5) for duplicates and 2.0 (range, 0.4-29.5) for main articles (P=.13). The median annual citation rate was 1.7 (range, 0-27) for duplicates and 2.1 (range, 0-31) for main articles (P=.45). The median number of authors was 4 (range, 1-14) for duplicates and 4 (range, 1-15) for corresponding main articles (P=.02). The median delay in publication between main articles and duplicates was 1 year (range, 0-7 years). Conclusions Duplication goes beyond simple copying. Six distinct duplication patterns were identified after comparing study samples and outcomes of duplicates and corresponding main articles. Authorship was an unreliable criterion. Duplicates were published in journals with similar impact factors and were cited as frequently as main articles.	Univ Hosp Geneva, Div Anesthesiol, Dept Anesthesiol Pharmacol & Surg Intens Care, CH-1211 Geneva 14, Switzerland	University of Geneva	Tramer, MR (corresponding author), Univ Hosp Geneva, Div Anesthesiol, Dept Anesthesiol Pharmacol & Surg Intens Care, CH-1211 Geneva 14, Switzerland.	martin.tramer@hcuge.ch		von Elm, Erik/0000-0002-7412-0406				ALDERSON P, 2000, COCHRANE DB SYST REV, V2; ALDERSON P, 2002, COCHRANE DB SYST REV, V1; [Anonymous], 1969, N Engl J Med, V281, P676; [Anonymous], COCHRANE DATABASE SY; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Bailey BJ, 2002, OTOLARYNG HEAD NECK, V126, P211, DOI 10.1067/mhn.2002.122698; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Barnard H, 1993, Ned Tijdschr Geneeskd, V137, P593; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; Blancett S S, 1995, Image J Nurs Sch, V27, P51; Bloemenkamp D G, 1999, Ned Tijdschr Geneeskd, V143, P2150; BROAD WJ, 1981, SCIENCE, V211, P1137, DOI 10.1126/science.7008199; BUNN F, 2003, COCHRANE DB SYST REV, V1, P1319; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Choi PTL, 2001, ANESTH ANALG, V92, P700; Collins SL, 1998, EUR J CLIN PHARMACOL, V54, P107, DOI 10.1007/s002280050430; COLLINS SL, 2000, COCHRANE DB SYST REV, V2; Curatolo M, 1998, ACTA ANAESTH SCAND, V42, P910, DOI 10.1111/j.1399-6576.1998.tb05349.x; Dexter F, 1998, REGION ANESTH PAIN M, V23, P439, DOI 10.1016/S1098-7339(98)90024-4; Domino KB, 1999, ANESTH ANALG, V88, P1370, DOI 10.1097/00000539-199906000-00032; Duggan L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001359.pub2; Eberhart LHJ, 1999, ANASTH INTENSIV NOTF, V34, P528, DOI 10.1055/s-1999-207; Edwards JE, 1999, PAIN, V81, P289, DOI 10.1016/S0304-3959(99)00022-6; Edwards JE, 2000, COCHRANE DB SYST REV, V4; Edwards JE, 2000, COCHRANE DB SYST REV, V2; Fergusson D, 1999, TRANSFUS MED REV, V13, P106, DOI 10.1016/S0887-7963(99)80005-4; Figueredo E, 1999, ACTA ANAESTH SCAND, V43, P637, DOI 10.1034/j.1399-6576.1999.430608.x; Figueredo E, 1999, J CLIN ANESTH, V11, P24, DOI 10.1016/S0952-8180(98)00124-X; Figueredo ED, 1998, J CLIN ANESTH, V10, P211, DOI 10.1016/S0952-8180(98)00009-9; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Henzi I, 1999, BRIT J ANAESTH, V83, P761, DOI 10.1093/bja/83.5.761; Henzi I, 2000, CAN J ANAESTH, V47, P537, DOI 10.1007/BF03018945; Howell C J, 1992, Int J Obstet Anesth, V1, P93, DOI 10.1016/0959-289X(92)90008-R; HOWELL CJ, 2000, COCHRANE DB SYST REV, V2; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; HUTH EJ, 1986, ANN INTERN MED, V104, P257, DOI 10.7326/0003-4819-104-2-257; International Committee of Medical Journal Editors, UN REQ MAN SUBM BIOM; Jefferson T, 1998, SCI ENG ETHICS, V4, P135, DOI 10.1007/s11948-998-0043-9; Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; Laupacis A, 1998, TRANSFUSION MED, V8, P309; Laupacis A, 1997, ANESTH ANALG, V85, P1258, DOI 10.1097/00000539-199712000-00014; Levi M, 1999, LANCET, V354, P1940, DOI 10.1016/S0140-6736(99)01264-7; Ling E, 2000, ANESTHESIOLOGY, V93, P1115, DOI 10.1097/00000542-200010000-00037; Loewen PS, 2000, CAN J ANAESTH, V47, P1008, DOI 10.1007/BF03024875; MANTHA S, 1994, ANESTH ANALG, V79, P422; McQuay HJ, 1999, J PAIN SYMPTOM MANAG, V17, P164, DOI 10.1016/S0885-3924(98)00126-2; Meiser A, 1997, ANAESTHESIST, V46, P867, DOI 10.1007/s001010050481; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moore A, 1997, PAIN, V70, P193, DOI 10.1016/S0304-3959(96)03319-2; Moore A., 2000, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD001547, DOI 10.1002/14651858.CD001547]; *NIH, 1997, GUID COND RES INTR R; PARKER MJ, 2000, COCHRANE DB SYST REV, V2; Picard P, 2000, ANESTH ANALG, V90, P963; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Robinson BJ, 1999, ACTA ANAESTH SCAND, V43, P185, DOI 10.1034/j.1399-6576.1999.430211.x; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Schein M, 2001, SURGERY, V129, P655, DOI 10.1067/msy.2001.114549; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; SMITH AF, 2000, COCHRANE DB SYST REV, V3; SORENSON RM, 1992, ANESTHESIOLOGY, V77, P1095, DOI 10.1097/00000542-199212000-00009; Tangkanakul C, 1997, EUR J VASC ENDOVASC, V13, P491, DOI 10.1016/S1078-5884(97)80178-5; TANGKANAKUL C, 2000, COCHRANE DB SYST REV, V2; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer MR, 1998, BMJ-BRIT MED J, V317, P875, DOI 10.1136/bmj.317.7162.875; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Urwin SC, 2000, BRIT J ANAESTH, V84, P450, DOI 10.1093/oxfordjournals.bja.a013468; vanderMast RC, 1996, J PSYCHOSOM RES, V41, P13, DOI 10.1016/0022-3999(96)00005-0; VELANOVICH V, 1989, SURGERY, V105, P65; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WALDRON T, 1992, BRIT MED J, V304, P1029, DOI 10.1136/bmj.304.6833.1029; Wulf H, 1996, CAN J ANAESTH, V43, P1260, DOI 10.1007/BF03013437; 2001, ISI J CITATION REPOR	76	192	198	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					974	980		10.1001/jama.291.8.974	http://dx.doi.org/10.1001/jama.291.8.974			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982913				2022-12-28	WOS:000189182000025
J	Eaton, WW; Mortensen, PB; Agerbo, E; Byrne, M; Mors, O; Ewald, H				Eaton, WW; Mortensen, PB; Agerbo, E; Byrne, M; Mors, O; Ewald, H			Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers	BRITISH MEDICAL JOURNAL			English	Article									Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA; Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; Psychiat Hosp Aarhus, Inst Basic Psychiat Res, DK-8240 Risskov, Denmark	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Aarhus University; Aarhus University	Eaton, WW (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway, Baltimore, MD 21205 USA.	weaton@jhsph.edu	Agerbo, Esben/A-2645-2012; Mortensen, Preben B/D-2358-2015	Agerbo, Esben/0000-0002-2849-524X; Mortensen, Preben B/0000-0002-5230-9865; Mors, Ole/0000-0002-5660-0393	PHS HHS [53188] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DOHAN FC, 1966, ACTA PSYCHIAT SCAND, V42, P125, DOI 10.1111/j.1600-0447.1966.tb01920.x; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; SINGH MM, 1976, SCIENCE, V191, P191; STRAUB RE, 1995, NAT GENET, V11, P287, DOI 10.1038/ng1195-287; Zhong F, 1996, NAT GENET, V14, P329, DOI 10.1038/ng1196-329	5	70	71	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					438	439		10.1136/bmj.328.7437.438	http://dx.doi.org/10.1136/bmj.328.7437.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976100	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000189161000019
J	Molyneux, AN				Molyneux, AN			ABC of smoking cessation - Nicotine replacement therapy	BRITISH MEDICAL JOURNAL			English	Review									City Hosp, Nottingham NG5 1PB, England	University of Nottingham	Molyneux, AN (corresponding author), City Hosp, Nottingham NG5 1PB, England.							Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; SILAGY C, 2000, COCHRANE DB SYST REV; Tobacco Advisory Group of the Royal College of Physicians, 2000, NIC ADD BRIT; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987	4	68	69	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					454	456		10.1136/bmj.328.7437.454	http://dx.doi.org/10.1136/bmj.328.7437.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976103	Green Published			2022-12-28	WOS:000189161000025
J	Varfolomeev, EE; Ashkenazi, A				Varfolomeev, EE; Ashkenazi, A			Tumor necrosis factor: An apoptosis JuNKie?	CELL			English	Review							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; TNF-ALPHA; DEPENDENT APOPTOSIS; BCL2 FAMILY; DEATH; SUPERFAMILY; PROTEINS; EIGER; LIFE	TNF's main function is to stimulate inflammation by turning on gene transcription through the IKK/NFkappaB and JNK/AP-1 signaling cascades. TNF also can trigger apoptosis through caspase-8, but the role and underlying mechanism of this activity are not fully understood. Here, we review recent data on the role of JNK in the regulation of TNF-dependent apoptosis and discuss what is known so far about how cells decide whether to live or die in response to TNF.	Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; DIETRICH N, 2003, IN PRESS CELL DEATH; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; NATERI AS, 2004, IN PRESS SCIENCE; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WERTZ IE, 2004, IN PRESS SCIENCE; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; YU C, 2004, MOL CELL, V13, P1	32	409	429	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					491	497		10.1016/S0092-8674(04)00166-7	http://dx.doi.org/10.1016/S0092-8674(04)00166-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980217	Bronze			2022-12-28	WOS:000189184200004
J	Kaplan, MM; Bianchi, DW				Kaplan, MM; Bianchi, DW			Primary billary cirrhosis: for want of an X chromosome?	LANCET			English	Editorial Material							PRIMARY BILIARY-CIRRHOSIS; PYRUVATE-DEHYDROGENASE COMPLEX; FETAL MICROCHIMERISM; TURNER-SYNDROME; AUTOIMMUNE; DISEASE; AUTOANTIBODIES; IDENTIFICATION; WOMEN; BLOOD		Tufts New England Med Ctr, Dept Med, Boston, MA 02111 USA; Tufts New England Med Ctr, Dept Pediat, Boston, MA 02111 USA; Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Kaplan, MM (corresponding author), Tufts New England Med Ctr, Dept Med, Boston, MA 02111 USA.	mkaplan@tufts-nemc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00054] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Bonamico M, 2002, J CLIN ENDOCR METAB, V87, P5495, DOI 10.1210/jc.2002-020855; Elsheikh M, 2001, CLIN ENDOCRINOL, V55, P223, DOI 10.1046/j.1365-2265.2001.01296.x; Invernizzi P, 2000, CLIN EXP IMMUNOL, V122, P418, DOI 10.1046/j.1365-2249.2000.01381.x; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; Jones DEJ, 2000, J HEPATOL, V33, P834, DOI 10.1016/S0168-8278(00)80317-7; Kita H, 2002, J EXP MED, V195, P113, DOI 10.1084/jem.20010956; Kita H, 2002, J CLIN INVEST, V109, P1231, DOI 10.1172/JCI200214698; Migliaccio C, 2001, HEPATOLOGY, V33, P792, DOI 10.1053/jhep.2001.23783; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; Selmi C, 2003, HEPATOLOGY, V38, P1250, DOI 10.1053/jhep.2003.50446; Shimoda S, 1998, J CLIN INVEST, V102, P1831, DOI 10.1172/JCI4213; SHIMODA S, 1995, J EXP MED, V181, P1835, DOI 10.1084/jem.181.5.1835; Sokol L, 2002, AM J HEMATOL, V70, P257, DOI 10.1002/ajh.10120; VANDEWATER J, 1995, J EXP MED, V181, P723, DOI 10.1084/jem.181.2.723; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; Zinn AR, 2001, J SOC GYNECOL INVEST, V8, pS34, DOI 10.1016/S1071-5576(00)00104-0	18	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					505	506		10.1016/S0140-6736(04)15576-1	http://dx.doi.org/10.1016/S0140-6736(04)15576-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975609				2022-12-28	WOS:000188999900004
J	Thompson, GR; Partridge, J				Thompson, GR; Partridge, J			Coronary calcification score: the coronary-risk impact factor	LANCET			English	Review							ELECTRON-BEAM TOMOGRAPHY; ARTERY CALCIUM; COMPUTED-TOMOGRAPHY; HEART-DISEASE; MYOCARDIAL-INFARCTION; ASSESSMENT STRATEGIES; VULNERABLE PATIENT; PROGNOSTIC VALUE; DEFINITIONS; PROGRESSION	Context Identification of asymptomatic high-risk individuals is integral to current policies for preventing coronary heart disease, but existing methods of estimating risk lack, sensitivity. To overcome this limitation increasing use is being made of non-invasive methods to detect subclinical coronary artery disease-eg, computed tomography (CT) to scan for coronary artery calcification. The location and extent of calcification correlate closely with pathological and angiographic abnormalities, but whether such calcification predicts clinical events, especially in younger individuals, is equivocal. Most data on coronary calcification have been obtained with electron-beam CT, but :recently multislice CT, which is more versatile, less expensive, and available in most large hospitals, has been increasingly used.	Hammersmith Hosp, Imperial Coll, Fac Med, Div Invest Sci, London W12 0NN, England; Harefield Hosp, Harefield UB9 6JH, Middx, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Thompson, GR (corresponding author), Hammersmith Hosp, Imperial Coll, Fac Med, Div Invest Sci, London W12 0NN, England.	g.thompson@ic.ac.uk						Achenbach S, 2002, CIRCULATION, V106, P1077, DOI 10.1161/01.CIR.0000027567.49283.FF; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Arad Y, 2001, CONTROL CLIN TRIALS, V22, P553, DOI 10.1016/S0197-2456(01)00146-5; Brown BG, 2001, AM J CARDIOL, V88, p23E; Budoff MJ, 2000, AM J CARDIOL, V86, P8, DOI 10.1016/S0002-9149(00)00820-1; Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Doherty TM, 1999, LANCET, V353, P41, DOI 10.1016/S0140-6736(05)74866-2; Elkeles RS, 2002, J CARDIOVASC RISK, V9, P349, DOI 10.1097/00043798-200212000-00008; Greenland P, 2003, NEW ENGL J MED, V349, P465, DOI 10.1056/NEJMcp023197; Kondos GT, 2003, CIRCULATION, V107, P2571, DOI 10.1161/01.CIR.0000068341.61180.55; Kopp AF, 2002, RADIOLOGY, V225, P113, DOI 10.1148/radiol.2251010173; Maher JE, 1996, AM J EPIDEMIOL, V144, P943, DOI 10.1093/oxfordjournals.aje.a008864; Naghavi M, 2003, CIRCULATION, V108, P1772, DOI 10.1161/01.CIR.0000087481.55887.C9; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Nasir K, 2003, J AM COLL CARDIOL, V41, p457A; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; O'Rourke RA, 2000, J AM COLL CARDIOL, V36, P326, DOI 10.1016/S0735-1097(00)00831-7; Peebles CR, 2003, HEART, V89, P591, DOI 10.1136/heart.89.6.591; Pohle K, 2003, HEART, V89, P625, DOI 10.1136/heart.89.6.625; Raggi P, 2000, CIRCULATION, V101, P850, DOI 10.1161/01.CIR.101.8.850; Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243; Schmermund A, 2002, AM J CARDIOL, V90, P168, DOI 10.1016/S0002-9149(02)02445-1; Schmermund A, 1998, J AM COLL CARDIOL, V31, P1267, DOI 10.1016/S0735-1097(98)00082-5; Shaw LJ, 2003, RADIOLOGY, V228, P826, DOI 10.1148/radiol.2283021006; Smith S C Jr, 2000, Circulation, V101, P111; Thompson GR, 1996, QJM-INT J MED, V89, P565; Vliegenthart R, 2002, EUR HEART J, V23, P1596, DOI 10.1053/euhj.2002.3240; WANG TJ, 2000, CIRCULATION, V1106, P1189	30	57	62	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					557	559		10.1016/S0140-6736(04)15544-X	http://dx.doi.org/10.1016/S0140-6736(04)15544-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14976978				2022-12-28	WOS:000188999900023
J	Herwald, H; Cramer, H; Morgelin, M; Russell, W; Sollenberg, U; Norrby-Teglund, A; Flodgaard, H; Lindbom, L; Bjorck, L				Herwald, H; Cramer, H; Morgelin, M; Russell, W; Sollenberg, U; Norrby-Teglund, A; Flodgaard, H; Lindbom, L; Bjorck, L			M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage	CELL			English	Article							A STREPTOCOCCAL INFECTIONS; HEPARIN-BINDING PROTEIN; HUMAN NEUTROPHILS; CYSTEINE PROTEINASE; SURFACE-PROTEINS; PATHOGENESIS; ACTIVATION; GENERATION; SECRETION; INSERTION	Increased vascular permeability is a key feature of inflammatory conditions. In severe infections, leakage of plasma from the vasculature induces a life-threatening hypotension. Streptococcus pyogenes, a major human bacterial pathogen, causes a toxic shock syndrome (STSS) characterized by excessive plasma leakage and multi-organ failure. Here we find that M protein, released from the streptococcal surface, forms complexes with fibrinogen, which by binding to beta(2) integrins of neutrophils, activate these cells. As a result, neutrophils release heparin binding protein, an inflammatory mediator inducing vascular leakage. in mice, injection of M protein or subcutaneous infection with S. pyogenes causes severe pulmonary damage characterized by leakage of plasma and blood cells. These lesions were prevented by treatment with a beta(2) integrin antagonist. In addition, M protein/fibrinogen complexes were identified in tissue biopsies from a patient with necrotizing fasciitis and STSS, further underlining the pathogenic significance of such complexes in severe streptococcal infections.	Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Ctr Infect Med, S-14186 Huddinge, Sweden; Leukotech AS, DK-2100 Copenhagen, Denmark	Lund University; Karolinska Institutet; Karolinska Institutet	Herwald, H (corresponding author), Lund Univ, Dept Cell & Mol Biol, Tornavagen 10, S-22184 Lund, Sweden.	heiko.herwald@medkem.lu.se	Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842; Lindbom, Lennart/0000-0001-9243-257X				AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; Altieri DC, 1999, THROMB HAEMOSTASIS, V82, P781; Axelsson L, 2000, EXP CELL RES, V256, P257, DOI 10.1006/excr.2000.4816; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Collin M, 2000, MOL MICROBIOL, V36, P1306, DOI 10.1046/j.1365-2958.2000.01942.x; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; Crockett-Torabi E, 1998, J LEUKOCYTE BIOL, V63, P1; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Edens HA, 2003, CURR OPIN HEMATOL, V10, P25, DOI 10.1097/00062752-200301000-00005; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; Herwald H, 2003, J THROMB HAEMOST, V1, P284, DOI 10.1046/j.1538-7836.2003.00105.x; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; KANTOR FS, 1965, J EXP MED, V121, P849, DOI 10.1084/jem.121.5.849; Kihlberg BM, 1995, MICROB PATHOGENESIS, V19, P299, DOI 10.1016/S0882-4010(96)80003-9; Kotb M, 2002, NAT MED, V8, P1398, DOI 10.1038/nm800; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIE.RC, 1969, J GEN MICROBIOL, V55, P161, DOI 10.1099/00221287-55-2-161; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lindmark A, 1999, J LEUKOCYTE BIOL, V66, P634, DOI 10.1002/jlb.66.4.634; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Norrby-Teglund A, 2001, J INFECT DIS, V184, P853, DOI 10.1086/323443; Norrby-Teglund A, 2000, EUR J IMMUNOL, V30, P3247, DOI 10.1002/1521-4141(200011)30:11<3247::AID-IMMU3247>3.0.CO;2-D; Ooe K, 1999, CLIN INFECT DIS, V28, P1317, DOI 10.1086/514785; Persson K, 2003, J BIOL CHEM, V278, P31884, DOI 10.1074/jbc.M302522200; Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4; Ringdahl U, 2000, MOL MICROBIOL, V37, P1318, DOI 10.1046/j.1365-2958.2000.02062.x; RUF A, 1995, BRIT J HAEMATOL, V90, P791, DOI 10.1111/j.1365-2141.1995.tb05197.x; Stevens Dennis L., 2003, Curr Infect Dis Rep, V5, P379, DOI 10.1007/s11908-003-0017-7; STEVENS DL, 1995, EMERG INFECT DIS, V1, P69, DOI 10.3201/eid0103.950301; Tapper H, 2002, BLOOD, V99, P1785, DOI 10.1182/blood.V99.5.1785; Yan SR, 1995, J INFLAMM, V45, P297	40	251	269	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					367	379		10.1016/S0092-8674(04)00057-1	http://dx.doi.org/10.1016/S0092-8674(04)00057-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016372	Bronze			2022-12-28	WOS:000188825800006
J	Vigneron, N; Stroobant, V; Chapiro, J; Ooms, A; Degiovanni, G; Morel, S; van der Bruggen, P; Boon, T; Van den Eynde, BJ				Vigneron, N; Stroobant, V; Chapiro, J; Ooms, A; Degiovanni, G; Morel, S; van der Bruggen, P; Boon, T; Van den Eynde, BJ			An antigenic peptide produced by peptide splicing in the proteasome	SCIENCE			English	Article							CYTOLYTIC T-LYMPHOCYTES; INTRON SEQUENCE; CANCER ANTIGEN; HUMAN-MELANOMA; GENE; RECOGNITION; GENERATION; PROTEINS; CELLS	CD8 T lymphocytes recognize peptides of 8 to 10 amino acids presented by class 1 molecules of the major histocompatibility complex. Here, CD8 T lymphocytes were found to recognize a nonameric peptide on melanoma cells that comprises two noncontiguous segments of melanocytic glycoprotein gp100(PMEL17). The production of this peptide involves the excision of four amino acids and splicing of the fragments. This process was reproduced in vitro by incubating a precursor peptide of 13 amino acids with highly purified proteasomes. Splicing appears to occur by transpeptidation involving an acyl-enzyme intermediate. Our results reveal an unanticipated aspect of the proteasome function of producing antigenic peptides.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium; Univ Liege, Chirurg Expt Lab, B-4000 Liege, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; University of Liege	Van den Eynde, BJ (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	benoit.vandeneynde@bru.licr.org						ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; COULIE PG, 1995, P NATL ACAD SCI USA, V92, P7976, DOI 10.1073/pnas.92.17.7976; Engelhard VH, 2002, MOL IMMUNOL, V39, P127, DOI 10.1016/S0161-5890(02)00096-2; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Guilloux Y, 1996, J EXP MED, V183, P1173, DOI 10.1084/jem.183.3.1173; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; Morel S, 1999, INT J CANCER, V83, P755, DOI 10.1002/(SICI)1097-0215(19991210)83:6<755::AID-IJC10>3.0.CO;2-S; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131	14	246	264	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	2004	304	5670					587	590		10.1126/science.1095522	http://dx.doi.org/10.1126/science.1095522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	814LB	15001714				2022-12-28	WOS:000220975100049
J	Miranda, DD; Ximenes, RAD; Barone, AA; Vaz, VL; Vieira, AG; Albuquerque, VMG				Miranda, DD; Ximenes, RAD; Barone, AA; Vaz, VL; Vieira, AG; Albuquerque, VMG			Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE; MANAGEMENT; COMPLICATIONS		Univ Fed Pernambuco, Fac Med Sci, Dept Clin Med, BR-50100130 Recife, PE, Brazil; Univ Fed Pernambuco, Oswaldo Cruz Univ Hosp, Recife, PE, Brazil; Univ Sao Paulo, Fac Med, Inst Trop Med, BR-05403000 Sao Paulo, Brazil	Universidade Federal de Pernambuco; Universidade Federal de Pernambuco; Universidade de Sao Paulo	Miranda, DD (corresponding author), Rua Cosme Bezerra 85-107, BR-50670310 Recife, PE, Brazil.	dmofilho@uol.com.br	Barone, Antonio A/C-5531-2013	Barone, Antonio A/0000-0001-9895-3886				ABRUTYN E, 1991, JAMA-J AM MED ASSOC, V266, P2262, DOI 10.1001/jama.266.16.2262; Agarwal M, 1998, NATL MED J INDIA, V11, P209; ARMITAGE P, 1978, J INFECT DIS, V138, P1, DOI 10.1093/infdis/138.1.1; Barone A A, 1976, Rev Hosp Clin Fac Med Sao Paulo, V31, P215; BLECK TP, 2000, MANDELL DOUGLAS BENN, P2537; EDMONDSON RS, 1979, BRIT MED J, V1, P1401, DOI 10.1136/bmj.1.6175.1401; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; GALLAIS H, 1977, NOUV PRESSE MED, V6, P571; GUPTA PS, 1980, LANCET, V2, P439; HARDINGGOLDSON HE, 1995, J TROP MED HYG, V98, P179; ILDIRIN I, 1972, PAN AM HLTH ORG SCI, V253, P119; Keswani N K, 1980, J Indian Med Assoc, V75, P67; List WF, 1981, NOTFALLMEDIZIN, V7, P731; MIRANDA D, 2003, BRAZ J INFECT DIS S1, V7, pS18; MIRANDA DB, 9 C BRAS INF 1996 AU; MIRANDA DB, 1996, 9 C BRAS INF 1996 AU; Miranda-Filho Democrito B., 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P333, DOI 10.1590/S0036-46652000000600006; Rossano C, 1970, Minerva Anestesiol, V36, P725; SANDERS RKM, 1977, LANCET, V1, P974; SUN KO, 1994, J ROY SOC MED, V87, P135; THOMAS PP, 1982, T ROY SOC TROP MED H, V76, P620, DOI 10.1016/0035-9203(82)90224-3; Thwaites CL, 2003, BMJ-BRIT MED J, V326, P117, DOI 10.1136/bmj.326.7381.117; UDWADIA FE, 1987, EPIDEMIOL INFECT, V99, P675, DOI 10.1017/S095026880006653X; VAKIL BJ, 1979, T ROY SOC TROP MED H, V73, P579, DOI 10.1016/0035-9203(79)90058-0; VERONESI R, 1980, REV BRAS CLIN TERAP, V9, P301	25	37	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					615	617		10.1136/bmj.38027.560347.7C	http://dx.doi.org/10.1136/bmj.38027.560347.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15003976	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220208100018
J	Michels, KB; Ekbom, A				Michels, KB; Ekbom, A			Caloric restriction and incidence of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECREATIONAL PHYSICAL-ACTIVITY; EPIDERMAL-GROWTH-FACTOR; ANOREXIA-NERVOSA; BODY-SIZE; ENERGY RESTRICTION; DIFFERENT PERIODS; MAMMARY-TUMORS; UNITED-STATES; YOUNG-WOMEN; LONG-TERM	Context Restricting caloric intake is one of the most effective ways to extend lifespan and to reduce spontaneous tumor occurrence in experimental animals, but whether similar associations hold in humans has not been appropriately studied. Objective To determine whether caloric restriction in early life reduces the risk of invasive breast cancer. Design, Setting, and Participants Retrospective cohort study using data from the Swedish Inpatient Registry, the Swedish Cancer Registry, the Swedish Death Registry, and the Swedish Fertility Registry. Participants were 7303 Swedish women hospitalized for anorexia nervosa prior to age 40 years between 1965 and 1998. Women were excluded (n=31)if they were diagnosed with cancer prior to their first discharge from hospitalization for anorexia nervosa. Main Outcome Measure Incidence of invasive breast cancer. Results Compared with the Swedish general population, women hospitalized for anorexia nervosa prior to age 40 years had a 53% (95% confidence interval [CI], 3%-81%) lower incidence of breast cancer; nulliparous women with anorexia nervosa had a 23% (95% CI, 79% higher to 75% lower) lower incidence, and parous women with anorexia nervosa had a 76% (95 % CI, 13%-97%) lower incidence. Conclusions Severe caloric restriction in humans may confer protection from invasive breast cancer. Low caloric intake prior to first birth followed by a subsequent pregnancy appears to be associated with an even more pronounced reduction in risk.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Karolinska Inst, Karolinska Hosp, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Karolinska Institutet; Karolinska University Hospital	Michels, KB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.	kmichels@rics.bwh.harvard.edu						Beaglehole R., 2003, WORLD HLTH REPORT 20; Berkey CS, 1999, CANCER-AM CANCER SOC, V85, P2400, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2400::AID-CNCR15>3.0.CO;2-O; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; Cleary MP, 2002, CANCER EPIDEM BIOMAR, V11, P836; Coates RJ, 1999, BRIT J CANCER, V81, P167, DOI 10.1038/sj.bjc.6690667; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; ENGELMAN RW, 1995, CANCER RES, V55, P1289; FERNANDES G, 1995, P NATL ACAD SCI USA, V92, P6494, DOI 10.1073/pnas.92.14.6494; Friedenreich CM, 2001, EUR J CANCER PREV, V10, P15, DOI 10.1097/00008469-200102000-00003; FRISCH RE, 1987, AM J CLIN NUTR, V45, P328, DOI 10.1093/ajcn/45.1.328; Gammon MD, 1998, AM J EPIDEMIOL, V147, P273; Gammon MD, 1998, JNCI-J NATL CANCER I, V90, P100, DOI 10.1093/jnci/90.2.100; Hall K., 1999, Journal of Endocrinological Investigation, V22, P48; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hilakivi-Clarke L, 2001, BRIT J CANCER, V85, P1680, DOI 10.1054/bjoc.2001.2109; KREIPE RE, 1989, AM J DIS CHILD, V143, P1322, DOI 10.1001/archpedi.1989.02150230080027; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; Mellemkjaer L, 2001, CANCER CAUSE CONTROL, V12, P173, DOI 10.1023/A:1008974414116; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Michels KB, 2002, BREAST CANCER RES, V4, P58, DOI 10.1186/bcr423; MITTENDORF R, 1995, CANCER CAUSE CONTROL, V6, P347, DOI 10.1007/BF00051410; Munoz MT, 2002, EUR J ENDOCRINOL, V147, P275, DOI 10.1530/eje.0.1470275; Patel AV, 2003, CANCER CAUSE CONTROL, V14, P519, DOI 10.1023/A:1024895613663; Rockhill B, 1998, J NATL CANCER I, V90, P1155, DOI 10.1093/jnci/90.15.1155; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Rous P, 1915, B JOHNS HOPKINS HOSP, V26, P146; RUGGERI BA, 1989, CANCER RES, V49, P4130; Spady TJ, 1999, J NUTR, V129, p587S, DOI 10.1093/jn/129.2.587S; *STAT SWED, 2002, 20025 SCB STAT SWED; SWANSON CA, 1988, CANCER RES, V48, P5363; *SWED CANC REG, 1993, CANC INC SWED 1990; TANNENBAUM A, 1953, CANCER RES, V13, P532; THEANDER S, 1985, J PSYCHIATR RES, V19, P493, DOI 10.1016/0022-3956(85)90059-7; THEANDER S, 1970, ACTA PSYCHIAT SCAND, P1; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; Trentham-Dietz A, 2000, CANCER CAUSE CONTROL, V11, P533, DOI 10.1023/A:1008961931534; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; Visscher MB, 1942, SURGERY, V11, P48; Zhu ZJ, 1999, MOL CARCINOGEN, V24, P241, DOI 10.1002/(SICI)1098-2744(199904)24:4<241::AID-MC1>3.0.CO;2-P	44	129	134	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1226	1230		10.1001/jama.291.10.1226	http://dx.doi.org/10.1001/jama.291.10.1226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010444				2022-12-28	WOS:000220061900023
J	Jones, MH; Virtanen, C; Honjoh, D; Miyoshi, T; Satoh, Y; Okumura, S; Nakagawa, K; Nomura, H; Ishikawa, Y				Jones, MH; Virtanen, C; Honjoh, D; Miyoshi, T; Satoh, Y; Okumura, S; Nakagawa, K; Nomura, H; Ishikawa, Y			Two prognostically significant subtypes of high-grade lung neuroendocrine turnours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles	LANCET			English	Article							MONOCLONAL-ANTIBODY; CLASSIFICATION; DIAGNOSIS; SIGNATURE; TUMORS; CANCER; CYCLE	Background Classification of high-grade neuroendocrine tumours (HGNT) of the lung currently recognises large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC) as distinct groups. However, a similarity in histology for these two carcinomas and uncertain clinical course have led to suggestions that a single HGNT classification would be more appropriate. Gene expression profiling, which can reproduce histopathological classification, and often defines new subclasses with prognostic significance, can be used to resolve HGNT classification. Methods We used cDNA microarrays with 40386 elements to analyse the gene expression profiles of 38 surgically resected samples of lung neuroendocrine tumours and 11 SCLC cell lines. Samples of large-cell carcinoma, adenocarcinoma, and normal lung were also included to give a total of 105 samples analysed. The data were subjected to filtering to yield informative genes before unsupervised hierarchical clustering that identified relatedness of tumour samples. Findings Distinct groups for carcinoids, large-cell carcinoma, adenocarcinoma, and normal lung were readily identified. However, we were unable to distinguish LCNEC from SCLC by gene expression profiling. Three independent rounds of unsupervised hierarchical clustering consistently divided SCLC samples into two main groups with LCNEC samples largely integrated with these groups. Furthermore, patients in one of the groups identified by clustering had a significantly better clinical outcome than the other (83% vs 12% survived for 5 years; p=0.0094. None of the highly proliferative SCLC cell lines subsequently analysed clustered with this good-prognosis group. Interpretation Our findings show that HGNT of the lung can be classified into two groups independent of SCLC and LCNEC. To this end, we have identified many genes, some of which encode well-characterised markers of cancer that distinguish the HGNT groups. These results have implications for the diagnosis, classification, and treatment of lung neuroendocrine tumours, and provide important insights into their underlying biology.	Univ Tokyo, Proliferat Signal Div, Chugai Pharmaceut Co Ltd, Tokyo, Japan; Invitrogen Japan, Tokyo, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 170, Japan; Canc Inst Hosp, Dept Chest Surg, Tokyo, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Ishikawa, Y (corresponding author), 1-37-1 Kami Ikebukuro,Toshima Ku, Tokyo 1708455, Japan.	ishikawa@jfcr.or.jp		Jones, Michael/0000-0002-2251-1990				Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Cerilli L A, 2001, Am J Clin Pathol, V116 Suppl, pS65; Chan HM, 2001, ESSAYS BIOCHEM, V37, P87, DOI 10.1042/bse0370087; GRAUS F, 1997, J CLIN ONCOL, V15, P266; Holzinger A, 1996, HYBRIDOMA, V15, P49, DOI 10.1089/hyb.1996.15.49; Kaufmann O, 1997, HUM PATHOL, V28, P1373, DOI 10.1016/S0046-8177(97)90226-4; Kellner U, 2002, LANCET ONCOL, V3, P235, DOI 10.1016/S1470-2045(02)00715-5; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Marchevsky AM, 2001, AM J CLIN PATHOL, V116, P466; Mariani L, 2001, CANCER RES, V61, P4190; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Simon GR, 2003, CHEST, V123, p259S, DOI 10.1378/chest.123.1_suppl.259S; 't Hoen PAC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng020; Travis W. D., 1999, WHO INT HISTOLOGICAL; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860	22	178	185	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					775	781		10.1016/S0140-6736(04)15693-6	http://dx.doi.org/10.1016/S0140-6736(04)15693-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016488				2022-12-28	WOS:000220092000008
J	Lee, WL; Grinstein, S				Lee, WL; Grinstein, S			The tangled webs that neutrophils weave	SCIENCE			English	Editorial Material							RECOMBINANT HUMAN DNASE; CYSTIC-FIBROSIS; INFLAMMATION		Mt Sinai Hosp, Dept Med, Div Crit Care Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Med, Div Respirol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Lee, WL (corresponding author), Mt Sinai Hosp, Dept Med, Div Crit Care Med, Toronto, ON M5G 1X5, Canada.	sga@sickkids.ca		Lee, Warren/0000-0002-1788-6587				Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; RICE WG, 1990, SCIENCE, V249, P178, DOI 10.1126/science.2371565; Robinson P, 2001, THORAX, V56, P237, DOI 10.1136/thorax.56.3.237; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; Suri R, 2002, AM J RESP CRIT CARE, V166, P352, DOI 10.1164/rccm.2110015	8	30	32	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1477	1478		10.1126/science.1095484	http://dx.doi.org/10.1126/science.1095484			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001765				2022-12-28	WOS:000220000100027
J	Nelson, WJ; Nusse, R				Nelson, WJ; Nusse, R			Convergence of Wnt, beta-catenin, and cadherin pathways	SCIENCE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITIONS; PROTEIN-TYROSINE-PHOSPHATASE; ADENOMATOUS POLYPOSIS-COLI; TRANSCRIPTION FACTOR SNAIL; APC TUMOR-SUPPRESSOR; STEM-CELLS; ALZHEIMERS-DISEASE; ALPHA-CATENIN; N-CADHERIN; ADHESION	The specification and proper arrangements of new cell types during tissue differentiation require the coordinated regulation of gene expression and precise interactions between neighboring cells. Of the many growth factors involved in these events, Wnts are particularly interesting regulators, because a key component of their signaling pathway, beta-catenin, also functions as a component of the cadherin complex, which controls cell-cell adhesion and influences cell migration. Here, we assemble evidence of possible interrelations between Wnt and other growth factor signaling, beta-catenin functions, and cadherin-mediated adhesion.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	wjnelson@stanford.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	NIGMS NIH HHS [R01 GM035527] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bonvini P, 2001, CANCER RES, V61, P1671; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gonzalez-Reyes A, 2003, J CELL SCI, V116, P949, DOI 10.1242/jcs.00310; Goodman RH, 2000, GENE DEV, V14, P1553; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kang DE, 1999, J NEUROSCI, V19, P4229; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ohsugi M, 1999, DEV DYNAM, V216, P168, DOI 10.1002/(SICI)1097-0177(199910)216:2<168::AID-DVDY7>3.0.CO;2-R; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Song XQ, 2003, DEVELOPMENT, V130, P3259, DOI 10.1242/dev.00524; Song XQ, 2002, SCIENCE, V296, P1855, DOI 10.1126/science.1069871; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	66	2069	2226	1	300	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1483	1487		10.1126/science.1094291	http://dx.doi.org/10.1126/science.1094291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001769	Green Accepted			2022-12-28	WOS:000220000100031
J	Wagers, AJ; Weissman, IL				Wagers, AJ; Weissman, IL			Plasticity of adult stem cells	CELL			English	Review							BONE-MARROW-CELLS; HEMATOPOIETIC STEM; LONG-TERM; PURKINJE NEURONS; NEURAL CREST; IN-VIVO; INFARCTED MYOCARDIUM; MUSCLE REGENERATION; MAMMALIAN FOREBRAIN; SKELETAL-MUSCLE	Recent years have seen much excitement over the possibility that adult mammalian stem cells may be capable of differentiating across tissue lineage boundaries, and as such may represent novel, accessible, and very versatile effectors of therapeutic tissue regeneration. Yet studies proposing such "plasticity" of adult somatic stem cells remain controversial, and in general, existing evidence suggests that in vivo such unexpected transformations are exceedingly rare and in some cases can be accounted for by equally unexpected alternative explanations.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Stanford University	Wagers, AJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	awagers@stanford.edu						Alison MR, 2003, J PATHOL, V200, P547, DOI 10.1002/path.1411; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752-200001000-00008; AUERBACH R, 1961, DEV BIOL, V3, P336, DOI 10.1016/0012-1606(61)90051-3; BALSAM LB, IN PRESS NATURE; Bel A, 2003, CIRCULATION, V108, P247, DOI 10.1161/01.cir.0000089040.11131.d4; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Caplice NM, 2003, CIRC RES, V92, P6, DOI 10.1161/01.RES.0000052826.35667.40; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Choi JB, 2003, DIABETOLOGIA, V46, P1366, DOI 10.1007/s00125-003-1182-9; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Forbes S, 2002, J PATHOL, V197, P510, DOI 10.1002/path.1163; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Fukada S, 2002, J CELL SCI, V115, P1285; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goodell MA, 2003, CURR OPIN HEMATOL, V10, P208, DOI 10.1097/00062752-200305000-00003; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HARRIS H, 1965, NATURE, V207, P606, DOI 10.1038/207606a0; HARRIS H, 1965, NATURE, V206, P583, DOI 10.1038/206583a0; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Issarachai S, 2002, EXP HEMATOL, V30, P366, DOI 10.1016/S0301-472X(02)00773-7; Ito M, 1999, DEV GROWTH DIFFER, V41, P429; IU NB, 2003, KARDIOLOGIYA, V43, P7; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jankowski RJ, 2002, GENE THER, V9, P642, DOI 10.1038/sj.gt.3301719; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; KIM WS, 1986, DEV BIOL, V114, P170, DOI 10.1016/0012-1606(86)90393-3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Langhans T, 1868, VIRCHOWS ARCH, V42, P382; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; McKinney-Freeman SL, 2003, EXP HEMATOL, V31, P806, DOI 10.1016/S0301-472X(03)00186-3; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; MOORE MAS, 1967, J EXP MED, V126, P715, DOI 10.1084/jem.126.4.715; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Ono K, 2003, J NEUROSCI RES, V72, P503, DOI 10.1002/jnr.10588; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pevny L, 2003, TRENDS NEUROSCI, V26, P351, DOI 10.1016/S0166-2236(03)00169-3; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; REYER RW, 1973, DEV BIOL, V32, P258, DOI 10.1016/0012-1606(73)90240-6; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; RUMYANTSEV PP, 1987, BIOMED BIOCHIM ACTA, V46, pS610; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; Stoner DS, 1996, P NATL ACAD SCI USA, V93, P15254, DOI 10.1073/pnas.93.26.15254; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Tanaka EM, 2003, CURR OPIN GENET DEV, V13, P497, DOI 10.1016/j.gde.2003.08.003; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Theise ND, 2002, EXP HEMATOL, V30, P1333, DOI 10.1016/S0301-472X(02)00931-1; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; UCHIDA N, 1992, THESIS STANFORD U ST; Vallieres L, 2003, J NEUROSCI, V23, P5197; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365-2613.2000.00164.x; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	136	826	900	1	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					639	648		10.1016/S0092-8674(04)00208-9	http://dx.doi.org/10.1016/S0092-8674(04)00208-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006347	Bronze			2022-12-28	WOS:000221499700005
J	Raghavan, SC; Swanson, PC; Wu, XT; Hsieh, CL; Lieber, MR				Raghavan, SC; Swanson, PC; Wu, XT; Hsieh, CL; Lieber, MR			A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex	NATURE			English	Article							V(D)J RECOMBINATION; CHROMOSOMAL TRANSLOCATIONS; MECHANISM; DIVERSITY; NICKING; STEPS	The causes of spontaneous chromosomal translocations in somatic cells of biological organisms are largely unknown, although double-strand DNA breaks are required in all proposed mechanisms(1-5).(.) The most common chromosomal abnormality in human cancer is the reciprocal translocation between chromosomes 14 and 18 (t(14;18)), which occurs in follicular lymphomas. The break at the immunoglobulin heavy-chain locus on chromosome 14 is an interruption of the normal V(D)J recombination process. But the breakage on chromosome 18, at the Bcl-2 gene, occurs within a confined 150-base-pair region (the major breakpoint region or Mbr) for reasons that have remained enigmatic. We have reproduced key features of the translocation process on an episome that propagates in human cells. The RAG complex-which is the normal enzyme for DNA cleavage at V, D or J segments-nicks the Bcl-2 Mbr in vitro and in vivo in a manner that reflects the pattern of the chromosomal translocations; however, the Mbr is not a V(D)J recombination signal. Rather the Bcl-2 Mbr assumes a non-B-form DNA structure within the chromosomes of human cells at 20-30% of alleles. Purified DNA assuming this structure contains stable regions of single-strandedness, which correspond well to the translocation regions in patients. Hence, a stable non-B-DNA structure in the human genome appears to be the basis for the fragility of the Bcl-2 Mbr, and the RAG complex is able to cleave this structure.	Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biol Sci, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Creighton Univ, Sch Med, Dept Immunol & Med Microbiol, Omaha, NE 68178 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Creighton University	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Room 5428,1441 Eastlake Ave,MC91176, Los Angeles, CA 90033 USA.	lieber@usc.edu		Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GOUGH GW, 1986, EMBO J, V5, P191, DOI 10.1002/j.1460-2075.1986.tb04195.x; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR., 1993, CAUSES CONSEQUENCES, P239; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Swanson PC, 2001, MOL CELL BIOL, V21, P449, DOI 10.1128/MCB.21.2.449-458.2001; Tevelev A, 2000, J BIOL CHEM, V275, P8341, DOI 10.1074/jbc.275.12.8341; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	18	191	197	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					88	93		10.1038/nature02355	http://dx.doi.org/10.1038/nature02355			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999286	Bronze			2022-12-28	WOS:000189363800041
J	Roden, DM				Roden, DM			Drug therapy: Drug-induced prolongation of the QT interval	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TORSADES-DE-POINTES; ACUTE PROMYELOCYTIC LEUKEMIA; CARDIAC-ARRHYTHMIA; POTASSIUM CHANNEL; M-CELLS; VENTRICULAR ARRHYTHMIAS; ANTIARRHYTHMIC DRUGS; ATRIAL-FIBRILLATION; TRIGGERED ACTIVITY; CLINICAL-FEATURES		Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Roden, DM (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, 532 Med Res Bldg 1, Nashville, TN 37232 USA.	dan.roden@vanderbilt.edu	Roden, Dan/ABD-5412-2021		NHLBI NIH HHS [HL49989, HL65962, HL46681] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065962, R01HL049989, P01HL046681, U19HL065962] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernethy DR, 2000, CIRCULATION, V101, P1749; Akar FG, 2002, CIRCULATION, V105, P1247, DOI 10.1161/hc1002.105231; Anderson ME, 2002, AM HEART J, V144, P769, DOI 10.1067/mhj.2002.125804; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; Burashnikov A, 2000, J CARDIOVASC ELECTR, V11, P458, DOI 10.1111/j.1540-8167.2000.tb00342.x; Burkhart GA, 1997, CLIN PHARMACOL THER, V61, P93, DOI 10.1016/S0009-9236(97)90185-5; CARLSSON L, 1993, CARDIOVASC RES, V27, P2186, DOI 10.1093/cvr/27.12.2186; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Choy AMJ, 1999, J AM COLL CARDIOL, V34, P396, DOI 10.1016/S0735-1097(99)00226-0; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; *DEP HLTH HUM SERV, 1999, ANT DRUGS ADV COMM 6; Dessertenne F, 1966, Arch Mal Coeur Vaiss, V59, P263; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; El-Sherif N, 1999, J AM COLL CARDIOL, V33, P1415, DOI 10.1016/S0735-1097(98)00700-1; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; *FOOD DRUG ADM CTR, 2000, PSYCH DRUGS ADV COMM; Gbadebo TD, 2002, CIRCULATION, V105, P770, DOI 10.1161/hc0602.103724; Gintant GA, 2001, J CARDIOVASC PHARM, V37, P607, DOI 10.1097/00005344-200105000-00012; Haverkamp W, 2000, EUR HEART J, V21, P1216, DOI 10.1053/euhj.2000.2249; Hennessy S, 2002, BRIT MED J, V325, P1070, DOI 10.1136/bmj.325.7372.1070; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P2088; Houltz B, 1998, PACE, V21, P1044, DOI 10.1111/j.1540-8159.1998.tb00150.x; Huang SY, 2000, LEUKEMIA LYMPHOMA, V38, P283, DOI 10.3109/10428190009087019; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; KAMISAKO T, 1995, INTERNAL MED, V34, P92, DOI 10.2169/internalmedicine.34.92; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Khongphatthanayothin A, 1998, J PEDIATR-US, V133, P51, DOI 10.1016/S0022-3476(98)70177-5; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; LAZZARA R, 1989, ANN INTERN MED, V111, P549, DOI 10.7326/0003-4819-111-7-549; Lee WM, 2003, NEW ENGL J MED, V349, P474, DOI 10.1056/NEJMra021844; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; Malik M, 2002, HEART, V87, P220, DOI 10.1136/heart.87.3.220; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Napolitano C, 2000, J CARDIOVASC ELECTR, V11, P691, DOI 10.1111/j.1540-8167.2000.tb00033.x; NATTEL S, 1988, CARDIOVASC RES, V22, P808, DOI 10.1093/cvr/22.11.808; Nowinski K, 2002, AM J MED, V113, P596, DOI 10.1016/S0002-9343(02)01274-3; Ohnishi K, 2000, ANN INTERN MED, V133, P881, DOI 10.7326/0003-4819-133-11-200012050-00012; Pham TV, 2001, CIRCULATION, V103, P2207; Pham TV, 2002, CIRCULATION, V106, P2132, DOI 10.1161/01.CIR.0000033596.21845.D8; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shimizu W, 2000, J AM COLL CARDIOL, V35, P778, DOI 10.1016/S0735-1097(99)00582-3; SICOURI S, 1993, J CARDIOVASC ELECTR, V4, P48, DOI 10.1111/j.1540-8167.1993.tb01211.x; SINGH BN, 1991, AM J CARDIOL, V68, P306, DOI 10.1016/0002-9149(91)90824-5; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Stambler BS, 1996, CIRCULATION, V94, P1613, DOI 10.1161/01.CIR.94.7.1613; Temple RJ, 2002, JAMA-J AM MED ASSOC, V287, P2273, DOI 10.1001/jama.287.17.2273; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; VELEBIT V, 1982, CIRCULATION, V65, P886, DOI 10.1161/01.CIR.65.5.886; VENTURINI E, 1992, Recenti Progressi in Medicina, V83, P21; Vila JA, 2000, IEEE T BIO-MED ENG, V47, P764, DOI 10.1109/10.844227; Viskin S, 2000, HEART, V83, P661, DOI 10.1136/heart.83.6.661; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103; Wei J, 1999, CIRCULATION, V100, P495; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Woosley RL, 2000, JAMA-J AM MED ASSOC, V284, P3047, DOI 10.1001/jama.284.23.3047; Wu YJ, 2002, CARDIOVASC RES, V53, P763, DOI 10.1016/S0008-6363(01)00387-X; Yan GX, 1998, CIRCULATION, V98, P1921, DOI 10.1161/01.CIR.98.18.1921; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Yang T, 2001, J CARDIOVASC PHARM, V38, P737, DOI 10.1097/00005344-200111000-00010; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Zhang ST, 1999, CIRC RES, V84, P989, DOI 10.1161/01.RES.84.9.989	79	1393	1457	4	80	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1013	1022		10.1056/NEJMra032426	http://dx.doi.org/10.1056/NEJMra032426			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999113				2022-12-28	WOS:000189363600009
J	Iezzoni, LI; O'Day, BL; Killeen, M; Harker, H				Iezzoni, LI; O'Day, BL; Killeen, M; Harker, H			Communicating about health care: Observations from persons who are deaf or hard of hearing	ANNALS OF INTERNAL MEDICINE			English	Article							DISABLING CONDITIONS; QUALITY; PEOPLE; ACCESS; SATISFACTION; DISABILITIES; INTERPRETER; MANAGEMENT; ADULTS; WOMEN	Background: Achieving patient-centered care requires effective communication between physicians and patients. Persons who are deaf or hard of hearing face considerable barriers to communicating with physicians. Objective: To understand perceptions of health care experiences and suggestions for improving care among deaf or hard-of-hearing individuals. Design: 4 semistructured group interviews, 2 conducted in American Sign Language (for deaf individuals) and 2 using Communication Access Realtime Translation (for hard-of-hearing individuals). Men and women were interviewed separately. Tapes of interviews were transcribed verbatim for analysis. Setting: Greater Boston, Massachusetts, and Washington, DC, in 2001. Participants: 14 deaf adults (23 to 51 years of age) and 12 hard-of-hearing adults (30 to 74 years of age). Measurements: Commonly expressed themes or views organized around dimensions of communication. Results: concerns coalesced around 6 broad themes: conflicting views between physicians and patients about being deaf or hard of hearing; different perceptions about what constitutes effective communication (such as lip reading, writing notes, and sign language interpreter); medication safety and other risks posed by inadequate communication; communication problems during physical examinations and procedures; difficulties interacting with office staff, including in waiting rooms; and problems with telephone communication, such as lengthy message menus. Participants offered extensive suggestions for improvements, starting with clinicians' asking patients about their preferred communication approach. Having patients repeat critical health information (such as medication instructions) can identify potentially dangerous miscommunication. Conclusions: As the population ages, physicians will encounter many more persons with hearing limitations. Physicians are not reimbursed for making some accommodations, such as hiring sign language interpreters. However, ensuring effective communication is essential to safe, timely, efficient, and patient-centered care.	Harvard Univ, Thorndike Lab, Div Gen Med & Primary Care,Charles A Dana Res Inst, Beth Israel Deaconess Med Ctr,Med Sch,Dept Med, Boston, MA 02215 USA; Third Sector New England, Boston, MA USA; Cherry Engn Support Serv Inc, Mclean, VA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Iezzoni, LI (corresponding author), Harvard Univ, Thorndike Lab, Div Gen Med & Primary Care,Charles A Dana Res Inst, Beth Israel Deaconess Med Ctr,Med Sch,Dept Med, RO-137,330 Brookline Ave, Boston, MA 02215 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010223] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS10223-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Adams P F, 1995, Vital Health Stat 10, P1; Allen Barbara, 2002, HEC Forum, V14, P197, DOI 10.1023/A:1020508511133; Baker DW, 1998, MED CARE, V36, P1461, DOI 10.1097/00005650-199810000-00004; Baker DW, 1996, JAMA-J AM MED ASSOC, V275, P783, DOI 10.1001/jama.275.10.783; Barnett S, 1999, Fam Med, V31, P17; Barnett S, 2002, ACAD MED, V77, P694, DOI 10.1097/00001888-200207000-00009; Barnett S, 2002, HEALTH SERV RES, V37, P105; Barnett S, 2002, FAM MED, V34, P376; Berwick DM, 2002, HEALTH AFFAIR, V21, P80, DOI 10.1377/hlthaff.21.3.80; Bogardus ST, 2003, JAMA-J AM MED ASSOC, V289, P1986, DOI 10.1001/jama.289.15.1986; Braddock David L., 2001, HDB DISABILITY STUDI, P11, DOI [DOI 10.4135/9781412976251.N2, DOI 10.4135/9781412976251]; Burch S, 2001, NEW DISABILITY HIST, P214; EBERT DA, 1995, JAMA-J AM MED ASSOC, V273, P227; Edwards R.A.R., 2001, NEW DISABILITY HIST, P58; GILCHRIST VJ, 1993, SUCCESSFUL FOCUS GRO, P70; HARTYGOLDER B, 1996, J FLA MED ASSOC, V83, P573; Hines J, 2000, Nurs Stand, V14, P33; Iezzoni LI, 2002, INT J QUAL HEALTH C, V14, P369, DOI 10.1093/intqhc/14.5.369; Iezzoni LI, 2003, ARCH INTERN MED, V163, P2085, DOI 10.1001/archinte.163.17.2085; Iezzoni LI, 2001, AM J MED QUAL, V16, P135; IEZZONI LI, 2003, HS10223 AG HEALTHC R; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jackler RK, 2003, JAMA-J AM MED ASSOC, V289, P1557, DOI 10.1001/jama.289.12.1557; Kreuger RA, 1998, ANAL REPORTING FOCUS; Krueger RA., 2009, FOCUS GROUPS PRACTIC; KULBACK SJ, 1995, JAMA-J AM MED ASSOC, V274, P795, DOI 10.1001/jama.1995.03530100034018; LOTKE M, 1995, ANN INTERN MED, V123, P54, DOI 10.7326/0003-4819-123-1-199507010-00008; MACKINNEY TG, 1995, J GEN INTERN MED, V10, P133, DOI 10.1007/BF02599667; MCEWEN E, 1988, J FAM PRACTICE, V26, P289; Miles M., 2013, QUALITATIVE DATA ANA; Morgan DL, 1993, SUCCESSFUL FOCUS GRO, P3, DOI [DOI 10.4135/9781483349008.N1, 10.4135/9781483349008]; Munoz-Baell IM, 2000, J EPIDEMIOL COMMUN H, V54, P40, DOI 10.1136/jech.54.1.40; O'Day B., 2002, J DISABIL POLICY STU, V13, P9, DOI [10.1177/10442073020130010201, DOI 10.1177/10442073020130010201]; Ralston E, 1996, J Am Board Fam Pract, V9, P167; Rivadeneyra R, 2000, AM J MED, V108, P470, DOI 10.1016/S0002-9343(99)00445-3; ROCKOW K, 2001, WORKING DEAF HARD PA; Steinberg AG, 1998, AM J PSYCHIAT, V155, P982, DOI 10.1176/ajp.155.7.982; Ubido J, 2002, HEALTH SOC CARE COMM, V10, P247, DOI 10.1046/j.1365-2524.2002.00365.x; Weil E, 2002, JAMA-J AM MED ASSOC, V288, P1265, DOI 10.1001/jama.288.10.1265; Witte T N, 2000, J Am Board Fam Pract, V13, P17; Yueh B, 2003, JAMA-J AM MED ASSOC, V289, P1976, DOI 10.1001/jama.289.15.1976; Zazove P, 1993, Arch Fam Med, V2, P745, DOI 10.1001/archfami.2.7.745; 1995, HOSP LAW NEWSL, V12, P1	43	186	195	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					356	362		10.7326/0003-4819-140-5-200403020-00011	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996677				2022-12-28	WOS:000189246800005
J	Barnes, PJ; Ito, K; Adcock, IM				Barnes, PJ; Ito, K; Adcock, IM			Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase	LANCET			English	Article							OXIDATIVE STRESS; INHALED CORTICOSTEROIDS; ALVEOLAR MACROPHAGES; INFLAMMATORY INDEXES; INDUCED SPUTUM; THEOPHYLLINE; 8-ISOPROSTANE; FLUTICASONE; ACETYLATION; EXPRESSION	By contrast with patients with asthma, those with chronic obstructive pulmonary disease (COPD) are poorly responsive to the anti-inflammatory actions of corticosteroids, and these drugs provide little clinical benefit. In both diseases, multiple inflammatory genes are activated, which results from acetylation of core histories around which DNA is wound. This acetylation opens up the chromatin structure allowing gene transcription and synthesis of inflammatory proteins to proceed. Corticosteroids recruit histone deacetylase 2 (HDAC2) to the actively transcribing gene, which reverses this process and switches off inflammatory gene transcription. We propose that in patients with COPD, HDAC2 function is impaired by cigarette smoking and oxidative stress, leading to a pronounced reduction in responsiveness to corticosteroids. Oxidative stress could generate peroxyriltrite, which impairs HDAC2 activity through nitration of critical tyrosine residues. This hypothesis raises the possibility that novel therapeutic approaches might unlock this corticosteroid resistance, leading to more effective anti-inflammatory treatments for COPD and other severe inflammatory diseases.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk	Adcock, Ian/L-3217-2019; Ito, Kazuhiro/AAF-5994-2019	Barnes, Peter/0000-0002-5122-4018; Adcock, Ian/0000-0003-2101-8843				Alsaeedi A, 2002, AM J MED, V113, P59, DOI 10.1016/S0002-9343(02)01143-9; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ito K, 2001, FASEB J, V15, pA473; ITO K, 2001, EUR RESPIR J, V18, P316; Ito K, 2002, AM J RESP CRIT CARE, V165, P625; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369, DOI 10.1164/ajrccm.162.2.9909025; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Tomita K, 2003, BIOCHEM BIOPH RES CO, V301, P572, DOI 10.1016/S0006-291X(02)03029-2	28	277	294	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					731	733		10.1016/S0140-6736(04)15650-X	http://dx.doi.org/10.1016/S0140-6736(04)15650-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001333				2022-12-28	WOS:000189266900026
J	Wheeler, JG; Keavney, BD; Watkins, H; Collins, R; Danesh, J				Wheeler, JG; Keavney, BD; Watkins, H; Collins, R; Danesh, J			Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls: meta-analysis of 43 studies	LANCET			English	Article							MYOCARDIAL-INFARCTION; ARTERY-DISEASE; GLN-ARG192 POLYMORPHISM; MOLECULAR-BASIS; HUMPONA GENE; RISK; ASSOCIATION; PON1; VARIANTS; CHINESE	Background Although there have been suggestions that serum paraoxonase is important in protecting against coronary heart disease (CHD), a large number of studies of genetic determinants of serum paraoxonase have reported apparently conflicting results about their association with CHID. Methods We conducted a meta-analysis of 43 studies of the Q192R, L55M, and T(-107)C polymorphisms in the paraoxonase PON1 gene and the S311C polymorphism in the PON2 gene (all of which are in moderately strong linkage disequilibrium with one another), involving a total of 11212 CHID cases and 12786 controls. We explored potential sources of heterogeneity. Findings In a combined analysis of all studies, the per-allele relative risk of R192 for CHID was 1.12 (95% CI 1.07-1.16), but in the five largest studies it was only 1.05 (0.98-1.13). Combined analyses of studies of the M55, (-107)T, and C311 variants showed no significant overall associations with CHID, yielding per-allele relative risks of 1.00 (0.95-1.06), 1.02 (0.92-1.14), and 1.04 (0.93-1.17), respectively. Interpretation In contrast to previous suggestions, this meta-analysis shows no significant association of CHD with the L55M or T(-107)C polymorphism in PON1 or with the S311C polymorphism in PON2. The weak overall association between the Q192R polymorphism and CHD is of uncertain relevance, particularly since there was no significant association among the larger studies which should be less prone to selective publication. These findings reinforce the need for much larger and more rigorous investigations of the genetic determinants of complex diseases than is now customary, as well as for regularly updated systematic appraisals of such studies to help improve interpretation and prioritise hypotheses.	Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; Newcastle Univ, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England	University of Cambridge; Newcastle University - UK; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Site,Worts Causeway, Cambridge CB1 8RN, England.	jd292@medschi.cam.ac.uk		Watkins, Hugh/0000-0002-5287-9016; Keavney, Bernard/0000-0001-9573-0812				ADKINS S, 1993, AM J HUM GENET, V52, P598; Antikainen M, 1996, J CLIN INVEST, V98, P883, DOI 10.1172/JCI118869; Arca M, 2002, EUR J CLIN INVEST, V32, P9, DOI 10.1046/j.1365-2362.2002.00935.x; Aubo C, 2000, EUR HEART J, V21, P33, DOI 10.1053/euhj.1999.1660; Aynacioglu AS, 2000, INT J CARDIOL, V74, P33, DOI 10.1016/S0167-5273(00)00242-4; Ayub A, 1999, ARTERIOSCL THROM VAS, V19, P330, DOI 10.1161/01.ATV.19.2.330; Cascorbi I, 1999, PHARMACOGENETICS, V9, P755, DOI 10.1097/00008571-199912000-00010; Chen Q, 2003, AM J HUM GENET, V72, P13, DOI 10.1086/345312; Cherry N, 2002, LANCET, V359, P763, DOI 10.1016/S0140-6736(02)07847-9; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Ferre N, 2002, CLIN BIOCHEM, V35, P197, DOI 10.1016/S0009-9120(02)00295-3; Gardemann A, 2000, ATHEROSCLEROSIS, V152, P421, DOI 10.1016/S0021-9150(99)00489-X; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; Hasselwander O, 1999, KIDNEY INT, V56, P289, DOI 10.1046/j.1523-1755.1999.00521.x; Heijmans BT, 2000, ATHEROSCLEROSIS, V149, P91, DOI 10.1016/S0021-9150(99)00311-1; Herrmann SM, 1996, ATHEROSCLEROSIS, V126, P299, DOI 10.1016/0021-9150(96)05917-5; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hong SH, 2001, CLIN BIOCHEM, V34, P475, DOI 10.1016/S0009-9120(01)00257-0; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; Imai Y, 2000, ATHEROSCLEROSIS, V149, P435, DOI 10.1016/S0021-9150(99)00340-8; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; James RW, 2000, DIABETES, V49, P1390, DOI 10.2337/diabetes.49.8.1390; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Keavney B, 2000, LANCET, V355, P434; Ko YL, 1998, ATHEROSCLEROSIS, V141, P259, DOI 10.1016/S0021-9150(98)00179-8; Letellier C, 2002, DIABETES METAB, V28, P297; Leus FR, 2001, ATHEROSCLEROSIS, V154, P641, DOI 10.1016/S0021-9150(00)00440-8; Leviev I, 2000, ARTERIOSCL THROM VAS, V20, P516, DOI 10.1161/01.ATV.20.2.516; Leviev N, 2001, J MOL MED, V79, P457, DOI 10.1007/s001090100240; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; Mackness B, 2001, ARTERIOSCL THROM VAS, V21, P1451, DOI 10.1161/hq0901.094247; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; Odawara M, 1997, J CLIN ENDOCR METAB, V82, P2257, DOI 10.1210/jc.82.7.2257; Ombres D, 1998, ARTERIOSCL THROM VAS, V18, P1611, DOI 10.1161/01.ATV.18.10.1611; Osei-Hyiaman D, 2001, EUR J ENDOCRINOL, V144, P639, DOI 10.1530/eje.0.1440639; Pan JP, 2002, ZHONGHUA YI XUE ZA Z, V65, P411; Pati N, 1998, INT J CARDIOL, V66, P165, DOI 10.1016/S0167-5273(98)00209-5; Pfohl M, 1999, DIABETES, V48, P623, DOI 10.2337/diabetes.48.3.623; Rice GI, 1997, CORONARY ARTERY DIS, V8, P677, DOI 10.1097/00019501-199711000-00001; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; Salonen JT, 1999, BRIT MED J, V319, P487, DOI 10.1136/bmj.319.7208.487; Sanghera DK, 1997, ARTERIOSCL THROM VAS, V17, P1067, DOI 10.1161/01.ATV.17.6.1067; Sanghera DK, 1998, AM J HUM GENET, V62, P36, DOI 10.1086/301669; Sanghera DK, 1998, ATHEROSCLEROSIS, V136, P217, DOI 10.1016/S0021-9150(97)00206-2; Sen-Banerjee S, 2000, ARTERIOSCL THROM VAS, V20, P2120, DOI 10.1161/01.ATV.20.9.2120; Senti M, 2001, ARTERIOSCL THROM VAS, V21, P415, DOI 10.1161/01.ATV.21.3.415; Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373; Suehiro T, 1996, INT J CARDIOL, V57, P69, DOI 10.1016/S0167-5273(96)02779-9; Turban S, 2001, ATHEROSCLEROSIS, V154, P633, DOI 10.1016/S0021-9150(00)00495-0; Wang XL, 2003, ARTERIOSCL THROM VAS, V23, P328, DOI 10.1161/01.ATV.0000051702.38086.C1; Watzinger N, 2002, CARDIOLOGY, V98, P116, DOI 10.1159/000066321; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445; Youngman LD, 2000, CIRCULATION, V102, P31; Zama T, 1997, ARTERIOSCL THROM VAS, V17, P3565, DOI 10.1161/01.ATV.17.12.3565	58	263	275	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					689	695		10.1016/S0140-6736(04)15642-0	http://dx.doi.org/10.1016/S0140-6736(04)15642-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001326				2022-12-28	WOS:000189266900009
J	Perrin, MD; Graham, JR; Kalas, P; Lloyd, JP; Max, CE; Gavel, DT; Pennington, DM; Gates, EL				Perrin, MD; Graham, JR; Kalas, P; Lloyd, JP; Max, CE; Gavel, DT; Pennington, DM; Gates, EL			Laser guide star adaptive optics imaging polarimetry of herbig Ae/Be stars	SCIENCE			English	Article							INTERMEDIATE-MASS STARS; 2-DIMENSIONAL RADIATIVE-TRANSFER; LKH-ALPHA 198; PROTOSTELLAR ENVELOPES; MOLECULAR CLOUDS; HIGH-RESOLUTION; SODIUM-LAYER; DISK; DUST; LKH-ALPHA-198	We have used laser guide star adaptive optics and a near-infrared dual-channel imaging polarimeter to observe light scattered in the circumstellar environment of Herbig Ae/Be stars on scales of 100 to 300 astronomical units. We revealed a strongly polarized, biconical nebula 10 arc seconds ( 6000 astronomical units) in diameter around the star LkHalpha 198 and also observed a polarized jet-like feature associated with the deeply embedded source LkHalpha 198-IR. The star LkHalpha 233 presents a narrow, unpolarized dark lane consistent with an optically thick circumstellar disk blocking our direct view of the star. These data show that the lower-mass T Tauri and intermediate mass Herbig Ae/Be stars share a common evolutionary sequence.	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Santa Cruz, Natl Sci Fdn, Ctr Adapt Opt, Santa Cruz, CA 95064 USA; CALTECH, Dept Astron, Pasadena, CA 91125 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Calif Santa Cruz, Lab Adapt Opt, Santa Cruz, CA 95064 USA; Univ Calif Observ, Lick Observ, Mt Hamilton, CA 95140 USA	University of California System; University of California Berkeley; National Science Foundation (NSF); University of California System; University of California Santa Cruz; California Institute of Technology; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Cruz	Perrin, MD (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	mperrin@astro.berkeley.edu	Lloyd, James P/B-3769-2011	Kalas, Paul/0000-0002-6221-5360; Max, Claire/0000-0003-0682-5436; Perrin, Marshall/0000-0002-3191-8151				ASPIN C, 1985, ASTRON ASTROPHYS, V144, P220; BASTIEN P, 1987, ASTROPHYS J, V317, P231, DOI 10.1086/165271; Bonnell IA, 1998, MON NOT R ASTRON SOC, V298, P93, DOI 10.1046/j.1365-8711.1998.01590.x; CANTO J, 1984, ASTROPHYS J, V282, P631, DOI 10.1086/162242; CORCORAN D, 1995, ASTRON ASTROPHYS, V293, P550; Corcoran M, 1998, ASTRON ASTROPHYS, V336, P535; DIFRANCESCO J, 1994, ASTROPHYS J, V432, P710, DOI 10.1086/174610; FUKAGAWA M, 2002, J PSYCHIATR NEUROSCI, V54, P969; Hajjar R, 2000, ASTROPHYS J, V531, P494, DOI 10.1086/308424; HAPPER W, 1994, J OPT SOC AM A, V11, P263, DOI 10.1364/JOSAA.11.000263; Henning T, 1998, ASTRON ASTROPHYS, V336, P565; HILLENBRAND LA, 1992, ASTROPHYS J, V397, P613, DOI 10.1086/171819; Koresko CD, 1997, ASTROPHYS J, V485, P213, DOI 10.1086/304415; Kuhn JR, 2001, ASTROPHYS J, V553, pL189, DOI 10.1086/320686; LAGAGE PO, 1993, ASTROPHYS J LETT, V417; LI WB, 1994, ASTROPHYS J, V433, P199, DOI 10.1086/174636; Lloyd JP, 2000, P SOC PHOTO-OPT INS, V4008, P814, DOI 10.1117/12.395540; Mannings V, 1997, ASTROPHYS J, V490, P792, DOI 10.1086/304897; Mannings V, 1997, NATURE, V388, P555, DOI 10.1038/41505; Max CE, 1997, SCIENCE, V277, P1649, DOI 10.1126/science.277.5332.1649; McKee CF, 2003, ASTROPHYS J, V585, P850, DOI 10.1086/346149; Natta A, 2001, ASTRON ASTROPHYS, V371, P186, DOI 10.1051/0004-6361:20010334; PALLA F, 1993, ASTROPHYS J, V418, P414, DOI 10.1086/173402; Potter DE, 2000, ASTROPHYS J, V540, P422, DOI 10.1086/309329; SANDELL G, 1994, ASTRON ASTROPHYS, V292, pL1; SHU F, 1994, ASTROPHYS J, V429, P781, DOI 10.1086/174363; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; TEREBEY S, 1984, ASTROPHYS J, V286, P529, DOI 10.1086/162628; Weintraub D. A., 2000, Protostars and planets 4, P247; Whitney BA, 2003, ASTROPHYS J, V598, P1079, DOI 10.1086/379068; Whitney BA, 2003, ASTROPHYS J, V591, P1049, DOI 10.1086/375415	31	63	63	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	2004	303	5662					1345	1348		10.1126/science.1094602	http://dx.doi.org/10.1126/science.1094602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988558	Green Accepted, Green Submitted			2022-12-28	WOS:000189238600044
J	Arluk, GM; Pickhardt, PJ				Arluk, GM; Pickhardt, PJ			Inflammatory pseudopolyposis in Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Naval Med Res Inst, Bethesda, MD 20889 USA	Naval Medical Research Center (NMRC)	Arluk, GM (corresponding author), Natl Naval Med Res Inst, Bethesda, MD 20889 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					923	923		10.1056/NEJMicm020629	http://dx.doi.org/10.1056/NEJMicm020629			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985490				2022-12-28	WOS:000189197300011
J	Thomas, I; Dixon, J				Thomas, I; Dixon, J			Lesson of the week - Bradycardia in acute haemorrhage	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RELATIVE BRADYCARDIA; TACHYCARDIC RESPONSE; SHOCK; HYPOTENSION		Royal United Hosp, Dept Anaesthet, Bath BA1 3NG, Avon, England; Weston Gen Hosp, Dept Anaesthet, Weston Super Mare BS23 4TQ, England		Thomas, I (corresponding author), Royal United Hosp, Dept Anaesthet, Bath BA1 3NG, Avon, England.	ThmsIa@aol.com						*ACOS, 1997, ADV TRAUM LIF SUPP D; ADAMS S L, 1986, Journal of Emergency Medicine, V4, P383, DOI 10.1016/0736-4679(86)90216-7; BARRIOT P, 1987, INTENS CARE MED, V13, P203; Demetriades D, 1998, J TRAUMA, V45, P534, DOI 10.1097/00005373-199809000-00020; JANSEN RPS, 1978, AUST NZ J OBSTET GYN, V18, P206, DOI 10.1111/j.1479-828X.1978.tb00051.x; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; OBERG P, 1970, ACTA PHYSL SCAND S, V80, pA22; SECHER NH, 1984, CIRC SHOCK, V14, P267; SNYDER H S, 1989, Journal of Emergency Medicine, V7, P335, DOI 10.1016/0736-4679(89)90294-1; SNYDER HS, 1990, AM J EMERG MED, V8, P23, DOI 10.1016/0735-6757(90)90288-B; THOMPSON D, 1990, ANN EMERG MED, V19, P268, DOI 10.1016/S0196-0644(05)82042-6; VAYER JS, 1988, ANN EMERG MED, V17, P227, DOI 10.1016/S0196-0644(88)80111-2	12	10	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					451	453		10.1136/bmj.328.7437.451	http://dx.doi.org/10.1136/bmj.328.7437.451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976102	Green Published			2022-12-28	WOS:000189161000024
J	Zambon, M				Zambon, M			The inexact science of influenza prediction	LANCET			English	Editorial Material							A H5N1 VIRUS; HUMAN-DISEASE; HONG-KONG; CONJUNCTIVITIS; INFECTION; HOST		Cent Publ Hlth Lab, Influenza Lab, Enter Resp & Neurol Virus Lab, London NW9 5HT, England	Public Health England	Zambon, M (corresponding author), Cent Publ Hlth Lab, Influenza Lab, Enter Resp & Neurol Virus Lab, London NW9 5HT, England.	Maria.Zambon@HPA.org.uk						Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; GAMBLIN SJ, 2004, SCIENCE; Harvey R, 2004, J VIROL, V78, P502, DOI 10.1128/JVI.78.1.502-507.2004; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	12	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					582	583		10.1016/S0140-6736(04)15624-9	http://dx.doi.org/10.1016/S0140-6736(04)15624-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987878				2022-12-28	WOS:000189104900002
J	Schaff, DP; Richards, PG				Schaff, DP; Richards, PG			Repeating seismic events in China	SCIENCE			English	Article							CALAVERAS FAULT; TEST-SITE; EARTHQUAKES; CALIFORNIA; LOCATIONS; MICROEARTHQUAKES; RECURRENCE; DEEP; SLIP	About 10% of seismic events in and near China from 1985 to 2000 were repeating events not more than about 1 kilometer from each other. We cross-correlated seismograms from similar to14,000 earthquakes and explosions and measured relative arrival times to similar to0.01 second, enabling lateral location precision of about 100 to 300 meters. Such precision is important for seismic hazard studies, earthquake physics, and nuclear test ban veri. cation. Recognition and measurement of repeating signals in archived data and the resulting improvement in location specificity quantifies the inaccuracy of current procedures for picking onset times and locating events.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Columbia University; Columbia University	Schaff, DP (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	dschaff@ldeo.columbia.edu						CTBTO, 2002, CTBTO ANN REP 2002; DEICHMANN N, 1992, GEOPHYS J INT, V110, P501, DOI 10.1111/j.1365-246X.1992.tb02088.x; ENGDAHL ER, 1998, B SEISMOL SOC AM, V22, P2317; Fisk MD, 2002, B SEISMOL SOC AM, V92, P2911, DOI 10.1785/0120010268; GELLER RJ, 1980, GEOPHYS RES LETT, V7, P821, DOI 10.1029/GL007i010p00821; Igarashi T, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001920; International Seismological Centre (ISC), ISC B; ISACKS BL, 1967, B SEISMOL SOC AM, V57, P935; *LAM EARTH OBS, LAM EARTH OBS CONTR, V6573; LEE WHK, 2003, INT HDB EARTHQUAKE B; NADEAU RM, 1995, SCIENCE, V267, P503, DOI 10.1126/science.267.5197.503; POUPINET G, 1984, J GEOPHYS RES, V89, P5719, DOI 10.1029/JB089iB07p05719; Rowe CA, 2002, PURE APPL GEOPHYS, V159, P563, DOI 10.1007/PL00001265; Rubin AM, 1999, NATURE, V400, P635, DOI 10.1038/23196; Rubin AM, 2002, B SEISMOL SOC AM, V92, P1647, DOI 10.1785/0120010180; Schaff DP, 1998, GEOPHYS RES LETT, V25, P4549, DOI 10.1029/1998GL900192; Schaff DP, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000633; SCHAFF DP, IN PRESS B SEISMOL S; Shearer PM, 1997, J GEOPHYS RES-SOL EA, V102, P8269, DOI 10.1029/96JB03228; Thurber C, 2001, PHYS EARTH PLANET IN, V123, P283, DOI 10.1016/S0031-9201(00)00215-6; VIDALE JE, 1994, NATURE, V368, P624, DOI 10.1038/368624a0; Waldhauser F, 1999, GEOPHYS RES LETT, V26, P3525, DOI 10.1029/1999GL010462; Wiens DA, 2001, SCIENCE, V293, P1463, DOI 10.1126/science.1063042	23	104	141	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1176	1178		10.1126/science.1093422	http://dx.doi.org/10.1126/science.1093422			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976310				2022-12-28	WOS:000189074700041
J	Sanai, N; Tramontin, AD; Quinones-Hinojosa, A; Barbaro, NM; Gupta, N; Kunwar, S; Lawton, MT; McDermott, MW; Parsa, AT; Verdugo, JMG; Berger, MS; Alvarez-Buylla, A				Sanai, N; Tramontin, AD; Quinones-Hinojosa, A; Barbaro, NM; Gupta, N; Kunwar, S; Lawton, MT; McDermott, MW; Parsa, AT; Verdugo, JMG; Berger, MS; Alvarez-Buylla, A			Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration	NATURE			English	Article							SUBVENTRICULAR ZONE; PROGENITOR CELLS; OLFACTORY-BULB; MAMMALIAN BRAIN; NEUROGENESIS; FOREBRAIN; GENERATION; NEURONS; DIFFERENTIATION; IDENTIFICATION	The subventricular zone (SVZ) is a principal source of adult neural stem cells in the rodent brain, generating thousands of olfactory bulb neurons every day(1). If the adult human brain contains a comparable germinal region, this could have considerable implications for future neuroregenerative therapy. Stem cells have been isolated from the human brain(2-7), but the identity, organization and function of adult neural stem cells in the human SVZ are unknown. Here we describe a ribbon of SVZ astrocytes lining the lateral ventricles of the adult human brain that proliferate in vivo and behave as multipotent progenitor cells in vitro. This astrocytic ribbon has not been observed in other vertebrates studied. Unexpectedly, we find no evidence of chains of migrating neuroblasts in the SVZ or in the pathway to the olfactory bulb. Our work identifies SVZ astrocytes as neural stem cells in a niche of unique organization in the adult human brain.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dev Stem Cell Biol Program, San Francisco, CA 94143 USA; Univ Valencia, Inst Cavanilles, E-46100 Valencia, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Valencia	Sanai, N (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	nsanai@itsa.ucsf.edu; abuylla@itsa.ucsf.edu	García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Alvarez-Buylla, Arturo/0000-0003-4426-8925				Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; BLAKEMORE WF, 1972, J NEUROCYTOL, V1, P69, DOI 10.1007/BF01098647; Bonfanti L, 1997, NEUROSCIENCE, V81, P489, DOI 10.1016/S0306-4522(97)00090-0; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Imura T, 2003, J NEUROSCI, V23, P2824; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leel-Ossy L, 1998, Pathol Oncol Res, V4, P212; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Perez-Martin M, 2000, CELL TISSUE RES, V300, P11, DOI 10.1007/s004410000190; Pincus D W, 1997, Clin Neurosurg, V44, P17; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Skogh C, 2001, MOL CELL NEUROSCI, V17, P811, DOI 10.1006/mcne.2001.0973; SMITH KR, 1994, COMPUT MED IMAG GRAP, V18, P247, DOI 10.1016/0895-6111(94)90049-3; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a	30	986	1023	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					740	744		10.1038/nature02301	http://dx.doi.org/10.1038/nature02301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973487				2022-12-28	WOS:000189026000045
J	Tomi, NS; Kranke, B; Aberer, W				Tomi, NS; Kranke, B; Aberer, W			A silver man	LANCET			English	Editorial Material									Karl Franzens Univ Graz, Dept Environm Dermatol, Graz, Austria	University of Graz	Aberer, W (corresponding author), Karl Franzens Univ Graz, Dept Environm Dermatol, Graz, Austria.	werner.aberer@klinikum-graz.at						BECHER E, 1994, Z HAUTKRANKHEITEN, V69, P388; Blumberg H, 1934, J AMER MED ASSOC, V103, P1521, DOI 10.1001/jama.1934.02750460025007; FROMMANN C, 1859, ARCH PATH ANAT, V17, P135; Olson GM, 1917, J AMER MED ASSOC, V69, P87; White JML, 2003, CLIN EXP DERMATOL, V28, P254, DOI 10.1046/j.1365-2230.2003.01214.x	5	40	40	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					532	532		10.1016/S0140-6736(04)15540-2	http://dx.doi.org/10.1016/S0140-6736(04)15540-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975616				2022-12-28	WOS:000188999900011
J	Kellis, M; Birren, BW; Lander, ES				Kellis, M; Birren, BW; Lander, ES			Proof and evolutionary analysis of ancient genome duplication in the yeast Saccharomyces cerevisiae	NATURE			English	Article							HEMIASCOMYCETOUS YEASTS; FUNCTIONAL HOMOLOG; GENE DUPLICATION; SEQUENCE; DIFFERENTIATION; PRESERVATION; EXPLORATION; EXPRESSION; MUTATIONS; ARACHNE	Whole-genome duplication followed by massive gene loss and specialization has long been postulated as a powerful mechanism of evolutionary innovation. Recently, it has become possible to test this notion by searching complete genome sequence for signs of ancient duplication. Here, we show that the yeast Saccharomyces cerevisiae arose from ancient whole-genome duplication, by sequencing and analysing Kluyveromyces waltii, a related yeast species that diverged before the duplication. The two genomes are related by a 1:2 mapping, with each region of K. waltii corresponding to two regions of S. cerevisiae, as expected for whole-genome duplication. This resolves the long-standing controversy on the ancestry of the yeast genome, and makes it possible to study the fate of duplicated genes directly. Strikingly, 95% of cases of accelerated evolution involve only one member of a gene pair, providing strong support for a specific model of evolution, and allowing us to distinguish ancestral and derived functions.	MIT, Broad Inst, Cambridge, MA 02138 USA; Harvard Univ, Cambridge, MA 02138 USA; MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Kellis, M (corresponding author), MIT, Broad Inst, Cambridge, MA 02138 USA.	manoli@mit.edu; lander@broad.mit.edu	Kellis, Manolis/ABE-7385-2020	Kellis, Manolis/0000-0001-7113-9630				BAILEY GS, 1978, P NATL ACAD SCI USA, V75, P5575, DOI 10.1073/pnas.75.11.5575; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Benard L, 1999, J VIROL, V73, P2893, DOI 10.1128/JVI.73.4.2893-2900.1999; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Boles E, 1997, J BACTERIOL, V179, P2987, DOI 10.1128/jb.179.9.2987-2993.1997; Coissac E, 1997, MOL BIOL EVOL, V14, P1062, DOI 10.1093/oxfordjournals.molbev.a025712; Force A, 1999, GENETICS, V151, P1531; Friedman R, 2001, GENOME RES, V11, P373, DOI 10.1101/gr.155801; Gallardo MH, 1999, NATURE, V401, P341, DOI 10.1038/43815; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; HUGHES MK, 1993, MOL BIOL EVOL, V10, P1360; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jaffe DB, 2003, GENOME RES, V13, P91, DOI 10.1101/gr.828403; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KELLIS M, IN PRESS J COMPUT BI; Kondrashov FA, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0008; Koszul R, 2004, EMBO J, V23, P234, DOI 10.1038/sj.emboj.7600024; Kurtzman CP, 2003, FEMS YEAST RES, V4, P233, DOI 10.1016/S1567-1356(03)00175-2; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Langkjaer RB, 2003, NATURE, V421, P848, DOI 10.1038/nature01419; Llorente B, 2000, FEBS LETT, V487, P122, DOI 10.1016/S0014-5793(00)02291-2; Llorente B, 2000, FEBS LETT, V487, P101, DOI 10.1016/S0014-5793(00)02289-4; Lorenz MC, 1998, GENETICS, V150, P1443; Lynch M, 2000, GENETICS, V154, P459; MAYER VW, 1990, MUTAT RES, V231, P177, DOI 10.1016/0027-5107(90)90024-X; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Ohno S., 1970, EVOLUTION GENE DUPLI; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Pebusque MJ, 1998, MOL BIOL EVOL, V15, P1145, DOI 10.1093/oxfordjournals.molbev.a026022; Philippsen P, 1997, NATURE, V387, P93, DOI 10.1038/387s093; Piskur J, 2001, TRENDS GENET, V17, P302, DOI 10.1016/S0168-9525(01)02308-3; Sanz M, 2002, MOL MICROBIOL, V43, P1183, DOI 10.1046/j.1365-2958.2002.02812.x; Sarthy AV, 1998, YEAST, V14, P239, DOI 10.1002/(SICI)1097-0061(199802)14:3<239::AID-YEA219>3.0.CO;2-B; Seoighe C, 1999, GENE, V238, P253, DOI 10.1016/S0378-1119(99)00319-4; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099	45	1079	1118	0	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	2004	428	6983					617	624		10.1038/nature02424	http://dx.doi.org/10.1038/nature02424			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810IE	15004568				2022-12-28	WOS:000220697200034
J	Brunet, A; Sweeney, LB; Sturgill, JF; Chua, KF; Greer, PL; Lin, YX; Tran, H; Ross, SE; Mostoslavsky, R; Cohen, HY; Hu, LS; Cheng, HL; Jedrychowski, MP; Gygi, SP; Sinclair, DA; Alt, FW; Greenberg, ME				Brunet, A; Sweeney, LB; Sturgill, JF; Chua, KF; Greer, PL; Lin, YX; Tran, H; Ross, SE; Mostoslavsky, R; Cohen, HY; Hu, LS; Cheng, HL; Jedrychowski, MP; Gygi, SP; Sinclair, DA; Alt, FW; Greenberg, ME			Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase	SCIENCE			English	Article							PROMOTES CELL-SURVIVAL; LIFE-SPAN EXTENSION; PROTEIN-KINASE B; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; CALORIE RESTRICTION; P53; LONGEVITY; NAD; PATHWAY	The Sir2 deacetylase modulates organismal life-span in various species. However, the molecular mechanisms by which Sir2 increases longevity are largely unknown. We show that in mammalian cells, the Sir2 homolog SIRT1 appears to control the cellular response to stress by regulating the FOXO family of Forkhead transcription factors, a family of proteins that function as sensors of the insulin signaling pathway and as regulators of organismal longevity. SIRT1 and the FOXO transcription factor FOXO3 formed a complex in cells in response to oxidative stress, and SIRT1 deacetylated FOXO3 in vitro and within cells. SIRT1 had a dual effect on FOXO3 function: SIRT1 increased FOXO3's ability to induce cell cycle arrest and resistance to oxidative stress but inhibited FOXO3's ability to induce cell death. Thus, one way in which members of the Sir2 family of proteins may increase organismal longevity is by tipping FOXO-dependent responses away from apoptosis and toward stress resistance.	Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,CBR,Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA.	michael.greenberg@childrens.harvard.edu		Sinclair, David/0000-0002-9936-436X; Cohen, Haim Y./0000-0002-6613-8710; /0000-0002-7002-1275; Sweeney, Lora/0000-0001-9242-5601	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035138] Funding Source: NIH RePORTER; NICHD NIH HHS [NIHP30-HD18655] Funding Source: Medline; NINDS NIH HHS [P01 NS35138-17] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNET A, UNPUB; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Guarente L, 2000, GENE DEV, V14, P1021; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin Y. P., UNPUB; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	28	2514	2655	7	302	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2011	2015		10.1126/science.1094637	http://dx.doi.org/10.1126/science.1094637			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	14976264				2022-12-28	WOS:000220429800040
J	Cowan, CA; Klimanskaya, I; McMahon, J; Atienza, J; Witmyer, J; Zucker, JP; Wang, SP; Morton, CC; McMahon, AP; Powers, D; Melton, DA				Cowan, CA; Klimanskaya, I; McMahon, J; Atienza, J; Witmyer, J; Zucker, JP; Wang, SP; Morton, CC; McMahon, AP; Powers, D; Melton, DA			Derivation of embryonic stem-cell lines from human blastocysts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFERENTIATION		Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Boston IVF, Waltham, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Cowan, CA (corresponding author), Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ANDREWS PW, 1984, HYBRIDOMA, V3, P347, DOI 10.1089/hyb.1984.3.347; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BONGSO A, 1994, HUM REPROD, V9, P2110, DOI 10.1093/oxfordjournals.humrep.a138401; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; EASTER SS, 1993, J NEUROSCI, V13, P285; Eggan K, 2002, NAT BIOTECHNOL, V20, P455, DOI 10.1038/nbt0502-455; Gardner DK, 2000, FERTIL STERIL, V73, P1155, DOI 10.1016/S0015-0282(00)00518-5; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KLIMANSKAYA I, IN PRESS HDB EMBRYON; Longo L, 1997, TRANSGENIC RES, V6, P321, DOI 10.1023/A:1018418914106; MACDONALD DJ, 1978, CLIN CHIM ACTA, V87, P367, DOI 10.1016/0009-8981(78)90180-8; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; Skotheim RI, 2002, CANCER RES, V62, P2359; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; Thomson JA, 1998, SCIENCE, V282, P1827	21	722	850	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1353	1356		10.1056/NEJMsr040330	http://dx.doi.org/10.1056/NEJMsr040330			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	14999088	Bronze			2022-12-28	WOS:000220393900017
J	Johnson, RJ; Rideout, BA				Johnson, RJ; Rideout, BA			Uric acid and diet - Insights into the epidemic of cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GOUT		Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32611 USA; Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA	State University System of Florida; University of Florida; Zoological Society of San Diego	Johnson, RJ (corresponding author), Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68607] Funding Source: Medline; NIDDK NIH HHS [DK-64233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CASSIM B, 1994, ANN RHEUM DIS, V53, P759, DOI 10.1136/ard.53.11.759; CLIFFORD AJ, 1976, J NUTR, V106, P428, DOI 10.1093/jn/106.3.428; Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; LENNANE GAQ, 1960, ANN RHEUM DIS, V19, P120, DOI 10.1136/ard.19.2.120; Oda M, 2002, MOL BIOL EVOL, V19, P640, DOI 10.1093/oxfordjournals.molbev.a004123	6	99	114	1	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1071	1073		10.1056/NEJMp048015	http://dx.doi.org/10.1056/NEJMp048015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014177				2022-12-28	WOS:000220110100001
J	Chertow, GM				Chertow, GM			A 43-year-old woman with chronic renal insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIETARY-PROTEIN RESTRICTION; GLOMERULAR-FILTRATION-RATE; PERITONEAL-DIALYSIS; BLOOD-PRESSURE; NUTRITIONAL-STATUS; SERUM CREATININE; HEMODIALYSIS; MORTALITY; SURVIVAL; PROGRESSION		Univ Calif San Francisco, Moffitt Hosp, Div Nephrol, San Francisco, CA USA; Long Hosp, Div Nephrol, San Francisco, CA USA; Univ Calif San Francisco, Mt Zion Med Ctr, Dept Med, San Francisco, CA 94120 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Chertow, GM (corresponding author), Univ Calif San Francisco, Dept Med Res, UCSF Laurel Hts,3333 Calif St,Suite 430, San Francisco, CA 94118 USA.	chertowg@medicine.ucsf.edu		Chertow, Glenn/0000-0002-7599-0534				[Anonymous], 1997, Am J Kidney Dis, V30, pS192; [Anonymous], 1997, Am J Kidney Dis, V30, pS150; Avram MM, 2001, AM J KIDNEY DIS, V37, pS77, DOI 10.1053/ajkd.2001.20754; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Bleyer AJ, 1999, KIDNEY INT, V55, P1553, DOI 10.1046/j.1523-1755.1999.00391.x; Bloembergen W E, 1996, Adv Ren Replace Ther, V3, P201; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; Callender Clive O, 2002, Ethn Dis, V12, pS1; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Chertow GM, 2001, J AM SOC NEPHROL, V12, P2850, DOI 10.1681/ASN.V12122850; Chertow GM, 1997, SEMIN DIALYSIS, V10, P108, DOI 10.1111/j.1525-139X.1997.tb00864.x; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Coles GA, 2000, ADV RENAL REPLACE TH, V7, P289, DOI 10.1053/jarr.2000.16268; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; DIJKHUIS HJ, 1973, JAMA-J AM MED ASSOC, V223, P441, DOI 10.1001/jama.1973.03220040055023; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Garg JP, 2002, VASC MED, V7, P35, DOI 10.1191/1358863x02vm412ra; Golper T, 2001, NEPHROL DIAL TRANSPL, V16, P20, DOI 10.1093/ndt/16.suppl_7.20; Goodman WG, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1002; Gotch FA, 2000, KIDNEY INT, V58, pS3, DOI 10.1046/j.1523-1755.2000.07602.x; Gunnell J, 1999, AM J KIDNEY DIS, V33, P63, DOI 10.1016/S0272-6386(99)70259-3; Holley JL, 2003, SEMIN DIALYSIS, V16, P384, DOI 10.1046/j.1525-139X.2003.16085.x; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; Hsu CY, 2002, NEPHROL DIAL TRANSPL, V17, P1419, DOI 10.1093/ndt/17.8.1419; Hsu CY, 2001, J HUM HYPERTENS, V15, P99, DOI 10.1038/sj.jhh.1001128; IKIZLER TA, 1995, J AM SOC NEPHROL, V6, P1386; Iseki K, 1996, AM J KIDNEY DIS, V28, P541, DOI 10.1016/S0272-6386(96)90465-5; Johnson EM, 1997, TRANSPLANTATION, V64, P1124, DOI 10.1097/00007890-199710270-00007; Karnik JA, 2001, KIDNEY INT, V60, P350, DOI 10.1046/j.1523-1755.2001.00806.x; KASISKE BL, 1995, KIDNEY INT, V48, P814, DOI 10.1038/ki.1995.355; Kasiske BL, 2001, AM J TRANSPLANT, V1, P7; Kaysen GA, 1998, J AM SOC NEPHROL, V9, P2368; Kaysen GA, 2001, KIDNEY INT, V60, P333, DOI 10.1046/j.1523-1755.2001.00804.x; Keshaviah P, 2002, J AM SOC NEPHROL, V13, pS48; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Kopple JD, 2000, KIDNEY INT, V57, P1688, DOI 10.1046/j.1523-1755.2000.00014.x; LAZARUS JM, 1996, KIDNEY, P2427; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Marr KA, 1997, ANN INTERN MED, V127, P275, DOI 10.7326/0003-4819-127-4-199708150-00003; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; McCullough PA, 2002, AM HEART J, V144, P226, DOI 10.1067/mhj.2002.125513; Mendelssohn DC, 2003, BLOOD PURIFICAT, V21, P24, DOI 10.1159/000067853; Miller PE, 1999, KIDNEY INT, V56, P275, DOI 10.1046/j.1523-1755.1999.00515.x; Mitch WE, 1996, MINER ELECTROL METAB, V22, P62; *NAT KIDN FDN, 2000, AM J KIDNEY DIS S, V35, pS1, DOI DOI 10.1053/KD.2000.6671; *NIH, HLTH PEOPL 2010, V1; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; Penn I, 2000, ADV RENAL REPLACE TH, V7, P147, DOI 10.1053/rr.2000.5269; Port FK, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341061; RAMOS EL, 1991, J AM SOC NEPHROL, V2, P109; REISER IW, 1995, TXB NEPHROLOGY; Renal Physicians Association and American Society of Nephrology Clinical Practice Guideline, 2000, SHAR DEC MAK APPR IN; Romao JE, 1997, NEPHROL DIAL TRANSPL, V12, P106, DOI 10.1093/ndt/12.1.106; Ruggenenti P, 1997, LANCET, V349, P1857; Shannon H, 2000, NEW ENGL J MED, V342, P381; Sherman DS, 2003, AM J KIDNEY DIS, V41, P269, DOI 10.1053/ajkd.2003.50035; Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59; Siminoff LA, 2001, JAMA-J AM MED ASSOC, V286, P71, DOI 10.1001/jama.286.1.71; Stack AG, 2002, J AM SOC NEPHROL, V13, P1279, DOI 10.1681/ASN.V1351279; Stenvinkel P, 2002, SEMIN DIALYSIS, V15, P329, DOI 10.1046/j.1525-139X.2002.00083.x; Swedko P, 2003, ARCH INTERN MED, V163, P356, DOI 10.1001/archinte.163.3.356; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; *US REN DAT SYST, 2003, USRDS 2003 ANN REP A; VANHOLDER R, 1987, NEPHRON, V47, P274, DOI 10.1159/000184523; VANHOLDER RC, 1994, KIDNEY INT, V45, P1754, DOI 10.1038/ki.1994.228; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wolfson M, 2002, AM J KIDNEY DIS, V40, P1055, DOI 10.1053/ajkd.2002.36344; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Xue JL, 2002, KIDNEY INT, V61, P734, DOI 10.1046/j.1523-1755.2002.00175.x; Xue JL, 2002, KIDNEY INT, V61, P741, DOI 10.1046/j.1523-1755.2002.00176.x	80	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1252	1259		10.1001/jama.291.10.1252	http://dx.doi.org/10.1001/jama.291.10.1252			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010448				2022-12-28	WOS:000220061900027
J	Picano, E				Picano, E			Sustainability of medical imaging	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RADIATION		CNR, Inst Clin Physiol, I-56124 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Picano, E (corresponding author), CNR, Inst Clin Physiol, Via Moruzzi 1, I-56124 Pisa, Italy.	picano@ifc.cnr.it	Picano, E/G-2261-2014					Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; CORMACK J, 1998, NUCL MED CLIN DIAGNO, P1655; *CTR DEV RAD HLTH, 2001, PUBL HLTH NOT RED RA; *CTR DEV RAD HLTH, WHOL BOD SCANN US CO; DAVIS GT, 1991, NEW ENGL J MED, V324, P7; *EUR COMM, RAD PROT 118 REF GUI; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Illich I., 1976, MED NEMESIS EXPROPRI; *INT COMM RAD PROT, 1991, RAD PROT BIOM RES; International Commission on Radiological Protection (ICRP), 2001, RAD YOUR PAT GUID ME; Kaiser J, 2003, SCIENCE, V302, P378, DOI 10.1126/science.302.5644.378; Morin RL, 2003, CIRCULATION, V107, P917, DOI 10.1161/01.CIR.0000048965.56529.C2; National Council on Radiation Protection and Measurements, 1987, 93 NCRP; Picano E, 2003, AM J MED, V114, P126, DOI 10.1016/S0002-9343(02)01427-4; Regulla Dieter, 2003, Z Med Phys, V13, P127; Ron E, 2002, PEDIATR RADIOL, V32, P232, DOI 10.1007/s00247-002-0672-0; Shiralkar S, 2003, BRIT MED J, V327, P371, DOI 10.1136/bmj.327.7411.371; *UN SCI COMM EFF A, 1996, SOURC EFF ION RAD; *UN SCI COMM SOURC, 2001, REP EFF AT RAD GEN A	19	210	217	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					578	580		10.1136/bmj.328.7439.578	http://dx.doi.org/10.1136/bmj.328.7439.578			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	15001510	Green Published			2022-12-28	WOS:000220091800030
J	Vulliet, PR; Greeley, M; Halloran, SM; MacDonald, KA; Kittleson, MD				Vulliet, PR; Greeley, M; Halloran, SM; MacDonald, KA; Kittleson, MD			Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs	LANCET			English	Article							MYOCARDIAL-INFARCTION	Mesenchymal stromal cells (MSCs) have the potential to treat many myocardial diseases. We investigated whether these multipotent stem cells derived from bone marrow could be administered safely into the coronary circulation of healthy dogs. We injected about 0.5 million cells per kg bodyweight of early passage autologous MSCs into the left circumflex coronary artery of anaesthetised dogs. During administration, we noted ST segment elevation and T wave changes characteristic of acute myocardial ischaemia. 7 days later, macroscopic and microscopic evidence of myocardial infarction was noted. Histological sections of myocardium showed several scattered regions of dense fibroplasia accompanied by macrophage infiltrates only in areas where the MSCs were observed. We also noted raised plasma concentrations of cardiac troponin I and collagen fibril deposition in the lesions. These findings show acute myocardial ischaemia and subacute myocardial microinfarction after intracoronary arterial injection of MSCs into dogs.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Vulliet, PR (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.	prvulliet@ucdavis.edu	Kittleson, Mark D/ABD-6706-2021	Kittleson, Mark D/0000-0002-1113-8369				Britten MB, 2003, CIRCULATION, V108, P2212, DOI 10.1161/01.CIR.0000095788.78169.AF; KITTLESON MD, 1987, AM HEART J, V114, P70, DOI 10.1016/0002-8703(87)90309-7; MOORE PF, 1990, TISSUE ANTIGENS, V36, P211, DOI 10.1111/j.1399-0039.1990.tb01831.x; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C	5	351	432	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					783	784		10.1016/S0140-6736(04)15695-X	http://dx.doi.org/10.1016/S0140-6736(04)15695-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016490				2022-12-28	WOS:000220092000010
J	Bringmann, H; Skiniotis, G; Spilker, A; Kandels-Lewis, S; Vernos, I; Surrey, T				Bringmann, H; Skiniotis, G; Spilker, A; Kandels-Lewis, S; Vernos, I; Surrey, T			A kinesin-like motor inhibits microtubule dynamic instability	SCIENCE			English	Article							ORGANIZATION; KINETICS; DOMAIN; ROLES; FORMS; MODEL	The motility of molecular motors and the dynamic instability of microtubules are key dynamic processes for mitotic spindle assembly and function. We report here that one of the mitotic kinesins that localizes to chromosomes, Xklp1 from Xenopus laevis, could inhibit microtubule growth and shrinkage. This effect appeared to be mediated by a structural change in the microtubule lattice. We also found that Xklp1 could act as a fast, nonprocessive, plus end-directed molecular motor. The integration of the two properties, motility and inhibition of microtubule dynamics, in one molecule emphasizes the versatile properties of kinesin family members.	European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Struct & Computat Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Surrey, T (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	surrey@embl.de	Surrey, Thomas/AAC-4608-2021; Vernos, Isabelle/C-1687-2015	Vernos, Isabelle/0000-0003-1469-9214; Surrey, Thomas/0000-0001-9082-1870; Skiniotis, Georgios/0000-0003-0238-7846				BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Cottingham FR, 1999, J CELL BIOL, V147, P335, DOI 10.1083/jcb.147.2.335; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Howard J., 2001, MECH MOTOR PROTEINS; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Kallipolitou A, 2001, EMBO J, V20, P6226, DOI 10.1093/emboj/20.22.6226; Kinoshita K, 2001, SCIENCE, V294, P1340, DOI 10.1126/science.1064629; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; Scholey J. M., 1993, METHODS CELL BIOL, V39; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; VERNOS I, UNPUB; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	31	119	120	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1519	1522		10.1126/science.1094838	http://dx.doi.org/10.1126/science.1094838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001780				2022-12-28	WOS:000220000100043
J	Janicki, SM; Tsukamoto, T; Salghetti, SE; Tansey, WP; Sachidanandam, R; Prasanth, KV; Ried, T; Shav-Tal, Y; Bertrand, E; Singer, RH; Spector, DL				Janicki, SM; Tsukamoto, T; Salghetti, SE; Tansey, WP; Sachidanandam, R; Prasanth, KV; Ried, T; Shav-Tal, Y; Bertrand, E; Singer, RH; Spector, DL			From silencing to gene expression: Real-time analysis in single cells	CELL			English	Article							POSITION-EFFECT VARIEGATION; FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; HETEROCHROMATIN PROTEIN-1 BINDS; HISTONE H3; RAPID EXCHANGE; LYSINE-9 METHYLATION; CHROMATIN-STRUCTURE; RNA; HP1; DROSOPHILA	We have developed an inducible system to visualize gene expression at the levels of DNA, RNA and protein in living cells. The system is composed of a 200 copy transgene array integrated into a euchromatic region of chromosome 1 in human U20S cells. The condensed array is heterochromatic as it is associated with HP1, histone H3 methylated at lysine 9, and several histone methyltransferases. Upon transcriptional induction, HP1alpha is depleted from the locus and the histone variant H3.3 is deposited suggesting that histone exchange is a mechanism through which heterochromatin is transformed into a transcriptionally active state. RNA levels at the transcription site increase immediately after the induction of transcription and the rate of synthesis slows over time. Using this system, we are able to correlate changes in chromatin structure with the progression of transcriptional activation allowing us to obtain a real-time integrative view of gene expression.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Utsunomiya Univ, Utsunomiya, Tochigi 321, Japan; NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; CNRS, Inst Genet Mol Montpellier, F-34293 Montpellier, France	Cold Spring Harbor Laboratory; Utsunomiya University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Spector, DL (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	spector@cshl.edu	sachidanandam, ravi/Q-6916-2019	sachidanandam, ravi/0000-0001-9844-4459; Shav-Tal, Yaron/0000-0002-8017-948X; bertrand, edouard/0000-0002-9642-7994	NIBIB NIH HHS [R01 EB002060] Funding Source: Medline; NIGMS NIH HHS [GM42694, GM067728, R01 GM067728, R01 GM042694] Funding Source: Medline; DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694, R01GM067728] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; BECKETT D, 1988, J MOL BIOL, V204, P927, DOI 10.1016/0022-2836(88)90052-6; Belmont AS, 2001, TRENDS CELL BIOL, V11, P250, DOI 10.1016/S0962-8924(01)02000-1; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bickmore WA, 2003, HUM MOL GENET, V12, pR207, DOI 10.1093/hmg/ddg260; Calapez A, 2002, J CELL BIOL, V159, P795, DOI 10.1083/jcb.200203046; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Clegg NJ, 1998, GENOME, V41, P495, DOI 10.1139/gen-41-4-495; Dietzel S, 2001, NAT CELL BIOL, V3, P767, DOI 10.1038/35087089; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Fanti L, 1998, CHROMOSOMA, V107, P286, DOI 10.1007/s004120050310; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Forrest KM, 2003, CURR BIOL, V13, P1159, DOI 10.1016/S0960-9822(03)00451-2; Fusco D, 2003, CURR BIOL, V13, P161, DOI 10.1016/S0960-9822(02)01436-7; Gottesman S, 2002, GENE DEV, V16, P2829, DOI 10.1101/gad.1030302; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; HEARN MG, 1991, GENETICS, V128, P785; Hsieh J, 2000, ANNU REV GENET, V34, P187, DOI 10.1146/annurev.genet.34.1.187; HUANG S, 1997, EUKARYOTIC MESSENGER, P33; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Janicki SM, 2003, CURR OPIN CELL BIOL, V15, P149, DOI 10.1016/S0955-0674(03)00012-7; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang GC, 2003, HUM MOL GENET, V12, P2909, DOI 10.1093/hmg/ddg323; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lau S, 1999, DEV DYNAM, V215, P126, DOI 10.1002/(SICI)1097-0177(199906)215:2<126::AID-DVDY5>3.3.CO;2-#; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Lu BY, 2000, GENETICS, V155, P699; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; Nelson P, 2003, TRENDS BIOCHEM SCI, V28, P534, DOI 10.1016/j.tibs.2003.08.005; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Ricci E, 1999, ANN NEUROL, V45, P751, DOI 10.1002/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Rook MS, 2000, J NEUROSCI, V20, P6385, DOI 10.1523/JNEUROSCI.20-17-06385.2000; Sabl JF, 1996, GENETICS, V142, P447; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugaya K, 2000, J CELL SCI, V113, P2679; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Zhao T, 2000, J BIOL CHEM, V275, P28332	83	531	550	2	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					683	698		10.1016/S0092-8674(04)00171-0	http://dx.doi.org/10.1016/S0092-8674(04)00171-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006351	Green Accepted, Bronze			2022-12-28	WOS:000221499700009
J	Milo, R; Itzkovitz, S; Kashtan, N; Levitt, R; Shen-Orr, S; Ayzenshtat, I; Sheffer, M; Alon, U				Milo, R; Itzkovitz, S; Kashtan, N; Levitt, R; Shen-Orr, S; Ayzenshtat, I; Sheffer, M; Alon, U			Superfamilies of evolved and designed networks	SCIENCE			English	Article							TRANSCRIPTIONAL REGULATION; SMALL-WORLD; DYNAMICS; LOOP; MOTIFS	Complex biological, technological, and sociological networks can be of very different sizes and connectivities, making it difficult to compare their structures. Here we present an approach to systematically study similarity in the local structure of networks, based on the significance profile (SP) of small subgraphs in the network compared to randomized networks. We find several superfamilies of previously unrelated networks with very similar SPs. One superfamily, including transcription networks of microorganisms, represents "rate-limited" information-processing networks strongly constrained by the response time of their components. A distinct superfamily includes protein signaling, developmental genetic networks, and neuronal wiring. Additional superfamilies include power grids, protein-structure networks and geometric networks, World Wide Web links and social networks, and word-adjacency networks from different languages.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Comp Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il	Yang, Chen/G-1379-2010; Milo, Hilla/C-8767-2016	Milo, Ron/0000-0003-1641-2299; Sheffer, Michal/0000-0001-5934-9950; Shen-Orr, Shai/0000-0002-6991-7736; Kashtan, Nadav/0000-0002-7475-1363; Ayzenshtat, Inbal/0000-0001-8975-3938				Allen J., 1995, NATURAL LANGUAGE UND; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Berg J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.228701; Cancho RFI, 2001, P ROY SOC B-BIOL SCI, V268, P2261, DOI 10.1098/rspb.2001.1800; CARTWRIGHT D, 1956, PSYCHOL REV, V63, P277, DOI 10.1037/h0046049; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Eckmann JP, 2002, P NATL ACAD SCI USA, V99, P5825, DOI 10.1073/pnas.032093399; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Goh KI, 2002, P NATL ACAD SCI USA, V99, P12583, DOI 10.1073/pnas.202301299; HOLLAND PW, 1975, SOCIOL METHODOL, P1, DOI DOI 10.2307/270703; Ishii T, 2001, NUCLEIC ACIDS RES, V29, P278, DOI 10.1093/nar/29.1.278; KASHTAN N, IN PRESS BIOINFORMAT; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Mangan S, 2003, J MOL BIOL, V334, P197, DOI 10.1016/j.jmb.2003.09.049; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Rosenfeld N, 2003, J MOL BIOL, V329, P645, DOI 10.1016/S0022-2836(03)00506-0; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; van Duijn MAJ, 2003, J MATH SOCIOL, V27, P153, DOI 10.1080/00222500305889; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	27	916	964	5	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1538	1542		10.1126/science.1089167	http://dx.doi.org/10.1126/science.1089167			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001784				2022-12-28	WOS:000220000100049
J	Juarez, MT; Kui, JS; Thomas, J; Heller, BA; Timmermans, MCP				Juarez, MT; Kui, JS; Thomas, J; Heller, BA; Timmermans, MCP			microRNA-mediated repression of rolled leaf1 specifies maize leaf polarity	NATURE			English	Article							LATERAL ORGANS; GENE; ARABIDOPSIS; MERISTEM; IDENTITY; PROTEIN; ENCODES; PLANT	In both animals and plants, many developmentally important regulatory genes have complementary microRNAs (miRNAs), which suggests that these miRNAs constitute a class of developmental signalling molecules(1). Leaves of higher plants exhibit a varying degree of asymmetry along the adaxial/abaxial (upper/lower) axis. This asymmetry is specified through the polarized expression of class III homeodomain/leucine zipper (HD-ZIPIII) genes(2-4). In Arabidopsis, three such genes, PHABULOSA (PHB), PHAVOLUTA (PHV) and REVOLUTA (REV), are expressed throughout the incipient leaf, but become adaxially localized after primordium emergence. Downregulation of the HD-ZIPIII genes allows expression of the KANADI and YABBY genes, which specify abaxial fate(5-8). PHB, PHV and REV transcripts contain a complementary site for miRNA165 and miRNA166, which can direct their cleavage in vitro(9-11). Here we show that miRNA166 constitutes a highly conserved polarizing signal whose expression pattern spatially defines the expression domain of the maize hd-zipIII family member rolled leaf1 (rld1). Moreover, the progressively expanding expression pattern of miRNA166 during leaf development and its accumulation in phloem suggests that miRNA166 may form a movable signal that emanates from a signalling centre below the incipient leaf.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Timmermans, MCP (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, POB 100, Cold Spring Harbor, NY 11724 USA.	timmerma@cshl.org		Juarez, Michelle/0000-0002-6910-0881; Heller, Bradley/0000-0002-8487-9088				Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; BURR B, 1988, GENETICS, V118, P519; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Eshed Y, 2001, CURR BIOL, V11, P1251, DOI 10.1016/S0960-9822(01)00392-X; Foster TM, 2002, PLANT CELL, V14, P1497, DOI 10.1105/tpc.001685; Jackson DP, 1991, MOL PLANT PATHOL, P163; Kerstetter RA, 2001, NATURE, V411, P706, DOI 10.1038/35079629; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; McConnell JR, 1998, DEVELOPMENT, V125, P2935; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Nelson JM, 2002, DEVELOPMENT, V129, P4581; Otsuga D, 2001, PLANT J, V25, P223, DOI 10.1046/j.1365-313x.2001.00959.x; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Ratcliffe OJ, 2000, PLANT CELL, V12, P315, DOI 10.1105/tpc.12.3.315; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; SNOW M., 1959, NEW PHYTOL, V58, P188, DOI 10.1111/j.1469-8137.1959.tb05351.x; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Timmermans MCP, 1996, GENETICS, V143, P1771; Timmermans MCP, 1998, DEVELOPMENT, V125, P2813; Zhong RQ, 1999, PLANT CELL, V11, P2139, DOI 10.1105/tpc.11.11.2139	27	540	619	10	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					84	88		10.1038/nature02363	http://dx.doi.org/10.1038/nature02363			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999285				2022-12-28	WOS:000189363800040
J	Maunz, P; Puppe, T; Schuster, I; Syassen, N; Pinkse, PWH; Rempe, G				Maunz, P; Puppe, T; Schuster, I; Syassen, N; Pinkse, PWH; Rempe, G			Cavity cooling of a single atom	NATURE			English	Article							MOTION	All conventional methods to laser-cool atoms rely on repeated cycles of optical pumping and spontaneous emission of a photon by the atom. Spontaneous emission in a random direction provides the dissipative mechanism required to remove entropy from the atom. However, alternative cooling methods have been proposed(1,2) for a single atom strongly coupled to a high-finesse cavity; the role of spontaneous emission is replaced by the escape of a photon from the cavity. Application of such cooling schemes would improve the performance of atom-cavity systems for quantum information processing(3,4). Furthermore, as cavity cooling does not rely on spontaneous emission, it can be applied to systems that cannot be laser-cooled by conventional methods; these include molecules(2) (which do not have a closed transition) and collective excitations of Bose condensates(5), which are destroyed by randomly directed recoil kicks. Here we demonstrate cavity cooling of single rubidium atoms stored in an intracavity dipole trap. The cooling mechanism results in extended storage times and improved localization of atoms. We estimate that the observed cooling rate is at least five times larger than that produced by free-space cooling methods, for comparable excitation of the atom.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Max Planck Society	Rempe, G (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	gerhard.rempe@mpq.mpg.de		Puppe, Thomas/0000-0002-1724-9019				ASPECT A, 1986, PHYS REV LETT, V57, P1688, DOI 10.1103/PhysRevLett.57.1688; Chan HW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.063003; DALIBARD J, 1985, J OPT SOC AM B, V2, P1707, DOI 10.1364/JOSAB.2.001707; Fischer T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.163002; GRIESSNER A, 2003, ORGQUANTPH0311054; Hechenblaikner G, 1998, PHYS REV A, V58, P3030, DOI 10.1103/PhysRevA.58.3030; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Horak P, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.023603; Horak P, 1997, PHYS REV LETT, V79, P4974, DOI 10.1103/PhysRevLett.79.4974; KRUSE D, 2003, ORGQUANTPH0305033; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; McKeever J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133602; Munstermann P, 1999, OPT COMMUN, V159, P63, DOI 10.1016/S0030-4018(98)00596-3; Munstermann P, 1999, PHYS REV LETT, V82, P3791, DOI 10.1103/PhysRevLett.82.3791; Nagorny B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.153003; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; SAUER JA, 2003, ORGQUANTPH0309052; Savard TA, 1997, PHYS REV A, V56, pR1095, DOI 10.1103/PhysRevA.56.R1095; van Enk SJ, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.013407; Vuletic V, 2000, PHYS REV LETT, V84, P3787, DOI 10.1103/PhysRevLett.84.3787; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987	23	287	297	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					50	52		10.1038/nature02387	http://dx.doi.org/10.1038/nature02387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999275	Green Submitted			2022-12-28	WOS:000189363800030
J	Hadziyannis, SJ; Sette, H; Morgan, TR; Balan, V; Diago, M; Marcellin, P; Ramadori, G; Bodenheimer, H; Bernstein, D; Rizzetto, M; Zeuzem, S; Pockros, PJ; Lin, A; Ackrill, AM				Hadziyannis, SJ; Sette, H; Morgan, TR; Balan, V; Diago, M; Marcellin, P; Ramadori, G; Bodenheimer, H; Bernstein, D; Rizzetto, M; Zeuzem, S; Pockros, PJ; Lin, A; Ackrill, AM		PEGASYS Int Study Grp	Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose	ANNALS OF INTERNAL MEDICINE			English	Article							INTERFERON-ALPHA-2B PLUS RIBAVIRIN; INITIAL TREATMENT; PEGYLATED INTERFERON-ALPHA-2B; ALPHA-2A; EFFICACY; SAFETY; TRIAL	Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. Objective: To assess the efficacy and safety of 24 or 48 weeks of treatment with peginterferon-alpha2a plus a low or standard dose of ribavirin. Design: Randomized, double-blind trial. Setting: 99 international centers. Patients: 1311 patients with chronic hepatitis C. Intervention: Peginterferon-alpha2a, 180 mug/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. Results: overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for peginterferon-a2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. Conclusion: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.	Scripps Clin, La Jolla, CA USA	Scripps Research Institute	Hadziyannis, SJ (corresponding author), Henry Dunant Hosp, Dept Med & Hepatol, 107 Mesoghion Ave, Athens 11526, Greece.	hadziyannis@ath.forthnet.gr	Zeuzem, Stefan/AAE-7435-2019; Yang, Chen/G-1379-2010; DIAGO, MOISES/AAH-5364-2019					Algranati NE, 1999, HEPATOLOGY, V30, p190A; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197; Davis GL, 2002, HEPATOLOGY, V36, pS145, DOI 10.1053/jhep.2002.36798; *EASL, 1999, J HEPATOL S1, V31, P3; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973; Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reddy KR, 2001, HEPATOLOGY, V33, P433, DOI 10.1053/jhep.2001.21747; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zeuzem S, 2003, J HEPATOL, V39, P106, DOI 10.1016/S0168-8278(03)00187-9	21	2356	2508	0	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					346	355		10.7326/0003-4819-140-5-200403020-00010	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996676				2022-12-28	WOS:000189246800004
J	Troughton, RW; Asher, CR; Klein, AL				Troughton, RW; Asher, CR; Klein, AL			Pericarditis	LANCET			English	Review							ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; CARDIAC TROPONIN-I; CONSTRICTIVE PERICARDITIS; RESTRICTIVE CARDIOMYOPATHY; TUBERCULOUS PERICARDITIS; DOPPLER-ECHOCARDIOGRAPHY; RECURRENT PERICARDITIS; RESPIRATORY VARIATION; FOLLOW-UP	Pericarditis is a common disorder that has multiple causes and presents in various primary-care and secondary-care settings. New diagnostic techniques have improved the sampling and analysis of pericardial fluid and allow comprehensive characterisation of cause. Despite this advance, pericarditis is most commonly idiopathic, and radiation therapy, cardiac surgery, and percutaneous procedures have become important causes. Pericarditis is frequently self-limiting, and non-steroidal anti-inflammatory agents remain the first-line treatment for uncomplicated cases. Integrated use of new imaging methods facilitates accurate detection and management of complications such as pericardial effusion or constriction. Differentiation of constrictive pericarditis from restrictive cardiomyopathy remains a clinical challenge but is facilitated by tissue doppler and colour M-mode echocardiography. Most pericardial effusions can be safely managed with an echo-guided percutaneous approach. Pericardiectomy remains the definitive treatment for constrictive pericarditis and provides symptomatic relief in most cases. In the future, the pericardial space might become a conduit for treatments directed at the pericardium and myocardium.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Cleveland Clin Florida, Dept Cardiol, Weston, FL 33331 USA	Cleveland Clinic Foundation; University of Otago; Cleveland Clinic Foundation	Klein, AL (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kleina@ccf.org		Troughton, Richard/0000-0001-7484-4036				Abdalla IA, 2002, ECHOCARDIOGR-J CARD, V19, P125, DOI 10.1046/j.1540-8175.2002.00125.x; Adler Y, 1998, CIRCULATION, V97, P2183, DOI 10.1161/01.CIR.97.21.2183; Akdemir I, 2002, ECHOCARDIOGR-J CARD, V19, P329, DOI 10.1046/j.1540-8175.2002.00329.x; ANAND IS, 1991, CIRCULATION, V83, P1880, DOI 10.1161/01.CIR.83.6.1880; ANTMAN EM, 1979, ANN INTERN MED, V91, P403, DOI 10.7326/0003-4819-91-3-403; APPLETON CP, 1988, J AM COLL CARDIOL, V11, P1020, DOI 10.1016/S0735-1097(98)90060-2; Armstrong G, 2001, J AM SOC ECHOCARDIOG, V14, P29, DOI 10.1067/mje.2001.106680; ARMSTRONG WF, 1982, CIRCULATION, V65, P1491, DOI 10.1161/01.CIR.65.7.1491; Arnold MF, 2001, J AM SOC ECHOCARDIOG, V14, P391, DOI 10.1067/mje.2001.113159; Barbaro Giuseppe, 2002, AIDS Reviews, V4, P93; BASHI VV, 1988, THORAX, V43, P637, DOI 10.1136/thx.43.8.637; BERTOG SC, IN PRESS J AM COLL C; Bonnefoy E, 2000, EUR HEART J, V21, P832, DOI 10.1053/euhj.1999.1907; Boonyaratavej S, 1998, J AM COLL CARDIOL, V32, P2043, DOI 10.1016/S0735-1097(98)00472-0; Brady WJ, 2000, ACAD EMERG MED, V7, P1256, DOI 10.1111/j.1553-2712.2000.tb00471.x; Breen JF, 2001, J THORAC IMAG, V16, P47, DOI 10.1097/00005382-200101000-00007; BUSH CA, 1977, CIRCULATION, V56, P924, DOI 10.1161/01.CIR.56.6.924; Calafiore AM, 1998, J THORAC CARDIOV SUR, V115, P763, DOI 10.1016/S0022-5223(98)70353-8; CALLAHAN JA, 1985, AM J CARDIOL, V55, P476, DOI 10.1016/0002-9149(85)90397-2; Callahan JA, 1997, ECHOCARDIOGR-J CARD, V14, P497, DOI 10.1111/j.1540-8175.1997.tb00757.x; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; CHANDRARATNA PAN, 1991, CIRCULATION, V84, pI303; Chen FE, 2002, CYTOTHERAPY, V4, P41, DOI 10.1080/146532402317251518; Choi JB, 2001, EUR J CARDIO-THORAC, V20, P1267, DOI 10.1016/S1010-7940(01)01027-2; CHUTTANI K, 1991, CIRCULATION, V83, P1999, DOI 10.1161/01.CIR.83.6.1999; Clark CB, 2001, J AM SOC ECHOCARDIOG, V14, P712, DOI 10.1067/mje.2001.113541; CORREALE E, 1993, AM J CARDIOL, V71, P1377, DOI 10.1016/0002-9149(93)90596-5; COUPLAND DB, 1992, CLIN NUCL MED, V17, P579, DOI 10.1097/00003072-199207000-00010; DEVALERIA PA, 1991, ANN THORAC SURG, V52, P219, DOI 10.1016/0003-4975(91)91339-W; DISEGNI E, 1995, EUR HEART J, V16, P184; Dooley DP, 1997, CLIN INFECT DIS, V25, P872, DOI 10.1086/515543; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Estok L, 1998, MT SINAI J MED, V65, P33; Fairley CK, 1996, J INFECTION, V32, P223, DOI 10.1016/S0163-4453(96)80023-5; Figueras J, 2002, AM HEART J, V144, P251, DOI 10.1067/mhj.2002.123840; FOWLER NO, 1986, J AM COLL CARDIOL, V7, P300, DOI 10.1016/S0735-1097(86)80495-8; FOWLER NO, 1991, JAMA-J AM MED ASSOC, V266, P99, DOI 10.1001/jama.266.1.99; FRAIS MA, 1990, CIRCULATION, V81, P1071, DOI 10.1161/01.CIR.81.3.1071; FRIMAN G, 1993, SCAND J INFECT DIS, P7; Fujioka S, 1996, AM HEART J, V131, P760, DOI 10.1016/S0002-8703(96)90284-7; Furnary AP, 2001, ANN THORAC SURG, V72, pS1077, DOI 10.1016/S0003-4975(01)02952-6; Garcia MJ, 1996, J AM COLL CARDIOL, V27, P108, DOI 10.1016/0735-1097(95)00434-3; GINZTON LE, 1982, CIRCULATION, V65, P1004, DOI 10.1161/01.CIR.65.5.1004; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; GUINDO J, 1990, CIRCULATION, V82, P1117, DOI 10.1161/01.CIR.82.4.1117; Ha JW, 2001, CIRCULATION, V104, P976, DOI 10.1161/hc3401.095705; Hakim JG, 2000, HEART, V84, P183, DOI 10.1136/heart.84.2.183; Haley JH, 2004, J AM COLL CARDIOL, V43, P271, DOI 10.1016/j.jacc.2003.08.032; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Hasuda T, 1999, CARDIOLOGY, V92, P214, DOI 10.1159/000006974; HATLE LK, 1989, CIRCULATION, V79, P357, DOI 10.1161/01.CIR.79.2.357; HIMELMAN RB, 1988, J AM COLL CARDIOL, V12, P1470, DOI 10.1016/S0735-1097(88)80011-1; HINDS SW, 1992, AM HEART J, V123, P143, DOI 10.1016/0002-8703(92)90758-N; Hoit BD, 2002, CIRCULATION, V105, P2939, DOI 10.1161/01.CIR.0000019421.07529.C5; Hurrell DG, 1996, CIRCULATION, V93, P2007, DOI 10.1161/01.CIR.93.11.2007; Imazio M, 2003, J AM COLL CARDIOL, V42, P2144, DOI 10.1016/j.jacc.2003.02.001; Karia Darshak H, 2002, Curr Cardiol Rep, V4, P33, DOI 10.1007/s11886-002-0124-3; KILLIAN DM, 1989, AM HEART J, V118, P563, DOI 10.1016/0002-8703(89)90273-1; KLEIN AL, 1993, J AM COLL CARDIOL, V22, P1935, DOI 10.1016/0735-1097(93)90782-V; KLEIN AL, 2002, TXB CARDIOVASCULAR M, P595; KOH KK, 1994, CIRCULATION, V89, P2728, DOI 10.1161/01.CIR.89.6.2728; Kojima S, 1999, NEW ENGL J MED, V341, P373, DOI 10.1056/NEJM199907293410515; KUTCHER MA, 1982, AM J CARDIOL, V50, P742, DOI 10.1016/0002-9149(82)91228-0; Launbjerg J, 1996, CARDIOLOGY, V87, P60, DOI 10.1159/000177061; Lawler LP, 2001, CRIT REV DIAGN IMAG, V42, P229; LEEMAN DE, 1988, J AM COLL CARDIOL, V11, P572, DOI 10.1016/0735-1097(88)91533-1; LeMaire SA, 1998, ANN THORAC SURG, V65, P1786, DOI 10.1016/S0003-4975(98)00246-X; LEVINE MJ, 1991, J AM COLL CARDIOL, V17, P59, DOI 10.1016/0735-1097(91)90704-D; Ling LH, 2000, ANN INTERN MED, V132, P444, DOI 10.7326/0003-4819-132-6-200003210-00004; Ling LH, 1999, CIRCULATION, V100, P1380, DOI 10.1161/01.CIR.100.13.1380; LING LH, 1997, J AM COLL CARDIOL, V29; Luison F, 2000, ANN THORAC SURG, V70, P2137, DOI 10.1016/S0003-4975(00)01944-5; Maisch B, 2000, HERZ, V25, P781, DOI 10.1007/PL00001997; MAISCH B, 1994, EUR HEART J, V15, P68, DOI 10.1093/eurheartj/15.suppl_C.68; MAISCH B, 1993, SCAND J INFECT DIS, P135; Maisch Bernhard, 2002, Curr Cardiol Rep, V4, P13, DOI 10.1007/s11886-002-0121-6; MANGA P, 1984, BRIT HEART J, V52, P465; Manner J, 2001, CELLS TISSUES ORGANS, V169, P89, DOI 10.1159/000047867; MARCOLONGO R, 1995, J AM COLL CARDIOL, V26, P1276, DOI 10.1016/0735-1097(95)00302-9; Martel MK, 1998, INT J RADIAT ONCOL, V40, P155, DOI 10.1016/S0360-3016(97)00584-1; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; Matsuyama K, 2001, JPN CIRC J, V65, P480, DOI 10.1253/jcj.65.480; Meng QY, 2002, ONCOL REP, V9, P85; MEYNS BP, 1994, ANN THORAC SURG, V57, P489, DOI 10.1016/0003-4975(94)91031-6; MILLAIRE A, 1992, AM HEART J, V124, P1030, DOI 10.1016/0002-8703(92)90988-8; MILLAIRE A, 1994, EUR HEART J, V15, P120, DOI 10.1093/oxfordjournals.eurheartj.a060363; MILLER RH, 1988, AM HEART J, V116, P1323, DOI 10.1016/0002-8703(88)90457-7; MINUTH ANW, 1975, ARCH INTERN MED, V135, P807, DOI 10.1001/archinte.135.6.807; MUIR P, 1989, LANCET, V1, P804; Myers RBH, 1999, AM HEART J, V138, P219, DOI 10.1016/S0002-8703(99)70105-5; NAGAHAMA Y, 1994, J AM COLL CARDIOL, V23, P885, DOI 10.1016/0735-1097(94)90633-5; Nagahama Y, 1998, EUR HEART J, V19, P287, DOI 10.1053/euhj.1997.0744; NICHOLSON WJ, 1980, AM J CARDIOL, V45, P378, DOI 10.1016/0002-9149(80)90662-1; Nishimura RA, 2001, HEART, V86, P619, DOI 10.1136/heart.86.6.619; Oakley CM, 2000, HEART, V84, P449, DOI 10.1136/heart.84.4.449; Oh JK, 1997, CIRCULATION, V95, P796; OH JK, 1994, J AM COLL CARDIOL, V23, P154, DOI 10.1016/0735-1097(94)90514-2; OLIVA PB, 1994, J AM COLL CARDIOL, V24, P1073, DOI 10.1016/0735-1097(94)90872-9; OLSEN PS, 1991, EUR J CARDIO-THORAC, V5, P430, DOI 10.1016/1010-7940(91)90189-Q; Olson M C, 1989, Radiographics, V9, P633; Palka P, 2000, CIRCULATION, V102, P655, DOI 10.1161/01.CIR.102.6.655; Pataki N, 2002, Surg Endosc, V16, P1105, DOI 10.1007/s00464-001-4253-3; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; PIOVACCARI G, 1995, INT J CARDIOL, V49, P39, DOI 10.1016/0167-5273(95)02276-3; POSNER MR, 1981, AM J MED, V71, P407, DOI 10.1016/0002-9343(81)90168-6; Pugliese A, 2000, J INFECTION, V40, P282, DOI 10.1053/jinf.2000.0672; QUIGG RJ, 1985, ARCH INTERN MED, V145, P2249; Rajagopalan N, 2001, AM J CARDIOL, V87, P86, DOI 10.1016/S0002-9149(00)01278-9; Sagrista-Sauleda J, 1999, NEW ENGL J MED, V341, P2054, DOI 10.1056/NEJM199912303412704; SAGRISTASAULEDA J, 1993, J AM COLL CARDIOL, V22, P1661, DOI 10.1016/0735-1097(93)90592-O; SAGRISTASAULEDA J, 1988, J AM COLL CARDIOL, V11, P724, DOI 10.1016/0735-1097(88)90203-3; SAGRISTASAULEDA J, 1987, AM J CARDIOL, V59, P961, DOI 10.1016/0002-9149(87)91134-9; SANTAMORE WP, 1986, CIRCULATION, V74, P597, DOI 10.1161/01.CIR.74.3.597; Scheinman MM, 2000, PACE, V23, P1020, DOI 10.1111/j.1540-8159.2000.tb00891.x; SECHTEM U, 1986, AM J ROENTGENOL, V147, P245, DOI 10.2214/ajr.147.2.245; SECHTEM U, 1986, AM J ROENTGENOL, V147, P239, DOI 10.2214/ajr.147.2.239; Seferovic PM, 2000, HERZ, V25, P741, DOI 10.1007/PL00001992; Senni M, 1999, J AM COLL CARDIOL, V33, P1182, DOI 10.1016/S0735-1097(98)00693-7; Shaver J A, 2001, J Cardiol, V37 Suppl 1, P71; Sivakumaran S, 2002, PACE, V25, P833, DOI 10.1046/j.1460-9592.2002.t01-1-00833.x; Smith WHT, 2001, BRIT J RADIOL, V74, P384, DOI 10.1259/bjr.74.880.740384; Soler-Soler J, 2001, HEART, V86, P235, DOI 10.1136/heart.86.2.235; Spodick David H, 2002, Curr Cardiol Rep, V4, P22, DOI 10.1007/s11886-002-0122-5; SPODICK DH, 1992, AM HEART J, V124, P1046, DOI 10.1016/0002-8703(92)90990-D; SPODICK DH, 1989, CRIT CARE CLIN, V5, P455; Spodick DH, 1997, CHEST, V111, P524, DOI 10.1378/chest.111.2.524; Spodick DH, 2003, NEW ENGL J MED, V349, P684, DOI 10.1056/NEJMra022643; Spodick DH, 2003, JAMA-J AM MED ASSOC, V289, P1150, DOI 10.1001/jama.289.9.1150; SPODICK DH, 1976, NEW ENGL J MED, V295, P523, DOI 10.1056/NEJM197609022951002; SPODICK DH, 1973, CIRCULATION, V48, P575, DOI 10.1161/01.CIR.48.3.575; Spodick DH, 2000, HERZ, V25, P720, DOI 10.1007/PL00001988; Spodick DH, 2001, HEART DIS, P1823; STRANG JIG, 1987, LANCET, V2, P1418; STUBBS DF, 1986, J INT MED RES, V14, P25, DOI 10.1177/03000605860140S105; Sun JP, 2001, J AM SOC ECHOCARDIOG, V14, P1119, DOI 10.1067/mje.2001.115458; SUWAN PK, 1995, BRIT HEART J, V73, P187; Tabata T, 2001, J AM COLL CARDIOL, V37, P1936, DOI 10.1016/S0735-1097(01)01252-9; Talreja DR, 2003, CIRCULATION, V108, P1852, DOI 10.1161/01.CIR.0000087606.18453.FD; TOFLER GH, 1989, AM HEART J, V117, P86, DOI 10.1016/0002-8703(89)90660-1; Totte E, 2002, SURG ENDOSC, V16, P859, DOI 10.1007/s004640090128; Trautner BW, 2001, CLIN INFECT DIS, V33, P954, DOI 10.1086/322621; Uchida T, 2001, ANN THORAC SURG, V72, P924, DOI 10.1016/S0003-4975(00)02436-X; VAITKUS PT, 1991, AM HEART J, V122, P1431, DOI 10.1016/0002-8703(91)90587-8; VAITKUS PT, 1994, JAMA-J AM MED ASSOC, V272, P59, DOI 10.1001/jama.272.1.59; Vasquez Alejandro, 2002, Curr Cardiol Rep, V4, P26, DOI 10.1007/s11886-002-0123-4; von Sohsten R, 2000, AM HEART J, V140, P279, DOI 10.1067/mhj.2000.107996; WALL TC, 1990, AM J CARDIOL, V66, P1418, DOI 10.1016/0002-9149(90)90526-7; Warren W H, 2000, Semin Thorac Cardiovasc Surg, V12, P119; WINKLER WB, 1994, LANCET, V344, P1541, DOI 10.1016/S0140-6736(94)90352-2; Wragg A, 2000, HEART, V84, P127, DOI 10.1136/heart.84.2.127; ZAYAS R, 1995, AM J CARDIOL, V75, P378, DOI 10.1016/S0002-9149(99)80558-X; ZEMER D, 1977, ISRAEL J MED SCI, V13, P55	152	270	301	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					717	727		10.1016/S0140-6736(04)15648-1	http://dx.doi.org/10.1016/S0140-6736(04)15648-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001332				2022-12-28	WOS:000189266900024
J	Callaway, RM; Thelen, GC; Rodriguez, A; Holben, WE				Callaway, RM; Thelen, GC; Rodriguez, A; Holben, WE			Soil biota and exotic plant invasion	NATURE			English	Article							ARBUSCULAR MYCORRHIZAL FUNGI; BIOLOGICAL-CONTROL; FEEDBACK; COMMUNITIES; PATHOGENS; GROWTH	Invasive plants are an economic problem and a threat to the conservation of natural systems. Escape from natural enemies might contribute to successful invasion(1), with most work emphasizing the role of insect herbivores(2-4); however, microbial pathogens are attracting increased attention(5). Soil biota in some invaded ecosystems may promote 'exotic' invasion(6-9), and plant-soil feedback processes are also important. Thus, relatively rare species native to North America consistently demonstrate negative feedbacks with soil microbes that promote biological diversity(10), whereas abundant exotic and native species demonstrate positive feedbacks that reduce biological diversity(10). Here we report that soil microbes from the home range of the invasive exotic plant Centaurea maculosa L. have stronger inhibitory effects on its growth than soil microbes from where the weed has invaded in North America. Centaurea and soil microbes participate in different plant-soil feedback processes at home compared with outside Centaurea's home range. In native European soils, Centaurea cultivates soil biota with increasingly negative effects on the weed's growth, possibly leading to its control. But in soils from North America, Centaurea cultivates soil biota with increasingly positive effects on itself, which may contribute to the success of this exotic species in North America.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Callaway, RM (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	ray.callaway@mso.umt.edu						ANGSPURGER CK, 1990, PESTS PATHOGENS PLAN, pCH3; Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; Bever JD, 2002, P ROY SOC B-BIOL SCI, V269, P2595, DOI 10.1098/rspb.2002.2162; BEVER JD, 1994, ECOLOGY, V75, P1965, DOI 10.2307/1941601; BRUNDRETT M, 1991, ADV ECOL RES, V21, P171, DOI 10.1016/S0065-2504(08)60099-9; BURDON JJ, 1993, ANNU REV PHYTOPATHOL, V31, P305, DOI 10.1146/annurev.py.31.090193.001513; Callaway RM, 2001, ECOL LETT, V4, P429, DOI 10.1046/j.1461-0248.2001.00251.x; Crawley MJ, 1992, NATURAL ENEMIES POPU; CROWLEY DE, 1991, PLANT SOIL, V130, P179, DOI 10.1007/BF00011873; Eom AH, 2000, OECOLOGIA, V122, P435, DOI 10.1007/s004420050050; GOEDEN RD, 1999, HDB BIOL CONTROL, pCH34; Holah JC, 1999, J ECOL, V87, P598, DOI 10.1046/j.1365-2745.1999.00383.x; Klironomos JN, 2002, NATURE, V417, P67, DOI 10.1038/417067a; Louda SM, 2003, ANNU REV ENTOMOL, V48, P365, DOI 10.1146/annurev.ento.48.060402.102800; Marler MJ, 1999, ECOLOGY, V80, P1180, DOI 10.1890/0012-9658(1999)080[1180:MIECEO]2.0.CO;2; McEvoy PB, 1999, ECOL APPL, V9, P387, DOI 10.1890/1051-0761(1999)009[0387:BCOPIR]2.0.CO;2; Mitchell CE, 2003, NATURE, V421, P625, DOI 10.1038/nature01317; NEWSHAM KK, 1994, J ECOL, V82, P805, DOI 10.2307/2261445; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; Richardson DM, 2000, BIOL REV, V75, P65, DOI 10.1017/S0006323199005435; Simberloff Daniel, 1999, Biological Invasions, V1, P21, DOI 10.1023/A:1010086329619; StreitwolfEngel R, 1997, J ECOL, V85, P181, DOI 10.2307/2960650; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Van der Putten WH, 2001, TRENDS ECOL EVOL, V16, P547, DOI 10.1016/S0169-5347(01)02265-0; VanderPutten WH, 1997, ECOLOGY, V78, P1785, DOI 10.1890/0012-9658(1997)078[1785:HSBPMA]2.0.CO;2; VANDERPUTTEN WH, 1993, NATURE, V362, P53; YOUNG NR, 1983, GRASS FORAGE SCI, V38, P13, DOI 10.1111/j.1365-2494.1983.tb01615.x	28	662	747	32	586	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					731	733		10.1038/nature02322	http://dx.doi.org/10.1038/nature02322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973484				2022-12-28	WOS:000189026000042
J	Volkov, I; Banavar, JR; Maritan, A; Hubbell, SP				Volkov, I; Banavar, JR; Maritan, A; Hubbell, SP			The stability of forest biodiversity	NATURE			English	Editorial Material									Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA; Univ Padua, Dipartimento Fis G Galilei, I-35131 Padua, Italy; INFM, I-35131 Padua, Italy; Abdus Salam Int Ctr Theoret Phys, I-34014 Trieste, Italy; Univ Georgia, Dept Plant Biol, Athens, GA 30602 USA; Smithsonian Trop Res Inst, Balboa, Panama	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Abdus Salam International Centre for Theoretical Physics (ICTP); University System of Georgia; University of Georgia; Smithsonian Institution; Smithsonian Tropical Research Institute	Volkov, I (corresponding author), Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA.	banavar@psu.edu	Volkov, Igor/GVT-6571-2022	Maritan, Amos/0000-0002-3535-7873				Clark D, 1998, IEEE CONCURR, V6, P13, DOI 10.1109/4434.678783; Clark JS, 2003, NATURE, V423, P635, DOI 10.1038/nature01632; HUHBELL SP, 2001, UNIFIED NEUTRAL THEO; MAC ARTHUR ROBERT H., 1967; Petit RJ, 2002, FOREST ECOL MANAG, V156, P49, DOI 10.1016/S0378-1127(01)00634-X; Volkov I, 2003, NATURE, V424, P1035, DOI 10.1038/nature01883	6	26	27	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					696	696		10.1038/427696a	http://dx.doi.org/10.1038/427696a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973471				2022-12-28	WOS:000189026000029
J	Perry, JN; Firbank, LG; Champion, GT; Clark, SJ; Heard, MS; May, MJ; Hawes, C; Squire, GR; Rothery, P; Wolwod, IP; Pidgeon, JD				Perry, JN; Firbank, LG; Champion, GT; Clark, SJ; Heard, MS; May, MJ; Hawes, C; Squire, GR; Rothery, P; Wolwod, IP; Pidgeon, JD			Ban on triazine herbicides likely to reduce but not negate relative benefits of GMHT maize cropping	NATURE			English	Article							CROPS	The UK Farm-Scale Evaluations (FSE) compared the effects on biodiversity of management of genetically modified herbicide-tolerant (GMHT) spring-sown crops with conventional crop management(1). The FSE reported larger weed abundance under GMHT management for fodder maize(2), one of three crops studied. Increased seed production may be important for the long-term persistence of these arable weeds and may benefit invertebrates, small mammals and seed-eating birds(1). In three-quarters of FSE maize fields, growers used atrazine on the conventionally managed half, reflecting contemporary commercial practice(3). Withdrawal of the triazine herbicides atrazine, simazine and cyanazine from approved lists of EU chemicals(4) could therefore reduce or even reverse the reported benefits of GMHT maize(1,2,5). Here we analyse effects of applications of triazine herbicides in conventional maize regimes on key indicators(6), using FSE data. Weed abundances were decreased greatly relative to all other regimes whenever atrazine was applied before weeds emerged. Here, we forecast weed abundances in posttriazine herbicide regimes(7,8). We predict weed abundances under future conventional herbicide management to be considerably larger than that for atrazine used before weeds emerged, but still smaller than for the four FSE sites analysed that used only nontriazine herbicides. Our overall conclusion is that the comparative benefits for arable biodiversity of GMHT maize cropping would be reduced, but not eliminated, by the withdrawal of triazines from conventional maize cropping.	Rothamsted Res, Harpenden AL5 2JQ, Herts, England; NERC, Ctr Ecol & Hydrol, Lancaster LA1 4AP, Cumbria, England; Brooms Barn Res Stn, Bury St Edmunds IP28 6NP, Suffolk, England; NERC, Ctr Ecol & Hydrol, Huntingdon PE28 2LS, Cambs, England; Scottish Crop Res Inst, Dundee DD2 5DA, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); James Hutton Institute	Perry, JN (corresponding author), Rothamsted Res, Harpenden AL5 2JQ, Herts, England.	joe.perry@bbsrc.ac.uk	Heard, Matthew/E-6743-2012; perry, joe n/B-2729-2010	Firbank, Leslie/0000-0003-1242-8293				*BRIT STAT NAT CON, 2003, ADV ACRE IMPL FARM S; Champion GT, 2003, PHILOS T ROY SOC B, V358, P1801, DOI 10.1098/rstb.2003.1405; Firbank LG, 1999, NATURE, V399, P727, DOI 10.1038/21516; Firbank LG., 2003, IMPLICATIONS SPRING; Heard MS, 2003, PHILOS T ROY SOC B, V358, P1833, DOI 10.1098/rstb.2003.1401; Heard MS, 2003, PHILOS T ROY SOC B, V358, P1819, DOI 10.1098/rstb.2003.1402; MARSHALL J, 2003, GLUFOSINATE TOLERANT; Perry JN, 2003, J APPL ECOL, V40, P17, DOI 10.1046/j.1365-2664.2003.00786.x; *PEST SAF DIR, 2003, EC REV PROGR EX ACT	9	30	31	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					313	316		10.1038/nature02374	http://dx.doi.org/10.1038/nature02374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15001990				2022-12-28	WOS:000220250200042
J	Friedli, A; Saurat, J				Friedli, A; Saurat, J			Oculo-orogenital syndrome - A deficiency of vitamins B-2 and B-6	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland	University of Geneva	Friedli, A (corresponding author), Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1130	1130		10.1056/NEJMicm980412	http://dx.doi.org/10.1056/NEJMicm980412			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014186				2022-12-28	WOS:000220110100010
J	Poo, MM				Poo, MM			Cultural reflections	NATURE			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA; Chinese Acad Sci, Inst Neurosci, Shanghai, Peoples R China	University of California System; University of California Berkeley; Chinese Academy of Sciences	Poo, MM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.							NEEDHAM J, 1964, SCI SOC, V28, P235	1	16	16	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					204	205		10.1038/428204a	http://dx.doi.org/10.1038/428204a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014506				2022-12-28	WOS:000220103600055
J	Yang, XZ				Yang, XZ			An embryonic nation	NATURE			English	Editorial Material							CELLS		Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA	University of Connecticut	Yang, XZ (corresponding author), Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA.							Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170; Dennis C, 2002, NATURE, V419, P334, DOI 10.1038/419334a; Gershon Diane, 2003, Nature, V422, P928, DOI 10.1038/nj6934-928a; Hwang W. S., 2004, SCIENCE; Lu CF, 2003, CHINESE SCI BULL, V48, P1840, DOI 10.1360/03wc0289; *OECD, 2002, OECD; *OFF SCI TECHN POL, 2003, OFF SCI TECHN POL US; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; ZENG Y, 1999, WORLD SCI TECHNOLOGY, V5, P1; Zhou Q, 2003, SCIENCE, V302, P1179, DOI 10.1126/science.1088313	10	12	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					210	212		10.1038/428210a	http://dx.doi.org/10.1038/428210a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014509				2022-12-28	WOS:000220103600058
J	Kang, HJ; Kim, HS; Zhang, SY; Park, KW; Cho, HJ; Koo, BK; Kim, YJ; Lee, DS; Sohn, DW; Han, KS; Oh, BH; Lee, MM; Park, YB				Kang, HJ; Kim, HS; Zhang, SY; Park, KW; Cho, HJ; Koo, BK; Kim, YJ; Lee, DS; Sohn, DW; Han, KS; Oh, BH; Lee, MM; Park, YB			Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial	LANCET			English	Article							BONE-MARROW; PROGENITOR CELLS; TRANSPLANTATION; REPAIR; SPECT; HEART; CORD	Background Bone-marrow stem-cell transplantation has been shown to improve cardiac function in patients with myocardial infarction. We examined the feasibility and efficacy of granulocyte-colony stimulating factor (G-CSF) therapy and subsequent intracoronary infusion of collected peripheral blood stem-cells (PBSCs) in such patients. Methods We prospectively randomised 27 patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction into three groups; cell infusion (n=10), G-CSF alone (n=10), and control group (n=7). Changes in left ventricular systolic function and perfusion were assessed after 6 months. By December, 2003, seven patients from the cell infusion group, three from the G-CSF group, and one from the control group had been assessed. Findings G-CSF injection and intracoronary infusion of the mobilised PBSC did not aggravate inflammation and ischaermia during the periprocedural period. Exercise capacity (mean treadmill exercise time: 450 s [SD 178] at baseline vs 578 s [168] at 6 months' follow-up, p=0.004), myocardial perfusion (perfusion defect 11.6% [9.6] vs 5.3% [5.0], p=0.020) and systolic function (left ventricular ejection fraction 48.7% [8.3] vs 55.1% [7.4], p=0.005) improved significantly in patients who received cell infusion. However, we noted an unexpectedly high rate of in-stent restenosis at culprit lesion in patients who received G-CSF, and therefore we stopped enrolment. Interpretation G-CSF therapy with intracoronary infusion of PBSC showed improved cardiac function, and promoted angiogenesis in patients with myocardial infarction. However, aggravation of restenosis could be a serious problem. In future studies with G-CSF based stem-cell therapy, patients should be carefully monitored for unexpected effects.	Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Cardiovasc Lab, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Ctr Cardiovasc, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Dept Nucl Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Dept Lab Med, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Kim, HS (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	hyosoo@snu.ac.kr	Kim, Hyo Soo/J-2753-2012; Sohn, Dae Won/J-5516-2012; Oh, Byung-Hee/G-9875-2011; Park, Kyung Woo/AAX-3046-2020; Koo, Bon-Kwon/J-5374-2012; Han, Kyou-Sup/J-5701-2012; Kang, Hyun-Jae/D-6121-2012; Park, Young-Bae/J-5490-2012; Lee, Dong Soo/J-2778-2012	Oh, Byung-Hee/0000-0002-9945-4306; Han, Kyou-Sup/0000-0001-5308-7814; Kang, Hyun-Jae/0000-0002-3500-1746; 				Anderlini P, 1996, BLOOD, V88, P2819, DOI 10.1182/blood.V88.8.2819.bloodjournal8882819; [Anonymous], 1999, COBE SPECTR APH SYST; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BENSINGER W, 1993, BLOOD, V81, P3158; Cavallaro AM, 2000, BONE MARROW TRANSPL, V25, P85, DOI 10.1038/sj.bmt.1702072; Cho HJ, 2003, CIRCULATION, V108, P2918, DOI 10.1161/01.CIR.0000097001.79750.78; ELLIS SG, 2003, MOL CARD S 1 MYOG SE; Fritsch G, 1996, BONE MARROW TRANSPL, V17, P169; GERMANO G, 1995, J NUCL MED, V36, P2138; Hill JM, 2003, CIRCULATION, V108, P478; Lee DS, 2000, NUCL MED COMMUN, V21, P1127, DOI 10.1097/00006231-200012000-00006; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Theilgaard-Monch K, 2001, BONE MARROW TRANSPL, V28, P1073, DOI 10.1038/sj.bmt.1703270; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365-2141.2003.04284.x	19	727	834	0	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					751	756		10.1016/S0140-6736(04)15689-4	http://dx.doi.org/10.1016/S0140-6736(04)15689-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016484				2022-12-28	WOS:000220092000005
J	O'Neill, LAJ				O'Neill, LAJ			After the toll rush	SCIENCE			English	Editorial Material							RECEPTORS; CELLS		Trinity Coll Dublin, Dept Biochem, Dublin, Ireland	Trinity College Dublin	O'Neill, LAJ (corresponding author), Trinity Coll Dublin, Dept Biochem, Dublin, Ireland.	laoneill@tcd.ie		O'Neill, Luke/0000-0002-4333-2748				Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DUNNE A, 2003, SCI STKE, V171, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	9	67	71	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1481	1482		10.1126/science.1096113	http://dx.doi.org/10.1126/science.1096113			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001768				2022-12-28	WOS:000220000100030
J	Soonawalla, ZF; Orug, T; Badminton, MN; Elder, GH; Rhodes, JM; Bramhall, SR; Elias, E				Soonawalla, ZF; Orug, T; Badminton, MN; Elder, GH; Rhodes, JM; Bramhall, SR; Elias, E			Liver transplantation as a cure for acute intermittent porphyria	LANCET			English	Article								Acute intermittent porphyria occasionally causes frequent and crippling acute neurovisceral attacks associated with increased hepatic production of porphyrin precursors, resulting in long-term damage, poor quality of life, and shortened life expectancy. There has been no cure for this condition, but replacement of deficient hepatic enzymes might restore excretion of porphyrin precursors to normal and prevent acute attacks. We aimed to treat severe acute intermittent porphyria in a 19-year-old woman by liver transplantation. After the transplant, concentrations of haem precursors in the patient's urine returned to normal, and 1.5 years later her quality of life was good. Our report suggests some hope of cure for selected patients with severe forms of this disease.	Queen Elizabeth Hosp, Liver Transplant Unit, Birmingham B15 2TH, W Midlands, England; Univ Wales Coll Med, Dept Biochem Med, Cardiff CF4 4XN, S Glam, Wales; Univ Liverpool, Dept Med, Liverpool L69 3BX, Merseyside, England	University of Birmingham; Cardiff University; University of Liverpool	Elias, E (corresponding author), Queen Elizabeth Hosp, Liver Transplant Unit, Nuffield House, Birmingham B15 2TH, W Midlands, England.	elwyn.elias@uhb.nhs.uk	Rhodes, Jonathan M/C-2496-2009					Anderson K.E., 2001, METABOLIC MOL BASES, P2961; Elder GH, 1997, LANCET, V349, P1613, DOI 10.1016/S0140-6736(96)09070-8; Jeans JB, 1996, AM J MED GENET, V65, P269, DOI 10.1002/(SICI)1096-8628(19961111)65:4<269::AID-AJMG4>3.0.CO;2-K; Nordmann Y, 1997, J INTERN MED, V242, P213, DOI 10.1046/j.1365-2796.1997.00189.x; THUNELL S, 1992, EUR J CLIN CHEM CLIN, V30, P599	5	122	124	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					705	706		10.1016/S0140-6736(04)15646-8	http://dx.doi.org/10.1016/S0140-6736(04)15646-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001330				2022-12-28	WOS:000189266900013
J	Klett, EL; Patel, SB				Klett, EL; Patel, SB			Will the real cholesterol transporter please stand up	SCIENCE			English	Editorial Material							DIETARY-CHOLESTEROL; ABSORPTION; MUTATIONS		Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA	Medical University of South Carolina	Klett, EL (corresponding author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA.	patelsb@musc.edu		Patel, Shailendra/0000-0003-0046-5513; Klett, Eric/0000-0002-8000-6810	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060613] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060613] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Klett EL, 2003, CURR OPIN LIPIDOL, V14, P341, DOI 10.1097/00041433-200308000-00001; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; SCHONHEIMER RUDOLF, 1929, ZEITSCHR PHYSIOL CHEM, V180, P1	10	29	29	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1149	1150		10.1126/science.1095519	http://dx.doi.org/10.1126/science.1095519			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976303	Green Accepted			2022-12-28	WOS:000189074700033
J	Surkan, PJ; Stephansson, O; Dickman, PW; Cnattingius, S				Surkan, PJ; Stephansson, O; Dickman, PW; Cnattingius, S			Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAUTERINE GROWTH-RETARDATION; FETAL DEATH; PERINATAL-MORTALITY; POPULATION; WEIGHT; OUTCOMES; COHORT; DETERMINANTS; PREGNANCIES; ULTRASOUND	Background: Some causes of stillbirth may also lead to fetuses that are small for gestational age (have a low birth weight with respect to their gestational age) or are delivered preterm (before 37 weeks of gestation). It is not known whether the birth of a previous small-for-gestational-age or preterm infant increases the subsequent risk of stillbirth. Methods: We assessed the associations between previous adverse outcomes of pregnancy and the risk of stillbirth in a nationwide Swedish study of 410,021 women who delivered first and second consecutive singleton infants between 1983 and 1997. There were 1842 and 1062 stillbirths during the first and second pregnancies, respectively. Results: As compared with women whose first infant was born at term (37 weeks of gestation or more) and was not small for gestational age, women whose first infant was born at term or preterm and was small for gestational age had an increased risk of stillbirth during their second pregnancy. The odds ratios for subsequent stillbirth, after adjustment for covariates known to be associated with an increased risk of stillbirth, were 2.1 (95 percent confidence interval, 1.6 to 2.8) among women with a first infant who was born at term and was small for gestational age, 3.4 (95 percent confidence interval, 2.1 to 5.6) among women with a first infant who was moderately (32 to 36 weeks of gestation) preterm and small for gestational age, and 5.0 (95 percent confidence interval, 2.5 to 9.8) among women with a first infant who was very (before 32 weeks of gestation) preterm and was small for gestational age. The odds ratio for subsequent stillbirth among women with a first stillborn infant was 2.5 (95 percent confidence interval, 1.4 to 4.7), as compared with women whose first infant was not stillborn. The rates of stillbirth in second pregnancies ranged from 2.4 per 1000 births among women whose first infant was born at term and was not small for gestational age to 19.0 per 1000 births among women whose first child was very preterm and was small for gestational age. Conclusions: Delivery of a previous small-for-gestational-age infant is an important predictor of the subsequent risk of stillbirth, particularly if the infant was delivered preterm.	Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA	Karolinska Institutet; Karolinska Institutet; Harvard University; Harvard T.H. Chan School of Public Health	Surkan, PJ (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.		Dickman, Paul W/B-4572-2013	Dickman, Paul W/0000-0002-5788-3380; Stephansson, Olof/0000-0003-1528-4563				Ananth CV, 1999, JAMA-J AM MED ASSOC, V282, P1646, DOI 10.1001/jama.282.17.1646; BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; Barfield WD, 2002, SEMIN PERINATOL, V26, P17, DOI 10.1053/sper.2002.29850; BENIRSCHKE K, 1987, CLIN OBSTET GYNECOL, V30, P2814; Clausson B, 2001, BRIT J OBSTET GYNAEC, V108, P830, DOI 10.1111/j.1471-0528.2001.00205.x; Cnattingius S, 1998, BRIT MED J, V316, P1483, DOI 10.1136/bmj.316.7143.1483; Cnattingius S, 2002, SEMIN PERINATOL, V26, P25, DOI 10.1053/sper.2002.29841; Emanuel I, 1997, AM J EPIDEMIOL, V146, P820; FREEMAN RK, 1985, AM J OBSTET GYNECOL, V151, P7, DOI 10.1016/0002-9378(85)90414-4; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; GARBACIAK JA, 1992, CLIN PERINATOL, V19, P275, DOI 10.1016/S0095-5108(18)30454-8; Gardosi J, 1998, BRIT J OBSTET GYNAEC, V105, P524, DOI 10.1111/j.1471-0528.1998.tb10153.x; GENEST DR, 1992, OBSTET GYNECOL, V80, P575; Hershkovitz R, 2001, EUR J OBSTET GYN R B, V97, P141, DOI 10.1016/S0301-2115(00)00517-0; HOFFMAN HJ, 1984, CLIN OBSTET GYNECOL, V27, P539, DOI 10.1097/00003081-198409000-00004; Hogberg U, 1997, ACTA OBSTET GYN SCAN, V76, P907, DOI 10.3109/00016349709034900; KHOURY MJ, 1988, PEDIATRICS, V82, P83; Lackman F, 2001, AM J OBSTET GYNECOL, V184, P946, DOI 10.1067/mob.2001.111719; Lindmark G, 1991, Acta Obstet Gynecol Scand, V70, P105, DOI 10.3109/00016349109006190; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Marsal K, 2002, CURR OPIN OBSTET GYN, V14, P127, DOI 10.1097/00001703-200204000-00005; Martin JA, 2002, SEMIN PERINATOL, V26, P3, DOI 10.1053/sper:2002.29834; MILLER HC, 1985, AM J OBSTET GYNECOL, V153, P20, DOI 10.1016/0002-9378(85)90583-6; Papiernik E, 1999, Matern Child Health J, V3, P63, DOI 10.1023/A:1021897125652; PATTERSON RM, 1986, OBSTET GYNECOL, V68, P464; Radestad I, 1996, BRIT MED J, V312, P1505, DOI 10.1136/bmj.312.7045.1505; Robson S, 2001, AUST NZ J OBSTET GYN, V41, P29, DOI 10.1111/j.1479-828X.2001.tb01290.x; SAMUELOFF A, 1993, J REPROD MED, V38, P883; SCHNEIDER J, 1973, Clinical Obstetrics and Gynecology, V16, P120, DOI 10.1097/00003081-197303000-00007; STEIN ZA, 1984, SEMIN PERINATOL, V8, P5; Stephansson O, 2001, INT J EPIDEMIOL, V30, P1296, DOI 10.1093/ije/30.6.1296; Stephansson O, 2003, OBSTET GYNECOL, V102, P101, DOI 10.1016/S0029-7844(03)00366-1; Tolockiene E, 2001, ACTA OBSTET GYN SCAN, V80, P511, DOI 10.1034/j.1600-0412.2001.080006511.x; Westergaard HB, 2001, ULTRASOUND OBST GYN, V17, P466, DOI 10.1046/j.1469-0705.2001.00415.x	35	119	127	1	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					777	785		10.1056/NEJMoa031587	http://dx.doi.org/10.1056/NEJMoa031587			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973215				2022-12-28	WOS:000189006400006
J	Invernizzi, P; Miozzo, M; Battezzati, PM; Bianchi, I; Grati, FR; Simoni, G; Selmi, C; Watnik, M; Gershwin, ME; Podda, M				Invernizzi, P; Miozzo, M; Battezzati, PM; Bianchi, I; Grati, FR; Simoni, G; Selmi, C; Watnik, M; Gershwin, ME; Podda, M			Frequency of monosomy X in women with primary biliary cirrhosis	LANCET			English	Article								The mechanisms that cause the female predominance of primary biliary cirrhosis (PBC) are uncertain, but the X chromosome includes genes involved in immunological tolerance. We assessed the rate of X monosomy in peripheral white blood cells from 100 women with PBC, 50 with chronic hepatitis C, and 50 healthy controls, by fluorescence in-situ hybridisation. Frequency of X monosomy increased with age In all groups, but was significantly higher in women with PBC than in controls (p<0.0001); age-adjusted back-transformed mean frequencies were 0.050 (95% CI 0.046-0.055) in women with PBC, 0.032 (0.028-0.036) in those with chronic hepatitis C, and 0.028 (0.025-0.032) in controls. We suggest that haploinsufficiency for specific X-linked genes leads to female susceptibility to PBC.	Univ Milan, San Pablo Sch Med, Dept Internal Med, I-20142 Milan, Italy; Univ Milan, San Pablo Sch Med, Lab Human Genet, I-20142 Milan, Italy; Univ Milan, San Pablo Sch Med, Dept Med Surg & Dent, I-20142 Milan, Italy; Univ Calif Davis, Dept Stat, Davis, CA 95616 USA; Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA	University of Milan; University of Milan; University of Milan; University of California System; University of California Davis; University of California System; University of California Davis	Invernizzi, P (corresponding author), Univ Milan, San Pablo Sch Med, Dept Internal Med, Via Rudini 8, I-20142 Milan, Italy.	pietro.invernizzi@unimi.it	Invernizzi, Pietro/AAB-8367-2022; Grati, Francesca Romana/H-7397-2019; Selmi, Carlo/ABG-4899-2021; Miozzo, Monica Rosa/AAC-6401-2022	Invernizzi, Pietro/0000-0003-3262-1998; Selmi, Carlo/0000-0002-0323-0376; Miozzo, Monica Rosa/0000-0002-6523-4575; Battezzati, Pier Maria/0000-0003-1344-3452; Watnik, Mitchell/0000-0002-0487-8430				Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; Ranke MB, 2001, LANCET, V358, P309, DOI 10.1016/S0140-6736(01)05487-3; Talwalkar JA, 2003, LANCET, V362, P53, DOI 10.1016/S0140-6736(03)13808-1; Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777; Zinn AR, 2001, J SOC GYNECOL INVEST, V8, pS34, DOI 10.1016/S1071-5576(00)00104-0	5	210	213	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					533	535		10.1016/S0140-6736(04)15541-4	http://dx.doi.org/10.1016/S0140-6736(04)15541-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975617				2022-12-28	WOS:000188999900012
J	Giannone, G; Dubin-Thaler, BJ; Dobereiner, HG; Kieffer, N; Bresnick, AR; Sheetz, MP				Giannone, G; Dubin-Thaler, BJ; Dobereiner, HG; Kieffer, N; Bresnick, AR; Sheetz, MP			Periodic lamellipodial contractions correlate with rearward actin waves	CELL			English	Article							DEPOLYMERIZING FACTOR COFILIN; FILAMENT TURNOVER; ARP2/3 COMPLEX; MYOSIN-II; MOTILITY; FORCE; LOCALIZATION; PHOSPHORYLATION; RAC; PROTRUSION	Cellular lamellipodia bind to the matrix and probe its rigidity through forces generated by rearward F-actin transport. Cells respond to matrix rigidity by moving toward more rigid matrices using an unknown mechanism. In spreading and migrating cells we find local periodic contractions of lamellipodia that depend on matrix rigidity, fibronectin binding and myosin light chain kinase (MLCK). These contractions leave periodic rows of matrix bound beta3-integrin and paxillin while generating waves of rearward moving actin bound alpha-actinin and MLCK. The period between contractions corresponds to the time for F-actin to move across the lamellipodia. Shortening lamellipodial width by activating cofilin decreased this period proportionally. Increasing lamellipodial width by Rac signaling activation increased this period. We propose that an actin bound, contraction-activated signaling complex is transported locally from the tip to the base of the lamellipodium, activating the next contraction/extension cycle.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Ctr, CNRS, CRP Sante, Lab Franco Luxembourgeois Rech Biomed, L-1511 Luxembourg, Luxembourg; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Columbia University; Luxembourg Institute of Health; Yeshiva University; Albert Einstein College of Medicine	Sheetz, MP (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	ms2001@columbia.edu	Döbereiner, Hans-Günther/F-7302-2012	Döbereiner, Hans-Günther/0000-0003-1691-634X; Giannone, Gregory/0000-0002-0932-1690	NIGMS NIH HHS [GM362] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Dobereiner HG, 1997, PHYS REV E, V55, P4458, DOI 10.1103/PhysRevE.55.4458; DUBINTHALER BJ, 2004, IN PRESS BIOPHYS J; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Munevar S, 2001, MOL BIOL CELL, V12, P3947, DOI 10.1091/mbc.12.12.3947; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Plancon S, 2001, BIOCHEM J, V357, P529, DOI 10.1042/0264-6021:3570529; Pletjushkina OJ, 2001, CELL MOTIL CYTOSKEL, V48, P235, DOI 10.1002/cm.1012.abs; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345, DOI 10.1152/ajpcell.2000.279.5.C1345; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	47	456	461	3	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					431	443		10.1016/S0092-8674(04)00058-3	http://dx.doi.org/10.1016/S0092-8674(04)00058-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016377	Bronze			2022-12-28	WOS:000188825800011
J	Ebrahim, S; Montaner, D; Lawlor, DA				Ebrahim, S; Montaner, D; Lawlor, DA			Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK; INSULIN-RESISTANCE; SOCIOECONOMIC CONDITIONS; DISEASE; MORTALITY; CORONARY; CIRCUMSTANCES; ASSOCIATION; PREDICTORS; PREVENTION	Objective To examine co-occurrence and clustering of risk factors used in the Framingham equation by social class in childhood and adult life. Design Cross sectional study. Setting 23 towns across England, Wales, and Scotland. Participants 2936 women aged 60-79 years. Main outcome measures Prevalence of risk factors (hypertension, obesity, smoking, left ventricular hypertrophy on electrocardiography, diabetes, and low concentration of high density cholesterol); ratios of observed to expected frequencies of clusters of risk factors. Results Risk factors were more common in women from manual social classes in either childhood or adult life, and the co-occurrence of three or four of these risk factors was greater among more disadvantaged groups. Within the four socioeconomic groups, these risk factors occur-red together more than would be expected from their individual frequency distributions, indicating that they were clustered. The extent of this clustering was similar in all four social class groups. Conclusions Clustering of risk factors included in the Framingham risk function occurs in all social class groups, but the lack of social patterning makes it unlikely that clustering is an explanation of socioeconomic inequalities in cardiovascular disease. As the proportion of women with co-occurrence of risk factors is greatest in those from manual social class in childhood, this measure of socioeconomic position might prove useful in risk prediction.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Ebrahim, S (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	Shah.ebrahim@bristol.ac.uk	; Montaner, David/A-9362-2014	Lawlor, Debbie A/0000-0002-6793-2262; Montaner, David/0000-0002-2484-3278				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brunner E, 1999, J EPIDEMIOL COMMUN H, V53, P757, DOI 10.1136/jech.53.12.757; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; ERENS B, 1999, HLTH SURVEY ENGLAND; Golden SH, 2002, DIABETES, V51, P3069, DOI 10.2337/diabetes.51.10.3069; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Hoeymans N, 1996, EUR HEART J, V17, P518; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; Lawlor DA, 2002, BRIT MED J, V325, P805, DOI 10.1136/bmj.325.7368.805; Lawlor DA, 2003, J EPIDEMIOL COMMUN H, V57, P134, DOI 10.1136/jech.57.2.134; LAWLOR DA, 2003, IN PRESS AM J PUBLIC; Liese AD, 1998, EPIDEMIOL REV, V20, P157, DOI 10.1093/oxfordjournals.epirev.a017978; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; Marmot M, 2001, J EPIDEMIOL COMMUN H, V55, P301, DOI 10.1136/jech.55.5.301; MYERS L, 1995, AM J EPIDEMIOL, V142, P918, DOI 10.1093/oxfordjournals.aje.a117739; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; Parsons TJ, 1999, INT J OBESITY, V23, pS1; RAITAKARI OT, 1994, J CLIN EPIDEMIOL, V47, P1085, DOI 10.1016/0895-4356(94)90094-9; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; Smith GD, 2002, STRESS AND THE HEART: PSYCHOSOCIAL PATHWAYS TO CORONARY HEART DISEASE, P20; Smith GD, 1997, LANCET, V349, P284, DOI 10.1016/S0140-6736(05)64894-5; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 2001, J EPIDEMIOL COMMUN H, V55, P340, DOI 10.1136/jech.55.5.340; Wallis EJ, 2000, BMJ-BRIT MED J, V320, P671, DOI 10.1136/bmj.320.7236.671; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WINGARD DL, 1983, AM J EPIDEMIOL, V117, P19, DOI 10.1093/oxfordjournals.aje.a113510; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X; Wood D, 1998, HEART, V80, pS1	30	61	65	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	2004	328	7444					861	864		10.1136/bmj.38034.702836.55	http://dx.doi.org/10.1136/bmj.38034.702836.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XE	15006898	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000220871400014
J	Calvert, AJ				Calvert, AJ			Seismic reflection imaging of two megathrust shear zones in the northern Cascadia subduction zone	NATURE			English	Article							DE-FUCA PLATE; CONVERGENT MARGIN; VANCOUVER-ISLAND; WESTERN CANADA; SILENT SLIP; EARTHQUAKES; DEHYDRATION; CONSTRAINTS; INTERFACE; BENEATH	At convergent continental margins, the relative motion between the subducting oceanic plate and the overriding continent is usually accommodated by movement along a single, thin interface known as a megathrust(1). Great thrust earthquakes occur on the shallow part of this interface where the two plates are locked together(2). Earthquakes of lower magnitude occur within the underlying oceanic plate, and have been linked to geochemical dehydration reactions caused by the plate's descent(3-7). Here I present deep seismic reflection data from the northern Cascadia subduction zone that show that the inter-plate boundary is up to 16 km thick and comprises two megathrust shear zones that bound a >5-km-thick, similar to110-km-wide region of imbricated crustal rocks. Earthquakes within the subducting plate occur predominantly in two geographic bands where the dip of the plate is inferred to increase as it is forced around the edges of the imbricated inter-plate boundary zone. This implies that seismicity in the subducting slab is controlled primarily by deformation in the upper part of the plate. Slip on the shallower megathrust shear zone, which may occur by aseismic slow slip, will transport crustal rocks into the upper mantle above the subducting oceanic plate and may, in part, provide an explanation for the unusually low seismic wave speeds that are observed there(8,9).	Simon Fraser Univ, Dept Earth Sci, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Calvert, AJ (corresponding author), Simon Fraser Univ, Dept Earth Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	acalvert@sfu.ca		Calvert, Andrew/0000-0002-1024-6640				BOLTON MK, 2002, SEISMOL RES LETT, V73, P214; BROCHER TM, 1994, J GEOPHYS RES-SOL EA, V99, P11663, DOI 10.1029/94JB00111; BROCHER TM, 1999, 99314 US GEOL SURV; Calvert AJ, 1996, CAN J EARTH SCI, V33, P1294, DOI 10.1139/e96-098; CALVERT AJ, 1990, GEOLOGY, V18, P1091, DOI 10.1130/0091-7613(1990)018<1091:DHARFA>2.3.CO;2; CASSIDY JF, 1991, J GEOPHYS RES-SOL EA, V96, P19843, DOI 10.1029/91JB01658; CLOWES RM, 1987, CAN J EARTH SCI, V24, P31, DOI 10.1139/e87-004; CLOWES RM, 1987, GEOPHYS J INT, V89, P79, DOI 10.1111/j.1365-246X.1987.tb04391.x; DEHLER SA, 1992, CAN J EARTH SCI, V29, P1492, DOI 10.1139/e92-119; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; FISHER MA, 1999, EOS T AGU, V80, P16; GREEN AG, 1986, NATURE, V319, P210, DOI 10.1038/319210a0; Hacker B.R., 2003, J GEOPHYS RES, V108; HASSELGREN EO, 1994, J GEOPHYS RES, V100, P6469; HYNDMAN RD, 1995, J GEOPHYS RES-SOL EA, V100, P22133, DOI 10.1029/95JB01970; HYNDMAN RD, 1988, J GEOPHYS RES-SOLID, V93, P13391, DOI 10.1029/JB093iB11p13391; KAO H, 2003, EOS S, V84, DOI UNSP S42G-02; KIRBY S, 1996, SUBDUCTION TOP BOTTO, P195, DOI DOI 10.1029/GM096P0195; Nedimovic MR, 2003, NATURE, V424, P416, DOI 10.1038/nature01840; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; Peacock SM, 1999, SCIENCE, V286, P937, DOI 10.1126/science.286.5441.937; Preston LA, 2003, SCIENCE, V302, P1197, DOI 10.1126/science.1090751; RAMACHANDRAN K, 2001, THESIS U VICTORIA; Ranero CR, 2000, NATURE, V404, P748, DOI 10.1038/35008046; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; ROGERS GC, 1988, CAN J EARTH SCI, V25, P844, DOI 10.1139/e88-083; SPENCE GD, 1985, J GEOPHYS RES-SOLID, V90, P6754, DOI 10.1029/JB090iB08p06754; STANLEY D, 1999, 99311 US GEOL SURV; Wells R.E, 2003, J GEOPHYS RES, V108; YORATH CJ, 1987, 1661 GEOL SURV CAN	30	58	63	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					163	167		10.1038/nature02372	http://dx.doi.org/10.1038/nature02372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014496				2022-12-28	WOS:000220103600044
J	Choi, HK; Atkinson, K; Karlson, EW; Willett, W; Curhan, G				Choi, HK; Atkinson, K; Karlson, EW; Willett, W; Curhan, G			Purine-rich foods, dairy and protein intake, and the risk of gout in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; URIC-ACID METABOLISM; FREQUENCY QUESTIONNAIRE; ELDERLY-MEN; WOMEN; SERUM; REPRODUCIBILITY; VALIDITY; HYPERURICEMIA; HEALTH	BACKGROUND: Various purine-rich foods and high protein intake have long been thought to be risk factors for gout. Similarly, the possibility that the consumption of dairy products has a role in protecting against gout has been raised by metabolic studies. We prospectively investigated the association of these dietary factors with new cases of gout. METHODS: Over a 12-year period, we prospectively examined the relationship between purported dietary risk factors and new cases of gout among 47,150 men who had no history of gout at base line. We used a supplementary questionnaire to ascertain whether participants met the American College of Rheumatology survey criteria for gout. Diet was assessed every four years by means of a food-frequency questionnaire. RESULTS: During the 12 years of the study, we documented 730 confirmed new cases of gout. The multivariate relative risk of gout among men in the highest quintile of meat intake, as compared with those in the lowest quintile, was 1.41 (95 percent confidence interval, 1.07 to 1.86; P for trend = 0.02), and the corresponding relative risk associated with seafood intake was 1.51 (95 percent confidence interval, 1.17 to 1.95; P for trend = 0.02). In contrast, the incidence of gout decreased with increasing intake of dairy products; the multivariate relative risk among men in the highest quintile, as compared with those in the lowest quintile, was 0.56 (95 percent confidence interval, 0.42 to 0.74; P for trend <0.001). The level of consumption of purine-rich vegetables and the total protein intake were not associated with an increased risk of gout. CONCLUSIONS: Higher levels of meat and seafood consumption are associated with an increased risk of gout, whereas a higher level of consumption of dairy products is associated with a decreased risk. Moderate intake of purine-rich vegetables or protein is not associated with an increased risk of gout.	Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Boston, MA 02114 USA; Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Choi, HK (corresponding author), Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Bulfinch 165,55 Fruit St, Boston, MA 02114 USA.	hchoi@partners.org			NCI NIH HHS [CA55075] Funding Source: Medline; NIDDK NIH HHS [DK58573] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT RD, 1988, J CLIN EPIDEMIOL, V41, P237, DOI 10.1016/0895-4356(88)90127-8; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; CLIFFORD AJ, 1976, J NUTR, V106, P435, DOI 10.1093/jn/106.3.435; CLIFFORD AJ, 1976, J NUTR, V106, P428, DOI 10.1093/jn/106.3.428; Dessein PH, 2000, ANN RHEUM DIS, V59, P539, DOI 10.1136/ard.59.7.539; Emmerson BT, 1996, NEW ENGL J MED, V334, P445, DOI 10.1056/NEJM199602153340707; Fam AG, 2002, J RHEUMATOL, V29, P1350; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GARREL DR, 1991, AM J CLIN NUTR, V53, P665; GHADIRIAN P, 1995, EUR J EPIDEMIOL, V11, P275, DOI 10.1007/BF01719431; GIBSON T, 1980, ANN RHEUM DIS, V39, P417, DOI 10.1136/ard.39.5.417; GIBSON T, 1983, ANN RHEUM DIS, V42, P123, DOI 10.1136/ard.42.2.123; GLYNN RJ, 1983, ARTHRITIS RHEUM-US, V26, P87, DOI 10.1002/art.1780260115; Griebsch A, 1974, Adv Exp Med Biol, V41, P443; HOCHBERG MC, 1995, ARTHRITIS RHEUM-US, V38, P628, DOI 10.1002/art.1780380508; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1999, AM J CLIN NUTR, V70, P221; Kramer HM, 2002, AM J KIDNEY DIS, V40, P37, DOI 10.1053/ajkd.2002.33911; Lewis HB, 1918, J BIOL CHEM, V36, P1; LOENEN HMJA, 1990, J CLIN EPIDEMIOL, V43, P1297, DOI 10.1016/0895-4356(90)90095-7; Matzkies F, 1980, Adv Exp Med Biol, V122A, P227; NUGENT CHARLES A., 1965, ARTHRITIS RHEUM, V8, P671, DOI 10.1002/art.1780080427; Raiziss GW, 1914, J BIOL CHEM, V19, P473; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROUBENOFF R, 1991, JAMA-J AM MED ASSOC, V266, P3004, DOI 10.1001/jama.266.21.3004; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; Shadick NA, 2000, J RHEUMATOL, V27, P1708; SHARPE CR, 1984, CAN MED ASSOC J, V131, P563; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; WASLIEN CI, 1968, AM J CLIN NUTR, V21, P892, DOI 10.1093/ajcn/21.9.892; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Zollner N, 1974, Adv Exp Med Biol, V41, P435; ZOLLNER N, 1973, BIBL NUTR DIET, V19, P34	35	663	724	5	147	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1093	1103		10.1056/NEJMoa035700	http://dx.doi.org/10.1056/NEJMoa035700			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014182				2022-12-28	WOS:000220110100006
J	Wang, ZG; Wang, DZ; Hockemeyer, D; McAnally, J; Nordheim, A; Olson, EN				Wang, ZG; Wang, DZ; Hockemeyer, D; McAnally, J; Nordheim, A; Olson, EN			Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression	NATURE			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTION FACTORS; CELL-DIFFERENTIATION; FACTOR ELK-1; DOMAIN; COACTIVATOR; ACTIVATION; PROMOTER; PROTEIN; SM22-ALPHA	Smooth muscle cells switch between differentiated and proliferative phenotypes in response to extracellular cues(1), but the transcriptional mechanisms that confer such phenotypic plasticity remain unclear. Serum response factor (SRF) activates genes involved in smooth muscle differentiation and proliferation by recruiting muscle-restricted cofactors, such as the transcriptional coactivator myocardin, and ternary complex factors (TCFs) of the ETS-domain family, respectively(2-9). Here we show that growth signals repress smooth muscle genes by triggering the displacement of myocardin from SRF by Elk-1, a TCF that acts as a myogenic repressor. The opposing influences of myocardin and Elk-1 on smooth muscle gene expression are mediated by structurally related SRF-binding motifs that compete for a common docking site on SRF. A mutant smooth muscle promoter, retaining responsiveness to myocardin and SRF but defective in TCF binding, directs ectopic transcription in the embryonic heart, demonstrating a role for TCFs in suppression of smooth muscle gene expression in vivo. We conclude that growth and developmental signals modulate smooth muscle gene expression by regulating the association of SRF with antagonistic cofactors.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ N Carolina, Dept Cell & Dev Biol, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ Tubingen, Dept Mol Biol, Inst Cell Biol, D-72704 Tubingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; Eberhard Karls University of Tubingen	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Eric.Olson@utsouthwestern.edu	Wang, Zhigao/ABE-9411-2021	Wang, Zhigao/0000-0002-6544-4302; Hockemeyer, Dirk/0000-0002-5598-5092				Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Mack CP, 1999, CIRC RES, V84, P852; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; OWENS GK, 1995, PHYSIOL REV, V75, P487; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Sharrocks AD, 2002, BIOCHEM SOC T, V30, P1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Shore P, 1996, MOL CELL BIOL, V16, P3338; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09	29	438	458	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					185	189		10.1038/nature02382	http://dx.doi.org/10.1038/nature02382			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014501				2022-12-28	WOS:000220103600050
J	Whitman, K; Starfield, AM; Quadling, HS; Packer, C				Whitman, K; Starfield, AM; Quadling, HS; Packer, C			Sustainable trophy hunting of African lions	NATURE			English	Article							COOPERATION; INFANTICIDE; MAMMALS; KINSHIP	In most species, sport hunting of male trophy animals can only reduce overall population size when the rate of removal of males is so high that females can no longer be impregnated(1). However, where males provide extensive paternal care, the removal of even a few individuals could harm the population as a whole(2,3). In species such as lions, excessive trophy hunting could theoretically cause male replacements (and associated infanticide(4,5)) to become sufficiently common to prevent cubs reaching adulthood. Here we simulate the population consequences of lion trophy hunting using a spatially explicit, individual-based, stochastic model parameterized with 40 years of demographic data from northern Tanzania. Although our simulations confirm that infanticide increases the risk of population extinction, trophy hunting could be sustained simply by hunting males above a minimum age threshold, and this strategy maximizes both the quantity and the quality of the long-term kill. We present a simple non-invasive technique for estimating lion age in populations lacking long-term records, and suggest that quotas would be unnecessary in any male-only trophy species where age determination could be reliably implemented.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Packer, C (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.	packer@cbs.umn.edu						BERTRAM BCR, 1975, J ZOOL, V177, P463; BYGOTT JD, 1979, NATURE, V282, P838; Caro TM, 1998, AFR J ECOL, V36, P321, DOI 10.1046/j.1365-2028.1998.00146.x; Coltman DW, 2003, NATURE, V426, P655, DOI 10.1038/nature02177; Greene C, 1998, BEHAVIORAL ECOLOGY AND CONSERVATION BIOLOGY, P271; GRINNELL J, 1995, ANIM BEHAV, V49, P95, DOI 10.1016/0003-3472(95)80157-X; Hillborn R., 1992, QUANTITATIVE FISHERI; LEADERWILLIAMS N, 1996, IUCN SPECIES SURVIVA, V14; Milner-Gulland EJ, 2003, NATURE, V422, P135, DOI 10.1038/422135a; Packer C, 1998, NATURE, V392, P807, DOI 10.1038/33910; Packer C., 1988, P363; Packer C, 2001, SCIENCE, V293, P690, DOI 10.1126/science.1062320; PACKER C, 1983, ANIM BEHAV, V31, P334, DOI 10.1016/S0003-3472(83)80051-7; Packer C, 2000, AM ANTHROPOL, V102, P829, DOI 10.1525/aa.2000.102.4.829; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; Quadling HS, 2002, S AFR J SCI, V98, P449; Schaller G. B., 1972, SERENGETI LION; Slotow R, 2000, NATURE, V408, P425, DOI 10.1038/35044191; Smith RJ, 2003, NATURE, V426, P67, DOI 10.1038/nature02025; Starfield A.M., 1981, P121; Sutherland WJ, 2001, WILDLIFE BIOL, V7, P131, DOI 10.2981/wlb.2001.017; Swenson JE, 1997, NATURE, V386, P450, DOI 10.1038/386450a0; West PM, 2002, SCIENCE, V297, P1339, DOI 10.1126/science.1073257	23	156	161	7	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					175	178		10.1038/nature02395	http://dx.doi.org/10.1038/nature02395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	14990967				2022-12-28	WOS:000220103600047
J	Blandin, S; Shiao, SH; Moita, LF; Janse, CJ; Waters, AP; Kafatos, FC; Levashina, EA				Blandin, S; Shiao, SH; Moita, LF; Janse, CJ; Waters, AP; Kafatos, FC; Levashina, EA			Complement-like protein TEP1 is a determinant of vectorial capacity in the malaria vector Anopheles gambiae	CELL			English	Article							QUANTITATIVE TRAIT LOCI; IMMUNE-RESPONSE; MOSQUITO; EXPRESSION; STEPHENSI; GENES	Anopheles mosquitoes are major vectors of human malaria in Africa. Large variation exists in the ability of mosquitoes to serve as vectors and to transmit malaria parasites, but the molecular mechanisms that determine vectorial capacity remain poorly understood. We report that the hemocyte-specific complement-like protein TEP1 from the mosquito Anopheles gambiae binds to and mediates killing of midgut stages of the rodent malaria parasite Plasmodium, berghei. The dsRNA knockdown of TEP1 in adults completely abolishes melanotic refractoriness in a genetically selected refractory strain, Moreover, in susceptible mosquitoes this knockdown increases the number of developing parasites. Our results suggest that the TEP1-dependent parasite killing is followed by a TEP1-independent clearance of dead parasites by lysis and/or melanization. Further elucidation of the molecular mechanisms of TEP1-mediated parasite killing will be of great importance for our understanding of the principles of vectorial capacity in insects.	European Mol Biol Lab, D-69117 Heidelberg, Germany; CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France; Leiden Univ, Med Ctr, Dept Parasitol, NL-9600 RC Leiden, Netherlands	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Levashina, EA (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	e.levashina@ibmc.u-strasbg.fr	Blandin, Stephanie/I-2786-2016; Waters, Andy P/C-9377-2009; Moita, Luis F./L-1296-2013; Moita, Luis/HCI-2793-2022; Blandin, Stephanie/ABH-2267-2021	Blandin, Stephanie/0000-0003-4566-1200; Waters, Andy P/0000-0001-8900-2982; Moita, Luis F./0000-0003-0707-315X; Moita, Luis/0000-0003-0707-315X; Blandin, Stephanie/0000-0003-4566-1200; Levashina, Elena/0000-0003-4605-906X; SHIAO, SHIN-HONG/0000-0002-7749-7807; Janse, Chris J/0000-0002-6410-6205				Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Carroll MC, 1997, CURR OPIN IMMUNOL, V9, P64, DOI 10.1016/S0952-7915(97)80160-4; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Danielli A, 2000, P NATL ACAD SCI USA, V97, P7136, DOI 10.1073/pnas.97.13.7136; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Law SKA, 1997, PROTEIN SCI, V6, P263; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; MEIS JFGM, 1989, PARASITOL RES, V76, P13, DOI 10.1007/BF00931065; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; SIMONETTI AB, 1993, J EUKARYOT MICROBIOL, V40, P569, DOI 10.1111/j.1550-7408.1993.tb06109.x; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Thummel CS, 1992, DROS INF SERV, V71, P150; VARGAS L, 1949, CULICINE AEDINE MOSQ, P526; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; Zheng LB, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-16; Zheng LB, 1997, SCIENCE, V276, P425, DOI 10.1126/science.276.5311.425	18	451	469	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					661	670		10.1016/S0092-8674(04)00173-4	http://dx.doi.org/10.1016/S0092-8674(04)00173-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006349	Bronze			2022-12-28	WOS:000221499700007
J	Nie, ZG; Schweitzer, P; Roberts, AJ; Madamba, SG; Moore, SD; Siggins, GR				Nie, ZG; Schweitzer, P; Roberts, AJ; Madamba, SG; Moore, SD; Siggins, GR			Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors	SCIENCE			English	Article							CORTICOTROPIN-RELEASING-FACTOR; ALCOHOL-DRINKING; OPIOID RECEPTOR; CENTRAL NUCLEUS; DRUG-ADDICTION; STRESS; ANXIETY; ACTIVATION; NEURONS; NEUROBIOLOGY	The central amygdala (CeA) plays a role in the relationship among stress, corticotropin-releasing factor (CRF), and alcohol abuse. In whole-cell recordings, both CRF and ethanol enhanced gamma-aminobutyric acid-mediated (GABAergic) neurotransmission in CeA neurons from wild-type and CRF2 receptor knockout mice, but not CRF1 receptor knockout mice. CRF1 (but not CRF2) receptor antagonists blocked both CRF and ethanol effects in wild-type mice. These data indicate that CRF1 receptors mediate ethanol enhancement of GABAergic synaptic transmission in the CeA, and they suggest a cellular mechanism underlying involvement of CRF in ethanol's behavioral and motivational effects.	Scripps Res Inst, Dept Neuropharmacol & Alcohol Res, La Jolla, CA 92037 USA; Duke Univ, Dept Psychiat, Durham, NC 27710 USA	Scripps Research Institute; Duke University	Siggins, GR (corresponding author), Scripps Res Inst, Dept Neuropharmacol & Alcohol Res, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	geobob@scripps.edu			NIAAA NIH HHS [AA06420, AA10994] Funding Source: Medline; NIDA NIH HHS [DA13658, DA03665] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010994, P60AA006420, P50AA006420, R01AA010994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003665, R01DA013658] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Blednov YA, 2003, J PHARMACOL EXP THER, V304, P30, DOI 10.1124/jpet.102.042960; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Day HEW, 1999, J COMP NEUROL, V413, P113; Holsboer Florian, 2003, Curr Opin Investig Drugs, V4, P46; Hsin LW, 2002, BIOORGAN MED CHEM, V10, P175, DOI 10.1016/S0968-0896(01)00261-9; Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x; Koob GF, 1998, ALCOHOL CLIN EXP RES, V22, P3, DOI 10.1097/00000374-199802000-00001; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Krysiak R, 2000, POL J PHARMACOL, V52, P15; LaForge KS, 2000, EUR J PHARMACOL, V410, P249, DOI 10.1016/S0014-2999(00)00819-0; Liu X, 2002, J NEUROSCI, V22, P7856; McBride WJ, 2002, PHARMACOL BIOCHEM BE, V71, P509, DOI 10.1016/S0091-3057(01)00680-3; Melis M, 2002, J NEUROSCI, V22, P2074, DOI 10.1523/JNEUROSCI.22-06-02074.2002; MOORE SP, UNPUB; Nie ZG, 2000, J PHARMACOL EXP THER, V293, P654; POHORECKY LA, 1990, ALCOHOL ALCOHOLISM, V25, P263, DOI 10.1093/oxfordjournals.alcalc.a045000; POHORECKY LA, 1991, ALCOHOL CLIN EXP RES, V15, P438, DOI 10.1111/j.1530-0277.1991.tb00543.x; Reul JMHM, 2002, CURR OPIN PHARMACOL, V2, P23, DOI 10.1016/S1471-4892(01)00117-5; Roberto M, 2003, P NATL ACAD SCI USA, V100, P2053, DOI 10.1073/pnas.0437926100; Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x; Ryabinin AE, 2002, ALCOHOL CLIN EXP RES, V26, P714; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; Sillaber I, 2002, SCIENCE, V296, P931, DOI 10.1126/science.1069836; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Valdez GR, 2002, ALCOHOL CLIN EXP RES, V26, P1494, DOI 10.1097/01.ALC.0000033120.51856.F0; Van Pett K, 2000, J COMP NEUROL, V428, P191, DOI 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U; Veinante P, 1997, NEUROREPORT, V8, P2985, DOI 10.1097/00001756-199709080-00035; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9	28	218	223	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1512	1514		10.1126/science.1092550	http://dx.doi.org/10.1126/science.1092550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001778				2022-12-28	WOS:000220000100040
J	Alter, DA; Iron, K; Austin, PC; Naylor, CD				Alter, DA; Iron, K; Austin, PC; Naylor, CD		SESAMI Study Grp	Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; HEALTH-CARE; CARDIOVASCULAR-DISEASE; CARDIAC PROCEDURES; OUTCOMES; ACCESS; ATHEROSCLEROSIS; PREFERENCES; EDUCATION; INCOME	Context Some have argued that Canada's uniquely restrictive approach to private health insurance keeps the socioeconomic elite inside the public system so that their demands and influence elevate the standard of service for all Canadian citizens. The extent to which this theory is a valid representation of Canadian health care is unknown. Objectives To explore how patients with acute myocardial infarction from different socioeconomic backgrounds perceive their care in Canada's universal health care system and to correlate patients' backgrounds and perceptions with actual care received. Design, Setting, and Patients Prospective observational cohort study with follow-up telephone interviews of 2256 patients 30 days following acute myocardial infarction discharged from 53 hospitals across Ontario, Canada, between December 1999 and June 2002. Main Outcome Measures Postdischarge use of cardiac specialty services; satisfaction with care; willingness to pay directly for faster service or more choice; and mortality according to income and education, adjusted for age, sex, ethnicity, clinical factors, onsite angiography capacity at the admitting hospital, and rural-urban residence. Results Compared with patients in lower socioeconomic strata, more affluent or better educated patients were more likely to undergo coronary angiography (67.8% vs 52.8%; P<.001), receive cardiac rehabilitation (43.9% vs 25.6%; P<.001), or be followed up by a cardiologist (56.7% vs 47.8%; P<.001). Socioeconomic differences in cardiac care persisted after adjustment for confounders. Despite receiving more specialized services, patients with higher socioeconomic status were more likely to be dissatisfied with their access to specialty care (adjusted RR, 2.02; 95% confidence interval, 1.20-3.32) and to favor out-of-pocket payments for quicker access to a wider selection of treatment options (30% vs 15% for patients with household incomes of Can $60000 or higher vs less than Can $30000, respectively; P<.001). After adjusting for baseline characteristics, socioeconomic status was not significantly associated with mortality at 1 year following hospitalization for myocardial infarction. Conclusions Compared with those with lower incomes or less education, upper middle-class Canadians gain preferential access to services within the publicly funded health care system yet remain more likely to favor supplemental coverage or direct purchase of services.	Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evalut, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Deans Off, Toronto, ON, Canada	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Alter, DA (corresponding author), Inst Clin Evaluat Sci, 2075 Bayview Ave,G106, Toronto, ON M4N 3M5, Canada.	david.alter@ices.on.ca		Austin, Peter/0000-0003-3337-233X				Alter DA, 1998, ANN INTERN MED, V129, P567, DOI 10.7326/0003-4819-129-7-199810010-00011; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Alter DA, 2003, AM HEART J, V146, P938, DOI 10.1016/S0002-8703(03)00449-6; Alter DA, 2001, JAMA-J AM MED ASSOC, V285, P2101, DOI 10.1001/jama.285.16.2101; ALTER DA, 2003, PHARMACOECONOMICS OU, V3, P691; Anand SS, 2001, LANCET, V358, P1147, DOI 10.1016/S0140-6736(01)06255-9; Anand SS, 2000, LANCET, V356, P279, DOI 10.1016/S0140-6736(00)02502-2; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; Choi BCK, 2001, DIABETOLOGIA, V44, P1221, DOI 10.1007/s001250100648; Dirnfeld V, 1996, CAN MED ASSOC J, V155, P407; Ganiats TG, 2000, MED DECIS MAKING, V20, P263, DOI 10.1177/0272989X0002000302; Hawker GA, 2002, ARTHRITIS RHEUM-US, V46, P3331, DOI 10.1002/art.10682; Klassen AC, 2002, AM J PUBLIC HEALTH, V92, P811, DOI 10.2105/AJPH.92.5.811; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; McIsaac W, 1997, J Health Serv Res Policy, V2, P94; *NAT POP HLTH SURV, 1997, STAT CAN; Naylor CD, 1999, HEALTH AFFAIR, V18, P9, DOI 10.1377/hlthaff.18.3.9; Ng E, 1993, Health Rep, V5, P179; Philbin EF, 2000, CIRCULATION, V102, P107; Pilote L, 2003, AM HEART J, V146, P1030, DOI 10.1016/S0002-8703(03)00448-4; Romanow RJ, 2002, BUILDING VALUES FUTU; Ross CE, 1997, J HEALTH SOC BEHAV, V38, P275, DOI 10.2307/2955371; ROSS CK, 1993, MED CARE, V31, P1138, DOI 10.1097/00005650-199312000-00006; Schoen C, 2000, HEALTH POLICY, V51, P67, DOI 10.1016/S0168-8510(99)00084-6; *STAND COMM SOC AF, 2004, HLTH CAN FED ROL, V6; Tang M, 2003, INT J EPIDEMIOL, V32, P381, DOI 10.1093/ije/dyg075; van Doorslaer E, 2000, J HEALTH ECON, V19, P553, DOI 10.1016/S0167-6296(00)00050-3; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZITNER D, 2002, 2 AIMS	29	108	108	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1100	1107		10.1001/jama.291.9.1100	http://dx.doi.org/10.1001/jama.291.9.1100			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	780AQ	14996779	Bronze			2022-12-28	WOS:000189348900027
J	Nguyen, C				Nguyen, C			Mycobacterium marinum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mem Univ Newfoundland, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Nguyen, C (corresponding author), Mem Univ Newfoundland, St Johns, NF A1B 3V6, Canada.								0	0	0	1	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					E8	E8		10.1056/ENEJMicm000083	http://dx.doi.org/10.1056/ENEJMicm000083			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985501				2022-12-28	WOS:000189197300012
J	Claeys, M; Graham, B; Vas, G; Wang, W; Vermeylen, R; Pashynska, V; Cafmeyer, J; Guyon, P; Andreae, MO; Artaxo, P; Maenhaut, W				Claeys, M; Graham, B; Vas, G; Wang, W; Vermeylen, R; Pashynska, V; Cafmeyer, J; Guyon, P; Andreae, MO; Artaxo, P; Maenhaut, W			Formation of secondary organic aerosols through photooxidation of isoprene	SCIENCE			English	Article							CLOUD-CONDENSATION-NUCLEI; ATMOSPHERIC PARTICLES; FOREST; LEVOGLUCOSAN; OXIDATION; ACIDS	Detailed organic analysis of natural aerosols from the Amazonian rain forest showed considerable quantities of previously unobserved polar organic compounds, which were identified as a mixture of two diastereoisomeric 2-methyltetrols: 2-methylthreitol and 2-methylerythritol. These polyols, which have the isoprene skeleton, can be explained by OH radical-initiated photooxidation of isoprene. They have low vapor pressure, allowing them to condense onto preexisting particles. It is estimated that photooxidation of isoprene results in an annual global production of about 2 teragrams of the polyols, a substantial fraction of the Intergovernmental Panel on Climate Change estimate of between 8 and 40 teragrams per year of secondary organic aerosol from biogenic sources.	Univ Antwerp, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium; Max Planck Inst Chem, Biogeochem Dept, D-55020 Mainz, Germany; CSIRO, Atmospher Res, Aspendale, Vic 3195, Australia; Univ Ghent, Inst Nucl Sci, Dept Analyt Chem, B-9000 Ghent, Belgium; Univ Sao Paulo, Inst Phys, BR-05508900 Sao Paulo, Brazil	University of Antwerp; Max Planck Society; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Ghent University; Universidade de Sao Paulo	Claeys, M (corresponding author), Univ Antwerp, Dept Pharmaceut Sci, Univ Pl 1, B-2610 Antwerp, Belgium.	magda.claeys@ua.ac.be	Pashynska, Vlada/R-2440-2018; Andreae, Meinrat O./B-1068-2008; Maenhaut, Willy/M-3091-2013; Artaxo, Paulo/E-8874-2010	Pashynska, Vlada/0000-0001-9786-6828; Andreae, Meinrat O./0000-0003-1968-7925; Maenhaut, Willy/0000-0002-4715-4627; Artaxo, Paulo/0000-0001-7754-3036; Graham, Bim/0000-0002-1160-7751				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; ATKINSON R, 1984, CHEM REV, V84, P437, DOI 10.1021/cr00063a002; COHEN S, 1993, J CHEM SOC FARADAY T, V89, P3271, DOI 10.1039/ft9938903271; Geiger H, 2003, ATMOS ENVIRON, V37, P1503, DOI 10.1016/S1352-2310(02)01047-6; Graham B, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003990; Graham B, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000336; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; Hoffmann T, 1997, J ATMOS CHEM, V26, P189, DOI 10.1023/A:1005734301837; Hoffmann T, 1998, J GEOPHYS RES-ATMOS, V103, P25569, DOI 10.1029/98JD01816; Houghton J. T., 2001, CLIMATE CHANGE 2001; Kavouras IG, 2002, ENVIRON SCI TECHNOL, V36, P5083, DOI 10.1021/es025811c; Kavouras IG, 1998, NATURE, V395, P683, DOI 10.1038/27179; Kawamura K, 1996, J GEOPHYS RES-ATMOS, V101, P18721, DOI 10.1029/96JD01541; Kesselmeier J, 2000, ATMOS ENVIRON, V34, P4063, DOI 10.1016/S1352-2310(00)00186-2; Leaitch WR, 1999, J GEOPHYS RES-ATMOS, V104, P8095, DOI 10.1029/1998JD100012; LEWIS DH, 1967, NEW PHYTOL, V66, P143, DOI 10.1111/j.1469-8137.1967.tb05997.x; Limbeck A, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017738; NOVAKOV T, 1993, NATURE, V365, P823, DOI 10.1038/365823a0; PANDIS SN, 1991, ATMOS ENVIRON A-GEN, V25, P997, DOI 10.1016/0960-1686(91)90141-S; Roberts MC, 2001, GEOPHYS RES LETT, V28, P2807, DOI 10.1029/2000GL012585; Ruppert L, 2000, ATMOS ENVIRON, V34, P1529, DOI 10.1016/S1352-2310(99)00408-2; Saxena P, 1996, J ATMOS CHEM, V24, P57, DOI 10.1007/BF00053823; Seinfeld J.H., 1998, ATMOSPHERIC CHEM PHY, V3, P724; Simoneit BRT, 1999, ATMOS ENVIRON, V33, P173, DOI 10.1016/S1352-2310(98)00145-9; TORRES AL, 1988, J GEOPHYS RES-ATMOS, V93, P1396, DOI 10.1029/JD093iD02p01396; WENT FW, 1960, NATURE, V187, P641, DOI 10.1038/187641a0; Zdrahal Z, 2002, ENVIRON SCI TECHNOL, V36, P747, DOI 10.1021/es015619v; Zhou JC, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000203	28	1057	1098	28	663	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1173	1176		10.1126/science.1092805	http://dx.doi.org/10.1126/science.1092805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976309				2022-12-28	WOS:000189074700040
J	Temiakov, D; Patlan, V; Anikin, M; McAllister, WT; Yokoyama, S; Vassylyev, DG				Temiakov, D; Patlan, V; Anikin, M; McAllister, WT; Yokoyama, S; Vassylyev, DG			Structural basis for substrate selection by T7 RNA polymerase	CELL			English	Article							ACTIVE-SITE MUTANTS; I KLENOW FRAGMENT; DNA-POLYMERASE; ELONGATION COMPLEX; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; TRANSCRIPTION ELONGATION; NUCLEOSIDE TRIPHOSPHATES; INITIATION COMPLEX; ALLOSTERIC BINDING	The mechanism by which nucleotide polymerases select the correct substrate is of fundamental importance to the fidelity of DNA replication and transcription. During the nucleotide addition cycle, pol I DNA polymerases undergo the transition from a catalytically inactive "open" to an active "closed" conformation. All known determinants of substrate selection are associated with the "closed" state. To elucidate if this mechanism is conserved in homologous single subunit RNA polymerases (RNAPs), we have determined the structure of T7 RNAP elongation complex with the incoming substrate analog. Surprisingly, the substrate specifically binds to RNAP in the "open" conformation, where it is base paired with the acceptor template base, while Tyr639 provides discrimination of ribose versus deoxyribose substrates. The structure therefore suggests a novel mechanism, in which the substrate selection occurs prior to the isomerization to the catalytically active conformation. Modeling of multisubunit RNAPs suggests that this mechanism might be universal for all RNAPs.	RIKEN, Harima Inst Spring 8, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst Spring 8, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; SUNY Hlth Sci Ctr, Morse Inst Mol Genet, Dept Microbiol, Brooklyn, NY 11203 USA; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; RIKEN; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; RIKEN; University of Tokyo	Yokoyama, S (corresponding author), RIKEN, Harima Inst Spring 8, Cellular Signaling Lab, 1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp; dmitry@yumiyoshi.harima.riken.go.jp	Patlan, Vsevolod/K-1825-2013; Vassylyev, Dmitry/A-9005-2008; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338	NIGMS NIH HHS [R01 GM038147-14S1, GM38147, R01 GM038147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BONNER G, 1994, J BIOL CHEM, V269, P25120; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOSTYUK DA, 1995, FEBS LETT, V369, P165, DOI 10.1016/0014-5793(95)00732-O; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2003, ACTA CRYSTALLOGR D, V59, P185, DOI 10.1107/S0907444902019777; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Tosaka A, 2001, J BIOL CHEM, V276, P27562, DOI 10.1074/jbc.M010635200; Tunitskaya VL, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1124, DOI 10.1023/A:1020911223250; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Woody AYM, 1998, BIOCHEMISTRY-US, V37, P15958, DOI 10.1021/bi9805801; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	54	156	167	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					381	391		10.1016/S0092-8674(04)00059-5	http://dx.doi.org/10.1016/S0092-8674(04)00059-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016373	Bronze			2022-12-28	WOS:000188825800007
J	Tomita, S; Fukata, M; Nicoll, RA; Bredt, DS				Tomita, S; Fukata, M; Nicoll, RA; Bredt, DS			Dynamic interaction of stargazin-like TARPs with cycling AMPA receptors at synapses	SCIENCE			English	Article							SYNAPTIC PLASTICITY; GLUTAMATE-RECEPTOR; MOUSE STARGAZER; PHOSPHORYLATION; MECHANISMS; PSD-95; PROTEINS; INTERNALIZATION; TRANSMISSION; ACTIVATION	Activity-dependent plasticity in the brain arises in part from changes in the number of synaptic AMPA receptors. Synaptic trafficking of AMPA receptors is controlled by stargazin and homologous transmembrane AMPA receptor regulatory proteins (TARPs). We found that TARPs were stable at the plasma membrane, whereas AMPA receptors were internalized in a glutamate-regulated manner. Interaction with AMPA receptors involved both extra- and intracellular determinants of TARPs. Upon binding to glutamate, AMPA receptors detached from TARPs. This did not require ion flux or intracellular second messengers. This allosteric mechanism for AMPA receptor dissociation from TARPs may participate in glutamate-mediated internalization of receptors in synaptic plasticity.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	bredt@itsa.ucsf.edu	Fukata, Masaki/AAZ-2476-2021	Fukata, Masaki/0000-0001-5200-9806				Antonova I, 2001, SCIENCE, V294, P1547, DOI 10.1126/science.1066273; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 2003, MOL PHARMACOL, V64, P703, DOI 10.1124/mol.64.3.703; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; Ziff EB, 1999, ANN NY ACAD SCI, V868, P465, DOI 10.1111/j.1749-6632.1999.tb11315.x	27	172	177	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1508	1511		10.1126/science.1090262	http://dx.doi.org/10.1126/science.1090262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001777				2022-12-28	WOS:000220000100039
J	Sumner, S; Hughes, WOH; Pedersen, JS; Boomsma, JJ				Sumner, S; Hughes, WOH; Pedersen, JS; Boomsma, JJ			Ant parasite queens revert to mating singly	NATURE			English	Editorial Material							SOCIAL HYMENOPTERA; TRANSITION; EVOLUTION; NUMBER		Univ Copenhagen, Dept Populat Biol, Inst Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Sumner, S (corresponding author), Smithsonian Trop Res Inst, Unit 0948, APO, AA 34002 USA.	jjboomsma@zi.ku.dk	Sumner, Seirian/E-6611-2011; Pedersen, Jes Søe/J-6337-2014; Boomsma, Jacobus J/M-2785-2014; Hughes, William OH/A-6957-2014	Pedersen, Jes Søe/0000-0002-4439-2638; Boomsma, Jacobus J/0000-0002-3598-1609; Hughes, William OH/0000-0003-0951-9768; Sumner, Seirian/0000-0003-0213-2018				Bekkevold D, 2000, J EVOLUTION BIOL, V13, P615, DOI 10.1046/j.1420-9101.2000.00201.x; CHAO A, 1992, J AM STAT ASSOC, V87, P210, DOI 10.2307/2290471; Crozier RH, 2001, ANN ZOOL FENN, V38, P267; Ortius-Lechner D, 2000, MOL ECOL, V9, P114, DOI 10.1046/j.1365-294x.2000.00764-5.x; Pedersen JS, 1999, MOL ECOL, V8, P577, DOI 10.1046/j.1365-294x.1999.00573.x; Simmons L. W., 2001, MG BEH ECOL; Sumner S, 2004, INSECT SOC, V51, P37, DOI 10.1007/s00040-003-0723-z; Sumner S, 2003, BEHAV ECOL SOCIOBIOL, V54, P256, DOI 10.1007/s00265-003-0633-0; Sumner S, 2003, P ROY SOC B-BIOL SCI, V270, P1315, DOI 10.1098/rspb.2003.2362; Villesen P, 2002, P ROY SOC B-BIOL SCI, V269, P1541, DOI 10.1098/rspb.2002.2044; Villesen P, 2002, MOL ECOL NOTES, V2, P320, DOI 10.1046/j.1471-8286.2002.00229.x	11	74	76	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					35	36		10.1038/428035a	http://dx.doi.org/10.1038/428035a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999273				2022-12-28	WOS:000189363800026
J	Stollman, N; Raskin, JB				Stollman, N; Raskin, JB			Diverticular disease of the colon	LANCET			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SIGMOID DIVERTICULITIS; COMPUTED-TOMOGRAPHY; NATURAL-HISTORY; LARGE-BOWEL; LAPAROSCOPIC SURGERY; URGENT COLONOSCOPY; BALLOON DILATION; FOLLOW-UP; MANAGEMENT	Colonic diverticulosis refers to small outpouchings from the colonic lumen due to mucosal herniation through the colonic wall at sites of vascular perforation. Abnormal colonic motility and inadequate intake of dietary fibre have been implicated in its pathogenesis. This acquired abnormality is typically found in developed countries, and its prevalence rises with age. Most patients affected will remain entirely asymptomatic; however, 10-20% of those affected can manifest clinical syndromes, mainly diverticulitis and diverticular haemorrhage. As our elderly population grows, we can anticipate a concomitant rise in the number of patients with diverticular disease. Here, we review the incidence, pathophysiology, clinical presentation, and management of diverticular disease of the colon and its complications.	San Francisco Gen Hosp, Div Gastroenterol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Miami, Sch Med, Jackson Mem Med Ctr, Div Gastroenterol, Miami, FL USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of Miami	Stollman, N (corresponding author), San Francisco Gen Hosp, Div Gastroenterol, 1001 Potrero Ave,Suite 3-D, San Francisco, CA 94110 USA.	NStollman@medsfgh.ucsf.edu						ACOSTA JA, 1992, AM SURGEON, V58, P605; ALAVI A, 1981, AM J ROENTGENOL, V137, P741, DOI 10.2214/ajr.137.4.741; Aldoori WH, 1998, J NUTR, V128, P714, DOI 10.1093/jn/128.4.714; Aldoori WH, 1998, ARCH FAM MED, V7, P255, DOI 10.1001/archfami.7.3.255; ALDOORI WH, 1994, AM J CLIN NUTR, V60, P757, DOI 10.1093/ajcn/60.5.757; Ambrosetti P, 2000, DIS COLON RECTUM, V43, P1363, DOI 10.1007/BF02236631; AMBROSETTI P, 1994, SURGERY, V115, P546; AMBROSETTI P, 1992, DIS COLON RECTUM, V35, P1072, DOI 10.1007/BF02252998; Anderson JC, 2001, GASTROINTEST ENDOSC, V54, P558, DOI 10.1067/mge.2001.118950; ANDRESS HJ, 1993, ENDOSCOPY, V25, P193, DOI 10.1055/s-2007-1010286; ARFWIDSSON S, 1964, ACTA CHIR SCAND    S, V342, P1; BERMAN LG, 1968, SURG GYNECOL OBSTETR, V127, P481; Berthou JC, 1999, SURG ENDOSC-ULTRAS, V13, P457, DOI 10.1007/s004649901012; BERTONI G, 1990, ENDOSCOPY, V22, P154, DOI 10.1055/s-2007-1012827; Bode MK, 2000, SCAND J GASTROENTERO, V35, P747; BOLEY SJ, 1979, AM J SURG, V137, P57, DOI 10.1016/0002-9610(79)90011-4; BOULOS PB, 1984, LANCET, V1, P95; BRODRIBB AJM, 1977, LANCET, V1, P664; BROWDER W, 1986, ANN SURG, V204, P530, DOI 10.1097/00000658-198611000-00004; BURKITT DP, 1972, LANCET, V1, P1408; CAOS A, 1986, J CLIN GASTROENTEROL, V8, P46, DOI 10.1097/00004836-198602000-00010; CASARELLA WJ, 1972, NEW ENGL J MED, V286, P450, DOI 10.1056/NEJM197203022860902; Chautems RC, 2002, DIS COLON RECTUM, V45, P962, DOI 10.1007/s10350-004-6336-4; CHIA JG, 1991, DIS COLON RECTUM, V34, P498, DOI 10.1007/BF02049937; CHO KC, 1990, RADIOLOGY, V176, P111, DOI 10.1148/radiology.176.1.2191360; CHOW A, 1994, APPENDICITIS DIVERTI; Cohn SM, 1998, ARCH SURG-CHICAGO, V133, P50, DOI 10.1001/archsurg.133.1.50; CORTESINI C, 1991, DIS COLON RECTUM, V34, P339, DOI 10.1007/BF02050595; DEYHLE P, 1974, ENDOSCOPY, V6, P229, DOI 10.1055/s-0028-1098628; DORINGER E, 1992, CRIT REV DIAGN IMAG, V33, P421; FISHER N, 1985, AM J CLIN NUTR, V42, P788, DOI 10.1093/ajcn/42.5.788; FORDE KA, 1985, DIS COLON RECTUM, V28, P699, DOI 10.1007/BF02560275; FORDE KA, 1981, GASTROINTEST ENDOSC, V27, P219, DOI 10.1016/S0016-5107(81)73225-5; Foutch PG, 1996, AM J GASTROENTEROL, V91, P2589; Franklin ME, 1997, SURG ENDOSC-ULTRAS, V11, P1021, DOI 10.1007/s004649900516; FREISCHLAG J, 1986, DIS COLON RECTUM, V29, P639, DOI 10.1007/BF02560326; Gordon RL, 1997, AM J SURG, V174, P24, DOI 10.1016/S0002-9610(97)00044-5; GOSTOUT CJ, 1992, J CLIN GASTROENTEROL, V14, P260, DOI 10.1097/00004836-199204000-00014; HODGSON J, 1972, BRIT MED J, V3, P729, DOI 10.1136/bmj.3.5829.729; Hokama A, 1997, AM J GASTROENTEROL, V92, P543; HORNER JL, 1958, AM J DIG DIS, V3, P343, DOI 10.1007/BF02232401; HULNICK DH, 1984, RADIOLOGY, V152, P491, DOI 10.1148/radiology.152.2.6739821; HUNTER JM, 1990, AM J SURG, V159, P504, DOI 10.1016/S0002-9610(05)81256-5; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; JENSEN DM, 1983, GASTROINTEST ENDOSC, V29, P177; JENSEN DM, 1988, GASTROENTEROLOGY, V95, P1569, DOI 10.1016/S0016-5085(88)80079-9; Jensen DM, 2000, NEW ENGL J MED, V342, P78, DOI 10.1056/NEJM200001133420202; JOHNSTON J, 1986, GASTROINTEST ENDOSC, V32, P160; KIM YI, 1993, J CLIN GASTROENTEROL, V17, P46, DOI 10.1097/00004836-199307000-00013; Kockerling F, 1999, SURG ENDOSC-ULTRAS, V13, P567, DOI 10.1007/s004649901042; Kohler L, 1999, SURG ENDOSC-ULTRAS, V13, P430, DOI 10.1007/s004649901007; KONVOLINKA CW, 1994, AM J SURG, V167, P562, DOI 10.1016/0002-9610(94)90098-1; KOURTESIS GJ, 1988, AUST NZ J SURG, V58, P955, DOI 10.1111/j.1445-2197.1988.tb00100.x; KOZAREK RA, 1986, GASTROINTEST ENDOSC, V32, P15, DOI 10.1016/S0016-5107(86)71721-5; KYLE J., 1967, SCAND J GASTROENTEROL, V2, P77, DOI 10.3109/00365526709180050; Lauro A, 2002, Minerva Chir, V57, P1; LEE YS, 1986, DIS COLON RECTUM, V29, P330, DOI 10.1007/BF02554125; LEVI DM, 1993, AM J GASTROENTEROL, V88, P139; Longstreth GF, 1997, AM J GASTROENTEROL, V92, P419; Makela J, 2002, DIS COLON RECTUM, V45, P955, DOI 10.1007/s10350-004-6335-5; MANTEN HD, 1986, GASTROINTEST ENDOSC, V32, P164; MARKHAM NI, 1992, GUT, V33, P547, DOI 10.1136/gut.33.4.547; Marlett JA, 2002, J AM DIET ASSOC, V102, P993, DOI 10.1016/S0002-8223(02)90228-2; MAULDIN JL, 1985, GASTROINTEST ENDOSC, V31, P290, DOI 10.1016/S0016-5107(85)72192-X; MCBEATH RB, 1994, UROLOGY, V44, P661, DOI 10.1016/S0090-4295(94)80200-9; MCGUIRE HH, 1972, ANN SURG, V175, P847, DOI 10.1097/00000658-197206010-00004; MCGUIRE HH, 1994, ANN SURG, V220, P653, DOI 10.1097/00000658-199411000-00008; MEYERS MA, 1976, GASTROENTEROLOGY, V71, P577; MORRIS J, 1986, ANN SURG, V204, P128, DOI 10.1097/00000658-198608000-00005; OGUNBIYI O A, 1989, African Journal of Medicine and Medical Sciences, V18, P241; ORNSTEIN MH, 1981, BRIT MED J, V282, P1353, DOI 10.1136/bmj.282.6273.1353; OZ MC, 1990, SURGERY, V108, P513; PAINTER N S, 1964, Ann R Coll Surg Engl, V34, P98; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAINTER NS, 1975, CLIN GASTROENTEROL, V4, P1; Painter NS, 1968, GASTROENTEROLOGY, V54, P778; PARKS TG, 1969, BRIT MED J, V4, P639, DOI 10.1136/bmj.4.5684.639; PARKS TG, 1975, CLIN GASTROENTEROL, V4, P53; Paul L, 2002, RADIOLOGY, V223, P715, DOI 10.1148/radiol.2233010866; PERKINS JD, 1984, AM J SURG, V148, P745, DOI 10.1016/0002-9610(84)90429-X; Peura DA, 1997, AM J GASTROENTEROL, V92, P924; POTTER GD, 1988, GASTROENTEROL CLIN N, V17, P341; REINUS JF, 1994, GASTROENTEROL CLIN N, V23, P1; Reisman Y, 1999, INT J COLORECTAL DIS, V14, P250, DOI 10.1007/s003840050219; ROBERTS P, 1995, DIS COLON RECTUM, V38, P126; Roberts P L, 1994, Adv Surg, V27, P189; RYAN P, 1983, DIS COLON RECTUM, V26, P12, DOI 10.1007/BF02554670; SAVIDES TJ, 1994, GASTROINTEST ENDOSC, V40, P70, DOI 10.1016/S0016-5107(94)70014-1; SCHAUER PR, 1992, AM J SURG, V164, P443, DOI 10.1016/S0002-9610(05)81177-8; SCHECHTER S, 1994, DIS COLON RECTUM, V37, P984, DOI 10.1007/BF02049309; SHINYA H, 1982, SURG CLIN N AM, V62, P897; SHRIER D, 1991, AM J GASTROENTEROL, V86, P1466; Simpson J, 2002, BRIT J SURG, V89, P546, DOI 10.1046/j.1365-2168.2002.02076.x; SLACK WW, 1962, BRIT J SURG, V50, P185, DOI 10.1002/bjs.18005022012; Smadja C, 1999, SURG ENDOSC-ULTRAS, V13, P645, DOI 10.1007/s004649901065; Spivak H, 1997, DIS COLON RECTUM, V40, P570, DOI 10.1007/BF02055381; STABILE BE, 1990, AM J SURG, V159, P99, DOI 10.1016/S0002-9610(05)80613-0; Stevenson ARL, 1998, ANN SURG, V227, P335, DOI 10.1097/00000658-199803000-00004; Stollman NH, 1999, AM J GASTROENTEROL, V94, P3110, DOI 10.1111/j.1572-0241.1999.01501.x; Stumpf M, 2001, INT J COLORECTAL DIS, V16, P271, DOI 10.1007/s003840100310; SUGIHARA K, 1983, GUT, V24, P1130, DOI 10.1136/gut.24.12.1130; Tamim WZ, 2000, ARCH SURG-CHICAGO, V135, P434, DOI 10.1001/archsurg.135.4.434; TEDESCO FJ, 1978, ANN INTERN MED, V89, P907, DOI 10.7326/0003-4819-89-6-907; Tomita R, 2000, HEPATO-GASTROENTEROL, V47, P692; TYAU ES, 1991, ARCH SURG-CHICAGO, V126, P855; WALKER ARP, 1979, ISRAEL J MED SCI, V15, P309; Wess L, 1996, GUT, V38, P701, DOI 10.1136/gut.38.5.701; WESS L, 1995, GUT, V37, P91, DOI 10.1136/gut.37.1.91; WHITEWAY J, 1985, GUT, V26, P258, DOI 10.1136/gut.26.3.258; Wilcox CM, 1997, DIGEST DIS SCI, V42, P990, DOI 10.1023/A:1018832902287; WILLIAMS CB, 1973, LANCET, V2, P729; Williams R, 1995, DIVERTICULAR DIS COL, V5th; Witte JT, 2000, GASTROINTEST ENDOSC, V52, P762, DOI 10.1067/mge.2000.109872; WOLFF WI, 1973, NEW ENGL J MED, V288, P975; Wong SK, 1997, DIS COLON RECTUM, V40, P344, DOI 10.1007/BF02050427; Wong WD, 2000, DIS COLON RECTUM, V43, P290; WOODS RJ, 1988, DIS COLON RECTUM, V31, P591, DOI 10.1007/BF02556792; Zuccaro G, 1998, AM J GASTROENTEROL, V93, P1202; Zuckerman GR, 1999, GASTROINTEST ENDOSC, V49, P228, DOI 10.1016/S0016-5107(99)70491-8	119	421	437	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					631	639		10.1016/S0140-6736(04)15597-9	http://dx.doi.org/10.1016/S0140-6736(04)15597-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987890				2022-12-28	WOS:000189104900023
J	Masip, L; Pan, JL; Haldar, S; Penner-Hahn, JE; DeLisa, MP; Georgiou, G; Bardwell, JCA; Collet, JF				Masip, L; Pan, JL; Haldar, S; Penner-Hahn, JE; DeLisa, MP; Georgiou, G; Bardwell, JCA; Collet, JF			An engineered pathway for the formation of protein disulfide bonds	SCIENCE			English	Article							IRON-SULFUR CLUSTERS; ESCHERICHIA-COLI; THIOREDOXIN; DESIGN	We have engineered a pathway for the formation of disulfide bonds. By imposing evolutionary pressure, we isolated mutations that changed thioredoxin, which is a monomeric disulfide reductase, into a [2Fe-2S] bridged dimer capable of catalyzing O-2-dependent sulfhydryl oxidation in vitro. Expression of the mutant protein in Escherichia coli with oxidizing cytoplasm and secretion via the Tat pathway restored disulfide bond formation in strains that lacked the complete periplasmic oxidative machinery (DsbA and DsbB). The evolution of [2Fe-2S] thioredoxin illustrates how mutations within an existing scaffold can add a cofactor and markedly change protein function.	Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.	gg@che.utexas.edu; jbardwel@umich.edu	DeLisa, Matthew/AAE-7361-2019; Masip, Lluis/F-9919-2015; Penner-Hahn, James/GYD-3750-2022; Collet, Jean Francois/F-2105-2010	Masip, Lluis/0000-0002-3938-4633; Penner-Hahn, James/0000-0003-0314-1274; DeLisa, Matthew/0000-0003-3226-1566; Collet, Jean-Francois/0000-0001-8069-7036	NCRR NIH HHS [P41-RR01633] Funding Source: Medline; NIGMS NIH HHS [GM-38047, GM-57039, GM-55090, GM-64662] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038047, R01GM057039, R01GM038047, R01GM064662, R01GM055090] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Benson DE, 1998, BIOCHEMISTRY-US, V37, P7070, DOI 10.1021/bi980583d; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Bessette PH, 1999, P NATL ACAD SCI USA, V96, P13703, DOI 10.1073/pnas.96.24.13703; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Lippard S.J, 1994, PRINCIPLES BIOINORGA, P115; MASIP L, UNPUB; Meyer J, 2001, FEBS LETT, V509, P1, DOI 10.1016/S0014-5793(01)03049-6; Mossner E, 1998, PROTEIN SCI, V7, P1233; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; [No title captured]	22	68	75	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1185	1189		10.1126/science.1092612	http://dx.doi.org/10.1126/science.1092612			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976313				2022-12-28	WOS:000189074700044
J	Ozbudak, EM; Thattai, M; Lim, HN; Shraiman, BI; van Oudenaarden, A				Ozbudak, EM; Thattai, M; Lim, HN; Shraiman, BI; van Oudenaarden, A			Multistability in the lactose utilization network of Escherichia coli	NATURE			English	Article							POSITIVE FEEDBACK; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; TOGGLE SWITCH; SYSTEMS; BISTABILITY; REPRESSION; HYSTERESIS; BINARY	Multistability, the capacity to achieve multiple internal states in response to a single set of external inputs, is the defining characteristic of a switch. Biological switches are essential for the determination of cell fate in multicellular organisms(1), the regulation of cell-cycle oscillations during mitosis(2,3) and the maintenance of epigenetic traits in microbes(4). The multistability of several natural(1-6) and synthetic(7-9) systems has been attributed to positive feedback loops in their regulatory networks(10). However, feedback alone does not guarantee multistability. The phase diagram of a multistable system, a concise description of internal states as key parameters are varied, reveals the conditions required to produce a functional switch(11,12). Here we present the phase diagram of the bistable lactose utilization network of Escherichia coli(13). We use this phase diagram, coupled with a mathematical model of the network, to quantitatively investigate processes such as sugar uptake and transcriptional regulation in vivo. We then show how the hysteretic response of the wildtype system can be converted to an ultrasensitive graded response(14,15). The phase diagram thus serves as a sensitive probe of molecular interactions and as a powerful tool for rational network design.	MIT, Dept Phys, Cambridge, MA 02139 USA; Rutgers State Univ, Dept Phys, Piscataway, NJ 08854 USA; Rutgers State Univ, BioMAPS Inst, Piscataway, NJ 08854 USA	Massachusetts Institute of Technology (MIT); Rutgers State University New Brunswick; Rutgers State University New Brunswick	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019	Ozbudak, Ertugrul/0000-0003-2858-4696				Atkinson MR, 2003, CELL, V113, P597, DOI 10.1016/S0092-8674(03)00346-5; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Blauwkamp TA, 2002, MOL MICROBIOL, V46, P203, DOI 10.1046/j.1365-2958.2002.03153.x; Boyd D, 2000, J BACTERIOL, V182, P842, DOI 10.1128/JB.182.3.842-847.2000; Chung JD, 1996, CHEM ENG SCI, V51, P1509, DOI 10.1016/0009-2509(95)00306-1; COHN M, 1959, J BACTERIOL, V78, P601, DOI 10.1128/JB.78.5.601-612.1959; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GRIFFITH JS, 1968, J THEOR BIOL, V20, P209, DOI 10.1016/0022-5193(68)90190-2; Hernday AD, 2003, MOL CELL, V12, P947, DOI 10.1016/S1097-2765(03)00383-6; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; LOUIS M, SCI STKE; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; M_uller-Hill B., 1996, LAC OPERON SHORT HIS; Ma S. K., 2000, MODERN THEORY CRITIC; Nobelmann B, 1996, J BACTERIOL, V178, P6790, DOI 10.1128/jb.178.23.6790-6795.1996; NOVICK A, 1957, P NATL ACAD SCI USA, V43, P553, DOI 10.1073/pnas.43.7.553; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Sha W, 2003, P NATL ACAD SCI USA, V100, P975, DOI 10.1073/pnas.0235349100; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Smolen P, 1998, AM J PHYSIOL-CELL PH, V274, pC531, DOI 10.1152/ajpcell.1998.274.2.C531; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; Stulke J, 1999, CURR OPIN MICROBIOL, V2, P195, DOI 10.1016/S1369-5274(99)80034-4; Thattai M, 2003, BIOPHYS J, V85, P744, DOI 10.1016/S0006-3495(03)74517-2; Tyson J., 1978, PROG THEOR BIOL, V5, P1	30	736	748	3	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					737	740		10.1038/nature02298	http://dx.doi.org/10.1038/nature02298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973486				2022-12-28	WOS:000189026000044
J	Zimmerman, C; Watts, C				Zimmerman, C; Watts, C			Risks and responsibilities: guidelines for interviewing trafficked women	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Zimmerman, C (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.	cathy.zimmerman@lshtm.ac.uk						ZIMMERMAN C, 2003, HLTH REISKS CONSEQUE; ZIMMERMAN C, 2003, WHO RECOMMENDATIONS	2	11	12	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	2004	363	9408					565	565		10.1016/S0140-6736(04)15547-5	http://dx.doi.org/10.1016/S0140-6736(04)15547-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14976980				2022-12-28	WOS:000188999900026
J	Yamachika, R; Grobis, M; Wachowiak, A; Crommie, MF				Yamachika, R; Grobis, M; Wachowiak, A; Crommie, MF			Controlled atomic doping of a single C-60 molecule	SCIENCE			English	Article							ELECTRONIC-STRUCTURE; DOPED C-60; STABILITY	We report a method for controllably attaching an arbitrary number of charge dopant atoms directly to a single, isolated molecule. Charge-donating K atoms adsorbed on a silver surface were reversibly attached to a C-60 molecule by moving it over K atoms with a scanning tunneling microscope tip. Spectroscopic measurements reveal that each attached K atom donates a constant amount of charge ( similar to 0.6 electron charge) to the C-60 host, thereby enabling its molecular electronic structure to be precisely and reversibly tuned.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Crommie, MF (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	crommie@socrates.berkeley.edu		Grobis, Michael/0000-0003-0362-6888				Aree T, 1998, CHEM PHYS LETT, V285, P221, DOI 10.1016/S0009-2614(98)00031-1; Cepek C, 2000, SURF SCI, V454, P467, DOI 10.1016/S0039-6028(00)00135-7; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; ERWIN SC, 1991, PHYS REV LETT, V67, P1610, DOI 10.1103/PhysRevLett.67.1610; Goldoni A, 1998, PHYS REV B, V58, P2228, DOI 10.1103/PhysRevB.58.2228; GUNNARSSON O, 1995, PHYS REV LETT, V74, P1875, DOI 10.1103/PhysRevLett.74.1875; Gunnarsson O, 1998, PHYS REV B, V57, P2159, DOI 10.1103/PhysRevB.57.2159; HARIGAYA K, 1992, PHYS REV B, V45, P13676, DOI 10.1103/PhysRevB.45.13676; Heath JR, 2003, PHYS TODAY, V56, P43, DOI 10.1063/1.1583533; Jahn HA, 1937, PROC R SOC LON SER-A, V161, P220, DOI 10.1098/rspa.1937.0142; Jung TA, 1996, SCIENCE, V271, P181, DOI 10.1126/science.271.5246.181; Kajueter H, 1996, PHYS REV B, V53, P16214, DOI 10.1103/PhysRevB.53.16214; Lu XH, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.096802; Packan PA, 1999, SCIENCE, V285, P2079, DOI 10.1126/science.285.5436.2079; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Schofield SR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.136104; Sze S.M., 2002, SEMICONDUCTOR DEVICE, V2nd; TERSOFF J, 1985, PHYS REV B, V31, P805, DOI 10.1103/PhysRevB.31.805; Tjeng LH, 1997, SOLID STATE COMMUN, V103, P31, DOI 10.1016/S0038-1098(97)00126-9; Wehrli S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.115412; WERTHEIM GK, 1991, SCIENCE, V252, P1419, DOI 10.1126/science.252.5011.1419; Yang WL, 2003, SCIENCE, V300, P303, DOI 10.1126/science.1082174	22	85	86	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					281	284		10.1126/science.1095069	http://dx.doi.org/10.1126/science.1095069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15016961				2022-12-28	WOS:000220719400044
J	Yamamoto, M; Saijoh, Y; Perea-Gomez, A; Shawlot, W; Behringer, RR; Ang, SL; Hamada, H; Meno, C				Yamamoto, M; Saijoh, Y; Perea-Gomez, A; Shawlot, W; Behringer, RR; Ang, SL; Hamada, H; Meno, C			Nodal antagonists regulate formation of the anteroposterior axis of the mouse embryo	NATURE			English	Article							NEURALIZING ACTIVITY; PRIMITIVE STREAK; XENOPUS EMBRYOS; CERBERUS-LIKE; EXPRESSION; ENDODERM; LEFTY-1; GENE; ESTABLISHMENT; INHIBITORS	Patterning of the mouse embryo along the anteroposterior axis during body plan development requires migration of the distal visceral endoderm (DVE) towards the future anterior side by a mechanism that has remained unknown. Here we show that Nodal signalling and the regionalization of its antagonists are required for normal migration of the DVE. Whereas Nodal signalling provides the driving force for DVE migration by stimulating the proliferation of visceral endoderm cells, the antagonists Lefty1 and Cerl determine the direction of migration by asymmetrically inhibiting Nodal activity on the future anterior side.	Osaka Univ, Grad Sch Frontier Biosci, Dev Genet Grp, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Univ Strasbourg 1, IGBMC, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	Osaka University; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Texas System; UTMD Anderson Cancer Center; MRC National Institute for Medical Research	Hamada, H (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Dev Genet Grp, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	hamada@fbs.osaka-u.ac.jp	Hamada, Hiroshi/N-6374-2015; yamamoto, masamichi/AAE-3273-2021	Hamada, Hiroshi/0000-0002-7196-5948; Saijoh, Yukio/0000-0002-7548-4789; Perea-Gomez, Aitana/0000-0002-7788-038X; Yamamoto, Masamichi/0000-0002-9088-8044	Medical Research Council [MC_U117570533] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belachew S, 2002, J NEUROSCI, V22, P8553; Belo JA, 2000, GENESIS, V26, P265, DOI 10.1002/(SICI)1526-968X(200004)26:4<265::AID-GENE80>3.3.CO;2-W; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bertocchini F, 2002, DEV CELL, V3, P735, DOI 10.1016/S1534-5807(02)00318-0; Chen Y, 2002, CURR BIOL, V12, P2124, DOI 10.1016/S0960-9822(02)01362-3; Cheng AMS, 2000, DEVELOPMENT, V127, P1049; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; EYALGILADI H, 1994, ADV SPACE RES-SERIES, V14, P271, DOI 10.1016/0273-1177(94)90411-1; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Norris DP, 1999, GENE DEV, V13, P1575, DOI 10.1101/gad.13.12.1575; Perea-Gomez A, 2002, DEV CELL, V3, P745, DOI 10.1016/S1534-5807(02)00321-0; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Saijoh Y, 1999, GENE DEV, V13, P259, DOI 10.1101/gad.13.3.259; Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x; Schier AF, 2001, CURR OPIN GENET DEV, V11, P393, DOI 10.1016/S0959-437X(00)00209-4; Shawlot W, 2000, GENESIS, V26, P253, DOI 10.1002/(SICI)1526-968X(200004)26:4<253::AID-GENE60>3.3.CO;2-4; Simpson EH, 1999, DEV BIOL, V213, P202, DOI 10.1006/dbio.1999.9372; Skromne I, 2001, DEVELOPMENT, V128, P2915; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Yamamoto M, 2001, GENE DEV, V15, P1242, DOI 10.1101/gad.883901	30	206	211	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					387	392		10.1038/nature02418	http://dx.doi.org/10.1038/nature02418			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15004567				2022-12-28	WOS:000220404300032
J	Schroter, S; Black, N; Evans, S; Carpenter, J; Godlee, F; Smith, R				Schroter, S; Black, N; Evans, S; Carpenter, J; Godlee, F; Smith, R			Effects of training on quality of peer review: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the effects of training on the quality of peer review Design Single blind randomised controlled trial with two intervention groups receiving different types of training plus a control group. Setting and participants Reviewers at a general medical journal. Interventions Attendance at a training workshop or reception of a self taught training package focusing on what editors want from reviewers and how to critically appraise randomised controlled trials. Main outcome measures Quality of reviews of three manuscripts sent to reviewers at four to six monthly intervals, evaluated using the validated review quality instrument; number of deliberate major errors identified; time taken to review the manuscripts; proportion recommending rejection of the manuscripts. Results Reviewers in the self taught group scored higher in review quality after training than did the control group (score 2.85 v 2. 6; difference 0.29, 95% confidence interval 0.14 to 0.44; P = 0.001), but the difference was not of editorial significance and was not maintained in the long term. Both intervention groups identified significantly more major errors after training than did the control group (3.14 and 2.96 v 2.13; P < 0.001), and this remained significant after the reviewers' performance at baseline assessment was taken into account. The evidence for benefit of training was no longer apparent on further testing six months after the interventions. Training had no impact on the time taken to review the papers but was associated with an increased likelihood of recommending rejection (92% and 84% v 76%; P = 0.002). Conclusions Short training packages have only a slight impact on the quality of peer review. The value of longer interventions needs to be assessed.	BMJ Editorial Off, London WC1H 9JR, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Schroter, S (corresponding author), BMJ Editorial Off, BMA House,Tavistock Sq, London WC1H 9JR, England.	sschroter@bmj.com	Schroter, Sara/G-3427-2012	Schroter, Sara/0000-0002-8791-8564; Carpenter, James/0000-0003-3890-6206; Evans, Stephen/0000-0002-1474-2596	Economic and Social Research Council [RES-333-34-3002] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Beaulieu MD, 2002, CAN MED ASSOC J, V167, P1241; Black N, 1998, JAMA-J AM MED ASSOC, V280, P231, DOI 10.1001/jama.280.3.231; Callaham ML, 1998, ANN EMERG MED, V32, P318, DOI 10.1016/S0196-0644(98)70007-1; Callahan ML, 2002, JAMA-J AM MED ASSOC, V287, P2781, DOI 10.1001/jama.287.21.2781; EVANS AT, 1993, J GEN INTERN MED, V8, P422, DOI 10.1007/BF02599618; OBRIEN MAT, 2003, COCHRANE DATABASE SY, DOI UNSP CD003030; Rennie D, 1999, PEER REV HLTH SCI; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Simon R, 2002, STAT MED, V21, P2909, DOI 10.1002/sim.1295; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; van Rooyen S, 1999, J CLIN EPIDEMIOL, V52, P625, DOI 10.1016/S0895-4356(99)00047-5; van Rooyen S, 1999, BRIT MED J, V318, P23; Walsh E, 2000, BRIT J PSYCHIAT, V176, P47, DOI 10.1192/bjp.176.1.47; WHITE I, ELICITING USING EXPE	14	145	151	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					673	675		10.1136/bmj.38023.700775.AE	http://dx.doi.org/10.1136/bmj.38023.700775.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	14996698	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000220392700017
J	Zendron, L; Fehrenbach, J; Taverna, C; Krause, M				Zendron, L; Fehrenbach, J; Taverna, C; Krause, M			Lesson of the week - Pitfalls in the diagnosis of phaeochromocytoma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PSEUDOPHAEOCHROMOCYTOMA		Kantonsspital Munsterlingen, Dept Internal Med, CH-8596 Munsterlingen, Switzerland; Univ Zurich Hosp, Dept Internal Med, Div Oncol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Krause, M (corresponding author), Kantonsspital Munsterlingen, Dept Internal Med, CH-8596 Munsterlingen, Switzerland.	martin.krause@stgag.ch						Krentz AJ, 2001, BRIT MED J, V322, P1213, DOI 10.1136/bmj.322.7296.1213; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; Mantero F, 2000, J CLIN ENDOCR METAB, V85, P637, DOI 10.1210/jc.85.2.637; Maurea S, 2002, NUCL MED COMMUN, V23, P951, DOI 10.1097/00006231-200210000-00004; MOCHIZUKI T, 1994, CLIN NUCL MED, V19, P1030, DOI 10.1097/00003072-199411000-00028; MONTASTRUC JL, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90313-6; Pacak K, 2001, ANN INTERN MED, V134, P315, DOI 10.7326/0003-4819-134-4-200102200-00016; Williams G. H., 2001, HARRISONS PRINCIPLES, V246, P1414	8	11	11	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					629	630		10.1136/bmj.328.7440.629	http://dx.doi.org/10.1136/bmj.328.7440.629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016696	Green Published			2022-12-28	WOS:000220208100022
J	Stanley, S; Bloxham, J				Stanley, S; Bloxham, J			Convective-region geometry as the cause of Uranus' and Neptune's unusual magnetic fields	NATURE			English	Article							INNER-CORE; INTERIOR; GEODYNAMO; DYNAMOS	The discovery of Uranus' and Neptune's non-dipolar, non-axisymmetric magnetic fields(1-4) destroyed the picture-established by Earth, Jupiter and Saturn(5-6)-that planetary magnetic fields are dominated by axial dipoles. Although various explanations for these unusual fields have been proposed(3,7-10), the cause of such field morphologies remains unexplained. Planetary magnetic fields are generated by complex fluid motions in electrically conducting regions of the planets (a process known as dynamo action), and so are intimately linked to the structure and evolution of planetary interiors. Determining why Uranus and Neptune have different field morphologies is not only critical for studying the interiors of these planets, but also essential for understanding the dynamics of magnetic-field generation in all planets. Here we present three-dimensional numerical dynamo simulations that model the dynamo source region as a convecting thin shell surrounding a stably stratified fluid interior. We show that this convective-region geometry produces magnetic fields similar in morphology to those of Uranus and Neptune. The fields are non-dipolar and non-axisymmetric, and result from a combination of the stable fluid's response to electromagnetic stress and the small length scales imposed by the thin shell.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Stanley, S (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	stanley@geophysics.harvard.edu		Stanley, Sabine/0000-0003-0469-4401; Bloxham, Jeremy/0000-0001-8556-2675				AUBERT J, IN PRESS EARTH PLANE; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; CONNERNEY JEP, 1987, J GEOPHYS RES, V92, P15329, DOI 10.1029/JA092iA13p15329; Dormy E, 2000, GEOCHEM GEOPHY GEOSY, V1; GLATZMAIER GA, 1995, NATURE, V377, P203, DOI 10.1038/377203a0; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; Grote E, 2000, PHYS EARTH PLANET IN, V117, P259, DOI 10.1016/S0031-9201(99)00101-6; Grote E, 2000, PHYS REV E, V62, P4457, DOI 10.1103/PhysRevE.62.4457; HOLLERBACH R, 1993, NATURE, V365, P541, DOI 10.1038/365541a0; Holme R, 1997, PHYS EARTH PLANET IN, V102, P105, DOI 10.1016/S0031-9201(96)03257-8; Holme R, 1996, J GEOPHYS RES-PLANET, V101, P2177, DOI 10.1029/95JE03437; Hubbard WB, 1995, SPACE SCI S, P109; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; Ishihara N, 2002, FLUID DYN RES, V31, P253, DOI 10.1016/S0169-5983(02)00118-1; JONES CA, 1995, PHYS EARTH PLANET IN, V92, P119, DOI 10.1016/0031-9201(95)03068-8; Kuang WJ, 1999, J COMPUT PHYS, V153, P51, DOI 10.1006/jcph.1999.6274; Kuang WL, 1997, NATURE, V389, P371, DOI 10.1038/38712; Kutzner C, 2002, PHYS EARTH PLANET IN, V131, P29, DOI 10.1016/S0031-9201(02)00016-X; MARLEY MS, 1995, J GEOPHYS RES-PLANET, V100, P23349, DOI 10.1029/95JE02362; MERRILL RT, 1996, MAGNETIC FIELD EARTH, P31; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; NESS NF, 1986, SCIENCE, V233, P85, DOI 10.1126/science.233.4759.85; NESS NF, 1989, SCIENCE, V246, P1473, DOI 10.1126/science.246.4936.1473; Podolak M., 1991, URANUS, P29; Roberts PH, 2001, GEOPHYS ASTRO FLUID, V94, P47, DOI 10.1080/03091920108204131; RUSSELL CT, 1993, J GEOPHYS RES-PLANET, V98, P18681, DOI 10.1029/93JE00981; RUZMAIKIN AA, 1991, ICARUS, V93, P82, DOI 10.1016/0019-1035(91)90165-P; Wicht J, 2002, PHYS EARTH PLANET IN, V132, P281, DOI 10.1016/S0031-9201(02)00078-X; Zhang KK, 2000, SCIENCE, V290, P1944, DOI 10.1126/science.290.5498.1944	30	145	147	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					151	153		10.1038/nature02376	http://dx.doi.org/10.1038/nature02376			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014493				2022-12-28	WOS:000220103600040
J	Fortini, ME				Fortini, ME			PAR-1 for the course of neurodegeneration	CELL			English	Editorial Material							TAU; KINASE; POLARITY; MARK	The large number of kinases that phosphorylate the microtubule binding protein tau has posed a challenge to understanding their individual roles in turning this protein into a killer of neurons. A study in this issue of Cell (Nishimura et al., 2004) uses an elegant fusion of loss-of-function genetics and transgenic overexpression to make the case that the PAR-1 kinase stands at the head of a temporally ordered series of tau phosphorylations.	NCI, Mol Genet Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fortini, ME (corresponding author), NCI, Mol Genet Sect, Bldg 560,Romm 22-12, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC010529] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jenkins SM, 2000, J NEUROCHEM, V74, P1463, DOI 10.1046/j.1471-4159.2000.0741463.x; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447	10	4	4	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	2004	116	5					631	632		10.1016/S0092-8674(04)00207-7	http://dx.doi.org/10.1016/S0092-8674(04)00207-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006343	Bronze			2022-12-28	WOS:000221499700001
J	Kurosawa, H; Kohzuki, M				Kurosawa, H; Kohzuki, M			Dynamic airway narrowing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tohoku Univ, Grad Sch Med, Sendai, Miyagi 9808574, Japan	Tohoku University	Kurosawa, H (corresponding author), Tohoku Univ, Grad Sch Med, Sendai, Miyagi 9808574, Japan.								0	16	18	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					1036	1036		10.1056/NEJMicm030626	http://dx.doi.org/10.1056/NEJMicm030626			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999115				2022-12-28	WOS:000189363600011
J	Murshed, R; Douglas, RM; Ranmuthugala, G; Caldwell, B				Murshed, R; Douglas, RM; Ranmuthugala, G; Caldwell, B			Clinicians' roles in management of arsenicosis in Bangladesh: interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WATER		Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia	Australian National University	Douglas, RM (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.	bobdouglas@netspeed.com.au	Ranmuthugala, Geetha/P-5041-2019; Ranmuthugala, Geetha/F-5938-2012	Ranmuthugala, Geetha/0000-0002-4893-5775; Ranmuthugala, Geetha/0000-0002-4893-5775				British Geological Survey, ARS CONT GROUNDW; MacDonald R, 2001, BMJ-BRIT MED J, V322, P626, DOI 10.1136/bmj.322.7287.626; Smith AH, 2000, B WORLD HEALTH ORGAN, V78, P1093	3	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					493	494		10.1136/bmj.328.7438.493	http://dx.doi.org/10.1136/bmj.328.7438.493			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988183	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000220002900020
J	Charon, R				Charon, R			Narrative and medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Coll Phys & Surg, Program Narrat Med, New York, NY 10032 USA	Columbia University	Charon, R (corresponding author), Columbia Univ, Coll Phys & Surg, Program Narrat Med, New York, NY 10032 USA.							Halpern J, 2001, DETACHED CONCERN EMP; Hurwitz, 1998, NARRATIVE BASED MED; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Pennebaker JW, 2000, LIT MED, V19, P3, DOI 10.1353/lm.2000.0011; Verghese A, 2001, ANN INTERN MED, V135, P1012, DOI 10.7326/0003-4819-135-11-200112040-00028	5	227	243	4	31	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					862	864		10.1056/NEJMp038249	http://dx.doi.org/10.1056/NEJMp038249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985483				2022-12-28	WOS:000189197300004
J	Koopmans, M; Wilbrink, B; Conyn, M; Natrop, G; van der Nat, H; Vennema, H; Meijer, A; van Steenbergen, J; Fouchier, R; Osterhaus, A; Bosman, A				Koopmans, M; Wilbrink, B; Conyn, M; Natrop, G; van der Nat, H; Vennema, H; Meijer, A; van Steenbergen, J; Fouchier, R; Osterhaus, A; Bosman, A			Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands	LANCET			English	Article							TO-HUMAN TRANSMISSION; HONG-KONG; H5N1 VIRUS; GENETIC REASSORTMENT; HUMAN INFECTION; AMERICAN PIGS; H9N2; CONJUNCTIVITIS; NEURAMINIDASE; EMERGENCE	Background An outbreak of highly pathogenic avian influenza A virus subtype H7N7 started at the end of February, 2003, in commercial poultry farms in the Netherlands. Although the risk of transmission of these viruses to humans was initially thought to be low, an outbreak investigation was launched to assess the extent of transmission of influenza A virus subtype H7N7 from chickens to humans. Methods All workers in poultry farms, poultry farmers, and their families were asked to report signs of conjunctivitis or influenza-like illness. People with complaints were tested for influenza virus type A subtype H7 (A/H7) infection and completed a health questionnaire about type of symptoms, duration of illness, and possible exposures to infected poultry. Findings 453 people had health complaints-349 reported conjunctivitis, 90 had influenza-like illness, and 67 had other complaints. We detected A/H7 in conjunctival samples from 78 (26.4%) people with conjunctivitis only, in five (9.4%) with influenza-like illness and conjunctivitis, in two (5.4%) with influenza-like illness only, and in four (6%) who reported other symptoms. Most positive samples had been collected within 5 days of symptom onset. A/H7 infection was confirmed in three contacts (of 83 tested), one of whom developed influenza-like illness. Six people had influenza A/H3N2 infection. After 19 people had been diagnosed with the infection, all workers received mandatory influenza virus vaccination and prophylactic treatment with oseltamivir. More than half (56%) of A/H7 infections reported here arose before the vaccination and treatment programme. Interpretation We noted an unexpectedly high number of transmissions of avian influenza A virus subtype H7N7 to people directly involved in handling infected poultry, and we noted evidence for person-to-person transmission. Our data emphasise the importance of adequate surveillance, outbreak preparedness, and pandemic planning.	Natl Inst Publ Hlth & Environm, Virol Sect, Diagnost Lab Infect Dis & Perinatal Sceening, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Ctr Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands; Netherlands Inst Hlth Serv Res, European Influenza Sueveillance Scheme, Utrecht, Netherlands; Erasmus Med Ctr, Dept Virol, Rotterdam, Netherlands; Natl Coordinat Ctr Communicable Dis Control, Utrecht, Netherlands; Municipal Hlth Ctr, Arnhem, Netherlands	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Netherlands Institute for Health Services Research; Erasmus University Rotterdam; Erasmus MC	Koopmans, M (corresponding author), Natl Inst Publ Hlth & Environm, Virol Sect, Diagnost Lab Infect Dis & Perinatal Sceening, NL-3720 BA Bilthoven, Netherlands.	marion.koopmans@rivm.nl	Fouchier, Ron A/A-1911-2014; Bosman, Arnold/G-9107-2016; Bosman, Arnold/U-2469-2019	Fouchier, Ron A/0000-0001-8095-2869; Bosman, Arnold/0000-0002-8662-7773; Bosman, Arnold/0000-0002-8662-7773; Osterhaus, Albert/0000-0002-6074-1172				Alexander DJ, 2000, REV SCI TECH OIE, V19, P197, DOI 10.20506/rst.19.1.1220; AYMARDHENRY M, 1973, B WORLD HEALTH ORGAN, V48, P199; Banks J, 1998, ARCH VIROL, V143, P781, DOI 10.1007/s007050050329; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Bridges CB, 2002, J INFECT DIS, V185, P1005, DOI 10.1086/340044; Capua I, 2002, ACTA TROP, V83, P7, DOI 10.1016/S0001-706X(02)00057-8; CASTRUCCI MR, 1993, VIROLOGY, V193, P503, DOI 10.1006/viro.1993.1155; CLAAS ECJ, 1994, VIROLOGY, V204, P453, DOI 10.1006/viro.1994.1553; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Dowdle W.A., 1979, DIAGNOSTIC PROCEDURE, V5th ed., P585; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000; Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; LENNETTE EH, 1992, LAB DIAGNOSIS VIRAL; Lin YP, 2000, P NATL ACAD SCI USA, V97, P9654, DOI 10.1073/pnas.160270697; Ninomiya A, 2002, VET MICROBIOL, V88, P107, DOI 10.1016/S0378-1135(02)00105-0; Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5; Saito T, 2001, VACCINE, V20, P125, DOI 10.1016/S0264-410X(01)00279-1; Schweiger B, 2000, J CLIN MICROBIOL, V38, P1552, DOI 10.1128/JCM.38.4.1552-1558.2000; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Tam JS, 2002, VACCINE, V20, pS77, DOI 10.1016/S0264-410X(02)00137-8; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Uyeki TM, 2002, EMERG INFECT DIS, V8, P154, DOI 10.3201/eid0802.010148; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; WEBSTER RG, 1993, INTERVIROLOGY, V35, P16, DOI 10.1159/000150292; Wetherall NT, 2003, J CLIN MICROBIOL, V41, P742, DOI 10.1128/JCM.41.2.742-750.2003; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhou NN, 2000, VET MICROBIOL, V74, P47, DOI 10.1016/S0378-1135(00)00165-6; Zhou NN, 1999, J VIROL, V73, P8851, DOI 10.1128/JVI.73.10.8851-8856.1999	30	615	690	2	67	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					587	593		10.1016/S0140-6736(04)15589-X	http://dx.doi.org/10.1016/S0140-6736(04)15589-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987882				2022-12-28	WOS:000189104900006
J	Eagleman, DM				Eagleman, DM			The where and when of intention	SCIENCE			English	Editorial Material							EVENT-RELATED FMRI; CORTEX; MOVEMENTS; ATTENTION; AWARENESS; REPRESENTATIONS; PERCEPTION; READINESS; DAMAGE; AREAS		Univ Texas, Houston Med Sch, Dept Neurobiol & Anat, Lab Percept & Act, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Eagleman, DM (corresponding author), Univ Texas, Houston Med Sch, Dept Neurobiol & Anat, Lab Percept & Act, Houston, TX 77030 USA.	david.eagleman@uth.tmc.edu						Binkofski F, 2002, J NEUROPHYSIOL, V88, P514, DOI 10.1152/jn.2002.88.1.514; Blakemore SJ, 2001, NEUROREPORT, V12, P1879, DOI 10.1097/00001756-200107030-00023; Cunnington R, 2003, NEUROIMAGE, V20, P404, DOI 10.1016/S1053-8119(03)00291-X; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; Desmurget M, 2000, TRENDS COGN SCI, V4, P423, DOI 10.1016/S1364-6613(00)01537-0; Eagleman DM, 2002, TRENDS COGN SCI, V6, P323, DOI 10.1016/S1364-6613(02)01945-9; FRIED I, 1991, J NEUROSCI, V11, P3656; Frith CD, 2000, BRAIN RES REV, V31, P357, DOI 10.1016/S0165-0173(99)00052-1; Griffin IC, 2003, J COGNITIVE NEUROSCI, V15, P1176, DOI 10.1162/089892903322598139; Haggard P, 1999, EXP BRAIN RES, V126, P128, DOI 10.1007/s002210050722; Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Lau HC, 2004, SCIENCE, V303, P1208, DOI 10.1126/science.1090973; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; Lotze M, 1999, J COGNITIVE NEUROSCI, V11, P491, DOI 10.1162/089892999563553; Pochon JB, 2001, CEREB CORTEX, V11, P260, DOI 10.1093/cercor/11.3.260; Rowe J, 2002, BRAIN, V125, P276, DOI 10.1093/brain/awf036; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sirigu A, 1999, BRAIN, V122, P1867, DOI 10.1093/brain/122.10.1867; Sirigu A, 2004, NAT NEUROSCI, V7, P80, DOI 10.1038/nn1160; THALER D, 1995, EXP BRAIN RES, V102, P445; Toni I, 2002, J COGNITIVE NEUROSCI, V14, P769, DOI 10.1162/08989290260138663; van den Bos E, 2002, COGNITION, V85, P177, DOI 10.1016/S0010-0277(02)00100-2; Wohlschlager A, 2003, CONSCIOUS COGN, V12, P708, DOI 10.1016/S1053-8100(03)00083-7; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	25	41	41	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1144	1146		10.1126/science.1095331	http://dx.doi.org/10.1126/science.1095331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	775RP	14976300				2022-12-28	WOS:000189074700030
J	Wager, TD; Rilling, JK; Smith, EE; Sokolik, A; Casey, KL; Davidson, RJ; Kosslyn, SM; Rose, RM; Cohen, JD				Wager, TD; Rilling, JK; Smith, EE; Sokolik, A; Casey, KL; Davidson, RJ; Kosslyn, SM; Rose, RM; Cohen, JD			Placebo-induced changes in fMRI in the anticipation and experience of pain	SCIENCE			English	Article							PREFRONTAL CORTEX; FUNCTIONAL MRI; ORBITOFRONTAL CORTEX; ANTERIOR CINGULATE; BRAIN RESPONSES; OPIOID SYSTEMS; ANALGESIA; MECHANISMS; ACTIVATION; ATTENTION	The experience of pain arises from both physiological and psychological factors, including one's beliefs and expectations. Thus, placebo treatments that have no intrinsic pharmacological effects may produce analgesia by altering expectations. However, controversy exists regarding whether placebos alter sensory pain transmission, pain affect, or simply produce compliance with the suggestions of investigators. In two functional magnetic resonance imaging (fMRI) experiments, we found that placebo analgesia was related to decreased brain activity in pain-sensitive brain regions, including the thalamus, insula, and anterior cingulate cortex, and was associated with increased activity during anticipation of pain in the prefrontal cortex, providing evidence that placebos alter the experience of pain.	Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Princeton Univ, Ctr Study Brain Mind & Behav, Princeton, NJ 08544 USA; Univ Michigan, Vet Affairs Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Univ Texas, Med Branch, Mind Brain Body & Hlth Initiat, Galveston, TX 77555 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	University of Michigan System; University of Michigan; Princeton University; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Wisconsin System; University of Wisconsin Madison; Harvard University; University of Texas System; University of Texas Medical Branch Galveston; Princeton University	Wager, TD (corresponding author), Columbia Univ, Dept Psychol, 1190 Amsterdam Ave, New York, NY 10027 USA.	torw@umich.edu	Li, Chong/F-4265-2015; anand, amit/A-7222-2009	Davidson, Richard/0000-0002-8506-4964				Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; Benedetti F, 1999, J NEUROSCI, V19, P3639; Brooks JCW, 2002, NEUROIMAGE, V15, P293, DOI 10.1006/nimg.2001.0974; Casey KL, 1999, P NATL ACAD SCI USA, V96, P7668, DOI 10.1073/pnas.96.14.7668; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; Davis KD, 1997, J NEUROPHYSIOL, V77, P3370, DOI 10.1152/jn.1997.77.6.3370; Davis KD, 2000, NEUROL RES, V22, P313; Dias R, 1997, J NEUROSCI, V17, P9285; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Ingvar M, 1999, PHILOS T R SOC B, V354, P1347, DOI 10.1098/rstb.1999.0483; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MELZACK R, 1968, P423; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; O'Reilly RC, 2002, CEREB CORTEX, V12, P246, DOI 10.1093/cercor/12.3.246; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Petrovic P, 2000, PAIN, V85, P19, DOI 10.1016/S0304-3959(99)00232-8; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Price DD, 2000, PROG BRAIN RES, V122, P255; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rolls Edmund T., 1995, P1091; Schneider F, 2001, NEUROPSYCHOBIOLOGY, V43, P175, DOI 10.1159/000054887; Schoenbaum G, 2001, LEARN MEMORY, V8, P134, DOI 10.1101/lm.39901; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; WALL PD, 1999, TXB PAIN, P1419	37	1311	1351	5	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1162	1167		10.1126/science.1093065	http://dx.doi.org/10.1126/science.1093065			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976306	Green Submitted			2022-12-28	WOS:000189074700037
J	Donovan, B				Donovan, B			Sexually transmissible infections other than HIV	LANCET			English	Review							HUMAN-PAPILLOMAVIRUS INFECTION; GENITAL CHLAMYDIAL INFECTIONS; PELVIC-INFLAMMATORY-DISEASE; SIMPLEX-VIRUS TYPE-1; FEMALE SEX WORKERS; TRANSMITTED-DISEASES; MYCOPLASMA-GENITALIUM; CERVICAL-CANCER; PUBLIC-HEALTH; TRICHOMONAS-VAGINALIS	Sexually transmitted, infections (STIs) are notable for their fastidious requirements for transmission and growth in the laboratory and for their high physical and psychosocial morbidity. The combination of subtle or absent symptoms and stigma preventing the seeking of health care, leaves many infections undiagnosed. The development of nucleic-acid amplification tests heralded a new era in sensitive and robust diagnostic procedures for STIs. Unfortunately, many of these tests are not commercially available or are too expensive for the populations that need them most. Single-dose oral azithromycin has improved the treatment of several bacterial STIs, but quinolones are rapidly becoming ineffective for gonorrhoea. Self-treatment of genital warts with podophyllotoxin or imiquimod preparations is attractive to patients and might be cost effective for health services. The prospect of effective vaccines against genital papillomaviruses in the near future is real. Such vaccines could reduce the global incidence of some anogenital cancers. Episodic treatment of genital herpes is getting easier and cheaper, and suppressive treatment can reduce transmission to regular sexual partners. A vaccine against herpes simplex virus type 2 has shown some limited efficacy. Ultimately, better control of STIs, and reduction of their contribution to the spread of HIV, will require a broad health-sector response with adequate resourcing, and a change in social and political attitudes.	Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney	Donovan, B (corresponding author), Sydney Hosp, Sydney Sexual Hlth Ctr, POB 1614, Sydney, NSW 2001, Australia.	donovanb@sesahs.nsw.gov.au	Donovan, Basil J/K-1246-2012	Donovan, Basil J/0000-0001-8851-4126				Adler MW, 2002, SEX TRANSM INFECT, V78, P83, DOI 10.1136/sti.78.2.83; Alary M, 1998, SEX TRANSM INFECT, V74, pS44; Alary M, 2002, AIDS, V16, P463, DOI 10.1097/00002030-200202150-00019; Alary M., 2001, GUIDELINES MANAGEMEN; Aral SO, 2002, SEX TRANSM INFECT, V78, P2, DOI 10.1136/sti.78.1.2; Asthana S, 2001, SOC SCI MED, V52, P707, DOI 10.1016/S0277-9536(00)00167-2; Augenbraun MH, 2002, CLIN INFECT DIS, V35, pS187, DOI 10.1086/342106; Beyrer C, 1998, J INFECT DIS, V178, P243, DOI 10.1086/515603; Bowden FJ, 2000, SEX TRANSM INFECT, V76, P248, DOI 10.1136/sti.76.4.248; Bowden FJ, 2002, MED J AUSTRALIA, V176, P551, DOI 10.5694/j.1326-5377.2002.tb04554.x; Bowden FJ, 2003, SEX TRANSM INFECT, V79, P263, DOI 10.1136/sti.79.3.263; Bowden FJ, 1999, SEX TRANSM INFECT, V75, P431, DOI 10.1136/sti.75.6.431; Bowden FJ, 1998, AUST NZ J PUBL HEAL, V22, P7, DOI 10.1111/j.1467-842X.1998.tb01136.x; Bradshaw CS, 2002, SEX TRANSM INFECT, V78, P445, DOI 10.1136/sti.78.6.445; Brandt Allan M., 1987, NO MAGIC BULLET SOCI; Brewer DD, 2000, P NATL ACAD SCI USA, V97, P12385, DOI 10.1073/pnas.210392097; Brook MG, 2002, SEX TRANSM INFECT, V78, P235, DOI 10.1136/sti.78.4.235; Brown ZA, 2003, JAMA-J AM MED ASSOC, V289, P203, DOI 10.1001/jama.289.2.203; Brugha R, 1999, SEX TRANSM INFECT, V75, P283, DOI 10.1136/sti.75.5.283; Brugha R, 1997, INT J EPIDEMIOL, V26, P698, DOI 10.1093/ije/26.4.698; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, pRR12; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, pRR6; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P773; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P971; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P709; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1067; Chalker J, 2000, SEX TRANSM INFECT, V76, P299, DOI 10.1136/sti.76.4.299; Chandeying V, 2000, INT J STD AIDS, V11, P402, DOI 10.1258/0956462001915985; Chen M, 2002, INT J STD AIDS, V13, P135, DOI 10.1258/0956462021924640; Chernesky MA, 2002, SEX TRANSM INFECT, V78, P232, DOI 10.1136/sti.78.4.232; Clausen HF, 2001, HUM REPROD, V16, P1866, DOI 10.1093/humrep/16.9.1866; Cohen CR, 2002, LANCET, V359, P765, DOI 10.1016/S0140-6736(02)07848-0; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Corey L, 2000, JAMA-J AM MED ASSOC, V283, P791, DOI 10.1001/jama.283.6.791; Crawford DH, 2002, J INFECT DIS, V186, P731, DOI 10.1086/342596; Dallabetta GA, 1998, SEX TRANSM INFECT, V74, pS1; Day S, 1997, GENITOURIN MED, V73, P161; Doherty L, 2002, BMJ-BRIT MED J, V325, P153, DOI 10.1136/bmj.325.7356.153; Donova Basil, 2002, Commun Dis Intell Q Rep, V26, P51; Donovan B, 2001, INT J STD AIDS, V12, P437, DOI 10.1258/0956462011923462; Donovan B, 2000, LANCET, V355, P1897, DOI 10.1016/S0140-6736(00)02302-3; Donovan B, 2000, SEX TRANSM INFECT, V76, P7, DOI 10.1136/sti.76.1.7; Donovan B, 2000, SEX TRANSM INFECT, V76, P88, DOI 10.1136/sti.76.2.88; DONOVAN B, 2002, AUSTRALASIAN CONTACT; DREW WL, 1999, SEXUALLY TRANSMITTED, P313; Dukers NHTM, 2000, AM J EPIDEMIOL, V152, P666, DOI 10.1093/aje/152.7.666; Eltom MA, 2002, AIDS, V16, P2473, DOI 10.1097/00002030-200212060-00014; ENG TR, 1997, HIDDEN EPIDEMIC CONF; Engelberg R, 2003, SEX TRANSM DIS, V30, P174, DOI 10.1097/00007435-200302000-00015; Evans C, 1997, SOC SCI MED, V44, P1791, DOI 10.1016/S0277-9536(96)00288-2; Farrell DJ, 1999, J CLIN MICROBIOL, V37, P386, DOI 10.1128/JCM.37.2.386-390.1999; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Fethers K, 2000, SEX TRANSM INFECT, V76, P345, DOI 10.1136/sti.76.5.345; Fisman DN, 2002, SEX TRANSM DIS, V29, P608, DOI 10.1097/00007435-200210000-00008; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Fletcher MA, 2001, INT J STD AIDS, V12, P419, DOI 10.1258/0956462011923354; Foley E, 2001, SEX TRANSM INFECT, V77, P306, DOI 10.1136/sti.77.5.306; Fortenberry JD, 2002, JAMA-J AM MED ASSOC, V287, P768, DOI 10.1001/jama.287.6.768; Fortenberry JD, 2002, AM J PUBLIC HEALTH, V92, P378, DOI 10.2105/AJPH.92.3.378; Garrow SC, 2002, SEX TRANSM INFECT, V78, P278, DOI 10.1136/sti.78.4.278; Genc M, 2000, SEX TRANSM INFECT, V76, P73, DOI 10.1136/sti.76.2.73; Gil VE, 1996, SOC SCI MED, V42, P141, DOI 10.1016/0277-9536(95)00064-X; Giuliano AR, 2002, J INFECT DIS, V186, P462, DOI 10.1086/341782; Goldie SJ, 2001, AM J MED, V111, P140, DOI 10.1016/S0002-9343(01)00780-X; Goldstein ST, 2002, J INFECT DIS, V185, P713, DOI 10.1086/339192; Green T, 2001, SEX TRANSM INFECT, V77, P214, DOI 10.1136/sti.77.3.214; Grosskurth H, 1996, BRIT MED J, V312, P277, DOI 10.1136/bmj.312.7026.277; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Grulich A, 2001, VENEREOLOGY, V14, P174; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; Hart G, 1997, CLIN INFECT DIS, V25, P24, DOI 10.1086/514495; Hart GJ, 2002, SEX TRANSM INFECT, V78, P396, DOI 10.1136/sti.78.6.396; Hawkes S, 2002, SEX TRANSM INFECT, V78, pI31, DOI 10.1136/sti.78.suppl_1.i31; Hawkes S, 2000, TROP MED INT HEALTH, V5, pA37, DOI 10.1046/j.1365-3156.2000.00594.x; HOLMES KK, 1994, P NATL ACAD SCI USA, V91, P2448, DOI 10.1073/pnas.91.7.2448; Honey E, 2002, SEX TRANSM INFECT, V78, P406, DOI 10.1136/sti.78.6.406; Kjaer SK, 2016, BMJ-BRIT MED J, V353, DOI [10.1136/bmj.325.7364.572, 10.1136/bmj.i2820]; Klebanoff MA, 2001, NEW ENGL J MED, V345, P487, DOI 10.1056/NEJMoa003329; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kouznetsov AV, 2002, LANCET, V360, P388, DOI 10.1016/S0140-6736(02)09598-3; Lafferty WE, 2000, J INFECT DIS, V181, P1454, DOI 10.1086/315395; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; Lau CY, 2002, SEX TRANSM DIS, V29, P497, DOI 10.1097/00007435-200209000-00001; Lewis DA, 2000, SEX TRANSM INFECT, V76, P137, DOI 10.1136/sti.76.2.137; Low W., 1999, SEX TRANSM DIS, P407; Lumbiganon P, 2002, INT J STD AIDS, V13, P486, DOI 10.1258/09564620260079653; Mabey D, 2002, SEX TRANSM INFECT, V78, P90, DOI 10.1136/sti.78.2.90; Mak DB, 2000, J PUBLIC HEALTH MED, V22, P540, DOI 10.1093/pubmed/22.4.540; Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018; Marrazzo JM, 2001, INT J STD AIDS, V12, P41, DOI 10.1258/0956462011916721; MCGEE ZA, 1991, SEX TRANSM DIS, V18, P69, DOI 10.1097/00007435-199118020-00002; McGee ZA, 2002, SEX TRANSM DIS, V29, P674, DOI 10.1097/00007435-200211000-00010; MEYER GS, 1991, B HIST MED, V65, P549; Mindel A, 2000, SEX TRANSM INFECT, V76, P287, DOI 10.1136/sti.76.4.287; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Morton RS, 2002, SEX TRANSM INFECT, V78, P20, DOI 10.1136/sti.78.1.20; Munday PE, 2001, INT J STD AIDS, V12, P784, DOI 10.1258/0956462011924399; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; *NAT I ALL INF DIS, 2001, SCI EV COND EFF SEX; O'Farrell N, 2002, SEX TRANSM INFECT, V78, P452, DOI 10.1136/sti.78.6.452; O'Farrell N, 2002, SEX TRANSM INFECT, V78, P143, DOI 10.1136/sti.78.2.143; O'Farrell N, 1999, SEX TRANSM INFECT, V75, P377, DOI 10.1136/sti.75.6.377; Paget WJ, 2002, SEX TRANSM DIS, V29, P715, DOI 10.1097/00007435-200211000-00016; Patel R, 2001, INT J STD AIDS, V12, P640, DOI 10.1258/0956462011923859; Patel S R, 2000, Infect Dis Obstet Gynecol, V8, P248, DOI 10.1155/S1064744900000375; Radcliffe KW, 2001, INT J STD AIDS, V12, P2, DOI 10.1258/0956462011924038; Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357; Rothenberg R, 2002, CLIN INFECT DIS, V35, pS138, DOI 10.1086/342101; Schmidt BL, 2000, J CLIN MICROBIOL, V38, P1279, DOI 10.1128/JCM.38.3.1279-1282.2000; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Scoular A, 2002, SEX TRANSM INFECT, V78, P160, DOI 10.1136/sti.78.3.160; SHAO C, 1998, SEXUALLY TRANSMITTED, P72; Simms I, 2003, SEX TRANSM INFECT, V79, P154, DOI 10.1136/sti.79.2.154; Simms I, 2000, SEX TRANSM INFECT, V76, P80, DOI 10.1136/sti.76.2.80; Slavinsky J, 2001, INT J STD AIDS, V12, P516, DOI 10.1258/0956462011923615; SMITH JS, 2002, JNCI-J NATL CANCER I, V94, P1592; St Lawrence JS, 2002, AM J PUBLIC HEALTH, V92, P1784, DOI 10.2105/AJPH.92.11.1784; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Steen R, 2001, B WORLD HEALTH ORGAN, V79, P818; Stone KM, 2002, J INFECT DIS, V186, P1396, DOI 10.1086/344354; Strand A, 2002, SEX TRANSM INFECT, V78, P435, DOI 10.1136/sti.78.6.435; SYED TA, 1994, DERMATOLOGY, V189, P65, DOI 10.1159/000246787; Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309; Taylor-Robinson D, 2002, INT J STD AIDS, V13, P145, DOI 10.1258/0956462021924776; TEMPLESMITH M, 1996, AUST FAM PHYSICIA S2, V23, pS71; Tikhonova L, 2003, SEX TRANSM INFECT, V79, P106, DOI 10.1136/sti.79.2.106; Tobin JM, 2000, SEX TRANSM INFECT, V76, P233, DOI 10.1136/sti.76.4.233; Turner CF, 2002, JAMA-J AM MED ASSOC, V287, P726, DOI 10.1001/jama.287.6.726; Van der Heyden JHA, 2000, SEX TRANSM INFECT, V76, P110, DOI 10.1136/sti.76.2.110; von Krogh G, 2001, SEX TRANSM INFECT, V77, P409, DOI 10.1136/sti.77.6.409; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 2002, INT J CANCER, V101, P371, DOI 10.1002/ijc.10639; Wang QQ, 2002, INT J STD AIDS, V13, P469, DOI 10.1258/09564620260079626; Watson EJ, 2002, J MED MICROBIOL, V51, P1021, DOI 10.1099/0022-1317-51-12-1021; White PJ, 1999, SEX TRANSM INFECT, V75, P49, DOI 10.1136/sti.75.1.49; WHO World Health Organisation STD Statistics, 2001, GLOB PREV INC SEL CU; Wiesenfeld HC, 2003, CLIN INFECT DIS, V36, P663, DOI 10.1086/367658; Wiley DJ, 2002, CLIN INFECT DIS, V35, pS210, DOI 10.1086/342109; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Young H, 1998, J CLIN MICROBIOL, V36, P913, DOI 10.1128/JCM.36.4.913-917.1998	142	49	50	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					545	556		10.1016/S0140-6736(04)15543-8	http://dx.doi.org/10.1016/S0140-6736(04)15543-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975619				2022-12-28	WOS:000188999900022
J	Ford, N; Wilson, D; Bunjumnong, O; Angerer, TV				Ford, N; Wilson, D; Bunjumnong, O; Angerer, TV			The role of civil society in protecting public health over commercial interests: lessons from Thailand	LANCET			English	Editorial Material							MEDICINES		Med Sans Frontieres, Bangkok 10240, Thailand		Ford, N (corresponding author), Med Sans Frontieres, 522 Mooban Nakorn Thai,Ladphrao 101-1, Bangkok 10240, Thailand.	Nathan.Ford@London.msf.org		von Schoen-Angerer, Tido/0000-0003-3601-7480				BARSHEFSKY C, 2000, COMMUNICATION   0207; BHATIASEVI A, 2000, BANGKOK POST    0211; BHATIASEVI A, 1999, BANGKOK POST    1110; BHATIASEVI A, 2000, BANGKOK POST    0118; Bond P, 1999, INT J HEALTH SERV, V29, P765, DOI 10.2190/4MA6-53E3-LE1X-C1YY; Boulet P., 2003, DRUG PATENTS SPOTLIG; BOULET P, 1999, ASSESSMENT SITUATION; CHASOMBAT S, 2003, 9 NAT AIDS SEM BANGK; CHITWARAKORN A, 2003, WHO BIR M SCAL UP HI; CORNISH WR, 1999, INTELLECTUAL PROPERT; Dukes MNG, 2002, LANCET, V360, P1682, DOI 10.1016/S0140-6736(02)11599-6; HECKLINGER RE, 1999, COMMUNICATION    NOV; KUANPOTH J, 2000, 3 S CURR ISS INT PRO; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; LIMPANANONT J, 2002, THAILAND IMPACT PRES, P41; LOVE J, 2000, COMMUNICATION   0122; MCGOWAN JJ, 1990, REV INFECT DIS, V12, pS513; PORAPAKKHAM Y, 1996, AIDSCAP POLICY WORKI; SAKBOON M, 2004, NATION BANGKOK  0117; SUPAKAKUNTI S, 1999, STUDY IMPLICATIONS W; ULLAH I, 1991, Patent No. 07733547; ULLAH I, 1992, Patent No. 07882204; ULLAH I, 1998, Patent No. 05245791; ULLAH I, 1999, Patent No. 5880106; ULLAH I, 1998, Patent No. 7600; ULLAH I, 1995, Patent No. 657337; VELASQUEZ G, 2000, WHO UNAIDS JOINT MIS; VIRAVAIDAYA M, 1995, P 3 INT C AIDS AS PA, P19; *WHO, 2001, IPCW305ADD3 WHO; *WHO, 2001, 5410 WHA WHO; Wilson D, 1999, LANCET, V354, P1893, DOI 10.1016/S0140-6736(99)06114-0; World Bank, 2000, THAIL RESP AIDS BUIL; 1995, P 3 INT C AIDS AS PA, P88; 2001, INTEGRATING INTELLEC, P51	34	34	34	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					560	563		10.1016/S0140-6736(04)15545-1	http://dx.doi.org/10.1016/S0140-6736(04)15545-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975620				2022-12-28	WOS:000188999900024
J	Kelleher, RJ; Govindarajan, A; Jung, HY; Kang, HJ; Tonegawa, S				Kelleher, RJ; Govindarajan, A; Jung, HY; Kang, HJ; Tonegawa, S			Translational control by MAPK signaling in long-term synaptic plasticity and memory	CELL			English	Article							PROTEIN-SYNTHESIS; LATE-PHASE; CA1 REGION; POTENTIATION; HIPPOCAMPUS; CONSOLIDATION; KNOCKOUT; KINASES; PHOSPHORYLATION; TRANSCRIPTION	Enduring forms of synaptic plasticity and memory require new protein synthesis, but little is known about the underlying regulatory mechanisms. Here, we investigate the role of MAPK signaling in these processes. Conditional expression of a dominant-negative form of MEK1 in the postnatal murine forebrain inhibited ERK activation and caused selective deficits in hippocampal memory retention and the translation-dependent, transcription-independent phase of hippocampal L-LTP. In hippocampal neurons, ERK inhibition blocked neuronal activity-induced translation as well as phosphorylation of the translation factors elF4E, 4EBP1, and ribosomal protein S6. Correspondingly, protein synthesis and translation factor phosphorylation induced in control hippocampal slices by L-LTP-generating tetanization were significantly reduced in mutant slices. Translation factor phosphorylation induced in the control hippocampus by memory formation was similarly diminished in the mutant hippocampus. These results suggest a crucial role for translational control by MAPK signaling in long-lasting forms of synaptic plasticity and memory.	MIT, RIKEN,Dept Biol, Neurosci Res Ctr,Howard Hughes Med Inst, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Memory Disorders Unit, Boston, MA 02114 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital	Tonegawa, S (corresponding author), MIT, RIKEN,Dept Biol, Neurosci Res Ctr,Howard Hughes Med Inst, Picower Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tonegawa@mit.edu						Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Antoniadis EA, 2000, BEHAV BRAIN RES, V108, P1, DOI 10.1016/S0166-4328(99)00121-7; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHATTARJI S, 1989, BRAIN RES, V495, P145, DOI 10.1016/0006-8993(89)91228-6; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Frey J U, 2001, Results Probl Cell Differ, V34, P27; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1996, J PHYSIOL-LONDON, V490, P703, DOI 10.1113/jphysiol.1996.sp021179; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Godsil BP, 2000, LEARN MEMORY, V7, P353, DOI 10.1101/lm.32800; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Huang Y Y, 1994, Learn Mem, V1, P74; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LIU G, 1995, NEUROPHARMACOLOGY, V34, P1407, DOI 10.1016/0028-3908(95)00143-T; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mazzucchelli C, 2000, CELL MOL LIFE SCI, V57, P604, DOI 10.1007/PL00000722; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Richter JD, 2002, CURR OPIN NEUROBIOL, V12, P300, DOI 10.1016/S0959-4388(02)00318-5; Schafe GE, 1999, LEARN MEMORY, V6, P97; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Williams SH, 1996, J NEUROSCI, V16, P3652; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zeng HK, 2001, CELL, V107, P617, DOI 10.1016/S0092-8674(01)00585-2	56	651	671	1	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					467	479		10.1016/S0092-8674(04)00115-1	http://dx.doi.org/10.1016/S0092-8674(04)00115-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016380	Bronze			2022-12-28	WOS:000188825800014
J	Miaczynska, M; Christoforidis, S; Giner, A; Shevchenko, A; Uttenweiler-Joseph, S; Habermann, B; Wilm, M; Parton, RG; Zerial, M				Miaczynska, M; Christoforidis, S; Giner, A; Shevchenko, A; Uttenweiler-Joseph, S; Habermann, B; Wilm, M; Parton, RG; Zerial, M			APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment	CELL			English	Article							EPIDERMAL-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEXES; TGF-BETA RECEPTOR; NUCLEOTIDE EXCHANGE; ENDOCYTIC PATHWAY; MEMBRANE-FUSION; GTPASE ACTIVITY; IDENTIFICATION; KINASE; DOMAIN	Signals generated in response to extracellular stimuli at the plasma membrane are transmitted through cytoplasmic transduction cascades to the nucleus. We report the identification of a pathway directly linking the small GTPase Rab5, a key regulator of endocytosis, to signal transduction and mitogenesis. This pathway operates via APPL1 and APPL2, two Rab5 effectors, which reside on a subpopulation of endosomes. In response to extracellular stimuli such as EGF and oxidative stress, APPL1 translocates from the membranes to the nucleus where it interacts with the nucleosome remodeling and histone deacetylase multiprotein complex NuRD/MeCP1, an established regulator of chromatin structure and gene expression. Both APPL1 and APPL2 are essential for cell proliferation and their function requires Rab5 binding. Our findings identify an endosomal compartment bearing Rab5 and APPL proteins as an intermediate in signaling between the plasma membrane and the nucleus.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Queensland, Sch Biomed Sci, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4006, Australia; Scion Comp Innovat GmbH, D-01307 Dresden, Germany	Max Planck Society; European Molecular Biology Laboratory (EMBL); University of Queensland	Zerial, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	zerial@mpi-cbg.de	Parton, Robert G/C-5673-2009; Habermann, Bianca/N-4886-2016	Parton, Robert G/0000-0002-7494-5248; Habermann, Bianca/0000-0002-2457-7504; Uttenweiler, Sandrine/0000-0001-9019-4766; Miaczynska, Marta/0000-0003-0031-5267; Wilm, Matthias/0000-0002-5461-6834; Christoforidis, Savvas/0000-0002-0210-0713				Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Feng Q, 2001, GENE DEV, V15, P827; Fischer D, 1999, PROTEINS, P209; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Johannessen LE, 2000, EXP CELL RES, V260, P136, DOI 10.1006/excr.2000.5004; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Unhavaithaya Y, 2002, CELL, V111, P991, DOI 10.1016/S0092-8674(02)01202-3; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Yarden Y, 2001, EUR J CANCER, V37, pS3; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	60	425	446	2	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					445	456		10.1016/S0092-8674(04)00117-5	http://dx.doi.org/10.1016/S0092-8674(04)00117-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016378	Bronze			2022-12-28	WOS:000188825800012
J	Koike, N; Fukumura, D; Gralla, O; Au, P; Schechner, JS; Jain, RK				Koike, N; Fukumura, D; Gralla, O; Au, P; Schechner, JS; Jain, RK			Creation of long-lasting blood vessels	NATURE			English	Editorial Material							IN-VIVO; CELLS		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Yale University	Koike, N (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA080124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yang JW, 2001, NAT BIOTECHNOL, V19, P219, DOI 10.1038/85655	10	539	575	7	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					138	139		10.1038/428138a	http://dx.doi.org/10.1038/428138a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014486				2022-12-28	WOS:000220103600033
J	Wei, W; Ayad, NG; Wan, Y; Zhang, GJ; Kirschner, MW; Kaelin, WG				Wei, W; Ayad, NG; Wan, Y; Zhang, GJ; Kirschner, MW; Kaelin, WG			Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex	NATURE			English	Article							BOX PROTEIN SKP2; DNA-REPLICATION; S-PHASE; MITOSIS; PROTEOLYSIS; RECOGNITION; EXPRESSION; P27(KIP1); BINDING; DESTRUCTION	Cell-cycle transitions are driven by waves of ubiquitin-dependent degradation of key cell-cycle regulators. SCF (Skp1/Cullin/F-box protein) complexes and anaphase-promoting complexes (APC) represent two major classes of ubiquitin ligases whose activities are thought to regulate primarily the G1/S and metaphase/anaphase cell-cycle transitions, respectively(1,2). The major target of the Skp1/Cul1/Skp2 (SCFSKP2) complex is thought to be the Cdk inhibitor p27 during S phase, whereas the principal targets for the APC are thought to be involved in chromatid separation (securin) and exit from mitosis (cyclin B). Although the role of the APC in mitosis is relatively clear, there is mounting evidence that APCs containing Cdh1 (APC(CDH1)) also have a function in the G1 phase of the cell cycle(2,3). Here, we show that the F-box protein Skp2 is polyubiquitinated, and hence earmarked for destruction, by APC(CDH1). As a result, accumulation of SCFSKP2 requires prior inactivation of APC(CDH1). These findings provide an insight into the orchestration of SCF and APC activities during cell-cycle progression, and into the involvement of the APC in G1.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	marc@hms.harvard.edu; william_kaelin@dfci.harvard.edu	Zhang, Guo-Jun/H-3890-2015	Zhang, Guo-Jun/0000-0001-5182-5887				Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Imaki H, 2003, CANCER RES, V63, P4607; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	30	387	399	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					194	198		10.1038/nature02381	http://dx.doi.org/10.1038/nature02381			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014503				2022-12-28	WOS:000220103600052
J	Hacke, W; Donnan, G; Fieschi, C; Kaste, M; von Kummer, R; Broderick, JP; Brott, T; Frankel, M; Grotta, JC; Haley, EC; Kwiatkowski, T; Levine, SR; Lewandowski, C; Lu, M; Lyden, P; Marler, JR; Patel, S; Tilley, BC; Albers, G; Brott, T; Grotta, J; Bluhmki, PE; Wilhelm, M; Hamilton, S				Hacke, W; Donnan, G; Fieschi, C; Kaste, M; von Kummer, R; Broderick, JP; Brott, T; Frankel, M; Grotta, JC; Haley, EC; Kwiatkowski, T; Levine, SR; Lewandowski, C; Lu, M; Lyden, P; Marler, JR; Patel, S; Tilley, BC; Albers, G; Brott, T; Grotta, J; Bluhmki, PE; Wilhelm, M; Hamilton, S		ATLANTIS Study Grp Investigators; ECASS Study Grp Investigators; NINDS Rt-PA Study Grp Investigato	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials	LANCET			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; THROMBOLYTIC THERAPY; DOUBLE-BLIND; ALTEPLASE; INFARCTION; TIME	Background Quick administration of intravenous recombinant tissue plasminogen activator (rt-PA) after stroke improved outcomes in previous trials. We aimed to analyse combined data for individual patients to confirm the importance of rapid treatment. Methods We pooled common data elements from six randomised placebo-controlled trials of intravenous rt-PA. Using multivariable logistic regression we assessed the relation of the interval from stroke onset to start of treatment (OTT) on favourable 3-month outcome and on the occurrence of clinically relevant parenchymal haemorrhage. Findings Treatment was started within 360 min of onset of stroke in 2775 patients randomly allocated to rt-PA or placebo. Median age was 68 years, median baseline National Institute of Health Stroke Scale (NIHSS) 11, and median OTT 243 min. Odds of a favourable 3-month outcome increased as OTT decreased (p=0.005). Odds were 2.8 (95% CI 1.8-4.5) for 0-90 min, 1.6 (1.1-2.2) for 91-180 min, 1.4 (1.1-1.9) for 181-270 min, and 1.2 (0.9-1.5) for 271-360 min in favour of the rt-PA group. The hazard ratio for death adjusted for baseline NIHSS was not different from 1.0 for the 0-90, 91-180, and 181-270 min intervals; for 271-360 min it was 1.45 (1.02-2.07). Haemorrhage was seen in 82 (5.9%) rt-PA patients and 15 (1.1%) controls (p<0.0001). Haemorrhage was not associated with OTT but was with rt-PA treatment (p=0.0001) and age (p=0.0002). Interpretation The sooner that rt-PA is given to stroke patients, the greater the benefit, especially if started within 90 min. Our results suggest a potential benefit beyond 3 h, but this potential might come with some risks.	NINDS, Clin Trial Grp, Rockville, MD 20852 USA; Med Univ Heidelberg, Heidelberg, Germany; Natl Stroke Res Inst, Melbourne, Vic, Australia; Univ Rome, Rome, Italy; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Tech Univ Dresden, D-8027 Dresden, Germany; Univ Cincinnati, Ctr Stroke Res, Cincinnati, OH 45221 USA; Mayo Clin, Rochester, MN USA; Emory Univ, Sch Med, Atlanta, GA 30322 USA; Univ Texas, Houston Med Ctr, Houston, TX USA; Univ Virginia Hlth Syst, Charlottesville, VA USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Henry Ford Hlth Syst, Detroit, MI USA; Henry Ford Hosp, Detroit, MI 48202 USA; Univ Calif San Diego, Stroke Ctr, La Jolla, CA 92093 USA; Med Univ S Carolina, Charleston, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Ruprecht Karls University Heidelberg; Florey Institute of Neuroscience & Mental Health; Sapienza University Rome; University of Helsinki; Helsinki University Central Hospital; Technische Universitat Dresden; University System of Ohio; University of Cincinnati; Mayo Clinic; Emory University; University of Texas System; University of Virginia; Northwell Health; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Diego; Medical University of South Carolina	Marler, JR (corresponding author), NINDS, Clin Trial Grp, 6001 Execut Blvd,Room 2216, Rockville, MD 20852 USA.	marlerj@ninds.nih.gov	SALAZAR, ANTONIO/A-5806-2013; Hacke, Werner/ABE-8661-2020; Grotta, James/AAH-7423-2021; DONNAN, GEOFFREY A/A-9947-2008; von Kummer, Rüdiger/AAA-4478-2019	SALAZAR, ANTONIO/0000-0003-2639-2340; von Kummer, Rüdiger/0000-0003-0119-4604; Albers, Gregory/0000-0003-0263-4632	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [N01NS002373, N01NS002382, N01NS002376, N01NS002380, N01NS002381, N01NS002377, P50NS022343, N01NS002378, N01NS002379, N01NS002374] Funding Source: NIH RePORTER; NINDS NIH HHS [N01-NS-02377, N01-NS-02381, N01-NS-02378, N01-NS-02379, N01-NS-02376, N01-NS-02382, N01-NS-2-2343, N01-NS-02373, N01-NS-02380, N01-NS-02374] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ASPLUND K, 1985, STROKE, V16, P885; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; Berger PB, 1999, CIRCULATION, V100, P14, DOI 10.1161/01.CIR.100.1.14; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Chareonthaitawee P, 2000, HEART, V84, P142, DOI 10.1136/heart.84.2.142; Christou I, 2000, STROKE, V31, P1812, DOI 10.1161/01.STR.31.8.1812; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Marler JR, 1997, P NAT S RAP ID TREAT, P157; Parsons MW, 2002, ANN NEUROL, V51, P28, DOI 10.1002/ana.10067; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; Tilley BC, 1997, ARCH NEUROL-CHICAGO, V54, P1466, DOI 10.1001/archneur.1997.00550240020008; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wardlaw JM, 2003, STROKE, V34, P1437, DOI 10.1161/01.STR.0000072513.72262.7E	25	1873	1991	1	79	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					768	774						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016487				2022-12-28	WOS:000220092000007
J	Basehoar, AD; Zanton, SJ; Pugh, BF				Basehoar, AD; Zanton, SJ; Pugh, BF			Identification and distinct regulation of yeast TATA box-containing genes	CELL			English	Article							PROMOTERS IN-VIVO; RNA-POLYMERASE-II; BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; ENVIRONMENTAL-CHANGES; EXPRESSION PATTERNS; CRYSTAL-STRUCTURE; GLOBAL REPRESSOR; DNA-SEQUENCES	Despite being one of the first eukaryotic transcriptional regulatory elements identified, the sequence of a native TATA box and its significance remain elusive. Applying criteria associated with TATA boxes we queried several Saccharomyces genomes and arrived at the consensus TATA(A/T)A(A/T)(A/G). Approximately 20% of yeast genes contain a TATA box. Strikingly, TATA box-containing genes are associated with responses to stress, are highly regulated, and preferentially utilize SAGA rather than TFIID when compared to TATA-less promoters. Transcriptional regulation in yeast appears to be mechanistically bipolar, possibly reflecting a need to balance inducible stress-related responses with constitutive housekeeping functions.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Grad Program Stat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	bfp2@psu.edu			NIGMS NIH HHS [R01 GM059055, GM059055] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Angus-Hill ML, 2001, MOL CELL, V7, P741, DOI 10.1016/S1097-2765(01)00219-2; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Barbaric S, 2003, MOL CELL BIOL, V23, P3468, DOI 10.1128/MCB.23.10.3468-3476.2003; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Cang Y, 2002, P NATL ACAD SCI USA, V99, P12727, DOI 10.1073/pnas.202236699; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kurdistani SK, 2003, METHODS, V31, P90, DOI 10.1016/S1046-2023(03)00092-6; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Sabet N, 2003, P NATL ACAD SCI USA, V100, P4084, DOI 10.1073/pnas.0637524100; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	57	481	496	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					699	709		10.1016/S0092-8674(04)00205-3	http://dx.doi.org/10.1016/S0092-8674(04)00205-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006352	Bronze			2022-12-28	WOS:000221499700010
J	Coull, JT; Vidal, F; Nazarian, B; Macar, F				Coull, JT; Vidal, F; Nazarian, B; Macar, F			Functional anatomy of the attentional modulation of time estimation	SCIENCE			English	Article							SUPPLEMENTARY MOTOR AREA; BRAIN ACTIVATION; NEURAL SYSTEMS; MOVEMENTS; CORTEX; FMRI; ORGANIZATION; INFORMATION; COMPONENTS; INTERVALS	Attention modulates our subjective perception of time. The less we attend to an event's duration, the shorter it seems to last. Attention to time or color stimulus attributes was modulated parametrically in an event-related functional magnetic resonance imaging study. Linear increases in task performance were accompanied by corresponding increases in brain activity. Increasing attention to time selectively increased activity in a corticostriatal network, including pre-supplementary motor area and right frontal operculum. Increasing attention to color selectively increased activity in area V4. By identifying areas whose activity was specifically modulated by attention to time, we have defined the core neuroanatomical substrates of timing behavior.	CNRS, Lab Neurobiol Cognit, F-13402 Marseille 20, France; IMNSSA, Toulon, France; CHU Timone, Ctr IRM Fonct Cerebrale, F-13385 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Coull, JT (corresponding author), CNRS, Lab Neurobiol Cognit, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	jcoull@lnf.cnrs-mrs.fr	Coull, Jennifer T/M-4243-2015	Coull, Jennifer T/0000-0002-8790-5835				Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; Chawla D, 1999, NAT NEUROSCI, V2, P671, DOI 10.1038/10230; Clower WT, 1998, J NEUROPHYSIOL, V80, P1562, DOI 10.1152/jn.1998.80.3.1562; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Coull JT, 2000, NEUROPSYCHOLOGIA, V38, P808, DOI 10.1016/S0028-3932(99)00132-3; Coull JT, 1998, J NEUROSCI, V18, P7426; Coull JT, 2003, COGNITIVE BRAIN RES, V17, P368, DOI 10.1016/S0926-6410(03)00138-1; Hadjikhani N, 1998, NAT NEUROSCI, V1, P235, DOI 10.1038/681; HICKS RE, 1976, AM J PSYCHOL, V89, P719, DOI 10.2307/1421469; Lewis PA, 2003, NEUROPSYCHOLOGIA, V41, P1583, DOI 10.1016/S0028-3932(03)00118-0; Macar F, 1999, EXP BRAIN RES, V125, P271, DOI 10.1007/s002210050683; MACAR F, 1994, MEM COGNITION, V22, P673, DOI 10.3758/BF03209252; Macar F, 2002, EXP BRAIN RES, V142, P475, DOI 10.1007/s00221-001-0953-0; Matell MS, 2000, BIOESSAYS, V22, P94, DOI 10.1002/(SICI)1521-1878(200001)22:1<94::AID-BIES14>3.0.CO;2-E; Miall C, 1989, NEURAL COMPUT, V1, P359, DOI 10.1162/neco.1989.1.3.359; Nenadic I, 2003, EXP BRAIN RES, V148, P238, DOI 10.1007/s00221-002-1188-4; Platel H, 1997, BRAIN, V120, P229, DOI 10.1093/brain/120.2.229; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; Rao SM, 1997, J NEUROSCI, V17, P5528; Rushworth MFS, 1997, NEUROPSYCHOLOGIA, V35, P1261, DOI 10.1016/S0028-3932(97)00050-X; Schubotz RI, 2001, COGNITIVE BRAIN RES, V11, P97, DOI 10.1016/S0926-6410(00)00069-0; Schubotz RI, 2001, CEREB CORTEX, V11, P210, DOI 10.1093/cercor/11.3.210; Shima K, 2000, J NEUROPHYSIOL, V84, P2148, DOI 10.1152/jn.2000.84.4.2148; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; TANJI J, 1994, NATURE, V371, P413, DOI 10.1038/371413a0; ZEKI S, 1991, J NEUROSCI, V11, P641	27	467	487	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	2004	303	5663					1506	1508		10.1126/science.1091573	http://dx.doi.org/10.1126/science.1091573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001776				2022-12-28	WOS:000220000100038
J	Greenberg, M				Greenberg, M			Occupational health and safety proposals: 2004-10	LANCET			English	Editorial Material											Greenberg, M (corresponding author), 74 N End Rd, London NW11 7SY, England.	gillmorris.greenberg@btinternet.com						Beck M., 2000, IND RELAT J, V31, P35, DOI [10.1111/1468-2338.00145, DOI 10.1111/1468-2338.00145]; *HLTH SAF EX, IN PRESS HLTH SAF EX; RIMINGTON J, 2003, OCCUP HLTH REV, V106, P35; RIMINGTON J, 2003, OCCUP HLTH REV, V105, P35; Robens L., 1972, SAFETY HLTH WORK REP; Topping MD, 1998, ANN OCCUP HYG, V42, P357, DOI 10.1016/S0003-4878(98)00054-4	6	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					673	674		10.1016/S0140-6736(04)15663-8	http://dx.doi.org/10.1016/S0140-6736(04)15663-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001322				2022-12-28	WOS:000189266900005
J	Hidalgo-Grass, C; Dan-Goor, M; Maly, A; Eran, Y; Kwinn, LA; Nizet, V; Ravins, M; Jaffe, J; Peyser, A; Moses, AE; Hanski, E				Hidalgo-Grass, C; Dan-Goor, M; Maly, A; Eran, Y; Kwinn, LA; Nizet, V; Ravins, M; Jaffe, J; Peyser, A; Moses, AE; Hanski, E			Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections	LANCET			English	Article							CYSTEINE PROTEASE; MOLECULAR-BASIS; FASCIITIS; PYOGENES; VIRULENCE; DISEASE; PATHOGENESIS; INFLAMMATION; INVASION; SURVIVAL	Background Necrotising soft-tissue infections due to group A streptococcus (GAS) are rare (about 0.2 cases per 100000 people). The disease progresses rapidly, causing severe necrosis and hydrolysis of soft tissues. Histopathological analysis of necrotic tissue debrided from two patients (one with necrotising fasciitis and one with myonecrosis) showed large quantities of bacteria but no infiltrating neutrophils. We aimed to investigate whether the poor neutrophil chemotaxis was linked with the ability of group A streptococcus (GAS) to degrade host chemokines. Methods We did RT-PCR, ELISA, and dot-blot assays to establish whether GAS induces synthesis of interleukin 8 mRNA, but subsequently degrades the released chemokine protein. Class-specific protease inhibitors were used to characterise the protease that degraded the chemokine. We used a mouse model of human soft-tissue infections to investigate the pathogenic relevance of GAS chemokine degradation, and to test the therapeutic effect of a GAS pheromone peptide (SilCR) that downregulates activity of chemokine protease. Findings The only isolates from the necrotic tissue were two beta-haemolytic GAS strains of an M14 serotype. A trypsin-like protease released by these strains degraded human interleukin 8 and its mouse homologue MIP2. When innoculated subcutaneously in mice, these strains produced a fatal necrotic soft-tissue infection that had reduced neutrophil recruitment to the site of injection. The M14 GAS strains have a missense mutation in the start codon of silCR, which encodes a predicted 17 aminoacid pheromone peptide, SilCR. Growth of the M14 strain in the presence of SilCR abrogated chemokine proteolysis. When SilCR was injected together with the bacteria, abundant neutrophils were recruited to the site of infection, bacteria were cleared without systemic spread, and the mice survived. The therapeutic effect of SilCR was also obtained in mice challenged with M1 and M3 GAS strains, a leading cause of invasive infections. Interpretation The unusual reduction in neutrophils in necrotic tissue of people with GAS soft-tissue infections is partly caused by a GAS protease that degrades interleukin 8. In mice, degradation can be controlled by administration of SilCR, which downregulates GAS chemokine protease activity. This downregulation increases neutrophil migration to the site of infection, preventing bacterial spread and development of a fulminant lethal systemic infection.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Microbiol, IL-91010 Jerusalem, Israel; Univ Calif San Diego, Sch Med, Dept Paediat, La Jolla, CA 92093 USA; Hadassah Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Orthoped, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; University of California System; University of California San Diego; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Hanski, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Microbiol, IL-91010 Jerusalem, Israel.	hanski@cc.huji.ac.il	Hidalgo-Grass, Carlos J/J-6488-2016; Nizet, Victor/AAF-3190-2019; hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628; Nizet, Victor/0000-0003-3847-0422	NIAID NIH HHS [AI-048694] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048694] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anastasiou R, 2002, J APPL MICROBIOL, V93, P52, DOI 10.1046/j.1365-2672.2002.01659.x; Banks DJ, 2002, TRENDS MICROBIOL, V10, P515, DOI 10.1016/S0966-842X(02)02461-7; Beall B, 1996, J CLIN MICROBIOL, V34, P953, DOI 10.1128/JCM.34.4.953-958.1996; Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; Cockerill FR, 1998, CLIN INFECT DIS, V26, P1448, DOI 10.1086/516376; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; Doran KS, 2002, J INFECT DIS, V185, P196, DOI 10.1086/338475; DRISCOLL KE, 1994, EXP LUNG RES, V20, P473, DOI 10.3109/01902149409031733; Fazeli MR, 2003, EUR J CLIN MICROBIOL, V22, P475, DOI 10.1007/s10096-003-0972-9; Goldstein JM, 2001, INFECT IMMUN, V69, P5494, DOI 10.1128/IAI.69.9.5494-5501.2001; Gresham HD, 2000, J IMMUNOL, V164, P3713, DOI 10.4049/jimmunol.164.7.3713; Harris TO, 2003, J CLIN INVEST, V111, P61, DOI 10.1172/JCI200316270; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; Hidalgo-Grass C, 2002, MOL MICROBIOL, V46, P87, DOI 10.1046/j.1365-2958.2002.03127.x; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Jones CH, 2001, INFECT IMMUN, V69, P5538, DOI 10.1128/IAI.69.9.5538-5545.2001; Kansal RG, 2003, J INFECT DIS, V187, P398, DOI 10.1086/368022; Kotb M, 2002, NAT MED, V8, P1398, DOI 10.1038/nm800; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; LOUDON I, 1994, LANCET, V344, P1416, DOI 10.1016/S0140-6736(94)90574-6; Lukomski S, 1999, INFECT IMMUN, V67, P1779; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Medina E, 2003, J INFECT DIS, V187, P597, DOI 10.1086/373998; Monnickendam MA, 1997, ADV EXP MED BIOL, V418, P87; Moses AE, 2003, J CLIN MICROBIOL, V41, P4655, DOI 10.1128/JCM.41.10.4655-4659.2003; Moses AE, 2002, EMERG INFECT DIS, V8, P421, DOI 10.3201/eid0804.010278; Norrby-Teglund A, 2001, J INFECT DIS, V184, P853, DOI 10.1086/323443; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; Seal DV, 1996, J HOSP INFECT, V33, P230, DOI 10.1016/S0195-6701(96)90009-2; SEAL DV, 1988, BRIT J EXP PATHOL, V69, P813; Seal DV, 2001, CURR OPIN INFECT DIS, V14, P127, DOI 10.1097/00001432-200104000-00003; Sharkawy A, 2002, CLIN INFECT DIS, V34, P454, DOI 10.1086/338466; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; Sriskandan S, 2000, CRIT CARE MED, V28, P3684, DOI 10.1097/00003246-200011000-00025; Taylor FB, 1999, CLIN INFECT DIS, V29, P167, DOI 10.1086/520147	38	110	116	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					696	703		10.1016/S0140-6736(04)15643-2	http://dx.doi.org/10.1016/S0140-6736(04)15643-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001327				2022-12-28	WOS:000189266900010
J	Kaufmann, P; Bose, P; Prescher, A				Kaufmann, P; Bose, P; Prescher, A			New insights into the soft-tissue anatomy anterior to the patella	LANCET			English	Editorial Material									Univ Technol Aachen, Dept Anat, D-52057 Aachen, Germany	RWTH Aachen University	Kaufmann, P (corresponding author), Univ Technol Aachen, Dept Anat, D-52057 Aachen, Germany.	pkaufmann@ukaachen.de						Dye SF, 2003, J BONE JOINT SURG AM, V85A, P1012, DOI 10.2106/00004623-200306000-00005; Federative Committee on Anatomical Terminology, 1998, TERM AN; FENEIS H, 1982, ANATOMISCHES BILDWOR; Fick R, 1904, HDB ANATOMIE MECHANI; RAUBER A, 1987, ANATOMIE MENSCHEN, V1; SIEGLBAUER F, 1944, LEHRBUCH NORMALEN AN; [No title captured]; [No title captured]; [No title captured]	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					586	586		10.1016/S0140-6736(04)15627-4	http://dx.doi.org/10.1016/S0140-6736(04)15627-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987881				2022-12-28	WOS:000189104900005
J	Alekseyenko, AA; Kuroda, MI				Alekseyenko, AA; Kuroda, MI			Filling gaps in genome organization	SCIENCE			English	Editorial Material							X-CHROMOSOME INACTIVATION; POSITION-EFFECT VARIEGATION; DOSAGE COMPENSATION; AUTOSOME TRANSLOCATION; DROSOPHILA; MOUSE; CHROMATIN; PROTEINS		Harvard Univ, Sch Med, Howard Hughes Med Inst, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Alekseyenko, AA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA.	aalekseyenko@rics.bwh.harvard.edu; mkuroda@genetics.med.harvard.edu						BELYAEVA ES, 1991, CHROMOSOMA, V100, P453, DOI 10.1007/BF00364556; Chu DS, 2002, GENE DEV, V16, P796, DOI 10.1101/gad.972702; Csankovszki G, 2004, SCIENCE, V303, P1182, DOI 10.1126/science.1092938; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; DISTECHE CM, 1995, TRENDS GENET, V11, P17, DOI 10.1016/S0168-9525(00)88981-7; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; Oh K, 2003, GENE DEV, V17, P1334, DOI 10.1101/gad.1082003; Park Y, 2002, SCIENCE, V298, P1620, DOI 10.1126/science.1076686; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Talbert PB, 2000, GENETICS, V154, P259; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; White WM, 1998, AM J HUM GENET, V63, P20, DOI 10.1086/301922	17	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1148	1149		10.1126/science.1095356	http://dx.doi.org/10.1126/science.1095356			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976302				2022-12-28	WOS:000189074700032
J	Le May, N; Dubaele, S; De Santis, LP; Billecocq, A; Bouloy, M; Egly, JM				Le May, N; Dubaele, S; De Santis, LP; Billecocq, A; Bouloy, M; Egly, JM			TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus	CELL			English	Article							NONSTRUCTURAL PROTEIN NSS; RNA-POLYMERASE-II; INFECTED-CELLS; DNA-REPAIR; GENE; INHIBITION; INTERFERON; POLIOVIRUS; KINASE; XPD	The Rift Valley fever virus (RVFV) is the causative agent of fatal hemorrhagic fever in humans and acute hepatitis in ruminants. We found that infection by RVFV leads to a rapid and drastic suppression of host cellular RNA synthesis that parallels a decrease of the TFIIH transcription factor cellular concentration. Using yeast two hybrid system, recombinant technology, and confocal microscopy, we further demonstrated that the nonstructural viral NSs protein interacts with the p44 component of TFIIH to form nuclear filamentous structures that also contain XPB subunit of TFIIH. By competing with XPD, the natural partner of p44 within TFIIH, and sequestering p44 and XPB subunits, NSs prevents the assembly of TFIIH subunits, thus destabilizing the normal host cell life. These observations shed light on the mechanism utilized by RVFV to evade the host response.	Inst Pasteur, Unite Genet Mol Bunyavirides, F-75724 Paris 15, France; CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bouloy, M (corresponding author), Inst Pasteur, Unite Genet Mol Bunyavirides, 25 Rue Dr Roux, F-75724 Paris 15, France.	mbouloy@pasteur.fr; egly@titus.u-strasbg.fr	Le May, Nicolas/R-4656-2019; Le May, Nicolas/O-1275-2016; De Santis, Luca Proietti/A-4119-2015	Le May, Nicolas/0000-0002-0172-8752; De Santis, Luca Proietti/0000-0002-2715-9113				[Anonymous], 2000, Wkly Epidemiol Rec, V75, P370; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P392; BALTIMORE D, 1962, P NATL ACAD SCI USA, V48, P1383, DOI 10.1073/pnas.48.8.1383; BILLECOCQ A, 2003, 12 INT C NEG STRAND, P137; BISHOP DH, 1996, BUNYAVIRIDAE; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; Bridgen A, 2001, P NATL ACAD SCI USA, V98, P664, DOI 10.1073/pnas.98.2.664; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CRAWFORD N, 1981, CELL, V27, P555, DOI 10.1016/0092-8674(81)90397-4; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; ELLIOTT RM, 2000, FAMILY BUNYAVIRIDAE, P614; Endrizzi MG, 2000, GENOME RES, V10, P1095, DOI 10.1101/gr.10.8.1095; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GERARD M, 1991, J BIOL CHEM, V266, P20940; GIORGI C, 1991, VIROLOGY, V180, P738, DOI 10.1016/0042-6822(91)90087-R; HE D, 2000, J CELL BIOL, V110, P569; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; LAUGHLIN LW, 1979, T ROY SOC TROP MED H, V73, P630, DOI 10.1016/0035-9203(79)90006-3; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MULLER R, 1995, AM J TROP MED HYG, V53, P405, DOI 10.4269/ajtmh.1995.53.405; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Santagati F, 2001, NUCLEIC ACIDS RES, V29, P1574, DOI 10.1093/nar/29.7.1574; SCHMALJOHN CAH, 2001, BUNYAVIRIDAE VIRUSES; STRUTHERS JK, 1982, J GEN VIROL, V60, P381, DOI 10.1099/0022-1317-60-2-381; SWANEPOEL R, 1977, J GEN VIROL, V34, P557, DOI 10.1099/0022-1317-34-3-557; THOMAS D, 2003, 12 INT C NEG STRAND, P127; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Turell MJ, 1996, AM J TROP MED HYG, V54, P136, DOI 10.4269/ajtmh.1996.54.136; Vialat P, 2000, J VIROL, V74, P1538, DOI 10.1128/JVI.74.3.1538-1543.2000; Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002; Yadani FZ, 1999, J VIROL, V73, P5018, DOI 10.1128/JVI.73.6.5018-5025.1999; Yalamanchili P, 1996, J VIROL, V70, P2922, DOI 10.1128/JVI.70.5.2922-2929.1996; Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413; ZIMMERMAN E, 1963, VIROLOGY, V19, P400, DOI 10.1016/0042-6822(63)90080-1; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	45	231	237	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					541	550		10.1016/S0092-8674(04)00132-1	http://dx.doi.org/10.1016/S0092-8674(04)00132-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980221	Bronze			2022-12-28	WOS:000189184200008
J	Del Bene, F; Tessmar-Raible, K; Wittbrodt, J				Del Bene, F; Tessmar-Raible, K; Wittbrodt, J			Direct interaction of geminin and Six3 in eye development	NATURE			English	Article							DNA-REPLICATION; HOMEOBOX GENE; XENOPUS-LAEVIS; REPRESSION; HOMOLOG; OVEREXPRESSION; INHIBITION; EXPRESSION; ZEBRAFISH; BINDING	Organogenesis in vertebrates requires the tight control of cell proliferation and differentiation. The homeobox-containing transcription factor Six3 plays a pivotal role(1,2) in the proliferation of retinal precursor cells. In a yeast two-hybrid screen, we identified the DNA replication-inhibitor geminin as a partner of Six3. Geminin inhibits cell-cycle progression(3) by sequestering Cdt1 (refs 4, 5), the key component for the assembly of the pre-replication complex(6). Here, we show that Six3 efficiently competes with Cdt1 directly to bind to geminin, which reveals how Six3 can promote cell proliferation without transcription. In common with Six3 inactivation(2,7), overexpression of the geminin gene (Gem; also known as Gmn) in medaka (Oryzias latipes) induces specific forebrain and eye defects that are rescued by Six3. Conversely, loss of Gem (in common with gain of Six3 (ref. 1)) promotes retinal precursor-cell proliferation and results in expanded optic vesicles, markedly potentiating Six3 gain-of-function phenotypes. Our data indicate that the transcription factor Six3 and the replication-initiation inhibitor geminin act antagonistically to control the balance between proliferation and differentiation during early vertebrate eye development.	European Mol Biol Lab, Dev Biol Programme, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Wittbrodt, J (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69012 Heidelberg, Germany.	Jochen.Wittbrodt@EMBL.de	del bene, filippo/D-1245-2010; Tessmar-Raible, Kristin/F-9642-2011; Wittbrodt, Joachim/D-4735-2014	del bene, filippo/0000-0001-8551-2846; Tessmar-Raible, Kristin/0000-0002-8038-1741; Wittbrodt, Joachim/0000-0001-8550-7377				Carl M, 2002, DEVELOPMENT, V129, P4057; Goudreau G, 2002, P NATL ACAD SCI USA, V99, P8719, DOI 10.1073/pnas.132195699; IWAMATSU T, 1994, ZOOL SCI, V11, P825; Koster R, 1997, DEVELOPMENT, V124, P3147; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; LIANG J, 1995, J BIOL CHEM, V270, P25520, DOI 10.1074/jbc.270.43.25520; Loosli F, 1998, MECH DEVELOP, V74, P159, DOI 10.1016/S0925-4773(98)00055-0; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; LUO L, 2000, NATURE, V427, P749; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sato S, 2002, HUM MOL GENET, V11, P1045, DOI 10.1093/hmg/11.9.1045; Sawai S, 1997, MECH DEVELOP, V65, P175, DOI 10.1016/S0925-4773(97)00071-3; Seimiya M, 2000, DEVELOPMENT, V127, P1879; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tessmar K, 2002, MECH DEVELOP, V117, P103, DOI 10.1016/S0925-4773(02)00185-5; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; Winkler S, 2000, DEVELOPMENT, V127, P1911; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7	25	202	208	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					745	749		10.1038/nature02292	http://dx.doi.org/10.1038/nature02292			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973488				2022-12-28	WOS:000189026000046
J	Iglehart, JK				Iglehart, JK			The new Medicare prescription-drug benefit - A pure power play	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRENDS; REFORM											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; Altman DE, 2004, NEW ENGL J MED, V350, P9, DOI 10.1056/NEJMp038224; ARMEY D, 2003, WALL STREET J   1121, pA12; BABINGTON C, 2003, WASHINGTON POST 1221, pB1; BRODER DS, 2003, WASHINGTON POST 1123, pA1; Brooks D., 2003, NY TIMES, pA15; BUTLER SM, 2003, 370 HER FDN; *C BUDG OFF, 2002, ISS DES PRESCR DRUG; Connolly, 2003, WASH POST, pA4; CUMMINGS J, 2003, WALL STREET J   0305, pA3; DALE SB, 2003, STATE MEDICAID PRESC; DALLEK G, 2003, WASHINGTON POST 1207, pB1; Dowd B, 2000, HEALTH AFFAIR, V19, P9, DOI 10.1377/hlthaff.19.5.9; FREUDENHEIM M, 2003, NY TIMES        0820, pA1; GOLDSTEIN A, 2003, WASH POST       0115, pA4; GOLDSTEIN A, 2003, WASHINGTON POST 1130, pA8; *HJ KAIS FAM FDN, 2003, EMPL HLTH BEN 2003 A; HOLTZEAKIN D, 2003, 815 HER FDN; HOLTZEAKIN D, 2003, EC COSTS LONG TERM F; HULSE C, 2003, NY TIMES        0628, pA9; HULSE C, 2003, NY TIMES        0729, pA1; HULSE C, 2003, NY TIMES        0622, pA22; HUNT AR, 2003, WALL STREET J   1120, pA21; Iglehart JK, 2003, NEW ENGL J MED, V348, P1590, DOI 10.1056/NEJMhpr035135; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; LUECK S, 2003, WALL STREET J   1118, pA4; MCARDLE FB, 2003, LARGE FIRMS RETIREE; Milbank Dana, 2003, WASH POST, pA1; MOFFIT RE, 2003, 1708 HER FDN; *NAT AC SOC INS, 2003, ROL PRIV HLTH PLANS; Nichols LM, 2000, HEALTH AFFAIR, V19, P30, DOI 10.1377/hlthaff.19.5.30; NICKLES D, 2003, COMMUNICATION   1120; PEAR R, 2004, NY TIMES        0130, pA1; Pear Robert, 2003, N Y Times Web, pA15; RIEDL BM, 2003, 1673 HER FDN; SAMUELSON RJ, 2003, WASHINGTON POST 1124, pA21; SCHULTZ EE, 2004, WALL STREET J   0108, pA3; Smith C, 2004, HEALTH AFFAIR, V23, P160, DOI 10.1377/hlthaff.23.1.160; TONER R, 2003, NY TIMES        0527, pA1; WELCH WM, 2003, WASHINGTON POST 1128, pA5; 2003, WALL STREET J   0811, pA8; 2003, WALL STREET J   1125, pA18	42	46	46	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					826	833		10.1056/NEJMhpr045002	http://dx.doi.org/10.1056/NEJMhpr045002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973209				2022-12-28	WOS:000189006400013
J	Kuriyan, J				Kuriyan, J			Allostery and coupled sequence variation in nuclear hormone receptors	CELL			English	Editorial Material							PROTEIN; SITE		Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94707 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Chem, Berkeley, CA 94707 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Kuriyan, J (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94707 USA.							CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Frauenfelder H, 2003, P NATL ACAD SCI USA, V100, P8615, DOI 10.1073/pnas.1633688100; Gaucher EA, 2003, GENETICS, V163, P1549; Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; NETTLES KW, 2004, IN PRESS MOL CELL, V13; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881	8	12	13	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	2004	116	3					354	356		10.1016/S0092-8674(04)00125-4	http://dx.doi.org/10.1016/S0092-8674(04)00125-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016369	Bronze			2022-12-28	WOS:000188825800003
J	Klempner, MS; Shapiro, DS				Klempner, MS; Shapiro, DS			Crossing the species barrier - One small step to man, one giant leap to mankind	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Klempner, MS (corresponding author), Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.								0	28	30	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1171	1172		10.1056/NEJMp048039	http://dx.doi.org/10.1056/NEJMp048039			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	14985471				2022-12-28	WOS:000220242400001
J	Diebold, SS; Kaisho, T; Hemmi, H; Akira, S; Sousa, CRE				Diebold, SS; Kaisho, T; Hemmi, H; Akira, S; Sousa, CRE			Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA	SCIENCE			English	Article							PLASMACYTOID DENDRITIC CELLS; INTERFERON-PRODUCING CELLS; INFLUENZA-VIRUS; CD8-ALPHA(+); ACTIVATION; PRECURSORS; REQUIRES; TLR7	Interferons (IFNs) are critical for protection from viral infection, but the pathways linking virus recognition to IFN induction remain poorly understood. Plasmacytoid dendritic cells produce vast amounts of IFN-alpha in response to the wild-type influenza virus. Here, we show that this requires endosomal recognition of influenza genomic RNA and signaling by means of Toll-like receptor 7 (TLR7) and MyD88. Single-stranded RNA (ssRNA) molecules of nonviral origin also induce TLR7-dependent production of inflammatory cytokines. These results identify ssRNA as a ligand for TLR7 and suggest that cells of the innate immune system sense endosomal ssRNA to detect infection by RNA viruses.	London Res Inst, Canc Res UK, Immunobiol Lab, London WC2A 3PX, England; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Corp, ERATO, Akira Innate Immun Project, Suita, Osaka 5650871, Japan	Cancer Research UK; Osaka University; RIKEN; Japan Science & Technology Agency (JST)	Sousa, CRE (corresponding author), London Res Inst, Canc Res UK, Immunobiol Lab, London WC2A 3PX, England.	caetano@cancer.org.uk	Reis e Sousa, Caetano/O-1657-2014; Akira, Shizuo/C-3134-2009; Yang, Chen/G-1379-2010; Kaisho, Tsuneyasu/B-4130-2012; Reis e Sousa, Caetano/ABD-7322-2021	Reis e Sousa, Caetano/0000-0001-7392-2119; Reis e Sousa, Caetano/0000-0001-7392-2119				Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; Bruno L, 2001, EUR J IMMUNOL, V31, P3403, DOI 10.1002/1521-4141(200111)31:11<3403::AID-IMMU3403>3.0.CO;2-T; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; DIEBOLD S, UNPUB; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Fonteneau JF, 2003, BLOOD, V101, P3520, DOI 10.1182/blood-2002-10-3063; Gilliet M, 2002, J EXP MED, V195, P953, DOI 10.1084/jem.20020045; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; KRUG A, 2003, BLOOD           1016, DOI DOI 10.1182/BLOOD-2003-08-2674; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; O'Keeffe M, 2002, J EXP MED, V196, P1307, DOI 10.1084/jem.20021031; Palmer P, 2000, VIROLOGY, V278, P86, DOI 10.1006/viro.2000.0627; Schulz O, 2002, IMMUNOLOGY, V107, P183, DOI 10.1046/j.1365-2567.2002.01513.x; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; 2003, WKLY EPIDEMIOL REC, V78, P39	28	2521	2801	8	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1529	1531		10.1126/science.1093616	http://dx.doi.org/10.1126/science.1093616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	14976261				2022-12-28	WOS:000220000100046
J	Miller, KG				Miller, KG			Converting a motor to an anchor	CELL			English	Editorial Material							MYOSIN-VI; VESICLES	Myosin VI can move along actin filaments to serve as a transport motor. It is also thought to anchor vesicles or proteins to actin. How these two diverse activities, which require very different modes of interaction with actin, are mediated is not understood. Using single molecule observations, Altman et al. (2004 [this issue of Cell]) demonstrate that load applied to myosin VI can convert this motor from a transporter to an anchor.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Miller, KG (corresponding author), Washington Univ, Dept Biol, 1 Brookings Dr,CB 1229, St Louis, MO 63130 USA.							Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Kelleher JF, 2000, CURR BIOL, V10, P1489, DOI 10.1016/S0960-9822(00)00828-9; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835	8	2	2	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	2004	116	5					635	636		10.1016/S0092-8674(04)00213-2	http://dx.doi.org/10.1016/S0092-8674(04)00213-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006345	Bronze			2022-12-28	WOS:000221499700003
J	Eggan, E; Baldwin, K; Tackett, M; Osborne, J; Gogos, J; Chess, A; Axel, R; Jaenisch, R				Eggan, E; Baldwin, K; Tackett, M; Osborne, J; Gogos, J; Chess, A; Axel, R; Jaenisch, R			Mice cloned from olfactory sensory neurons	NATURE			English	Article							END-JOINING PROTEINS; EMBRYONIC STEM-CELLS; RECEPTOR GENE; NUCLEAR TRANSPLANTATION; SOMATIC RECOMBINATION; MONOCLONAL-ANTIBODY; ODORANT RECEPTORS; TOPOGRAPHIC MAP; NERVOUS-SYSTEM; BASAL-CELLS	Cloning by nuclear transplantation has been successfully carried out in various mammals, including mice. Until now mice have not been cloned from post-mitotic cells such as neurons. Here, we have generated fertile mouse clones derived by transferring the nuclei of post-mitotic, olfactory sensory neurons into oocytes. These results indicate that the genome of a post-mitotic, terminally differentiated neuron can re-enter the cell cycle and be reprogrammed to a state of totipotency after nuclear transfer. Moreover, the pattern of odorant receptor gene expression and the organization of odorant receptor genes in cloned mice was indistinguishable from wild-type animals, indicating that irreversible changes to the DNA of olfactory neurons do not accompany receptor gene choice.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Columbia University; Howard Hughes Medical Institute	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	achess@wi.mit.edu; jaenisch@wi.mit.edu		Baldwin, Kristin/0000-0002-6137-030X; Axel, Richard/0000-0002-3141-4076				BRACK C, 1978, CELL, V15, P1, DOI 10.1016/0092-8674(78)90078-8; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; Chun J, 1999, NEURON, V22, P7, DOI 10.1016/S0896-6273(00)80671-6; Chun J, 2001, ADV IMMUNOL, V77, P297, DOI 10.1016/S0065-2776(01)77020-4; Ebrahimi FAW, 2000, DEV DYNAM, V217, P225, DOI 10.1002/(SICI)1097-0177(200002)217:2<225::AID-DVDY9>3.0.CO;2-3; Edelman GM, 1987, NEURAL DARWINISM THE; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GERDES J, 1984, J IMMUNOL, V133, P1710; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; Goldstein BJ, 1996, J NEUROSCI, V16, P4005; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P8048, DOI 10.1073/pnas.1337135100; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Hochedlinger K, 2002, CURR OPIN CELL BIOL, V14, P741, DOI 10.1016/S0955-0674(02)00380-0; HOLBROOK EH, 1995, J COMP NEUROL, V363, P129, DOI 10.1002/cne.903630111; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; Ishii T, 2001, GENES CELLS, V6, P71, DOI 10.1046/j.1365-2443.2001.00398.x; Kaushal D, 2003, J NEUROSCI, V23, P5599; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; NAGY A, 1990, DEVELOPMENT, V110, P815; Ohnuma S, 2003, NEURON, V40, P199, DOI 10.1016/S0896-6273(03)00632-9; Ohta Y, 2000, ANN OTO RHINOL LARYN, V109, P1046, DOI 10.1177/000348940010901110; Osada T, 2002, CYTOGENET GENOME RES, V97, P7, DOI 10.1159/000064037; Qasba P, 1998, J NEUROSCI, V18, P227; Rehen SK, 2001, P NATL ACAD SCI USA, V98, P13361, DOI 10.1073/pnas.231487398; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Rossant J, 2002, NATURE, V415, P967, DOI 10.1038/415967a; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Yagi T, 2003, GENES CELLS, V8, P1, DOI 10.1046/j.1365-2443.2003.00614.x; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	43	277	303	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					44	49		10.1038/nature02375	http://dx.doi.org/10.1038/nature02375			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14990966				2022-12-28	WOS:000189363800029
J	Fishman, M; Antonia, S				Fishman, M; Antonia, S			Specific antitumour vaccine for renal cancer	LANCET			English	Editorial Material							CELL CARCINOMA; ADJUVANT; TRIAL; INTERLEUKIN-2		H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Fishman, M (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.	FishmaMN@moffitt.usf.edu						Almand B, 2000, CLIN CANCER RES, V6, P1755; Antonia SJ, 2002, J UROLOGY, V167, P1995, DOI 10.1016/S0022-5347(05)65071-9; Berd D, 2004, J CLIN ONCOL, V22, P403, DOI 10.1200/JCO.2004.06.043; Clark JI, 2003, J CLIN ONCOL, V21, P3133, DOI 10.1200/JCO.2003.02.014; Mazzaferro V, 2003, CLIN CANCER RES, V9, P3235; Messing EM, 2003, J CLIN ONCOL, V21, P1214, DOI 10.1200/JCO.2003.02.005; Ohm JE, 2003, BLOOD, V101, P4878, DOI 10.1182/blood-2002-07-1956; Pizzocaro G, 2001, J CLIN ONCOL, V19, P425, DOI 10.1200/JCO.2001.19.2.425; Repmann R, 2003, ANTICANCER RES, V23, P969; Ries LAG, 2003, SEER CANC STAT REV 1; Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0; Su Z, 2003, CANCER RES, V63, P2127	12	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					583	584		10.1016/S0140-6736(04)15625-0	http://dx.doi.org/10.1016/S0140-6736(04)15625-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987879				2022-12-28	WOS:000189104900003
J	Ems-McClung, SC; Walczak, CE				Ems-McClung, SC; Walczak, CE			Catastrophic kinesins: Piecing together their mechanism by 3D reconstruction	CELL			English	Editorial Material							MCAK	Kin Is, kinesins with an internal catalytic domain, depolymerize microtubules; from both ends, and the KIF2C crystal structure presented by Ogawa et al. (2004, [this issue of Cell]) provides provocative evidence to support the theory that the highly conserved sequences are critical structural elements in these catastrophic kinesins.	Indiana Univ, Med Sci Program, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Ems-McClung, SC (corresponding author), Indiana Univ, Med Sci Program, 915 E 3rd St, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059618] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059618] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Hertzer KM, 2003, CRIT REV BIOCHEM MOL, V38, P453, DOI 10.1080/10409230390267419; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Moores CA, 2003, J CELL BIOL, V163, P963, DOI 10.1083/jcb.200304034; Niederstrasser H, 2002, J MOL BIOL, V316, P817, DOI 10.1006/jmbi.2001.5360; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; Ovechkina Y, 2002, J CELL BIOL, V159, P557, DOI 10.1083/jcb.200205089	9	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	2004	116	4					485	486		10.1016/S0092-8674(04)00168-0	http://dx.doi.org/10.1016/S0092-8674(04)00168-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980215	Bronze			2022-12-28	WOS:000189184200002
J	Zahl, PH; Strand, H; Maehlen, J				Zahl, PH; Strand, H; Maehlen, J			Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY	Objective To determine whether any increase in the incidence of breast cancer in women detected by mammography is compensated for by a drop in the incidence after age 69, years when women are no longer invited for screening. Design Population based cohort study of incidence of breast cancer during the introduction of nationwide screening programmes. Setting Norway and Sweden. Participants Ail women aged above 30 years (1.4 and 2.9 million, respectively, in 2000). Main outcome measures Changes in age specific incidence rates of invasive breast cancer associated with the introduction of the screening programmes. Results As a result of screening the recorded incidence of breast cancer in women aged 50-69 years increased by 54% in Norway and 45% in Sweden. There was no corresponding decline in incidence after the age of 69 years. Conclusions Without screening one third of all invasive breast cancers in the age group 50-69 years would not have been detected in the patients' lifetime. This level of overdiagnosis is larger than previously reported.	Ullevaal Univ Hosp, Dept Pathol, N-0407 Oslo, Norway; Norwegian Inst Publ Hlth, N-0403 Oslo, Norway	University of Oslo; Norwegian Institute of Public Health (NIPH)	Maehlen, J (corresponding author), Ullevaal Univ Hosp, Dept Pathol, N-0407 Oslo, Norway.	jan.mahlen@ioks.uio.no		Strand, Bjorn Heine/0000-0003-4385-8886				BOER R, 1994, LANCET, V343, P979, DOI 10.1016/S0140-6736(94)90105-8; *CANC REG NORW, 2003, CANC NORW 2000; *CANC REG NORW, 2000, MAMM NORG EV PROV 19; Etzioni R, 2002, J NATL CANCER I, V94, P981; Fletcher SW, 2003, NEW ENGL J MED, V348, P1672, DOI 10.1056/NEJMcp021804; Hakama M, 1999, J MED SCREEN, V6, P209, DOI 10.1136/jms.6.4.209; Harmer C, 1999, CANCER CAUSE CONTROL, V10, P333, DOI 10.1023/A:1008949819969; *HLTH COUNC NETH, 2002, PUBL HLTH COUNC NETH; *NAT BOARD HLTH WE, 2002, CANC INC SWED 2000; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Thornton H, 2003, BMJ-BRIT MED J, V327, P101, DOI 10.1136/bmj.327.7406.101; vandenAkkervanMarle ME, 1997, INT J CANCER, V73, P464, DOI 10.1002/(SICI)1097-0215(19971114)73:4<464::AID-IJC2>3.0.CO;2-Y	12	195	198	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					921	924		10.1136/bmj.38044.666157.63	http://dx.doi.org/10.1136/bmj.38044.666157.63			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	15013948	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220994400016
J	Cannon, CP; Braunwald, E; McCabe, CH; Rader, DJ; Rouleau, JL; Belder, R; Joyal, SV; Hill, KA; Pfeffer, MA; Skene, AM				Cannon, CP; Braunwald, E; McCabe, CH; Rader, DJ; Rouleau, JL; Belder, R; Joyal, SV; Hill, KA; Pfeffer, MA; Skene, AM		Pravastatin Atorvastatin Evaluatio	Intensive versus moderate lipid lowering with statins after acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE; TASK-FORCE; PRAVASTATIN; ATHEROSCLEROSIS; ATORVASTATIN; THERAPY; PROGRESSION; PREVENTION	BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Montreal, Montreal, PQ, Canada; Bristol Myers Squibb Co, Princeton, NJ USA; Nottingham Clin Res Grp, Nottingham, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Universite de Montreal; Bristol-Myers Squibb	Cannon, CP (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.	cpcannon@partners.org	Cannon, Christopher P/AAY-7644-2020	Cannon, Christopher P/0000-0003-4596-2791				Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4; Asakura M, 2001, J AM COLL CARDIOL, V37, P1284, DOI 10.1016/S0735-1097(01)01135-4; Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195-668X(02)00419-0; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Campeau L, 1999, CIRCULATION, V99, P3241, DOI 10.1161/01.CIR.99.25.3241; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; Cannon CP, 2002, AM J CARDIOL, V89, P860, DOI 10.1016/S0002-9149(02)02201-4; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Davidson MH, 1997, AM J CARDIOL, V80, P347, DOI 10.1016/S0002-9149(97)00360-3; De Backer G, 2003, ATHEROSCLEROSIS, V171, P145, DOI 10.1016/j.atherosclerosis.2003.10.001; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Goldstein JA, 2000, NEW ENGL J MED, V343, P915, DOI 10.1056/NEJM200009283431303; Kent SM, 2004, CLIN CARDIOL, V27, P17, DOI 10.1002/clc.4960270105; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; LaRosa John C, 2004, Curr Atheroscler Rep, V6, P12, DOI 10.1007/s11883-004-0111-9; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; Taylor AJ, 2002, CIRCULATION, V106, P2055, DOI 10.1161/01.CIR.0000034508.55617.65; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	27	3538	3823	0	136	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	2004	350	15					1495	1504		10.1056/NEJMoa040583	http://dx.doi.org/10.1056/NEJMoa040583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	810CI	15007110	Bronze			2022-12-28	WOS:000220682000005
J	Ganem, D; Prince, AM				Ganem, D; Prince, AM			Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							E-ANTIGEN; ADEFOVIR DIPIVOXIL; LAMIVUDINE THERAPY; LIVER-TRANSPLANTATION; REVERSE TRANSCRIPTION; ANICTERIC HEPATITIS; INTERFERON-ALPHA; WILD-TYPE; DNA; REPLICATION		New York Blood Ctr, Lindsley F Kimball Res Inst, Virol Lab, New York, NY 10021 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; NYU, Sch Med, Dept Pathol, New York, NY USA	New York Blood Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; New York University	Prince, AM (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Virol Lab, 310 E 67th St, New York, NY 10021 USA.	aprince@nybloodcenter.org						Anselmo DM, 2002, ANN SURG, V235, P611, DOI 10.1097/00000658-200205000-00002; BARKER LF, 1975, J INFECT DIS, V132, P451, DOI 10.1093/infdis/132.4.451; Baron JL, 2002, IMMUNITY, V16, P583, DOI 10.1016/S1074-7613(02)00305-9; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BRUNETTO MR, 1991, P NATL ACAD SCI USA, V88, P4186, DOI 10.1073/pnas.88.10.4186; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; Cavanaugh VJ, 1998, J VIROL, V72, P2630, DOI 10.1128/JVI.72.4.2630-2637.1998; Chien RN, 1999, HEPATOLOGY, V30, P770, DOI 10.1002/hep.510300313; Chin R, 2001, ANTIMICROB AGENTS CH, V45, P2495, DOI 10.1128/AAC.45.9.2495-2501.2001; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; CHUNG WK, 1964, ARCH INTERN MED, V113, P535, DOI 10.1001/archinte.1964.00280100043008; DANE DS, 1970, LANCET, V1, P695; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GANEM D, 1991, CURR TOP MICROBIOL, V168, P61; GANEM D, 2001, FIELDS VIROLOGY, P2923; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; HALPERN MS, 1983, P NATL ACAD SCI-BIOL, V80, P4865, DOI 10.1073/pnas.80.15.4865; Honkoop P, 2000, HEPATOLOGY, V32, P635, DOI 10.1053/jhep.2000.16333; HOOFNAGLE JH, 1981, ANNU REV MED, V32, P1, DOI 10.1146/annurev.me.32.020181.000245; Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G; KAJINO K, 1994, J VIROL, V68, P5792, DOI 10.1128/JVI.68.9.5792-5803.1994; Kao JH, 2002, J GASTROEN HEPATOL, V17, P643, DOI 10.1046/j.1440-1746.2002.02737.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KLINGMULLER U, 1993, J VIROL, V67, P7414; KOFF RS, 1977, GASTROENTEROLOGY, V72, P297; KORBA BE, 1988, VIROLOGY, V165, P172, DOI 10.1016/0042-6822(88)90670-8; KRUGMAN S, 1970, J AMER MED ASSOC, V212, P1019, DOI 10.1001/jama.212.6.1019; KRUGMAN S, 1967, J AMER MED ASSOC, V200, P365, DOI 10.1001/jama.200.5.365; Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559; Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; MARION PL, 1988, PROG MED VIROL, V35, P43; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243; Nelson M, 2003, AIDS, V17, pF7, DOI 10.1097/00002030-200301030-00002; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; Perrillo R, 1999, HEPATOLOGY, V29, P1581, DOI 10.1002/hep.510290507; Perrillo R, 2000, HEPATOLOGY, V32, P129, DOI 10.1053/jhep.2000.8626; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; PRINCE AM, 1979, YALE J BIOL MED, V52, P159; PRINCE AM, 1970, NEW ENGL J MED, V282, P987, DOI 10.1056/NEJM197004302821801; PRINCE AM, 1968, LANCET, V2, P462; PRINCE AM, 1964, AM J HYG, V79, P365, DOI 10.1093/oxfordjournals.aje.a120391; Prince AM, 2001, TRANSFUSION, V41, P329, DOI 10.1046/j.1537-2995.2001.41030329.x; PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814; Puoti Massimo, 2002, AIDS Reviews, V4, P27; Ribeiro RM, 2002, MICROBES INFECT, V4, P829, DOI 10.1016/S1286-4579(02)01603-9; Ristig MB, 2002, J INFECT DIS, V186, P1844, DOI 10.1086/345770; ROBINSON WS, 1976, NEW ENGL J MED, V295, P1168, DOI 10.1056/NEJM197611182952105; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; Standring David N., 2001, Antiviral Chemistry and Chemotherapy, V12, P119; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUMMERS J, 1975, P NATL ACAD SCI USA, V72, P4597, DOI 10.1073/pnas.72.11.4597; Sung JJY, 2002, J VIRAL HEPATITIS, V9, P229, DOI 10.1046/j.1365-2893.2002.00352.x; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; Tedder RS, 2002, J MED VIROL, V68, P505, DOI 10.1002/jmv.10241; Terrault NA, 1996, HEPATOLOGY, V24, P1327, DOI 10.1053/jhep.1996.v24.pm0008938155; Trepo C, 2001, J AUTOIMMUN, V16, P269, DOI 10.1006/jaut.2000.0502; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1; Villeneuve JP, 2000, HEPATOLOGY, V31, P207, DOI 10.1002/hep.510310130; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; Weinberger KM, 2000, J VIROL METHODS, V85, P75, DOI 10.1016/S0166-0934(99)00154-8; WILL H, 1987, J VIROL, V61, P904, DOI 10.1128/JVI.61.3.904-911.1987; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215; Yang HL, 2002, HEPATOLOGY, V36, P464, DOI 10.1053/jhep.2002.34740; Ying C, 2000, J VIRAL HEPATITIS, V7, P161; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	80	1754	1997	2	191	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1118	1129		10.1056/NEJMra031087	http://dx.doi.org/10.1056/NEJMra031087			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014185				2022-12-28	WOS:000220110100009
J	Henrich, J				Henrich, J			Inequity aversion in capuchins?	NATURE			English	Letter									Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA	Emory University	Henrich, J (corresponding author), Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA.	jhenric@emory.edu						BOLTON GE, 1995, GAME ECON BEHAV, V10, P95, DOI 10.1006/game.1995.1026; Brosnan SF, 2003, NATURE, V425, P297, DOI 10.1038/nature01963; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Henrich J, 2000, AM ECON REV, V90, P973, DOI 10.1257/aer.90.4.973; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; HENRICH J, IN PRESS FDN HUMAN S	6	36	37	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					139	139		10.1038/428139a	http://dx.doi.org/10.1038/428139a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014487				2022-12-28	WOS:000220103600034
J	Morison, WL				Morison, WL			Photosensitivity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMORPHOUS LIGHT ERUPTION; CHRONIC ACTINIC DERMATITIS; CONTROLLED-TRIAL; PUVA; PHOTOTHERAPY; THERAPY; DISEASE	A 30-year-old white woman has a 72-hour history of a pruritic rash on her arms and chest. This is the third episode of the rash this summer, and each episode began in the evening after she had spent less than 30 minutes by a swimming pool in the morning. She has no history of sensitivity to sunlight and is taking no medications. Both the rash and the pruritus are improving, but she still has discomfort. How should this woman be evaluated and treated?	Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA	Johns Hopkins University	Morison, WL (corresponding author), Johns Hopkins Greenspring, Suite 355,10753 Falls Rd, Lutherville Timonium, MD 21093 USA.	wmorison@jhmi.edu						BILSLAND D, 1993, BRIT J DERMATOL, V129, P708, DOI 10.1111/j.1365-2133.1993.tb03337.x; CORBETT MF, 1982, BRIT J DERMATOL, V107, P571, DOI 10.1111/j.1365-2133.1982.tb00409.x; DUSCHET P, 1988, ACTA DERM-VENEREOL, V68, P176; ELPERN DJ, 1985, ARCH DERMATOL, V121, P1286, DOI 10.1001/archderm.121.10.1286; Ferguson J, 1995, PHOTOCHEM PHOTOBIOL, V62, P954; Ferguson J, 2002, PHOTODERMATOL PHOTO, V18, P262, DOI 10.1034/j.1600-0781.2002.02778.x; GSCHNAIT F, 1978, BRIT J DERMATOL, V99, P293, DOI 10.1111/j.1365-2133.1978.tb01999.x; Hasan T, 1998, ARCH DERMATOL, V134, P1081, DOI 10.1001/archderm.134.9.1081; HOOD AF, 1986, J CUTAN PATHOL, V13, P13, DOI 10.1111/j.1600-0560.1986.tb00456.x; LEIGH IM, 1984, BRIT J DERMATOL, V110, P691, DOI 10.1111/j.1365-2133.1984.tb04706.x; LEVINE JI, 1991, HHS PUBLICATION; LIM HW, 1994, ARCH DERMATOL, V130, P1284, DOI 10.1001/archderm.130.10.1284; LOWE NJ, 1994, CLIN PHARMACOL THER, V56, P587, DOI 10.1038/clpt.1994.180; MORISON WL, 1982, BRIT J DERMATOL, V106, P231, DOI 10.1111/j.1365-2133.1982.tb00935.x; MORISON WL, 1982, ACTA DERM-VENEREOL, V62, P237; MURPHY GM, 1987, BRIT J DERMATOL, V116, P531, DOI 10.1111/j.1365-2133.1987.tb05874.x; NORRIS PG, 1990, ARCH DERMATOL, V126, P376, DOI 10.1001/archderm.126.3.376; PAO C, 1994, BRIT J DERMATOL, V130, P62, DOI 10.1111/j.1365-2133.1994.tb06884.x; PARRISH JA, 1979, BRIT J DERMATOL, V100, P187, DOI 10.1111/j.1365-2133.1979.tb05560.x; Patel DC, 2000, BRIT J DERMATOL, V143, P828, DOI 10.1046/j.1365-2133.2000.03840.x; PROBY CM, 1993, LANCET, V341, P1347, DOI 10.1016/0140-6736(93)90856-C; Provost TT, 1996, J AM ACAD DERMATOL, V35, P147, DOI 10.1016/S0190-9622(96)90315-1; ROBINSON HN, 1985, ARCH DERMATOL, V121, P522, DOI 10.1001/archderm.121.4.522; ROELANDTS R, 1993, J AM ACAD DERMATOL, V28, P240, DOI 10.1016/0190-9622(93)70034-Q; ROS AM, 1986, PHOTODERMATOLOGY, V3, P298	25	26	34	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1111	1117		10.1056/NEJMcp022558	http://dx.doi.org/10.1056/NEJMcp022558			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014184				2022-12-28	WOS:000220110100008
J	Wallsten, S				Wallsten, S			High-tech cluster bombs - Why successful biotech hubs are the exception, not the rule.	NATURE			English	Editorial Material									AEI Brookings Joint Ctr Regulatory Studies, Washington, DC 20036 USA; Amer Enterprise Inst Publ Policy Res, Washington, DC 20036 USA	American Enterprise Institute for Public Policy Research	Wallsten, S (corresponding author), AEI Brookings Joint Ctr Regulatory Studies, 1150 17th St NW, Washington, DC 20036 USA.		Wallsten, Scott/ABF-2887-2021					Howard K, 2003, NATURE, V426, P689, DOI 10.1038/426689; JAFFE AB, 1989, AM ECON REV, V79, P957; Krugman P., 1991, GEOGRAPHY TRADE; Marshall A., 1920, IND TRADE STUDY IND; Wallsten S., 2004, DO SCI PARKS GENERAT; WILEN J, 2003, BALTIMORE BUSIN 0613; 2003, NATURE, V426, P4	7	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					121	122		10.1038/428121a	http://dx.doi.org/10.1038/428121a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014470				2022-12-28	WOS:000220103600019
J	Grumbach, K; Bodenheimer, T				Grumbach, K; Bodenheimer, T			Can health care teams improve primary care practice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; NURSE-PRACTITIONERS; CLINICAL PHARMACIST; QUALITY IMPROVEMENT; CASE-MANAGEMENT; PHYSICIAN; METAANALYSIS; PERFORMANCE; EVENTS	In health care settings, individuals from different disciplines come together to care for patients. Although these groups of health care personnel are generally called teams, they need to earn true team status by demonstrating teamwork. Developing health care teams requires attention to 2 central questions: who is on the team and how do team members work together? This article chiefly focuses on the second question. Cohesive health care teams have 5 key characteristics: clear goals with measurable outcomes, clinical and administrative systems, division of labor, training of all team members, and effective communication. Two organizations are described that demonstrate these components: a private primary care practice in Bangor, Me, and Kaiser Permanente's Georgia region primary care sites. Research on patient care teams suggests that teams with greater cohesiveness are associated with better clinical outcome measures and higher patient satisfaction. In addition, medical settings in which physicians and nonphysician professionals work together as teams can demonstrate improved patient outcomes. A number of barriers to team formation exist, chiefly related to the challenges of human relationships and personalities. Taking small steps toward team development may improve the work environment in primary care practices.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodie@earthlink.net	Grumbach, Kevin/L-9222-2016					Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; BALDWIN DC, 1994, ROLE INTERDISCIPLINA; BARR DA, 1995, ANN INTERN MED, V122, P353, DOI 10.7326/0003-4819-122-5-199503010-00006; BETTENHAUSEN KL, 1991, J MANAGE, V17, P345, DOI 10.1177/014920639101700205; Bogden PE, 1998, J GEN INTERN MED, V13, P740, DOI 10.1046/j.1525-1497.1998.00225.x; Brown SA, 1995, NURS RES, V44, P332; Campbell S. M., 2001, BMJ-BRIT MED J, V323, P1; Cannon-Bowers J.A., 1992, TEAMS THEIR TRAINING; Cohen SG, 1997, J MANAGE, V23, P239, DOI 10.1177/014920639702300303; DEANGELIS CD, 1994, JAMA-J AM MED ASSOC, V271, P868, DOI 10.1001/jama.271.11.868; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Flood AB, 1998, HEALTH SERV RES, V33, P79; FRIED BR, 2000, HLTH CARE MANAGEMENT; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; Goni S, 1999, HEALTH POLICY, V48, P107, DOI 10.1016/S0168-8510(99)00036-6; Grzybicki DM, 2002, AM J MANAG CARE, V8, P613; GULLY SM, 1995, SMALL GR RES, V26, P497, DOI 10.1177/1046496495264003; HALSTEAD LS, 1976, ARCH PHYS MED REHAB, V57, P507; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Hooker Roderick S, 2002, JAAPA, V15, P39; Hooker RS, 2002, JAAPA, V15, P45; Hooker RS, 2002, JAAPA-J AM ACAD PHYS, V15, P48; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; Institute of Medicine, 2001, CROSSING QUALITY CHA; Keely JL, 2002, ANN INTERN MED, V136, P79, DOI 10.7326/0003-4819-136-1-200201010-00014; LASHOF JC, 1968, B NEW YORK ACAD MED, V44, P1363; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Lencioni P., 2002, 5 DYSFUNCTIONS TEAM; Morrison I, 2000, BRIT MED J, V321, P1541, DOI 10.1136/bmj.321.7276.1541; ROBLIN DW, IN PRESS HLTH SERV R; ROBLIN DW, 2002, ANN M AC HLTH SERV R; RUBIN IM, 1972, MILBANK MEML FUND Q, V50, P317, DOI 10.2307/3349352; Scheffler R M, 1996, J Allied Health, V25, P207; SCHMITT MH, 1988, GERONTOLOGIST, V28, P753, DOI 10.1093/geront/28.6.753; Seashore S., 1954, GROUP COHESIVENESS I; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; Sommers LS, 2000, ARCH INTERN MED, V160, P1825, DOI 10.1001/archinte.160.12.1825; STARFIELD B, 1998, PRIMARY CARE; Stevenson K, 2001, FAM PRACT, V18, P21, DOI 10.1093/fampra/18.1.21; VANZWANENBERG TD, 1991, BRIT J GEN PRACT, V41, P31; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; VINOKURKAPLAN D, 1995, ADM POLICY MENT HLTH, V22, P521, DOI 10.1007/BF02106536; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Williams ES, 1999, MED CARE, V37, P1140, DOI 10.1097/00005650-199911000-00006; WISE H, 1972, ARCH INTERN MED, V130, P438, DOI 10.1001/archinte.130.3.438; WISE H, 1974, MAKING HLTH TEAMS WO	48	476	485	3	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1246	1251		10.1001/jama.291.10.1246	http://dx.doi.org/10.1001/jama.291.10.1246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800XV	15010447				2022-12-28	WOS:000220061900026
J	Holroyd-Leduc, JM; Straus, SE				Holroyd-Leduc, JM; Straus, SE			Management of urinary incontinence in women - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; HEALTH-CARE-SEEKING; OVERACTIVE BLADDER; HELP-SEEKING; TOLTERODINE; OXYBUTYNIN; SYMPTOMS; EFFICACY; OLDER; TOLERABILITY	Urinary incontinence, defined as involuntary loss of urine, is a common health problem among women. The prevalence rate is between 12% and 55% for having ever experienced urinary incontinence. It is associated with poor self-rated health, impaired quality of life, social isolation, and depressive symptoms. However, physicians are usually not the ones to initiate discussion about incontinence with their patients. We present clinical cases to illustrate common scenarios in which a physician may be able to help a female patient manage her urinary incontinence by specifically addressing associated factors and offering treatments to improve or possibly even cure her symptoms. Several evidence-based effective nonpharmacological, pharmacological, and surgical treatment options are outlined.	San Francisco Vet Affairs Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; Univ Toronto, Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Holroyd-Leduc, JM (corresponding author), SFVAMC 181G, 4150 Clement St,Bldg 1, San Francisco, CA 94121 USA.	Jayna.Holroyd-Leduc@med.va.gov; sstraus@mtsinai.on.ca						Abrams P, 2000, LANCET, V355, P2153; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Appell RA, 2001, MAYO CLIN PROC, V76, P358; BEZERRA CA, 2003, COCHRANE LIB; EUSTICE S, 2003, COCHRANE LIB; FANTL J, 1996, PUBLICATION US DEP H; Hannestad YS, 2002, SCAND J PRIM HEALTH, V20, P102, DOI 10.1080/713796408; HAYSMITH EJ, 2003, COCHRANE LIB; LAPITAN MC, 2003, COCHRANE LIB; Lee JG, 2002, INT J UROL, V9, P247, DOI 10.1046/j.1442-2042.2002.00460.x; Malone-Lee J, 2001, J UROLOGY, V165, P1452, DOI 10.1016/S0022-5347(05)66326-4; Norton PA, 2002, AM J OBSTET GYNECOL, V187, P40, DOI 10.1067/mob.2002.124840; Ricci JA, 2001, CLIN THER, V23, P1245, DOI 10.1016/S0149-2918(01)80104-1; Roberts RO, 1998, J AM GERIATR SOC, V46, P467, DOI 10.1111/j.1532-5415.1998.tb02468.x; Shaw C, 2001, FAM PRACT, V18, P48, DOI 10.1093/fampra/18.1.48; Stoddart H, 2001, BRIT J GEN PRACT, V51, P548; Wyman JF, 1998, AM J OBSTET GYNECOL, V179, P999, DOI 10.1016/S0002-9378(98)70206-6; Yamanishi T, 2000, UROLOGY, V55, P353, DOI 10.1016/S0090-4295(99)00476-8; Zinner NR, 2002, J AM GERIATR SOC, V50, P799, DOI 10.1046/j.1532-5415.2002.50203.x	19	28	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					996	999		10.1001/jama.291.8.996	http://dx.doi.org/10.1001/jama.291.8.996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982916	Bronze			2022-12-28	WOS:000189182000028
J	Altmann, SW; Davis, HR; Zhu, LJ; Yao, XR; Hoos, LM; Tetzloff, G; Iyer, SPN; Maguire, M; Golovko, A; Zeng, M; Wang, LQ; Murgolo, N; Graziano, MP				Altmann, SW; Davis, HR; Zhu, LJ; Yao, XR; Hoos, LM; Tetzloff, G; Iyer, SPN; Maguire, M; Golovko, A; Zeng, M; Wang, LQ; Murgolo, N; Graziano, MP			Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption	SCIENCE			English	Article							DIETARY-CHOLESTEROL; 2-AZETIDINONE CLASS; GENE; IDENTIFICATION; MICE; INHIBITORS; METABOLISM; HYPERCHOLESTEROLEMIA; GLYCOPROTEIN; ACCUMULATION	Dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol levels, a risk factor for coronary heart disease. The molecular mechanism of sterol uptake from the lumen of the small intestine is poorly defined. We show that Niemann-Pick C1 Like 1 (NPC1L1) protein plays a critical role in the absorption of intestinal cholesterol. NPC1L1 expression is enriched in the small intestine and is in the brush border membrane of enterocytes. Although otherwise phenotypically normal, NPC1L1-deficient mice exhibit a substantial reduction in absorbed cholesterol, which is unaffected by dietary supplementation of bile acids. Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout mice, suggesting that NPC1L1 resides in an ezetimibe-sensitive pathway responsible for intestinal cholesterol absorption.	Schering Plough Corp, Res Inst, Dept Cardiovasc Endocrine Res, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Discovery Technol, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Altmann, SW (corresponding author), Schering Plough Corp, Res Inst, Dept Cardiovasc Endocrine Res, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	scott.altmann@spcorp.com						Altmann SW, 2002, BBA-MOL CELL BIOL L, V1580, P77, DOI 10.1016/S1388-1981(01)00190-1; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BORGSTROM B, 1960, J CLIN INVEST, V39, P809, DOI 10.1172/JCI104100; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Burnett DA, 2002, BIOORG MED CHEM LETT, V12, P315, DOI 10.1016/S0960-894X(01)00752-1; Burnett DA, 2002, BIOORG MED CHEM LETT, V12, P311, DOI 10.1016/S0960-894X(01)00750-8; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; GLOVER J, 1958, BRIT MED BULL, V14, P226, DOI 10.1093/oxfordjournals.bmb.a069688; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosenblum SB, 1998, J MED CHEM, V41, P973, DOI 10.1021/jm970701f; Schoenheimer R, 1931, SCIENCE, V74, P579, DOI 10.1126/science.74.1928.579; Schulthess G, 1996, J LIPID RES, V37, P2405; Schwarz M, 1998, J LIPID RES, V39, P1833; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200	30	1273	1359	3	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1201	1204		10.1126/science.1093131	http://dx.doi.org/10.1126/science.1093131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976318				2022-12-28	WOS:000189074700049
J	Banerjee, RR; Rangwala, SM; Shapiro, JS; Rich, AS; Rhoades, B; Qi, Y; Wang, J; Rajala, MW; Pocai, A; Scherer, PE; Steppan, CM; Ahima, RS; Obici, S; Rossetti, L; Lazar, MA				Banerjee, RR; Rangwala, SM; Shapiro, JS; Rich, AS; Rhoades, B; Qi, Y; Wang, J; Rajala, MW; Pocai, A; Scherer, PE; Steppan, CM; Ahima, RS; Obici, S; Rossetti, L; Lazar, MA			Regulation of fasted blood glucose by resistin	SCIENCE			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; RECOMBINANT RESISTIN; ADIPOSE-TISSUE; EXPRESSION; GENE; OBESITY; ADIPOCYTE; INFLAMMATION; ASSOCIATION	The association between obesity and diabetes supports an endocrine role for the adipocyte in maintaining glucose homeostasis. Here we report that mice lacking the adipocyte hormone resistin exhibit low blood glucose levels after fasting, due to reduced hepatic glucose production. This is partly mediated by activation of adenosine monophosphate-activated protein kinase and decreased expression of gluconeogenic enzymes in the liver. The data thus support a physiological function for resistin in the maintenance of blood glucose during fasting. Remarkably, lack of resistin diminishes the increase in post-fast blood glucose normally associated with increased weight, suggesting a role for resistin in mediating hyperglycemia associated with obesity.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA; Albert Einstein Coll Med, Dept Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	University of Pennsylvania; University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Scherer, Philipp E/K-7819-2012; Ahima, Rexford/W-1394-2019; Lazar, Mitchell A/AAF-3738-2019; Banerjee, Ronadip/U-6649-2019	Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, P01DK049210, P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008216] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20541, P01 DK49210, P30 DK19525] Funding Source: Medline; NIGMS NIH HHS [NIH T32-GM008216] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Azuma K, 2003, OBES RES, V11, P997, DOI 10.1038/oby.2003.137; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Hartman HB, 2002, J BIOL CHEM, V277, P19754, DOI 10.1074/jbc.M201451200; Haugen F, 2001, FEBS LETT, V507, P105, DOI 10.1016/S0014-5793(01)02968-4; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Hotamisligil GS, 2003, J CLIN INVEST, V111, P173, DOI 10.1172/JCI200317605; Iglesias MA, 2002, DIABETES, V51, P2886, DOI 10.2337/diabetes.51.10.2886; Juan CC, 2003, J BIOTECHNOL, V103, P113, DOI 10.1016/S0168-1656(03)00099-3; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Pizzuti A, 2002, J CLIN ENDOCR METAB, V87, P4403, DOI 10.1210/jc.2002-020096; Pravenec M, 2003, J BIOL CHEM, V278, P45209, DOI 10.1074/jbc.M304869200; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Shojima N, 2002, DIABETES, V51, P1737, DOI 10.2337/diabetes.51.6.1737; Smith SR, 2003, DIABETES, V52, P1611, DOI 10.2337/diabetes.52.7.1611; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tan MS, 2003, J CLIN ENDOCR METAB, V88, P1258, DOI 10.1210/jc.2002-021453; Wang H, 2002, J CLIN ENDOCR METAB, V87, P2520, DOI 10.1210/jc.87.6.2520; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	38	563	604	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1195	1198		10.1126/science.1092341	http://dx.doi.org/10.1126/science.1092341			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976316				2022-12-28	WOS:000189074700047
J	Paltiel, O; Friedlander, Y; Tiram, EA; Barchana, M; Xue, XN; Harlap, S				Paltiel, O; Friedlander, Y; Tiram, EA; Barchana, M; Xue, XN; Harlap, S			Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MICROSOMAL EPOXIDE HYDROLASE; BREAST-CANCER; RISK; PREGNANCY; POLYMORPHISM; MUTATION	Objective To compare the incidence of cancer among women with and without a history of pre-eclampsia. Design Cohort Study. Setting Jerusalem perinatal Study of women who delivered in three large hospitals in West Jerusalem during 1964-76. Participants 37 033 women. Main outcome measures Age adjusted and multivariable adjusted hazard ratios for cancer incidence for the entire cohort and for women who were primiparous at study entry. Results Cancer developed in 91 women who had pre-eclampsia and 2204 who did not (hazard ratio 1.27, 95% confidence interval 1.03 to 1.57). The risk of site specific cancers was increased, particularly of the stomach, ovary epithelium, breast, and lung or larynx. The incidence of cancer of the stomach, breast, ovary kidney. and lung or larynx was increased in primiparous women at study entry who had a history of pre-eclampsia. Conclusions A history of pre-eclampsia is associated with increases in overall risk of cancer and incidence at several sites. This may be explained by environmental and genetic factors common to the development of pre-eclampsia and cancer in this population.	Hadassah Hebrew Univ, Braun Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel; Minist Hlth, Israel Canc Registry, IL-91010 Jerusalem, Israel; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA	Hebrew University of Jerusalem; Hadassah University Medical Center; Yeshiva University; Albert Einstein College of Medicine; Columbia University	Paltiel, O (corresponding author), Hadassah Hebrew Univ, Braun Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel.	ora@vms.huji.ac.il			NCI NIH HHS [R01 CA80197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chikosi AB, 1999, BRIT J OBSTET GYNAEC, V106, P1219, DOI 10.1111/j.1471-0528.1999.tb08152.x; Cohn BA, 2001, J NATL CANCER I, V93, P1133, DOI 10.1093/jnci/93.15.1133; DAVIES AM, 1969, ISRAEL J MED SCI, V5, P1095; Higgins JR, 2001, LANCET, V357, P131, DOI 10.1016/S0140-6736(00)03552-2; Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013; Irgens HU, 2001, BRIT MED J, V323, P1213, DOI 10.1136/bmj.323.7323.1213; *ISR CTR DIS CONTR, 2003, PUBL ISR CTR DIS CON, V230, P31; *ISR CTR DIS CONTR, 2000, PUBL ISR CTR DIS CON, V230, P31; Mogren I, 2001, ACTA ONCOL, V40, P849; Odegard RA, 2000, BRIT J OBSTET GYNAEC, V107, P1410, DOI 10.1111/j.1471-0528.2000.tb11657.x; Park JY, 2003, ORAL ONCOL, V39, P483, DOI 10.1016/S1368-8375(03)00008-3; Peleg L, 2002, ISRAEL MED ASSOC J, V4, P95; POLEDNAK AP, 1983, J REPROD MED, V28, P314; Pridjian G, 2002, OBSTET GYNECOL SURV, V57, P619, DOI 10.1097/00006254-200209000-00024; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Sherer DM, 2001, PLACENTA, V22, P1, DOI 10.1053/plac.2000.0588; STEINITZ R, SCI PUBLICATION WHO, V98; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tamimi R, 2003, CANCER EPIDEM BIOMAR, V12, P647; THOMPSON WD, 1989, JNCI-J NATL CANCER I, V81, P1571, DOI 10.1093/jnci/81.20.1571; Troisi R, 1998, EPIDEMIOLOGY, V9, P641, DOI 10.1097/00001648-199811000-00014; Troisi R, 2003, INT J EPIDEMIOL, V32, P455, DOI 10.1093/ije/dyg094; Vatten LJ, 2002, BRIT J CANCER, V87, P971, DOI 10.1038/sj.bjc.6600581; Zhao H, 2002, MOL CARCINOGEN, V33, P99, DOI 10.1002/mc.10023; Zusterzeel PLM, 2001, J MED GENET, V38, P234, DOI 10.1136/jmg.38.4.234	25	32	32	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					919	+		10.1136/bmj.38032.820451.7C	http://dx.doi.org/10.1136/bmj.38032.820451.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	15003975	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220994400015
J	Cox, D; Meyers, E; Sinha, P				Cox, D; Meyers, E; Sinha, P			Contextually evoked object-specific responses in human visual cortex	SCIENCE			English	Article							HUMAN EXTRASTRIATE CORTEX; FUSIFORM FACE AREA; NATURAL IMAGES; CORTICAL-CELLS; PERCEPTION; NEURONS; RECOGNITION; BRAIN; IDENTIFICATION; ATTENTION	Human visual recognition processes are remarkably robust and can function effectively even under highly degraded viewing conditions. Contextual information may play a critical role in such circumstances. Here, we provide neurophysiological evidence that contextual cues can elicit object-specific neural responses, which have hitherto been believed to be based on intrinsic cues alone. Specifically, we find that the "fusiform face area" (FFA) maintains its selectivity for faces without regard to whether the faces are defined intrinsically or contextually. This finding further elucidates the role of the FFA and reveals neural correlates of contextual processing in the service of robust object recognition.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sinha, P (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	psinha@mit.edu	Cox, David/C-4888-2008	Cox, David/0000-0002-2189-9743				Baddeley R, 1997, P ROY SOC B-BIOL SCI, V264, P1775, DOI 10.1098/rspb.1997.0246; Baddeley R, 1996, NATURE, V381, P560, DOI 10.1038/381560a0; Bar M, 2003, NEURON, V38, P347, DOI 10.1016/S0896-6273(03)00167-3; Bar M, 1996, PERCEPTION, V25, P343, DOI 10.1068/p250343; Barlow H, 2001, BEHAV BRAIN SCI, V24, P602, DOI 10.1017/S0140525X01000024; Barlow H. B., 1961, CURRENT PROBLEMS ANI, P330; Barton JJS, 2002, NEUROLOGY, V58, P71, DOI 10.1212/WNL.58.1.71; BIEDERMAN I, 1982, COGNITIVE PSYCHOL, V14, P143, DOI 10.1016/0010-0285(82)90007-X; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Dolan RJ, 1997, NATURE, V389, P596, DOI 10.1038/39309; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Ganis G, 2003, COGNITIVE BRAIN RES, V16, P123, DOI 10.1016/S0926-6410(02)00244-6; Grill-Spector K, 2001, VISION RES, V41, P1409, DOI 10.1016/S0042-6989(01)00073-6; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; Kanwisher N, 1999, NEUROREPORT, V10, P183, DOI 10.1097/00001756-199901180-00035; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KERSTEN D, 1987, J OPT SOC AM A, V4, P2395, DOI 10.1364/JOSAA.4.002395; O'Craven KM, 2000, J COGNITIVE NEUROSCI, V12, P1013, DOI 10.1162/08989290051137549; PALMER SE, 1975, MEM COGNITION, V3, P519, DOI 10.3758/BF03197524; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; Puce A, 1996, J NEUROSCI, V16, P5205; Rolls ET, 2000, NEURON, V27, P205, DOI 10.1016/S0896-6273(00)00030-1; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Wallis G, 1999, TRENDS COGN SCI, V3, P22, DOI 10.1016/S1364-6613(98)01261-3; WEBBER CJS, 1991, NETWORK-COMP NEURAL, V2, P169, DOI 10.1088/0954-898X/2/2/003; Wojciulik E, 1998, J NEUROPHYSIOL, V79, P1574, DOI 10.1152/jn.1998.79.3.1574	29	127	131	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					115	117		10.1126/science.1093110	http://dx.doi.org/10.1126/science.1093110			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15001712				2022-12-28	WOS:000220567900050
J	Coleman, T				Coleman, T			ABC of smoking cessation - Cessation interventions in routine health care	BRITISH MEDICAL JOURNAL			English	Review									Univ Nottingham Hosp, Queens Med Ctr, Div Primary Care, Sch Community Hlth Sci, Nottingham NG7 2UH, England	University of Nottingham	Coleman, T (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Div Primary Care, Sch Community Hlth Sci, Nottingham NG7 2UH, England.			Coleman, Tim/0000-0002-7303-4805				Butler CC, 1998, BMJ-BRIT MED J, V316, P1878; Coleman T, 2000, BRIT J GEN PRACT, V50, P207; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987	4	12	12	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 13	2004	328	7440					631	633		10.1136/bmj.328.7440.631	http://dx.doi.org/10.1136/bmj.328.7440.631			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016697	Green Published			2022-12-28	WOS:000220208100023
J	Alatalo, RV; Aragon, S; Aviles, JM; Barbosa, A; Gomes, CB; Cadee, N; Christe, P; Cuervo, JJ; Diaz, M; Erritzoe, J; Galeotti, P; Garamszegi, LZ; Gil, D; Gontard-Danek, M; Legendre, S; Martin, TE; Martinez, J; Martin-Vivaldi, M; Martinez, JG; Merino, S; Moreno, J; Mousseau, T; Ninni, P; Petrie, M; Pulido, F; Rubolini, D; Saino, N; Soler, JJ; Soler, M; Spottiswoode, C; Szep, T; Thornhill, R; Zamora, C; Sacchi, R				Alatalo, RV; Aragon, S; Aviles, JM; Barbosa, A; Gomes, CB; Cadee, N; Christe, P; Cuervo, JJ; Diaz, M; Erritzoe, J; Galeotti, P; Garamszegi, LZ; Gil, D; Gontard-Danek, M; Legendre, S; Martin, TE; Martinez, J; Martin-Vivaldi, M; Martinez, JG; Merino, S; Moreno, J; Mousseau, T; Ninni, P; Petrie, M; Pulido, F; Rubolini, D; Saino, N; Soler, JJ; Soler, M; Spottiswoode, C; Szep, T; Thornhill, R; Zamora, C; Sacchi, R			Support for a colleague	SCIENCE			English	Letter									Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla 40500, Finland; Univ Paris 06, Mol Endocrinol Lab, F-75252 Paris 05, France; CSIC, Dept Ecol Func & Evolut, Estac Expt Zonas Aridas, E-04001 Almeria, Spain; Univ Paris 06, CNRS, UMR 7103, Lab Parasitol Evolut, F-75252 Paris 05, France; Univ Lausanne, Inst Ecol, Lab Zool & Anim Ecol, CH-1015 Lausanne, Switzerland; Univ Castilla La Mancha, Fac Ciencias Med Ambiente, Dept Ciencias Ambientales, E-45071 Toledo, Spain; Taps Old Rectory, DK-6070 Christiansfeld, Denmark; Univ Pavia, Dipartimento Biol Anim, Lab Ecoetol, I-27100 Pavia, Italy; Univ Instelling Antwerp, Dept Biol, B-2610 Antwerp, Belgium; CSIC, Museo Nacl Ciencias Nat, Dept Ecol Evolut, E-28006 Madrid, Spain; Ecole Normale Super, Lab Ecol Ecoevolutionary Team, F-75230 Paris 05, France; Univ Montana, US Geol Survey, Biol Resources Div,Avian Studies Program, Montana Cooperat Wildlife Res Unit, Missoula, MT 59812 USA; Univ Alcala de Henares, Fac Farm, Dept Microbiol & Parasitol, Alcala De Henares 28871, Spain; Univ Granada, Fac Ciencias, Dept Biol Anim & Ecol, E-18071 Granada, Spain; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; Newcastle Univ, Dept Psychol, Evolut & Behav Res Grp, Newcastle Upon Tyne NE1 4HH, Tyne & Wear, England; Univ Extremadura, Grp Invest Forestal, Dept Biol & Prod Vegetales, EIT Forestal, Plasencia 10600, Caceres, Spain; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Coll Nyiregyhaza, Dept Environm Sci, H-4401 Nyiregyhaza, Hungary; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	University of Jyvaskyla; UDICE-French Research Universities; Sorbonne Universite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Zonas Aridas (EEZA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Lausanne; Universidad de Castilla-La Mancha; University of Pavia; University of Antwerp; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); United States Department of the Interior; United States Geological Survey; University of Montana System; University of Montana; Universidad de Alcala; University of Granada; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Newcastle University - UK; Universidad de Extremadura; University of Milan; University of Cambridge; University of New Mexico	Alatalo, RV (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, Survontie 9, Jyvaskyla 40500, Finland.		Martinez, Javier/H-2827-2015; Pulido, Fernando/A-2031-2009; Cuervo, José Javier/K-1646-2014; Zamora-Muñoz, Carmen/K-7050-2014; Martinez, Juan/GXM-4393-2022; Barbosa, Andrés/C-3208-2008; Avilés, Jesús/K-3332-2014; Rubolini, Diego/F-2851-2011; Garamszegi, Laszlo/M-1488-2015; Garamszegi, Laszlo Z/B-5089-2011; Mousseau, Timothy A/A-1253-2011; Martínez, Juan Gabriel/L-9471-2014; Soler, J. J./H-2363-2011; Merino, Santiago/A-6183-2008; Christe, Philippe/X-4493-2018	Martinez, Javier/0000-0003-2657-1154; Cuervo, José Javier/0000-0001-7943-7835; Zamora-Muñoz, Carmen/0000-0002-3037-1529; Barbosa, Andrés/0000-0001-8434-3649; Avilés, Jesús/0000-0002-1463-8393; Rubolini, Diego/0000-0003-2703-5783; Garamszegi, Laszlo/0000-0001-8920-2183; Martínez, Juan Gabriel/0000-0001-5277-4620; Soler, J. J./0000-0003-2990-1489; Merino, Santiago/0000-0003-0603-8280; Christe, Philippe/0000-0002-8605-7002; Moreno, Juan/0000-0003-1508-7295; Pulido, Fernando/0000-0001-5620-1918; Mousseau, Timothy/0000-0002-2235-4868					0	0	0	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1612	1612						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016981				2022-12-28	WOS:000220151400019
J	Durham, PL				Durham, PL			CGRP-Receptor antagonists - A fresh approach to migraine therapy?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									SW Missouri State Univ, Dept Biol, Springfield, MO 65804 USA	Missouri State University	Durham, PL (corresponding author), SW Missouri State Univ, Dept Biol, Springfield, MO 65804 USA.								0	74	94	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1073	1075		10.1056/NEJMp048016	http://dx.doi.org/10.1056/NEJMp048016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014178				2022-12-28	WOS:000220110100002
J	Turai, I; Veress, K; Gunalp, B; Souchkevitch, G				Turai, I; Veress, K; Gunalp, B; Souchkevitch, G			Medical response to radiation incidents and radionuclear threats	BRITISH MEDICAL JOURNAL			English	Review							NUCLEAR TERRORISM		WHO, Dept Protect Human Environm, CH-1211 Geneva 27, Switzerland; Semmelweis Univ, Dept Publ Hlth, Budapest, Hungary; Gulhane Med Acad, Dept Nucl Med, Ankara, Turkey; Inst Pathol & Pathophysiol, Moscow, Russia	World Health Organization; Semmelweis University; Gulhane Military Medical Academy; Russian Academy of Medical Sciences; Institute of General Pathology & Pathophysiology, RAMS	Turai, I (corresponding author), WHO, Dept Protect Human Environm, CH-1211 Geneva 27, Switzerland.	Turaii@who.int						COSSET JM, 2002, HLTH CONSEQUENCES LI, P49; GONZALEZ AJ, 2002, HLTH PHYSICS SOC NEW, V30, P3; Gower-Thomas K, 2002, BRIT MED J, V324, P919; Helfand I, 2002, BRIT MED J, V324, P356, DOI 10.1136/bmj.324.7333.356; Hogan DE, 2002, AM J MED SCI, V323, P341, DOI 10.1097/00000441-200206000-00006; *IAEA, 1996, ASS TREATM EXT INT R, P62; *IAEA WHO, 2000, RECN IN RESP ACC RAD; *IAEA WHO, 1998, IAEA SAF REP SER, V2, P49; *IAEA WHO, 2002, FOLL DEL HLTH CONS A, P129; Kilpatrick Joseph J, 2002, RN, V65, P46; Leikin JB, 2003, DM-DIS MON, V49, P485, DOI 10.1016/S0011-5029(03)00100-7; Meineke V, 2003, MIL MED, V168, P219, DOI 10.1093/milmed/168.3.219; Mettler FA, 2002, NEW ENGL J MED, V346, P1554, DOI 10.1056/NEJMra000365; RICKS R, 2001, REAC TS REGISTRY RAD; SOUCHKEVITCH G, 2002, RAD EMERGENCY RESPON, P27; Timins Julie K, 2003, N J Med, V100, P14; Turai I., 2001, Radioprotection, V36, P459, DOI 10.1051/radiopro:2001104; Turai I, 2002, NEW ENGL J MED, V347, P946; TURAI I, 1993, NEPEGESZSEGUGY, V74, P203; Turai I., 2001, CENTRAL EURO J OCCUP, V7, P3; TURAI I, 2002, BR J RADIOL S, V26, pS80; Yehezkelli Y, 2002, ISRAEL MED ASSOC J, V4, P530; ZAHARIA M, 2002, 1300 IAEA, P57	23	27	31	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2004	328	7439					568	572		10.1136/bmj.328.7439.568	http://dx.doi.org/10.1136/bmj.328.7439.568			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	15001507	Green Published			2022-12-28	WOS:000220091800026
J	Begun, DR				Begun, DR			The earliest hominins - Is less more?	SCIENCE			English	Editorial Material							MIDDLE AWASH; MIOCENE; ARAMIS		Univ Toronto, Dept Anthropol, Toronto, ON M5S 3G3, Canada	University of Toronto	Begun, DR (corresponding author), Univ Toronto, Dept Anthropol, Toronto, ON M5S 3G3, Canada.	begun@chass.utoronto.ca						Begun DR, 2001, HOM EVOLUT CLIMAT CH, V2, P231; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Haile-Selassie Y, 2004, SCIENCE, V303, P1503, DOI 10.1126/science.1092978; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; LOVEJOY CO, 1981, SCIENCE, V211, P341, DOI 10.1126/science.211.4480.341; Pickford M, 2002, C R PALEVOL, V1, P191, DOI 10.1016/S1631-0683(02)00028-3; Plavcan JM, 2001, ADV PRIMATO, P297; ROSE MD, 1986, J HUM EVOL, V15, P333, DOI 10.1016/S0047-2484(86)80016-1; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WoldeGabriel G, 2001, NATURE, V412, P175, DOI 10.1038/35084058; Wolpoff MH, 2002, NATURE, V419, P581, DOI 10.1038/419581a	13	14	15	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1478	1480		10.1126/science.1095516	http://dx.doi.org/10.1126/science.1095516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001766				2022-12-28	WOS:000220000100028
J	Gillespie, SH				Gillespie, SH			New tricks from an old dog: streptococcal necrotising soft-tissue infections	LANCET			English	Editorial Material							GROUP-A STREPTOCOCCUS; M-PROTEIN; BINDING; VIRULENCE; PYOGENES		UCL, London NW3 2PF, England	University of London; University College London	Gillespie, SH (corresponding author), UCL, Royal Free Campus, London NW3 2PF, England.	stepheng@rfc.ucl.ac.uk						Berggard K, 2001, MOL MICROBIOL, V42, P539, DOI 10.1046/j.1365-2958.2001.02664.x; Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; Collin M, 2003, INFECT IMMUN, V71, P2983, DOI 10.1128/IAI.71.6.2983-2992.2003; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; Martin B, 2000, MOL MICROBIOL, V38, P867, DOI 10.1046/j.1365-2958.2000.02187.x; Moses AE, 1997, INFECT IMMUN, V65, P64, DOI 10.1128/IAI.65.1.64-71.1997; Neeman R, 1998, LANCET, V352, P1974, DOI 10.1016/S0140-6736(97)12452-7; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Perez-Caballero D, 2000, EUR J IMMUNOL, V30, P1243, DOI 10.1002/(SICI)1521-4141(200004)30:4<1243::AID-IMMU1243>3.0.CO;2-D	13	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					672	673		10.1016/S0140-6736(04)15662-6	http://dx.doi.org/10.1016/S0140-6736(04)15662-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001321				2022-12-28	WOS:000189266900004
J	Koren, I; Kaufman, YJ; Remer, LA; Martins, JV				Koren, I; Kaufman, YJ; Remer, LA; Martins, JV			Measurement of the effect of Amazon smoke on inhibition of cloud formation	SCIENCE			English	Article							AEROSOLS; CLIMATE; MICROPHYSICS; ATMOSPHERE; POLLUTION; ALBEDO	Urban air pollution and smoke from. res have been modeled to reduce cloud formation by absorbing sunlight, thereby cooling the surface and heating the atmosphere. Satellite data over the Amazon region during the biomass burning season showed that scattered cumulus cloud cover was reduced from 38% in clean conditions to 0% for heavy smoke ( optical depth of 1.3). This response to the smoke radiative effect reverses the regional smoke instantaneous forcing of climate from - 28 watts per square meter in cloud-free conditions to +8 watts per square meter once the reduction of cloud cover is accounted for.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CNR, Washington, DC 20001 USA; Univ Maryland, Joint Ctr Earth Syst Technol, Baltimore, MD 21250 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland Baltimore; University of Maryland Baltimore County	Koren, I (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.	ilank@climate.gsfc.nasa.gov	Koren, Ilan/K-1417-2012	Koren, Ilan/0000-0001-6759-6265				Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; Alpert P, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013554; CHOU MD, 1991, J CLIMATE, V4, P424, DOI 10.1175/1520-0442(1991)004<0424:IRPINC>2.0.CO;2; CHOU MD, 1992, J ATMOS SCI, V49, P762, DOI 10.1175/1520-0469(1992)049<0762:ASRMFU>2.0.CO;2; Cohan DS, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001441; Dubovik O, 2002, J ATMOS SCI, V59, P590, DOI 10.1175/1520-0469(2002)059<0590:VOAAOP>2.0.CO;2; Eck TF, 1998, J GEOPHYS RES-ATMOS, V103, P31865, DOI 10.1029/98JD00399; Feingold G, 2001, J GEOPHYS RES-ATMOS, V106, P22907, DOI 10.1029/2001JD000732; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; Heymsfield AJ, 2001, J GEOPHYS RES-ATMOS, V106, P28653, DOI 10.1029/2000JD900776; Hobbs PV, 1997, SCIENCE, V275, P1776, DOI [10.1126/science.278.5344.1776, 10.1126/science.275.5307.1777]; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jacobson MZ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD002044; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kaufman YJ, 2002, NATURE, V419, P215, DOI 10.1038/nature01091; Kaufman YJ, 1997, J GEOPHYS RES-ATMOS, V102, P17051, DOI 10.1029/96JD03988; Lelieveld J, 2002, SCIENCE, V298, P794, DOI 10.1126/science.1075457; MARTINS JV, 2002, GEOPHYS RES LETT, V29, P8009, DOI DOI 10.1029/2001GL013252; Menon S, 2002, SCIENCE, V297, P2250, DOI 10.1126/science.1075159; NOBRE CA, 1988, J GEOPHYS RES, V103, P31809; PENNER JE, 1992, SCIENCE, V256, P1432, DOI 10.1126/science.256.5062.1432; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rudich Y, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003472; Salati E, 1987, FOREST HYDROLOGICAL, P273; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Yu HB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000754	29	486	504	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1342	1345		10.1126/science.1089424	http://dx.doi.org/10.1126/science.1089424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988557				2022-12-28	WOS:000189238600043
J	Ahluwalia, J; Tinker, A; Clapp, LH; Duchen, MR; Abramov, AY; Pope, S; Nobles, M; Segal, AW				Ahluwalia, J; Tinker, A; Clapp, LH; Duchen, MR; Abramov, AY; Pope, S; Nobles, M; Segal, AW			RETRACTED: The large-conductance Ca2+-activated K+ channel is essential for innate immunity (Retracted article. See vol. 468, 2010)	NATURE			English	Article; Retracted Publication							ACTIVATED POTASSIUM CHANNEL; NADPH OXIDASE; HUMAN-NEUTROPHILS; ELECTRON CURRENTS; RESPIRATORY BURST; HUMAN EOSINOPHILS; PHORBOL ESTER; PH CHANGES; CALCIUM; PHAGOCYTES	Neutrophil leukocytes have a pivotal function in innate immunity. Dogma dictates that the lethal blow is delivered to microbes by reactive oxygen species (ROS) and halogens(1,2), products of the NADPH oxidase, whose impairment causes immunodeficiency. However, recent evidence indicates that the microbes might be killed by proteases, activated by the oxidase through the generation of a hypertonic, K+-rich and alkaline environment in the phagocytic vacuole(3). Here we show that K+ crosses the membrane through large-conductance Ca2+-activated K+ (BKCa) channels. Specific inhibitors of these channels, iberiotoxin and paxilline, blocked oxidase-induced Rb-86(+) fluxes and alkalinization of the phagocytic vacuole, whereas NS1619, a BKCa channel opener, enhanced both. Characteristic outwardly rectifying K+ currents, reversibly inhibited by iberiotoxin, were demonstrated in neutrophils and eosinophils and the expression of the alpha-subunit of the BK channel was confirmed by western blotting. The channels were opened by the combination of membrane depolarization and elevated Ca2+ concentration, both consequences of oxidase activity. Remarkably, microbial killing and digestion were abolished when the BKCa channel was blocked, revealing an essential and unexpected function for this K+ channel in the microbicidal process.	UCL, Dept Med, London WC1E 6BT, England; UCL, Dept Physiol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Segal, AW (corresponding author), UCL, Dept Med, Gower St, London WC1E 6BT, England.	t.segal@ucl.ac.uk	Clapp, Lucie/B-1088-2008; duchen, michael/A-2116-2009; Abramov, Andrey Y/H-9053-2012; Clapp, Lucie/L-4199-2019; Abramov, Andrey/AAC-6712-2019	Clapp, Lucie/0000-0001-7802-4481; duchen, michael/0000-0003-2548-4294; Abramov, Andrey Y/0000-0002-7646-7235; Clapp, Lucie/0000-0001-7802-4481; Abramov, Andrey/0000-0002-7646-7235; Segal, Anthony/0000-0001-7602-9043; Pope, Simon Alexander Samuel/0000-0002-2991-3722	Wellcome Trust [067287] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Cherny VV, 2001, J PHYSIOL-LONDON, V535, P783, DOI 10.1111/j.1469-7793.2001.00783.x; Clapp LH, 1998, CURR OPIN NEPHROL HY, V7, P91; Da Silva-Santos JE, 2002, J PHARMACOL EXP THER, V300, P946, DOI 10.1124/jpet.300.3.946; DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; Lawson K, 2000, KIDNEY INT, V57, P838, DOI 10.1046/j.1523-1755.2000.00923.x; Mahomed AG, 2000, INFLAMMATION, V24, P559, DOI 10.1023/A:1007029524141; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Salvemini D, 2002, NAT REV DRUG DISCOV, V1, P367, DOI 10.1038/nrd796; Sanchez M, 1996, NEUROPHARMACOLOGY, V35, P963, DOI 10.1016/0028-3908(96)00137-2; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Willoughby D, 2001, J PHYSIOL-LONDON, V530, P405, DOI 10.1111/j.1469-7793.2001.0405k.x	30	157	166	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					853	858		10.1038/nature02356	http://dx.doi.org/10.1038/nature02356			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985765	Green Accepted			2022-12-28	WOS:000189207500043
J	Almaas, E; Kovacs, B; Vicsek, T; Oltvai, ZN; Barabasi, AL				Almaas, E; Kovacs, B; Vicsek, T; Oltvai, ZN; Barabasi, AL			Global organization of metabolic fluxes in the bacterium Escherichia coli	NATURE			English	Article							DEFINITION	Cellular metabolism, the integrated interconversion of thousands of metabolic substrates through enzyme-catalysed biochemical reactions, is the most investigated complex intracellular web of molecular interactions. Although the topological organization of individual reactions into metabolic networks is well understood(1-4), the principles that govern their global functional use under different growth conditions raise many unanswered questions(5-7). By implementing a flux balance analysis(8-12) of the metabolism of Escherichia coli strain MG1655, here we show that network use is highly uneven. Whereas most metabolic reactions have low fluxes, the overall activity of the metabolism is dominated by several reactions with very high fluxes. E. coli responds to changes in growth conditions by reorganizing the rates of selected fluxes predominantly within this high-flux backbone. This behaviour probably represents a universal feature of metabolic activity in all cells, with potential implications for metabolic engineering.	Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Eotvos Lorand Univ, Biol Phys Dept, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Res Grp HAS, H-1117 Budapest, Hungary; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	University of Notre Dame; Eotvos Lorand University; Eotvos Lorand University; Northwestern University	Barabasi, AL (corresponding author), Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA.	alb@nd.edu	Vicsek, Tamas/A-3305-2009; Barabasi, Albert-Laszlo/S-6474-2017	Barabasi, Albert/0000-0002-4028-3522; Almaas, Eivind/0000-0002-9125-326X				Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barthelemy M, 2003, PHYSICA A, V319, P633, DOI 10.1016/S0378-4371(02)01382-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Canonaco F, 2001, FEMS MICROBIOL LETT, V204, P247, DOI 10.1111/j.1574-6968.2001.tb10892.x; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2002, BIOTECHNOL BIOENG, V77, P27, DOI 10.1002/bit.10047; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Goh KI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.278701; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Heinrich R., 1996, REGULATION CELLULAR; Holme P, 2003, BIOINFORMATICS, V19, P532, DOI 10.1093/bioinformatics/btg033; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Lovasz L, 1999, MATH PROGRAM, V86, P443, DOI 10.1007/s101070050099; Ma HW, 2003, BIOINFORMATICS, V19, P1423, DOI 10.1093/bioinformatics/btg177; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; SMITH RL, 1984, OPER RES, V32, P1296, DOI 10.1287/opre.32.6.1296; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Wolf DM, 2003, CURR OPIN MICROBIOL, V6, P125, DOI 10.1016/S1369-5274(03)00033-X	29	496	527	5	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					839	843		10.1038/nature02289	http://dx.doi.org/10.1038/nature02289			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985762	Green Submitted			2022-12-28	WOS:000189207500040
J	Misbah, SA; Aslam, A; Costello, C				Misbah, SA; Aslam, A; Costello, C			Whipple's disease	LANCET			English	Editorial Material							TROPHERYMA-WHIPPLEI; BACILLUS		John Radcliffe Hosp, Dept Clin Immunol, Oxford OX3 9DU, England; Chelsea & Westminster Hosp, Dept Haematol, London, England	University of Oxford; Imperial College London	Misbah, SA (corresponding author), John Radcliffe Hosp, Dept Clin Immunol, Level 7, Oxford OX3 9DU, England.	Siraj.misbah@orh.nhs.uk						Bentley SD, 2003, LANCET, V361, P637, DOI 10.1016/S0140-6736(03)12597-4; CORNER GW, 1963, GH WHIPPLE HIS FRIEN, P45; Dumler JS, 2003, NEW ENGL J MED, V348, P1411, DOI 10.1056/NEJM200304033481425; Marth T, 2003, LANCET, V361, P239, DOI 10.1016/S0140-6736(03)12274-X; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; Misbah SA, 2000, J CLIN PATHOL, V53, P750, DOI 10.1136/jcp.53.10.750; Misbah SA, 1997, QJM-MON J ASSOC PHYS, V90, P765; NUZUM CT, 1981, GASTROENTEROLOGY, V80, P1465; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; Raoult D, 2000, NEW ENGL J MED, V342, P620, DOI 10.1056/NEJM200003023420903; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schneider T, 1998, ANN INTERN MED, V129, P875, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00006; Street S, 1999, LANCET, V354, P1178, DOI 10.1016/S0140-6736(99)03065-2; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	14	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					654	656		10.1016/S0140-6736(04)15600-6	http://dx.doi.org/10.1016/S0140-6736(04)15600-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987893				2022-12-28	WOS:000189104900026
J	Baptiste, N; Prives, C				Baptiste, N; Prives, C			p53 in the cytoplasm: A question of overkill?	CELL			English	Editorial Material							APOPTOSIS	The tumor suppressor p53 regulates cellular responses to stress by serving in the nucleus to regulate transcription of genes involved in processes including cell cycle arrest, DNA repair, and apoptosis. Nevertheless, recent papers show that p53 may have a separate cytoplasmic role in directly regulating the Bax-dependent mitochondrial pathway to cell death.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Baptiste, N (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.							Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHIPUK JE, 2004, IN PRESS SCIENCE; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	10	42	45	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	2004	116	4					487	489		10.1016/S0092-8674(04)00164-3	http://dx.doi.org/10.1016/S0092-8674(04)00164-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980216	Bronze			2022-12-28	WOS:000189184200003
J	Faller, M; Niederweis, M; Schulz, GE				Faller, M; Niederweis, M; Schulz, GE			The structure of a mycobacterial outer-membrane channel	SCIENCE			English	Article							CELL-WALL; RHODOBACTER-CAPSULATUS; MYCOLIC ACIDS; PORIN; SMEGMATIS; ENVELOPE; PROTEIN; MSPA; ORGANIZATION; TUBERCULOSIS	Mycobacteria have low-permeability outer membranes that render them resistant to most antibiotics. Hydrophilic nutrients can enter by way of transmembrane-channel proteins called porins. An x-ray analysis of the main porin from Mycobacterium smegmatis, MspA, revealed a homooctameric goblet-like conformation with a single central channel. This is the first structure of a mycobacterial outermembrane protein. No structure-related protein was found in the Protein Data Bank. MspA contains two consecutive beta barrels with nonpolar outer surfaces that form a ribbon around the porin, which is too narrow to fit the thickness of the mycobacterial outer membrane in contemporary models.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	University of Freiburg; University of Erlangen Nuremberg	Schulz, GE (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	schulz@bio.chemie.uni-freiburg.de						Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BLEED D, 2001, GLOBAL TUBERCULOSIS; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dmitriev BA, 2000, INT J MED MICROBIOL, V290, P251; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; Fu LM, 2002, TUBERCULOSIS, V82, P85, DOI 10.1054/tube.2002.0328; Heinz C, 2003, J CHROMATOGR B, V790, P337, DOI 10.1016/S1570-0232(03)00130-2; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kartmann B, 1999, J BACTERIOL, V181, P6543, DOI 10.1128/JB.181.20.6543-6546.1999; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Lambert PA, 2002, J APPL MICROBIOL, V92, p46S, DOI 10.1046/j.1365-2672.92.5s1.7.x; Lichtinger T, 1999, FEBS LETT, V454, P349, DOI 10.1016/S0014-5793(99)00844-3; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Meyer JEW, 1997, PROTEIN SCI, V6, P1084, DOI 10.1002/pro.5560060515; MINNIKIN DE, 1991, RES MICROBIOL, V142, P423, DOI 10.1016/0923-2508(91)90114-p; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PAUL TR, 1992, J BACTERIOL, V174, P6508, DOI 10.1128/JB.174.20.6508-6517.1992; PITULLE C, 1992, INT J SYST BACTERIOL, V42, P337, DOI 10.1099/00207713-42-3-337; Rastogi N, 2001, REV SCI TECH OIE, V20, P21, DOI 10.20506/rst.20.1.1265; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; Watanabe M, 2001, MICROBIOL-SGM, V147, P1825, DOI 10.1099/00221287-147-7-1825; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2	30	257	296	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1189	1192		10.1126/science.1094114	http://dx.doi.org/10.1126/science.1094114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976314				2022-12-28	WOS:000189074700045
J	Quayle, AJ; Fidel, P; Rosenberg, ES				Quayle, AJ; Fidel, P; Rosenberg, ES			Sex, allolmmunisation, and susceptibility to HIV infection	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; SEMINAL PLASMA; TRANSMISSION; INDUCTION; ALLOIMMUNIZATION; PREECLAMPSIA; CHEMOKINES; PREGNANCY; MACAQUES; PARTNERS		Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Quayle, AJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA.	AQuayl@LSUHSC.EDU						ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Bienzle D, 2000, J INFECT DIS, V182, P123, DOI 10.1086/315670; BOWDEN RA, 1990, AM J MED, V88, pN49; BUSCH MP, 1992, BLOOD, V80, P2128; CHAN WL, 1992, J EXP MED, V176, P1203, DOI 10.1084/jem.176.4.1203; Dekker G, 2002, J REPROD IMMUNOL, V57, P203, DOI 10.1016/S0165-0378(02)00039-6; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; Hoglund Petter, 2003, Cancer Immun, V3, P6; Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193; Kelly RW, 1997, HUM REPROD, V12, P677, DOI 10.1093/humrep/12.4.677; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Moriuchi H, 1999, J IMMUNOL, V162, P7543; Murphey-Corb M, 1999, J IMMUNOL, V162, P540; Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200; PANDYA IJ, 1985, FERTIL STERIL, V43, P45; Robertson SA, 1997, AM J REPROD IMMUNOL, V37, P438; Robertson SA, 2002, J REPROD IMMUNOL, V57, P109, DOI 10.1016/S0165-0378(02)00015-3; Robertson SA, 2001, SEMIN IMMUNOL, V13, P243, DOI 10.1006/smim.2000.0320; Shearer GM, 1999, IMMUNOL TODAY, V20, P66, DOI 10.1016/S0167-5699(98)01392-9; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; Wang JX, 2002, LANCET, V359, P673, DOI 10.1016/S0140-6736(02)07804-2; Wang YF, 1999, NAT MED, V5, P1004, DOI 10.1038/12440; Wang YF, 1998, P NATL ACAD SCI USA, V95, P5223, DOI 10.1073/pnas.95.9.5223	24	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					503	504		10.1016/S0140-6736(04)15575-X	http://dx.doi.org/10.1016/S0140-6736(04)15575-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975608				2022-12-28	WOS:000188999900003
J	Dietrich, FS; Voegeli, S; Brachat, S; Lerch, A; Gates, K; Steiner, S; Mohr, C; Pohlmann, R; Luedi, P; Choi, SD; Wing, RA; Flavier, A; Gaffney, TD; Phillippsen, P				Dietrich, FS; Voegeli, S; Brachat, S; Lerch, A; Gates, K; Steiner, S; Mohr, C; Pohlmann, R; Luedi, P; Choi, SD; Wing, RA; Flavier, A; Gaffney, TD; Phillippsen, P			The Ashbya gossypii genome as a tool for mapping the ancient Saccharomyces cerevisiae genome	SCIENCE			English	Article							SEQUENCE; TRANSFORMATION; DUPLICATION; EVOLUTION; GENES	We have sequenced and annotated the genome of the filamentous ascomycete Ashbya gossypii. With a size of only 9.2 megabases, encoding 4718 protein-coding genes, it is the smallest genome of a free-living eukaryote yet characterized. More than 90% of A. gossypii genes show both homology and a particular pattern of synteny with Saccharomyces cerevisiae. Analysis of this pattern revealed 300 inversions and translocations that have occurred since divergence of these two species. It also provided compelling evidence that the evolution of S. cerevisiae included a whole genome duplication or fusion of two related species and showed, through inferred ancient gene orders, which of the duplicated genes lost one copy and which retained both copies.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Duke Univ, Med Ctr, Dept Microbiol & Mol Genet, Durham, NC 27710 USA; Syngenta Biotechnol Inc, Res Triangle Pk, NC 27709 USA; Clemson Univ, Dept Agron, Clemson, SC 29634 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA	University of Basel; Duke University; Syngenta; Clemson University; Clemson University	Phillippsen, P (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50, CH-4056 Basel, Switzerland.	Peter.philippsen@unibas.ch	Wing, Rod A/Z-2885-2019; Lerch, Anita/AAR-4467-2020	Wing, Rod A/0000-0001-6633-6226; Lerch, Anita/0000-0003-3062-5901; Lemire-Brachat, Sophie/0000-0002-3398-8225				Alberti-Segui C, 2001, J CELL SCI, V114, P975; AltmannJohl R, 1996, MOL GEN GENET, V250, P69, DOI 10.1007/BF02191826; Ayad-Durieux Y, 2000, J CELL SCI, V113, P4563; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Delneri D, 2003, NATURE, V422, P68, DOI 10.1038/nature01418; Fischer G, 2000, NATURE, V405, P451, DOI 10.1038/35013058; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; KELLIS M, 2004, IN PRESS NATURE; KNECHTLE P, 1993, MOL BIOL CELL, V14, P4140; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; Philippsen P, 1997, NATURE, V387, P93, DOI 10.1038/387s093; Stahmann KP, 2000, APPL MICROBIOL BIOT, V53, P509, DOI 10.1007/s002530051649; STEINER S, 1995, GENETICS, V140, P973; Wendland J, 2000, GENE, V242, P381, DOI 10.1016/S0378-1119(99)00509-0; Wendland J, 2001, GENETICS, V157, P601; Wendland J, 1999, CURR GENET, V35, P618, DOI 10.1007/s002940050460; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; WRIGHT MC, 1991, GENE, V109, P99, DOI 10.1016/0378-1119(91)90593-Z	20	503	1452	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					304	307		10.1126/science.1095781	http://dx.doi.org/10.1126/science.1095781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15001715				2022-12-28	WOS:000220719400051
J	Wennberg, JE; Fisher, ES; Stukel, TA; Skinner, JS; Sharp, SM; Bronner, KK				Wennberg, JE; Fisher, ES; Stukel, TA; Skinner, JS; Sharp, SM; Bronner, KK			Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE; NEW-HAVEN; MEDICARE BENEFICIARIES; REGIONAL-VARIATIONS; SERVICES; BOSTON; DELIVERY; DEATH	Objective To evaluate the use of healthcare resources during the last six months of life among patients of US hospitals with strong reputations for high quality care in managing chronic illness. Design Retrospective cohort study based on claims data from the US Medicare programme. Participants Cohorts receiving most of their hospital care from 77 hospitals that appeared on the 2001 US News and World Report "best hospitals" list for heart and pulmonary disease, cancer, and geriatric services. Main outcome measures Use of healthcare resources in the last six months of life: number of days spent in hospital and in intensive care units; number of physician visits; percentage of patients seeing 10 or more physicians; percentage enrolled in hospice. Terminal care: percentage of deaths occurring in hospital; percentage of deaths occurring in association with a stay in an intensive care unit. Results Extensive variation in each measure existed among the 77 hospital cohorts. Days in hospital per decedent ranged from 9.4 to 27.1 (interquartile range 11.6-16.1); days in intensive care units ranged from 1.6 to 9.5 (2.6-4.5); number of physician visits ranged from 17.6 to 76.2 (25.5-39.5); percentage of patients seeing 10 or more physicians ranged from 16.9% to 58.5% (29.4-43.4%); and hospice enrolment ranged from 10.8% to 43.8% (22.0-32.0%). The percentage of deaths occurring in hospital ranged from 15.9% to 55.6% (35.4-43.1%), and the percentage of deaths associated with a stay in intensive care ranged from 8.4% to 36.8% (20.2-27.1%). Conclusion Striking variation exists in the utilisation of end of life care among US medical centres with strong national reputations for clinical care.	Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; VA Outcomes Grp, White River Jct, VT 05001 USA; Inst Clin Evaluat Sci, Toronto, ON, Canada; Dartmouth Coll, Hanover, NH 03755 USA	Dartmouth College; VA Outcomes Group; University of Toronto; Dartmouth College	Wennberg, JE (corresponding author), Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, 7251 Strasenburgh, Hanover, NH 03755 USA.	john.wennberg@Dartmouth.edu		Stukel, Therese/0000-0002-2951-1360	NIA NIH HHS [P01 AG019783-04, P01 AG019783, 1PO1AG19783-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; IEZZONI LI, 1994, HEALTH SERV RES, V29, P435; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MILLER DAF, 1993, ADOLESCENCE, V28, P621; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wennberg J., 1999, QUALITY MED CARE US; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNBERG JE, 2002, GEOGRAPHY DEBATE MED; WENNBERG JE, HLTH AFFAIRS; 2001, US NEWS WORLD REPORT, V131	22	216	219	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					607	610A		10.1136/bmj.328.7440.607	http://dx.doi.org/10.1136/bmj.328.7440.607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803CB	15016692	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220208100015
J	Blinov, BB; Moehring, DL; Duan, LM; Monroe, C				Blinov, BB; Moehring, DL; Duan, LM; Monroe, C			Observation of entanglement between a single trapped atom and a single photon	NATURE			English	Article							QUANTUM COMMUNICATION; GENERATION	An outstanding goal in quantum information science is the faithful mapping of quantum information between a stable quantum memory and a reliable quantum communication channel(1). This would allow, for example, quantum communication over remote distances(2), quantum teleportation(3) of matter and distributed quantum computing over a 'quantum internet'. Because quantum states cannot in general be copied, quantum information can only be distributed in these and other applications by entangling the quantum memory with the communication channel. Here we report quantum entanglement between an ideal quantum memory-represented by a single trapped Cd-111(+) ion-and an ideal quantum communication channel, provided by a single photon that is emitted spontaneously from the ion. Appropriate coincidence measurements between the quantum states of the photon polarization and the trapped ion memory are used to verify their entanglement directly. Our direct observation of entanglement between stationary and 'flying' qubits(4) is accomplished without using cavity quantum electrodynamic techniques(5-7) or prepared non-classical light sources(3). We envision that this source of entanglement used for a variety of quantum communication protocols(2,8) and for seeding large-scale entangled states of trapped ion qubits for scalable quantum computing(9).	FOCUS Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Blinov, BB (corresponding author), FOCUS Ctr, Ann Arbor, MI 48109 USA.	bblinov@umich.edu	Monroe, Christopher R/G-8105-2011					ASPECT A, 1982, PHYS REV LETT, V49, P91, DOI 10.1103/PhysRevLett.49.91; Badziag P, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012311; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Blatt R., 1988, European Journal of Physics, V9, P250, DOI 10.1088/0143-0807/9/4/002; BOUWMEESTER D, 2000, QUANTUM CRYPTOGRAPHY; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Cabrillo C, 1999, PHYS REV A, V59, P1025, DOI 10.1103/PhysRevA.59.1025; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; DeVoe RG, 1996, PHYS REV LETT, V76, P2049, DOI 10.1103/PhysRevLett.76.2049; DiVincenzo DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E; Duan LM, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.253601; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; DUAN LM, 2004, SCALABLE TRAPPED ION; EICHMANN U, 1993, PHYS REV LETT, V70, P2359, DOI 10.1103/PhysRevLett.70.2359; FREEDMAN SJ, 1972, PHYS REV LETT, V28, P938, DOI 10.1103/PhysRevLett.28.938; Garcia-Ripoll JJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.157901; Gheri KM, 1998, FORTSCHR PHYS, V46, P401, DOI 10.1002/(SICI)1521-3978(199806)46:4/5<401::AID-PROP401>3.0.CO;2-W; Guthohrlein GR, 2001, NATURE, V414, P49, DOI 10.1038/35102129; HAROCHE S, 2002, EXPT QUANTUM COMPUTA, P3; Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524; KUHN A, 2002, EXPT QUANTUM COMPUTA, P37; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; McKeever J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133602; Mundt AB, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.103001; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Simon C, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.110405; van der Wal CH, 2003, SCIENCE, V301, P196, DOI 10.1126/science.1085946	30	487	501	6	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					153	157		10.1038/nature02377	http://dx.doi.org/10.1038/nature02377			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014494	Green Published			2022-12-28	WOS:000220103600041
J	Horton, R				Horton, R			The lessons of MMR	LANCET			English	Editorial Material							CONFLICTS-OF-INTEREST; LANCETS POLICY; IMMUNIZATION; DISORDER; AUTISM		The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Calman KC, 2002, LANCET, V360, P166, DOI 10.1016/S0140-6736(02)09421-7; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; DeFelice ML, 2003, AM J GASTROENTEROL, V98, P1777, DOI 10.1016/S0002-9270(03)00444-1; Farthing M, 2000, LANCET, V356, P2030, DOI 10.1016/S0140-6736(00)03398-5; GOODE E, 2004, NY TIMES        0126, pA1; Horton R, 2004, LANCET, V363, P820, DOI 10.1016/S0140-6736(04)15699-7; James A, 2004, LANCET, V363, P2, DOI 10.1016/S0140-6736(03)15229-4; James A, 2003, LANCET, V361, P8, DOI 10.1016/S0140-6736(03)12184-8; Jefferson T, 2004, LANCET INFECT DIS, V4, P135, DOI 10.1016/S1473-3099(04)00934-X; Jefferson T, 2003, VACCINE, V21, P3954, DOI 10.1016/S0264-410X(03)00271-8; Kanner L, 1943, NERV CHILD, V2, P217; MCBRIDE WG, 1961, LANCET, V2, P1358; Medical Research Council, 2001, MRC REV AUT RES EP C; Murch SH, 2004, LANCET, V363, P750, DOI 10.1016/S0140-6736(04)15715-2; Roberts KA, 2002, LANCET, V360, P1596, DOI 10.1016/S0140-6736(02)11560-1; Shapin S, 1995, SOCIAL HIST TRUTH; TORRENTE F, IN PRESS AM J GASTRO; VOLKMAR FR, 1989, J CHILD PSYCHOL PSYC, V30, P717, DOI 10.1111/j.1469-7610.1989.tb00784.x; Volkmar FR, 2003, LANCET, V362, P1133, DOI 10.1016/S0140-6736(03)14471-6; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; 2004, TIMES HIGHER ED 0227, P14; 2004, INDEPENDENT     0224, P16; 2003, DRUG THER B, V41, P1	23	42	42	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					747	749		10.1016/S0140-6736(04)15714-0	http://dx.doi.org/10.1016/S0140-6736(04)15714-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016482				2022-12-28	WOS:000220092000003
J	Brinkmann, V; Reichard, U; Goosmann, C; Fauler, B; Uhlemann, Y; Weiss, DS; Weinrauch, Y; Zychlinsky, A				Brinkmann, V; Reichard, U; Goosmann, C; Fauler, B; Uhlemann, Y; Weiss, DS; Weinrauch, Y; Zychlinsky, A			Neutrophil extracellular traps kill bacteria	SCIENCE			English	Article								Neutrophils engulf and kill bacteria when their antimicrobial granules fuse with the phagosome. Here, we describe that, upon activation, neutrophils release granule proteins and chromatin that together form extracellular fibers that bind Gram-positive and -negative bacteria. These neutrophil extracellular traps (NETs) degrade virulence factors and kill bacteria. NETs are abundant in vivo in experimental dysentery and spontaneous human appendicitis, two examples of acute inflammation. NETs appear to be a form of innate response that binds microorganisms, prevents them from spreading, and ensures a high local concentration of antimicrobial agents to degrade virulence factors and kill bacteria.	Max Planck Inst Infect Biol, Dept Cellular Microbiol, D-10117 Berlin, Germany; Max Planck Inst Infect Biol, Microscopy Core Facil, D-10117 Berlin, Germany; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	Max Planck Society; Max Planck Society; New York University	Zychlinsky, A (corresponding author), Max Planck Inst Infect Biol, Dept Cellular Microbiol, Schumannstr 21-22, D-10117 Berlin, Germany.	zychlinsky@mpiib-berlin.mpg.de	Brinkmann, Volker/A-6015-2009		NIAID NIH HHS [AI037720] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bainton DF, 1999, J IMMUNOL METHODS, V232, P153, DOI 10.1016/S0022-1759(99)00173-8; Balloy V, 2003, AM J RESP CELL MOL, V28, P746, DOI 10.1165/rcmb.2002-0119OC; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Elsbach P, 1992, INFLAMMATION BASIC P, P603; Elsbach Peter, 1994, Trends in Microbiology, V2, P324, DOI 10.1016/0966-842X(94)90449-9; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HIRSCH JG, 1958, J EXP MED, V108, P925, DOI 10.1084/jem.108.6.925; Junqueira LC., 1998, ALANGE MED BOOK BASI; Kim HS, 1996, BIOCHEM BIOPH RES CO, V229, P381, DOI 10.1006/bbrc.1996.1814; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; LOSMAN MJ, 1992, J IMMUNOL, V148, P1561; MALANSKI NA, 2002, BLOOD, V101, P1987; Movitz C, 2001, CELL BIOL INT, V25, P963, DOI 10.1006/cbir.2001.0760; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; ZHDAN-PUSHKINA S M, 1976, Mikrobiologiya, V45, P60	19	5691	6024	38	655	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1532	1535		10.1126/science.1092385	http://dx.doi.org/10.1126/science.1092385			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001782				2022-12-28	WOS:000220000100047
J	Vajda, V; McLoughlin, S				Vajda, V; McLoughlin, S			Fungal proliferation at the Cretaceous-Tertiary boundary	SCIENCE			English	Article							EXTINCTION		Lund Univ, Geobiosphere Sci Ctr, SE-22362 Lund, Sweden; Queensland Univ Technol, Sch Nat Resource Sci, Brisbane, Qld 4001, Australia	Lund University; Queensland University of Technology (QUT)	Vajda, V (corresponding author), Lund Univ, Geobiosphere Sci Ctr, Solvegatan 12, SE-22362 Lund, Sweden.	vivi.vajda@geol.lu.se; s.mcloughlin@qut.edu.au	Vajda, Vivi/N-7693-2018	Vajda, Vivi/0000-0003-2987-5559				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; ELSIK W, COMMUNICATION; Nichols DJ, 2002, GEOL S AM S, P95; Pope KO, 1997, J GEOPHYS RES-PLANET, V102, P21645, DOI 10.1029/97JE01743; Sweet AR, 1999, CAN J EARTH SCI, V36, P743, DOI 10.1139/e98-061; Vajda V, 2001, SCIENCE, V294, P1700, DOI 10.1126/science.1064706; WOLFE JA, 2001, PALAEOBIOLOGY, V2, P232	8	95	103	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1489	1489		10.1126/science.1093807	http://dx.doi.org/10.1126/science.1093807			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001770	Green Submitted			2022-12-28	WOS:000220000100032
J	Zhang, DK; Zhang, GL; Hayden, MS; Greenblatt, MB; Bussey, C; Flavell, RA; Ghosh, S				Zhang, DK; Zhang, GL; Hayden, MS; Greenblatt, MB; Bussey, C; Flavell, RA; Ghosh, S			A toll-like receptor that prevents infection by uropathogenic bacteria	SCIENCE			English	Article							ESCHERICHIA-COLI; URINARY-TRACT; RESPONSES; PATHOGENS; ACTIVATION	Toll-like receptors (TLRs) recognize molecular patterns displayed by microorganisms, and their subsequent activation leads to the transcription of appropriate host-defense genes. Here we report the cloning and characterization of a member of the mammalian TLR family, TLR11, that displays a distinct pattern of expression in macrophages and liver, kidney, and bladder epithelial cells. Cells expressing TLR11 fail to respond to known TLR ligands but instead respond specifically to uropathogenic bacteria. Mice lacking TLR11 are highly susceptible to infection of the kidneys by uropathogenic bacteria, indicating a potentially important role for TLR11 in preventing infection of internal organs of the urogenital system.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu	Zhang, Guolong/AAU-8197-2020; Zhang, Guolong/HCI-5587-2022; Hayden, Matthew/C-1263-2008	Zhang, Guolong/0000-0003-4781-5816; 	NIAID NIH HHS [R37-AI33443, R01-AI59440] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059440, R37AI033443] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Guyer DM, 2001, J INFECT DIS, V183, pS32, DOI 10.1086/318854; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Hedlund M, 1999, MOL MICROBIOL, V33, P693, DOI 10.1046/j.1365-2958.1999.01513.x; Johnson JR, 2001, J INFECT DIS, V184, P1556, DOI 10.1086/323891; Klumpp DJ, 2001, INFECT IMMUN, V69, P6689, DOI 10.1128/IAI.69.11.6689-6695.2001; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ronald A, 2002, AM J MED, V113, p14S; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; ZHANG D, UNPUB	19	777	869	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1522	1526		10.1126/science.1094351	http://dx.doi.org/10.1126/science.1094351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001781				2022-12-28	WOS:000220000100044
J	Auerbach, AD; Kleinbart, J				Auerbach, AD; Kleinbart, J			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; B-NATRIURETIC PEPTIDE; CARDIAC TROPONIN-T; ELDERLY-PATIENTS; BETA-BLOCKERS; SURVIVAL; OUTCOMES; THERAPY; FAILURE; UTILITY		Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Emory University; University of California System; University of California San Francisco	Kleinbart, J (corresponding author), Emory Univ, Sch Med, Div Gen Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.							Aronow WS, 2002, DRUG SAFETY, V25, P753, DOI 10.2165/00002018-200225110-00001; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; Frankel WL, 1996, AM J CLIN PATHOL, V106, P118; Krishnaswamy P, 2001, AM J MED, V111, P274, DOI 10.1016/S0002-9343(01)00841-5; Krumholz HM, 1999, ANN INTERN MED, V131, P648, DOI 10.7326/0003-4819-131-9-199911020-00003; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Maisel AS, 2001, AM HEART J, V141, P367, DOI 10.1067/mhj.2001.113215; *MED STAT SERV, 1997, MEDPAR INP HOSP FISC; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; White CM, 1999, ANN PHARMACOTHER, V33, P1063, DOI 10.1345/aph.18395	16	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					363	369		10.7326/0003-4819-140-5-200403020-00012	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996678				2022-12-28	WOS:000189246800006
J	Dinh, HT; Kuever, J; Mussmann, M; Hassel, AW; Stratmann, M; Widdel, F				Dinh, HT; Kuever, J; Mussmann, M; Hassel, AW; Stratmann, M; Widdel, F			Iron corrosion by novel anaerobic microorganisms	NATURE			English	Article							SULFATE-REDUCING BACTERIA; MILD-STEEL; CATHODIC HYDROGEN; METHANOGENESIS; IDENTIFICATION	Corrosion of iron presents a serious economic problem. Whereas aerobic corrosion is a chemical process(1), anaerobic corrosion is frequently linked to the activity of sulphate-reducing bacteria (SRB)(2-6). SRB are supposed to act upon iron primarily by produced hydrogen sulphide as a corrosive agent(3,5,7) and by consumption of 'cathodic hydrogen' formed on iron in contact with water(2-6,8). Among SRB, Desulfovibrio species - with their capacity to consume hydrogen effectively - are conventionally regarded as the main culprits of anaerobic corrosion(2-6,8-10); however, the underlying mechanisms are complex and insufficiently understood. Here we describe novel marine, corrosive types of SRB obtained via an isolation approach with metallic iron as the only electron donor. In particular, a Desulfobacterium-like isolate reduced sulphate with metallic iron much faster than conventional hydrogen-scavenging Desulfovibrio species, suggesting that the novel surface-attached cell type obtained electrons from metallic iron in a more direct manner than via free hydrogen. Similarly, a newly isolated Methanobacterium-like archaeon produced methane with iron faster than do known hydrogen-using methanogens, again suggesting a more direct access to electrons from iron than via hydrogen consumption.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Inst Mat Testing, D-28199 Bremen, Germany; Max Planck Inst Iron Res, D-40237 Dusseldorf, Germany	Max Planck Society; Max Planck Society	Widdel, F (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	fwiddel@mpi-bremen.de	Mussmann, Marc/AAA-6108-2021; Mussmann, Marc/A-8649-2017; Hassel, Achim Walter/C-3932-2009	Mussmann, Marc/0000-0003-3102-8703; , Marc/0000-0003-2785-2521				Appia-Ayme C, 1999, APPL ENVIRON MICROB, V65, P4781; BEECH IB, 1994, INT BIODETER BIODEGR, V34, P289, DOI 10.1016/0964-8305(94)90089-2; Bockris J. O. M., 1970, MODERN ELECTROCHEMIS, V2; Bond DR, 2003, APPL ENVIRON MICROB, V69, P1548, DOI 10.1128/AEM.69.3.1548-1555.2003; BOOTH GH, 1968, CORROS SCI, V8, P583, DOI 10.1016/S0010-938X(68)80094-0; Cord-Ruwisch R, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P159; CORDRUWISCH R, 1986, APPL MICROBIOL BIOT, V25, P169, DOI 10.1007/BF00938942; COSTELLO JA, 1974, S AFR J SCI, V70, P202; DANIELS L, 1987, SCIENCE, V237, P509, DOI 10.1126/science.237.4814.509; Deckena S., 1992, BIOFOULING, V5, P287; Deppenmeier U, 2002, PROG NUCLEIC ACID RE, V71, P223, DOI 10.1016/S0079-6603(02)71045-3; Hamilton WA, 2003, BIOFOULING, V19, P65, DOI 10.1080/0892701021000041078; HARDY JA, 1983, BRIT CORROS J, V18, P190, DOI 10.1179/000705983798273642; Huber H, 2002, NATURE, V417, P63, DOI 10.1038/417063a; IVERSON WP, 1984, CURRENT PERSPECTIVES, P623; Laishley EJ, 2003, BIOCHEMISTRY AND PHYSIOLOGY OF ANAEROBIC BACTERIA, P252, DOI 10.1007/0-387-22731-8_18; LEE W, 1995, BIOFOULING, V8, P165, DOI 10.1080/08927019509378271; LUDWIG W, 2002, ARB SOFTWARE ENV SEQ; Manz W, 1998, FEMS MICROBIOL ECOL, V25, P43; MUYZER G, 1995, ARCH MICROBIOL, V164, P165, DOI 10.1007/BF02529967; Pankhania I. P, 1988, Biofouling, V1, P27, DOI 10.1080/08927018809378094; PANKHANIA IP, 1986, J GEN MICROBIOL, V132, P3357; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P3094, DOI 10.1128/AEM.68.6.3094-3101.2002; Rabus R, 2000, PROKARYOTES EVOLVING; Schlegel HG, 1993, GEN MICROBIOLOGY, V7th; Uhlig H. H., 1985, CORROSION CORROSION; Van der Vlugt L.S., 1934, WATER-SUI, V18, P147; WIDDEL F, 1992, PROKARYOTES, V6, P3352; [No title captured]	29	498	523	19	356	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					829	832		10.1038/nature02321	http://dx.doi.org/10.1038/nature02321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985759				2022-12-28	WOS:000189207500037
J	Nykjaer, A; Lee, R; Teng, KK; Jansen, P; Madsen, P; Nielsen, MS; Jacobsen, C; Kliemannel, M; Schwarz, E; Willnow, TE; Hempstead, BL; Petersen, CM				Nykjaer, A; Lee, R; Teng, KK; Jansen, P; Madsen, P; Nielsen, MS; Jacobsen, C; Kliemannel, M; Schwarz, E; Willnow, TE; Hempstead, BL; Petersen, CM			Sortilin is essential for proNGF-induced neuronal cell death	NATURE			English	Article							NERVE GROWTH-FACTOR; 100-KDA NEUROTENSIN RECEPTOR; P75 NEUROTROPHIN RECEPTOR; SYMPATHETIC NEURONS; BINDING; EXPRESSION; PROTEIN; INTERNALIZATION; DOMAINS; BRAIN	Sortilin(1) (similar to95 kDa) is a member of the recently discovered family of Vps10p-domain receptors(2,3), and is expressed in a variety of tissues, notably brain, spinal cord and muscle. It acts as a receptor for neurotensin(4,5), but predominates in regions of the nervous system that neither synthesize nor respond to this neuropeptide(6), suggesting that sortilin has additional roles. Sortilin is expressed during embryogenesis(7) in areas where nerve growth factor ( NGF) and its precursor, proNGF, have well-characterized effects(6,7). These neurotrophins can be released by neuronal tissues(8,9), and they regulate neuronal development through cell survival and cell death signalling. NGF regulates cell survival and cell death via binding to two different receptors, TrkA and p75(NTR) (ref. 10). In contrast, proNGF selectively induces apoptosis through p75(NTR) but not TrkA(11). However, not all p75(NTR)-expressing cells respond to proNGF, suggesting that additional membrane proteins are required for the induction of cell death. Here we report that proNGF creates a signalling complex by simultaneously binding to p75(NTR) and sortilin. Thus sortilin acts as a co-receptor and molecular switch governing the p75(NTR)-mediated pro-apoptotic signal induced by proNGF.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; ReceptIcon Aps, DK-8000 Aarhus C, Denmark; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany	Aarhus University; Cornell University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Martin Luther University Halle Wittenberg	Nykjaer, A (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle 170, DK-8000 Aarhus C, Denmark.	an@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Madsen, Peder Sondergaard/0000-0002-8845-4802; Willnow, Thomas/0000-0001-9515-7921; Nykjaer, Anders/0000-0001-6422-6736; Teng, Kenneth/0000-0002-9392-2172				Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Gargano N, 1997, J NEUROSCI RES, V50, P1; Hasan W, 2003, J NEUROBIOL, V57, P38, DOI 10.1002/neu.10250; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; Hermans-Borgmeyer I, 1999, MOL BRAIN RES, V65, P216, DOI 10.1016/S0169-328X(99)00022-4; Hermey G, 2003, J BIOL CHEM, V278, P7390, DOI 10.1074/jbc.M210851200; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mitsui C, 2001, J NEUROSCI RES, V66, P601, DOI 10.1002/jnr.10008; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Rattenholl A, 2001, EUR J BIOCHEM, V268, P3296, DOI 10.1046/j.1432-1327.2001.02232.x; Sarret P, 2003, J COMP NEUROL, V461, P483, DOI 10.1002/cne.10708; Shonukan T, 2003, ONCOGENE, V22, P3616, DOI 10.1038/sj.onc.1206561; Wang JL, 2000, BIORESOURCE TECHNOL, V75, P157, DOI 10.1016/S0960-8524(00)00041-9	29	723	795	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					843	848		10.1038/nature02319	http://dx.doi.org/10.1038/nature02319			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985763				2022-12-28	WOS:000189207500041
J	Madhusudan, S; Deplanque, G; Braybrooke, JP; Cattell, E; Taylor, M; Price, P; Tsaloumas, MD; Moore, N; Huson, SM; Adams, C; Frith, P; Scigalla, P; Harris, AL				Madhusudan, S; Deplanque, G; Braybrooke, JP; Cattell, E; Taylor, M; Price, P; Tsaloumas, MD; Moore, N; Huson, SM; Adams, C; Frith, P; Scigalla, P; Harris, AL			Antiangiogenic therapy for von Hippel-Lindau disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR INHIBITOR SU5416; HEMANGIOBLASTOMAS		Oxford Radcliffe Hosp, Canc Res UK Med Oncol Unit, Oxford, England; Christie Hosp, Acad Dept Radiat Oncol, Manchester, Lancs, England; Birmingham & Midland Eye Clin, Dept Ophthalmol, Birmingham, W Midlands, England; Oxford Radcliffe Hosp, Dept Radiol, Oxford, England; Oxford Radcliffe Hosp, Dept Clin Genet, Oxford, England; Oxford Radcliffe Hosp, Dept Neurosurg, Oxford, England; Oxford Radcliffe Hosp, Dept Ophthalmol, Oxford, England; SUGEN Inc, San Francisco, CA USA	Cancer Research UK; University of Oxford; Christie NHS Foundation Trust; Christie Hospital; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Pfizer	Madhusudan, S (corresponding author), Oxford Radcliffe Hosp, Canc Res UK Med Oncol Unit, Oxford, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Madhusudan, Srinivasan/0000-0002-5354-5480; Braybrooke, Jeremy/0000-0003-1943-7360				Aiello LP, 2002, OPHTHALMOLOGY, V109, P1745, DOI 10.1016/S0161-6420(02)01159-4; Fong TAT, 1999, CANCER RES, V59, P99; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; Girmens JF, 2003, AM J OPHTHALMOL, V136, P194, DOI 10.1016/S0002-9394(03)00101-6; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; *NCI, 2004, COMM TOX CRIT; Stopeck A, 2002, CLIN CANCER RES, V8, P2798; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358	9	47	48	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					943	944		10.1001/jama.291.8.943	http://dx.doi.org/10.1001/jama.291.8.943			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982909				2022-12-28	WOS:000189182000020
J	Jocham, D; Richter, A; Hoffmann, L; Iwig, K; Fahlenkamp, D; Zakrzewski, G; Schmitt, E; Dannenberg, T; Lehmacher, W; von Wietersheim, J; Doehn, C				Jocham, D; Richter, A; Hoffmann, L; Iwig, K; Fahlenkamp, D; Zakrzewski, G; Schmitt, E; Dannenberg, T; Lehmacher, W; von Wietersheim, J; Doehn, C			Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial	LANCET			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; HISTOCOMPATIBILITY ANTIGEN EXPRESSION; INTERFERON-GAMMA; LYSATE VACCINE; IFN-GAMMA; STAGE-II; CANCER; IMMUNOTHERAPY; THERAPY; ALPHA	Background Organ-confined renal-cell carcinoma is associated with tumour progression in up to 50% of patients after radical nephrectomy. At present, no effective adjuvant treatment is established. We aimed to investigate the effect of an autologous renal tumour cell vaccine on risk of tumour progression in patients with stage pT2-3b pNO-3 MO renal-cell carcinoma. Methods Between January, 1997, and September, 1998, 558 patients with a renal tumour scheduled for radical nephrectomy were enrolled at 55 institutions in Germany. Before surgery, all patients were centrally randomised to receive autologous renal tumour cell vaccine (six intradermal applications at 4-week intervals postoperatively; vaccine group) or no adjuvant treatment (control group). The primary endpoint of the trial was to reduce the risk of tumour progression, defined as progression or death. All patients were assessed after standardised diagnostic investigations at 6-month intervals for a minimum of 4.5 years. Findings By preoperative and postoperative inclusion criteria, 379 patients were assessable for the intention-to-treat analysis. At 5-year and 70-month follow-up, the hazard ratios for tumour progression were 1.58 (95% CI 1.05-2.37) and 1.59 (1.07-2.36), respectively, in favour of the vaccine group (p=0.0204, log-rank test). 5-year and 70-month progression-free survival rates were 77.4% and 72%, respectively, in the vaccine group and 67.8% and 59.3%, respectively, in the control group. The vaccine was well tolerated, with only 12 adverse events associated with the treatment. Interpretation Adjuvant treatment with autologous renal tumour cell vaccine in patients with renal-cell carcinoma after radical nephrectomy seems to be beneficial and can be considered in patients undergoing radical nephrectomy due to organ-confined renal-cell carcinoma of more than 2.5 cm in diameter.	Univ Lubeck, Sch Med, Dept Urol, D-23538 Lubeck, Germany; Klinikum St Georg, Dept Urol, Leipzig, Germany; Wald Klinikum Gera, Dept Urol, Gera, Germany; Klinikum Meiningen, Dept Urol, Meiningen, Germany; Ruppiner Kliniken, Dept Urol, Neuruppin, Germany; Eichsfeld Klinikum Haus Reifenstein, Dept Urol, Reifenstein, Germany; Kreiskliniken Aschersleben Stassfurt, Dept Urol, Aschersleben, Germany; Klinikum Offenbach, Dept Urol, Offenbach, Germany; Univ Cologne, Sch Med, Inst Med Stat Informat & Epidemiol, Cologne, Germany; Univ Ulm, Sch Med, Dept Psychosomat Med & Psychotherapy, Ulm, Germany	University of Lubeck; Ruppiner Kliniken GmbH; Sana Klinikum Offenbach; University of Cologne; Ulm University	Jocham, D (corresponding author), Univ Lubeck, Sch Med, Dept Urol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Prof.Jocham.MUL@t-online.de						AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ANGUS R, 1993, EUR J CANCER, V29A, P1879, DOI 10.1016/0959-8049(93)90542-N; Armstrong AC, 2001, BRIT J RADIOL, V74, P991, DOI 10.1259/bjr.74.887.740991; BIANCO MD, 1988, EUR UROL, V15, P73; Clark JI, 2003, J CLIN ONCOL, V21, P3133, DOI 10.1200/JCO.2003.02.014; DINNEY CPN, 1992, UROLOGY, V39, P122, DOI 10.1016/0090-4295(92)90267-Z; Doehn C, 2003, FOLIA BIOL-PRAGUE, V49, P69; Elmadfa I, 2003, INT J VITAM NUTR RES, V73, P89, DOI 10.1024/0300-9831.73.2.89; Figlin RA, 1999, J UROLOGY, V161, P381, DOI 10.1016/S0022-5347(01)61897-4; Galligioni E, 1996, CANCER, V77, P2560, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P; Gastl G, 1996, J UROLOGY, V155, P361, DOI 10.1016/S0022-5347(01)66661-8; GIULIANI L, 1990, J UROLOGY, V143, P468, DOI 10.1016/S0022-5347(17)39992-5; HANSEN AB, 1994, UROL RES, V22, P85, DOI 10.1007/BF00310997; HERMANEK P, 1990, J UROLOGY, V144, P238, DOI 10.1016/S0022-5347(17)39420-X; HILLMAN GG, 1994, CLIN EXP IMMUNOL, V96, P476; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KJAER M, 1987, INT J RADIAT ONCOL, V13, P665, DOI 10.1016/0360-3016(87)90283-5; Messing EM, 2003, J CLIN ONCOL, V21, P1214, DOI 10.1200/JCO.2003.02.005; Michael A, 2003, LANCET ONCOL, V4, P215, DOI 10.1016/S1470-2045(03)01044-1; Morse MA, 2001, EXPERT OPIN BIOL TH, V1, P153, DOI 10.1517/14712598.1.2.153; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Pizzocaro G, 2001, J CLIN ONCOL, V19, P425, DOI 10.1200/JCO.2001.19.2.425; PIZZOCARO G, 1987, J UROLOGY, V138, P1379, DOI 10.1016/S0022-5347(17)43647-0; Repmann R, 2003, ANTICANCER RES, V23, P969; Repmann R, 1997, ANTICANCER RES, V17, P2879; SANTAROSA M, 1995, INT J CANCER, V62, P271, DOI 10.1002/ijc.2910620307; Seliger B, 1997, CLIN CANCER RES, V3, P573; SPIESSL B, 1993, TNM ATLAS ILLUSTRIER; STORKEL S, 1989, EUR UROL, V16, P416; Tanabe K, 1997, UROL RES, V25, P231, DOI 10.1007/BF00942091; Zisman A, 2002, J CLIN ONCOL, V20, P4559, DOI 10.1200/JCO.2002.05.111	31	311	346	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2004	363	9409					594	599		10.1016/S0140-6736(04)15590-6	http://dx.doi.org/10.1016/S0140-6736(04)15590-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	776EZ	14987883				2022-12-28	WOS:000189104900007
J	Caplan, A				Caplan, A			Bioethics - Is biomedical research too dangerous to pursue?	SCIENCE			English	Editorial Material									Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Caplan, A (corresponding author), Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA.	caplan@mail.upenn.edu						Callahan D, 2003, CAL MILBANK BOOK HEA, V9, P1; Elliott Carl, 2003, BETTER THAN WELL; Fukuyama Francis, 2002, OUR POSTHUMAN FUTURE; GREENBERG DS, 2001, SCI MONEY POLITICS; Kass L, 2003, THER BIOT PURS HAPP; KASS LR, 1972, PUBLIC INTEREST, P18; Krimsky S., 2004, SCI PRIVATE INTEREST; Kristol William, 2002, FUTURE IS NOW AM CON; McKibben Bill, 2003, ENOUGH GENETIC ENG E; Smith B. L. R., 1990, AM SCI POLICY WORLD; TENNER Edward, 2003, OUR OWN DEVICES; WOLFSON A, 2003, NEW ATLANTIS, V2003, P55	12	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1142	1142		10.1126/science.1095698	http://dx.doi.org/10.1126/science.1095698			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976298				2022-12-28	WOS:000189074700028
J	Chamberlain, JR; Schwarze, U; Wang, PR; Hirata, RK; Hankenson, KD; Pace, JM; Underwood, RA; Song, KM; Sussman, M; Byers, PH; Russell, DW				Chamberlain, JR; Schwarze, U; Wang, PR; Hirata, RK; Hankenson, KD; Pace, JM; Underwood, RA; Song, KM; Sussman, M; Byers, PH; Russell, DW			Gene targeting in stem cells from individuals with osteogenesis imperfecta	SCIENCE			English	Article							ADENOASSOCIATED VIRUS VECTORS; MARROW STROMAL CELLS; I COLLAGEN; NONHEMATOPOIETIC TISSUES; MESENCHYMAL CELLS; NULL-ALLELE; MUTATION; PROCOLLAGEN; SEQUENCES; MOSAICISM	Adult stem cells offer the potential to treat many diseases through a combination of ex vivo genetic manipulation and autologous transplantation. Mesenchymal stem cells (MSCs, also referred to as marrow stromal cells) are adult stem cells that can be isolated as proliferating, adherent cells from bones. MSCs can differentiate into multiple cell types present in several tissues, including bone, fat, cartilage, and muscle, making them ideal candidates for a variety of cell-based therapies. Here, we have used adeno-associated virus vectors to disrupt dominant-negative mutant COL1A1 collagen genes in MSCs from individuals with the brittle bone disorder osteogenesis imperfecta, demonstrating successful gene targeting in adult human stem cells.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Michigan, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; Childrens Hosp & Med Ctr, Seattle, WA 98105 USA; Shriners Hosp Children, Portland, OR 97201 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Seattle Children's Hospital	Russell, DW (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	drussell@u.washington.edu	Hankenson, Kurt/ABI-1547-2020; Hankenson, Kurt/AFS-9417-2022	Hankenson, Kurt/0000-0001-6361-143X; Byers, Peter H./0000-0001-7786-7030				BONADIO J, 1985, J BIOL CHEM, V260, P1734; BYERS PH, 2000, METABOLIC MOL BASIS, P5241; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; CONSTANTINOU CD, 1990, AM J HUM GENET, V47, P670; Edwards Matthew J., 1992, Human Mutation, V1, P47, DOI 10.1002/humu.1380010108; FEDARKO NS, 1992, J BONE MINER RES, V7, P921; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Inoue N, 1999, J VIROL, V73, P7376, DOI 10.1128/JVI.73.9.7376-7380.1999; Inoue N, 2001, MOL THER, V3, P526, DOI 10.1006/mthe.2001.0283; Korkko J, 1998, AM J HUM GENET, V62, P98, DOI 10.1086/301689; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PLOETZ C, 1991, J STRUCT BIOL, V106, P73, DOI 10.1016/1047-8477(91)90064-4; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325; WALLIS GA, 1990, AM J HUM GENET, V46, P1034; WILLING MC, 1992, AM J HUM GENET, V51, P508	21	211	259	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1198	1201		10.1126/science.1088757	http://dx.doi.org/10.1126/science.1088757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976317				2022-12-28	WOS:000189074700048
J	Terman, JR; Kolodkin, AL				Terman, JR; Kolodkin, AL			Nervy links protein kinase A to plexin-mediated semaphorin repulsion	SCIENCE			English	Article							GROWTH CONE GUIDANCE; DROSOPHILA; IDENTIFICATION	Cyclic nucleotides regulate axonal responses to a number of guidance cues through unknown molecular events. We report here that Drosophila nervy, a member of the myeloid translocation gene family of A kinase anchoring proteins (AKAPs), regulates repulsive axon guidance by linking the cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) to the Semaphorin 1a (Sema-1a) receptor Plexin A (PlexA). Nervy and PKA antagonize Sema-1a-PlexA-mediated repulsion, and the AKAP binding region of Nervy is critical for this effect. Thus, Nervy couples cAMP-PKA signaling to PlexA to regulate Sema-1a-mediated axonal repulsion, revealing a simple molecular mechanism that allows growing axons to integrate inputs from multiple guidance cues.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Kolodkin, AL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 1001 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	kolodkin@jhmi.edu						Chalasani SH, 2003, J NEUROSCI, V23, P1360, DOI 10.1523/JNEUROSCI.23-04-01360.2003; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; Dontchev VD, 2002, J NEUROSCI, V22, P6659; FEINSTEIN PG, 1995, GENETICS, V140, P573; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Schillace RV, 2002, J IMMUNOL, V168, P1590, DOI 10.4049/jimmunol.168.4.1590; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Winberg ML, 2001, NEURON, V32, P53, DOI 10.1016/S0896-6273(01)00446-9; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X	19	79	79	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1204	1207		10.1126/science.1092121	http://dx.doi.org/10.1126/science.1092121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976319				2022-12-28	WOS:000189074700050
J	Lahdenpera, M; Lummaa, V; Helle, S; Tremblay, M; Russell, AF				Lahdenpera, M; Lummaa, V; Helle, S; Tremblay, M; Russell, AF			Fitness benefits of prolonged post-reproductive lifespan in women	NATURE			English	Article							EVOLUTIONARY-THEORY; GRANDMOTHERS; SURVIVAL; HELPERS; HISTORY; SUCCESS	Most animals reproduce until they die, but in humans, females can survive long after ceasing reproduction(1,2). In theory, a prolonged post-reproductive lifespan will evolve when can gain greater fitness by increasing the success of their offspring than by continuing to breed themselves(3-6). Although reproductive success is known to decline in old age(1-6), it is unknown whether women gain fitness by prolonging lifespan post-reproduction. Using complete multi-generational demographic records, we show that women with a prolonged post-reproductive lifespan have more grandchildren, and hence greater fitness, in pre-modern populations of both Finns and Canadians. This fitness benefit arises because post-reproductive mothers enhance the lifetime reproductive success of their offspring by allowing them to breed earlier, more frequently and more successfully. Finally, the fitness benefits of prolonged lifespan diminish as the reproductive output of offspring declines. This suggests that in female humans, selection for deferred ageing should wane when one's own offspring become post-reproductive and, correspondingly, we show that rates of female mortality accelerate as their offspring terminate reproduction.	Univ Turku, Dept Biol, Sect Ecol, FIN-20014 Turku, Finland; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Quebec Chicoutimi, Interdisciplinary Res Grp Demog & Genet Epidemiol, Chicoutimi, PQ G7H 2B1, Canada	University of Turku; University of Sheffield; University of Cambridge; University of Quebec; University of Quebec Chicoutimi	Lahdenpera, M (corresponding author), Univ Turku, Dept Biol, Sect Ecol, FIN-20014 Turku, Finland.	mipayl@utu.fi	Lummaa, Virpi/AHB-0181-2022	Lahdenpera, Mirkka/0000-0003-0062-6284; Russell, Andy/0000-0002-1299-8555				BOUCHARD G, 1995, INFORMATION KNOWLEDG, P201; Bouchard Gerard, 1996, QUELQUES ARPENTS AM; BROWN JL, 1982, SCIENCE, V215, P421, DOI 10.1126/science.215.4531.421; Clutton-Brock TH, 2001, SCIENCE, V293, P2446, DOI 10.1126/science.1061274; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; EMLEN ST, 1991, J ANIM ECOL, V60, P309, DOI 10.2307/5462; EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092; Gille H, 1949, POP STUD-J DEMOG, V3, P3, DOI 10.2307/2172491; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Hawkes K, 1997, CURR ANTHROPOL, V38, P551, DOI 10.1086/204646; Hawkes K, 2003, AM J HUM BIOL, V15, P380, DOI 10.1002/ajhb.10156; Hawkes K, 1998, P NATL ACAD SCI USA, V95, P1336, DOI 10.1073/pnas.95.3.1336; Jamison CS, 2002, AM J PHYS ANTHROPOL, V119, P67, DOI 10.1002/ajpa.10070; Karskela S, 2001, SUKUTUTKIJAN TIETOKI; Lee RD, 2003, P NATL ACAD SCI USA, V100, P9637, DOI 10.1073/pnas.1530303100; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Lummaa V, 1998, NATURE, V394, P533, DOI 10.1038/28977; Lummaa V, 2003, P ROY SOC B-BIOL SCI, V270, P2355, DOI 10.1098/rspb.2003.2507; Luther G., 1993, SUOMEN TILASTOTOIMEN; McGraw JB, 1996, AM NAT, V147, P47, DOI 10.1086/285839; MORING B, 1993, J FAM HIST, V18, P395, DOI 10.1177/036319909301800407; Russell AF, 2003, BEHAV ECOL, V14, P486, DOI 10.1093/beheco/arg022; SCHALL R, 1991, BIOMETRIKA, V78, P719; Sear R, 2000, P ROY SOC B-BIOL SCI, V267, P1641, DOI 10.1098/rspb.2000.1190; Sear R, 2003, EVOL HUM BEHAV, V24, P25, DOI 10.1016/S1090-5138(02)00105-8; Shanley DP, 2001, BIOESSAYS, V23, P282, DOI 10.1002/1521-1878(200103)23:3<282::AID-BIES1038>3.0.CO;2-9; Soininen AM, 1974, OLD TRADITIONAL AGR; Voland E, 2002, BEHAV ECOL SOCIOBIOL, V52, P435, DOI 10.1007/s00265-002-0539-2; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	29	316	321	2	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					178	181		10.1038/nature02367	http://dx.doi.org/10.1038/nature02367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014499	Green Accepted			2022-12-28	WOS:000220103600048
J	Qureshi, AI				Qureshi, AI			Endovascular treatment of cerebrovascular diseases and intracranial neoplasms	LANCET			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; GUGLIELMI DETACHABLE COILS; UNRUPTURED CEREBRAL ANEURYSMS; ACUTE ISCHEMIC-STROKE; CAROTID-ARTERY ANGIOPLASTY; HEALTH-CARE PROFESSIONALS; PREOPERATIVE RISK-FACTORS; N-BUTYL CYANOACRYLATE; STENT PLACEMENT; ARTERIOVENOUS-MALFORMATIONS	Cerebrovascular diseases are an important cause of morbidity and mortality worldwide. Endovascular treatment has emerged as a minimally invasive approach to treat cerebrovascular diseases and possibly intracranial neoplasms. Practice patterns for selection of patients for endovascular treatment are continuously being modified on the basis of new information derived from clinical studies. In this review, I discuss the various endovascular treatments for diseases such as ischaemic stroke, carotid and intracranial stenosis, intracranial aneurysms, arteriovenous malformations, malignant gliomas, and meningiomas.	Univ Med & Dent New Jersey, Neurol Inst New Jersey, Dept Neurol & Neurosci, Cerebral Dis Program, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Qureshi, AI (corresponding author), Univ Med & Dent New Jersey, Neurol Inst New Jersey, Dept Neurol & Neurosci, Cerebral Dis Program, 90 Bergen St,D0C-8100, Newark, NJ 07103 USA.	aiqureshi@hotmail.com		Qureshi, Adnan/0000-0003-4962-540X				Adami CA, 2002, J ENDOVASC THER, V9, P147, DOI 10.1583/1545-1550(2002)009<0147:UOTPAE>2.0.CO;2; Al-Mubarak N, 2002, J AM COLL CARDIOL, V39, P841, DOI 10.1016/S0735-1097(02)01692-3; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alberts MJ, 2001, STROKE, V32, P325; Ali Z, 2002, NEUROLOGY, V58, pA313; Babatasi G, 1997, EUR J CARDIO-THORAC, V11, P547, DOI 10.1016/S1010-7940(96)01105-0; Baltsavias GS, 2000, NEUROSURGERY, V47, P1320, DOI 10.1097/00006123-200012000-00010; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Barth A, 2000, STROKE, V31, P1824, DOI 10.1161/01.STR.31.8.1824; Bendszus M, 2000, NEUROSURGERY, V47, P1306, DOI 10.1097/00006123-200012000-00008; BOGOUSSLAVSKY J, 1986, STROKE, V17, P1112, DOI 10.1161/01.STR.17.6.1112; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Brooks B, 1931, TR SOUTH SURG ASS, V43, P176; Brooks WH, 2001, J AM COLL CARDIOL, V38, P1589, DOI 10.1016/S0735-1097(01)01595-9; Brown MM, 2001, LANCET, V357, P1729; Chalela JA, 2001, STROKE, V32, P1365, DOI 10.1161/01.STR.32.6.1365; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Chow KL, 2000, AM J NEURORADIOL, V21, P471; Cloughesy TF, 1999, NEUROSURGERY, V44, P270, DOI 10.1097/00006123-199902000-00015; Cloughesy TF, 1997, J NEURO-ONCOL, V35, P121, DOI 10.1023/A:1005856002264; Cottier JP, 2001, AM J NEURORADIOL, V22, P345; DEAN BL, 1994, AM J NEURORADIOL, V15, P1675; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DEMERITT JS, 1995, AM J NEURORADIOL, V16, P1801; Eckert B, 2002, STROKE, V33, P1424, DOI 10.1161/01.STR.0000014247.70674.7F; Engelhard HH, 2001, SURG NEUROL, V55, P89, DOI 10.1016/S0090-3019(01)00349-4; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Fessler RD, 2000, NEUROSURGERY, V46, P1524, DOI 10.1097/00006123-200006000-00044; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Gobin YP, 1996, J NEUROSURG, V85, P19, DOI 10.3171/jns.1996.85.1.0019; GOLDSTEIN LB, 1994, STROKE, V25, P1116, DOI 10.1161/01.STR.25.6.1116; Goldstein LB, 1998, STROKE, V29, P750, DOI 10.1161/01.STR.29.4.750; Gomez CR, 2000, STROKE, V31, P95, DOI 10.1161/01.STR.31.1.95; Grube E, 2003, CATHETER CARDIO INTE, V58, P139, DOI 10.1002/ccd.10348; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hanel Ricardo A, 2003, Curr Cardiol Rep, V5, P153, DOI 10.1007/s11886-003-0084-2; Henkes H, 1998, NEUROL RES, V20, P479; Hobson RW, 2003, STROKE, V34, P239; Hofmann R, 2002, STROKE, V33, P725, DOI 10.1161/hs0302.104545; Hopkins LN, 2001, NEUROSURGERY, V48, P463, DOI 10.1097/00006123-200103000-00001; Houdart E, 2001, STROKE, V32, P118, DOI 10.1161/01.STR.32.1.118; *IMS INV, 2003, STROKE, V34, P247; INAMURA T, 1994, J NEUROSURG, V81, P752, DOI 10.3171/jns.1994.81.5.0752; JAFAR JJ, 1993, J NEUROSURG, V78, P60, DOI 10.3171/jns.1993.78.1.0060; Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799; Johnston SC, 2000, ANN NEUROL, V48, P11; Johnston SC, 2002, STROKE, V33, P2536, DOI 10.1161/01.STR.0000034708.66191.7D; Johnston SC, 2001, STROKE, V32, P597, DOI 10.1161/01.STR.32.3.597; Kai Y, 2002, AM J NEURORADIOL, V23, P139; KALACHE A, 1995, HEALTH POLICY PLANN, V10, P1, DOI 10.1093/heapol/10.1.1; Kastrup A, 2003, STROKE, V34, P813, DOI 10.1161/01.STR.0000058160.53040.5F; KERBER CW, 1980, AM J NEURORADIOL, V1, P348; Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8; KIM S, 2003, NEUROINTERVENTIONIST, V4, P15; KIM SH, 1998, NEUROSURGERY, V43, P708; Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369; Kremer C, 1999, STROKE, V30, P2617, DOI 10.1161/01.STR.30.12.2617; Kuether TA, 1998, NEUROSURGERY, V43, P1016, DOI 10.1097/00006123-199811000-00007; LANGEN KJ, 1989, NUCL MED COMMUN, V10, P779, DOI 10.1097/00006231-198911000-00002; Lanzino G, 1999, J NEUROSURG, V91, P538, DOI 10.3171/jns.1999.91.4.0538; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Link J, 2000, RADIOLOGE, V40, P813, DOI 10.1007/s001170050828; Lopes DK, 2002, J NEUROSURG, V96, P490, DOI 10.3171/jns.2002.96.3.0490; LUESSENHOP AJ, 1964, J NEUROSURG, V21, P85, DOI 10.3171/jns.1964.21.2.0085; LUESSENHOP AJ, 1965, J NEUROSURG, V23, P400, DOI 10.3171/jns.1965.23.4.0400; Lutsep HL, 2003, STROKE, V34, P253; Lutsep HL, 2001, STROKE, V32, P319; Macdonald RL, 1998, STROKE, V29, P478; Mahon BR, 2003, AM J NEURORADIOL, V24, P534; Makoui AS, 2000, J NEUROSURG, V92, P355, DOI 10.3171/jns.2000.92.2.0355; Malek AM, 2000, AM J NEURORADIOL, V21, P1280; Malisch TW, 1997, J NEUROSURG, V87, P176, DOI 10.3171/jns.1997.87.2.0176; Marks MP, 1999, STROKE, V30, P1065, DOI 10.1161/01.STR.30.5.1065; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mawad ME, 2002, J NEUROSURG, V96, P474, DOI 10.3171/jns.2002.96.3.0474; Mericle RA, 1999, J NEUROSURG, V90, P1031, DOI 10.3171/jns.1999.90.6.1031; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Moran CJ, 2000, J NEUROSURG, V92, P510; Morizane A, 1999, NEUROL SURG TOKYO, V27, P941; Mukherjee D, 2001, J Invasive Cardiol, V13, P732; Murphy KJ, 2000, NEUROSURGERY, V46, P497, DOI 10.1097/00006123-200002000-00048; Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X; New G, 2000, J ENDOVASC THER, V7, P345, DOI 10.1583/1545-1550(2000)007<0345:SEADOC>2.0.CO;2; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; Ouriel K, 2001, J VASC SURG, V33, P728, DOI 10.1067/mva.2001.111981; Purdy P, 2002, AM J NEURORADIOL, V23, P748; PURDY PD, 1992, J NEUROSURG, V77, P217, DOI 10.3171/jns.1992.77.2.0217; Qureshi AI, 2000, NEUROSURGERY, V46, P1360, DOI 10.1097/00006123-200006000-00014; Qureshi AI, 2002, STROKE, V33, P353; Qureshi AI, 2001, J NEUROSURG, V94, P880, DOI 10.3171/jns.2001.94.6.0880; Qureshi AI, 2003, J NEUROSURG, V99, P264, DOI 10.3171/jns.2003.99.2.0264; Qureshi AI, 2003, J ENDOVASC THER, V10, P42, DOI 10.1583/1545-1550(2003)010<0042:AUOPGI>2.0.CO;2; Qureshi AI, 2003, NEUROSURGERY, V52, P1033, DOI 10.1227/01.NEU.0000057744.96295.9F; Qureshi AI, 2002, J NEUROSURG, V96, P830, DOI 10.3171/jns.2002.96.5.0830; Qureshi AI, 2002, NEUROSURGERY, V51, P1319, DOI 10.1097/00006123-200211000-00040; Qureshi AI, 2002, NEUROSURGERY, V50, P466, DOI 10.1097/00006123-200203000-00006; Qureshi AI, 2002, NEUROSURGERY, V50, P1405, DOI 10.1097/00006123-200206000-00049; Qureshi AI, 2001, NEUROSURGERY, V48, P998, DOI 10.1097/00006123-200105000-00005; Qureshi AI, 2001, NEUROSURGERY, V49, P41, DOI 10.1097/00006123-200107000-00006; Qureshi AI, 2000, NEUROSURGERY, V47, P473; Qureshi AI, 2000, STROKE, V31, P376, DOI 10.1161/01.STR.31.2.376; Qureshi AI, 2000, J ENDOVASC THER, V7, P423, DOI 10.1583/1545-1550(2000)007<0423:AIFISP>2.0.CO;2; Raymond J, 2001, RADIOLOGY, V221, P318, DOI 10.1148/radiol.2212010474; Reimers B, 2001, CIRCULATION, V104, P12, DOI 10.1161/hc2601.092495; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Rothwell PM, 1997, BMJ-BRIT MED J, V315, P1571, DOI 10.1136/bmj.315.7122.1571; Roubin GS, 2001, CIRCULATION, V103, P532, DOI 10.1161/01.CIR.103.4.532; Roy D, 1997, NEUROSURGERY, V40, P1133, DOI 10.1097/00006123-199706000-00004; Sedat J, 2002, STROKE, V33, P2620, DOI 10.1161/01.STR.0000034788.70971.14; SELDINGER SI, 1953, ACTA RADIOL, V39, P368, DOI 10.3109/00016925309136722; Sen S, 2003, STROKE, V34, P284; SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125; SHAPIRO WR, 1992, J NEUROSURG, V76, P772, DOI 10.3171/jns.1992.76.5.0772; STARKMAN S, 2002, 7 INT S THROMB AC ST; Stiver SI, 1998, NEUROSURGERY, V43, P1203, DOI 10.1097/00006123-199811000-00106; Stukenborg GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826, DOI 10.1001/archneur.1997.00550190018009; Suarez JI, 1999, STROKE, V30, P2094, DOI 10.1161/01.STR.30.10.2094; SUSSMAN BJ, 1958, JAMA-J AM MED ASSOC, V167, P1705, DOI 10.1001/jama.1958.02990310011002; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THERON J, 1987, AM J NEURORADIOL, V8, P495; Thijs VN, 2000, NEUROLOGY, V55, P490, DOI 10.1212/WNL.55.4.490; Tomsick T, 1996, AM J NEURORADIOL, V17, P79; Tubler T, 2001, CIRCULATION, V104, P2791, DOI 10.1161/hc4801.100353; Ueda T, 1999, STROKE, V30, P2360, DOI 10.1161/01.STR.30.11.2360; Vallee JN, 2003, RADIOLOGY, V226, P867, DOI 10.1148/radiol.2263011957; van Heesewijk HPM, 2002, RADIOLOGY, V224, P361, DOI 10.1148/radiol.2242011302; Vanninen R, 1999, RADIOLOGY, V211, P325, DOI 10.1148/radiology.211.2.r99ap06325; VINUELA F, 1991, J NEUROSURG, V75, P856, DOI 10.3171/jns.1991.75.6.0856; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; Werner SC, 1941, J AMER MED ASSOC, V116, P578, DOI 10.1001/jama.1941.02820070028006; Whitlow PL, 2002, STROKE, V33, P1308, DOI 10.1161/01.STR.0000013947.17575.B3; WHOLEY MH, 2003, AM COLL CARD 52 ANN; Wityk RJ, 1996, STROKE, V27, P1974, DOI 10.1161/01.STR.27.11.1974; YADAR I, 2003, 15 ANN TRANSC CARD T; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; Zlokovic BV, 1997, NEUROSURGERY, V40, P805, DOI 10.1097/00006123-199704000-00028	140	96	117	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					804	813		10.1016/S0140-6736(04)15697-3	http://dx.doi.org/10.1016/S0140-6736(04)15697-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016492				2022-12-28	WOS:000220092000021
J	Altman, D; Sweeney, HL; Spudich, JA				Altman, D; Sweeney, HL; Spudich, JA			The mechanism of myosin VI translocation an its load-induced anchoring	CELL			English	Article							ACTIN-BASED MOTOR; OPTICAL TWEEZERS; FORCE; MOLECULES; STEPS; PROCESSIVITY; MODEL	Myosin VI is thought to function as both a transporter and an anchor. While in vitro studies suggest possible mechanisms for processive stepping, a biochemical basis for anchoring has not been demonstrated. Using optical trapping, we observed myosin VI stepping against applied forces. Step size is not strongly affected by such loads. At saturating ATP, myosin VI kinetics shows little dependence on load until, at forces near stall, its stepping slows dramatically as load increases. At subsaturating ATP or in the presence of ADP, stepping kinetics is significantly inhibited by load. From our results, we propose a mechanism of myosin VI stepping that predicts a regulation through load of the motor's roles as transporter and anchor.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Stanford University; University of Pennsylvania; Stanford University	Spudich, JA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	jspudich@stanford.edu	Sweeney, H Lee/F-1862-2010		NIGMS NIH HHS [GM33289, R01 GM033289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLOUL A, IN PRESS P NATL ACAD; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Boal D. H., 2002, MECH CELL; Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; Cramer LP, 2000, J CELL BIOL, V150, pF121, DOI 10.1083/jcb.150.6.F121; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Fabrizio JJ, 1998, DEVELOPMENT, V125, P1833; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fisher ME, 1999, P NATL ACAD SCI USA, V96, P6597, DOI 10.1073/pnas.96.12.6597; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Howard J., 2001, MECH MOTOR PROTEINS; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Mathews C.K., 1996, BIOCHEMISTRY; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rock RS, 2000, METHODS, V22, P373, DOI 10.1006/meth.2000.1089; Rogat AD, 2002, J CELL SCI, V115, P4855, DOI 10.1242/jcs.00149; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schwaiger I, 2002, NAT MATER, V1, P232, DOI 10.1038/nmat776; SHEETZ M, 1998, LASER TWEEZERS CELL; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Zhuang XW, 2003, CURR OPIN STRUC BIOL, V13, P88, DOI 10.1016/S0959-440X(03)00011-3	40	201	205	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2004	116	5					737	749		10.1016/S0092-8674(04)00211-9	http://dx.doi.org/10.1016/S0092-8674(04)00211-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006355	Bronze			2022-12-28	WOS:000221499700013
J	Chakravarty, S; Kee, HY; Volker, K				Chakravarty, S; Kee, HY; Volker, K			An explanation for a universality of transition temperatures in families of copper oxide superconductors	NATURE			English	Article							CARRIER DISTRIBUTION; PHASE FLUCTUATIONS; KINETIC-ENERGY; PSEUDOGAP; SIGNATURE; ORDER	A remarkable mystery of the copper oxide high-transition-temperature (T-c) superconductors is the dependence of T-c on the number of CuO2 layers, n, in the unit cell of a crystal. In a given family of these superconductors, T-c rises with the number of layers, reaching a peak at n = 3, and then declines(1): the result is a bell-shaped curve. Despite the ubiquity of this phenomenon, it is still poorly understood and attention has instead been mainly focused on the properties of a single CuO2 plane. Here we show that the quantum tunnelling of Cooper pairs between the layers(2) simply and naturally explains the experimental results, when combined with the recently quantified charge imbalance of the layers(3) and the latest notion of a competing order(4-9) nucleated by this charge imbalance that suppresses superconductivity. We calculate the bell-shaped curve and show that, if materials can be engineered so as to minimize the charge imbalance as n increases, T-c can be raised further.	Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada	University of California System; University of California Los Angeles; University of Toronto	Chakravarty, S (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.	sudip@physics.ucla.edu	Kee, Hae-Young/L-3991-2019					Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ARRIGONI E, 2003, ORGABSCONDMAT0309572; Balakirev FF, 2003, NATURE, V424, P912, DOI 10.1038/nature01890; Boris AV, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.277001; Bozovic I, 2003, NATURE, V422, P873, DOI 10.1038/nature01544; Carlson EW, 1999, PHYS REV LETT, V83, P612, DOI 10.1103/PhysRevLett.83.612; Chakravarty S, 1998, EUR PHYS J B, V5, P337, DOI 10.1007/s100510050451; Chakravarty S, 2001, INT J MOD PHYS B, V15, P2901, DOI 10.1142/S0217979201007002; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Chakravarty S, 1999, PHYS REV LETT, V82, P2366, DOI 10.1103/PhysRevLett.82.2366; CHAKRAVARTY S, 1993, SCIENCE, V261, P337, DOI 10.1126/science.261.5119.337; Feng DL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.107001; Jansen L, 2001, PHYSICA A, V289, P165, DOI 10.1016/S0378-4371(00)00480-5; Khlebnikov S, 1996, PHYS REV B, V53, P11964, DOI 10.1103/PhysRevB.53.R11964; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Kotegawa H, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.064515; Kotegawa H, 2001, J PHYS CHEM SOLIDS, V62, P171, DOI 10.1016/S0022-3697(00)00122-0; Kuzemskaya IG, 2000, J LOW TEMP PHYS, V118, P147, DOI 10.1023/A:1004638822300; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; Perali A, 1996, PHYS REV B, V54, P16216, DOI 10.1103/PhysRevB.54.16216; Sato T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067005; SCOTT BA, 1994, PHYSICA C, V230, P239, DOI 10.1016/0921-4534(94)90835-4; Tallon JL, 1999, PHYS STATUS SOLIDI B, V215, P531, DOI 10.1002/(SICI)1521-3951(199909)215:1<531::AID-PSSB531>3.0.CO;2-W; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; Tokunaga Y, 2000, PHYS REV B, V61, P9707, DOI 10.1103/PhysRevB.61.9707; Varma CM, 1999, PHYS REV LETT, V83, P3538, DOI 10.1103/PhysRevLett.83.3538; Yamauchi H, 1996, PHYSICA C, V263, P146, DOI 10.1016/0921-4534(96)00075-5	30	104	105	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					53	55		10.1038/nature02348	http://dx.doi.org/10.1038/nature02348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999276	Green Submitted			2022-12-28	WOS:000189363800031
J	Kidner, CA; Martienssen, RA				Kidner, CA; Martienssen, RA			Spatially restricted microRNA directs leaf polarity through ARGONAUTE1	NATURE			English	Article							FILAMENTOUS-FLOWER; RNA INTERFERENCE; CELL FATE; ARABIDOPSIS; GENE; MERISTEM; PLANTS; ENCODES; PROTEIN; FAMILY	Gene regulation by RNA interference requires the functions of the PAZ domain protein Argonaute. In plants, mutations in ARGONAUTE1 (AGO1) are associated with distinctive developmental defects that suggest a role for microRNA (miRNA) in organ polarity. Potential targets of miRNA regulation are the homeodomain/leucine zipper genes PHABULOSA (PHB) and PHAVOLUTA (PHV)(1). These genes are expressed in a polar fashion in leaf primordia and are required for adaxial cell fate(2,3). Here we show that a 21-nucleotide miRNA that directs cleavage of PHB/PHV messenger RNA accumulates first in the embryonic meristem, and then in the abaxial domain of the developing leaf. miRNA distribution is disrupted by mutations in AGO1, indicating that AGO1 affects the regulation of miRNA. In addition, interactions between homeodomain/leucine zipper genes and an allelic series of ago1 indicate that miRNA acts as a signal to specify leaf polarity.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Martienssen, RA (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	martiens@cshl.org		Kidner, Catherine/0000-0001-6426-3000				Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chen QY, 1999, DEVELOPMENT, V126, P2715; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Eshed Y, 2001, CURR BIOL, V11, P1251, DOI 10.1016/S0960-9822(01)00392-X; Foster TM, 2002, PLANT CELL, V14, P1497, DOI 10.1105/tpc.001685; Harris AN, 2001, DEVELOPMENT, V128, P2823; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kerstetter RA, 2001, NATURE, V411, P706, DOI 10.1038/35079629; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Lynn K, 1999, DEVELOPMENT, V126, P469; McConnell JR, 1998, DEVELOPMENT, V125, P2935; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; Otsuga D, 2001, PLANT J, V25, P223, DOI 10.1046/j.1365-313x.2001.00959.x; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Williams RW, 2002, P NATL ACAD SCI USA, V99, P6889, DOI 10.1073/pnas.072190799	30	392	452	4	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					81	84		10.1038/nature02366	http://dx.doi.org/10.1038/nature02366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999284				2022-12-28	WOS:000189363800039
J	Bagger, JP; Zindrou, D; Taylor, KM				Bagger, JP; Zindrou, D; Taylor, KM			Postoperative infection with meticillin-resistant Staphylococcus aureus and socioeconomic background	LANCET			English	Article								Infectious disease can be linked to social deprivation. We investigated whether postoperative infection with meticillin-resistant Staphylococcus aureus (MRSA) is related to socioeconomic background. Patients were stratified by social deprivation according to postcode. In a consecutive series of 1739 UK residents undergoing isolated coronary artery bypass grafting, 23 (1.3%) were infected with MRSA. We noted a graded relation between incidence of infection and social deprivation. Patients from the most deprived areas had a seven-fold higher infection rate (13 of 579 [2.2%]) than those from the least deprived areas (two of 580 [0.3%]; p=0.0040). Patients with MRSA infection had a six-fold higher mortality rate and a longer hospital stay than patients with no such infection. Our findings suggest that patients from deprived areas might be especially susceptible to postoperative infection with MRSA.	Univ London Imperial Coll Sci Technol & Med, London, England; Hammersmith Hosp, Cardiothorac Directorate, London W12 0HS, England	Imperial College London; Imperial College London	Bagger, JP (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.	p.bagger@ic.ac.uk						ARSENSIO A, 1996, CLIN PERFORM QUAL CA, V4, P67; Carstairs V., 1991, DEPRIVATION HLTH SCO; Coello R, 1997, J HOSP INFECT, V37, P39, DOI 10.1016/S0195-6701(97)90071-2; KIRKLIN JW, 1993, CARDIAC SURG, P195; LOURIA DB, 1996, INT J INFECT DIS, V1, P59; Samad A, 2002, J HOSP INFECT, V51, P43, DOI 10.1053/jhin.2002.1182	6	45	46	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	2004	363	9410					706	708		10.1016/S0140-6736(04)15647-X	http://dx.doi.org/10.1016/S0140-6736(04)15647-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001331				2022-12-28	WOS:000189266900014
J	Chen, J; de Felipe, KS; Clarke, M; Lu, H; Anderson, OR; Segal, G; Shuman, HA				Chen, J; de Felipe, KS; Clarke, M; Lu, H; Anderson, OR; Segal, G; Shuman, HA			Legionella effectors that promote nonlytic release from protozoa	SCIENCE			English	Article							LEGIONNAIRES-DISEASE; HUMAN-MONOCYTES; ACANTHAMOEBA-CASTELLANII; PNEUMOPHILA; CELLS; PHAGOSOME; DICTYOSTELIUM; SYSTEM; GROWTH; AMEBAS	Legionella pneumophila, the bacterial agent of legionnaires' disease, replicates intracellularly within a specialized vacuole of mammalian and protozoan host cells. Little is known about the specialized vacuole except that the Icm/Dot type IV secretion system is essential for its formation and maintenance. The Legionella genome database contains two open reading frames encoding polypeptides (LepA and LepB) with predicted coiled-coil regions and weak homology to SNAREs; these are delivered to host cells by an Icm/Dot - dependent mechanism. Analysis of mutant strains suggests that the Lep proteins may enable the Legionella to commandeer a protozoan exocytic pathway for dissemination of the pathogen.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Columbia Univ, Lamont Doherty Earth Observ, Dept Biol, Palisades, NY 10964 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Columbia University; Columbia University; Oklahoma Medical Research Foundation; Columbia University; Tel Aviv University	Shuman, HA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	has7@columbia.edu	Segal, Gil/H-7987-2019	Segal, Gil/0000-0003-0392-253X; Chen, John/0000-0002-2318-1823	NIAID NIH HHS [NIH-R01 AI23549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abd H, 2003, APPL ENVIRON MICROB, V69, P600, DOI 10.1128/AEM.69.1.600-606.2003; Berk SG, 1998, APPL ENVIRON MICROB, V64, P279; BREIMAN RF, 1990, JAMA-J AM MED ASSOC, V263, P2924, DOI 10.1001/jama.263.21.2924; Clarke M, 2002, J CELL SCI, V115, P2893; Coers J, 1999, NAT CELL BIOL, V1, P451, DOI 10.1038/15687; Conover GM, 2003, MOL MICROBIOL, V48, P305, DOI 10.1046/j.1365-2958.2003.03400.x; DEFELIPE KS, UNPUB; Essig A, 1997, APPL ENVIRON MICROB, V63, P1396, DOI 10.1128/AEM.63.4.1396-1399.1997; Harb OS, 2000, ENVIRON MICROBIOL, V2, P251, DOI 10.1046/j.1462-2920.2000.00112.x; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; JEON KW, 1995, J EUKARYOT MICROBIOL, V42, P1, DOI 10.1111/j.1550-7408.1995.tb01532.x; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; Maniak M, 2002, INT REV CYTOL, V221, P257; Molmeret M, 2002, MOL MICROBIOL, V43, P1139, DOI 10.1046/j.1365-2958.2002.02842.x; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; ROWBOTHAM TJ, 1986, ISRAEL J MED SCI, V22, P678; Segal G, 1999, MOL MICROBIOL, V33, P669, DOI 10.1046/j.1365-2958.1999.01512.x; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Sollner TH, 2002, DEV CELL, V2, P377, DOI 10.1016/S1534-5807(02)00161-2; Solomon JM, 2000, TRENDS MICROBIOL, V8, P478, DOI 10.1016/S0966-842X(00)01852-7; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; Steinert M, 1998, APPL ENVIRON MICROB, V64, P2256; Sturgill-Koszycki S, 2000, J EXP MED, V192, P1261, DOI 10.1084/jem.192.9.1261; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873	26	228	242	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1358	1361		10.1126/science.1094226	http://dx.doi.org/10.1126/science.1094226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988561				2022-12-28	WOS:000189238600048
J	Dietz, WH				Dietz, WH			Overweight in childhood and adolesence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Dietz, WH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30333 USA.							Strauss RS, 1998, J PEDIATR-US, V133, P67, DOI 10.1016/S0022-3476(98)70180-5	1	378	391	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					855	857		10.1056/NEJMp048008	http://dx.doi.org/10.1056/NEJMp048008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985480				2022-12-28	WOS:000189197300001
J	Fukami, H; Budd, AF; Paulay, G; Sole-Cava, A; Chen, CLA; Iwao, K; Knowlton, N				Fukami, H; Budd, AF; Paulay, G; Sole-Cava, A; Chen, CLA; Iwao, K; Knowlton, N			Conventional taxonomy obscures deep divergence between Pacific and Atlantic corals	NATURE			English	Article							EVOLUTIONARY RELATIONSHIPS; MITOCHONDRIAL-DNA; SUBSTITUTIONS; REGION	Only 17% of 111 reef-building coral genera and none of the 18 coral families with reef-builders are considered endemic to the Atlantic, whereas the corresponding percentages for the Indowest Pacific are 76% and 39%(1,2). These figures depend on the assumption that genera and families spanning the two provinces belong to the same lineages ( that is, they are monophyletic). Here we show that this assumption is incorrect on the basis of analyses of mitochondrial and nuclear genes. Pervasive morphological convergence at the family level has obscured the evolutionary distinctiveness of Atlantic corals. Some Atlantic genera conventionally assigned to different families are more closely related to each other than they are to their respective Pacific 'congeners'. Nine of the 27 genera of reef-building Atlantic corals belong to this previously unrecognized lineage, which probably diverged over 34 million years ago. Although Pacific reefs have larger numbers of more narrowly distributed species, and therefore rank higher in biodiversity hotspot analyses(3), the deep evolutionary distinctiveness of many Atlantic corals should also be considered when setting conservation priorities.	Smithsonian Trop Res Inst, Naos Marine Lab, Balboa, Panama; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biodivers & Conservat, La Jolla, CA 92093 USA; Univ Iowa, Dept Geosci, Iowa City, IA 52242 USA; Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA; Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; Acad Sinica, Inst Zool, Taipei 115, Taiwan; Akajima Marine Sci Lab, Okinawa 9013311, Japan	Smithsonian Institution; Smithsonian Tropical Research Institute; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Iowa; State University System of Florida; University of Florida; Universidade Federal do Rio de Janeiro; Academia Sinica - Taiwan	Knowlton, N (corresponding author), Smithsonian Trop Res Inst, Naos Marine Lab, Box 2072, Balboa, Panama.	nknowlton@ucsd.edu	Sole-Cava, Antonio M/G-4209-2011	Sole-Cava, Antonio M/0000-0003-0363-5821				Budd AF, 2000, CORAL REEFS, V19, P25, DOI 10.1007/s003380050222; Chen L, 2002, BIOORG MED CHEM LETT, V12, P137, DOI 10.1016/S0960-894X(01)00711-9; Cuif JP, 2003, ZOOL SCR, V32, P459, DOI 10.1046/j.1463-6409.2003.00133.x; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; KIMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P454, DOI 10.1073/pnas.78.1.454; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lopez Jose V., 1997, P1613; Mace GM, 2003, SCIENCE, V300, P1707, DOI 10.1126/science.1085510; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Paulay Gustav, 1997, P298; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Romano SL, 2000, B MAR SCI, V67, P1043; Shearer TL, 2002, MOL ECOL, V11, P2475, DOI 10.1046/j.1365-294X.2002.01652.x; Stolarski J, 2001, J PALEONTOL, V75, P1090, DOI 10.1666/0022-3360(2001)075<1090:TANSOE>2.0.CO;2; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; VAUGHAN TW, 1943, SPEC PAP GEOL SOC AM, V44, P1; Veron J.E.N., 2000, CORALS WORLD, V1-3; Veron J. E. N., 1995, CORALS SPACE TIME; Veron JEN, 1996, CORAL REEFS, V15, P1; WALLACE CC, 2002, P 9 INT COR REEF S B, V1, P33; Wells J. W., 1964, Zoologische Mededeelingen Leiden, V39, P375; Williams ST, 2001, MOL PHYLOGENET EVOL, V20, P375, DOI 10.1006/mpev.2001.0976	24	243	261	2	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					832	835		10.1038/nature02339	http://dx.doi.org/10.1038/nature02339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985760				2022-12-28	WOS:000189207500038
J	Sharpe, RM; Irvine, DS				Sharpe, RM; Irvine, DS			How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POLYBROMINATED DIPHENYL ETHERS; ESTROGEN SULFOTRANSFERASE; POLYCHLORINATED-BIPHENYLS; POTENT INHIBITION; SEMEN QUALITY; EXPOSURE; CANCER; HYPOSPADIAS; METABOLITES; PHTHALATE		Univ Edinburgh, Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh	Sharpe, RM (corresponding author), Univ Edinburgh, Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland.	r.sharpe@hrsu.mrc.ac.uk	Sharpe, Richard M/D-2725-2013	Sharpe, Richard M/0000-0003-1686-8085				Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.1289/ehp.00108979; Brouwer A, 1998, CHEMOSPHERE, V37, P1627, DOI 10.1016/S0045-6535(98)00230-6; Calle EE, 2002, CA-CANCER J CLIN, V52, P301, DOI 10.3322/canjclin.52.5.301; Cobellis L, 2003, HUM REPROD, V18, P1512, DOI 10.1093/humrep/deg254; Cohn BA, 2003, LANCET, V361, P2205, DOI 10.1016/S0140-6736(03)13776-2; Czene K, 2002, INT J CANCER, V99, P260, DOI 10.1002/ijc.10332; Damstra T., 2002, GLOBAL ASSESSMENT ST; Darbre PD, 2003, J APPL TOXICOL, V23, P89, DOI 10.1002/jat.899; Dhara VR, 2002, ARCH ENVIRON HEALTH, V57, P391, DOI 10.1080/00039890209601427; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Duty SM, 2003, EPIDEMIOLOGY, V14, P269, DOI 10.1097/00001648-200305000-00005; EVANS N, 2003, ENV HLTH WHAT IS CON; Evans SM, 2000, SCI TOTAL ENVIRON, V258, P73, DOI 10.1016/S0048-9697(00)00507-6; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Foster W, 2000, J CLIN ENDOCR METAB, V85, P2954, DOI 10.1210/jc.85.8.2954; Guvenius DM, 2003, ENVIRON HEALTH PERSP, V111, P1235, DOI 10.1289/ehp.5946; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; HOULIHAN J, 2003, NOT TOO PRETTY PHTHA; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kester MHA, 2002, J CLIN ENDOCR METAB, V87, P1142, DOI 10.1210/jc.87.3.1142; Koch HM, 2003, INT J HYG ENVIR HEAL, V206, P77, DOI 10.1078/1438-4639-00205; Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202; Mazdai A, 2003, ENVIRON HEALTH PERSP, V111, P1249, DOI 10.1289/ehp.6146; Mylchreest E, 1999, TOXICOL APPL PHARM, V156, P81, DOI 10.1006/taap.1999.8643; Nakai K, 2002, TOHOKU J EXP MED, V196, P89, DOI 10.1620/tjem.196.89; *NHANES, 2003, PUBL NAT CTR ENV HLT; OBRIEN P, 1999, FETAL PROGRAMMING IN; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; Pelletier C, 2003, Obes Rev, V4, P17, DOI 10.1046/j.1467-789X.2003.00085.x; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Pierik FH, 2002, HUM REPROD, V17, P1112, DOI 10.1093/humrep/17.4.1112; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917, DOI 10.1289/ehp.02110917; Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271; Schildkraut JM, 1999, CANCER EPIDEM BIOMAR, V8, P179; Sharpe RM, 2002, NAT CELL BIOL, V4, pS33, DOI 10.1038/ncb-nm-fertilityS33; Siddiqui MKJ, 2003, INT ARCH OCC ENV HEA, V76, P75, DOI 10.1007/s00420-002-0393-6; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Storgaard L, 2003, EPIDEMIOLOGY, V14, P278, DOI 10.1097/00001648-200305000-00006; Surveillance Epidemiology and End Results (SEER), PROGR SEER STAT DAT; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P1478, DOI 10.1289/ehp.6417; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P414, DOI 10.1289/ehp.5927; Toppari J, 2001, HUM REPROD UPDATE, V7, P282, DOI 10.1093/humupd/7.3.282; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; Wolff MS, 2000, ENVIRON RES, V84, P151, DOI 10.1006/enrs.2000.4075; Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89	51	305	316	1	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	2004	328	7437					447	451		10.1136/bmj.328.7437.447	http://dx.doi.org/10.1136/bmj.328.7437.447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976101	Green Published, Green Submitted			2022-12-28	WOS:000189161000023
J	Dian, BC; Clarkson, JR; Zwier, TS				Dian, BC; Clarkson, JR; Zwier, TS			Direct measurement of energy thresholds to conformational isomerization in tryptamine	SCIENCE			English	Article							RESOLVED ELECTRONIC SPECTROSCOPY; FLEXIBLE BIOMOLECULES; DYNAMICS; ACID; JET	Stimulated emission pumping (SEP)-hole filling spectroscopy and SEP-induced population transfer spectroscopy have been used to place narrow bounds on the energy thresholds for isomerization between individual reactant-product isomer pairs involving the seven conformational minima of tryptamine. The thresholds for isomerizing conformer A to all six other conformations divided into three groups at 750 wavenumbers (cm(-1)) (A-->B, F), 1000 cm(-1) [A-->C(2)], and 1280 to 1320 cm(-1) [A-->D, E, and C(1)]. The appearance of the first band and the absence of the band below it were used to place upper and lower bounds to the barrier heights for each process. The thresholds for A-->B and B-->A isomerizations were also combined to determine the relative energies of these two lowest energy minima. The combined data from all X-->Y isomerizations identify important isomerization pathways on the potential energy surface linking the minima.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zwier, TS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	zwier@purdue.edu						BURGI T, 1995, CHEM PHYS LETT, V246, P291, DOI 10.1016/0009-2614(95)01107-K; Carney JR, 2001, CHEM PHYS LETT, V341, P77, DOI 10.1016/S0009-2614(01)00464-X; Carney JR, 2000, J PHYS CHEM A, V104, P8677, DOI 10.1021/jp001433r; CONNELL LL, 1990, J PHYS CHEM-US, V94, P1229, DOI 10.1021/j100367a009; Dian BC, 2004, J CHEM PHYS, V120, P133, DOI 10.1063/1.1626540; DIAN BC, IN PRESS J CHEM PHYS; Ebata T, 2003, J CHEM PHYS, V119, P2947, DOI 10.1063/1.1596831; Evans DA, 2004, J CHEM PHYS, V120, P148, DOI 10.1063/1.1626541; Evans DA, 2003, J CHEM PHYS, V118, P3891, DOI 10.1063/1.1540099; Keske JC, 2000, ANNU REV PHYS CHEM, V51, P323, DOI 10.1146/annurev.physchem.51.1.323; KORTER TM, 2003, COMMUNICATION; Leitner DM, 2003, J PHYS CHEM A, V107, P10706, DOI 10.1021/jp0305180; PARK YD, 1986, J CHEM PHYS, V84, P6539, DOI 10.1063/1.450705; PHILIPS LA, 1988, J CHEM PHYS, V89, P85, DOI 10.1063/1.455464; Silva M, 2001, ANNU REV PHYS CHEM, V52, P811, DOI 10.1146/annurev.physchem.52.1.811; Wales D. J., 2003, ENERGY LANDSCAPES; WU YR, 1989, J CHEM PHYS, V91, P5278, DOI 10.1063/1.457573	17	148	148	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1169	1173		10.1126/science.1093731	http://dx.doi.org/10.1126/science.1093731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976308				2022-12-28	WOS:000189074700039
J	Garrett, BC				Garrett, BC			Ions at the air/water interface	SCIENCE			English	Editorial Material							SUM-FREQUENCY SPECTROSCOPY; ATMOSPHERIC CHEMISTRY; AQUEOUS SURFACES; WATER; SIMULATIONS; BR		PNNL, Div Chem Sci, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Garrett, BC (corresponding author), PNNL, Div Chem Sci, Richland, WA 99352 USA.	bruce.garrett@pnl.gov	Garrett, Bruce C/F-8516-2011					Ayotte P, 1999, J PHYS CHEM A, V103, P10665, DOI 10.1021/jp991963r; Dang LX, 2002, J PHYS CHEM B, V106, P235, DOI 10.1021/jp011853w; HU JH, 1995, J PHYS CHEM-US, V99, P8768, DOI 10.1021/j100021a050; Jungwirth P, 2001, J PHYS CHEM B, V105, P10468, DOI 10.1021/jp012750g; Jungwirth P, 2002, J PHYS CHEM B, V106, P6361, DOI 10.1021/jp020242g; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Laskin A, 2003, SCIENCE, V301, P340, DOI 10.1126/science.1085374; Liu DF, 2004, J PHYS CHEM B, V108, P2252, DOI 10.1021/jp036169r; Raymond EA, 2003, J PHYS CHEM B, V107, P546, DOI 10.1021/jp021366w; RAYMOND EA, IN PRESS J PHYS CH B; Richmond GL, 2002, CHEM REV, V102, P2693, DOI 10.1021/cr0006876; SAYKALLY RJ, COMMUNICATION; Seinfeld JH, 2000, SCIENCE, V288, P285, DOI 10.1126/science.288.5464.285; Wilson KR, 2002, J CHEM PHYS, V117, P7738, DOI 10.1063/1.1508364	14	215	216	5	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1146	1147		10.1126/science.1089801	http://dx.doi.org/10.1126/science.1089801			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976301				2022-12-28	WOS:000189074700031
J	Pawlowska, TE; Taylor, JW				Pawlowska, TE; Taylor, JW			Organization of genetic variation in individuals of arbuscular mycorrhizal fungi	NATURE			English	Article							EVOLUTION; EXCHANGES; ORIGIN; DRIVE	Arbuscular mycorrhizal (AM) fungi (Glomeromycota) are thought to be the oldest group of asexual multicellular organisms. They colonize the roots of most land plants, where they facilitate mineral uptake from the soil in exchange for plant-assimilated carbon(1). Cells of AM fungi contain hundreds of nuclei. Unusual polymorphism of ribosomal DNA observed in individual spores of AM fungi inspired a hypothesis that heterokaryosis-that is, the coexistence of many dissimilar nuclei in cells-occurs throughout the AM fungal life history(2,3). Here we report a genetic approach to test the hypothesis of heterokaryosis in AM fungi. Our study of the transmission of polymorphic genetic markers in natural isolates of Glomus etunicatum, coupled with direct amplification of rDNA from microdissected nuclei by polymerase chain reaction, supports the alternative hypothesis of homokaryosis, in which nuclei populating AM fungal individuals are genetically uniform. Intrasporal rDNA polymorphism contained in each nucleus signals a relaxation of concerted evolution(4), a recombination-driven process that is responsible for homogenizing rDNA repeats(5). Polyploid organization of glomeromycotan genomes could accommodate intranuclear rDNA polymorphism and buffer these apparently asexual organisms against the effects of accumulating mutations.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Pawlowska, TE (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	tpawlows@nature.berkeley.edu						ARNHEIM N, 1982, P NATL ACAD SCI-BIOL, V79, P4677, DOI 10.1073/pnas.79.15.4677; ARNHEIM N, 1980, P NATL ACAD SCI-BIOL, V77, P7323, DOI 10.1073/pnas.77.12.7323; BECARD G, 1993, PROTOPLASMA, V174, P62, DOI 10.1007/BF01404043; Bever JD, 1999, AM J BOT, V86, P1209, DOI 10.2307/2656768; Birky CW, 1996, GENETICS, V144, P427; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; Giovannetti M, 2003, APPL ENVIRON MICROB, V69, P616, DOI 10.1128/AEM.69.1.616-624.2003; Hosny M, 1998, GENOME, V41, P422, DOI 10.1139/gen-41-3-422; Kasuga T, 2002, MOL BIOL EVOL, V19, P2318, DOI 10.1093/oxfordjournals.molbev.a004056; Klironomos JN, 1999, BIOL FERT SOILS, V29, P277, DOI 10.1007/s003740050553; KONDRASHOV AS, 1994, NATURE, V370, P213, DOI 10.1038/370213a0; Kuhn G, 2001, NATURE, V414, P745, DOI 10.1038/414745a; MOGIE M, 1988, BIOL J LINN SOC, V35, P155, DOI 10.1111/j.1095-8312.1988.tb00463.x; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Redecker D, 2000, SCIENCE, V289, P1920, DOI 10.1126/science.289.5486.1920; Redecker D, 1999, FUNGAL GENET BIOL, V28, P238, DOI 10.1006/fgbi.1999.1173; REMY W, 1994, P NATL ACAD SCI USA, V91, P11841, DOI 10.1073/pnas.91.25.11841; SCHLOTTERER C, 1994, CURR BIOL, V4, P777, DOI 10.1016/S0960-9822(00)00175-5; Schussler A, 1999, NEW PHYTOL, V144, P205, DOI 10.1046/j.1469-8137.1999.00526.x; SIMON L, 1993, NATURE, V363, P67, DOI 10.1038/363067a0; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211; WENDEL JF, 1995, P NATL ACAD SCI USA, V92, P280, DOI 10.1073/pnas.92.1.280; Zhang JZ, 1997, MOL BIOL EVOL, V14, P1335, DOI 10.1093/oxfordjournals.molbev.a025743	25	167	180	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					733	737		10.1038/nature02290	http://dx.doi.org/10.1038/nature02290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973485				2022-12-28	WOS:000189026000043
J	Gerdes, K; Moller-Jensen, J; Ebersbach, G; Kruse, T; Nordstrom, K				Gerdes, K; Moller-Jensen, J; Ebersbach, G; Kruse, T; Nordstrom, K			Bacterial mitotic machineries	CELL			English	Review							CHROMOSOME PARTITIONING PROTEIN; P1 PLASMID CENTROMERE; ACTIN-LIKE FILAMENTS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CELL-CYCLE; DNA SEGREGATION; F PLASMID; REPLICATION ORIGIN; POLAR LOCALIZATION		Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	University of Southern Denmark; MRC Laboratory Molecular Biology; Uppsala University	Gerdes, K (corresponding author), Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark.	kgerdes@bmb.sdu.dk	Møller-Jensen, Jakob/AAO-8480-2020; Gerdes, Kenn/M-2420-2014; Gerdes, Kenn/AAS-5548-2021	Møller-Jensen, Jakob/0000-0002-6008-3771; Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612; Kruse, Thomas/0000-0002-2619-7388				AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Breuner A, 1996, MOL MICROBIOL, V20, P581, DOI 10.1046/j.1365-2958.1996.5351063.x; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Carballido-Lopez R, 2003, DEV CELL, V4, P19, DOI 10.1016/S1534-5807(02)00403-3; DAM M, 1994, J MOL BIOL, V236, P1289, DOI 10.1016/0022-2836(94)90058-2; Daniel RA, 2003, CELL, V113, P767, DOI 10.1016/S0092-8674(03)00421-5; Dasgupta S, 2000, EMBO REP, V1, P323, DOI 10.1093/embo-reports/kvd077; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; Easter J, 2002, MOL CELL, V10, P427, DOI 10.1016/S1097-2765(02)00594-4; Ebersbach G, 2001, P NATL ACAD SCI USA, V98, P15078, DOI 10.1073/pnas.261569598; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Errington J, 2001, NAT REV MOL CELL BIO, V2, P538, DOI 10.1038/35080005; Espeli O, 2003, MOL MICROBIOL, V50, P495, DOI 10.1046/j.1365-2958.2003.03736.x; Espeli O, 2003, MOL CELL, V11, P189, DOI 10.1016/S1097-2765(03)00013-3; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Godfrin-Estevenon AM, 2002, MOL MICROBIOL, V43, P39, DOI 10.1046/j.1365-2958.2002.02735.x; Gordon GS, 2002, MOL MICROBIOL, V44, P501, DOI 10.1046/j.1365-2958.2002.02901.x; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Graumann PL, 2001, BIOCHIMIE, V83, P53, DOI 10.1016/S0300-9084(00)01218-9; Hao JJ, 2002, J BACTERIOL, V184, P4857, DOI 10.1128/JB.184.17.4857-4867.2002; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; Ho TQ, 2002, EMBO J, V21, P1864, DOI 10.1093/emboj/21.7.1864; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jensen RB, 1997, J MOL BIOL, V269, P505, DOI 10.1006/jmbi.1997.1061; Jensen RB, 2002, NAT REV MOL CELL BIO, V3, P167, DOI 10.1038/nrm758; Jensen RB, 1999, P NATL ACAD SCI USA, V96, P10661, DOI 10.1073/pnas.96.19.10661; Jensen RB, 1999, EMBO J, V18, P4076, DOI 10.1093/emboj/18.14.4076; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kadoya R, 2002, MOL MICROBIOL, V45, P73, DOI 10.1046/j.1365-2958.2002.03016.x; Kim HJ, 2000, J BACTERIOL, V182, P1313, DOI 10.1128/JB.182.5.1313-1320.2000; Kim SK, 1999, P NATL ACAD SCI USA, V96, P8557, DOI 10.1073/pnas.96.15.8557; Kim SK, 1998, P NATL ACAD SCI USA, V95, P1523, DOI 10.1073/pnas.95.4.1523; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Koppes LJH, 1999, BIOCHIMIE, V81, P803, DOI 10.1016/S0300-9084(00)87163-1; Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504; Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x; Lee PS, 2003, J BACTERIOL, V185, P1326, DOI 10.1128/JB.185.4.1326-1337.2003; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lewis RA, 2002, MICROBIOL-SGM, V148, P537, DOI 10.1099/00221287-148-2-537; Li YF, 2002, PLASMID, V48, P174, DOI 10.1016/S0147-619X(02)00104-X; Li YF, 2002, MOL MICROBIOL, V46, P985, DOI 10.1046/j.1365-2958.2002.03234.x; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Marston AL, 1999, MOL CELL, V4, P673, DOI 10.1016/S1097-2765(00)80378-0; Mohl DA, 2001, MOL MICROBIOL, V42, P741, DOI 10.1046/j.1365-2958.2001.02643.x; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; MORI H, 1989, J BIOL CHEM, V264, P15535; Niki H, 1999, MOL MICROBIOL, V34, P498, DOI 10.1046/j.1365-2958.1999.01611.x; Niki H, 2000, GENE DEV, V14, P212; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; Niki H, 1998, GENE DEV, V12, P1036, DOI 10.1101/gad.12.7.1036; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; NORRIS V, 1995, MOL MICROBIOL, V16, P1051, DOI 10.1111/j.1365-2958.1995.tb02330.x; Onogi T, 2002, J BACTERIOL, V184, P3142, DOI 10.1128/JB.184.11.3142-3145.2002; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Quisel JD, 1999, MOL CELL, V4, P665, DOI 10.1016/S1097-2765(00)80377-9; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Roos M, 1999, BIOCHIMIE, V81, P797, DOI 10.1016/S0300-9084(00)87162-X; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Sharpe ME, 1998, MOL MICROBIOL, V28, P981, DOI 10.1046/j.1365-2958.1998.00857.x; Sherratt DJ, 2003, SCIENCE, V301, P780, DOI 10.1126/science.1084780; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Soufo HJD, 2003, CURR BIOL, V13, P1916, DOI 10.1016/j.cub.2003.10.024; Teleman AA, 1998, CURR BIOL, V8, P1102, DOI 10.1016/S0960-9822(98)70464-6; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; WATANABE E, 1989, MOL GEN GENET, V218, P431, DOI 10.1007/BF00332406; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Woldringh CL, 2002, MOL MICROBIOL, V45, P17, DOI 10.1046/j.1365-2958.2002.02993.x; Wu LJ, 2003, MOL MICROBIOL, V49, P1463, DOI 10.1046/j.1365-2958.2003.03643.x; Yamaichi Y, 2000, P NATL ACAD SCI USA, V97, P14656, DOI 10.1073/pnas.97.26.14656; Yates P, 1999, J MOL BIOL, V290, P627, DOI 10.1006/jmbi.1999.2909; YEHUDA SB, 2003, SCIENCE, V299, P532	92	105	108	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	2004	116	3					359	366		10.1016/S0092-8674(04)00116-3	http://dx.doi.org/10.1016/S0092-8674(04)00116-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016371	Bronze			2022-12-28	WOS:000188825800005
J	Samuels, Y; Wang, ZH; Bardelli, A; Silliman, N; Ptak, J; Szabo, S; Yan, H; Gazdar, A; Powell, DM; Riggins, GJ; Willson, JKV; Markowitz, S; Kinzler, KW; Vogelstein, B; Velculescu, VE				Samuels, Y; Wang, ZH; Bardelli, A; Silliman, N; Ptak, J; Szabo, S; Yan, H; Gazdar, A; Powell, DM; Riggins, GJ; Willson, JKV; Markowitz, S; Kinzler, KW; Vogelstein, B; Velculescu, VE			High frequency of mutations of the PIK3CA gene in human cancers	SCIENCE			English	Article									Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Virginia Hlth Syst, Div Gastroenterol Hepatol, Charlottesville, VA 22908 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Virginia; Howard Hughes Medical Institute; University Hospitals of Cleveland; Case Western Reserve University	Velculescu, VE (corresponding author), Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	velculescu@jhmi.edu	ravegnini, gloria/K-1330-2016; Velculescu, Victor/ABF-4846-2020; BARDELLI, Alberto/J-9721-2018	ravegnini, gloria/0000-0002-7774-402X; Velculescu, Victor/0000-0003-1195-438X; Samuels, Yardena/0000-0002-3349-7266; BARDELLI, Alberto/0000-0003-1647-5070	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA067900, R37CA057345, R29CA067900, R01CA057345, P50CA062924, U01CA088128, R01CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 62924, CA 57345, CA 67900, CA 43460, CA 88128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang TL, 2002, P NATL ACAD SCI USA, V99, P3076, DOI 10.1073/pnas.261714699	4	2701	2938	2	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	2004	304	5670					554	554		10.1126/science.1096502	http://dx.doi.org/10.1126/science.1096502			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	814LB	15016963				2022-12-28	WOS:000220975100039
J	Ferster, D				Ferster, D			Blocking plasticity in the visual cortex	SCIENCE			English	Editorial Material							PERIOD		Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Northwestern University	Ferster, D (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	ferster@northwestern.edu						Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HARLOW HF, 1959, SCI AM, V200, P68, DOI 10.1038/scientificamerican0659-68; Hensch TK, 2004, SCIENCE, V303, P1678, DOI 10.1126/science.1091031; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Matsuda Yuji, UNPUB; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Schneider JS, 2003, P NATL ACAD SCI USA, V100, P2951, DOI 10.1073/pnas.0130100100	12	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	2004	303	5664					1619	1621		10.1126/science.1096224	http://dx.doi.org/10.1126/science.1096224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016985				2022-12-28	WOS:000220151400028
J	Brugge, WR; Bounds, BC; Harris, NL; Cohen, A; Misdraji, J; Kotton, CN				Brugge, WR; Bounds, BC; Harris, NL; Cohen, A; Misdraji, J; Kotton, CN			A 28-year-old man with abdominal pain, fever, and a mass in the region of the pancreas. Tuberculous lymphadenitis involving the peripancreatic lymph nodes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SOLID-PSEUDOPAPILLARY TUMOR; MUCINOUS CYSTIC TUMORS; RARE CAUSE; OBSTRUCTIVE-JAUNDICE; FEATURES; INFECTIONS; MIMICKING; MARKERS		Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Brugge, WR (corresponding author), Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA.		Misdraji, Joseph/AAD-4588-2019; Misdraji, Joseph/AGX-4779-2022					Ahrendt SA, 2002, J GASTROINTEST SURG, V6, P66, DOI 10.1016/S1091-255X(01)00020-8; Al Muneef M, 2001, SCAND J GASTROENTERO, V36, P528, DOI 10.1080/003655201750153412; Auerbach O, 1944, AM J PATHOL, V20, P121; Balci NC, 2001, EUR J RADIOL, V38, P113, DOI 10.1016/S0720-048X(01)00296-0; Baril NB, 2000, ANN SURG, V231, P361, DOI 10.1097/00000658-200003000-00009; Borgdorff MW, 1998, AM J EPIDEMIOL, V147, P187; Compton CC, 2000, SEMIN DIAGN PATHOL, V17, P43; CROWSON MC, 1984, BRIT J SURG, V71, P239, DOI 10.1002/bjs.1800710328; Day AA, 1930, J INFECT DIS, V46, P26, DOI 10.1093/infdis/46.1.26; FAN ST, 1986, BRIT J SURG, V73, P373, DOI 10.1002/bjs.1800730517; Franco-Paredes C, 2002, AM J MED SCI, V323, P54, DOI 10.1097/00000441-200201000-00010; Gotzinger P, 2000, SHOCK, V14, P320, DOI 10.1097/00024382-200014030-00014; Ibrahim E M, 1987, Trop Gastroenterol, V8, P167; Klimstra DS, 2000, SEMIN DIAGN PATHOL, V17, P66; Kouraklis G, 2001, INT J PANCREATOL, V29, P151, DOI 10.1385/IJGC:29:3:151; Liu QD, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-1; Mallery JS, 2002, GASTROINTEST ENDOSC, V56, P218, DOI 10.1067/mge.2002.125826; Nataraj G, 2002, J Postgrad Med, V48, P113; Notohara K, 2000, AM J SURG PATHOL, V24, P1361, DOI 10.1097/00000478-200010000-00005; Ohiwa K, 1997, HPB Surg, V10, P315, DOI 10.1155/1997/61689; Paraf A, 1966, Rev Med Chir Mal Foie, V41, P101; Procacci C, 2001, EUR RADIOL, V11, P1626, DOI 10.1007/s003300100855; Procacci C, 1999, J COMPUT ASSIST TOMO, V23, P906, DOI 10.1097/00004728-199911000-00014; RADIN DR, 1991, AM J ROENTGENOL, V156, P487, DOI 10.2214/ajr.156.3.1899742; Redha S, 2001, Med J Malaysia, V56, P95; Riaz AA, 2002, SCAND J INFECT DIS, V34, P303, DOI 10.1080/00365540110077416; Robert JH, 2002, WORLD J SURG, V26, P612, DOI 10.1007/s00268-001-0278-y; Schneider A, 2002, PANCREATOLOGY, V2, P69, DOI 10.1159/000049451; Shan YS, 2000, PANCREAS, V21, P100, DOI 10.1097/00006676-200007000-00059; TRAVERSO LW, 1992, INFECT DIS CLIN N AM, V6, P601; Ueda K, 2000, J Hepatobiliary Pancreat Surg, V7, P610, DOI 10.1007/s005340070013; Verma Kusum, 2002, Indian Journal of Pediatrics, V69, pS39; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005	33	11	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1131	1138		10.1056/NEJMcpc030040	http://dx.doi.org/10.1056/NEJMcpc030040			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014187				2022-12-28	WOS:000220110100012
J	Johnson, J; Canning, J; Kaneko, T; Pru, JK; Tilly, JL				Johnson, J; Canning, J; Kaneko, T; Pru, JK; Tilly, JL			Germline stem cells and follicular renewal in the postnatal mammalian ovary	NATURE			English	Article							MEIOTIC RECOMBINATION; PRIMORDIAL FOLLICLES; HOMING EFFICIENCY; GENE-EXPRESSION; MICE; MOUSE; PROTEIN; TRANSPLANTATION; APOPTOSIS; PROPHASE	A basic doctrine of reproductive biology is that most mammalian females lose the capacity for germ-cell renewal during fetal life, such that a fixed reserve of germ cells (oocytes) enclosed within follicles is endowed at birth. Here we show that juvenile and adult mouse ovaries possess mitotically active germ cells that, based on rates of oocyte degeneration (atresia) and clearance, are needed to continuously replenish the follicle pool. Consistent with this, treatment of prepubertal female mice with the mitotic germ-cell toxicant busulphan eliminates the primordial follicle reserve by early adulthood without inducing atresia. Furthermore, we demonstrate cells expressing the meiotic entry marker synaptonemal complex protein 3 in juvenile and adult mouse ovaries. Wild-type ovaries grafted into transgenic female mice with ubiquitous expression of green fluorescent protein (GFP) become infiltrated with GFP-positive germ cells that form follicles. Collectively, these data establish the existence of proliferative germ cells that sustain oocyte and follicle production in the postnatal mammalian ovary.	Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tilly, JL (corresponding author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA.	jtilly@partners.org	Johnson, Johnson/HDL-9124-2022; Kaneko-Tarui, Tomoko/E-3319-2010; Canning, John/R-7421-2019	Kaneko-Tarui, Tomoko/0000-0001-5463-1551; Johnson, Joshua/0000-0002-6016-8089				Anderson L D, 1992, Md Med J, V41, P614; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; Brinster CJ, 2003, BIOL REPROD, V69, P412, DOI 10.1095/biolreprod.103.016519; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BUCCI LR, 1987, MUTAT RES, V176, P259, DOI 10.1016/0027-5107(87)90057-1; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Canning J, 2003, ENDOCRINOLOGY, V144, P9, DOI 10.1210/en.2002-220988; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; CRONE M, 1965, EXP CELL RES, V39, P678, DOI 10.1016/0014-4827(65)90071-6; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; FADDY MJ, 1976, J EXP ZOOL, V197, P173, DOI 10.1002/jez.1401970203; Faddy MJ, 2000, MOL CELL ENDOCRINOL, V163, P43, DOI 10.1016/S0303-7207(99)00238-5; FADDY MJ, 1987, CELL TISSUE KINET, V20, P551, DOI 10.1111/j.1365-2184.1987.tb01364.x; Foley JGD, 2002, J ANAT, V201, P477, DOI 10.1046/j.1469-7580.2002.00114.x; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; GENEROSO WM, 1971, MUTAT RES, V13, P171, DOI 10.1016/0027-5107(71)90010-8; Gosden R.G., 2003, REPROD MED MOL CELLU, P365; GOSDEN RG, 1983, BIOL REPROD, V28, P255, DOI 10.1095/biolreprod28.2.255; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; MATTISON DR, 1980, TOXICOL APPL PHARM, V53, P249, DOI 10.1016/0041-008X(80)90424-X; McLaren A, 1984, Symp Soc Exp Biol, V38, P7; Morita Y, 1999, ENDOCRINOLOGY, V140, P941, DOI 10.1210/en.140.2.941; Nagano MC, 2003, BIOL REPROD, V69, P701, DOI 10.1095/biolreprod.103.016352; Noce T, 2001, CELL STRUCT FUNCT, V26, P131, DOI 10.1247/csf.26.131; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Pearl R, 1921, J EXP ZOOL, V34, P101; PELLOUX MC, 1988, ACTA ENDOCRINOL-COP, V118, P218, DOI 10.1530/acta.0.1180218; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; PETERS H, 1970, PHILOS T R SOC B, V259, P91, DOI 10.1098/rstb.1970.0048; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; RICHARDSON SJ, 1987, J CLIN ENDOCR METAB, V65, P1231, DOI 10.1210/jcem-65-6-1231; Russell LB, 2000, MUTAT RES-GEN TOX EN, V464, P201, DOI 10.1016/S1383-5718(99)00185-0; SELDEN JR, 1993, CYTOMETRY, V14, P154, DOI 10.1002/cyto.990140207; SHIROMIZU K, 1984, PEDIATR PHARMACOL, V4, P213; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Szilvassy SJ, 2003, EXP HEMATOL, V31, P331, DOI 10.1016/S0301-472X(03)00005-5; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Tilly Jonathan L, 2003, Reprod Biol Endocrinol, V1, P11, DOI 10.1186/1477-7827-1-11; Torrente Y, 2003, J CELL BIOL, V162, P511, DOI 10.1083/jcb.200210006; Walpita D, 1999, P NATL ACAD SCI USA, V96, P5622, DOI 10.1073/pnas.96.10.5622; Walter I, 2000, HISTOCHEM J, V32, P99, DOI 10.1023/A:1004014211408; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yuan L, 2002, SCIENCE, V296, P1115, DOI 10.1126/science.1070594; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9; ZUCKERMAN S, 1951, RECENT PROG HORM RES, V6, P63	50	850	927	5	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					145	150		10.1038/nature02316	http://dx.doi.org/10.1038/nature02316			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014492				2022-12-28	WOS:000220103600039
J	Olesen, J; Diener, H; Husstedt, IW; Goadsby, PJ; Hall, D; Meier, U; Pollentier, S; Lesko, LM				Olesen, J; Diener, H; Husstedt, IW; Goadsby, PJ; Hall, D; Meier, U; Pollentier, S; Lesko, LM		BIBN 4096 BS Clinical Proof of Con	Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPERIOR SAGITTAL SINUS; EXTRACEREBRAL CIRCULATION; CEREBRAL-ARTERIES; CGRP-ANTAGONIST; NEUROPEPTIDE-Y; NERVE-FIBERS; SUBSTANCE-P; AGONISTS; RELEASE; PLACEBO	BACKGROUND: Calcitonin gene-related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks. METHODS: In an international, multicenter, double-blind, randomized clinical trial of BIBN 4096 BS, a highly specific and potent nonpeptide CGRP-receptor antagonist, 126 patients with migraine received one of the following: placebo or 0.25, 0.5, 1, 2.5, 5, or 10 mg of BIBN 4096 BS intravenously over a period of 10 minutes. A group-sequential adaptive treatment-assignment design was used to minimize the number of patients exposed. RESULTS: The 2.5-mg dose was selected, with a response rate of 66 percent, as compared with 27 percent for placebo (P=0.001). The BIBN 4096 BS group as a whole had a response rate of 60 percent. Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief. An effect was apparent after 30 minutes and increased over the next few hours. The overall rate of adverse events was 25 percent after the 2.5-mg dose of the drug and 20 percent for the BIBN 4096 BS group as a whole, as compared with 12 percent for placebo. The most frequent side effect was paresthesia. There were no serious adverse events. CONCLUSIONS: The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.	Univ Copenhagen, Glostrup Hosp, Dept Neurol, Copenhagen, Denmark; Univ Essen Gesamthsch, Dept Neurol, D-4300 Essen, Germany; Univ Hosp, Dept Neurol, Munster, Germany; Inst Neurol, London WC1N 3BG, England; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany	University of Copenhagen; University of Duisburg Essen; University of Munster; University of London; University College London; Boehringer Ingelheim; Boehringer Ingelheim	Olesen, J (corresponding author), Univ Copenhagen, Glostrup Hosp, Dept Neurol, DK-2600 Glostrup, Denmark.	jeol@glostruphosp.kbhamt.dk	Goadsby, Peter J/Z-1970-2019; Diener, Hans-Christoph/AAF-7275-2019; Goadsby, Peter J/B-2267-2009	Goadsby, Peter J/0000-0003-3260-5904; Olesen, Jes/0000-0002-6712-2702				Akerman S, 2002, BRIT J PHARMACOL, V137, P62, DOI 10.1038/sj.bjp.0704842; Bendtsen L, 2003, CEPHALALGIA, V23, P487, DOI 10.1046/j.1468-2982.2003.00528.x; BUZZI MG, 1991, NEUROPHARMACOLOGY, V30, P1193, DOI 10.1016/0028-3908(91)90165-8; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Edvinsson L., 2002, CEREBRAL BLOOD FLOW, V2nd ed; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Goadsby PJ, 2000, PROG NEUROBIOL, V62, P509, DOI 10.1016/S0301-0082(00)00010-1; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Hrobjartsson A, 2001, NEW ENGL J MED, V345, P304; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; IOVINO M, IN PRESS CEPHALALGIA; JANSEN I, 1986, ANN NEUROL, V20, P496, DOI 10.1002/ana.410200409; JANSEN I, 1992, PEPTIDES, V13, P527, DOI 10.1016/0196-9781(92)90084-G; JansenOlesen I, 1996, CEPHALALGIA, V16, P310, DOI 10.1046/j.1468-2982.1996.1605310.x; Jennison C, 2000, GROUP SEQUENTIAL MET; Lassen LH, 2002, CEPHALALGIA, V22, P54, DOI 10.1046/j.1468-2982.2002.00310.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Menken M, 2000, ARCH NEUROL-CHICAGO, V57, P418, DOI 10.1001/archneur.57.3.418; MOLLER S, 1995, STAT MED, V14, P911, DOI 10.1002/sim.4780140909; Moreno MJ, 2002, NEUROPHARMACOLOGY, V42, P568, DOI 10.1016/S0028-3908(02)00008-4; Petersen KA, 2003, CEPHALALGIA, V23, P729; Petersen KA, 2003, CEPHALALGIA, V23, P725; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; Roon KI, 2000, ANN NEUROL, V47, P238, DOI 10.1002/1531-8249(200002)47:2<238::AID-ANA15>3.3.CO;2-C; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Storer RJ, 1997, BRAIN, V120, P2171, DOI 10.1093/brain/120.12.2171; Storer RJ, 2003, CEPHALALGIA, V23, P726; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; UDDMAN R, 1985, NEUROSCI LETT, V62, P131, DOI 10.1016/0304-3940(85)90296-4; Williamson DJ, 1997, CEPHALALGIA, V17, P518, DOI 10.1046/j.1468-2982.1997.1704518.x; Williamson DJ, 1997, CEPHALALGIA, V17, P525, DOI 10.1046/j.1468-2982.1997.1704525.x; ZAGAMI AS, 1990, NEUROPEPTIDES, V16, P69, DOI 10.1016/0143-4179(90)90114-E	36	907	967	3	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1104	1110		10.1056/NEJMoa030505	http://dx.doi.org/10.1056/NEJMoa030505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014183	Green Published			2022-12-28	WOS:000220110100007
J	Ziebland, S; Chapple, A; Dumelow, C; Evans, D; Prinjha, S; Rozmovits, L				Ziebland, S; Chapple, A; Dumelow, C; Evans, D; Prinjha, S; Rozmovits, L			How the internet affects patients' experience of cancer: a qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH INFORMATION; SEEKING; NEEDS; CARE	Objective To explore how men and women with cancer talk about using the internet. Design Qualitative study using semistructured interviews collected by maximum variation sampling. Setting Respondents recruited throughout the United Kingdom during 2001-2. Participants 175 men and women aged 19-83 years, with one of five cancers (prostate, testicular, breast, cervical, or bowel) diagnosed since 1992 and selected to include different stages of treatment and follow up. Results Internet use, either directly or via friend or family, was widespread and reported by patients at all stages of cancer care, from early investigations to follow up after treatment. Patients used the internet to find second opinions, seek support and experiential information from other patients, interpret symptoms, seek information about tests and treatments, help interpret consultations, identify questions for doctors, make anonymous private inquiries, and raise awareness of the cancer. Patients also used it to check their doctors' advice covertly and to develop an expertise in their cancer. This expertise, reflecting familiarity with computer technology and medical terms, enabled patients to present a new type of "social fitness." Conclusion Cancer patients used the internet for a wide range of information and support needs, many of which are unlikely to be met through conventional health care. Serious illness often undermines people's self image as a competent member of society. Cancer patients may use the internet to acquire expertise to display competence in the face of serious illness.	Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, DIPEx Res Grp, Oxford OX3 7LF, England	University of Oxford	Ziebland, S (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, DIPEx Res Grp, Oxford OX3 7LF, England.	Sue.ziebland@dphpc.ox.ac.uk		Ziebland, Sue/0000-0002-6496-4859; Prinjha, Suman/0000-0001-8299-6646				Cant S., 1999, NEW MED PLURALISM AL; Cline RJW, 2001, HEALTH EDUC RES, V16, P671, DOI 10.1093/her/16.6.671; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Coyne IT, 1997, J ADV NURS, V26, P623, DOI 10.1046/j.1365-2648.1997.t01-25-00999.x; EATON L, 2002, BMJ-BRIT MED J, V325, P989; Eng TR, 1998, JAMA-J AM MED ASSOC, V280, P1371, DOI 10.1001/jama.280.15.1371; Eysenbach G, 2002, JAMA-J AM MED ASSOC, V287, P2691, DOI 10.1001/jama.287.20.2691; Goffman E, 1955, PSYCHIATR, V18, P213, DOI 10.1080/00332747.1955.11023008; GRAY JAM, 2002, RESOURCEFUL PATIENT; GROL R, 2001, EVIDENCE BASED PATIE; Hardey M, 1999, SOCIOL HEALTH ILL, V21, P820, DOI 10.1111/1467-9566.00185; Herxheimer A, 2000, LANCET, V355, P1540, DOI 10.1016/S0140-6736(00)02174-7; Jadad AR, 2003, BRIT MED J, V326, P1293, DOI 10.1136/bmj.326.7402.1293; Jenkins V, 2001, BRIT J CANCER, V84, P48, DOI 10.1054/bjoc.2000.1573; Leydon GM, 2000, BMJ-BRIT MED J, V320, P909, DOI 10.1136/bmj.320.7239.909; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; Marshall MN, 1996, FAM PRACT, V13, P522, DOI 10.1093/fampra/13.6.522; Mead Nicola, 2003, J Health Serv Res Policy, V8, P33, DOI 10.1258/13558190360468209; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Radley A, 1996, SOCIOL HEALTH ILL, V18, P220, DOI 10.1111/1467-9566.ep10934984; Reeves PM, 2001, HEALTH EDUC RES, V16, P709, DOI 10.1093/her/16.6.709; ROZMOVITS L, IN PRESS PATIENT ED; Stevenson FA, 2003, SOC SCI MED, V57, P513, DOI 10.1016/S0277-9536(02)00377-5; Strauss A., 1990, BASICS QUALITATIVE R	24	297	300	5	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					564	+		10.1136/bmj.328.7439.564	http://dx.doi.org/10.1136/bmj.328.7439.564			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	801JI	15001506	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000220091800025
J	Corbel, S				Corbel, S			Watching black holes spin	SCIENCE			English	Editorial Material							EXTRACTION; RADIATION; ENERGY; ORBIT		Univ Paris 07, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CEA, Serv Astrophys, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Corbel, S (corresponding author), Univ Paris 07, F-91191 Gif Sur Yvette, France.	corbel@discovery.saclay.cea.fr						Agol E, 2000, ASTROPHYS J, V528, P161, DOI 10.1086/308177; Begelman MC, 2003, SCIENCE, V300, P1898, DOI 10.1126/science.1085325; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Colbert EJM, 1999, ASTROPHYS J, V519, P89, DOI 10.1086/307356; CUI W, 1998, APJ, V492, P53; FENDER RP, COMPACT STELLAR XRAY; Genzel R, 2003, NATURE, V425, P934, DOI 10.1038/nature02065; Longair M. S., 1994, HIGH ENERGY ASTROPHY, V2; MCCLINTOCK JE, IN PRESS COMPACT STE; Miller JM, 2002, ASTROPHYS J, V570, pL69, DOI 10.1086/341099; MILLER JM, UNPUB ASTROPHYS J; MINIUTTI G, UNPUB; NOWAK MA, 1992, ASTROPHYS J, V393, P697, DOI 10.1086/171538; Orosz JA, 2002, ASTROPHYS J, V568, P845, DOI 10.1086/338984; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Wilms J, 2001, MON NOT R ASTRON SOC, V328, pL27, DOI 10.1046/j.1365-8711.2001.05066.x	17	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR  5	2004	303	5663					1480	1481		10.1126/science.1091768	http://dx.doi.org/10.1126/science.1091768			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800AA	15001767				2022-12-28	WOS:000220000100029
J	Ngai, J				Ngai, J			Science imitates art: The cloning of mice from olfactory sensory neurons	CELL			English	Editorial Material							EXPRESSION; MOUSE	The functional identity of an olfactory sensory neuron is defined by its expression of one odorant receptor from a large multigene family. The complexity of this process has led to speculation that DNA rearrangements are used to limit the expression of one receptor gene per cell. However, a recent report in Nature directly rules out irreversible DNA rearrangements as a mechanism for odorant receptor gene choice.	Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ngai, J (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.							Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chun J, 1999, CURR BIOL, V9, pR251, DOI 10.1016/S0960-9822(99)80156-0; EGGAN K, 2004, IN PRESS NATURE; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; Qasba P, 1998, J NEUROSCI, V18, P227; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398	10	0	0	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	2004	116	5					636	637		10.1016/S0092-8674(04)00212-0	http://dx.doi.org/10.1016/S0092-8674(04)00212-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YQ	15006346	Bronze			2022-12-28	WOS:000221499700004
J	Pomerantz, RJ; Nunnari, G				Pomerantz, RJ; Nunnari, G			HIV and GB virus C - Can two viruses be better than one?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Thomas Jefferson Univ, Ctr Human Virol & Biodef, Div Infect Dis & Environm Med, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Ctr Human Virol & Biodef, Div Infect Dis & Environm Med, Philadelphia, PA 19107 USA.		Nunnari, Giuseppe/AAC-1928-2019	Nunnari, Giuseppe/0000-0002-8113-8452					0	27	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					963	965		10.1056/NEJMp048004	http://dx.doi.org/10.1056/NEJMp048004			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999105				2022-12-28	WOS:000189363600001
J	Juul, K; Tybjaerg-Hansen, A; Schnohr, P; Nordestgaard, BG				Juul, K; Tybjaerg-Hansen, A; Schnohr, P; Nordestgaard, BG			Factor V Leiden and the risk for venous thromboembolism in the adult Danish population	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; PULMONARY-EMBOLISM; G20210A MUTATION; PREVALENCE; GENE; PROTHROMBIN; RESISTANCE; ASSOCIATION; CARRIERS	Background: Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case-control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers. Objective: To estimate risks for venous thromboembolism in the adult Danish population according to factor V Leiden genotype. Design: Cohort study with 23 years of follow-up. Setting: Adult Danish population. Participants: 9253 randomly selected individuals. Measurements: Hospitalization and death from venous thromboembolism, factor V Leiden genotype, and additional thromboembolic risk factors. Results: Adjusted hazard ratios in heterozygotes; and homozygotes compared with noncarriers were 2.7 (95% CI, 1.8 to 3.8) and 18 (CI, 4.1 to 41) for venous thromboembolism overall, 2.4 (CI, 1.3 to 3.8) and 22 (CI, 0 to 60) for deep venous thrombosis, and 3.0 (CI, 1.7 to 4.9) and 11 (CI, 0 to 33) for pulmonary embolism. The lowest absolute 10-year risks for venous thromboembolism in factor V Leiden heterozygotes; and homozygotes-0.7% (CI, 0.5% to 1.0%) and 3% (CI, 1% to 8%)-were found in nonsmokers younger than 40 years of age with a body mass index below 25 kg/m(2); the corresponding highest risks-10% (Cl, 7% to 14%) and 51% (CI, 13% to 100%)-were found in smokers older than 60 years of age with a body mass index above 30 kg/m(2). Conclusions: Hazard ratios for venous thromboembolism in factor V Leiden heterozygotes and homozygotes compared with noncarriers in the adult Danish population were approximately 3 and 18, respectively. The simultaneous presence of smoking, obesity, and old age resulted in absolute 10-year thromboembolic risks of 10% in heterozygotes and 51% in homozygotes.	Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Univ Copenhagen, Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark; Bispebjerg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Nordestgaard, BG (corresponding author), Herlev Univ Hosp, Dept Clin Biochem, Herlev Ringvej 75, DK-2730 Herlev, Denmark.	brno@herlevhosp.kbhamt.dk	Nordestgaard, Borge Gronne/ABF-1310-2020					Appleyard M., 1989, SCAND J SOC MED, V41, P1; Aznar J, 2000, HAEMATOLOGICA, V85, P1271; Bounameaux H, 2000, LANCET, V356, P182, DOI 10.1016/S0140-6736(00)02476-4; Cattaneo M, 1999, THROMB RES, V93, P1, DOI 10.1016/S0049-3848(98)00136-4; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; Chamouard P, 1999, GASTROENTEROLOGY, V116, P144, DOI 10.1016/S0016-5085(99)70238-6; de Moerloose P, 2000, BRIT J HAEMATOL, V110, P125, DOI 10.1046/j.1365-2141.2000.02039.x; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Franco RF, 2001, HUM GENET, V109, P369, DOI 10.1007/s004390100593; Gaustadnes M, 1999, BLOOD COAGUL FIBRIN, V10, P251, DOI 10.1097/00001721-199907000-00006; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; JENSEN G, 1984, ACTA MED SCAND, P11; Juul K, 2002, BLOOD, V100, P3, DOI 10.1182/blood-2002-01-0111; Larsen TB, 1998, THROMB RES, V89, P211, DOI 10.1016/S0049-3848(98)00010-3; Leroyer C, 1997, CHEST, V111, P1603, DOI 10.1378/chest.111.6.1603; Manten B, 1996, THROMB HAEMOSTASIS, V76, P510; Margaglione M, 1998, ANN INTERN MED, V129, P89, DOI 10.7326/0003-4819-129-2-199807150-00003; Marinelli I, 1997, THROMB HAEMOSTASIS, V77, P440; Meyer G, 2001, AM J MED, V110, P12, DOI 10.1016/S0002-9343(00)00653-7; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Salomon O, 1999, ARTERIOSCL THROM VAS, V19, P511, DOI 10.1161/01.ATV.19.3.511; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Turkstra F, 1999, THROMB HAEMOSTASIS, V81, P345	27	139	141	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					330	337		10.7326/0003-4819-140-5-200403020-00008	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996674				2022-12-28	WOS:000189246800002
J	McPherson, K; Hemminki, E				McPherson, K; Hemminki, E			Synthesising licensing data to assess drug safety	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL HORMONE-THERAPY; REPLACEMENT THERAPY; CLINICAL-TRIALS; MORTALITY; DISEASE; EVENTS; HEALTH; RISK		Churchill Hosp, Res Inst, Nuffield Dept Obstet & Gynaecol, Oxford OX3 7LJ, England; Hlth & Social Serv, Natl Res & Dev Ctr Welf & Hlth, Helsinki 00531, Finland	University of Oxford; Finland National Institute for Health & Welfare	McPherson, K (corresponding author), Churchill Hosp, Res Inst, Nuffield Dept Obstet & Gynaecol, Oxford OX3 7LJ, England.	klim.mcpherson@obstetrics-gynaecology.oxford.ac.uk						Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Cuervo LG, 2003, BMJ-BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Daly E, 1996, MATURITAS, V23, P247, DOI 10.1016/0378-5122(95)00978-7; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1993, J CLIN EPIDEMIOL, V46, P211, DOI 10.1016/0895-4356(93)90068-C; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Hemminki E, 2000, LANCET, V355, P566, DOI 10.1016/S0140-6736(99)03432-7; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MATHEWS KA, 1989, NEW ENGL J MED, V321, P641; Michels KB, 2003, CIRCULATION, V107, P1830, DOI 10.1161/01.CIR.0000064601.65196.DF; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; Roberts I, 1998, LANCET, V352, P726, DOI 10.1016/S0140-6736(98)07600-4; SKEGG DCG, 1977, BRIT MED J, V2, P1523, DOI 10.1136/bmj.2.6101.1523; *WRIT GROUP WOM HL, 2002, JAMA-J AM MED ASSOC, V288, P942; 1997, BMJ, V315, P676	16	24	25	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					518	520		10.1136/bmj.328.7438.518	http://dx.doi.org/10.1136/bmj.328.7438.518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988197	Green Published			2022-12-28	WOS:000220002900038
J	Roddy, E				Roddy, E			ABC of smoking cessation - Bupropion and other non-nicotine pharmacotherapies	BRITISH MEDICAL JOURNAL			English	Review									Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG7 2RD, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Roddy, E (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG7 2RD, England.							Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; *ROYAL COLL PHYS L, 2000, NIC ADD BRIT; 2003, COCHRANE DATABASE SY	3	54	59	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					509	511		10.1136/bmj.328.7438.509	http://dx.doi.org/10.1136/bmj.328.7438.509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988194	Green Published			2022-12-28	WOS:000220002900035
J	Klaholz, BP; Myasnikov, AG; van Heel, M				Klaholz, BP; Myasnikov, AG; van Heel, M			Visualization of release factor 3 on the ribosome during termination of protein synthesis	NATURE			English	Article							ELONGATION-FACTOR-G; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI; FACTOR-TU; ANGSTROM RESOLUTION; CODON-RECOGNITION; CRYSTAL-STRUCTURE; GTPASE ACTIVITY; 70S RIBOSOME; FACTOR RF3	Termination of protein synthesis by the ribosome requires two release factor (RF) classes. The class II RF3 is a GTPase that removes class I RFs (RF1 or RF2) from the ribosome after release of the nascent polypeptide(1-3). RF3 in the GDP state binds to the ribosomal class I RF complex, followed by an exchange of GDP for GTP and release of the class I RF. As GTP hydrolysis triggers release of RF3 (ref. 4), we trapped RF3 on Escherichia coli ribosomes using a nonhydrolysable GTP analogue. Here we show by cryo-electron microscopy that the complex can adopt two different conformational states. In 'state 1', RF3 is pre-bound to the ribosome, whereas in 'state 2' RF3 contacts the ribosome GTPase centre. The transfer RNA molecule translocates from the peptidyl site in state 1 to the exit site in state 2. This translocation is associated with a large conformational rearrangement of the ribosome. Because state 1 seems able to accommodate simultaneously both RF3 and RF2, whose position is known from previous studies(5,6), we can infer the release mechanism of class I RFs.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; Univ Strasbourg 1, CNRS, INSERM,Dept Struct Biol & Gen, Inst Genet & Mol & Cellular Biol, F-67404 Illkirch Graffenstaden, France; Moscow MV Lomonosov State Univ, Dept Mol Biol, Belozersky Inst, Moscow 119899, Russia	Imperial College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Lomonosov Moscow State University	Klaholz, BP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England.	klaholz@igbmc.u-strasbg.fr	Myasnikov, Alexander/T-4654-2018					Aevarsson A, 1995, J MOL EVOL, V41, P1096; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Grentzmann G, 1998, RNA, V4, P973, DOI 10.1017/S1355838298971576; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; Laurberg M, 2000, J MOL BIOL, V303, P593, DOI 10.1006/jmbi.2000.4168; Matadeen R, 1999, STRUCTURE, V7, P1575, DOI 10.1016/S0969-2126(00)88348-3; Mora L, 2003, MOL MICROBIOL, V50, P1467, DOI 10.1046/j.1365-2958.2003.03799.x; Plewniak F, 2003, NUCLEIC ACIDS RES, V31, P3829, DOI 10.1093/nar/gkg518; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; ROSENTHAL PB, 2003, J MOL BIOL, V31, P721; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wilson DN, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P495; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	28	106	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	2004	427	6977					862	865		10.1038/nature02332	http://dx.doi.org/10.1038/nature02332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985767				2022-12-28	WOS:000189207500045
J	Wyithe, JSB; Loeb, A				Wyithe, JSB; Loeb, A			A large neutral fraction of cosmic hydrogen a billion years after the Big Bang	NATURE			English	Article							PROBE WMAP OBSERVATIONS; BLACK-HOLE; QUASAR; REIONIZATION; HELIUM; GALAXY	The fraction of ionized hydrogen left over from the Big Bang provides evidence for the time of formation of the first stars and quasar black holes in the early Universe; such objects provide the high-energy photons necessary to ionize hydrogen. Spectra of the two most distant known quasars(1) show nearly complete absorption of photons with wavelengths shorter than the Lyman alpha transition of neutral hydrogen, indicating that hydrogen in the intergalactic medium (IGM) had not been completely ionized at a redshift of z approximate to 6.3, about one billion years after the Big Bang. Here we show that the IGM surrounding these quasars had a neutral hydrogen fraction of tens of per cent before the quasar activity started, much higher than the previous lower limits(1,2) of similar to0.1 per cent. Our results, when combined with the recent inference of a large cumulative optical depth to electron scattering after cosmological recombination(3) therefore suggest the presence of a second peak in the mean ionization history of the Universe.	Harvard Univ, Dept Astron, Cambridge, MA 02138 USA; Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia	Harvard University; University of Melbourne	Loeb, A (corresponding author), Harvard Univ, Dept Astron, 60 Garden St, Cambridge, MA 02138 USA.	aloeb@cfa.harvard.edu		Wyithe, Stuart/0000-0001-7956-9758				Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; BARKANA R, 2003, IN PRESS ASTROPHYS J; Cen RY, 2000, ASTROPHYS J, V542, pL75, DOI 10.1086/312937; Cen RY, 2003, ASTROPHYS J, V591, pL5, DOI 10.1086/377068; ELVIS M, 1994, ASTROPHYS J SUPPL S, V95, P1, DOI 10.1086/192093; Fan XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030; Ferrarese L, 2002, ASTROPHYS J, V578, P90, DOI 10.1086/342308; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Haiman Z, 2002, ASTROPHYS J, V576, pL1, DOI 10.1086/343101; Hu EM, 2002, ASTROPHYS J, V568, pL75, DOI 10.1086/340424; Jakobsen P, 2003, ASTRON ASTROPHYS, V397, P891, DOI 10.1051/0004-6361:20021579; Kogut A, 2003, ASTROPHYS J SUPPL S, V148, P161, DOI 10.1086/377219; Madau P, 2000, ASTROPHYS J, V542, pL69, DOI 10.1086/312934; Martini P, 2001, ASTROPHYS J, V547, P12, DOI 10.1086/318331; MARTINI P, 2003, ORGASTROPH0309650; MARTINI P, 2003, ORGASTROPH0304009; Miralda-Escude J, 1998, ASTROPHYS J, V501, P15, DOI 10.1086/305799; Miralda-Escude J, 2000, ASTROPHYS J, V530, P1, DOI 10.1086/308330; Pentericci L, 2002, ASTRON J, V123, P2151, DOI 10.1086/340077; Richards GT, 2002, ASTRON J, V124, P1, DOI 10.1086/341167; SHAPIRO PR, 1987, ASTROPHYS J, V321, pL107, DOI 10.1086/185015; Shields GA, 2003, ASTROPHYS J, V583, P124, DOI 10.1086/345348; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Telfer RC, 2002, ASTROPHYS J, V565, P773, DOI 10.1086/324689; Volonteri M, 2003, ASTROPHYS J, V582, P559, DOI 10.1086/344675; Walter F, 2003, NATURE, V424, P406, DOI 10.1038/nature01821; White RL, 2003, ASTRON J, V126, P1, DOI 10.1086/375547; Willott CJ, 2003, ASTROPHYS J, V587, pL15, DOI 10.1086/375126; Wyithe JSB, 2003, ASTROPHYS J, V586, P693, DOI 10.1086/367721; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x	30	118	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2004	427	6977					815	817		10.1038/nature02336	http://dx.doi.org/10.1038/nature02336			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777WU	14985754	Green Submitted			2022-12-28	WOS:000189207500032
J	Malterud, K				Malterud, K			Health needs of women who have sex with women - Methodological assumptions underlying conclusions should have been questioned	BRITISH MEDICAL JOURNAL			English	Letter									Univ Bergen, Div Gen Practice, N-5018 Bergen, Norway	University of Bergen	Malterud, K (corresponding author), Univ Bergen, Div Gen Practice, Kalfarvn 31, N-5018 Bergen, Norway.	kirsti.malterud@isf.uib.no						Hughes C, 2003, BMJ-BRIT MED J, V327, P939, DOI 10.1136/bmj.327.7421.939; Solarz A.L., 1999, LESBIAN HLTH CURRENT	2	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					463	464		10.1136/bmj.328.7437.463-b	http://dx.doi.org/10.1136/bmj.328.7437.463-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976115	Green Published			2022-12-28	WOS:000189161000038
J	Lindsay, R				Lindsay, R			Bone loss after cardiac transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA		Lindsay, R (corresponding author), Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA.								0	9	14	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					751	754		10.1056/NEJMp038240	http://dx.doi.org/10.1056/NEJMp038240			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973219				2022-12-28	WOS:000189006400002
J	Gearhart, J				Gearhart, J			New human embryonic stem-cell lines - More is better	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOUSE EMBRYOS		Johns Hopkins Univ, Inst Cell Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Gearhart, J (corresponding author), Johns Hopkins Univ, Inst Cell Engn, Baltimore, MD 21218 USA.							Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Dawson L, 2003, FERTIL STERIL, V80, P1077, DOI 10.1016/S0015-0282(03)02218-0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Thomson JA, 1998, SCIENCE, V282, P1827	5	28	29	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1275	1276		10.1056/NEJMp048045	http://dx.doi.org/10.1056/NEJMp048045			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	14999089				2022-12-28	WOS:000220393900001
J	Venkatramani, J; Mitchell, P				Venkatramani, J; Mitchell, P			Ocular and systemic causes of retinopathy in patients without diabetes mellitus	BRITISH MEDICAL JOURNAL			English	Review							RETINAL MICROVASCULAR ABNORMALITIES; LUPUS-ERYTHEMATOSUS; VEIN OCCLUSION; OLDER PERSONS; RISK-FACTORS; HYPERTENSION; DISEASE; POPULATION; EYE; MANIFESTATIONS		Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore; Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia	National University of Singapore; University of Sydney	Mitchell, P (corresponding author), Westmead Hosp, Westmead Millennium Inst, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.	paul_mitchell@wmi.usyd.edu.au	Mitchell, Paul/P-1498-2014					BROWN GC, 1988, INT OPHTHALMOL, V11, P239, DOI 10.1007/BF00131023; BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494; Budning A S, 1998, J AAPOS, V2, P356, DOI 10.1016/S1091-8531(98)90034-9; Charache S, 1996, HEMATOL ONCOL CLIN N, V10, P1357, DOI 10.1016/S0889-8588(05)70406-8; Chatterjee S, 2002, J HUM HYPERTENS, V16, P667, DOI 10.1038/sj.jhh.1001472; Demirci FYK, 1998, INT OPHTHALMOL, V22, P323, DOI 10.1023/A:1006305705080; Dominguez L N, 1997, Trans Am Ophthalmol Soc, V95, P367; Dominguez LN, 1997, T AM OPHTHAL SOC, P95; JABS DA, 1989, OPHTHALMOLOGY, V96, P1092; JABS DA, 1986, ARCH OPHTHALMOL-CHIC, V104, P564; JABS DA, 2001, RETINA, V2, P1410; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; KLINKHOFF AV, 1986, ARTHRITIS RHEUM-US, V29, P1152, DOI 10.1002/art.1780290914; Mansour AM, 2000, OPHTHALMOLOGICA, V214, P399, DOI 10.1159/000027532; Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012; RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9; SCHACHAT AP, 1989, ARCH OPHTHALMOL-CHIC, V107, P697, DOI 10.1001/archopht.1989.01070010715033; SCHOUTEN EG, 1986, INT J EPIDEMIOL, V15, P234; Shields JA, 2001, AM J OPHTHALMOL, V131, P561, DOI 10.1016/S0002-9394(00)00883-7; STOLK RP, 1995, DIABETES, V44, P11, DOI 10.2337/diabetes.44.1.11; van Leiden HA, 2003, ARCH OPHTHALMOL-CHIC, V121, P245, DOI 10.1001/archopht.121.2.245; Williamson TH, 1997, BRIT J OPHTHALMOL, V81, P698, DOI 10.1136/bjo.81.8.698; Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X; Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83	26	25	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 13	2004	328	7440					625	629		10.1136/bmj.328.7440.625	http://dx.doi.org/10.1136/bmj.328.7440.625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016695	Green Published			2022-12-28	WOS:000220208100021
J	Ravelli, RBG; Gigant, B; Curmi, PA; Jourdain, I; Lachkar, S; Sobel, A; Knossow, M				Ravelli, RBG; Gigant, B; Curmi, PA; Jourdain, I; Lachkar, S; Sobel, A; Knossow, M			Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain	NATURE			English	Article							ALPHA-BETA-TUBULIN; BINDING-SITE; IN-VITRO; PROTEIN; FAMILY; IDENTIFICATION; MODEL	Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions. Their dynamic instability is controlled by numerous compounds and proteins, including colchicine(1) and stathmin family proteins(2,3). The way in which microtubule instability is regulated at the molecular level has remained elusive, mainly because of the lack of appropriate structural data. Here, we present the structure, at 3.5 Angstrom resolution, of tubulin in complex with colchicine and with the stathmin-like domain (SLD) of RB3. It shows the interaction of RB3-SLD with two tubulin heterodimers in a curved complex capped by the SLD amino-terminal domain, which prevents the incorporation of the complexed tubulin into microtubules. A comparison with the structure of tubulin in protofilaments(4) shows changes in the subunits of tubulin as it switches from its straight conformation to a curved one. These changes correlate with the loss of lateral contacts and provide a rationale for the rapid microtubule depolymerization characteristic of dynamic instability. Moreover, the tubulin-colchicine complex sheds light on the mechanism of colchicine's activity: we show that colchicine binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.	CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; UPMC, INSERM, U440, Inst Fer Moulin, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; European Molecular Biology Laboratory (EMBL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Knossow, M (corresponding author), CNRS, UPR 9063, Lab Enzymol & Biochim Struct, Batiment 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	knossow@lebs.cnrs-gif.fr	CURMI, Patrick/G-4036-2013	CURMI, Patrick A./0000-0001-5045-8501; Ravelli, Raimond/0000-0001-6056-5888; Gigant, Benoit/0000-0002-5946-6759				Bai RL, 2000, J BIOL CHEM, V275, P40443, DOI 10.1074/jbc.M005299200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; BURNS RG, 1992, FEBS LETT, V297, P205, DOI 10.1016/0014-5793(92)80538-R; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diederichs K, 2003, ACTA CRYSTALLOGR D, V59, P903, DOI 10.1107/S0907444903006516; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; Honnappa S, 2003, J BIOL CHEM, V278, P38926, DOI 10.1074/jbc.M305546200; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; Steinman M, 2000, CHIM OGGI, V18, P19; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WILSON L, 1974, FED PROC, V33, P158; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	30	1240	1268	6	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					198	202		10.1038/nature02393	http://dx.doi.org/10.1038/nature02393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014504				2022-12-28	WOS:000220103600053
J	Schmidt, MW; Spero, HJ; Lea, DW				Schmidt, MW; Spero, HJ; Lea, DW			Links between salinity variation in the Caribbean and North Atlantic thermohaline circulation	NATURE			English	Article							SEA-SURFACE TEMPERATURE; TROPICAL ATLANTIC; OCEAN; MG/CA; FORAMINIFERA; VARIABILITY; CLIMATE; ICE; AGE	Variations in the strength of the North Atlantic Ocean thermohaline circulation have been linked to rapid climate changes(1) during the last glacial cycle through oscillations in North Atlantic Deep Water formation and northward oceanic heat flux(2-4). The strength of the thermohaline circulation depends on the supply of warm, salty water to the North Atlantic, which, after losing heat to the atmosphere, produces the dense water masses that sink to great depths and circulate back south(2). Here we analyse two Caribbean Sea sediment cores, combining Mg/Ca palaeo-thermometry with measurements of oxygen isotopes in foraminiferal calcite in order to reconstruct tropical Atlantic surface salinity(5,6) during the last glacial cycle. We find that Caribbean salinity oscillated between saltier conditions during the cold oxygen isotope stages 2, 4 and 6, and lower salinities during the warm stages 3 and 5, covarying with the strength of North Atlantic Deep Water formation(7). At the initiation of the Bolling/Allerod warm interval, Caribbean surface salinity decreased abruptly, suggesting that the advection of salty tropical waters into the North Atlantic amplified thermohaline circulation and contributed to high-latitude warming.	Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	University of California System; University of California Davis; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Schmidt, MW (corresponding author), Univ Calif Davis, Dept Geol, Davis, CA 95616 USA.	schmidt@geology.ucdavis.edu		Spero, Howard/0000-0001-5465-8607				BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Boyle EA, 2000, QUATERNARY SCI REV, V19, P255, DOI 10.1016/S0277-3791(99)00065-7; Broecker WS, 1990, PALEOCEANOGRAPHY, V5, P469, DOI 10.1029/PA005i004p00469; BROECKER WS, 1990, CLIM DYNAM, V4, P73, DOI DOI 10.1007/BF00208902; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; CONKRIGHT M, 1998, NODC INTERNAL REPORT; Craig H., 1965, DEUTERIUM OXYGEN 18, P9, DOI DOI 10.1109/ISSRE.1993.624301; Curry WB, 1997, PALEOCEANOGRAPHY, V12, P1, DOI 10.1029/96PA02413; Dekens PS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000200; DUPLESSY JC, 1992, NATURE, V358, P485, DOI 10.1038/358485a0; Durkoop A, 1997, PALEOCEANOGRAPHY, V12, P764, DOI 10.1029/97PA02270; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Hastings DW, 1998, PALEOCEANOGRAPHY, V13, P161, DOI 10.1029/97PA03147; Johns WE, 2002, DEEP-SEA RES PT I, V49, P211, DOI 10.1016/S0967-0637(01)00041-3; Jouzel J, 2000, QUATERNARY SCI REV, V19, P363, DOI 10.1016/S0277-3791(99)00069-4; Keigwin LD, 1999, PALEOCEANOGRAPHY, V14, P164, DOI 10.1029/1998PA900026; Knorr G, 2003, NATURE, V424, P532, DOI 10.1038/nature01855; Lea DW, 2003, SCIENCE, V301, P1361, DOI 10.1126/science.1088470; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lynch-Stieglitz J, 1999, NATURE, V402, P644, DOI 10.1038/45204; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Ruhlemann C, 1999, NATURE, V402, P511, DOI 10.1038/990069; Stidd C. K., 1967, J APPL METEOROL, V6, P255, DOI [10.1175/1520-0450(1967)006<0255:TUOEFC>2.0.CO;2, DOI 10.1175/1520-0450(1967)006<0255:TU0EFC>2.0.C0;2]; Thunell R, 1999, GEOLOGY, V27, P843, DOI 10.1130/0091-7613(1999)027<0843:SSTAAW>2.3.CO;2; Vellinga M, 2002, CLIMATIC CHANGE, V54, P251, DOI 10.1023/A:1016168827653; Vink A, 2001, PALEOCEANOGRAPHY, V16, P479, DOI 10.1029/2000PA000582; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Watanabe T, 2001, MAR GEOL, V173, P21, DOI 10.1016/S0025-3227(00)00166-3; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002	30	216	222	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					160	163		10.1038/nature02346	http://dx.doi.org/10.1038/nature02346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014495				2022-12-28	WOS:000220103600043
J	Elzinga, G; Raviglione, MC; Maher, D				Elzinga, G; Raviglione, MC; Maher, D			Scale up: meeting targets in global tuberculosis control	LANCET			English	Article							DOTS STRATEGY; PREVALENCE; COUNTRIES; HEALTH; MORTALITY; BURDEN	Despite great progress, global targets for tuberculosis case detection and cure might not be reached by 2005. In particular, there is a serious case-detection gap between estimated annual incident cases and those reported under the strategy for tuberculosis control branded as DOTS. Delays in reaching targets result in lack of effect on incidence of disease, which is of particular concern in regions where incidence is increasing-eg, sub-Saharan Africa and the former Soviet Union. Four key actions will speed up progress towards reaching global targets: 1) equipping national tuberculosis programmes to have a stewardship role in engaging all health providers in implementing the DOTS strategy; 2) establishing the feasibility of national certification systems of DOTS coverage; 3) promoting community action to contribute to patient care and to voice demand for the DOTS strategy; and 4) increasing support to sub-Saharan Africa for implementation of a strategy of expanded scope to counter HIV-1-fuelled tuberculosis.	WHO, Stop TB Dept, CH-1211 Geneva 27, Switzerland; Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands	World Health Organization; Netherlands National Institute for Public Health & the Environment	Raviglione, MC (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva 27, Switzerland.	raviglionem@who.int		Maher, Dermot/0000-0003-0466-1976; RAVIGLIONE, Mario/0000-0002-9331-2067				Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402; Brugha R, 2001, BRIT MED J, V323, P152, DOI 10.1136/bmj.323.7305.152; Caldwell J. C., 1999, Resistances to behavioural change to reduce HIV/AIDS infection in predominantly heterosexual epidemics in Third World countries., P241; CHAKRABORTY AK, 1995, URBAN TUBERCULOSIS C; Chen XY, 2002, B WORLD HEALTH ORGAN, V80, P430; Coninx R, 2000, BRIT MED J, V320, P440, DOI 10.1136/bmj.320.7232.440; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 2003, TUBERCULOSIS, V83, P35, DOI 10.1016/S1472-9792(02)00056-2; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Floyd K, 2002, SCIENCE, V295, P2040, DOI 10.1126/science.1069771; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Maher D, 1999, INT J TUBERC LUNG D, V3, P762; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354; Nyirenda T, 1998, INT J TUBERC LUNG D, V2, P944; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; Styblo K, 1991, SELECTED PAPERS, V24; Styblo K, 1991, TUBERCULOSIS CAN BE, V2, P60; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; *UNAIDS, 2002, REP GLOB HIV AIDS EP; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; *WHO, 2002, WHOCDSTB2002296WHOHI; *WHO, 2001, WHOCDSSTB200111; WHO, 1998, WHOTB98245; *WHO, 2003, WHOCDSTB2003312; *WHO, 2001, WHOCDSSTB200217; *WHO, 2000, 53 WORLD HLTH ASS RE; *WHO, 2002, WHOCDSSTB200116; WHO, 2000, WHOCDSSTB20006; *WHO, 2002, WHOCDSTR2002297; *WHO, 2001, WHOCDSSTD200110A; *WHO, 2001, WHOCDSTB2001290; *WHO, 2003, WHOCDSTB2003316; *WHO INT LAB OFF, 2003, WHOCDSTB2003323; World Health Organization, 1991, 44 WORLD HLTH ASS RE	40	66	72	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					814	819		10.1016/S0140-6736(04)15698-5	http://dx.doi.org/10.1016/S0140-6736(04)15698-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15016493				2022-12-28	WOS:000220092000022
J	Aronson, B				Aronson, B			Improving online acess to medical information for low-income countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									WHO, HINARI Program, CH-1211 Geneva, Switzerland	World Health Organization	Aronson, B (corresponding author), WHO, HINARI Program, CH-1211 Geneva, Switzerland.								0	75	76	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					966	968		10.1056/NEJMp048009	http://dx.doi.org/10.1056/NEJMp048009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999107				2022-12-28	WOS:000189363600003
J	Ramsey, JM; Chester, FM				Ramsey, JM; Chester, FM			Hybrid fracture and the transition from extension fracture to shear fracture	NATURE			English	Article							TRIAXIAL STRESS CONDITIONS; FAILURE; ROCK; INITIATION; TENSION; GRANITE; STRAIN	Fracture is a fundamental mechanism of material failure. Two basic types of brittle fractures are commonly observed in rock deformation experiments-extension (opening mode) fractures and shear fractures(1,2). For nearly half a century it has been hypothesized that extension and shear fractures represent end-members of a continuous spectrum of brittle fracture types(3-6). However, observations of transitional fractures that display both opening and shear modes (hybrids) in naturally deformed rock have often remained ambiguous, and a clear demonstration of hybrid fracture formation has not been provided by experiments(4). Here we present the results of triaxial extension experiments on Carrara marble that show a continuous transition from extension fracture to shear fracture with an increase in compressive stress. Hybrid fractures form under mixed tensile and compressive stress states at acute angles to the maximum principal compressive stress. Fracture angles are greater than those observed for extension fractures and less than those observed for shear fractures. Fracture surfaces also display a progressive change from an extension to shear fracture morphology.	Texas A&M Univ, Ctr Tectonophys, Dept Geol & Geophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Chester, FM (corresponding author), Texas A&M Univ, Ctr Tectonophys, Dept Geol & Geophys, College Stn, TX 77843 USA.	chesterf@geo.tamu.edu	Chester, Frederick M/U-6789-2017; Chester, Frederick/X-4706-2019	Chester, Frederick M/0000-0001-7665-3647; 				Brace W.F., 1964, STATE STRESS EARTHS, P111; BRACE WF, 1960, J GEOPHYS RES, V65, P3477, DOI 10.1029/JZ065i010p03477; Engelder T, 1999, J STRUCT GEOL, V21, P1049, DOI 10.1016/S0191-8141(99)00023-1; ENGELDER T, 1989, GEOLOGY, V17, P564, DOI 10.1130/0091-7613(1989)017<0564:AOPJIT>2.3.CO;2; Griffith A., 1924, P 1 INT C APPL MECH, V1, P55; Griggs D., 1960, GEOL SOC AM MEM, P347, DOI [10.1130/MEM79-p347, DOI 10.1130/MEM79]; Hancock P.L., 1986, GEOLOGY REAL WORLD K, P155; HANDIN J, 1969, J GEOPHYS RES, V74, P5343, DOI 10.1029/JB074i022p05343; HANDIN J, 1972, FLOW FRACTURE ROCKS, P1; HOSKINS ER, 1969, INT J ROCK MECH MIN, V6, P99, DOI 10.1016/0148-9062(69)90030-8; Jaeger J. C., 1979, FUNDAMENTALS ROCK ME; JAEGER JC, 1966, BRIT J APPL PHYS, V17, P685, DOI 10.1088/0508-3443/17/5/316; LEON A, 1934, BAUNINGENIEUR, V15, P318; MCCLINTOCK FA, 1962, 4TH P US NAT C APP M, V2, P1015; MOGI K, 1967, J GEOPHYS RES, V72, P5117, DOI 10.1029/JZ072i020p05117; MUEHLBERGER WR, 1961, J GEOL, V69, P211, DOI 10.1086/626729; Murrell S. A. F., 1965, GEOPHYS J INT, V10, P231, DOI [10.1111/j.1365-246X.1965.tb03155.x, DOI 10.1111/J.1365-246X.1965.TB03155.X]; MURRELL SAF, 1970, GEOPHYS J ROY ASTR S, V19, P309, DOI 10.1111/j.1365-246X.1970.tb06050.x; MURRELL SAF, 1970, GEOPHYS J ROY ASTR S, V19, P499, DOI 10.1111/j.1365-246X.1970.tb00155.x; NADAI A, 1934, THEORY FLOW FRACTURE; NEUBER H, 1937, THEORY NOTCH STRESSE; Paterson M, 1978, EXPT ROCK DEFORMATIO; Pieri M, 2001, J STRUCT GEOL, V23, P1393, DOI 10.1016/S0191-8141(01)00006-2; Ramsey J. M., 2003, EXPT STUDY TRANSITIO; RECHES Z, 1994, J GEOPHYS RES-SOL EA, V99, P18159, DOI 10.1029/94JB00115; SCHOCK RN, 1982, J GEOPHYS RES, V87, P7817, DOI 10.1029/JB087iB09p07817; Secor DT, 1965, ROLE FLUID PRESSURE, V263, P633, DOI [10.2475/ajs.263.8.633, DOI 10.2475/AJS.263.8.633]; Sibson RH, 2003, AAPG BULL, V87, P901, DOI 10.1306/01290300181	28	220	235	8	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					63	66		10.1038/nature02333	http://dx.doi.org/10.1038/nature02333			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999279				2022-12-28	WOS:000189363800034
J	Bruce, ML; Ten Have, TR; Reynolds, CF; Katz, II; Schulberg, HC; Mulsant, BH; Brown, GK; McAvay, GJ; Pearson, JL; Alexopoulos, GS				Bruce, ML; Ten Have, TR; Reynolds, CF; Katz, II; Schulberg, HC; Mulsant, BH; Brown, GK; McAvay, GJ; Pearson, JL; Alexopoulos, GS			Reducing suicidal ideation and depressive symptoms in depressed older primary care patients - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOGISTIC-REGRESSION MODELS; IMPROVING PRIMARY-CARE; BINARY RESPONSE DATA; LATE-LIFE DEPRESSION; MAJOR DEPRESSION; QUALITY IMPROVEMENT; CONSENSUS STATEMENT; MINOR DEPRESSION; TERM TREATMENT; RISK-FACTORS	Context Suicide rates are highest in late life; the majority of older adults who die by suicide have seen a primary care physician in preceding months. Depression is the strongest risk factor for late-life suicide and for suicide's precursor, suicidal ideation. Objective To determine the effect of a primary care intervention on suicidal ideation and depression in older patients. Design and Setting Randomized controlled trial known as PROSPECT (Prevention of Suicide in Primary Care Elderly: Collaborative Trial) with patient recruitment from 20 primary care practices in New York City, Philadelphia, and Pittsburgh regions, May 1999 through August 2001. Participants Two-stage, age-stratified (60-74, greater than or equal to75 years) depression screening of randomly sampled patients; enrollment included patients who screened positive and a random sample of screened negative patients. This analysis included patients with a depression diagnosis (N=598). Intervention Treatment guidelines tailored for the elderly with care management compared with usual care. Main Outcome Measures Assessment of suicidal ideation and depression severity at baseline, 4 months, 8 months, and 12 months. Results Rates of suicidal ideation declined faster (P=.01) in intervention patients compared with usual care patients; at 4 months, in the intervention group, raw rates of suicidal ideation declined 12.9% points (29.4% to 16.5%) compared with 3.0% points (20.1% to 17.1% in usual care [P=.01]). Among patients reporting suicidal ideation, resolution of ideation was faster among intervention patients (P=.03); differences peaked at 8 months (70.7% vs 43.9% resolution; P=.005). Intervention patients had a more favorable course of depression in both degree and speed of symptom reduction; group difference peaked at 4 months. The effects on depression were not significant among,, patients with minor depression unless suicidal ideation was present. Conclusions Evidence of the intervention's effectiveness in community-based primary care with a heterogeneous sample of depressed patients introduces new challenges related to its sustainability and dissemination. The intervention's effectiveness in reducing suicidal ideation, regardless of depression severity, reinforces its role as a prevention strategy to reduce risk factors for suicide in late life.	Univ Pittsburgh, Dept Psychiat, WPIC, Sch Med, Pittsburgh, PA 15213 USA; Cornell Univ, Weill Med Coll, Dept Psychiat, White Plains, NY USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA; VA Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; NIMH, Div Intervent & Serv Res, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cornell University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Reynolds, CF (corresponding author), Univ Pittsburgh, Dept Psychiat, WPIC, Sch Med, Room 1135-E,3811 Ohara St, Pittsburgh, PA 15213 USA.	ReynoldsCF@msx.upmc.edu		Alexopoulos, George/0000-0001-5677-7001; Post, Edward/0000-0002-5782-8736	NIMH NIH HHS [R01 MH59381, P30 MH68638, P30 MH52247, K01 MH01613, P30 MH52129, K02 MH01634, R01 MH59380, R01 MH59366] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001634, R01MH059380, R01MH059366, P30MH068638, P30MH052247, P30MH052129, R01MH059381, K01MH001613] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexopoulos GS, 1999, ARCH GEN PSYCHIAT, V56, P1048, DOI 10.1001/archpsyc.56.11.1048; Alexopoulos GS, 2002, BIOL PSYCHIAT, V52, P164, DOI 10.1016/S0006-3223(02)01381-1; American Psychiatric Association, 2003, PRACT GUID ASS TREAT; ARIAS E, NATL VITAL STAT REPO, V52, P2003; Bartels SJ, 2002, AM J GERIAT PSYCHIAT, V10, P417, DOI 10.1176/appi.ajgp.10.4.417; Beck AT, 1997, BEHAV RES THER, V35, P1039, DOI 10.1016/S0005-7967(97)00073-9; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Brown GK, 2001, INT J GERIATR PSYCH, V16, P593, DOI 10.1002/gps.468; Bruce M L, 1999, Dialogues Clin Neurosci, V1, P100; CALLAHAN CM, 1992, J GEN INTERN MED, V7, P26, DOI 10.1007/BF02599097; Charney DS, 2003, ARCH GEN PSYCHIAT, V60, P664, DOI 10.1001/archpsyc.60.7.664; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Conwell Y, 1995, Int Psychogeriatr, V7, P149, DOI 10.1017/S1041610295001943; CONWELL Y., 1994, DIAGNOSIS TREATMENT, P397; Cramer JA, 1998, PSYCHIATR SERV, V49, P196, DOI 10.1176/ps.49.2.196; *DEPR GUID PAN, 1993, AHCPR PUBL; DIEKSTRA RFW, 1989, ACTA PSYCHIAT SCAND, V79, P268, DOI 10.1111/j.1600-0447.1989.tb10257.x; Entsuah AR, 2001, J CLIN PSYCHIAT, V62, P869, DOI 10.4088/JCP.v62n1106; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Gerrity MS, 1999, J FAM PRACTICE, V48, P949; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harman JS, 2001, INT J PSYCHIAT MED, V31, P239, DOI 10.2190/Q3VY-T8V9-30MA-VC5C; Hogan JW, 1996, BIOMETRICS, V52, P1002, DOI 10.2307/2533061; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; Katon W, 2003, GEN HOSP PSYCHIAT, V25, P158, DOI 10.1016/S0163-8343(03)00013-6; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; Klerman GL, 1984, INTERPERSONAL PSYCHO; Lave JR, 1998, ARCH GEN PSYCHIAT, V55, P645, DOI 10.1001/archpsyc.55.7.645; Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186; Lecrubier Y, 2002, ACTA PSYCHIAT SCAND, V106, P7, DOI 10.1034/j.1600-0447.106.s415.2.x; Lish JD, 1996, PSYCHOSOMATICS, V37, P413, DOI 10.1016/S0033-3182(96)71528-1; Lyness JM, 1999, J GEN INTERN MED, V14, P249, DOI 10.1046/j.1525-1497.1999.00326.x; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; LYNESS JM, 1995, J AM GERIATR SOC, V43, P216, DOI 10.1111/j.1532-5415.1995.tb07325.x; Maidment R, 2002, INT J GERIATR PSYCH, V17, P752, DOI 10.1002/gps.688; Meredith LS, 2000, J GEN INTERN MED, V15, P868, DOI 10.1046/j.1525-1497.2000.91149.x; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MILIKEN GA, 1984, ANAL MESSY DATA, V1, pCH26; Mulsant BH, 2001, INT J GERIATR PSYCH, V16, P585, DOI 10.1002/gps.465; Olfson M, 2000, ARCH FAM MED, V9, P876, DOI 10.1001/archfami.9.9.876; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; Oxman TE, 2002, PSYCHOSOMATICS, V43, P441, DOI 10.1176/appi.psy.43.6.441; Pearson J L, 1997, New Dir Ment Health Serv, P13; Pearson JL, 2000, CLIN PSYCHOL REV, V20, P685, DOI 10.1016/S0272-7358(99)00066-5; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raue PJ, 2001, INT J GERIATR PSYCH, V16, P560, DOI 10.1002/gps.469; Roeloffs C, 2003, GEN HOSP PSYCHIAT, V25, P311, DOI 10.1016/S0163-8343(03)00066-5; Rollman BL, 2002, J GEN INTERN MED, V17, P493, DOI 10.1046/j.1525-1497.2002.10421.x; Rost K, 2001, J GEN INTERN MED, V16, P143, DOI 10.1111/j.1525-1497.2001.00537.x; Schulberg HC, 1998, ARCH GEN PSYCHIAT, V55, P1121, DOI 10.1001/archpsyc.55.12.1121; Schulberg HC, 2001, INT J GERIATR PSYCH, V16, P577, DOI 10.1002/gps.470; Schulberg HC, 1998, INT J PSYCHIAT MED, V28, P421, DOI 10.2190/G23R-NGGN-K1P1-MQ8N; SHROUT PE, 1992, PRIMARY HEALTH CARE AND PSYCHIATRIC EPIDEMIOLOGY, P293; Simon GE, 1998, AM J EPIDEMIOL, V147, P155; Spitzer RL, 1995, STRUCTURED CLIN INTE; Szanto K, 2003, ARCH GEN PSYCHIAT, V60, P610, DOI 10.1001/archpsyc.60.6.610; Ten Have TR, 1998, BIOMETRICS, V54, P367; Ten Have TR, 1999, STAT MED, V18, P947, DOI 10.1002/(SICI)1097-0258(19990430)18:8<947::AID-SIM95>3.3.CO;2-2; TENHAVE TR, 1994, APPL STAT-J ROY ST C, V43, P371; Thomas L, 2002, AM J GERIAT PSYCHIAT, V10, P583, DOI 10.1176/appi.ajgp.10.5.583; Turvey CL, 2002, AM J GERIAT PSYCHIAT, V10, P398; Unutzer J, 1999, MILBANK Q, V77, P225, DOI 10.1111/1468-0009.00132; Unutzer J, 2003, J AM GERIATR SOC, V51, P505, DOI 10.1046/j.1532-5415.2003.51159.x; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; *US PUBL HLTH SERV, 2001, NAT STRAT SUIC PREV; Waern M, 2003, GERONTOLOGY, V49, P328, DOI 10.1159/000071715; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519; WINER BJ, 1971, STATISTICAL PRINCIPL, pCH4	76	705	713	6	79	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2004	291	9					1081	1091		10.1001/jama.291.9.1081	http://dx.doi.org/10.1001/jama.291.9.1081			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	780AQ	14996777	Bronze			2022-12-28	WOS:000189348900025
J	Kirkwood, C				Kirkwood, C			Viral gastroenteritis in Europe: a new norovirus variant?	LANCET			English	Editorial Material							NORWALK-LIKE VIRUSES; HUMAN CALICIVIRUS		Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Murdoch Childrens Res Inst, Enter Virus Res Grp, Melbourne, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Kirkwood, C (corresponding author), Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Murdoch Childrens Res Inst, Enter Virus Res Grp, Flemington Rd, Melbourne, Vic 3052, Australia.	carl.kirkwood@mcri.edu.au						Ando T, 2000, J INFECT DIS, V181, pS336, DOI 10.1086/315589; Fankhauser RL, 2002, J INFECT DIS, V186, P1, DOI 10.1086/341085; Kirkwood CD, 2001, J CLIN MICROBIOL, V39, P2722, DOI 10.1128/JCM.39.7.2722-2724.2001; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; Lopman BA, 2002, J CLIN VIROL, V24, P137, DOI 10.1016/S1386-6532(01)00243-8; Nilsson M, 2003, J VIROL, V77, P13117, DOI 10.1128/JVI.77.24.13117-13124.2003; Noel JS, 1999, J INFECT DIS, V179, P1334, DOI 10.1086/314783; Rockx B, 2002, CLIN INFECT DIS, V35, P246, DOI 10.1086/341408; Vinje J, 2003, J CLIN MICROBIOL, V41, P1423, DOI 10.1128/JCM.41.4.1423-1433.2003	9	17	17	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					671	672		10.1016/S0140-6736(04)15661-4	http://dx.doi.org/10.1016/S0140-6736(04)15661-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001320				2022-12-28	WOS:000189266900003
J	Lopman, B; Vennema, H; Kohli, E; Pothier, P; Sanchez, A; Negredo, A; Buesa, J; Schreier, E; Reacher, M; Brown, D; Gray, J; Iturriza, M; Gallimore, C; Bottiger, B; Hedlund, KO; Torven, M; von Bonsdorff, CH; Maunula, L; Poljsak-Prijatelj, M; Zimsek, J; Reuter, G; Szucs, G; Melegh, B; Svennson, L; van Duijnhoven, Y; Koopmans, M				Lopman, B; Vennema, H; Kohli, E; Pothier, P; Sanchez, A; Negredo, A; Buesa, J; Schreier, E; Reacher, M; Brown, D; Gray, J; Iturriza, M; Gallimore, C; Bottiger, B; Hedlund, KO; Torven, M; von Bonsdorff, CH; Maunula, L; Poljsak-Prijatelj, M; Zimsek, J; Reuter, G; Szucs, G; Melegh, B; Svennson, L; van Duijnhoven, Y; Koopmans, M		European Food-Borne Viruses Network	Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant	LANCET			English	Article							ROUND-STRUCTURED VIRUSES; NORWALK-LIKE VIRUSES; MOLECULAR EPIDEMIOLOGY; IDENTIFICATION; CALICIVIRUSES; NETHERLANDS; INFECTION	Background Highly publicised outbreaks of norovirus gastroenteritis in hospitals in the UK and Ireland and cruise ships in the USA sparked speculation about whether this reported activity was unusual. Methods We analysed data collected through a collaborative research and surveillance network of viral gastroenteritis in ten European countries (England and Wales were analysed as one region). We compiled data on total number of outbreaks by month, and compared genetic sequences from the isolated viruses. Data were compared with historic data from a systematic retrospective review of surveillance systems and with a central database of viral sequences. Findings Three regions (England and Wales, Germany, and the Netherlands) had sustained epidemiological and viral characterisation data from 1995 to 2002. In all three, we noted a striking increase in norovirus outbreaks in 2002 that coincided with the detection and emergence of a new predominant norovirus variant of genogroup II4, which had a consistent mutation in the polymerase gene. Eight of nine regions had an annual peak in 2002 and the new genogroup 114 variant was detected in nine countries. Also, the detection of the new variant preceded an atypical spring and summer peak of outbreaks in three countries. Interpretation Our data from ten European countries show a striking increase and unusual seasonal pattern of norovirus gastroenteritis in 2002 that occurred concurrently with the emergence of a novel genetic variant. In addition to showing the added value of an international network for viral gastroenteritis outbreaks, these observations raise questions about the biological properties of the variant and the mechanisms for its rapid dissemination.	Natl Inst Publ Hlth & Environm, Diagnost Lab Infect Dis, NL-3720 BA Bilthoven, Netherlands; Hlth Protect Agcy, London, England; Virol Lab, Dijon, France; Inst Salud Carlos III, Madrid, Spain; Univ Valencia, E-46003 Valencia, Spain; Robert Koch Inst, D-1000 Berlin, Germany; Statens Serum Inst, DK-2300 Copenhagen, Denmark; Swedish Inst Infect Dis Control, Solna, Sweden; Univ Helsinki, Helsinki, Finland; Inst Microbiol & Immunol, Ljubljana, Slovenia; Inst State Publ Hlth Serv, Pecs, Hungary; Univ Pecs, Pecs, Hungary; Linkoping Univ, S-58183 Linkoping, Sweden	Netherlands National Institute for Public Health & the Environment; Health Protection Agency; Instituto de Salud Carlos III; University of Valencia; Robert Koch Institute; Statens Serum Institut; Swedish Institute for Infectious Disease Control; University of Helsinki; University of Pecs; Linkoping University	Koopmans, M (corresponding author), Natl Inst Publ Hlth & Environm, Diagnost Lab Infect Dis, POB 1, NL-3720 BA Bilthoven, Netherlands.	marion.koopmans@rivm.nl	Gomara, Miren Iturriza/B-4351-2013; Reuter, Gábor/I-7412-2013; Kohli, Evelyne/A-7612-2011; Buesa, Javier/D-8927-2014; Reacher, Mark/Y-6979-2018	Gomara, Miren Iturriza/0000-0001-5816-6423; Reuter, Gábor/0000-0002-5857-4934; Kohli, Evelyne/0000-0002-9383-6573; Buesa, Javier/0000-0002-3328-3428; Reacher, Mark/0000-0001-6871-7903; Widdowson, Marc-Alain/0000-0002-0682-6933; Maunula, Leena/0000-0002-0841-5353; Negredo, ANA/0000-0001-7491-1032				Caul EO, 1996, J CLIN PATHOL, V49, P874, DOI 10.1136/jcp.49.11.874; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P41; GREEN J, 1995, J MED VIROL, V47, P392, DOI 10.1002/jmv.1890470416; Green KY, 2002, J INFECT DIS, V185, P133, DOI 10.1086/338365; Hale A, 2000, J MED VIROL, V62, P99, DOI 10.1002/1096-9071(200009)62:1&lt;99::AID-JMV15&gt;3.0.CO;2-0; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; Koopmans M, 2000, J INFECT DIS, V181, pS262, DOI 10.1086/315573; Koopmans M, 2003, EMERG INFECT DIS, V9, P1136; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; Lopman BA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-13; LOPMAN BA, 2002, EUROSURVEILLANCE; LOPMAN BA, 2002, INT C EM INF DIS 200; Mounts AW, 2000, J INFECT DIS, V181, pS284, DOI 10.1086/315586; Noel JS, 1999, J INFECT DIS, V179, P1334, DOI 10.1086/314783; Rockx B, 2002, CLIN INFECT DIS, V35, P246, DOI 10.1086/341408; Schreier E, 2000, ARCH VIROL, V145, P443, DOI 10.1007/s007050050038; Vinje J, 2003, J CLIN MICROBIOL, V41, P1423, DOI 10.1128/JCM.41.4.1423-1433.2003; Vinje J, 1996, J INFECT DIS, V174, P610, DOI 10.1093/infdis/174.3.610; Wall PG, 1996, CDR REV, V6, P93	19	418	443	2	55	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2004	363	9410					682	688		10.1016/S0140-6736(04)15641-9	http://dx.doi.org/10.1016/S0140-6736(04)15641-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778XP	15001325				2022-12-28	WOS:000189266900008
J	Rabiriowitz, I; Luzzatti, R; Tamir, A; Reis, S				Rabiriowitz, I; Luzzatti, R; Tamir, A; Reis, S			Length of patient's monologue, rate of completion, and relation to other components of the clinical encounter: observational intervention study in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIME		Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Family Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Clalit Hlth Serv, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Epidemiol & Community Hlth, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Reis, S (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Med Educ, POB 9649, IL-31096 Haifa, Israel.	reis@tx.technion.ac.il						BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BLAU JN, 1989, BRIT MED J, V298, P39, DOI 10.1136/bmj.298.6665.39; Langewitz W, 2002, BRIT MED J, V325, P682, DOI 10.1136/bmj.325.7366.682; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283; Svab I, 1993, Aten Primaria, V11, P175	5	27	29	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					501	502		10.1136/bmj.328.7438.501	http://dx.doi.org/10.1136/bmj.328.7438.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988186	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000220002900027
J	Roberts, H; Liabo, K; Lucas, P; DuBois, D; Sheldon, TA				Roberts, H; Liabo, K; Lucas, P; DuBois, D; Sheldon, TA			Mentoring to reduce antisocial behaviour in childhood	BRITISH MEDICAL JOURNAL			English	Article							CONDUCT-PROBLEM CHILDREN; FOLLOW-UP; PROGRAMS; FAMILIES; YOUTH; COST	The effects of social interventions need to be examined in real life situations as well as studies	City Univ London, Inst Hlth Sci, Child Hlth Res & Policy Unit, London EC1A 7QN, England; Univ Illinois, Sch Publ Hlth MC 923, Chicago, IL 60612 USA; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	City University London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of York - UK	Roberts, H (corresponding author), City Univ London, Inst Hlth Sci, Child Hlth Res & Policy Unit, London EC1A 7QN, England.	h.roberts@city.ac.uk	DuBois, David/F-9967-2013; Lucas, Patricia/P-5349-2017; Sheldon, Trevor/AAK-7088-2021	DuBois, David/0000-0002-9955-7954; Sheldon, Trevor/0000-0002-7479-5913; Lucas, Patricia Jane/0000-0002-0469-8085; Roberts, Helen/0000-0002-6319-061X				BARLOW J, 1999, SYSTEMATIC REV EFFEC; Cavell TA, 2000, J SCHOOL PSYCHOL, V38, P199, DOI 10.1016/S0022-4405(99)00040-0; DAVIDSON WS, 1987, J CONSULT CLIN PSYCH, V55, P68, DOI 10.1037/0022-006X.55.1.68; DuBois DL, 2002, AM J COMMUN PSYCHOL, V30, P157, DOI 10.1023/A:1014628810714; Glass N, 1999, CHILD SOC, V13, P257, DOI DOI 10.1002/CHI569; GLASS N, 2001, CHILDREN SOC, V15, P14, DOI DOI 10.1111/J.1099-0860.2001.TB00198.X; Grossman JB, 1998, EVALUATION REV, V22, P403, DOI 10.1177/0193841X9802200304; Grossman JB, 2002, AM J COMMUN PSYCHOL, V30, P199, DOI 10.1023/A:1014680827552; *HOM OFF, MENT CAP GRAND ROUND; O'Donnell C.R., 1979, CHILD BEHAVIOR THERA, V1, P161, DOI 10.1300/J473v01n02_03; Olds DL, 2002, PEDIATRICS, V110, P486, DOI 10.1542/peds.110.3.486; Roberts H, 1997, BRIT MED J, V314, P1122, DOI 10.1136/bmj.314.7087.1122; SCHWEINHART L, 1993, SUMMARY SIGNIFICANT; Scott S, 1998, BRIT MED J, V316, P202; Scott S, 2001, BRIT MED J, V323, P191, DOI 10.1136/bmj.323.7306.191; Sheldon T A, 2001, J Health Serv Res Policy, V6, P3, DOI 10.1258/1355819011927125; STJAMESROBERTS I, 2001, MENTORS HELP PRIMARY; TARLING R, 2001, DALSTON YOUTH PROJEC; Tierney Joseph P, 2000, MAKING DIFFERENCE IM; WEBSTERSTRATTON C, 1989, J CONSULT CLIN PSYCH, V57, P550, DOI 10.1037/0022-006X.57.4.550; WEBSTERSTRATTON C, 1990, J CLIN CHILD PSYCHOL, V19, P144, DOI 10.1207/s15374424jccp1902_6; WORKS CHILDREN	22	26	26	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					512	514		10.1136/bmj.328.7438.512	http://dx.doi.org/10.1136/bmj.328.7438.512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800BC	14988195	Green Published, Green Accepted			2022-12-28	WOS:000220002900036
J	Palacios, IM; Gatfield, D; St Johnston, D; Izaurralde, E				Palacios, IM; Gatfield, D; St Johnston, D; Izaurralde, E			An eIF4AIII-containing complex required for mRNA localization and nonsense-mediated mRNA decay	NATURE			English	Article							INITIATION-FACTOR 4AIII; EXON JUNCTION COMPLEX; MAGO NASHI; DROSOPHILA-MELANOGASTER; PROTEIN; POSTERIOR; OOCYTE; TRANSLATION; COMPONENT; BINDING	The specification of both the germ line and abdomen in Drosophila depends on the localization of oskar messenger RNA to the posterior of the oocyte(1,2). This localization requires several transacting factors, including Barentsz and the Mago-Y14 heterodimer, which assemble with oskar mRNA into ribonucleoprotein particles (RNPs) and localize with it at the posterior pole(3-7). Although Barentsz localization in the germ line depends on Mago-Y14, no direct interaction between these proteins has been detected(5). Here, we demonstrate that the translation initiation factor eIF4AIII interacts with Barentsz and is a component of the oskar messenger RNP localization complex. Moreover, eIF4AIII interacts with Mago-Y14 and thus provides a molecular link between Barentsz and the heterodimer. The mammalian Mago (also known as Magoh)-Y14 heterodimer is a component of the exon junction complex(8-11). The exon junction complex is deposited on spliced mRNAs and functions in nonsense-mediated mRNA decay (NMD)(9,11-14), a surveillance mechanism that degrades mRNAs with premature translation-termination codons. We show that both Barentsz and eIF4AIII are essential for NMD in human cells. Thus, we have identified eIF4AIII and Barentsz as components of a conserved protein complex that is essential for mRNA localization in flies and NMD in mammals.	Univ Cambridge, Wellcome Trust Canc Res UK Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Cambridge; University of Cambridge; European Molecular Biology Laboratory (EMBL)	St Johnston, D (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	ds139@mole.bio.cam.ac.uk; izaurralde@embl-heidelberg.de	St Johnston, Daniel/C-9568-2009; Gatfield, David/C-2354-2011; Palacios, Isabel/X-4807-2019; Izaurralde, Elisa/G-3239-2012	Gatfield, David/0000-0001-5114-2824; St Johnston, Daniel/0000-0001-5582-3301; Izaurralde, Elisa/0000-0001-7365-2649				BAKER BS, 1991, GENETICS, V127, P125; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Chou TB, 1996, GENETICS, V144, P1673; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; Hachet O, 2001, CURR BIOL, V11, P1666, DOI 10.1016/S0960-9822(01)00508-5; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li QY, 1999, MOL CELL BIOL, V19, P7336; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Macchi P, 2003, J NEUROSCI, V23, P5778; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; Mohr SE, 2001, GENE DEV, V15, P2886; Newmark PA, 1997, DEVELOPMENT, V124, P3197; SMITH RA, 1998, THESIS CAMBRIDGE U; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Weinstein DC, 1997, DEVELOPMENT, V124, P4235	28	287	296	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					753	757		10.1038/nature02351	http://dx.doi.org/10.1038/nature02351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973490				2022-12-28	WOS:000189026000048
J	Pessoa, L				Pessoa, L			Seeing the world in the same way	SCIENCE			English	Editorial Material							CORTEX; PERCEPTION		Brown Univ, Dept Psychol, Providence, RI 02912 USA	Brown University	Pessoa, L (corresponding author), Brown Univ, Dept Psychol, Providence, RI 02912 USA.	pessoa@brown.edu						Hasson U, 2004, SCIENCE, V303, P1634, DOI 10.1126/science.1089506; Hasson U, 2003, NEURON, V37, P1027, DOI 10.1016/S0896-6273(03)00144-2; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.0.CO;2-1; Mourao-Miranda J, 2003, NEUROIMAGE, V20, P1955, DOI 10.1016/j.neuroimage.2003.08.011; Pessoa L, 2002, COGNITIVE BRAIN RES, V15, P31, DOI 10.1016/S0926-6410(02)00214-8; Wandell BA, 1999, ANNU REV NEUROSCI, V22, P145, DOI 10.1146/annurev.neuro.22.1.145; Zacks JM, 2001, NAT NEUROSCI, V4, P651, DOI 10.1038/88486	11	5	5	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	2004	303	5664					1617	1618		10.1126/science.1096416	http://dx.doi.org/10.1126/science.1096416			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016983				2022-12-28	WOS:000220151400026
J	Bashir, T; Dorrello, NV; Amador, V; Guardavaccaro, D; Pagano, M				Bashir, T; Dorrello, NV; Amador, V; Guardavaccaro, D; Pagano, M			Control of the SCFSkp2-Cks1 ubiquitin ligase by the APC/C-Cdh1 ubiquitin ligase	NATURE			English	Article							ANAPHASE-PROMOTING COMPLEX; BOX PROTEIN SKP2; CELL-CYCLE; DEGRADATION; BINDING; UBIQUITYLATION; PROGRESSION; MITOSIS	Skp2 and its cofactor Cks1 are the substrate-targeting subunits of the SCFSkp2-Cks1 (Skp1/Cul1/F-box protein) ubiquitin ligase complex that regulates entry into S phase by inducing the degradation of the cyclin-dependent kinase inhibitors p21 and p27 (ref. 1). Skp2 is an oncoprotein that often shows increased expression in human cancers(2); however, the mechanism that regulates its cellular abundance is not well understood. Here we show that both Skp2 and Cks1 proteins are unstable in G1 and that their degradation is mediated by the ubiquitin ligase APC/C-Cdh1 (anaphase-promoting complex/cyclosome and its activator Cdh1). Silencing of Cdh1 by RNA interference in G1 cells stabilizes Skp2 and Cks1, with a consequent increase in p21 and p27 proteolysis. Depletion of Cdh1 also increases the percentage of cells in S phase, whereas concomitant downregulation of Skp2 reverses this effect, showing that Skp2 is an essential target of APC/C-Cdh1. Expression of a stable Skp2 mutant that cannot bind APC/C-Cdh1 induces premature entry into S phase. Thus, the induction of Skp2 and Cks1 degradation in G1 represents a principal mechanism by which APC/C-Cdh1 prevents the unscheduled degradation of SCFSkp2-Cks1 substrates and maintains the G1 state.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Inst Canc, New York, NY 10016 USA	New York University; New York University	Pagano, M (corresponding author), NYU, Sch Med, Dept Pathol, MSB 599,550 1st Ave, New York, NY 10016 USA.	michele.pagano@med.nyu.edu		Guardavaccaro, Daniele/0000-0002-4517-1765; pagano, michele/0000-0003-3210-2442				Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362	12	396	409	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					190	193		10.1038/nature02330	http://dx.doi.org/10.1038/nature02330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014502				2022-12-28	WOS:000220103600051
J	Wynne, CDL				Wynne, CDL			Fair refusal by capuchin monkeys	NATURE			English	Letter									Univ Florida, Dept Psychol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Wynne, CDL (corresponding author), Univ Florida, Dept Psychol, Box 112250, Gainesville, FL 32611 USA.	wynne@ufl.edu		Wynne, Clive/0000-0001-8408-1466				Brosnan SF, 2003, NATURE, V425, P297, DOI 10.1038/nature01963; WYNNE CDL, IN PRESS DO ANIMALS	2	69	70	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	2004	428	6979					140	140		10.1038/428140a	http://dx.doi.org/10.1038/428140a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014490	Bronze			2022-12-28	WOS:000220103600035
J	[Anonymous]				[Anonymous]			Getting up speed	NATURE			English	Article																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	2004	428	6979					229	229		10.1038/428229a	http://dx.doi.org/10.1038/428229a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	801NW	15014517	Bronze			2022-12-28	WOS:000220103600066
J	Newacheck, PW; Park, MJ; Brindis, CD; Biehl, M; Irwin, CE				Newacheck, PW; Park, MJ; Brindis, CD; Biehl, M; Irwin, CE			Trends in private and public health insurance for adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; AMBULATORY CARE; CHILDREN; ACCESS; COVERAGE; CROWD; EXPANSIONS; MEDICAID; PROFILE	Context Previous studies (1984-1995) of adolescent health insurance have shown little change in the proportion with coverage. Federally mandated expansions in Medicaid were offset by declines in private coverage. Further expansions of Medicaid and implementation of the State Children's Health Insurance Program (SCHIP) have opened new avenues for increasing coverage rates. Objectives To assess the current health insurance status of adolescents, the demographic and socioeconomic correlates of insurance coverage, and document recent changes in public and private coverage rates. Design, Setting, and Participants We analyzed data on 12995 adolescents aged 10 to 18 years, who had been included in the 2002 National Health Interview Survey. We conducted multivariate analyses to assess the independent association of age, sex, race, poverty status, family structure, family size, and region on the likelihood of having insurance coverage. Results are compared with previously published findings on adolescent health insurance coverage spanning 1984 to 1995. Main Outcome Measure Insurance coverage for adolescents. Results An estimated 12.2% of adolescents were uninsured in 2002, which is a decrease from 14.1% in 1995 (P<.003). The decrease occurred entirely because of an expansion of public coverage and is concentrated among children in poor (<100% of the federal poverty level) and near-poor (100%-199% of the federal poverty level) families. A substantial decrease in the differences between poor and higher-income groups occurred between 1995 and 2002 due to gains in coverage for adolescents in poor and near-poor families and losses in coverage among those in middle- and upper-income families (greater than or equal to200% of the federal poverty level). Specifically, the proportion of adolescents in poor families without coverage declined from 27.4% in 1995 to 19.7% in 2002 (P<.001). The proportion of adolescents in near-poor families without coverage declined from 24.8% in 1995 to 19.2% in 2002 (P<.002). In contrast, the proportion of adolescents in middle- and higher-income families without insurance increased from 4.1% in 1995 to 6.3% in 2002 because availability of insurance through the private market declined (P<.001). Conclusions A modest but significant reduction in the percentage of adolescents without insurance has occurred since 1995, largely as a result of expansions in public coverage. An even larger reduction in the proportion of adolescents without coverage would have occurred, if not for a reduction in private coverage for adolescents in middle- and higher-income families.	Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94118 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Social Dispar Hlth, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Newacheck, PW (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St,Suite 265, San Francisco, CA 94118 USA.	pauln@itsa.ucsf.edu		Brindis, Claire/0000-0002-2284-3936	PHS HHS [6U93 MC00023] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANTHIN J, 2003, ABCS CHILDRENS HLTH; Bartman BA, 1997, J HEALTH CARE POOR U, V8, P214; BENSON V, 1994, VITAL HLTH STAT, V10; Brindis CD, 2003, FUTURE CHILD, V13, P117; BRINDIS CD, 1999, ADOLESCENTS STATE CH; CUNNINGHAM PJ, 2002, 7 CTR STUD HLTH SYST; Dubay L, 2001, HEALTH AFFAIR, V20, P112, DOI 10.1377/hlthaff.20.1.112; EDWARDS JN, 2002, EROSION EMPLOYER BAS; ENGLISH A, 1999, ADOLESCENTS PUBLIC H; Ford CA, 1999, JAMA-J AM MED ASSOC, V282, P2227, DOI 10.1001/jama.282.23.2227; FRONSTIN P, 2002, EBRI ISSUE BRIEF, V252, P1; Holahan J, 2003, FUTURE CHILD, V13, P55; HOLL JL, 1995, ARCH PEDIAT ADOL MED, V149, P398, DOI 10.1001/archpedi.1995.02170160052008; Kenney G, 2003, MED CARE, V41, P337; Lewit EM, 2003, FUTURE CHILD, V13, P5; LIEU TA, 1993, AM J PUBLIC HEALTH, V83, P960, DOI 10.2105/AJPH.83.7.960; Mann C, 2003, FUTURE CHILD, V13, P31; Marquis MS, 2003, MED CARE, V41, P344; Morreale MC, 2003, J ADOLESCENT HEALTH, V32, P25, DOI 10.1016/S1054-139X(03)00066-1; Newacheck PW, 2000, PEDIATRICS, V105, P989; NEWACHECK PW, 1992, PEDIATRICS, V90, P589; NEWACHECK PW, 1989, PEDIATRICS, V84, P699; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Newacheck PW, 1999, PEDIATRICS, V104, P195, DOI 10.1542/peds.104.2.195; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; Ross DC, 2003, FUTURE CHILD, V13, P81; Selden TM, 1998, HEALTH AFFAIR, V17, P192, DOI 10.1377/hlthaff.17.3.192; Shah BV, 1996, SUDAAN USERS MANUAL; Shenkman E, 1999, PEDIATRICS, V104, P507, DOI 10.1542/peds.104.3.507; Tobler Laura, 2003, State Legis, V29, P16; *US CENS BUR, POV THRESH 2001 SIZ; WOOLDRIDGE J, 2003, INTERIM EVALUATION R; 1997, HLTH INSURANCE COVER	33	49	49	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1231	1237		10.1001/jama.291.10.1231	http://dx.doi.org/10.1001/jama.291.10.1231			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800XV	15010445	Bronze			2022-12-28	WOS:000220061900024
J	McCulloch, SD; Kokoska, RJ; Masutani, C; Iwai, S; Hanaoka, F; Kunkel, TA				McCulloch, SD; Kokoska, RJ; Masutani, C; Iwai, S; Hanaoka, F; Kunkel, TA			Preferential cis-syn thymine dimer bypass by DNA polymerase eta occurs with biased fidelity	NATURE			English	Article							LESION-BYPASS; XERODERMA-PIGMENTOSUM; CRYSTAL-STRUCTURE; ERROR-PRONE; POL-ETA; YEAST; SITE; GENE; SPECIFICITY; MUTAGENESIS	Human DNA polymerase eta (Pol eta) modulates susceptibility to skin cancer by promoting DNA synthesis past sunlight-induced cyclobutane pyrimidine dimers that escape nucleotide excision repair (NER)(1,2). Here we have determined the efficiency and fidelity of dimer bypass. We show that Pol eta copies thymine dimers and the flanking bases with higher processivity than it copies undamaged DNA, and then switches to less processive synthesis. This ability of Pol eta to sense the dimer location as synthesis proceeds may facilitate polymerase switching before and after lesion bypass. Pol eta bypasses a dimer with low fidelity and with higher error rates at the 3' thymine than at the 5' thymine. A similar bias is seen with Sulfolobus solfataricus DNA polymerase 4, which forms a Watson-Crick base pair at the 3' thymine of a dimer but a Hoogsteen base pair at the 5' thymine (ref. 3). Ultraviolet-induced mutagenesis is also higher at the 3' base of dipyrimidine sequences(4-6). Thus, in normal people and particularly in individuals with NER-defective xeroderma pigmentosum who accumulate dimers, errors made by Pol eta uring dimer bypass could contribute to mutagenesis and skin cancer.	NIEHS, Genet Mol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Engn Sci, Div Chem, Osaka 5608531, Japan; RIKEN, Discovery Res Inst, Wako, Saitama 3510198, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Osaka University; Japan Science & Technology Agency (JST); Osaka University; RIKEN	Kunkel, TA (corresponding author), NIEHS, Genet Mol Lab, NIH, DHHS, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Masutani, Chikahide/I-6160-2014	Kunkel, Thomas A./0000-0002-9900-1788; Masutani, Chikahide/0000-0002-8600-8227	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P544; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; Ohashi E, 2000, GENE DEV, V14, P1589; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SHCHERBAKOVA PV, 2003, SCI AGING KNOWL 0226; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2003, P NATL ACAD SCI USA, V100, P12093, DOI 10.1073/pnas.2134223100; Zhang H, 2002, NUCLEIC ACIDS RES, V30, P1262, DOI 10.1093/nar/30.5.1262; Zhang YB, 2002, J BIOL CHEM, V277, P44582, DOI 10.1074/jbc.M207297200	28	209	214	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	2004	428	6978					97	100		10.1038/nature02352	http://dx.doi.org/10.1038/nature02352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	780GK	14999287				2022-12-28	WOS:000189363800043
J	Nelson, HD; Nygren, P; McInerney, Y; Klein, J				Nelson, HD; Nygren, P; McInerney, Y; Klein, J			Screening women and elderly adults for family and intimate partner violence: A review of the evidence for the US preventive services task force	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE CHILDHOOD EXPERIENCES; DOMESTIC VIOLENCE; PRIMARY-CARE; HOUSEHOLD DYSFUNCTION; PREGNANT-WOMEN; PHYSICAL ABUSE; HEALTH; EMERGENCY; PREVALENCE; CHILDREN	Background: Family and intimate partner violence is common in the United States and is often associated with acute and chronic health problems. Although the clinician's role in identification and intervention is considered a professional, ethical, and sometimes legal responsibility, the effectiveness of screening is uncertain. Purpose: To examine evidence on the benefits and harms of screening women and elderly adults in health care settings for family and intimate partner violence. Data Sources: MEDLINE, PsycINFO, CINAHL, Health & Psychosocial Instruments, AARP Ageline, Cochrane Controlled Trials Register, reference lists, and experts. Study Selection: The authors selected English-language studies that included original data focusing on the performance of screening instruments (14 studies for women, 3 for elderly persons) and the effectiveness of interventions based in health care settings (2 studies for women, none for elderly persons). Data Extraction: Study design, patient samples and settings, methods of assessment or intervention, and outcome measures were extracted, and a set of criteria was applied to evaluate study quality. Data Synthesis: No trials of the effectiveness of screening in a health care setting for reducing harm have been published. Several screening instruments have been developed; some have demonstrated fair to good internal consistency and some have been validated with longer instruments, but none have been evaluated against measurable violence or health outcomes. Few intervention studies have been conducted. Existing intervention studies focused on pregnant women, and study limitations restrict their interpretation. Conclusion: Although the literature on family and intimate partner violence is extensive, few studies provide data on detection and management to guide clinicians.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA; Univ Rochester, Rochester, NY USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Rochester	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.							ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; *AG HEALTHC RES QU, 2002, EV DOM VIOL PROGR; *AM MED ASS COUNC, 1984, DIAGN TREATM GUID CO; American Medical Association Council on Scientific Affairs, 1992, DIAGN TREATM GUID EL; Anda RF, 2002, OBSTET GYNECOL, V100, P37, DOI 10.1016/S0029-7844(02)02063-X; Borowsky IW, 2002, PEDIATRICS, V110, P509, DOI 10.1542/peds.110.3.509; Brewster AL, 2002, MIL MED, V167, P464, DOI 10.1093/milmed/167.6.464; Brown JB, 2000, J FAM PRACTICE, V49, P896; Campbell Doris Williams, 2002, Online J Issues Nurs, V7, P5; Campbell JC, 2003, AM J PUBLIC HEALTH, V93, P1089, DOI 10.2105/AJPH.93.7.1089; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; Canterino JC, 1999, AM J OBSTET GYNECOL, V181, P1049, DOI 10.1016/S0002-9378(99)70079-7; Chamberlain L, 2002, WOMEN HEALTH, V35, P55, DOI 10.1300/J013v35n02_04; Chamberlain L, 2000, Matern Child Health J, V4, P141, DOI 10.1023/A:1009530523057; Coker A L, 2001, J Am Med Womens Assoc (1972), V56, P19; Coker AL, 2000, ARCH FAM MED, V9, P451, DOI 10.1001/archfami.9.5.451; Coker AL, 2002, J WOMEN HEALTH GEN-B, V11, P465, DOI 10.1089/15246090260137644; Cole TB, 2000, JAMA-J AM MED ASSOC, V284, P551, DOI 10.1001/jama.284.5.551; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; Diaz A, 2002, ARCH PEDIAT ADOL MED, V156, P811, DOI 10.1001/archpedi.156.8.811; Dowd MD, 2002, ARCH PEDIAT ADOL MED, V156, P794, DOI 10.1001/archpedi.156.8.794; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; DURANT RH, 1994, J ADOLESCENT HEALTH, V15, P311, DOI 10.1016/1054-139X(94)90604-1; Erickson MJ, 2001, PEDIATRICS, V108, P98, DOI 10.1542/peds.108.1.98; Ernst Amy A, 2002, Med Sci Monit, V8, pCR197; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fogarty Colleen T, 2002, J Am Board Fam Pract, V15, P101; Furbee PM, 1998, ANN EMERG MED, V31, P495, DOI 10.1016/S0196-0644(98)70260-4; GARBARINO J, 1991, AM PSYCHOL, V46, P376, DOI 10.1037/0003-066X.46.4.376; Gielen A C, 2000, Matern Child Health J, V4, P111, DOI 10.1023/A:1009522321240; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; Glass N, 2001, J Emerg Nurs, V27, P141, DOI 10.1067/men.2001.114387; Hamberger L K, 1992, Fam Med, V24, P283; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P966; Joint Commission on Accreditation of Healthcare Organizations, 1992, ACCR MAN HOSP, V1, P21; Jones DPH, 1999, CHILD ABUSE NEGLECT, V23, P1341, DOI 10.1016/S0145-2134(99)00087-3; KARUS D, 1999, AIDS BEHAV, V3, P227; Lansford JE, 2002, ARCH PEDIAT ADOL MED, V156, P824, DOI 10.1001/archpedi.156.8.824; Martins R., 1992, J WOMENS HEALTH, V1, P77; Maxfield MG, 1996, ARCH PEDIAT ADOL MED, V150, P390, DOI 10.1001/archpedi.1996.02170290056009; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; McFarlane J, 2000, PUBLIC HEALTH NURS, V17, P443, DOI 10.1046/j.1525-1446.2000.00443.x; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; Moody L E, 2000, J Nurs Meas, V8, P61; Moore M L, 1998, J Obstet Gynecol Neonatal Nurs, V27, P175, DOI 10.1111/j.1552-6909.1998.tb02608.x; Morrison LJ, 2000, J EMERG MED, V19, P117, DOI 10.1016/S0736-4679(00)00204-3; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; *NAT I JUST CTR DI, 1998, PREV INC CONS VIOL W; *NEAIS, 1998, FIN REP NATL CTR ELD; Neale AV., 1991, J APPL GERONTOL, V10, P406, DOI DOI 10.1177/073346489101000403; NELSON H, 2004, IN PRESS ANN FAMILY; NORTON LB, 1995, OBSTET GYNECOL, V85, P321, DOI 10.1016/0029-7844(94)00429-H; OSOFSKY JD, 1993, PSYCHIATRY, V56, P36; Pan H S, 1997, Fam Med, V29, P492; Parker B, 1999, RES NURS HEALTH, V22, P59; PILLEMER K, 1988, HDB FAMILY VIOLENCE, P247; Ramsay J, 2002, BRIT MED J, V325, P314, DOI 10.1136/bmj.325.7359.314; Rath G D, 1989, J Am Board Fam Pract, V2, P227; REIS M, 1995, CAN J AGING, V14, P45, DOI 10.1017/S0714980800005584; Reis M, 1998, GERONTOLOGIST, V38, P471, DOI 10.1093/geront/38.4.471; Richardson J, 2002, BRIT MED J, V324, P274, DOI 10.1136/bmj.324.7332.274; Rodriguez MA, 2001, J FAM PRACTICE, V50, P338; Sachs CJ, 2002, WOMEN HEALTH, V35, P121, DOI 10.1300/J013v35n02_08; SHAKOOR BH, 1991, J NATL MED ASSOC, V83, P233; Sherin K M, 1998, Fam Med, V30, P508; Silverman JG, 2001, JAMA-J AM MED ASSOC, V286, P572, DOI 10.1001/jama.286.5.572; Smith M, 1995, Medsurg Nurs, V4, P21; Stenson K, 2001, MIDWIFERY, V17, P2, DOI 10.1054/midw.2000.0241; The Commonwealth Fund, 1999, HLTH CONC WOM LIF CO; The Commonwealth Fund, 1993, 1 COMPR NAT HLTH SUR; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Voelker R, 2002, JAMA-J AM MED ASSOC, V288, P2254, DOI 10.1001/jama.288.18.2254; Wathen CN, 2003, JAMA-J AM MED ASSOC, V289, P589, DOI 10.1001/jama.289.5.589; Webster J, 2001, MIDWIFERY, V17, P289, DOI 10.1054/midw.2001.0279; WOLFE DA, 1993, CLIN PSYCHOL REV, V13, P473, DOI 10.1016/0272-7358(93)90043-L	78	184	187	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					387	396		10.7326/0003-4819-140-5-200403020-00015	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	778NC	14996681				2022-12-28	WOS:000189246800009
J	Zeuzem, S				Zeuzem, S			Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well?	ANNALS OF INTERNAL MEDICINE			English	Review							ALPHA-2B PLUS RIBAVIRIN; QUASI-SPECIES HETEROGENEITY; TREATMENT-NAIVE PATIENTS; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; PEGYLATED INTERFERON-ALPHA-2B; COMBINATION THERAPY; SUSTAINED RESPONSE; DIALYSIS PATIENTS; VIRUS GENOTYPE	The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated interferons and combination therapy with ribavirin, has resulted in substantial improvements in sustained virologic response rates. However, treatment remains a challenge, particularly for certain patient populations, because several virus-related and patient-related factors are associated with a lower virologic response to therapy. Hepatitis C virus genotype 1 and a high baseline viral load are the major viral factors associated with lower response. Patient-related factors include previous relapse or nonresponse to treatment, the presence of cirrhosis, African-American ethnicity, older age, contraindications to treatment, and obesity. This article reviews the data on interferon-based therapies among patients with lower chances for sustained virologic response and discusses the potential of the new pegylated interferons.	Saarland Univ Hosp, Dept Internal Med 2, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes	Zeuzem, S (corresponding author), Saarland Univ Hosp, Dept Internal Med 2, Kirrberger Str, D-66421 Homburg, Germany.	Zeuzem@uniklinik-saarland.de	Zeuzem, Stefan/AAE-7435-2019					Alberti A, 1997, HEPATOLOGY, V26, pS137, DOI 10.1002/hep.510260724; [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; [Anonymous], 1999, J Hepatol, V30, P956; Attia MA, 1998, ANTIVIR THER, V3, P1; Berg T, 2003, HEPATOLOGY, V38, p317A; Berg T, 2003, HEPATOLOGY, V37, P1359, DOI 10.1053/jhep.2003.50219; Bressler BL, 2003, HEPATOLOGY, V38, P639, DOI 10.1053/jhep.2003.50350; Bruchfeld A, 2001, J VIRAL HEPATITIS, V8, P287, DOI 10.1046/j.1365-2893.2001.00300.x; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Buti M, 2003, HEPATOLOGY, V37, P1226, DOI 10.1053/jhep.2003.50107; Castera L, 2003, GUT, V52, P1531, DOI 10.1136/gut.52.10.1531; Cheng SJ, 2001, HEPATOLOGY, V33, P231, DOI 10.1053/jhep.2001.20675; Cummings KJ, 2001, JAMA-J AM MED ASSOC, V285, P193, DOI 10.1001/jama.285.2.193; Davis GL, 2003, HEPATOLOGY, V38, P645, DOI 10.1053/jhep.2003.50364; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Diago M, 2004, ANN INTERN MED, V140, P72, DOI 10.7326/0003-4819-140-1-200401060-00035; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Fabrizi F, 2002, HEPATOLOGY, V36, P3, DOI 10.1053/jhep.2002.34613; Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599; Foster GR, 2003, HEPATOLOGY, V38, p246A; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Fried MW, 2002, HEPATOLOGY, V36, pS237, DOI 10.1053/jhep.2002.36810; Gonzalez-Roncero F, 2003, TRANSPL P, V35, P1745, DOI 10.1016/S0041-1345(03)00717-6; Gupta SK, 2002, J CLIN PHARMACOL, V42, P1109, DOI 10.1177/009127002237996; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Herrmann E, 2000, ANTIVIR THER, V5, P85; Hickman IJ, 2002, GUT, V51, P89, DOI 10.1136/gut.51.1.89; Howell C, 2000, GASTROENTEROLOGY, V119, P1385, DOI 10.1053/gast.2000.19582; Ioannou GN, 2003, HEPATOLOGY, V37, P795, DOI 10.1053/jhep.2003.50147; Kamar N, 2003, J AM SOC NEPHROL, V14, P2092, DOI 10.1097/01.ASN.0000079613.81511.3C; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; Koretz RL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003617.pub2; Koshy A, 2000, LIVER, V20, P335, DOI 10.1034/j.1600-0676.2000.020004335.x; Koshy A, 2002, J CLIN GASTROENTEROL, V35, P82, DOI 10.1097/00004836-200207000-00017; Lamb MW, 2001, HEPATOLOGY, V34, p326A; Layden-Almer JE, 2003, HEPATOLOGY, V37, P1343, DOI 10.1053/jhep.2003.50217; Lindsay KL, 2002, HEPATOLOGY, V36, pS114, DOI 10.1053/jhep.2002.36226; Lindsay KL, 2000, HEPATOLOGY, V32, p347A; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Mangia A, 2001, HEPATOLOGY, V33, P989, DOI 10.1053/jhep.2001.23537; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; Martin P, 2000, HEPATOLOGY, V32, p370A; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; McHutchison JG, 2000, GASTROENTEROLOGY, V119, P1317, DOI 10.1053/gast.2000.19289; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950; Monto A, 2002, HEPATOLOGY, V36, P729, DOI 10.1053/jhep.2002.35064; MORIBE T, 1995, GASTROENTEROLOGY, V108, P789, DOI 10.1016/0016-5085(95)90452-2; Neumann AU, 2000, J INFECT DIS, V182, P28, DOI 10.1086/315661; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; Ortiz V, 2002, AM J GASTROENTEROL, V97, P2408, DOI 10.1111/j.1572-0241.2002.05995.x; Pawlotsky JM, 2002, HEPATOLOGY, V36, pS65, DOI 10.1053/jhep.2002.36815; Pawlotsky JM, 2000, HEPATOLOGY, V32, P654, DOI 10.1053/jhep.2000.16603; Pereira BJG, 1999, ARTIF ORGANS, V23, P51, DOI 10.1046/j.1525-1594.1999.06274.x; Poynard T, 2003, HEPATOLOGY, V38, P75, DOI 10.1053/jhep.2003.50267; Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Russo MW, 2003, AM J GASTROENTEROL, V98, P1610, DOI 10.1111/j.1572-0241.2003.07526.x; Saracco G, 2002, HEPATOLOGY, V36, P959, DOI 10.1053/jhep.2002.35442; Sarrazin C, 2002, J VIROL, V76, P11079, DOI 10.1128/JVI.76.21.11079-11090.2002; Sarrazin C, 2001, VIROLOGY, V289, P150, DOI 10.1006/viro.2001.1092; Schalm SW, 1999, GASTROENTEROLOGY, V117, P408, DOI 10.1053/gast.1999.0029900408; Shiffman M, 2002, HEPATOLOGY, V36, p295A; Shiffman ML, 1999, GASTROENTEROLOGY, V117, P1164, DOI 10.1016/S0016-5085(99)70402-6; Shiffman ML, 2000, HEPATOLOGY, V32, p348A; Shobokshi OA, 1999, J MED VIROL, V58, P44, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;44::AID-JMV6&gt;3.0.CO;2-U; Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4; Soler M, 2002, VIROLOGY, V298, P160, DOI 10.1006/viro.2002.1494; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Wright TL, 2002, HEPATOLOGY, V36, pS185, DOI 10.1053/jhep.2002.36812; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zeuzem S, 2003, HEPATOLOGY, V38, p310A; Zeuzem S, 2003, SEMIN LIVER DIS, V23, P23; Zeuzem S, 2001, Clin Liver Dis, V5, P917, DOI 10.1016/S1089-3261(05)70201-4; Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006; Zeuzem S, 2000, Forum (Genova), V10, P32; Zeuzem S, 2000, HEPATOLOGY, V32, P835, DOI 10.1053/jhep.2000.17740; Zylberberg H, 2000, ANN INTERN MED, V132, P845, DOI 10.7326/0003-4819-132-10-200005160-00029	86	202	215	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					370	381		10.7326/0003-4819-140-5-200403020-00033	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00033			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996679				2022-12-28	WOS:000189246800007
J	Young, BA; Gruber, TM; Gross, CA				Young, BA; Gruber, TM; Gross, CA			Minimal machinery of RNA polymerase holoenzyme sufficient for promoter melting	SCIENCE			English	Article							SINGLE-STRANDED-DNA; OPEN COMPLEX; TRANSCRIPTION INITIATION; STRUCTURAL ORGANIZATION; ANGSTROM RESOLUTION; SIGMA FACTORS; AMINO-ACIDS; SUBUNIT; BINDING; RECOGNITION	We determined the minimal portion of Escherichia coli RNA polymerase ( RNAP) holoenzyme able to accomplish promoter melting, the crucial step in transcription initiation that provides RNAP access to the template strand. Upon duplex DNA binding, the N terminus of the beta' subunit ( amino acids 1 to 314) and amino acids 94 to 507 of the sigma subunit, together comprising less than one-fifth of RNAP holoenzyme, were able to melt an extended - 10 promoter in a reaction remarkably similar to that of authentic holoenzyme. Our results support the model that capture of nontemplate bases extruded from the DNA helix underlies the melting process.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.	cgross@cgl.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Chung WH, 2003, MOL CELL, V12, P1003, DOI 10.1016/S1097-2765(03)00387-3; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Lilley, 1997, NUCL ACIDS MOL BIOL, P41, DOI 10.1007/978-3-642-60691-5_4; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Minakhin L, 2003, J BIOL CHEM, V278, P29710, DOI 10.1074/jbc.M304906200; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1	20	66	68	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2004	303	5662					1382	1384		10.1126/science.1092462	http://dx.doi.org/10.1126/science.1092462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778JN	14988563				2022-12-28	WOS:000189238600055
J	Sands, BE; Anderson, FH; Bernstein, CN; Chey, WY; Feagan, BG; Fedorak, RN; Kamm, MA; Korzenik, JR; Lashner, BA; Onken, JE; Rachmilewitz, D; Rutgeerts, P; Wild, G; Wolf, DC; Marsters, PA; Travers, SB; Blank, MA; van Deventer, SJ				Sands, BE; Anderson, FH; Bernstein, CN; Chey, WY; Feagan, BG; Fedorak, RN; Kamm, MA; Korzenik, JR; Lashner, BA; Onken, JE; Rachmilewitz, D; Rutgeerts, P; Wild, G; Wolf, DC; Marsters, PA; Travers, SB; Blank, MA; van Deventer, SJ			Infliximab maintenance therapy for fistulizing Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM; FISTULAS; 6-MERCAPTOPURINE; METRONIDAZOLE; LYMPHOMA; EFFICACY; TRIAL	BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas. METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration. Patients received 5 mg of infliximab per kilogram of body weight intravenously on weeks 0, 2, and 6. A total of 195 patients who had a response at weeks 10 and 14 and 87 patients who had no response were then randomly assigned to receive placebo or 5 mg of infliximab per kilogram every eight weeks and to be followed to week 54. The primary analysis was the time to the loss of response among patients who had a response at week 14 and underwent randomization. RESULTS: The time to loss of response was significantly longer for patients who received infliximab maintenance therapy than for those who received placebo maintenance (more than 40 weeks vs. 14 weeks, P<0.001). At week 54, 19 percent of patients in the placebo maintenance group had a complete absence of draining fistulas, as compared with 36 percent of patients in the infliximab maintenance group (P=0.009). CONCLUSIONS: Patients with fistulizing Crohn's disease who have a response to induction therapy with infliximab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Vancouver Hosp, Dept Med, Vancouver, BC, Canada; Univ Manitoba, Hlth Sci Ctr, Gastroenterol Sect, Winnipeg, MB, Canada; Rochester Inst Digest Dis & Sci, Rochester, NY USA; Univ Western Ontario, Robarts Res Inst, London, ON, Canada; Univ Alberta, Div Gastroenterol, Edmonton, AB, Canada; St Marks Hosp, Physiol Unit, London EC1V 2PS, England; Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO USA; Cleveland Clin Fdn, Dept Gastroenterol, Ctr Inflammatory Bowel Dis, Cleveland, OH 44195 USA; Duke Univ, Med Ctr, Dept Gastroenterol, Durham, NC USA; Tel Aviv Sourasky Med Ctr, Div Med, Tel Aviv, Israel; Univ Hosp Leuven, Div Gastroenterol, Louvain, Belgium; Montreal Gen Hosp, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada; Altanta Gastroenterol Associates, Atlanta, GA USA; Centocor Inc, Malvern, PA 19355 USA; Univ Amsterdam, Acad Med Ctr, Afdeling Gastroenterol, NL-1105 AZ Amsterdam, Netherlands	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba; Western University (University of Western Ontario); University of Alberta; Imperial College London; Washington University (WUSTL); Cleveland Clinic Foundation; Duke University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; KU Leuven; University Hospital Leuven; McGill University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Amsterdam; Academic Medical Center Amsterdam	Sands, BE (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ 7, Boston, MA 02114 USA.		Feagan, Brian/G-3292-2011; Feagan, Brian G/M-4283-2015; Sands, Bruce/R-7887-2019	Sands, Bruce/0000-0001-5762-5042; Fedorak, Richard/0000-0002-7382-0080	NIDDK NIH HHS [K23 DK002850] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK002850] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Bickston SJ, 1999, GASTROENTEROLOGY, V117, P1433, DOI 10.1016/S0016-5085(99)70294-5; Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Cohen RB, 2001, CAN J GASTROENTEROL, V15, P376, DOI 10.1155/2001/403102; Egan LJ, 1998, AM J GASTROENTEROL, V93, P442, DOI 10.1111/j.1572-0241.1998.00442.x; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; JAKOBOVITS J, 1984, AM J GASTROENTEROL, V79, P533; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KOGANEI K, 1995, SURG TODAY, V25, P32, DOI 10.1007/BF00309382; Lapidus A, 1998, GASTROENTEROLOGY, V114, P1151, DOI 10.1016/S0016-5085(98)70420-2; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Sandborn WJ, 2003, GASTROENTEROLOGY, V125, P380, DOI 10.1016/S0016-5085(03)00877-1; Sands BE, 2002, SLEISENGER FORDTRANS, P2005; SCHNEIDER MU, 1985, DEUT MED WOCHENSCHR, V110, P1724, DOI 10.1055/s-2008-1069077; Schwartz DA, 2001, ANN INTERN MED, V135, P906, DOI 10.7326/0003-4819-135-10-200111200-00011; Van Assche G, 2003, AM J GASTROENTEROL, V98, P332, DOI 10.1016/S0002-9270(02)05909-9; van Bodegraven AA, 2002, DIS COLON RECTUM, V45, P39, DOI 10.1007/s10350-004-6111-6; Yamamoto T, 2000, WORLD J SURG, V24, P1258, DOI 10.1007/s002680010250	22	1529	1625	0	32	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					876	885		10.1056/NEJMoa030815	http://dx.doi.org/10.1056/NEJMoa030815			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985485				2022-12-28	WOS:000189197300006
J	Swartz, MN				Swartz, MN			Cellulitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; THREATENING FOOT INFECTIONS; STREPTOCOCCAL CELLULITIS; NECROTIZING FASCIITIS; CUTANEOUS CELLULITIS; COST-EFFECTIVENESS; NEEDLE ASPIRATION; DIABETIC-PATIENTS		Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Jackson Firm, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Swartz, MN (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.	mswartz@partners.org						BADDOUR LM, 1985, AM J MED, V79, P155, DOI 10.1016/0002-9343(85)90003-8; Barzilai A, 1998, PEDIATR INFECT DIS J, V17, P358, DOI 10.1097/00006454-199804000-00024; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; BRADSHER RW, 1984, AM J MED, V77, P63; Chao HC, 2000, J ULTRAS MED, V19, P743, DOI 10.7863/jum.2000.19.11.743; CHUANG YC, 1992, CLIN INFECT DIS, V15, P271, DOI 10.1093/clinids/15.2.271; Dancer SJ, 2002, J MED MICROBIOL, V51, P278, DOI 10.1099/0022-1317-51-3-278; Dupuy A, 1999, BRIT MED J, V318, P1591, DOI 10.1136/bmj.318.7198.1591; DUVANEL T, 1989, ARCH INTERN MED, V149, P293, DOI 10.1001/archinte.149.2.293; Eady EA, 2003, CURR OPIN INFECT DIS, V16, P103, DOI 10.1097/00001432-200304000-00007; Faber J, 2002, LANCET, V359, P1025, DOI 10.1016/S0140-6736(02)08093-5; Fernandez JM, 2000, DIAGN MICR INFEC DIS, V37, P77, DOI 10.1016/S0732-8893(99)00153-4; Gach JE, 2002, CLIN EXP DERMATOL, V27, P523; GENTRY LO, 1989, ARCH INTERN MED, V149, P2579, DOI 10.1001/archinte.149.11.2579; Graham DR, 2002, CLIN INFECT DIS, V35, P381, DOI 10.1086/341026; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; GRAYSON ML, 1994, CLIN INFECT DIS, V19, P820; Grayson ML, 2002, CLIN INFECT DIS, V34, P1440, DOI 10.1086/340056; Groom AV, 2001, JAMA-J AM MED ASSOC, V286, P1201, DOI 10.1001/jama.286.10.1201; HOOK EW, 1986, ARCH INTERN MED, V146, P295, DOI 10.1001/archinte.146.2.295; HORREVORTS AM, 1994, SCAND J INFECT DIS, V26, P623, DOI 10.3109/00365549409011823; HOWE PM, 1987, PEDIATR INFECT DIS J, V6, P685, DOI 10.1097/00006454-198707000-00014; KIEHLBAUCH JA, 1994, ANN INTERN MED, V121, P90, DOI 10.7326/0003-4819-121-2-199407150-00002; KIELHOFNER MA, 1988, ARCH INTERN MED, V148, P2451, DOI 10.1001/archinte.148.11.2451; KREMER M, 1991, J INFECTION, V22, P37, DOI 10.1016/0163-4453(91)90898-3; Liu V, 1999, CURR CLIN TOPICS INF, V19, P305; MAJEED HA, 1990, Q J MED, V75, P607; McKinnon PS, 1997, CLIN INFECT DIS, V24, P57, DOI 10.1093/clinids/24.1.57; Meltzer A, 1938, AM J CANCER, V33, P33, DOI DOI 10.1158/AJC.1938.33; Mertz KR, 1998, CLIN INFECT DIS, V26, P481, DOI 10.1086/516322; Miller SR, 1998, J SURG ONCOL, V67, P242, DOI 10.1002/(SICI)1096-9098(199804)67:4<242::AID-JSO6>3.3.CO;2-K; Morgan KW, 2001, J AM ACAD DERMATOL, V45, P590, DOI 10.1067/mjd.2001.119032; Muijsers RBR, 2002, DRUGS, V62, P967, DOI 10.2165/00003495-200262060-00008; Nucci M, 2002, CLIN INFECT DIS, V35, P909, DOI 10.1086/342328; Parada JP, 2000, SCAND J INFECT DIS, V32, P133, DOI 10.1080/003655400750045213; Perl B, 1999, CLIN INFECT DIS, V29, P1483, DOI 10.1086/313525; Porras MC, 2001, SCAND J INFECT DIS, V33, P56, DOI 10.1080/003655401750064086; SACHS MK, 1990, ARCH INTERN MED, V150, P1907, DOI 10.1001/archinte.150.9.1907; SACHS MK, 1991, ARCH INTERN MED, V151, P244; Schmid MR, 1998, AM J ROENTGENOL, V170, P615, DOI 10.2214/ajr.170.3.9490940; Sheard RM, 2000, J PEDIAT OPHTH STRAB, V37, P123; SIGURDSSON AF, 1989, SCAND J INFECT DIS, V21, P537, DOI 10.3109/00365548909037882; SIMON MS, 1992, AM J MED, V93, P543, DOI 10.1016/0002-9343(92)90583-W; STAMENKOVIC I, 1984, NEW ENGL J MED, V310, P1689, DOI 10.1056/NEJM198406283102601; Stevens DL, 2002, CLIN INFECT DIS, V34, P1481, DOI 10.1086/340353; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Stevens DL, 2000, ANTIMICROB AGENTS CH, V44, P3408, DOI 10.1128/AAC.44.12.3408-3413.2000; Suga K, 2001, CLIN NUCL MED, V26, P791, DOI 10.1097/00003072-200109000-00015; Wang JH, 1997, CLIN INFECT DIS, V25, P685, DOI 10.1086/513752; Woo PCY, 2000, EUR J CLIN MICROBIOL, V19, P294, DOI 10.1007/s100960050478	50	229	235	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					904	912		10.1056/NEJMcp031807	http://dx.doi.org/10.1056/NEJMcp031807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985488				2022-12-28	WOS:000189197300009
J	McCauley, J; Tarpley, MJ				McCauley, J; Tarpley, MJ			Irritability (yours and theirs)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jmccaul@jhmi.edu	Tarpley, Margaret/AAR-6488-2021						0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					921	922		10.1001/jama.291.8.921	http://dx.doi.org/10.1001/jama.291.8.921			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982893				2022-12-28	WOS:000189182000001
J	Murray, E; Fitzmaurice, D; McCahon, D; Fuller, C; Sandhur, H				Murray, E; Fitzmaurice, D; McCahon, D; Fuller, C; Sandhur, H			Training for patients in a randomised controlled trial of self management of warfarin treatment	BRITISH MEDICAL JOURNAL			English	Article							ORAL ANTICOAGULATION		Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Murray, E (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	e.t.murray@bham.ac.uk						Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Morsdorf S, 1999, SEMIN THROMB HEMOST, V25, P109, DOI 10.1055/s-2007-996433; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145	4	29	29	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					437	438		10.1136/bmj.328.7437.437	http://dx.doi.org/10.1136/bmj.328.7437.437			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976099	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000189161000018
J	Richardson, DR				Richardson, DR			Mysteries of the transferrin-transferrin receptor 1 interaction uncovered	CELL			English	Editorial Material							C-LOBE; IRON; TRANSPORT; METABOLISM; COMPLEX; CELLS	How does the iron (Fe) binding protein, transferrin (Tf), bind to the transferrin receptor 1 (TfR1) to donate Fe to cells? In this issue of Cell, Cheng et al., describe the molecular structure of the human TfR1-Tf complex, This atomic model shows that Tf binds laterally to the TfR1 dimer and extends into the gap between the bottom of the receptor ectodomain and the membrane.	Childrens Canc Inst Australia Med Res, Iron Metab & Chelat Program, Sydney, NSW 2031, Australia	Children's Cancer Institute; Children's Medical Research Institute - Australia	Richardson, DR (corresponding author), Childrens Canc Inst Australia Med Res, Iron Metab & Chelat Program, POB 81,High St, Sydney, NSW 2031, Australia.			Richardson, Des/0000-0003-0960-6415; Richardson, Des/0000-0002-5506-3274				Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GIANNETTI AM, 2003, PLOS BIOL E51; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Vyoral D, 1998, BBA-MOL CELL RES, V1403, P179, DOI 10.1016/S0167-4889(98)00039-1; Zak O, 2003, BIOCHEMISTRY-US, V42, P12330, DOI 10.1021/bi034991f	12	23	24	3	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	2004	116	4					483	485		10.1016/S0092-8674(04)00165-5	http://dx.doi.org/10.1016/S0092-8674(04)00165-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	777NJ	14980214	Bronze			2022-12-28	WOS:000189184200001
J	Hwang, J; Timusk, T; Gu, GD				Hwang, J; Timusk, T; Gu, GD			High-transition-temperature superconductivity in the absence of the magnetic-resonance mode	NATURE			English	Article							T-C; NEUTRON-SCATTERING; SPIN FLUCTUATIONS; PSEUDOGAP; STATE; EXCITATION; INPLANE; PEAK	The fundamental mechanism that gives rise to high-transition-temperature (high-T-c) superconductivity in the copper oxide materials has been debated since the discovery of the phenomenon. Recent work has focused on a sharp 'kink' in the kinetic energy spectra of the electrons as a possible signature of the force that creates the superconducting state(1-14). The kink has been related to a magnetic resonance(13,15-17) and also to phonons(18). Here we report that infrared spectra of Bi2Sr2CaCu2O8+delta (Bi-2212), shows that this sharp feature can be separated from a broad background and, interestingly, weakens with doping before disappearing completely at a critical doping level of 0.23 holes per copper atom. Superconductivity is still strong in terms of the transition temperature at this doping (T-c approximate to 55 K), so our results rule out both the magnetic resonance peak and phonons as the principal cause of high-T-c superconductivity. The broad background, on the other hand, is a universal property of the copper-oxygen plane and provides a good candidate signature of the 'glue' that binds the electrons.	McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada; Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA	McMaster University; United States Department of Energy (DOE); Brookhaven National Laboratory	Timusk, T (corresponding author), McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada.	timusk@mcmaster.ca	Hwang, Jungseek/ABF-5223-2020	hwang, jungseek/0000-0002-2555-1218				Abanov A, 1999, PHYS REV LETT, V83, P1652, DOI 10.1103/PhysRevLett.83.1652; Campuzano JC, 1999, PHYS REV LETT, V83, P3709, DOI 10.1103/PhysRevLett.83.3709; Carbotte JP, 1999, NATURE, V401, P354, DOI 10.1038/43843; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Dai PC, 2000, NATURE, V406, P965, DOI 10.1038/35023094; Dai PC, 1999, SCIENCE, V284, P1344, DOI 10.1126/science.284.5418.1344; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; EISAKI H, 2004, IN PRESS PHYS REV B; Fong HF, 1999, NATURE, V398, P588, DOI 10.1038/19255; He H, 2001, PHYS REV LETT, V86, P1610, DOI 10.1103/PhysRevLett.86.1610; HOMES CC, 1993, APPL OPTICS, V32, P2976, DOI 10.1364/AO.32.002976; HWANG J, 2003, MARGINAL FERMI LIQUI; Johnson PD, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.177007; Kaminski A, 2001, PHYS REV LETT, V86, P1070, DOI 10.1103/PhysRevLett.86.1070; Kaminski A, 2000, PHYS REV LETT, V84, P1788, DOI 10.1103/PhysRevLett.84.1788; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Loram JW, 2000, PHYSICA C, V341, P831, DOI 10.1016/S0921-4534(00)00706-1; MILLIS AJ, 2003, QUASIPARTICLES HIGH; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; Munzar D, 1999, PHYSICA C, V317, P547, DOI 10.1016/S0921-4534(99)00126-4; Norman MR, 1998, PHYS REV B, V57, pR11089, DOI 10.1103/PhysRevB.57.R11089; Puchkov AV, 1996, PHYS REV LETT, V77, P3212, DOI 10.1103/PhysRevLett.77.3212; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Scalapino DJ, 1999, SCIENCE, V284, P1282, DOI 10.1126/science.284.5418.1282; Schachinger E, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.214508; Shibauchi T, 2001, PHYS REV LETT, V86, P5763, DOI 10.1103/PhysRevLett.86.5763; TAKENAKA K, 1994, PHYS REV B, V50, P6534, DOI 10.1103/PhysRevB.50.6534; THOMAS GA, 1988, PHYS REV LETT, V61, P1313, DOI 10.1103/PhysRevLett.61.1313; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; ZADADZINSKI JF, 2001, PHYS REV LETT, V87	30	170	173	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2004	427	6976					714	717		10.1038/nature02347	http://dx.doi.org/10.1038/nature02347			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775DT	14973479	Green Submitted			2022-12-28	WOS:000189026000037
J	Ouslander, JG				Ouslander, JG			Drug therapy - Management of overactive bladder	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BENIGN PROSTATIC HYPERPLASIA; GERIATRIC VOIDING DYSFUNCTION; LOWER URINARY-TRACT; QUALITY-OF-LIFE; STANDARDIZATION SUB-COMMITTEE; CONTROLLED-RELEASE OXYBUTYNIN; RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; LONG-TERM EFFICACY; DOUBLE-BLIND		Emory Univ, Wesley Woods Ctr, Div Geriatr Med & Gerontol, Ctr Hlth Aging, Atlanta, GA 30329 USA; Birmingham Atlanta Vet Affairs Geriatr Res Educ C, Atlanta, GA USA	Emory University; Geriatric Research Education & Clinical Center	Ouslander, JG (corresponding author), Emory Univ, Wesley Woods Ctr, Div Geriatr Med & Gerontol, Ctr Hlth Aging, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.	jouslan@emory.edu						Abrams P, 1998, BRIT J UROL, V81, P801; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Abrams P, 1997, UROLOGY, V50, P1, DOI 10.1016/S0090-4295(97)00577-3; Abrams P, 2000, UROLOGY, V55, P1, DOI 10.1016/S0090-4295(99)00523-3; Anderson RU, 1999, J UROLOGY, V161, P1809, DOI 10.1016/S0022-5347(05)68810-6; Andersson KE, 2002, UROLOGY, V60, P13, DOI 10.1016/S0090-4295(02)01786-7; ANDERSSON KE, 2002, INCONTINENCE, P481; Appell RA, 2001, MAYO CLIN PROC, V76, P358; ASPLUND R, 1991, J INTERN MED, V229, P131, DOI 10.1111/j.1365-2796.1991.tb00320.x; ASPLUND R, 1993, SCAND J UROL NEPHROL, V27, P77, DOI 10.3109/00365599309180419; Atala A, 2000, BJU Int, V85 Suppl 3, P24; ATALA A, 2000, BJU INT S, V85, P36; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Barry MJ, 1992, J UROLOGY, V148, P1564, DOI DOI 10.1016/S0022-5347(17)36966-5; Birns J, 2000, BJU INT, V85, P793, DOI 10.1046/j.1464-410x.2000.00623.x; Blaivas JG, 1997, NEUROUROL URODYNAM, V16, P145, DOI 10.1002/(SICI)1520-6777(1997)16:3<145::AID-NAU2>3.0.CO;2-E; Blaivas JG, 2002, NEUROUROL URODYNAM, V21, P523, DOI 10.1002/nau.10098; Boyle P, 2001, UROLOGY, V58, P717, DOI 10.1016/S0090-4295(01)01344-9; Brading AF, 1997, UROLOGY, V50, P57, DOI 10.1016/S0090-4295(97)00591-8; BRENDLER CB, 1989, J UROLOGY, V141, P1350, DOI 10.1016/S0022-5347(17)41304-8; Brown JS, 1999, J AM GERIATR SOC, V47, P980, DOI 10.1111/j.1532-5415.1999.tb01294.x; Brown JS, 2000, J AM GERIATR SOC, V48, P721, DOI 10.1111/j.1532-5415.2000.tb04744.x; Brubaker L, 2000, UROLOGY, V55, P17, DOI 10.1016/S0090-4295(99)00488-4; Burgio KL, 2000, J AM GERIATR SOC, V48, P370, DOI 10.1111/j.1532-5415.2000.tb04692.x; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Chancellor M, 2000, CLIN DRUG INVEST, V19, P83, DOI 10.2165/00044011-200019020-00001; Chancellor MB, 1999, J UROLOGY, V162, P3, DOI 10.1097/00005392-199907000-00002; *CTR EV BAS MED, LEV EV GRAD REC; Davila GW, 2001, J UROLOGY, V166, P140, DOI 10.1016/S0022-5347(05)66095-8; Debruyne FMJ, 1996, EUR UROL, V30, P369; Debruyne FMJ, 1997, EUR UROL, V31, P458; DeRidder D, 1997, J UROLOGY, V158, P2087, DOI 10.1016/S0022-5347(01)68162-X; Diokno AC, 2003, MAYO CLIN PROC, V78, P687, DOI 10.4065/78.6.687; Dmochowski RR, 2002, J UROLOGY, V168, P580, DOI 10.1016/S0022-5347(05)64684-8; Drutz H P, 1999, Int Urogynecol J Pelvic Floor Dysfunct, V10, P283, DOI 10.1007/s001929970003; DuBeau CE, 1998, J AM GERIATR SOC, V46, P1118, DOI 10.1111/j.1532-5415.1998.tb06650.x; DuBeau CE, 1999, J AM GERIATR SOC, V47, P989, DOI 10.1111/j.1532-5415.1999.tb01295.x; DUBEAU CE, 1995, J AM GERIATR SOC, V43, P985, DOI 10.1111/j.1532-5415.1995.tb05562.x; Dugan E, 2000, J AM GERIATR SOC, V48, P413, DOI 10.1111/j.1532-5415.2000.tb04699.x; Edwards KR, 2002, J AM GERIATR SOC, V50, P1165, DOI 10.1046/j.1532-5415.2002.50281.x; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; Elbadawi A, 1997, J UROLOGY, V157, P1802, DOI 10.1016/S0022-5347(01)64867-5; ELBADAWI A, 1993, J UROLOGY, V150, P1657, DOI 10.1016/S0022-5347(17)35867-6; Elbadawi A, 1997, J UROLOGY, V157, P1814, DOI 10.1016/S0022-5347(01)64868-7; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; Fantl JA, 1996, OBSTET GYNECOL, V88, P745; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FANTL JA, 1996, AHCPR PUBLICATION; FISSER AJ, 2003, J UROLOGY, V169, P529; Fonda D, 1998, NEUROUROL URODYNAM, V17, P273, DOI 10.1002/(SICI)1520-6777(1998)17:3<273::AID-NAU12>3.0.CO;2-L; Garnett S, 2003, J UROLOGY, V169, P843, DOI 10.1097/01.ju.0000050305.05345.40; Gleason DM, 1999, UROLOGY, V54, P420, DOI 10.1016/S0090-4295(99)00259-9; Graham CW, 2002, NEUROUROL URODYNAM, V21, P473, DOI 10.1002/nau.10015; Gupta SK, 1999, J CLIN PHARMACOL, V39, P289; HEDGE SS, 1997, BRIT J PHARMACOL, V120, P1409; Herbison P, 2003, BMJ-BRIT MED J, V326, P841, DOI 10.1136/bmj.326.7394.841; Hohenfellner M, 2000, BJU Int, V85 Suppl 3, P10; HOHENFELLNER M, 2000, BJU INT S, V85, P22; HOLMES DM, 1989, BRIT J OBSTET GYNAEC, V96, P607, DOI 10.1111/j.1471-0528.1989.tb03263.x; HU TW, 2002, INCONTINENCE, P3; Igawa Y, 1999, BRIT J PHARMACOL, V126, P819, DOI 10.1038/sj.bjp.0702358; Johnson TM, 2003, J UROLOGY, V170, P480, DOI 10.1097/01.ju.0000071406.18453.5f; Johnson TM, 2003, J UROLOGY, V170, P145, DOI 10.1097/01.ju.0000069827.09120.79; Johnson TM, 2001, J AM GERIATR SOC, V49, P710, DOI 10.1046/j.1532-5415.2001.49146.x; Johnson TM, 2000, J AM GERIATR SOC, V48, P894; Jonas U, 1997, WORLD J UROL, V15, P144, DOI 10.1007/BF02201987; Jonas U, 1997, WORLD J UROL, V15, P210, DOI 10.1007/BF02201860; Jung SY, 1999, J UROLOGY, V162, P204, DOI 10.1097/00005392-199907000-00069; Katz IR, 1998, J AM GERIATR SOC, V46, P8, DOI 10.1111/j.1532-5415.1998.tb01006.x; Kaufman A, 2000, UROLOGY, V55, P31; Kobelt G, 1997, UROLOGY, V50, P100, DOI 10.1016/S0090-4295(97)00602-X; Lepor H, 1998, J UROLOGY, V160, P1358, DOI 10.1016/S0022-5347(01)62536-9; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; Lepor H, 1998, UROLOGY, V51, P892, DOI 10.1016/S0090-4295(98)00126-5; Lepor H, 1997, J UROLOGY, V157, P525, DOI 10.1016/S0022-5347(01)65193-0; Locher JL, 2001, J GERONTOL A-BIOL, V56, pM32, DOI 10.1093/gerona/56.1.M32; Lose G, 2003, AM J OBSTET GYNECOL, V189, P1106, DOI 10.1067/S0002-9378(03)00593-3; Madersbacher H, 1999, BJU INT, V84, P646; Madersbacher H, 2000, BJU Int, V85 Suppl 3, P1; MADERSBACHER H, 1995, BRIT J UROL, V75, P452, DOI 10.1111/j.1464-410X.1995.tb07264.x; Madersbacher H, 2001, WORLD J UROL, V19, P324, DOI 10.1007/s003450100223; MADERSBACHER H, 2000, BJU INT S, V85, P8; Malone-Lee J, 2001, J UROLOGY, V165, P1452, DOI 10.1016/S0022-5347(05)66326-4; Malone-Lee JG, 2001, J AM GERIATR SOC, V49, P700, DOI 10.1046/j.1532-5415.2001.49144.x; Marks LS, 1997, UROLOGY, V50, P341, DOI 10.1016/S0090-4295(97)00293-8; Martin SW, 1997, BRIT J UROL, V80, P405, DOI 10.1046/j.1464-410X.1997.00257.x; Mattiasson A, 2003, BJU INT, V91, P54, DOI 10.1046/j.1464-410X.2003.03076.x; Mattiasson A, 2002, BJU INT, V89, P855, DOI 10.1046/j.1464-410X.2002.02791.x; MAZUR D, 1995, SCAND J UROL NEPHROL, V29, P289, DOI 10.3109/00365599509180578; MCCONNELL JD, 1994, AHCPR PUBLICATION; Miller M, 2000, J AM GERIATR SOC, V48, P1321, DOI 10.1111/j.1532-5415.2000.tb02608.x; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; MILSOM I, 2001, BJU INT, V88, P807; Morrison J, 2002, INCONTINENCE, 2ND EDITION, P83; O'Reilly BA, 2002, J UROLOGY, V167, P157, DOI 10.1016/S0022-5347(05)65403-1; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; Ouslander J G, 2001, J Am Med Dir Assoc, V2, P207, DOI 10.1097/00130535-200109000-00002; Ouslander JG, 1998, J AM GERIATR SOC, V46, P1274, DOI 10.1111/j.1532-5415.1998.tb04545.x; OUSLANDER JG, 1995, J AM GERIATR SOC, V43, P610, DOI 10.1111/j.1532-5415.1995.tb07193.x; OUSLANDER JG, 1995, JAMA-J AM MED ASSOC, V273, P1366; Ouslander JG, 1999, J AM GERIATR SOC, V47, P481; Ouslander JG, 2001, J AM GERIATR SOC, V49, P803, DOI 10.1046/j.1532-5415.2001.49160.x; P Abrams, 2002, INCONTINENCE; Payne C, 2002, INCONTINENCE, 2ND EDITION, P1045; Peters TJ, 1997, J UROLOGY, V157, P885, DOI 10.1016/S0022-5347(01)65075-4; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; Roehrborn CG, 2003, BJU INT, V92, P257, DOI 10.1046/j.1464-410X.2003.04309.x; Schurch B, 2000, J UROLOGY, V164, P692, DOI 10.1016/S0022-5347(05)67283-7; Sharma A, 2000, J CLIN PHARMACOL, V40, P161, DOI 10.1177/00912700022008810; Silva C, 2002, J UROLOGY, V168, P575, DOI 10.1016/S0022-5347(05)64683-6; Smith Christopher P., 2001, Journal of Urology, V165, P37; Staskin DR, 2002, UROLOGY, V60, P1, DOI 10.1016/S0090-4295(02)01783-1; Stewart W., 2001, Neurourology and Urodynamics, V20, P406; SULTANA CJ, 1994, MATURITAS, V20, P129, DOI 10.1016/0378-5122(94)90008-6; Sussman D, 2002, CURR MED RES OPIN, V18, P177, DOI 10.1185/030079902125000570; Thomas A W, 2000, BJU Int, V85 Suppl 3, P57; Thomas AW, 2000, BJU INT, V85, P70; THUROFF JW, 1991, J UROLOGY, V145, P813, DOI 10.1016/S0022-5347(17)38459-8; Todorova A, 2001, J CLIN PHARMACOL, V41, P636, DOI 10.1177/00912700122010528; Tse V, 2000, J UROLOGY, V163, P535, DOI 10.1016/S0022-5347(05)67919-0; van Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053; Van Kerrebroeck P, 2001, UROLOGY, V57, P414, DOI 10.1016/S0090-4295(00)01113-4; Weiss JP, 2000, J UROLOGY, V163, P5, DOI 10.1016/S0022-5347(05)67961-X; WYMAN JF, 1988, OBSTET GYNECOL, V71, P812; YARKER YE, 1995, DRUG AGING, V6, P243, DOI 10.2165/00002512-199506030-00007; Yoshimura N, 2002, J UROLOGY, V168, P1897, DOI 10.1016/S0022-5347(05)64261-9; Zinner NR, 2002, J AM GERIATR SOC, V50, P799, DOI 10.1046/j.1532-5415.2002.50203.x	128	293	311	2	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					786	799		10.1056/NEJMra032662	http://dx.doi.org/10.1056/NEJMra032662			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774VM	14973214				2022-12-28	WOS:000189006400007
J	Kaul, P; Newby, LK; Fu, YL; Mark, DB; Califf, RM; Topol, EJ; Aylward, P; Granger, CB; Van de Werf, F; Armstrong, PW				Kaul, P; Newby, LK; Fu, YL; Mark, DB; Califf, RM; Topol, EJ; Aylward, P; Granger, CB; Van de Werf, F; Armstrong, PW		VIGOUR Grp	International differences in evolution of early discharge after acute myocardial infarction	LANCET			English	Article							RISK STRATIFICATION; COST-EFFECTIVENESS; THROMBOLYSIS; ANGIOPLASTY; SAFETY; TRIAGE	Background Early discharge of low-risk patients with acute myocardial infarction is feasible and can be achieved at no additional risk of adverse events. We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge. Methods The study population consisted of 54 174 patients enrolled in GUSTO-I, GUSTO-III, and ASSENT-2 studies (enrolment period 1990-98) in the USA, Canada, Australia, New Zealand, Belgium, France, Germany, Spain, and Poland. We identified patients with uncomplicated acute myocardial infarction who were eligible for early discharge on the basis of previously established criteria, and assessed the extent to which these patients were discharged early-defined as discharged alive within 4 days of admission. The economic consequences (defined as potentially unnecessary hospital days consumed per 100 patients enrolled) were also investigated. Findings Patients in all European countries had significantly longer stays than did those from. non-European countries. Over the study period, the number of eligible patients discharged on or before day 4 increased in the USA, Canada, Australia, and New Zealand. Despite this increase, no more than 40% of patients who were eligible for early discharge were actually discharged early. The rate of early discharge of eligible patients was consistently low (<2%) in Belgium, France, Germany, Spain, and Poland. In ASSENT-2, which is the most recent trial in this study, the number of potentially unnecessary hospital days (per 100 patients enrolled) ranged from 65 in New Zealand to 839 in Germany. Interpretation Despite more than a decade of research, there is still a lot of variation between countries in international length-of-stay patterns in acute myocardial infarction. The potential for more efficient discharge of low-risk patients exists in all countries investigated, but was especially evident in the European countries included in the study (Belgium, France, Germany, Spain, and Poland).	Univ Alberta, Edmonton, AB T6G 2B7, Canada; Duke Clin Res Inst, Durham, NC USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Flinders Med Ctr, Adelaide, SA, Australia; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	University of Alberta; Duke University; Cleveland Clinic Foundation; Flinders Medical Centre; KU Leuven; University Hospital Leuven	Kaul, P (corresponding author), Univ Alberta, 7221 Aberhart Ctr I, Edmonton, AB T6G 2B7, Canada.	pkaul@ualberta.ca	Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Van de Werf, Frans/0000-0001-9479-7767; Kaul, Padma/0000-0003-2239-3944; Aylward, Philip/0000-0002-5358-8552; Armstrong, Paul/0000-0002-0460-3445; Topol, Eric/0000-0002-1478-4729; Mark, Daniel/0000-0001-6340-8087				DIXON A, 2002, HLTH CARE SYSTEMS 8; Every NR, 1996, J AM COLL CARDIOL, V28, P287, DOI 10.1016/0735-1097(96)00168-4; Fu YL, 2001, CIRCULATION, V104, P2653, DOI 10.1161/hc4701.099731; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; HARPUR JE, 1971, LANCET, V2, P1331; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Morrow DA, 2001, LANCET, V358, P1571, DOI 10.1016/S0140-6736(01)06649-1; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Ohman EM, 1999, AM J CARDIOL, V84, P1281, DOI 10.1016/S0002-9149(99)00558-5; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; SANZ G, 1993, J AM COLL CARDIOL, V22, P1795, DOI 10.1016/0735-1097(93)90759-T; Snijders T.A., 1999, INTRO BASIC ADV MULT; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8	21	51	51	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					511	517		10.1016/S0140-6736(04)15536-0	http://dx.doi.org/10.1016/S0140-6736(04)15536-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975612				2022-12-28	WOS:000188999900007
J	Ridley, AJ				Ridley, AJ			Pulling back to move forward	CELL			English	Editorial Material							ACTIN; KINASE		UCL, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.			Ridley, Anne/0000-0001-8186-5708				ALENGHAT FJ, 2002, SCI STKE 2002; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Zhang XF, 2003, NEURON, V40, P931, DOI 10.1016/S0896-6273(03)00754-2; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	10	27	27	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 6	2004	116	3					357	358		10.1016/S0092-8674(04)00123-0	http://dx.doi.org/10.1016/S0092-8674(04)00123-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016370	Bronze			2022-12-28	WOS:000188825800004
